PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tang, HL; Cyster, JG				Tang, HL; Cyster, JG			Chemokine up-regulation and activated T cell attraction by maturing dendritic cells	SCIENCE			English	Article							MACROPHAGE-DERIVED-CHEMOKINE; C-C CHEMOKINE; MOLECULAR-CLONING; FLUORESCEIN ISOTHIOCYANATE; LANGERHANS CELLS; IN-VIVO; EXPRESSION; LYMPHOCYTES; RECEPTOR; MURINE	Langerhans' cells migrating from contact-sensitized skin were found to upregulate expression of macrophage-derived chemokine (MDC) during maturation into Lymph node dendritic cells (DCs), Naive T cells did not migrate toward MDC, but antigen-specific T cells rapidly acquired MDC responsiveness in vivo after a subcutaneous injection of antigen. In chemotaxis assays, maturing DCs attracted activated T cells more strongly than naive T cells. These studies identified chemokine up-regulation as part of the Langerhans' cell maturation program to immunogenic T cell-zone DC. Preferential recruitment of activated T cells may be a mechanism used by maturing DCs to promote encounters with antigen-specific T cells.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040098, R01AI040098] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40098] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Andrew DP, 1998, J IMMUNOL, V161, P5027; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; FOSSUM S, 1989, RES IMMUNOL, V140, P883, DOI 10.1016/0923-2494(89)90048-5; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; HILL S, 1990, IMMUNOLOGY, V71, P277; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; MACATONIA SE, 1986, IMMUNOLOGY, V59, P509; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606, DOI 10.1002/jlb.63.5.606; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; THOMAS WR, 1980, IMMUNOLOGY, V39, P21; Wang BH, 1997, J IMMUNOL, V159, P6148; Youn BS, 1997, BLOOD, V89, P4448, DOI 10.1182/blood.V89.12.4448; [No title captured]	33	245	252	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					819	822		10.1126/science.284.5415.819	http://dx.doi.org/10.1126/science.284.5415.819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221917				2022-12-28	WOS:000080056200051
J	Rodeghiero, F; Tosetto, A				Rodeghiero, F; Tosetto, A			Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism	ANNALS OF INTERNAL MEDICINE			English	Article						protein C; thromboembolism; venous thrombosis; mutation; factor V	POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; INHERITED THROMBOPHILIA; VITA PROJECT; FAMILY HISTORY; FV LEIDEN; THROMBOSIS; GENE; COFACTOR; BLOOD	Background: Resistance to activated protein C due to the factor V R506Q (Leiden) mutation is the most common clotting abnormality in patients with venous thromboembolism. Objective: To evaluate the risk for venous thromboembolism associated with the factor V Leiden mutation or with resistance to activated protein C in the general population. Design: Cross-sectional survey. Setting: General community of Vicenza, Italy. Patients: A population-based sample of 15 109 white persons 18 to 65 years of age who were randomly selected from the census list. Measurements: Sequential validated approach based on participants' reports and Doppler ultrasonography. Resistance to activated protein C was investigated in all participants; 2134 participants with resistance to activated protein C were screened for the factor V Leiden mutation. Results: Carriers of the factor V Leiden mutation had a relative risk of 3.3 (95% CI, 1.7 to 6.1) for venous thromboembolism before 65 years of age. The fraction of cases attributable to the factor V Leiden mutation was 6.6%. By 65 years of age, 5.7% of carriers of the mutation had had venous thromboembolism, mostly after surgery. Participants with a reduced response to activated protein C were at higher risk even if they did not carry the mutation (odds ratio, 1.7 [CI, 1.0 to 2.7]); the attributable risk for venous thromboembolism was 5.1%. Conclusions: The factor V Leiden mutation and resistance to activated protein C are important, independent risk factors for venous thromboembolism. Screening strategies for the factor V Leiden mutation in patients undergoing surgery or experiencing major trauma cannot be recommended, but phenotypic evaluation of resistance to activated protein C should be encouraged in patients with venous thromboembolism.	San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy	ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Rodeghiero, F (corresponding author), San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy.		Tosetto, Alberto/AAB-9320-2022; Tosetto, Alberto/AAM-3200-2020	Tosetto, Alberto/0000-0002-0119-5204				ADELI K, 1990, CLIN CHEM, V36, P261; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; Brown K, 1997, BRIT J HAEMATOL, V98, P907, DOI 10.1046/j.1365-2141.1997.3093130.x; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; De Visser MCH, 1998, BRIT J HAEMATOL, V102, P146; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; EHRENFORTH S, 1995, THROMB HAEMOSTASIS, V74, P797; FAIONI EM, 1995, THROMB HAEMOSTASIS, V73, P1375; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; GRIFFIN JH, 1993, BLOOD, V82, P1989; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; Hills, 1993, STAT MODELS EPIDEMIO; HSIEH CC, 1991, STAT MED, V10, P361, DOI 10.1002/sim.4780100308; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kleinbaum D, 1988, APPL REGRESSION ANAL; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Mari D, 1996, LANCET, V347, P1044, DOI 10.1016/S0140-6736(96)90181-6; RAO AK, 1995, THROMB HAEMOSTASIS, V73, P1126; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Rodeghiero F, 1996, THROMB HAEMOSTASIS, V76, P226; RODEGHIERO F, 1993, THROMB HAEMOSTASIS, V69, P527; Rodeghiero F, 1997, THROMB HAEMOSTASIS, V78, P636; Ryan DH, 1998, ANN INTERN MED, V128, P270, DOI 10.7326/0003-4819-128-4-199802150-00003; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; *STAT CORP, 1997, STAT STAT SOFTW REL; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THIAGARAJAN P, 1986, BLOOD, V68, P869; Tosetto A, 1997, THROMB HAEMOSTASIS, V78, P859; TOSETTO A, 1995, BRIT J HAEMATOL, V89, P227, DOI 10.1111/j.1365-2141.1995.tb08940.x; Tosetto A, 1998, BRIT J HAEMATOL, V102, P147; Tripodi A, 1997, THROMB HAEMOSTASIS, V77, P436; van den Belt AGM, 1998, THROMB HAEMOSTASIS, V79, P259, DOI 10.1055/s-0037-1614975; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; Weiss K. M., 1993, GENETIC VARIATION HU; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623	43	197	197	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					643	+		10.7326/0003-4819-130-8-199904200-00004	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215560				2022-12-28	WOS:000079786600003
J	Beecham, L				Beecham, L			Consultants receive guidance on clinical governance	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205127				2022-12-28	WOS:000080140000077
J	Malek, AM; Higashida, RT; Phatouros, CC; Halbach, VV				Malek, AM; Higashida, RT; Phatouros, CC; Halbach, VV			A strangled wife	LANCET			English	Article							CAROTID-ARTERY DISSECTION; DOMESTIC VIOLENCE		Univ Calif San Francisco, Dept Radiol, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Malek, AM (corresponding author), Univ Calif San Francisco, Dept Radiol, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA.							Brookoff D, 1997, JAMA-J AM MED ASSOC, V277, P1369, DOI 10.1001/jama.277.17.1369; Guillon B, 1998, J NEUROL SCI, V153, P146, DOI 10.1016/S0022-510X(97)00287-6; Lucas C, 1998, STROKE, V29, P2646, DOI 10.1161/01.STR.29.12.2646; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; Mulloy JP, 1998, RADIOLOGY, V207, P571, DOI 10.1148/radiology.207.3.9609876	5	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1324	1324		10.1016/S0140-6736(98)12179-7	http://dx.doi.org/10.1016/S0140-6736(98)12179-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218532				2022-12-28	WOS:000080278100014
J	Pownall, M				Pownall, M			Free eye tests introduced for people over 60 in England and Wales	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1030	1030		10.1136/bmj.318.7190.1030	http://dx.doi.org/10.1136/bmj.318.7190.1030			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205096	Green Published			2022-12-28	WOS:000080140000017
J	Belluscio, L; Koentges, G; Axel, R; Dulac, C				Belluscio, L; Koentges, G; Axel, R; Dulac, C			A map of pheromone receptor activation in the mammalian brain	CELL			English	Article							ACCESSORY OLFACTORY-BULB; MULTIGENE FAMILY; ODORANT RECEPTORS; ORGANIZATION; SYSTEM; RAT	In mammals, the detection of pheromones is mediated by the vomeronasal system. We have employed gene targeting to visualize the pattern of projections of axons from vomeronasal sensory neurons in the accessory olfactory bulb. Neurons expressing a specific receptor project to multiple glomeruli that reside within spatially restricted domains. The formation of this sensory map in the accessory olfactory bulb and the survival of vomeronasal organ sensory neurons require the expression of pheromone receptors. In addition, we observe individual glomeruli in the accessory olfactory bulb that receive input from more than one type of sensory neuron. These observations indicate that the organization of the vomeronasal sensory afferents is dramatically different from that of the main olfactory system, and these differences have important implications for the logic of olfactory coding in the vomeronasal organ.	Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Harvard University; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Dulac, C (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dulac@fas.harvard.edu		Axel, Richard/0000-0002-3141-4076; Dulac, Catherine/0000-0001-5024-5418	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA-23767-20A1] Funding Source: Medline; NINDS NIH HHS [NS29832-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAJAL SRY, 1901, TRAB LAB INVEST BIOL, V1, P141; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Christensen TA, 1997, J NEUROPHYSIOL, V77, P775, DOI 10.1152/jn.1997.77.2.775; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; FARBMAN AI, 1992, CELL BIOL OLFACTION; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sorensen PW, 1998, CURR OPIN NEUROBIOL, V8, P458, DOI 10.1016/S0959-4388(98)80032-9; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; TAKAMI S, 1990, BRAIN RES, V510, P339, DOI 10.1016/0006-8993(90)91387-V; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	21	201	208	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					209	220		10.1016/S0092-8674(00)80731-X	http://dx.doi.org/10.1016/S0092-8674(00)80731-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219242	Bronze			2022-12-28	WOS:000079779800010
J	Handa, N; Nureki, O; Kurimoto, K; Kim, I; Sakamoto, H; Shimura, Y; Muto, Y; Yokoyama, S				Handa, N; Nureki, O; Kurimoto, K; Kim, I; Sakamoto, H; Shimura, Y; Muto, Y; Yokoyama, S			Structural basis for recognition of the tra mRNA precursor by the sex-lethal protein	NATURE			English	Article							TRANSFER-RNA-SYNTHETASE; CRYSTAL-STRUCTURE; BINDING DOMAINS; ANTICODON RECOGNITION; ANGSTROM RESOLUTION; SPLICE SITE; COMPLEX; SPECIFICITY; TRANSCRIPT; ELEMENT	The Sex-lethal (Sxl) protein of Drosophila melanogaster regulates alternative splicing of the transformer (tra) messenger RNA precursor by binding to the tra polypyrimidine tract during the sex-determination process. The crystal structure has now been determined at 2.6 Angstrom resolution of the complex formed between two tandemly arranged RNA-binding domains of the Sxl protein and a 12-nucleotide, single-stranded RNA derived from the tra polypyrimidine tract. The two RNA-binding domains have their beta-sheet platforms facing each other to form a V-shaped cleft. The RNA is characteristically extended and bound in this cleft, where the UGUUUUUUU sequence is specifically recognized by the protein. This structure offers the first insight, to our knowledge, into how a protein binds specifically to a cognate RNA without any intramolecular base-pairing.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Genom Sci Ctr, Wako, Saitama 3510106, Japan; RIKEN, Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 3510106, Japan; Kobe Univ, Fac Sci, Dept Biol, Naka Ku, Kobe, Hyogo 6570013, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068224, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	University of Tokyo; RIKEN; RIKEN; Kobe University; Kyoto University	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURDON IP, 1994, POWER ENG J, V8, P265, DOI 10.1049/pe:19940603; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COLLETTI V, 1994, SKULL BASE SURG, V4, P1, DOI 10.1055/s-2008-1058981; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Harford JB, 1997, MRNA METABOLISM POST; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; Inoue M, 1997, J MOL BIOL, V272, P82, DOI 10.1006/jmbi.1997.1213; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; Kim I, 1997, NUCLEIC ACIDS RES, V25, P1565, DOI 10.1093/nar/25.8.1565; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lee AL, 1997, BIOCHEMISTRY-US, V36, P14306, DOI 10.1021/bi970830y; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Sakashita E, 1996, J BIOCHEM, V120, P1028; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; Samuels M, 1998, NUCLEIC ACIDS RES, V26, P2625, DOI 10.1093/nar/26.11.2625; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SIMONS RW, 1998, RNA STRUCTURE FUNCTI; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	311	319	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					579	585		10.1038/19242	http://dx.doi.org/10.1038/19242			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217141				2022-12-28	WOS:000079754700046
J	Wolfe, MS; Xia, WM; Ostaszewski, BL; Diehl, TS; Kimberly, WT; Selkoe, DJ				Wolfe, MS; Xia, WM; Ostaszewski, BL; Diehl, TS; Kimberly, WT; Selkoe, DJ			Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; C-TERMINAL FRAGMENTS; CAENORHABDITIS-ELEGANS; SEL-12 PRESENILIN; BETA-PROTEIN; CLEAVAGE; CELLS; LOCALIZATION; EXPRESSION; MUTATION	Accumulation of the amyloid-beta protein (A beta) in the cerebral cortex is an early and invariant event in the pathogenesis of Alzheimer's disease. The final step in the generation of A beta from the beta-amyloid precursor protein is an apparently intramembranous proteolysis by the elusive gamma-secretase(s)(1). The most common cause of familial Alzheimer's disease is mutation of the genes encoding presenilins 1 and 2, which alters gamma-secretase activity to increase the production of the highly amyloidogenic A beta, isoform(2). Moreover, deletion of presenilin-2 in mice greatly reduces gamma-secretase activity(3), indicating that presenilin-1 mediates most of this proteolytic event. Here we report that mutation of either of two conserved transmembrane (TM) aspartate residues in presenilin-1, Asp 257 (in TM6) and Asp 385 (in TM7), substantially reduces A beta production and increases the amounts of the carboxy-terminal fragments of beta-amyloid precursor protein that are the substrates of gamma-secretase. We observed these effects in three different cell lines as well as in cell-free microsomes. Either of the Asp-->Ala mutations also prevented the normal endoproteolysis of preseniIin-1 in the TM6 -->TM7 cytoplasmic loop. In a functional presenilin-1 variant (carrying a deletion in exon 9) that is associated with familial Alzheimer's disease and which does not require this cleavage(4), the Asp385-->Ala mutation still inhibited gamma-secretase activity. Our results indicate that the two transmembrane aspartate residues are critical for both presenilin-1 endoproteolysis and gamma-secretase activity, and suggest that presenilin-1 is either a unique diaspartyl cofactor for gamma-secretase or is itself gamma-secretase, an autoactivated intramembranous aspartyl protease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Tennessee System; University of Tennessee Health Science Center	Wolfe, MS (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@utmem.edu; selkoe@cnd.bwh.harvard.edu	xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295				Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Johnson D, 1997, EDN, V42, P94; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Levitan D, 1998, DEVELOPMENT, V125, P3599; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VENTER JC, 1989, BIOCHEM PHARMACOL, V38, P1197, DOI 10.1016/0006-2952(89)90325-0; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; WOLFE MS, IN PRESS BIOCHEMISTR; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	30	1644	1700	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					513	517		10.1038/19077	http://dx.doi.org/10.1038/19077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206644				2022-12-28	WOS:000079662800048
J	Zhang, HS; Postigo, AA; Dean, DC				Zhang, HS; Postigo, AA; Dean, DC			Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16(INK4a), TGF beta, and contact inhibition	CELL			English	Article							CELL-CYCLE ARREST; S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; E2F FAMILY MEMBERS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; DEPENDENT KINASE; DEREGULATED EXPRESSION; CDK INHIBITOR; DNA-BINDING	Rb inhibits progression from G1 to S phase of the cell cycle. It associates with a number of cellular proteins; however, the nature of these interactions and their relative significance in cell cycle regulation are still unclear. We present evidence that Rb must normally interact with the E2F family of transcription factors to arrest cells in G1, and that this arrest results from active transcriptional repression by the Rb-E2F complex, not from inactivation of E2F. Thus, a major role of E2F in cell cycle regulation is assembly of this repressor complex. We demonstrate that active repression by Rb-E2F mediates the G1 arrest triggered by TGF beta, p16(INK4a), and contact inhibition.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.			Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Iavarone A, 1997, NATURE, V387, P417; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; Palmero I, 1996, CANCER SURV, V27, P351; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	65	270	278	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					53	61		10.1016/S0092-8674(00)80714-X	http://dx.doi.org/10.1016/S0092-8674(00)80714-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199402	Bronze			2022-12-28	WOS:000079843900008
J	Beecham, L				Beecham, L			GMC plans revalidation model within two years	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1218	1218						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221968				2022-12-28	WOS:000080277900074
J	Hillier, BJ; Christopherson, KS; Prehoda, KE; Bredt, DS; Lim, WA				Hillier, BJ; Christopherson, KS; Prehoda, KE; Bredt, DS; Lim, WA			Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; MULTIPLE ISOMORPHOUS REPLACEMENT; SKELETAL-MUSCLE; RECEPTOR LOCALIZATION; SIGNALING COMPLEXES; PROTEIN; RECOGNITION; DYSTROPHIN; CHANNELS; MOTIFS	The PDZ protein interaction domain of neuronal nitric oxide synthase (nNOS) can heterodimerize with the PDZ domains of postsynaptic density protein 95 and syntrophin through interactions that are not mediated by recognition of a typical carboxyl-terminal motif, The nNOS-syntrophin PDZ complex structure revealed that the domains interact in an unusual Linear head-to-tail arrangement, The nNOS PDZ domain has two opposite interaction surfaces-one face has the canonical peptide binding groove, whereas the other has a beta-hairpin "finger." This nNOS beta finger docks in the syntrophin peptide binding groove, mimicking a peptide Ligand, except that a sharp beta turn replaces the normally required carboxyl terminus, This structure explains how PDZ domains can participate in diverse interaction modes to assemble protein networks.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1979, SUIT PROGR PROT CRYS; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; JONES TA, 1996, ACTA CRYSTALLOGR D, V52, P30; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	30	440	450	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					812	815		10.1126/science.284.5415.812	http://dx.doi.org/10.1126/science.284.5415.812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221915				2022-12-28	WOS:000080056200049
J	Ligtenberg, G; Blankestijn, PJ; Oey, PL; Klein, IHH; Dijkhorst-Oei, LT; Boomsma, F; Wieneke, GH; van Huffelen, AC; Koomans, HA				Ligtenberg, G; Blankestijn, PJ; Oey, PL; Klein, IHH; Dijkhorst-Oei, LT; Boomsma, F; Wieneke, GH; van Huffelen, AC; Koomans, HA			Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOPULMONARY BAROREFLEX CONTROL; CONGESTIVE-HEART-FAILURE; NERVE ACTIVITY; CARDIOVASCULAR FUNCTION; ESSENTIAL-HYPERTENSION; CALCIUM-CHANNEL; ACE-INHIBITION; PLASMA; HUMANS; CATECHOLAMINES	Background Inhibition of angiotensin-converting enzyme (ACE) reduces the risk of cardiovascular problems in patients with chronic renal failure. This effect may be due in part to a decrease in sympathetic nervous activity, but no direct evidence of such an action is available. Methods We studied muscle sympathetic-nerve activity in 14 patients with hypertension, chronic renal failure, and increased plasma renin activity before, during, and after administration of the ACE inhibitor enalapril. Ten other patients with similar clinical characteristics were studied before and during treatment with the calcium-channel blocker amlodipine. Normal subjects matched for age and weight were included in both studies. Results At base line, mean (+/-SD) muscle sympathetic-nerve activity was higher in the group of patients who received enalapril than in the control subjects (35+/-17 vs. 19+/-9 bursts per minute, P = 0.004). The baroreflex curve, which reflects changes in muscle sympathetic-nerve activity caused by manipulations of blood pressure with sodium nitroprusside and phenylephrine, was shifted to the right in the patients, but baroreflex sensitivity was similar to that in the control subjects (-2.1+/-1.9 and -2.7+/-1.3 bursts per minute per mm Hg, respectively; P = 0.36). A single dose of the sympatholytic drug clonidine caused a greater fall in blood pressure in the patients than in the control subjects. Treatment with enalapril normalized blood pressure and muscle sympathetic-nerve activity (at 23+/-10 bursts per minute) in the patients and shifted the baroreflex curve to the left, reflecting normal blood-pressure levels, without significantly changing sensitivity (-2.3+/-1.8 bursts per minute per mm Hg, P = 0.96). In the patients who received amlodipine, treatment also lowered blood pressure but increased muscle sympathetic-nerve activity, from 41+/-19 to 56+/-14 bursts per minute (P = 0.02). Conclusions Increased sympathetic activity contributes to hypertension in patients with chronic renal disease. ACE inhibition controls hypertension and decreases sympathetic hyperactivity. (N Engl J Med 1999;340:1321-8.) (C)1999, Massachusetts Medical Society.	Univ Utrecht Hosp, Dept Hypertens & Nephrol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Dept Clin Neurophysiol, NL-3508 GA Utrecht, Netherlands; Univ Rotterdam Hosp, Dept Internal Med, Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC	Ligtenberg, G (corresponding author), Univ Utrecht Hosp, Dept Hypertens & Nephrol, Rm F03-226,POB 85-500, NL-3508 GA Utrecht, Netherlands.		Oey, P.Liam/A-9164-2008					ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; BOER P, 1984, AM J PHYSIOL, V247, pF632, DOI 10.1152/ajprenal.1984.247.4.F632; BOER P, 1985, CLIN CHEM, V31, P149; CAMPESE VM, 1995, HYPERTENSION, V25, P878, DOI 10.1161/01.HYP.25.4.878; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; DAVIS D, 1988, AM J PHYSIOL, V254, P760; DibnerDunlap ME, 1996, J AM COLL CARDIOL, V27, P358, DOI 10.1016/0735-1097(95)00484-X; ESLER M, 1986, J CARDIOVASC PHAR S5, V8, P539; FABER JE, 1985, CIRC RES, V57, P676, DOI 10.1161/01.RES.57.5.676; FERGUSON DW, 1989, CIRCULATION, V80, P285, DOI 10.1161/01.CIR.80.2.285; FROLICH ED, 1992, NEW ENGL J MED, V327, P1768; FROLICH ED, 1992, NEW ENGL J MED, V327, P998; GIANNATTASIO C, 1992, J HYPERTENS, V10, P373, DOI 10.1097/00004872-199204000-00009; Grassi G, 1997, CIRCULATION, V96, P1173, DOI 10.1161/01.CIR.96.4.1173; Grassi G, 1997, CLIN SCI, V92, P285, DOI 10.1042/cs0920285; KAILASAM MT, 1995, HYPERTENSION, V26, P143, DOI 10.1161/01.HYP.26.1.143; Kelm M, 1996, J HYPERTENS, V14, P1357, DOI 10.1097/00004872-199611000-00015; LAEDERACH K, 1987, KIDNEY INT, V31, P107, DOI 10.1038/ki.1987.16; Ligtenberg G, 1997, CIRCULATION, V95, P2271, DOI 10.1161/01.CIR.95.9.2271; LONDON GM, 1994, CIRCULATION, V90, P2786, DOI 10.1161/01.CIR.90.6.2786; MATSUKAWA T, 1993, J CLIN INVEST, V92, P25, DOI 10.1172/JCI116558; Noll G, 1997, CIRCULATION, V95, P2286, DOI 10.1161/01.CIR.95.9.2286; REID IA, 1992, AM J PHYSIOL, V262, pE763, DOI 10.1152/ajpendo.1992.262.6.E763; SNEL YEM, 1995, EUR J CLIN INVEST, V25, P708, DOI 10.1111/j.1365-2362.1995.tb01990.x; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VANDERHOORN FAJ, 1989, J CHROMATOGR-BIOMED, V487, P17, DOI 10.1016/S0378-4347(00)83003-0; VANDERHOORN FAJ, 1991, J CHROMATOGR-BIOMED, V563, P348, DOI 10.1016/0378-4347(91)80041-A; VISSING SF, 1989, CIRC RES, V65, P1710, DOI 10.1161/01.RES.65.6.1710; WALLIN BG, 1992, J PHYSIOL-LONDON, V455, P219, DOI 10.1113/jphysiol.1992.sp019298; WEIDMANN P, 1971, NEW ENGL J MED, V285, P757, DOI 10.1056/NEJM197109302851401; WILLIAMS JL, 1992, NEWS PHYSIOL SCI, V7, P30; Ye SH, 1997, KIDNEY INT, V51, P722, DOI 10.1038/ki.1997.103	34	333	419	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1321	1328		10.1056/NEJM199904293401704	http://dx.doi.org/10.1056/NEJM199904293401704			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219067				2022-12-28	WOS:000080001700004
J	Knoll, GA; Bell, RC				Knoll, GA; Bell, RC			Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials	BRITISH MEDICAL JOURNAL			English	Article							KIDNEY-TRANSPLANTATION; US MULTICENTER; SYSTEMATIC REVIEWS; CLINICAL-TRIALS; FK-506; REJECTION; FK506; QUALITY; RECIPIENTS; PREVENTION	Objective To compare tacrolimus with cyclosporin for immunosuppression in renal transplantation. Design Meta-analysis of randomised trials of two treatments after kidney transplantation. Identification Four studies involving 1037 patients. Trials were included if they were randomised, the intervention group received tacrolimus, the control group received cyclosporin, the patients were followed for a minimum of 12 months, and patient survival, graft survival, incidence of acute rejection, need for antilymphocyte treatment, or the prevalence of diabetes mellitus after transplant was reported. Main outcome measures Pooled estimates of patient mortality; allograft loss, and episodes of acute rejection 1) ear after transplantation. Results The odds ratio for loss of allograft with tacrolimus compared with cyclosporin was 0.95 (95% confidence interval 0.65 to 1.40). The odds ratio for mortality with tacrolimus was 1.07 (0.47 to 2.48). Treatment with tacrolimus was associated with a reduction in episodes of acute rejection (0.52; 0.36 to 0.75), a reduction in the use of antilymphocyte antibodies to treat rejection (0.37; 0.25 to 0.56), and an increased prevalence of diabetes mellitus after transplantation (5.03; 2.04 to 12.36) compared with treatment with cyclosporin. Conclusions After renal transplantation, immunosuppression with tacrolimus results in a significant reduction in acute rejection compared with cyclosporin. Follow up studies of high methodological quality are needed to determine wether tacrolimus improves long term renal graft survival.	Univ Ottawa, Ottawa Hosp, Dept Med, Div Nephrol, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute	Knoll, GA (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Med, Div Nephrol, Ottawa, ON K1H 8L6, Canada.			Knoll, Greg/0000-0001-5442-9310				CECKA J, 1998, CLIN TRANSPLANTS 199; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Gjertson DW, 1995, TRANSPLANTATION, V60, P1384, DOI 10.1097/00007890-199560120-00002; Halloran P, 1997, TRANSPLANTATION, V63, P39, DOI 10.1097/00007890-199701150-00008; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jensik SC, 1998, TRANSPLANT P, V30, P1216, DOI 10.1016/S0041-1345(98)00216-4; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; Mayer AD, 1997, TRANSPLANTATION, V64, P436, DOI 10.1097/00007890-199708150-00012; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MELOSKY B, 1992, J AM SOC NEPHROL, V2, pS290; Miller J, 1997, TRANSPL P, V29, P304, DOI 10.1016/S0041-1345(96)00270-9; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Neylan JF, 1998, TRANSPL P, V30, P1355, DOI 10.1016/S0041-1345(98)00274-7; Neylan JF, 1998, TRANSPLANTATION, V65, P515, DOI 10.1097/00007890-199802270-00011; OCHIAI T, 1995, TRANSPLANT P, V27, P50; OH CS, 1988, TRANSPLANTATION, V45, P68, DOI 10.1097/00007890-198801000-00016; Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013; Pirsch JD, 1998, TRANSPLANTATION, V65, P144; SCANTLEBURY V, 1991, TRANSPLANT P, V23, P3169; SHAPIRO R, 1991, TRANSPLANT P, V23, P3065; STARZL TE, 1989, LANCET, V2, P1000; TRAMER MR, 1997, BRIT MED J, V315, P535; US Renal Data System, 1997, USRDS 1997 ANN DAT R; Vincenti F, 1996, TRANSPLANTATION, V61, P1576, DOI 10.1097/00007890-199606150-00005	27	189	197	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1104	1107		10.1136/bmj.318.7191.1104	http://dx.doi.org/10.1136/bmj.318.7191.1104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213717	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080166000022
J	Morris, CA; Anderson, ML; Stroud, RM; Merzbacher, CI; Rolison, DR				Morris, CA; Anderson, ML; Stroud, RM; Merzbacher, CI; Rolison, DR			Silica sol as a nanoglue: Flexible synthesis of composite aerogels	SCIENCE			English	Article							COLLOIDAL PLATINUM; NANOCOMPOSITE; PARTICLES	Low-density nanoscale mesoporous composites may be readily synthesized by adding a colloidal or dispersed solid to an about-to-gel silica set. The silica sol can "glue" a range of chemically and physically diverse particles into the three-dimensional silica network formed upon gelation. If the composite gel is supercritically dried so as to maintain the high porosity of the wet gel,:a composite aerogel is formed In which the nanoscopic surface and bulk properties of each component are retained in the solid composite. The,volume fraction of the second solid can be varied above or below a percolation threshold to tune the transport properties of the composite aerogel and thereby design nanoscale materials for chemical, electronic, and optical applications.	USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Rolison, DR (corresponding author), USN, Res Lab, Code 6170, Washington, DC 20375 USA.	cam32@cornell.edu; rolison@nrl.navy.mil	Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022; Stroud, Rhonda M/S-4584-2018	Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015; Stroud, Rhonda M/0000-0001-5242-8015; Rolison, Debra/0000-0003-0493-9931				ABRAMOFF B, 1992, CHEMICAL PROCESSING OF ADVANCED MATERIALS, P815; Akbarian F, 1996, J RAMAN SPECTROSC, V27, P775, DOI 10.1002/(SICI)1097-4555(199610)27:10<775::AID-JRS28>3.0.CO;2-8; Anderson ML, 1999, LANGMUIR, V15, P674, DOI 10.1021/la980784i; Ayers MR, 1996, J MATER SCI, V31, P6251, DOI 10.1007/BF00354446; BARTLETT JR, 1987, SPECTROCHIM ACTA A, V43, P1543, DOI 10.1016/S0584-8539(87)80045-4; BRECK DW, 1984, ZEOLITE MOL SIEVES, P742; Brinker C.J., 1990, SOL GEL SCI, DOI [10.1016/B978-0-08-057103-4.50013-1, DOI 10.1016/C2009-0-22386-5]; CROSS J, 1989, REV PHYS APPL, V24, P185; DAGAN G, 1993, J PHYS CHEM-US, V97, P12651, DOI 10.1021/j100151a001; DIRE S, 1992, J NON-CRYST SOLIDS, V147, P62, DOI 10.1016/S0022-3093(05)80594-0; FRICKE J, 1992, CHEMICAL PROCESSING OF ADVANCED MATERIALS, P3; Fujiki K, 1998, J MATER SCI, V33, P1871, DOI 10.1023/A:1004309522653; FURLONG DN, 1984, J CHEM SOC FARAD T 1, V80, P571, DOI 10.1039/f19848000571; HENGLEIN A, 1995, J PHYS CHEM-US, V99, P14129, DOI 10.1021/j100038a053; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Hogarth M. P., 1996, PLATIN MET REV, V40, P150, DOI DOI 10.1149/1.1837166; Husing N, 1998, ANGEW CHEM INT EDIT, V37, P23, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<22::AID-ANIE22>3.0.CO;2-I; Kordesch K., 1996, FUEL CELLS THEIR APP; Kutsch B, 1997, J NON-CRYST SOLIDS, V217, P143, DOI 10.1016/S0022-3093(97)00215-9; Lorenz C, 1998, J NON-CRYST SOLIDS, V238, P1, DOI 10.1016/S0022-3093(98)00679-6; Mitrikas G, 1998, J NON-CRYST SOLIDS, V224, P17, DOI 10.1016/S0022-3093(97)00451-1; MIZUSHIMA Y, 1992, APPL CATAL A-GEN, V88, P137, DOI 10.1016/0926-860X(92)80211-T; Mo CM, 1998, J APPL PHYS, V83, P4389, DOI 10.1063/1.367198; Morterra C, 1997, J CATAL, V165, P172, DOI 10.1006/jcat.1997.1487; Ollis DF, 1989, PHOTOCATALYSIS FUNDA; PELIZZETTI E, 1993, ELECTROCHIM ACTA, V38, P47, DOI 10.1016/0013-4686(93)80009-O; RUSSO RE, 1986, J NON-CRYST SOLIDS, V86, P219, DOI 10.1016/0022-3093(86)90490-4; RUTISER C, 1994, MATER LETT, V19, P221, DOI 10.1016/0167-577X(94)90160-0; SCHAEFER DW, 1986, PHYS REV LETT, V56, P2199, DOI 10.1103/PhysRevLett.56.2199; Schneider M, 1997, CATAL TODAY, V35, P339, DOI 10.1016/S0920-5861(96)00164-2; Senaratne C, 1996, J PHYS CHEM-US, V100, P5849, DOI 10.1021/jp951923x; SONG XY, 1995, J MATER RES, V10, P251, DOI 10.1557/JMR.1995.0251; Swider KE, 1997, CHEM MATER, V9, P1248, DOI 10.1021/cm960622c; Tillotson TM, 1998, J NON-CRYST SOLIDS, V225, P358, DOI 10.1016/S0022-3093(98)00055-6; WANG J, 1995, J NON-CRYST SOLIDS, V186, P296, DOI 10.1016/0022-3093(95)00068-2; Ye SY, 1997, CAN J CHEM, V75, P1666, DOI 10.1139/v97-198	36	332	366	23	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	1999	284	5414					622	624		10.1126/science.284.5414.622	http://dx.doi.org/10.1126/science.284.5414.622			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213681				2022-12-28	WOS:000079951100039
J	Barton, MB; Elmore, JG; Fletcher, SW				Barton, MB; Elmore, JG; Fletcher, SW			Breast symptoms among women enrolled in a health maintenance organization: Frequency, evaluation, and outcome	ANNALS OF INTERNAL MEDICINE			English	Article						breast diseases; breast neoplasms; health maintenance organizations; primary health care; outcome and process assessment (health care)	MALPRACTICE LITIGATION; GENERAL SURGEON; FAMILY HISTORY; MEDICAL-CARE; CANCER; DISEASE; AGE; GUIDELINES; DIAGNOSIS; BIOPSY	Background: Few data exist about visits to primary care clinicians for breast symptoms in the United States. Objective: To determine how often women present with breast symptoms, how these symptoms are evaluated, and how often cancer is diagnosed. Design: Retrospective cohort study. Setting: Staff-model division of a large health maintenance organization (HMO) in New England. Patients: 2400 women who were 40 to 69 years of age as of 1 July 1983 and were continuously enrolled in the HMO until 30 June 1995. Measurements: Information on all breast-related encounters from 1 July 1983 to 30 June 1993 was abstracted. Type of symptom, clinicians' findings and recommendations, and all subsequent evaluations were recorded. Cases of cancer diagnosed subsequent to the symptom were determined. Results: Sixteen percent of the HMO population presented with a breast symptom during the 10-year period, for a rate of 22.8 presentations per 1000 person-years. Women younger than 50 years of age presented nearly twice as often as older women (P = 0.001). Women with breast symptoms had lower rates of screening than other women before presenting but higher rates of screening afterward (P < 0.001). Symptoms were evaluated beyond the initial visit in 66% of patients, and invasive procedures were performed in 27% of patients. Cancer was found in 6.2% of patients and 4.5% of episodes; rates of cancer detection varied significantly by type of symptom but not by patient age. Conclusions: Breast symptoms among women 40 to 70 years of age were common in this primary care practice. Evaluation beyond initial examinations was frequent, and invasive procedures were performed for 27% of patients. Cancer was diagnosed in more than 4% of episodes, indicating that follow-up of breast symptoms is important in primary care practices.	Harvard Pilgrim Hlth Care Fdn, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle	Barton, MB (corresponding author), Harvard Pilgrim Hlth Care Fdn, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.	mary_barton@hms.harvard.edu						*AM COLL PHYS, 1985, ANN INTERN MED, V103, P143; *AM COLL RAD, 1995, BREAST IM REP DAT SY; *AM COLL RAD, 1993, BREAST IM REP DAT SY; *AM MED ASS, 1994, PHYS CURR PROC TERM; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; [Anonymous], 1986, CAN MED ASSOC J, V134, P724; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Ballo MS, 1996, CANCER, V78, P773; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; BERNSTEIN AB, 1991, MED CARE, V29, P196; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Bywaters J L, 1977, J R Coll Gen Pract, V27, P353; Cochrane RA, 1997, EUR J SURG ONCOL, V23, P198, DOI 10.1016/S0748-7983(97)92220-4; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; DAWSON C, 1993, ANN ROY COLL SURG, V75, P83; DAWSON C, 1993, ANN ROY COLL SURG, V75, P79; DEVITT JE, 1989, LANCET, V2, P1257; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; GOODSON WH, 1985, AM J SURG, V150, P271, DOI 10.1016/0002-9610(85)90135-7; GUI GPH, 1995, ANN ROY COLL SURG, V77, P24; Gundry KR, 1998, AM J ROENTGENOL, V171, P41, DOI 10.2214/ajr.171.1.9648760; Healy BP, 1997, J WOMENS HEALTH, V6, P141, DOI 10.1089/jwh.1997.6.141; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KERN KA, 1992, ARCH SURG-CHICAGO, V127, P542; Liberman L, 1998, AM J ROENTGENOL, V171, P35, DOI 10.2214/ajr.171.1.9648759; LOCKER AP, 1989, LANCET, V1, P887; *MAP CORP, 1995, MAPM 2 0 DESKT MAPP; MCKINNA JA, 1992, EUR J CANCER, V28A, P911; MITNICK JS, 1995, J AM COLL SURGEONS, V181, P315; MOORE FD, 1978, NEW ENGL J MED, V299, P304, DOI 10.1056/NEJM197808102990610; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; NICHOLS S, 1980, BRIT MED J, V281, P1450, DOI 10.1136/bmj.281.6253.1450; Physician Insurers Association of America, 1995, BREAST CANC STUD JUN; Pijnappel RM, 1997, EUR J RADIOL, V24, P120, DOI 10.1016/S0720-048X(96)01140-0; PREECE PE, 1976, LANCET, V2, P670; ROBERTS MM, 1987, BRIT J SURG, V74, P1020, DOI 10.1002/bjs.1800741121; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; *SAS I INC, 1996, SAS VERS 6 10; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; Shaw A D, 1995, Eur J Surg Oncol, V21, P284, DOI 10.1016/S0748-7983(95)91525-7; STANDERTSKJOLDNORDENSTAM CG, 1980, ANN CHIR GYNAECOL, V69, P48; STERNS EE, 1992, CAN J SURG, V35, P41; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; 1997, MMWR MORB MORTAL WKL, V46, P937; 1996, FED REG, V61, P59490; 1990, CA CANC J CLIN, V40, P77	46	107	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					651	+		10.7326/0003-4819-130-8-199904200-00005	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215561				2022-12-28	WOS:000079786600004
J	Gianakos, D				Gianakos, D			Conversations with Stella	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA		Gianakos, D (corresponding author), Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA.	dean.gianakos@centrahealth.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					698	699		10.7326/0003-4819-130-8-199904200-00020	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215570				2022-12-28	WOS:000079786600013
J	Dickenson, DL				Dickenson, DL			Can children and young people consent to be tested for adult onset genetic disorders?	BRITISH MEDICAL JOURNAL			English	Article									Univ London Sch Pharm, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	University of London; University College London; University of London School of Pharmacy	Dickenson, DL (corresponding author), Univ London Sch Pharm, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.							Alderson P., 1990, CHOOSING CHILDREN; Alderson P., 1993, CHILDRENS CONSENT SU; BLOCH M, 1993, AM J MED GENET, V47, P368, DOI 10.1002/ajmg.1320470314; *BRIT MED ASS, 1998, HUM GEN CHOIC RESP, P68; BROHOLM J, 1994, NEUROLOGY, V44, P1533; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; *NUFF COUNC, 1998, MENT DIS GEN ETH CON; Nuffield Council on Bioethics, 1998, MENT DIS GEN ETH CON	8	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1063	1065		10.1136/bmj.318.7190.1063	http://dx.doi.org/10.1136/bmj.318.7190.1063			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205110	Green Published			2022-12-28	WOS:000080140000036
J	Chen, YA; Scales, SJ; Patel, SM; Doung, YC; Scheller, RH				Chen, YA; Scales, SJ; Patel, SM; Doung, YC; Scheller, RH			SNARE complex formation is triggered by Ca2+ and drives membrane fusion	CELL			English	Article							NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; SECRETORY VESICLES; CALCIUM CHANNELS; SYNAPTOTAGMIN-I; CORE COMPLEX; N-TYPE; PROTEIN; IDENTIFICATION; NEUROTOXINS	Neurotransmitter exocytosis, a process mediated by a core complex of syntaxin, SNAP-25, and VAMP (SNAREs), is inhibited by SNARE-cleaving neurotoxins. Botulinum neurotoxin E inhibition of norepinephrine release in permeabilized PC12 cells can be rescued by adding a 65 aa C-terminal fragment of SNAP-25 (S25-C). Mutations along the hydrophobic face of the S25-C helix result in SNARE complexes with different thermostabilities, and these mutants rescue exocytosis to different extents. Rescue depends on the continued presence of both S25-C and Ca2+ and correlates with complex formation. The data suggest that Ca2+ triggers S25-C binding to a low-affinity site, initiating trans-complex formation. Pairing of SNARE proteins on apposing membranes leads to bilayer fusion and results in a high-affinity cis-SNARE complex.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	scheller@cmgm.stanford.edu	Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUERFEIND R, 1995, FEBS LETT, V364, P328, DOI 10.1016/0014-5793(95)00419-A; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BINZ T, 1994, J BIOL CHEM, V269, P1617; Blank PS, 1998, J GEN PHYSIOL, V112, P559, DOI 10.1085/jgp.112.5.559; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Matthews G, 1996, ANNU REV NEUROSCI, V19, P219; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Montecucco C, 1998, CURR OPIN CELL BIOL, V10, P530, DOI 10.1016/S0955-0674(98)80069-0; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; Schekman R, 1998, NATURE, V396, P514, DOI 10.1038/24986; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STEEGMAIER M, 1998, J BIOL CHEM, V143, P957; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	42	350	359	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					165	174		10.1016/S0092-8674(00)80727-8	http://dx.doi.org/10.1016/S0092-8674(00)80727-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219238	Bronze			2022-12-28	WOS:000079779800006
J	Garbutt, JC; West, SL; Carey, TS; Lohr, KN; Crews, FT				Garbutt, JC; West, SL; Carey, TS; Lohr, KN; Crews, FT			Pharmacological treatment of alcohol dependence - A review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; DISULFIRAM TREATMENT; FOLLOW-UP; RELAPSE PREVENTION; LITHIUM-CARBONATE; UNITED-STATES; DSM-IV; NALTREXONE; FLUOXETINE	Context Alcoholism affects approximately 10% of Americans at some time in their lives. Treatment consists of psychosocial interventions, pharmacological interventions, or both, but which drugs are most effective at enhancing abstinence and preventing relapse has not been systematically reviewed. Objective To evaluate the efficacy of 5 categories of drugs used to treat alcohol dependence-disulfiram; the opioid antagonists naltrexone and nalmefene, acamprosate, various serotonergic agents (including selective serotonergic reuptake inhibitors), and lithium. Data Sources Reports of randomized controlled trials, nonrandomized trials, and other study designs in English, French, and German identified from multiple searches of MEDLINE, EMBASE, and specialized databases; hand searching bibliographies of review articles; searches for unpublished literature; and discussions with investigators in the field. Study Selection We included all studies on alcohol-dependent human subjects aged 18 years or older from all inpatient and outpatient settings between 1966 and December 1997 that met our inclusion criteria. Data Extraction We abstracted the following information: study design and binding, diagnostic instrument and severity assessment, drug interventions and cointerventions, demographic and comorbidity details about patients, compliance, and numerous outcome measures (eg, relapse, return to drinking, drinking or nondrinking days, time to first drink, alcohol consumed per unit of time, craving). We graded quality of the individual articles (scale, 0-100) independently from the strength of evidence for each drug class (A, strong and consistent evidence of efficacy in studies of large size and/or high quality; B, mixed evidence of efficacy; C, evidence of lack of efficacy; and I, insufficient evidence). Data Synthesis Of 375 articles evaluated, we abstracted and analyzed data from 41 studies and 11 follow-up or subgroup studies. Naltrexone (grade A) reduces the risk of relapse to heavy drinking and the frequency of drinking compared with placebo but does not substantially enhance abstinence, ie, avoidance of any alcohol consumption. Acamprosate (grade A, from large-scale studies in Europe) reduces drinking frequency,al though its effects on enhancing abstinence or reducing time to first drink are less clear. Controlled studies of disulfiram (grade B) reveal a mixed outcome pattern--some evidence that drinking frequency is reduced but minimal evidence to support improved continuous abstinence rates. The limited data on serotonergic agents were not very promising (grade I), although most studies were confounded by high rates of comorbid mood disorders. Lithium lacks efficacy (grade C) in the treatment of primary alcohol dependence. Conclusions Recent reports documenting that naltrexone and acamprosate are more effective than placebo in the treatment of alcoholism justify clinical interest in use of these medications for alcohol-dependent patients. Use-of disulfiram is widespread but less clearly supported by the clinical trial evidence; however, targeted studies on supervised administration of disulfiram may be warranted. Useof existing serotonergic agents or lithium for patients with primary alcohol dependence does not appear to be supported by the efficacy data available at this time; these medications may still have a positive effect in patients with coexisting psychiatric disorders.	Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA	Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	West, SL (corresponding author), Res Triangle Inst, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.	swest@rti.org	Crews, Fulton/T-1181-2019	Crews, Fulton/0000-0003-2393-4976; Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BISCHOF T, 1995, SCHWEIZ RUNDSCH MED, V84, P698; BREWER C, 1993, ALCOHOL ALCOHOLISM, V28, P383; CAETANO R, 1995, ALCOHOL ALCOHOLISM, V30, P177; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; Clark D C, 1989, Recent Dev Alcohol, V7, P315; COMELIUS JR, 1997, ARCH GEN PSYCHIAT, V54, P700; Croop RS, 1997, ARCH GEN PSYCHIAT, V54, P1130; DELAFUENTE JR, 1989, MAYO CLIN PROC, V64, P177, DOI 10.1016/S0025-6196(12)65672-9; DORUS W, 1989, JAMA-J AM MED ASSOC, V262, P1646, DOI 10.1001/jama.262.12.1646; FAWCETT J, 1984, J CLIN PSYCHIAT, V45, P494; FAWCETT J, 1987, ARCH GEN PSYCHIAT, V44, P248; FULLER R, 1983, J CHRON DIS, V36, P161, DOI 10.1016/0021-9681(83)90090-5; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; Geerlings PJ, 1997, EUR ADDICT RES, V3, P129, DOI 10.1159/000259166; GERRA G, 1992, CURR THER RES CLIN E, V52, P291, DOI 10.1016/S0011-393X(05)80480-1; GORELICK DA, 1992, ALCOHOL CLIN EXP RES, V16, P261, DOI 10.1111/j.1530-0277.1992.tb01373.x; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; Grant BF, 1997, J STUD ALCOHOL, V58, P464, DOI 10.15288/jsa.1997.58.464; Janiri L, 1996, INT CLIN PSYCHOPHARM, V11, P109, DOI 10.1097/00004850-199611020-00005; JOHNSEN J, 1987, BRIT J ADDICT, V82, P607; JOHNSEN J, 1991, ALCOHOL CLIN EXP RES, V15, P532, DOI 10.1111/j.1530-0277.1991.tb00555.x; Kabel DI, 1996, ALCOHOL CLIN EXP RES, V20, P780, DOI 10.1111/j.1530-0277.1996.tb01686.x; KLINE NS, 1974, AM J MED SCI, V268, P15, DOI 10.1097/00000441-197407000-00002; Kranzler HR, 1996, ALCOHOL CLIN EXP RES, V20, P1534, DOI 10.1111/j.1530-0277.1996.tb01696.x; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; Ladewig D, 1993, Ther Umsch, V50, P182; MALCOLM R, 1992, ALCOHOL CLIN EXP RES, V16, P1007, DOI 10.1111/j.1530-0277.1992.tb00691.x; Malec E, 1996, ALCOHOL CLIN EXP RES, V20, P307, DOI 10.1111/j.1530-0277.1996.tb01644.x; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MERRY J, 1976, LANCET, V2, P481, DOI 10.1016/S0140-6736(76)90784-4; *NAT I DRUG AB, 1998, EC COSTS ALC DRUG AB; OBrien CP, 1996, ALCOHOL, V13, P35, DOI 10.1016/0741-8329(95)02038-1; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; OMalley SS, 1996, ARCH GEN PSYCHIAT, V53, P217; OMalley SS, 1996, AM J PSYCHIAT, V153, P281; PAILLE FM, 1995, ALCOHOL ALCOHOLISM, V30, P239; Pelc I, 1997, BRIT J PSYCHIAT, V171, P73, DOI 10.1192/bjp.171.1.73; PISANI VD, 1993, J STUD ALCOHOL, V54, P115, DOI 10.15288/jsa.1993.54.115; Poldrugo F, 1997, ADDICTION, V92, P1537; POND SM, 1981, ALCOHOL CLIN EXP RES, V5, P247, DOI 10.1111/j.1530-0277.1981.tb04896.x; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Roussaux J P, 1996, J Pharm Belg, V51, P65; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; SCHUCKIT MA, 1985, J STUD ALCOHOL, V46, P191, DOI 10.15288/jsa.1985.46.191; SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x; Tiihonen J, 1996, PHARMACOPSYCHIATRY, V29, P27, DOI 10.1055/s-2007-979538; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613; VOLPICELLI JR, 1995, J CLIN PSYCHIAT, V56, P39; WEST SL, 1999, AHCPR PUBL; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7; WHYTE CR, 1974, BRIT J PSYCHIAT, V124, P42, DOI 10.1192/bjp.124.1.42; WILSON A, 1978, J STUD ALCOHOL, V39, P809, DOI 10.15288/jsa.1978.39.809; WILSON A, 1976, BRIT J PSYCHIAT, V129, P277, DOI 10.1192/bjp.129.3.277; WILSON A, 1980, J STUD ALCOHOL, V41, P429, DOI 10.15288/jsa.1980.41.429	60	311	320	0	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1318	1325		10.1001/jama.281.14.1318	http://dx.doi.org/10.1001/jama.281.14.1318			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184TC	10208148				2022-12-28	WOS:000079628700037
J	Pronovost, PJ; Jenckes, MW; Dorman, T; Garrett, E; Breslow, MJ; Rosenfeld, BA; Lipsett, PA; Bass, E				Pronovost, PJ; Jenckes, MW; Dorman, T; Garrett, E; Breslow, MJ; Rosenfeld, BA; Lipsett, PA; Bass, E			Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT CHARACTERISTICS; MORTALITY; MEDICARE; VOLUME; IMPACT; POPULATION; HOSPITALS; MARYLAND; QUALITY; DISEASE	Context Morbidity and mortality rates in intensive care units (ICUs) vary widely among institutions, but whether ICU structure and care processes affect these outcomes is unknown. Objective To determine whether organizational characteristics of ICUs are related to clinical and economic outcomes for abdominal aortic surgery patients who typically; receive care in an ICU. Design Observational study, with patient data collected retrospectively and ICU data collected prospectively. Setting All Maryland hospitals that performed abdominal aortic surgery from 1994 to 1996. Patients and Participants We analyzed hospital discharge data for patients in nonfederal acute care hospitals in Maryland who had a principal procedure code for abdominal aortic surgery from January 1994 through December 1996 (n = 2987) We obtained information about ICU organizational characteristics by surveying ICU medical directors at the 46 Maryland hospitals that performed abdominal aortic surgery. Thirty-nine (85%) of the ICU directors completed this survey. Main Outcome Measures In-hospital mortality and hospital and ICU length of stay. Results For patients undergoing abdominal aortic surgery, in-hospital mortality varied among hospitals from 0% to 66%. In multivariate analysis adjusted for patient demographics, comorbid disease, severity of illness, hospital and surgeon volume, and hospital characteristics, not having daily rounds by an ICU physician was associated with a 3-fold increase in in-hospital mortality (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.9-4.9). Furthermore, not having daily rounds by an ICU physician was associated with an increased risk of cardiac arrest (OR, 2.9; 95% CI, 1.2-7.0), acute renal failure (OR, 2.2; 95% CI, 1.3-3.9), septicemia (OR, 1.8, 95 % CI, 1.2-2.6), platelet transfusion (OR, 6.4; 95% CI, 3.2-12.4), and reintubation (OR, 2.0; 95% CI, 1.0-4.1). Not having daily rounds by an ICU physician, having an ICU nurse-patient ratio of less than 1:2, not having monthly review of morbidity and mortality, and extubating patients in the operating room were associated with increased resource use. Conclusions Organizational characteristics of ICUs are related to differences among hospitals in outcomes of abdominal aortic surgery. Clinicians and hospital leaders should consider the potential impact of ICU organizational characteristics on outcomes of patients having high-risk operations.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Program Med Technol & Practice Assessment, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Pronovost, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care, 600 N Wolfe St,Meyer 297A, Baltimore, MD 21287 USA.			Bass, Eric/0000-0001-9106-527X; dorman, todd/0000-0002-8616-8677				Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; Berenson RA., 1984, INTENSIVE CARE UNITS; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHASSIN MR, 1989, HEALTH SERV RES, V24, P1; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dardik A, 1998, J VASC SURG, V28, P413, DOI 10.1016/S0741-5214(98)70126-0; *DEL HASK SELLS, 1996, J HOPK HOSP REP CLIN; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Gould W., 1993, STATA TECHNICAL B, P13; GREENBAUM DM, 1984, CRIT CARE MED, V12, P1073, DOI 10.1097/00003246-198412000-00016; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; HANNON EL, 1992, HEALTH SERV RES, V27, P527; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Jiang HJ, 1997, CRIT CARE MED, V25, P773, DOI 10.1097/00003246-199705000-00011; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Paterson L, 1991, BRIT EDUC RES J, V17, P387, DOI [DOI 10.1080/0141192910170408, 10.1080/0141192910170408]; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; SHORTELL SM, 1991, MED CARE, V29, P709, DOI 10.1097/00005650-199108000-00004; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VEITH FJ, 1991, J VASC SURG, V13, P523, DOI 10.1016/0741-5214(91)90313-J; WACKSMAN R, 1996, CRIT CARE MED, V24, pA21; WAGNER DP, 1987, CHEST, V92, P423, DOI 10.1378/chest.92.3.423; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010; [No title captured]	40	485	491	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1310	1317		10.1001/jama.281.14.1310	http://dx.doi.org/10.1001/jama.281.14.1310			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208147	Bronze			2022-12-28	WOS:000079628700036
J	Villar, RG; Shapiro, RL; Busto, S; Riva-Posse, C; Verdejo, G; Farace, MI; Rosetti, F; San Juan, JA; Julia, CM; Becher, J; Maslanka, SE; Swerdlow, DL				Villar, RG; Shapiro, RL; Busto, S; Riva-Posse, C; Verdejo, G; Farace, MI; Rosetti, F; San Juan, JA; Julia, CM; Becher, J; Maslanka, SE; Swerdlow, DL			Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHROTROPHIC CLOSTRIDIUM; FOODBORNE BOTULISM; UNITED-STATES; SPOILAGE; GROWTH	Context Botulism is an important public health problem in Argentina, but obtaining antitoxin rapidly has been difficult because global supplies are limited. in January 1998, a botulism outbreak occurred in Buenos Aires. Objectives To determine the source of the outbreak, improve botulism surveillance, and establish an antitoxin supply and release system in Argentina. Design, Setting, and Participants Cohort study in January 1998 of 21 drivers of a specific bus route in urban Buenos Aires. Main Outcome Measure Occurrence of botulism and implication of a particular food as the vehicle causing this outbreak. Results Nine (43%) of 21 bus drivers developed botulism; presenting with gastroenteritis, symptoms of acute cranial nerve dysfunction including ptosis, dysphagia, blurred vision, and motor weakness. One driver experienced respiratory failure. Type A toxin was detected from 3 of 9 patients' serum samples. All drivers received botulism antitoxin; there were no fatalities. Consumption of matambre (Argentine meat roll) was significantly associated with illness. Among 11 persons who ate matambre, 9 developed illness, compared with none of those who did not eat it (P < .001). The matambre had been cooked in water at 78 degrees C to 80 degrees C for 4 hours, sealed in heat-shrinked plastic wrap, and stored in refrigerators that did not cool adequately. Subsequently, a botulism surveillance and antitoxin release system was established. Conclusions Insufficient cooking time and temperatures, storage in heat-shrinked plastic wrap, and inadequate refrigeration likely contributed to Clostridium botulinum spore survival, germination, and toxin production. A rapid-response botulism surveillance and antitoxin release system in Argentina should provide more timely distribution of antitoxin to patients and may serve as a model for other nations.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Sci Resources Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Minist Salud Reg 5, Buenos Aires, DF, Argentina; Minist Salud & Acc Social, Buenos Aires, DF, Argentina; Med Sanitaria, Buenos Aires, DF, Argentina; Direcc Epidemiol, Buenos Aires, DF, Argentina; Pan Amer Hlth Org, Buenos Aires, DF, Argentina; ANLIS Carlos G Malbran, Inst Nacl Enfermedades Infecc, Dept Bacteriol, Buenos Aires, DF, Argentina; Hosp FJ Muniz, Buenos Aires, DF, Argentina	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pan American Health Organization; University of Buenos Aires	Swerdlow, DL (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.							Aureli P, 1996, LANCET, V348, P1594, DOI 10.1016/S0140-6736(05)66220-4; Broda DM, 1996, INT J FOOD MICROBIOL, V29, P335, DOI 10.1016/0168-1605(95)00070-4; Broda DM, 1996, INT J FOOD MICROBIOL, V29, P371, DOI 10.1016/0168-1605(95)00071-2; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P22; Centers for Disease Control and Prevention, 1998, HDB EPID CLIN LAB WO; *CHILL FOOD ASS, 1997, GUID GOOD HYG PRACT; Conner D. E., 1989, Journal of Food Safety, V10, P131; DOYLE M, 1991, FOOD TECHNOL, V44, P154; Graham AF, 1996, APPL ENVIRON MICROB, V62, P2664, DOI 10.1128/AEM.62.7.2664-2668.1996; HATHEWAY CL, 1998, INFECT DIS, P1919; Hauschild AHW, 1993, CLOSTRIDIUM BOTULINU, P69; HUGHES J, 1981, ANN INTERN MED, V95, P422; Juneja VK, 1996, INT J FOOD MICROBIOL, V32, P115, DOI 10.1016/0168-1605(96)01111-7; LECOUR H, 1988, ARCH INTERN MED, V148, P578, DOI 10.1001/archinte.148.3.578; MARTIN D, 1996, EPIDEMIOLOGY, V7, P2933; ROBOLOT P, 1994, J MED MICROBIOL, V40, P379; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; Shapiro RL, 1997, JAMA-J AM MED ASSOC, V278, P433, DOI 10.1001/jama.278.5.433; STLOUIS ME, 1991, BACTERIAL INFECT HUM, P115; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; TROILLET N, 1995, SCHWEIZ MED WSCHR, V125, P1805; *USDA EXT SERV, 1994, USDA EXT SERV AGR B, V539; WEBER JT, 1993, J INFECT DIS, V167, P451, DOI 10.1093/infdis/167.2.451; Weber JT, 1994, INFECT DIS, P1185; WILCOX P, 1989, AM REV RESPIR DIS, V139, P157, DOI 10.1164/ajrccm/139.1.157; WOODRUFF BA, 1992, J INFECT DIS, V166, P1281, DOI 10.1093/infdis/166.6.1281	26	29	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1334	+		10.1001/jama.281.14.1334	http://dx.doi.org/10.1001/jama.281.14.1334			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208152				2022-12-28	WOS:000079628700041
J	Farre, R; Hernandez, L; Montserrat, JM; Rotger, M; Ballester, E; Navajas, D				Farre, R; Hernandez, L; Montserrat, JM; Rotger, M; Ballester, E; Navajas, D			Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea	LANCET			English	Article							APNEA		Univ Barcelona, Fac Med, Dept Ciencies Fisiol 1, Unitat Biofis & Bioengn, E-08026 Barcelona, Spain; Hosp Clin Barcelona, Serv Pneumol & Allergia Resp, Barcelona, Spain; Inst Invest Biomed August Pi Sunyer, Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Farre, R (corresponding author), Univ Barcelona, Fac Med, Dept Ciencies Fisiol 1, Unitat Biofis & Bioengn, E-08026 Barcelona, Spain.		Navajas, Daniel/E-4233-2010; Farre, Ramon/L-2664-2017	Navajas, Daniel/0000-0001-7150-9363; Farre, Ramon/0000-0002-9084-7824; MONTSERRAT, Josep Maria/0000-0003-3098-4605				Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Stradling J, 1997, LANCET, V349, P201, DOI 10.1016/S0140-6736(96)08166-4; SULLIVAN CE, 1981, LANCET, V1, P862; Wright J, 1997, BRIT MED J, V314, P851	5	71	71	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1154	1154		10.1016/S0140-6736(99)01056-9	http://dx.doi.org/10.1016/S0140-6736(99)01056-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209985				2022-12-28	WOS:000079858400019
J	Jick, H				Jick, H			A database worth saving	LANCET			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RISK				Jick, H (corresponding author), BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992				DERBY LE, 1993, MED J AUSTRALIA, V158, P596, DOI 10.5694/j.1326-5377.1993.tb137624.x; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1995, BRIT J GEN PRACT, V45, P107; JICK H, 1995, PHARMACOTHERAPY, V15, P428; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; Turnbull S, 1996, BRIT J PSYCHIAT, V169, P705, DOI 10.1192/bjp.169.6.705; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106	12	68	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1045	1046		10.1016/S0140-6736(05)70451-7	http://dx.doi.org/10.1016/S0140-6736(05)70451-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213544				2022-12-28	WOS:A1997YA73400005
J	Abbasi, K				Abbasi, K			The World Bank and world health - Focus on South Asia - II: India and Pakistan	BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Abbasi, K (corresponding author), BMJ, London WC1H 9JR, England.							ABBASI K, 1998, BRIT MED J, V318, P1066; CONLY SR, 1998, FALLING SHORT WORLD; *HLTH NUTR POP UN, 1998, PAK HLTH SECT STRAT; Ministry of Health, 1997, NAT HLTH POL; TINKER AG, 1998, HLTH NUTR POP SER; *VIT STAT DIV, 1992, CENS IND 1991 1; *VIT STAT DIV, 1994, SAMPL REG SYST FERT; *WORLD BANK, 1996, DEV PRACT SER; *WORLD BANK, 1999, WORLD BANK ANN FISC; *WORLD BANK, 1998, WORLD BANK FALL SHOR; 1997, DAWN            0406; 1998, PRESS TRUST IND 0608	12	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1132	1135		10.1136/bmj.318.7191.1132	http://dx.doi.org/10.1136/bmj.318.7191.1132			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213734	Green Published			2022-12-28	WOS:000080166000039
J	Balfour, HH				Balfour, HH			Antiviral drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; VARICELLA-ZOSTER VIRUS; CHRONIC HEPATITIS-B; RECURRENT GENITAL HERPES; LIVER-TRANSPLANT RECIPIENTS; BONE-MARROW TRANSPLANTATION; HUMAN CYTOMEGALO-VIRUS; DOUBLE-BLIND; ORAL ACYCLOVIR; INTRAVENOUS ACYCLOVIR		Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Balfour, HH (corresponding author), Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Box 437 Mayo,420 Delaware St SE, Minneapolis, MN 55455 USA.				PHS HHS [A127661] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AIDS RES GROUP AI, 1992, NEW ENGL J MED, V326, P1172; ANDERSON RD, 1995, CLIN THER, V17, P425, DOI 10.1016/0149-2918(95)80107-3; AOKI FY, 1985, CLIN PHARMACOL THER, V37, P137, DOI 10.1038/clpt.1985.25; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1983, NEW ENGL J MED, V308, P1448, DOI 10.1056/NEJM198306163082404; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BALFOUR HH, 1984, J PEDIATR-US, V104, P134, DOI 10.1016/S0022-3476(84)80611-3; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BALFOUR HH, 1988, ANTIMICROBIAL AGENTS, V3, P345; Bell WR, 1997, MEDICINE, V76, P369, DOI 10.1097/00005792-199709000-00004; BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; BIRON KK, 1980, ANTIMICROB AGENTS CH, V18, P443, DOI 10.1128/AAC.18.3.443; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; Bodsworth NJ, 1997, GENITOURIN MED, V73, P110; BOYD MR, 1987, ANTIMICROB AGENTS CH, V31, P1238, DOI 10.1128/AAC.31.8.1238; Carcao MD, 1998, PEDIATR INFECT DIS J, V17, P626, DOI 10.1097/00006454-199807000-00010; COBO LM, 1986, OPHTHALMOLOGY, V93, P763; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; Connor E, 1997, PEDIATRICS, V99, P93; CONNPOWERS MC, 1990, TOP EARLY CHILD SPEC, V9, P91, DOI 10.1177/027112149000900409; Cope AV, 1997, J INFECT DIS, V176, P1484, DOI 10.1086/514145; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DERAY G, 1989, AM J NEPHROL, V9, P316, DOI 10.1159/000167987; DERSE D, 1981, J BIOL CHEM, V256, P1447; DI BA, 1989, NEW ENGL J MED, V321, P1506; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; EARNSHAW DL, 1992, ANTIMICROB AGENTS CH, V36, P2747, DOI 10.1128/AAC.36.12.2747; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; Englund Janet A., 1997, American Journal of Medicine, V102, P61, DOI 10.1016/S0002-9343(97)00014-4; ERICE A, 1987, JAMA-J AM MED ASSOC, V257, P3082, DOI 10.1001/jama.257.22.3082; Erice A, 1997, J INFECT DIS, V175, P1087, DOI 10.1086/516446; ERON LJ, 1986, NEW ENGL J MED, V315, P1059, DOI 10.1056/NEJM198610233151704; Feinberg JE, 1998, J INFECT DIS, V177, P48, DOI 10.1086/513804; Fife KH, 1997, SEX TRANSM DIS, V24, P481, DOI 10.1097/00007435-199709000-00007; FLETCHER CV, 1991, ANTIMICROB AGENTS CH, V35, P938, DOI 10.1128/AAC.35.5.938; FURMAN PA, 1984, J BIOL CHEM, V259, P9575; FYFE JA, 1978, J BIOL CHEM, V253, P8721; Gane E, 1998, LANCET, V351, P454; Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HAMZEH FM, 1991, ANTIMICROB AGENTS CH, V35, P1818, DOI 10.1128/AAC.35.9.1818; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hayden Frederick G., 1997, American Journal of Medicine, V102, P55, DOI 10.1016/S0002-9343(97)80013-7; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P1765, DOI 10.1128/AAC.33.10.1765; Holwerda BC, 1997, ANTIVIR RES, V35, P1, DOI 10.1016/S0166-3542(97)00012-0; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; HUFF JC, 1988, AM J MED, V85, P84; HUGGINS JW, 1991, J INFECT DIS, V164, P1119, DOI 10.1093/infdis/164.6.1119; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; Jacobson MA, 1997, NEW ENGL J MED, V337, P1019; Kimberlin D, 1996, PEDIATR INFECT DIS J, V15, P247, DOI 10.1097/00006454-199603000-00014; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; KROWN SE, 1983, NEW ENGL J MED, V308, P1071, DOI 10.1056/NEJM198305053081806; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; LAZARUS H, 1997, 37 INT C ANT AG CHEM, P226; Levy BT, 1997, J FAM PRACTICE, V45, P473; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; LOWANCE D, IN PRESS N ENGL J ME; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MEYERS JD, 1982, AM J MED, V73, P229, DOI 10.1016/0002-9343(82)90097-3; OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1; PARONI R, 1989, INT J CLIN PHARM TH, V27, P302; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; PROBER CG, 1982, J PEDIATR-US, V101, P622, DOI 10.1016/S0022-3476(82)80725-7; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; SAFRIN S, 1991, ANN INTERN MED, V115, P19, DOI 10.7326/0003-4819-115-1-19; SARAL R, 1981, NEW ENGL J MED, V305, P63, DOI 10.1056/NEJM198107093050202; Scott LL, 1996, OBSTET GYNECOL, V87, P69, DOI 10.1016/0029-7844(95)00357-6; SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759; SPRUANCE SL, 1988, JAMA-J AM MED ASSOC, V260, P1597, DOI 10.1001/jama.260.11.1597; SPRUANCE SL, 1990, J INFECT DIS, V161, P185, DOI 10.1093/infdis/161.2.185; Spruance SL, 1997, JAMA-J AM MED ASSOC, V277, P1374, DOI 10.1001/jama.277.17.1374; SULLIVAN V, 1993, NATURE, V366, P756, DOI 10.1038/366756a0; Tominack R L, 1987, Infect Dis Clin North Am, V1, P459; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; WINTERMEYER SM, 1995, ANN PHARMACOTHER, V29, P299, DOI 10.1177/106002809502900312; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; WRAY SK, 1985, ANTIVIR RES, V5, P29, DOI 10.1016/0166-3542(85)90012-9; WRAY SK, 1985, ANTIVIR RES, V5, P39, DOI 10.1016/0166-3542(85)90013-0	102	226	242	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1255	1268		10.1056/NEJM199904223401608	http://dx.doi.org/10.1056/NEJM199904223401608			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210711				2022-12-28	WOS:000079833800008
J	Coats, TJ; Goode, A				Coats, TJ; Goode, A			Opportunity to improve pre-hospital care in the UK	LANCET			English	Editorial Material									Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Surg, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Coats, TJ (corresponding author), Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Surg, London E1 1BB, England.		Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1292	1292		10.1016/S0140-6736(99)00126-9	http://dx.doi.org/10.1016/S0140-6736(99)00126-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218525				2022-12-28	WOS:000080278100007
J	Kachalova, GS; Popov, AN; Bartunik, HD				Kachalova, GS; Popov, AN; Bartunik, HD			A steric mechanism for inhibition of CO binding to heme proteins	SCIENCE			English	Article							X-RAY STRUCTURE; CARBONMONOXY-MYOGLOBIN; INFRARED CRYSTALLOGRAPHY; MOLECULAR-DYNAMICS; ACTIVE-SITE; MODELS; STEREOCHEMISTRY; HEMOGLOBIN; REFINEMENT; RESOLUTION	The crystal structures of myoglobin in the deoxy- and carbon monoxide-ligated states at a resolution of 1.15 angstroms show that carbon monoxide binding at ambient temperatures requires concerted motions of the heme, the iron, and helices E and F for relief of steric inhibition. These steps constitute the main mechanism by which heme proteins lower the affinity of the heme group for the toxic ligand carbon monoxide.	Max Planck Arbeitsgrp Strukturelle Mol Biol, Arbeitsgrp Prot Dynam, D-22603 Hamburg, Germany	Max Planck Society	Bartunik, HD (corresponding author), Max Planck Arbeitsgrp Strukturelle Mol Biol, Arbeitsgrp Prot Dynam, Notkestr 85, D-22603 Hamburg, Germany.		Popov, Alexander/A-8827-2008; Kachalova, Galina S/J-9437-2015	Kachalova, Galina S/0000-0002-8240-6287; Popov, Alexander/0000-0002-3058-8912				CASE DA, 1978, J MOL BIOL, V123, P697, DOI 10.1016/0022-2836(78)90214-0; Collman JP, 1997, J AM CHEM SOC, V119, P3481, DOI 10.1021/ja963945i; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; COTTON FA, 1965, INORG CHEM, V4, P314, DOI 10.1021/ic50025a012; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HU SZ, 1994, J AM CHEM SOC, V116, P11187, DOI 10.1021/ja00103a056; IVANOV D, 1994, J AM CHEM SOC, V116, P4139, DOI 10.1021/ja00088a084; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; JEWSBURY P, 1994, J AM CHEM SOC, V116, P11586, DOI 10.1021/ja00104a056; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; McMahon MT, 1998, J AM CHEM SOC, V120, P4784, DOI 10.1021/ja973272j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; QUILLIN M L, 1992, Biophysical Journal, V61, pA466; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEL A, 1992, BURBO FRODO BIOGRAPH; Sage JT, 1997, J MOL BIOL, V274, P21, DOI 10.1006/jmbi.1997.1367; Sage JT, 1997, APPL SPECTROSC, V51, P568, DOI 10.1366/0003702971940611; SCHEIDT WR, 1981, BIOCHEMISTRY-US, V20, P3653, DOI 10.1021/bi00515a054; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Sheldrick G. M., 1997, SHELXL 97; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; Vitkup D, 1997, NAT STRUCT BIOL, V4, P202, DOI 10.1038/nsb0397-202; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	35	304	305	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					473	476		10.1126/science.284.5413.473	http://dx.doi.org/10.1126/science.284.5413.473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205052				2022-12-28	WOS:000079792200043
J	Shi, HQ; Tsai, WB; Garrison, MD; Ferrari, S; Ratner, BD				Shi, HQ; Tsai, WB; Garrison, MD; Ferrari, S; Ratner, BD			Template-imprinted nanostructured surfaces for protein recognition	NATURE			English	Article							MOLECULAR RECOGNITION; BIOMATERIALS; ENTRAPMENT; ANTIBODIES; ADSORPTION; POLYMERS; WATER	Synthetic materials capable of selectively recognizing proteins are important in separations(1), biosensors(2) and the development of biomedical materials(3-5). The technique of molecular imprinting creates specific recognition sites in polymers by using template molecules(6-9). Molecular recognition is attributed to binding sites that complement molecules in size, shape and chemical functionality(10). But attempts to imprint proteins have met with only limited success(11-15). Here we report a method for imprinting surfaces with protein-recognition sites. We use radio-frequency glow-discharge plasma deposition to form polymeric thin films(16) around proteins coated with disaccharide molecules. The disaccharides become covalently attached to the polymer film, creating polysaccharide-like cavities that exhibit highly selective recognition for a variety of template proteins, including albumin, immunoglobulin G, lysozyme, ribonuclease and streptavidin, Direct imaging of template recognition is achieved by patterning a surface at the micrometre scale with imprinted regions.	Univ Washington, Ctr Bioengn, Seattle, WA 98195 USA; Univ Trento, Trento, Italy; Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Trento; University of Washington; University of Washington Seattle	Ratner, BD (corresponding author), Univ Washington, Ctr Bioengn, Box 351720, Seattle, WA 98195 USA.		Tsai, Wei-Bor/B-7953-2011					Andrade JD, 1985, SURFACE INTERFACIAL, P1; Ariga K, 1998, ACCOUNTS CHEM RES, V31, P371, DOI 10.1021/ar970014i; Bernard A, 1998, LANGMUIR, V14, P2225, DOI 10.1021/la980037l; BRASH JL, 1991, ACS ADV CHEM SERIES, V199, P3; BYFIELD MP, 1994, BIOSENS BIOELECTRON, V9, P373, DOI 10.1016/0956-5663(94)80038-3; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; CROWE JH, 1990, CRYOBIOLOGY, V27, P219, DOI 10.1016/0011-2240(90)90023-W; GLAD M, 1985, J CHROMATOGR, V347, P11, DOI 10.1016/S0021-9673(01)95465-2; Hjerten S, 1997, CHROMATOGRAPHIA, V44, P227, DOI 10.1007/BF02466386; HORBATSCH M, 1986, Z PHYS D ATOM MOL CL, V2, P183, DOI 10.1007/BF01429072; Horbett TA, 1993, CARDIOVASC PATHOL, V2, P137, DOI DOI 10.1016/1054-8807(93)90054-6); James CD, 1998, LANGMUIR, V14, P741, DOI 10.1021/la9710482; KEMPE M, 1995, J MOL RECOGNIT, V8, P35, DOI 10.1002/jmr.300080106; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; MALLICK N, 1994, BIOMETALS, V7, P299; Mosbach K, 1996, BIO-TECHNOL, V14, P163, DOI 10.1038/nbt0296-163; Nock S, 1997, FEBS LETT, V414, P233, DOI 10.1016/S0014-5793(97)01040-5; NORDE W, 1992, COLLOID SURFACE, V66, P73, DOI 10.1016/0166-6622(92)80122-I; Paleos CM, 1997, ADV MATER, V9, P695, DOI 10.1002/adma.19970090904; Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D; RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702; SHEA KJ, 1994, TRENDS POLYM SCI, V2, P166; SHI H, UNPUB ADV MAT; SHI H, IN PRESS J BIOMED MA; SHIRAHAMA H, 1990, J COLLOID INTERF SCI, V139, P177, DOI 10.1016/0021-9797(90)90455-W; STEINKE J, 1995, ADV POLYM SCI, V123, P80; VENTON DL, 1995, BBA-PROTEIN STRUCT M, V1250, P117, DOI 10.1016/0167-4838(95)00079-A; VIJAYALAKSHMI MA, 1989, TRENDS BIOTECHNOL, V7, P71, DOI 10.1016/0167-7799(89)90067-X; WEAVER DR, 1992, BIOMATERIALS, V13, P577, DOI 10.1016/0142-9612(92)90025-J; WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121; Yu C, 1997, J ORG CHEM, V62, P4057, DOI 10.1021/jo961784v	31	583	630	4	291	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					593	597		10.1038/19267	http://dx.doi.org/10.1038/19267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217142				2022-12-28	WOS:000079754700050
J	Siegel, MJ; Evens, RG				Siegel, MJ; Evens, RG			Advances in the use of computed tomography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNENHANCED HELICAL CT; SPIRAL CT; PULMONARY-EMBOLISM; URETERAL CALCULI; APPENDICITIS; DIAGNOSIS		Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Siegel, MJ (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd, St Louis, MO 63110 USA.	siegelm@mirlink.wustl.edu						Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; Bell TV, 1998, RADIOLOGY, V207, P363, DOI 10.1148/radiology.207.2.9577482; Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; Federle MP, 1998, RADIOGRAPHICS, V18, P1555, DOI 10.1148/radiographics.18.6.9821199; Fielding JR, 1998, AM J ROENTGENOL, V171, P1051, DOI 10.2214/ajr.171.4.9762995; Fiorino AS, 1998, ANN INTERN MED, V128, P839, DOI 10.7326/0003-4819-128-10-199805150-00008; Garg K, 1998, RADIOLOGY, V208, P201, DOI 10.1148/radiology.208.1.9646814; Ha HK, 1998, AM J ROENTGENOL, V171, P1587, DOI 10.2214/ajr.171.6.9843293; Hara AK, 1997, RADIOLOGY, V205, P59, DOI 10.1148/radiology.205.1.9314963; Kaatee R, 1997, RADIOLOGY, V205, P121, DOI 10.1148/radiology.205.1.9314973; Levine JA, 1997, RADIOLOGY, V204, P27, DOI 10.1148/radiology.204.1.9205218; Mayo JR, 1997, RADIOLOGY, V205, P447, DOI 10.1148/radiology.205.2.9356627; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Remy-Jardin M, 1998, RADIOLOGY, V208, P761, DOI 10.1148/radiology.208.3.9722857; Rhea JT, 1997, AM J ROENTGENOL, V169, P113, DOI 10.2214/ajr.169.1.9207509	15	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1252	1254		10.1001/jama.281.14.1252	http://dx.doi.org/10.1001/jama.281.14.1252			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208125				2022-12-28	WOS:000079628700001
J	Reidpath, DD; Glasziou, PP; Del Mar, C				Reidpath, DD; Glasziou, PP; Del Mar, C			Systematic review of autoinflation for treatment of glue ear in children	BRITISH MEDICAL JOURNAL			English	Article							SECRETORY OTITIS-MEDIA; MIDDLE-EAR; EFFUSION		Univ Queensland, Grad Med Sch, Herston, Qld 4006, Australia	University of Queensland	Reidpath, DD (corresponding author), Deakin Univ, Sch Hlth Sci, Burwood, Vic 3125, Australia.		Del Mar, Chris B/B-1136-2008; Glasziou, Paul/A-7832-2008	Del Mar, Chris B/0000-0003-3821-8163; Glasziou, Paul/0000-0001-7564-073X; Reidpath, Daniel/0000-0002-8796-0420				BLANSHARD JD, 1993, CLIN OTOLARYNGOL, V18, P188; BROOKER DS, 1992, CLIN OTOLARYNGOL, V17, P289, DOI 10.1111/j.1365-2273.1992.tb00997.x; CHAN KH, 1989, OTOLARYNG HEAD NECK, V100, P317, DOI 10.1177/019459988910000412; FRASER JG, 1977, J LARYNGOL OTOL, V91, P757, DOI 10.1017/S0022215100084334; STANGERUP SE, 1992, ARCH OTOLARYNGOL, V118, P149	5	22	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1177	1177						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221942				2022-12-28	WOS:000080277900029
J	Cashmore, AR; Jarillo, JA; Wu, YJ; Liu, DM				Cashmore, AR; Jarillo, JA; Wu, YJ; Liu, DM			Cryptochromes: Blue light receptors for plants and animals	SCIENCE			English	Review							DISRUPTS CIRCADIAN-RHYTHMS; DNA PHOTOLYASE; PHOTORECEPTOR FAMILY; ELECTRON-TRANSFER; ESCHERICHIA-COLI; PHYTOCHROME-A; PROTEIN; CLOCK; DROSOPHILA; PHOTOTROPISM	Cryptochromes are blue, ultraviolet-A photoreceptors. They were first characterized for Arabidopsis and are also found in ferns and algae; they appear to be ubiquitous in the plant kingdom. They are flavoproteins similar in sequence to photolyases, their presumptive evolutionary ancestors. Cryptochromes mediate a variety of Light responses, including entrainment of circadian rhythms in Arabidopsis, Drosophila, and mammals. Sequence comparison indicates that the plant and animal cryptochrome families have distinct evolutionary histories, with the plant cryptochromes being of ancient evolutionary origin and the animal cryptochromes having evolved relatively recently. This process of repeated evolution may have coincided with the origin in animals of a modified circadian clock based on the PERIOD, TIMELESS, CLOCK, and CYCLE proteins.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Cashmore, AR (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	cashmore@upenn.sas.edu		wu, yingjie/0000-0002-2694-1971; Jarillo, Jose Antonio/0000-0002-2963-7641	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051956] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38409, GM51956] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Barinaga M, 1998, SCIENCE, V282, P1628, DOI 10.1126/science.282.5394.1628; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Cseke L, 1998, MOL BIOL EVOL, V15, P1491, DOI 10.1093/oxfordjournals.molbev.a025876; Darwin CR., 1881, POWER MOVEMENT PLANT; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Furuya Masaki, 1994, P105; GALSTON AW, 1950, SCIENCE, V111, P619, DOI 10.1126/science.111.2893.619; GRESSEL J, 1979, PHOTOCHEM PHOTOBIOL, V30, P749, DOI 10.1111/j.1751-1097.1979.tb07209.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Janoudi AK, 1997, PHYSIOL PLANTARUM, V101, P278, DOI 10.1034/j.1399-3054.1997.1010204.x; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kanegae T, 1998, MOL GEN GENET, V259, P345, DOI 10.1007/s004380050821; KIM ST, 1991, BIOCHEMISTRY-US, V30, P11262, DOI 10.1021/bi00111a011; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; SMALL GD, 1995, PLANT MOL BIOL, V28, P443, DOI 10.1007/BF00020393; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x	50	725	778	8	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					760	765		10.1126/science.284.5415.760	http://dx.doi.org/10.1126/science.284.5415.760			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221900				2022-12-28	WOS:000080056200034
J	Beecham, L				Beecham, L			Scottish juniors resume talks on hours of work	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205127				2022-12-28	WOS:000080140000079
J	Niklason, LE; Gao, J; Abbott, WM; Hirschi, KK; Houser, S; Marini, R; Langer, R				Niklason, LE; Gao, J; Abbott, WM; Hirschi, KK; Houser, S; Marini, R; Langer, R			Functional arteries grown in vitro	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; BLOOD-VESSEL; CONSCIOUS DOGS; COLLAGEN; ELASTIN; VEIN; DIFFERENTIATION; PATHOGENESIS; DENSITY	A tissue engineering approach was developed to produce arbitrary lengths of vascular graft material from smooth muscle and endothelial cells that were derived from a biopsy of vascular tissue. Bovine vessels cultured under pulsatile conditions had rupture strengths greater than 2000 millimeters of mercury, suture retention strengths of up to 90 grams, and collagen contents of up to 50 percent. Cultured vessels also showed contractile responses to pharmacological agents and contained smooth muscle cells that displayed markers of differentiation such as calponin and myosin heavy chains. Tissue-engineered arteries were implanted in miniature swine, with patency documented up to 24 days by digital angiography.	Duke Univ, Dept Anesthesia, Durham, NC 27710 USA; Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; MIT, Dept Comparat Med, Cambridge, MA 02139 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Duke University; Duke University; Case Western Reserve University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Niklason, LE (corresponding author), Duke Univ, Dept Anesthesia, Durham, NC 27710 USA.	nikla001@mc.duke.edu			NHLBI NIH HHS [K08HL03492, HL60435] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003492, R01HL060435] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMENTANO RL, 1991, AM J PHYSIOL, V260, pH1870, DOI 10.1152/ajpheart.1991.260.6.H1870; *ASS ADV MED INSTR, 1994, AM NAT STAND CARD IM; BARRA JG, 1993, CIRC RES, V73, P1040, DOI 10.1161/01.RES.73.6.1040; Caro C. G., 2012, MECH CIRCULATION, VSecond; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; CROSS KS, 1994, BRIT J SURG, V81, P699, DOI 10.1002/bjs.1800810524; Davidson JM, 1997, J BIOL CHEM, V272, P345, DOI 10.1074/jbc.272.1.345; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DODGE AB, 1993, J CELL BIOCHEM, V53, P21, DOI 10.1002/jcb.240530104; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; Gao JM, 1998, J BIOMED MATER RES, V42, P417, DOI 10.1002/(SICI)1097-4636(19981205)42:3<417::AID-JBM11>3.0.CO;2-D; Greisler HP, 1996, BIOMATERIALS, V17, P329, DOI 10.1016/0142-9612(96)85571-2; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; LLTALIEN GJ, 1994, AM J PHYSIOL, V267, pH574; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; Owens GK, 1996, CIRC RES, V79, P1054, DOI 10.1161/01.RES.79.5.1054; OWENS GK, 1995, PHYSIOL REV, V75, P487; Rao SK, 1996, ANN NY ACAD SCI, V800, P131; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sayers RD, 1998, BRIT J SURG, V85, P934; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	30	1308	1437	5	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					489	493		10.1126/science.284.5413.489	http://dx.doi.org/10.1126/science.284.5413.489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205057				2022-12-28	WOS:000079792200048
J	Rodriguez, I; Feinstein, P; Mombaerts, P				Rodriguez, I; Feinstein, P; Mombaerts, P			Variable patterns of axonal projections of sensory neurons in the mouse vomeronasal system	CELL			English	Article							PUTATIVE PHEROMONE RECEPTORS; GREEN FLUORESCENT PROTEIN; ACCESSORY OLFACTORY-BULB; MULTIGENE FAMILY; GENE-EXPRESSION; ODORANT RECEPTORS; MOLECULAR-BASIS; ORGANIZATION; MAMMALS; MAP	The vomeronasal system mediates pheromonal effects in mammals. We have employed gene targeting technology to introduce mutations in a putative pheromone receptor gene, VR(i)2, in the germline of mice. By generating alleles differentially tagged with the histological markers taulacZ and tauGFP, we show that VR(i)2 is monoallelically expressed in a given neuron. Axons of VR(i)2-expressing neurons converge onto numerous glomeruli in the accessory olfactory bulb. The pattern of axonal projections is complex and variable. This wiring diagram is substantially different from that of the main olfactory system. The projection pattern is disrupted by deleting the coding region of VR(i)2, but an unrelated seven-transmembrane protein, the odorant receptor M71, can partially substitute for VR(i)2.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			rodriguez, ivan/0000-0002-6468-0565				Berghard A, 1996, J NEUROSCI, V16, P909; BRAND A, 1995, TRENDS GENET, V11, P324, DOI 10.1016/S0168-9525(00)89091-5; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CAJAL SRY, 1911, HISTOLOGIE SYSTEME N, V2, P647; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chess A, 1998, ADV IMMUNOL, V69, P437, DOI 10.1016/S0065-2776(08)60613-6; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; FARBMAN AI, 1992, CELL BIOL OLFACTION; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LANCET D, 1994, NATURE, V372, P321, DOI 10.1038/372321a0; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Meisami E, 1998, MICROSC RES TECHNIQ, V43, P476, DOI 10.1002/(SICI)1097-0029(19981215)43:6<476::AID-JEMT2>3.3.CO;2-M; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Saito H, 1998, MOL BRAIN RES, V60, P215, DOI 10.1016/S0169-328X(98)00183-1; Silver LM, 1995, MOUSE GENETICS CONCE, P3; Sorensen PW, 1996, CHEM SENSES, V21, P245, DOI 10.1093/chemse/21.2.245; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	46	299	309	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					199	208		10.1016/S0092-8674(00)80730-8	http://dx.doi.org/10.1016/S0092-8674(00)80730-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219241	Bronze			2022-12-28	WOS:000079779800009
J	Morrow, AL; Guerrero, ML; Shults, J; Calva, JJ; Lutter, C; Bravo, J; Ruiz-Palacios, G; Morrow, RC; Butterfoss, FD				Morrow, AL; Guerrero, ML; Shults, J; Calva, JJ; Lutter, C; Bravo, J; Ruiz-Palacios, G; Morrow, RC; Butterfoss, FD			Efficacy of home-based peer counselling to promote exclusive breastfeeding: a randomised controlled trial	LANCET			English	Article							INFANT-FEEDING PRACTICES; BREAST-FED INFANTS; LATIN-AMERICAN; HUMAN-MILK; PROTECTION; DIARRHEAL; DISEASES; SUCCESS; HEALTH; INFECTION	Background Exclusive breastfeeding is recommended worldwide but not commonly practised. We undertook a randomised controlled study of the efficacy of home-based peer counselling to increase the proportion of exclusive breastfeeding among mothers and infants residing in periurban Mexico City. Methods Two intervention groups with different counselling frequencies, six visits (44) and three visits (52), were compared with a control group (34) that had no intervention. From March, 1995, to September, 1996, 170 pregnant women were identified by census and invited to participate in the study. Home visits were made during pregnancy and early post partum by peer counsellors recruited from the same community and trained by La Leche League. Data were collected by independent interview. Exclusive breastfeeding was defined by WHO criteria. Findings 130 women participated in the study. Only 12 women refused participation. Study groups did not differ in baseline factors. At 3 months post partum, exclusive breastfeeding was practised by 67% of six-visit, 50% of three-visit, and 12% of control mothers (intervention groups vs controls, p<0.001; six-visit vs three-visit, p=0.02). Duration of breastfeeding was significantly (p=0.02) longer in intervention groups than in controls, and fewer-intervention than control infants had an episode of diarrhoea (12% vs 26%, p=0.03). Interpretation This is the first reported community-based randomised trial of breastfeeding promotion. Early and repeated contact with peer counsellors was associated with a significant increase in breastfeeding exclusivity and duration. The two-fold decrease in diarrhoea demonstrates the importance of breastfeeding promotion to infant health.	Childrens Hosp Kings Daughters, Eastern Virginia Med Sch, Ctr Pediat Res, Norfolk, VA 23510 USA; Inst Nacl Nutr, Dept Infectol, Mexico City, DF, Mexico; Panamer Hlth Org, Washington, DC USA; La Leche League Mexico, Mexico City, DF, Mexico	Eastern Virginia Medical School	Morrow, AL (corresponding author), Childrens Hosp Kings Daughters, Eastern Virginia Med Sch, Ctr Pediat Res, Norfolk, VA 23510 USA.		Morrow, Ardythe/GQO-8482-2022; Ruiz-Palacios, Guillermo/GYQ-5462-2022	Calva, Juan/0000-0002-8693-8942	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armstrong H C, 1991, J Hum Lact, V7, P51, DOI 10.1177/089033449100700201; BROWN KH, 1989, PEDIATRICS, V83, P31; BURKHALTER BR, 1991, INT J GYNECOL OBSTET, V34, P353, DOI 10.1016/0020-7292(91)90604-4; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; DIMOND HJ, 1987, J HUM NUTR APPL NU A, V41, P51; Eng E, 1997, HEALTH EDUC BEHAV, V24, P413, DOI 10.1177/109019819702400402; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; FRANK DA, 1987, PEDIATRICS, V80, P845; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; Grummer-Strawn L M, 1997, Matern Child Health J, V1, P35, DOI 10.1023/A:1026224402712; GUERRERO ML, IN PRESS B WHO; Haider R, 1996, B WORLD HEALTH ORGAN, V74, P173; HAYANI KC, 1992, J PEDIATR-US, V121, P852, DOI 10.1016/S0022-3476(05)80327-0; JONES DA, 1986, J EPIDEMIOL COMMUN H, V40, P45, DOI 10.1136/jech.40.1.45; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Kistin N, 1994, J Hum Lact, V10, P11, DOI 10.1177/089033449401000121; KYENKYAISABIRYE M, 1990, INT J GYNECOL OBSTET, V31, P85, DOI 10.1016/0020-7292(90)90084-X; Love MB, 1997, HEALTH EDUC BEHAV, V24, P510, DOI 10.1177/109019819702400409; Lutter CK, 1997, AM J PUBLIC HEALTH, V87, P659, DOI 10.2105/AJPH.87.4.659; LYNCH SA, 1986, CAN J PUBLIC HEALTH, V77, P190; MORROW AL, 1992, J PEDIATR-US, V121, P363, DOI 10.1016/S0022-3476(05)81787-1; Newburg DS, 1998, LANCET, V351, P1160, DOI 10.1016/S0140-6736(97)10322-1; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; PEREZESCAMILLA R, 1995, J NUTR, V125, P2972; PEREZESCAMILLA R, 1992, EARLY HUM DEV, V31, P25, DOI 10.1016/0378-3782(92)90012-6; PEREZESCAMILLA R, 1994, J TROP PEDIATRICS, V40, P137, DOI 10.1093/tropej/40.3.137; POPKIN BM, 1990, PEDIATRICS, V86, P874; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; VALDES V, 1993, J TROP PEDIATRICS, V39, P142, DOI 10.1093/tropej/39.3.142; VICTORA CG, 1987, LANCET, V2, P319; WHO UNICEF, 1989, PROT PROM SUPP BREAS	31	273	286	1	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1226	1231		10.1016/S0140-6736(98)08037-4	http://dx.doi.org/10.1016/S0140-6736(98)08037-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186TB	10217083				2022-12-28	WOS:000079744100011
J	Schafer, DF; Sorrell, MF				Schafer, DF; Sorrell, MF			Hepatocellular carcinoma	LANCET			English	Article							HEPATITIS-B-VIRUS; ETHANOL INJECTION THERAPY; LIVER-CELL DYSPLASIA; PROGNOSTIC FACTORS; ALPHA-FETOPROTEIN; P53; CIRRHOSIS; SURVIVAL; CHEMOEMBOLIZATION; HEMOCHROMATOSIS	Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival Is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection acid improvements in medical techniques for hepatitis C; for which no vaccine has yet been developed.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center	Sorrell, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE USA.							ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217; AUSTIN H, 1991, ETIOLOGY PATHOLOGY T; BEASLEY RP, 1981, LANCET, V2, P1129; BEEBE GW, 1991, ADV AP BIOT, V13, P3; BHATTACHARYA S, 1995, SEMIN LIVER DIS, V15, P390, DOI 10.1055/s-2007-1007289; Bismuth H, 1993, Prog Liver Dis, V11, P269; Bosch FX, 1997, LIVER CANCER, P13; Bruix J, 1997, HEPATOLOGY, V25, P259; CASTELLS A, 1995, GASTROENTEROLOGY, V109, P917, DOI 10.1016/0016-5085(95)90402-6; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COLOMBO M, 1997, LIVER CANCER, P407; COTTONE M, 1994, J HEPATOL, V21, P1029, DOI 10.1016/S0168-8278(05)80613-0; ElAssal ON, 1997, SURGERY, V122, P571, DOI 10.1016/S0039-6060(97)90130-6; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FERRELL L, 1993, AM J SURG PATHOL, V17, P23; Gouillat C, 1997, J HEPATOL, V26, P1324, DOI 10.1016/S0168-8278(97)80468-0; HANLEY AJG, 1995, INT J EPIDEMIOL, V24, P255, DOI 10.1093/ije/24.2.255; HERMANEK P, 1992, UICC TNM CLASSIFICAT; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Ishak KG, 1994, WHO INT CLASSIFICATI; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; KEW MC, 1997, LIVER CANCER, P315; KONDO Y, 1997, LIVER CANCER, P135; KOTOH K, 1994, AM J GASTROENTEROL, V89, P194; Kouroumalis E, 1998, GUT, V42, P442, DOI 10.1136/gut.42.3.442; Kubota K, 1997, HEPATOLOGY, V26, P1176; LAMBERT V, 1991, J GEN VIROL, V72, P417, DOI 10.1099/0022-1317-72-2-417; Lasky T, 1997, ENVIRON HEALTH PERSP, V105, P392, DOI 10.2307/3433335; Leonhardt U, 1997, LANGENBECK ARCH CHIR, V382, P83; Liver Cancer Study Group of Japan, 1992, GEN RUL CLIN PATH ST; Lo CM, 1998, ANN SURG, V227, P527, DOI 10.1097/00000658-199804000-00013; Majno PE, 1997, ANN SURG, V226, P688, DOI 10.1097/00000658-199712000-00006; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NALPAS B, 1995, ALCOHOL CLIN EXP RES, V19, P1089, DOI 10.1111/j.1530-0277.1995.tb01585.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; ODA T, 1994, CANCER LETT, V83, P197, DOI 10.1016/0304-3835(94)90319-0; OKADA S, 1992, HEPATOLOGY, V16, P112, DOI 10.1002/hep.1840160119; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; OKUDA K, 1987, CANCER RES, V47, P4967; OKUDA K, 1997, LIVER CANC, P39; Okuda K, 1997, LIVER CANCER, P435; OKUDA K, 1997, LIVER CANC; PENN I, 1991, SURGERY, V110, P726; ROMANI F, 1992, TRANSPLANTATION, V55, P215; SATO Y, 1993, NEW ENGL J MED, V328, P1802, DOI 10.1056/NEJM199306243282502; SHIINA S, 1993, AM J ROENTGENOL, V160, P1023, DOI 10.2214/ajr.160.5.7682378; Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736; SPIESSEL B, 1989, TMN ATLAS; STUART K, 1993, CANCER, V72, P3202, DOI 10.1002/1097-0142(19931201)72:11<3202::AID-CNCR2820721112>3.0.CO;2-4; SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215; Tabor E, 1991, ETIOLOGY PATHOLOGY T; TAKADA A, 1993, GASTROENTEROL JPN, V28, P137; TAKAYASU K, 1997, IMAGING LIVER DIS; TOBE T, 1994, CANCER-AM CANCER SOC, V74, P2772, DOI 10.1002/1097-0142(19941115)74:10<2772::AID-CNCR2820741006>3.0.CO;2-V; TRICHET JC, 1997, J HEPATOL, V27, P756; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; VANTHIEL DH, 1991, ADV AP BIOT, V13, P309; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATANABE S, 1983, CANCER, V51, P2197, DOI 10.1002/1097-0142(19830615)51:12<2197::AID-CNCR2820511208>3.0.CO;2-5	63	481	504	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1999	353	9160					1253	1257		10.1016/S0140-6736(98)09148-X	http://dx.doi.org/10.1016/S0140-6736(98)09148-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217098				2022-12-28	WOS:000079744100040
J	Birmingham, CL				Birmingham, CL			Total parenteral nutrition in the critically ill patient	LANCET			English	Editorial Material							SURGERY		Univ British Columbia, Div Internal Med, Vancouver, BC V6Z 1Y6, Canada	University of British Columbia	Birmingham, CL (corresponding author), Univ British Columbia, Div Internal Med, Vancouver, BC V6Z 1Y6, Canada.			Birmingham, Carl/0000-0003-4331-2664				[Anonymous], 1993, JPEN-PARENTER ENTER, V17, pSA1; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BUZBY G P, 1991, New England Journal of Medicine, V325, P525; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; Doglietto GB, 1996, ANN SURG, V223, P357, DOI 10.1097/00000658-199604000-00003; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013	9	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1999	353	9159					1116	1117		10.1016/S0140-6736(99)00006-9	http://dx.doi.org/10.1016/S0140-6736(99)00006-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209972				2022-12-28	WOS:000079858400005
J	de Silva, NR; Sirisena, JLGJ; Gunasekera, DPS; Ismail, MM; de Silva, HJ				de Silva, NR; Sirisena, JLGJ; Gunasekera, DPS; Ismail, MM; de Silva, HJ			Effect of mebendazole therapy during pregnancy on birth outcome	LANCET			English	Article								Background In areas endemic for hookworm, routine antenatal mebendazole therapy could greatly reduce the prevalence of anaemia in pregnancy. At present, however, this is not a widely accepted control strategy because of a lack of data on the safety of the drug. We assessed the effect of mebendazole therapy during pregnancy on birth outcome. Methods A cross-sectional study was done in Sri Lanka, where prescription of mebendazole to women in the second trimester of pregnancy is recommended. Two hospitals were chosen for the study, and women who gave birth there between May, 1996, and March, 1997, were recruited. We compared the rates of major congenital defects, stillbirth, perinatal death, and low birthweight (less than or equal to 1500 g) among babies of mothers who had taken mebendazole during pregnancy with those whose mothers had not taken an anthelmintic (controls). Findings The rate of major congenital defects was not significantly higher in the mebendazole group than in the control group (97 [1.8%] of 5275 vs 26 [1.5%] of 1737; odds ratio 1.24 [95% CI 0.8-1.91], p=0.39). Among 407 women who had taken mebendazole in the first trimester (contrary to medical advice), 10 (2.5%) had major congenital defects (odds ratio vs controls 1.66 [0.81-3.56], p=0.23). The proportions of stillbirths and perinatal deaths were significantly lower in the mebendazole group (1.9 vs 3.3%, 0.55 [95% CI 0.4-0.77]), as was the proportion of low-birthweight babies (1.1 vs 2.3%, 0.47 [95% CI 0.32-0.71]). Interpretation Mebendazole therapy during pregnancy is not associated with a significant increase in major congenital defects, but our results indicate that it should be avoided during the first trimester. This therapy could offer beneficial effects to pregnant women in developing countries, where intestinal helminthiases are endemic.	Univ Kelaniya, Fac Med, Dept Parasitol, Ragama, Sri Lanka; Univ Colombo, Fac Med, Colombo, Sri Lanka	University Kelaniya; University of Colombo	de Silva, NR (corresponding author), Univ Kelaniya, Fac Med, Dept Parasitol, POB 6, Ragama, Sri Lanka.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				[Anonymous], 1994, NAT STRAT BROAD PLAN; ATUKORALA TMS, 1994, AM J CLIN NUTR, V60, P286, DOI 10.1093/ajcn/60.2.286; Auer H., 1994, Applied Parasitology, V35, P146; BASKERVILLE M, 1988, LAB ANIM, V22, P263, DOI 10.1258/002367788780746412; DELATOUR P, 1976, THERAPIE, V31, P505; deSilva N, 1997, DRUGS, V53, P769, DOI 10.2165/00003495-199753050-00004; DOLLERY C, 1991, THERAPEUTIC DRUGS, V2, pM12; GILMAN AG, 1992, GOODMAN GILMANS PHAR, V2, P964; *GOV SRI LANK MIN, 1997, ANN HLTH B 1996; GRAHAMESMITH DG, 1992, OXFORD TXB CLIN PHAR, P248; LEACH FN, 1990, ARCH DIS CHILD, V65, P399, DOI 10.1136/adc.65.4.399; NEVIN C, 1982, CLIN OBSTET GYNECOL, V9, P3; Pawlowski ZS, 1991, HOOKWORM INFECT ANAE; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA; SHEPARD TH, 1983, CATALOG TERATOGENIC; SIRISENA J, 1993, KANDY MED J, V2, P58; Sorensen Eigil, 1996, Ceylon Medical Journal, V41, P37; WHO, 1994, WHOCTDSIP961; WHO, 1996, WORLD HLTH REP 1996, P43; WHO, 1997, WORLD HLTH REP 1997, P51	20	96	99	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1145	1149		10.1016/S0140-6736(98)06308-9	http://dx.doi.org/10.1016/S0140-6736(98)06308-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209979				2022-12-28	WOS:000079858400013
J	Zinn, K; Sun, Q				Zinn, K; Sun, Q			Slit branches out: A secreted protein mediates both attractive and repulsive axon guidance	CELL			English	Review							CNS MIDLINE; NERVOUS-SYSTEM; DROSOPHILA; CHEMOREPULSION; ROUNDABOUT; EGF		CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Zinn, K (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	zinnk@cco.caltech.edu						Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BATTYE R, 1999, IN PRESS DEVELOPMENT; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GUTHRIE S, 1995, NEURON, V14, P1117, DOI 10.1016/0896-6273(95)90260-0; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	18	67	68	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					1	4		10.1016/S0092-8674(00)80707-2	http://dx.doi.org/10.1016/S0092-8674(00)80707-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199395	Bronze			2022-12-28	WOS:000079843900001
J	Pollock, AM				Pollock, AM			Devolution and health: challenges for Scotland and Wales	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1 9EZ, England	University of London; University College London	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1 9EZ, England.			pollock, allyson/0000-0002-7388-3110				ASHCROFT B, 1999, Q EC COMMENTARY, V25, P1; Carstairs V., 1991, DEPRIVATION HLTH SCO; *DEP HLTH, 1998, STAT B, V13; DREVER F, 1997, HLTH INEQUALITIES; EDWARDS P, 1998, COMMUNITY CARE TREND; GINN J, 1999, STAT SOC, P115; *GOV STAT SERV, 1997, REG TRENDS, V32; *GOV STAT SERV, 1998, REG TRENDS, V33; Heald D., 1998, REGIONAL FEDERAL STU, V8, P23; HM Treasury, 1999, MOD BRIT TAX BEN SYS; MACFARLANE A, 1999, STAT SOC, P252; Marang-van de Mheen PJ, 1998, J EPIDEMIOL COMMUN H, V52, P214, DOI 10.1136/jech.52.4.214; MORGAN K, 1988, OTHER WALES CASE OBJ; *STAT OFF, 1997, 2 STAT OFF; *STAT OFF, 1997, 4 STAT OFF; TWIGGER R, 1998, 988 EC STAT SECT HOU	16	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1195	1198						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221950				2022-12-28	WOS:000080277900037
J	Sawyers, CL				Sawyers, CL			Chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW TRANSPLANTATION; BCR-ABL ONCOGENE; POLYMERASE CHAIN-REACTION; TYROSINE KINASE-ACTIVITY; HEMATOPOIETIC-CELL LINES; BCR/ABL TRANSGENIC MICE; DNA-BINDING ACTIVITY; VERSUS-HOST DISEASE; PHILADELPHIA-CHROMOSOME		Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Sawyers, Charles/G-5327-2016					Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ARCESE W, 1993, BLOOD, V82, P3211; BARNETT MJ, 1994, BLOOD, V84, P724; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BEELEN DW, 1995, BLOOD, V85, P2981, DOI 10.1182/blood.V85.10.2981.bloodjournal85102981; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; Carella AM, 1996, BONE MARROW TRANSPL, V17, P201; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Choudhury A, 1997, BLOOD, V89, P1133, DOI 10.1182/blood.V89.4.1133; Clift RA, 1997, BAILLIERE CLIN HAEM, V10, P319, DOI 10.1016/S0950-3536(97)80010-8; Cortez D, 1996, ONCOGENE, V13, P2589; CROSS NCP, 1993, BLOOD, V82, P1929; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEFABRITIIS P, 1995, LEUKEMIA, V9, P662; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DROBYSKI WR, 1993, BLOOD, V82, P2310; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EVANS CA, 1993, CANCER RES, V53, P1735; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GEWIRTZ AM, 1994, BONE MARROW TRANSPL, V14, pS57; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GIRALT SA, 1993, J CLIN ONCOL, V11, P1055, DOI 10.1200/JCO.1993.11.6.1055; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; HEHLMANN R, 1994, BLOOD, V84, P41064; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Higano CS, 1997, BLOOD, V90, P2549, DOI 10.1182/blood.V90.7.2549.2549_2549_2554; HOCHHAUS A, 1995, BRIT J HAEMATOL, V91, P126, DOI 10.1111/j.1365-2141.1995.tb05257.x; Horowitz MM, 1996, BONE MARROW TRANSPL, V17, pS5; HUGHES TP, 1991, BLOOD, V77, P874; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KELLIHER M, 1990, P NATL ACAD SCI USA, V87, P9072; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Lardon F, 1997, IMMUNOLOGY, V91, P553, DOI 10.1046/j.1365-2567.1997.00295.x; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; MANDANAS RA, 1993, BLOOD, V82, P1838; McGlave P., 1996, Blood, V88, p483A; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MIYAMURA K, 1993, BLOOD, V81, P1089; NICHOLS GL, 1994, BLOOD, V84, P2912; Nieda M, 1998, BLOOD, V91, P977, DOI 10.1182/blood.V91.3.977.977_977_983; Nishii K, 1996, ONCOGENE, V13, P2225; NOWELL PC, 1960, SCIENCE, V132, P1497; OBrien SG, 1997, BAILLIERE CLIN HAEM, V10, P369, DOI 10.1016/S0950-3536(97)80013-3; ODA T, 1994, J BIOL CHEM, V269, P22925; OHNISHI K, 1995, BLOOD, V86, P906; OKUDA K, 1994, EXP HEMATOL, V22, P1111; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PANE F, 1997, BLOOD, V89, P4244; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; RADICH JP, 1995, BLOOD, V85, P2632, DOI 10.1182/blood.V85.9.2632.bloodjournal8592632; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REIFFERS J, 1994, BONE MARROW TRANSPL, V14, P407; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; SHARP JC, 1979, LANCET, V1, P1370; Shuai K, 1996, ONCOGENE, V13, P247; SILL H, 1995, BLOOD, V85, P2013, DOI 10.1182/blood.V85.8.2013.bloodjournal8582013; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SMALLEY RV, 1977, BLOOD, V50, P107; TALPAZ M, 1983, BLOOD, V62, P689; TENHOEVE J, 1994, BLOOD, V84, P1731; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; Toren A, 1995, MED ONCOL, V12, P177, DOI 10.1007/BF01571195; TURA S, 1994, NEW ENGL J MED, V330, P820; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; vanRhee F, 1997, BONE MARROW TRANSPL, V20, P553, DOI 10.1038/sj.bmt.1700933; Verfaillie CM, 1996, BLOOD, V87, P4770, DOI 10.1182/blood.V87.11.4770.bloodjournal87114770; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zuffa E, 1998, HAEMATOLOGICA, V83, P231	100	1117	1180	1	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1330	1340		10.1056/NEJM199904293401706	http://dx.doi.org/10.1056/NEJM199904293401706			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219069				2022-12-28	WOS:000080001700006
J	Schaeffer, EM; Debnath, J; Yap, G; McVicar, D; Liao, XC; Littman, DR; Sher, A; Varmus, HE; Lenardo, MJ; Schwartzberg, PL				Schaeffer, EM; Debnath, J; Yap, G; McVicar, D; Liao, XC; Littman, DR; Sher, A; Varmus, HE; Lenardo, MJ; Schwartzberg, PL			Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity	SCIENCE			English	Article							TYROSINE KINASES; ANTIGEN RECEPTOR; PROTEIN-KINASE; TRANSDUCTION; PHOSPHORYLATION; RESISTANCE; ACTIVATION; FAMILY; MICE	T cell receptor (TCR) signaling requires activation of Zap-70 and Src family tyrosine kinases, but requirements for other tyrosine kinases are Less clear. Combined deletion in;mice of two Tec kinases, Rlk and Itk, caused marked defects in TCR responses including proliferation, cytokine production, and apoptosis in vitro and adaptive:immune responses to Toxoplasma gondii in vivo. Molecular events immediately downstream from the TCR were intact in rlk(-/-)itk(-/-) cells, but intermediate events including inositol trisphosphate production, calcium mobilization, and mitogen-activated protein kinase activation were impaired, establishing Tec kinases as critical regulators of TCR signaling required for phospholipase C-gamma activation.	Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; Tularik, S San Francisco, CA 94080 USA; NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); New York University	Schwartzberg, PL (corresponding author), Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA.			McVicar, Daniel/0000-0002-1112-5111; Debnath, Jayanta/0000-0002-8745-4069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000627] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachmann MF, 1997, J VIROL, V71, P7253, DOI 10.1128/JVI.71.10.7253-7257.1997; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Denkers EY, 1997, J IMMUNOL, V159, P1903; DESIDERIO S, 1994, CHEM IMMUNOL, V59, P191; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; SCHAEFFER E, UNPUB; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SchartonKersten TM, 1997, CURR OPIN IMMUNOL, V9, P44, DOI 10.1016/S0952-7915(97)80157-4; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SOZERI O, 1992, ONCOGENE, V7, P2259; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	21	324	342	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					638	641		10.1126/science.284.5414.638	http://dx.doi.org/10.1126/science.284.5414.638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213685				2022-12-28	WOS:000079951100043
J	Kenny-Walsh, E				Kenny-Walsh, E		Irish Hepatol Res Grp	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D IMMUNOGLOBULIN; NATURAL-HISTORY; BLOOD-DONORS; NON-A; POSTTRANSFUSION HEPATITIS; VIRUS-INFECTION; LIVER-DISEASE; FOLLOW-UP; TRANSMISSION; TRANSFUSION	Background and Methods In February 1994, batches of anti-D immune globulin used in Ireland during 1977 and 1978 to prevent Rh isoimmunization were found to be contaminated with hepatitis C virus (HCV) from a single infected donor. In March 1994, a national screening program was initiated for all women who had received anti-D immune globulin between 1970 and 1994. Of the 62,667 women who had been screened when this study began, 704 (1.1 percent) had evidence of past or current HCV infection, and 390 of those 704 (55 percent) had positive tests for serum HCV RNA on reverse-transcription-polymerase-chain-reaction analysis. All 390 Were offered a referral for clinical assessment and therapy. We evaluated 376 of these 390 women (96 percent); the other 14 were not seen at one of the designated treatment centers. Results The mean (+/-SD) age of the 376 women was 45+/-6 years at the time of screening. They had been infected with hepatitis C for about 17 years. A total of 304 women (81 percent) reported symptoms, most commonly fatigue (248 women [66 percent]). Serum alanine aminotransferase concentrations were slightly elevated (40 to 99 U per liter) in 176 of 371 women (47 percent), and the concentrations were 100 U per liter or higher in 31 (8 percent). Liver biopsies showed inflammation in 356 of 363 women (98 percent); in most cases the inflammation was slight (41 percent) or moderate (52 percent). Although the biopsy samples from 186 of the 363 women (51 percent) showed evidence of fibrosis, only 7 women (2 percent) had probable or definite cirrhosis. Two of the seven reported excessive alcohol consumption. Conclusions Most of the women with HCV infection 17 years after receiving HCV-contaminated anti-D immune globulin had evidence of slight or moderate hepatic inflammation on liver biopsy, about half had fibrosis, and 2 percent had probable or definite cirrhosis, (N Engl J Med 1999;340:1228-33.) (C) 1999, Massachusetts Medical Society.	Cork Univ Hosp, Dept Med, Cork, Ireland	University College Cork	Kenny-Walsh, E (corresponding author), Cork Univ Hosp, Dept Med, Cork, Ireland.							ALTER HJ, 1993, VIRAL HEPATITIS SCI, P467; ALTER MJ, 1994, NEW ENGL J MED, V330, P784, DOI 10.1056/NEJM199403173301111; Armitage P., 2001, STAT METHODS MED RES; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; *BLOOD TRANSF SERV, 1995, REP EXP GROUP BLOOD; BRECHOT CB, 1993, MOL DIAGN, V1, P2; *CENTR STAT OFF, 1977, ANN VIT STAT; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Dienstag JL, 1997, GASTROENTEROLOGY, V112, P651, DOI 10.1053/gast.1997.v112.agast970651; DITTMANN S, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P422; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; FINLAY TA, 1997, REPORT TRIBUNAL INQU, P176; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LUDWIG J, 1994, AM J GASTROENTEROL, V89, pS177; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; Muller R, 1996, J HEPATOL, V24, P52; NISHIOKA K, 1991, LANCET, V338, P1040; PATON A, 1981, BRIT MED J, V283, P1248, DOI 10.1136/bmj.283.6301.1248; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; POWER JP, 1995, LANCET, V345, P1211, DOI 10.1016/S0140-6736(95)91993-7; Poynard T, 1996, NEW ENGL J MED, V334, P1143; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; SCHIFF RI, 1994, NEW ENGL J MED, V331, P1649, DOI 10.1056/NEJM199412153312409; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Sheehan MM, 1997, HISTOPATHOLOGY, V30, P512, DOI 10.1046/j.1365-2559.1997.5530803.x; SIMMONDS P, 1993, MOL DIAGN, V1, P4; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Yamakawa Y, 1996, J VIRAL HEPATITIS, V3, P317, DOI 10.1111/j.1365-2893.1996.tb00104.x; Zeuzem S, 1996, J HEPATOL, V24, P3	40	723	745	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1228	1233		10.1056/NEJM199904223401602	http://dx.doi.org/10.1056/NEJM199904223401602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210705	Bronze			2022-12-28	WOS:000079833800002
J	Levine, M; Rumsey, SC; Daruwala, R; Park, JB; Wang, YH				Levine, M; Rumsey, SC; Daruwala, R; Park, JB; Wang, YH			Criteria and recommendations for vitamin C intake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; ASCORBIC-ACID SUPPLEMENTATION; DEHYDROASCORBIC ACID; UNITED-STATES; ANTIOXIDANT VITAMINS; HUMAN NEUTROPHILS; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION; CHRONIC-HEMODIALYSIS	Recommendations for vitamin C intake are under revision by the Food and Nutrition Board of the National Academy of Sciences, Since 1989 when the last recommended dietary allowance (RDA) of 60 mg was published, extensive biochemical, molecular, epidemiologic, and clinical data have become available. New recommendations can be based on the following 9 criteria: dietary availability, steady-state concentrations in plasma in relationship to dose, steady-state concentrations in tissues in relationship to dose, bioavailability, urine excretion, adverse effects, biochemical and molecular function in relationship to vitamin concentration, direct beneficial effects and epidemiologic observations in relationship to dose, and prevention of deficiency, We applied these criteria to the Food and Nutrition Board's new guidelines, the Dietary Reference Intakes, which include 4 reference values, The estimated average requirement (EAR) is the amount of nutrient estimated to meet the requirement of half the healthy individuals in a life-stage and gender group, Based on an EAR of 100 mg/d of vitamin C, the RDA is proposed to be 120 mg/d, If the EAR cannot be determined, an adequate intake (AI) amount is recommended instead of an RDA. The AI was estimated to be either 200 mg/d from 5 servings of fruits and vegetables or 100 mg/d of vitamin C to prevent deficiency with a margin of safety, The final classification, the tolerable upper intake level, is the highest daily level of nutrient intake that does not pose risk or adverse health effects to almost all individuals in the population. This amount is proposed to be less than 1 g of vitamin C daily. Physicians can tell patients that 5 servings of fruits and vegetables per day may be beneficial in preventing cancer and providing sufficient vitamin C intake for healthy people, and that 1 g or more of vitamin C may have adverse consequences in some people.	NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; USDA, Beltsville Human Nutr Res Ctr, Phytonutrients Lab, Beltsville, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Agriculture (USDA)	Levine, M (corresponding author), NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Room 4D52, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054506, Z01DK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013; Auer BL, 1998, CLIN CHEM LAB MED, V36, P143, DOI 10.1515/CCLM.1998.027; BAKER EM, 1971, AM J CLIN NUTR, V24, P444; BALCKE P, 1984, ANN INTERN MED, V101, P344, DOI 10.7326/0003-4819-101-3-344; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BASCH CE, 1994, AM J PUBLIC HEALTH, V84, P814, DOI 10.2105/AJPH.84.5.814; BLOCK G, 1994, AM J CLIN NUTR, V59, p232S, DOI 10.1093/ajcn/59.1.232S; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BUTZ M, 1994, UROLITHIASIS 2, P133; BYERS T, 1995, AM J CLIN NUTR, V62, P1385, DOI 10.1093/ajcn/62.6.1385S; BYERS T, 1998, VITAMIN C STATE OF T, P29; CAMPBELL GD, 1975, ANN INTERN MED, V82, P810, DOI 10.7326/0003-4819-82-6-810_1; COOK JD, 1984, BLOOD, V64, P721; CORREA P, 1992, CANCER RES, V52, P6735; CROSS CE, 1990, J LAB CLIN MED, V115, P396; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; ERDMAN JW, 1982, ASCORBIC ACID CHEM M, P533; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; *FOOD NUTR BOARD, 1994, SHOULD REC DIET ALL; Friedman GJ, 1940, J CLIN INVEST, V19, P685, DOI 10.1172/JCI101171; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Galley HF, 1996, FREE RADICAL BIO MED, V20, P139, DOI 10.1016/0891-5849(95)02022-5; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GOGEL HK, 1989, AM J EMERG MED, V7, P474, DOI 10.1016/0735-6757(89)90248-9; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023; Goodman Gilman G, 1996, GOODMAN GILMANS PHAR, V9th, P3; Graumlich JF, 1997, PHARMACEUT RES, V14, P1133, DOI 10.1023/A:1012186203165; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HALLBERG L, 1987, ANN NY ACAD SCI, V498, P324, DOI 10.1111/j.1749-6632.1987.tb23771.x; HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335; HELSER MA, 1992, CARCINOGENESIS, V13, P2277, DOI 10.1093/carcin/13.12.2277; Hemila H, 1997, BRIT J NUTR, V77, P59, DOI 10.1017/S0007114500002889; Hitomi K, 1996, Subcell Biochem, V25, P41; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911; JAFFE RM, 1975, ANN INTERN MED, V83, P824, DOI 10.7326/0003-4819-83-6-824; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; JIALAL I, 1995, CAN J CARDIOL, V11, pG97; KOPLAN JP, 1986, AM J PUBLIC HEALTH, V76, P287, DOI 10.2105/AJPH.76.3.287; Krebs-Smith SM, 1998, CANCER-AM CANCER SOC, V83, P1425, DOI 10.1002/(SICI)1097-0142(19981001)83:7&lt;1425::AID-CNCR21&gt;3.0.CO;2-5; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; LACHANCE P, 1994, NUTR REV, V52, P266; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; LEVINE M, 1995, AM J CLIN NUTR, V62, P1347, DOI 10.1093/ajcn/62.6.1347S; Levine M, 1997, METHOD ENZYMOL, V281, P425; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; Levine M, 1998, NATURE, V395, P231, DOI 10.1038/26137; Levine M, 1997, METHOD ENZYMOL, V279, P43; LEVINE M, 1993, WORLD REV NUTR DIET, V72, P114; Levine M, 1996, PRESENT KNOWLEDGE NU, P146; LI MG, 1989, CLIN CHEM, V35, P2330; *LIF SCI RES OFF, 1995, 3 LIF SCI RES OFF; LIND J, 1756, TREATISE SCURVY; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MaresPerlman JA, 1997, AM J CLIN NUTR, V66, P739, DOI 10.1093/ajcn/66.4.739; MEHTA JB, 1990, LANCET, V336, P944, DOI 10.1016/0140-6736(90)92317-B; MITCH WE, 1981, CLIN PHARMACOL THER, V29, P318, DOI 10.1038/clpt.1981.42; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Patterson BH, 1997, NEW ENGL J MED, V337, P1846, DOI 10.1056/NEJM199712183372513; PATTERSON BH, 1990, AM J PUBLIC HEALTH, V80, P1443, DOI 10.2105/AJPH.80.12.1443; PATTERSON JA, 1995, J AM GERIATR SOC, V43, P919, DOI 10.1111/j.1532-5415.1995.tb05538.x; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; REES DC, 1993, BRIT MED J, V306, P841, DOI 10.1136/bmj.306.6881.841; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTSON JM, 1991, AM J CLIN NUTR, V53, pS346, DOI 10.1093/ajcn/53.1.346S; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; Sahyoun NR, 1996, AM J EPIDEMIOL, V144, P501, DOI 10.1093/oxfordjournals.aje.a008957; SCHECTMAN G, 1993, ANN NY ACAD SCI, V686, P335, DOI 10.1111/j.1749-6632.1993.tb39197.x; Schorah CJ, 1996, AM J CLIN NUTR, V63, P760, DOI 10.1093/ajcn/63.5.760; SCHORAH CJ, 1998, VITAMIN C STATE OF T, P41; SCOTT P, 1993, BRIT J SURG, V80, P750, DOI 10.1002/bjs.1800800632; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; Simon JA, 1998, EPIDEMIOLOGY, V9, P316, DOI 10.1097/00001648-199805000-00017; SIMON JA, 1993, EPIDEMIOLOGY, V4, P537, DOI 10.1097/00001648-199311000-00010; SINGH RB, 1995, AM J CARDIOL, V76, P1233, DOI 10.1016/S0002-9149(99)80348-8; SOBALA GM, 1993, CARCINOGENESIS, V14, P291, DOI 10.1093/carcin/14.2.291; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEIN HB, 1976, ANN INTERN MED, V84, P385, DOI 10.7326/0003-4819-84-4-385; SULLIVAN JF, 1970, AM J CLIN NUTR, V23, P1339; SUTTON JL, 1983, HUM NUTR-APPL NUTR, V37, P136; TAYLOR TV, 1974, LANCET, V2, P544; TINCHIERI A, 1991, BR J UROL, V67, P230; URIVETZKY M, 1992, J UROLOGY, V147, P1215, DOI 10.1016/S0022-5347(17)37521-3; *USDA, 1998, USDA NUTR DAT STAND; VALLANCE S, 1988, BRIT J SURG, V75, P366, DOI 10.1002/bjs.1800750424; VANDERSLICE JT, 1991, AM J CLIN NUTR, V54, pS1323, DOI 10.1093/ajcn/54.6.1323s; VITALE S, 1993, EPIDEMIOLOGY, V4, P195, DOI 10.1097/00001648-199305000-00003; WANDZILAK TR, 1994, J UROLOGY, V151, P834, DOI 10.1016/S0022-5347(17)35100-5; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WILSON DM, 1991, CLIN CHEM, V37, P1229; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; Yong LC, 1997, AM J EPIDEMIOL, V146, P231, DOI 10.1093/oxfordjournals.aje.a009258; YOUNG IS, 1994, FREE RADICAL BIO MED, V16, P393, DOI 10.1016/0891-5849(94)90041-8; [No title captured]	106	348	356	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1415	1423		10.1001/jama.281.15.1415	http://dx.doi.org/10.1001/jama.281.15.1415			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217058				2022-12-28	WOS:000079701000032
J	Force, T; Rosenzweig, A; Choukroun, G; Hajjar, R				Force, T; Rosenzweig, A; Choukroun, G; Hajjar, R			Calcineurin inhibitors and cardiac hypertrophy	LANCET			English	Editorial Material							ACTIVATED PROTEIN-KINASES		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Force, T (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA 02129 USA.		Rosenzweig, Anthony/AAD-7893-2019; Gabriel, Choukroun/AAL-4969-2021	Force, Thomas/0000-0002-0450-8659				Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; CHOUKROUN G, 1998, CIRCULATION S1, V98, P69; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOLKENTIN JD, 1998, SCIENCE, V282, P1007; MULLER JG, 1998, SCIENCE, V282, P1007; Pitt B, 1998, CIRCULATION, V98, P1987, DOI 10.1161/01.CIR.98.19.1987; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	17	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1290	1292		10.1016/S0140-6736(99)90016-8	http://dx.doi.org/10.1016/S0140-6736(99)90016-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218524				2022-12-28	WOS:000080278100006
J	Abbott, GW; Sesti, F; Splawski, I; Buck, ME; Lehmann, WH; Timothy, KW; Keating, MT; Goldstein, SAN				Abbott, GW; Sesti, F; Splawski, I; Buck, ME; Lehmann, WH; Timothy, KW; Keating, MT; Goldstein, SAN			MiRP1 forms I-Kr potassium channels with HERG and is associated with cardiac arrhythmia	CELL			English	Article							LONG-QT SYNDROME; RECTIFIER K+ CURRENT; TORSADES-DE-POINTES; LANGE-NIELSEN-SYNDROME; TIME-DEPENDENT BLOCK; VENTRICULAR MYOCYTES; EXTERNAL CA2+; RAPID COMPONENT; XENOPUS OOCYTES; CAUSE JERVELL	A novel potassium channel gene has been cloned, characterized, and associated with cardiac arrhythmia. The gene encodes MinK-related peptide 1 (MiRP1), a small integral membrane subunit that assembles with HERO, a pore-forming protein, to alter its function. Unlike channels formed only with HERG, mixed complexes resemble native cardiac I-Kr channels in their gating, unitary conductance, regulation by potassium, and distinctive biphasic inhibition by the class III antiarrhythmic E-4031. Three missense mutations associated with long QT syndrome and ventricular fibrillation are identified in the gene for MiRP1. Mutants form channels that open slowly and close rapidly, thereby diminishing potassium currents. One variant, associated with clarithromycin-induced arrhythmia, increases channel blockade by the antibiotic. A mechanism for acquired arrhythmia is revealed: genetically based reduction in potassium currents that remains clinically silent until combined with additional stressors.	Yale Univ, Sch Med, Dept Pediat, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; VA Med Ctr, Ann Arbor, MI 48109 USA	Yale University; Yale University; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338, R01HL046401] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [P50-HL52338, R01-HL46401] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 1996, J AM COLL CARDIOL, V28, P1836, DOI 10.1016/S0735-1097(96)00377-4; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CARMELIET E, 1993, CIRC RES, V73, P857, DOI 10.1161/01.RES.73.5.857; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DALEAU P, 1995, CIRCULATION, V91, P3010, DOI 10.1161/01.CIR.91.12.3010; Drici MD, 1998, JAMA-J AM MED ASSOC, V280, P1774, DOI 10.1001/jama.280.20.1774; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; Ho WK, 1998, J PHYSIOL-LONDON, V507, P631, DOI 10.1111/j.1469-7793.1998.631bs.x; Ho WK, 1996, J PHYSIOL-LONDON, V494, P727, DOI 10.1113/jphysiol.1996.sp021528; Howarth FC, 1996, PFLUG ARCH EUR J PHY, V431, P713, DOI 10.1007/BF02253834; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Lee KL, 1998, AM J MED, V104, P395, DOI 10.1016/S0002-9343(98)00059-X; LeesMiller JP, 1997, CIRC RES, V81, P719; Liu SG, 1996, BIOPHYS J, V70, P2704, DOI 10.1016/S0006-3495(96)79840-5; London B, 1997, CIRC RES, V81, P870; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1992, PFLUG ARCH EUR J PHY, V420, P180, DOI 10.1007/BF00374988; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SCAMPS F, 1989, AM J PHYSIOL, V257, pC1086, DOI 10.1152/ajpcell.1989.257.6.C1086; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; VELDKAMP MW, 1995, CIRCULATION, V92, P3497, DOI 10.1161/01.CIR.92.12.3497; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870; Yang T, 1997, CIRC RES, V80, P782; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Yang YS, 1998, J GEN PHYSIOL, V112, P665, DOI 10.1085/jgp.112.6.665; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zou AR, 1997, AM J PHYSIOL-HEART C, V272, pH1309, DOI 10.1152/ajpheart.1997.272.3.H1309	56	1008	1076	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					175	187		10.1016/S0092-8674(00)80728-X	http://dx.doi.org/10.1016/S0092-8674(00)80728-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219239	Green Published, hybrid			2022-12-28	WOS:000079779800007
J	Baker, CS; Evans, TW; Randle, BJ; Haslam, PL				Baker, CS; Evans, TW; Randle, BJ; Haslam, PL			Damage to surfactant-specific protein in acute respiratory distress syndrome	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE; NEUTROPHIL ELASTASE; PATHOGENESIS; FAILURE; SEPSIS; FLUID; MICE	Background Acute respiratory distress syndrome (ARDS) develops in association with many serious medical disorders. Mortality is at least 40%, and there is no specific therapy. A massive influx of activated neutrophils, which damage pulmonary vascular endothelium and alveolar epithelium, leads to alveolar oedema and pulmonary surfactant dysfunction. In-vitro studies show that neutrophil elastase can cleave surfactant-specific proteins and impair surfactant function. If this happens in vivo in ARDS, the response to surfactant therapy will be limited. Methods Samples of pulmonary surfactant were obtained from the lungs of 18 patients with ARDS and six healthy controls by bronchoalveolar lavage. We separated proteins in these samples according to molecular weight by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). We then used western blotting with monoclonal antibody E8 to detect the major surfactant-specific protein A (SP-A). Findings By contrast with controls, 14 of 18 patients had evidence of in-vivo damage to SP-A that resembled damage caused to SP-A when it is cleaved by neutrophil elastase. Controls showed a single band of normal dimers at 66 kDa, whereas 14 of 18 patients showed multiple bands at 66 kDa, 55 kDA, and 30-36 kDa, and six showed additional bands at 36-40 kDa. Interpretation Direct damage to surfactant-specific proteins occurs in lungs of patients with ARDS, probably by proteolysis. Trials of protein-containing therapeutic surfactant are in progress in ARDS, and our results indicate that the frequent failure to maintain response may result from continuing damage to surfactant by products of activated neutrophils. A combination of surfactant and antiprotease therapy may improve therapeutic prospects.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Cell Biol Unit, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Crit Care Unit, London SW3 6LY, England; Univ Bristol, Dept Obstet & Gynaecol, Bristol BS8 1TH, Avon, England	Imperial College London; Imperial College London; University of Bristol	Haslam, PL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Cell Biol Unit, London SW3 6LY, England.							Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; CORBET A, 1992, AM J MED SCI, V304, P246, DOI 10.1097/00000441-199210000-00004; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Haslam P. L., 1995, European Respiratory Journal, V8, p397S; Haslam P. L., 1997, European Respiratory Journal Supplement, V10, p171S; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; JOHANSSON J, 1994, EUR RESPIR J, V7, P372, DOI 10.1183/09031936.94.07020372; KARINCH AM, 1995, AM J RESP CELL MOL, V12, P77, DOI 10.1165/ajrcmb.12.1.7811473; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CT, 1981, NEW ENGL J MED, V304, P192, DOI 10.1056/NEJM198101223040402; LeVine AM, 1997, J IMMUNOL, V158, P4336; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Liau DF, 1996, BBA-LIPID LIPID MET, V1302, P117, DOI 10.1016/0005-2760(96)00042-2; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; OOSTING RS, 1991, AM J PHYSIOL, V261, pL77, DOI 10.1152/ajplung.1991.261.2.L77; PISON U, 1989, BIOCHIM BIOPHYS ACTA, V992, P251, DOI 10.1016/0304-4165(89)90082-2; RANDLE BJ, 1992, Patent No. 0511011; ROBERTSON B, 1991, PEDIATR RES, V30, P239, DOI 10.1203/00006450-199109000-00007; RYAN SF, 1991, AM J RESP CELL MOL, V4, P33, DOI 10.1165/ajrcmb/4.1.33; SEEGER W, 1993, EUR RESPIR J, V6, P971; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; Torres A, 1996, THORAX, V51, P378, DOI 10.1136/thx.51.4.378; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; YASUI S, 1995, EUR RESPIR J, V8, P1293, DOI 10.1183/09031936.95.08081293	35	77	84	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1232	1237		10.1016/S0140-6736(98)09449-5	http://dx.doi.org/10.1016/S0140-6736(98)09449-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217084				2022-12-28	WOS:000079744100012
J	Shuper, A; Gutman, A; Mimouni, M				Shuper, A; Gutman, A; Mimouni, M			Intractable epilepsy	LANCET			English	Article							CARNITINE		Schneider Childrens Med Ctr Israel, Dept Pediat E, IL-49202 Petah Tiqwa, Israel; Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Shuper, A (corresponding author), Schneider Childrens Med Ctr Israel, Dept Pediat E, Beilinson Campus, IL-49202 Petah Tiqwa, Israel.	avinoams@post.tau.ac.il						Hirose S, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e9; MARKS WA, 1988, ARCH NEUROL-CHICAGO, V45, P903, DOI 10.1001/archneur.1988.00520320101022; Stanley C A, 1995, Adv Pediatr, V42, P209; TEIN I, 1995, J INHERIT METAB DIS, V18, P313, DOI 10.1007/BF00710422; WEAVER LT, 1992, ACTA PAEDIATR, V81, P79, DOI 10.1111/j.1651-2227.1992.tb12085.x	5	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1999	353	9160					1238	1238		10.1016/S0140-6736(98)11444-7	http://dx.doi.org/10.1016/S0140-6736(98)11444-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217085				2022-12-28	WOS:000079744100013
J	McCollum, MA				McCollum, MA			The robust australopithecine face: A morphogenetic perspective	SCIENCE			English	Article							MACACA-MULATTA; FACIAL FORM; MORPHOLOGY; PARANTHROPUS; PHYLOGENY; ONTOGENY	The robust australopithecines were a side branch of human evolution. They share a number of unique craniodental features that suggest their monophyletic origin. However, virtually all of these traits appear to reflect a singular pattern of nasomaxillary modeling derived from their unusual dental proportions. Therefore, recent cladistic analyses have not resolved the phylogenetic history of these early hominids. Efforts to increase cladistic resolution by defining traits at greater levels of anatomical detail have instead introduced substantial phyletic error.	Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University	McCollum, MA (corresponding author), Case Western Reserve Univ, Dept Anat, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mam17@po.cwru.edu						BJORK A, 1976, MONOGRAPH U MICHIGAN, V6, P61; BRAVO LA, 1989, AM J ORTHOD DENTOFAC, V96, P26, DOI 10.1016/0889-5406(89)90225-4; BROMAGE TG, 1989, J HUM EVOL, V18, P751, DOI 10.1016/0047-2484(89)90088-2; BROMAGE TG, 1995, J HUM EVOL, V28, P71, DOI 10.1006/jhev.1995.1007; CONROY GC, 1987, NATURE, V329, P625, DOI 10.1038/329625a0; Delson E., 1988, P317; Enlow DH, 1996, ESSENTIALS FACIAL GR; GANS C, 1988, DEVELOPMENT, V103, P3; Gilbert SF, 1996, DEV BIOL, V173, P357, DOI 10.1006/dbio.1996.0032; KEAN MR, 1987, ANAT RECORD, V218, P107, DOI 10.1002/ar.1092180202; Lieberman DE, 1996, J HUM EVOL, V30, P97, DOI 10.1006/jhev.1996.0008; McCollum MA, 1997, AM J PHYS ANTHROPOL, V102, P377, DOI 10.1002/(SICI)1096-8644(199703)102:3<377::AID-AJPA7>3.0.CO;2-S; McCollum MA, 1997, AM J PHYS ANTHROPOL, V103, P375, DOI 10.1002/(SICI)1096-8644(199707)103:3<375::AID-AJPA7>3.3.CO;2-J; MCCOLLUM MA, 1994, AM J PHYS ANTHROPOL, V93, P259, DOI 10.1002/ajpa.1330930209; MCNAMARA JA, 1976, AM J PHYS ANTHROPOL, V44, P15, DOI 10.1002/ajpa.1330440104; Moss ML, 1997, AM J ORTHOD DENTOFAC, V112, P338, DOI 10.1016/S0889-5406(97)70265-8; MOSS ML, 1961, ACTA ANAT, V44, P263; Moss ML, 1997, AM J ORTHOD DENTOFAC, V112, P8, DOI 10.1016/S0889-5406(97)70267-1; MOSS ML, 1960, AM J PHYS ANTHROPOL, V18, P281, DOI 10.1002/ajpa.1330180406; Moss ML, 1997, AM J ORTHOD DENTOFAC, V112, P410, DOI 10.1016/S0889-5406(97)70049-0; Moss ML, 1997, AM J ORTHOD DENTOFAC, V112, P221, DOI 10.1016/S0889-5406(97)70249-X; MOSS ML, 1967, ANGLE ORTHOD, V37, P151, DOI 10.1043/0003-3219(1967)037<0151:FCAOTH>2.0.CO;2; MOSS ML, 1969, AM J ORTHOD, V55, P567; MOSS ML, 1969, AM J ORTHOD, V56, P475; Raff R. A., 1996, SHAPE LIFE GENES DEV; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; Robinson JT, 1954, AM J PHYS ANTHROP-NE, V12, P181, DOI 10.1002/ajpa.1330120216; SCHNEIDERMAN ED, 1992, FACIAL GROWTH THESUS; Strait DS, 1997, J HUM EVOL, V32, P17, DOI 10.1006/jhev.1996.0097; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; Tobias P. V, 1967, OLDUVAI GORGE CRANIU; Van der KLAAUW C. J., 1948, ARCH NORLAND ZOOL, V9, P1; WARD SC, 1980, AM J PHYS ANTHROPOL, V53, P383, DOI 10.1002/ajpa.1330530310; WHITE TD, 1981, S AFR J SCI, V77, P445; Wood B., 1991, HOMINID CRANIAL REMA, V4	35	92	94	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					301	305		10.1126/science.284.5412.301	http://dx.doi.org/10.1126/science.284.5412.301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	184WH	10195892				2022-12-28	WOS:000079636400038
J	Nightingale, SL				Nightingale, SL			New easy-to-understand labels for OTC drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-28	WOS:000079464400010
J	Turner, PE; Chao, L				Turner, PE; Chao, L			Prisoner's dilemma in an RNA virus	NATURE			English	Article							PARASITE VIRULENCE; EVOLUTION; PSEUDOMONAS; SELECTION; MUTANTS; MODEL; HOST	The evolution of competitive interactions among viruses(1) was studied in the RNA phage phi 6 at high and low multiplicities of infection (that is, at high and low ratios of infecting phage to host cells). At high multiplicities, many phage infect and reproduce in the same host cell, whereas at low multiplicities the viruses reproduce mainly as clones. An unexpected result of this study(1) was that phage grown at high rates of co-infection increased in fitness initially, but then evolved lowered fitness. Here we show that the fitness of the high-multiplicity phage relative to their ancestors generates a pay-off matrix conforming to the prisoner's dilemma strategy of game theory(2,3). In this strategy, defection (selfishness) evolves, despite the greater fitness pay-off that would result if all players were to cooperate. Viral cooperation and defection can be defined as, respectively, the manufacturing and sequestering of diffusible (shared) intracellular products. Because the low-multiplicity phage did not evolve lowered fitness, we attribute the evolution of selfishness to the lack of clonal structure and the mixing of unrelated genotypes at high multiplicity(4-6).	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Turner, PE (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	paul.e.turner@uv.es						AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BONHOEFFER S, 1994, P NATL ACAD SCI USA, V91, P8062, DOI 10.1073/pnas.91.17.8062; BREMERMANN HJ, 1983, J THEOR BIOL, V100, P411, DOI 10.1016/0022-5193(83)90438-1; Chao L, 1997, BEHAV ECOL, V8, P668, DOI 10.1093/beheco/8.6.668; Chao Lin, 1994, P233; CRAIG JL, 1984, BEHAV ECOL SOCIOBIOL, V14, P147, DOI 10.1007/BF00291905; DUGATKIN LA, 1997, ANIMALS EVOLUTIONARY; FISCHER EA, 1988, ETHOL SOCIOBIOL, V9, P119, DOI 10.1016/0162-3095(88)90017-9; Fisher R.A., 1930, GENETICAL THEORY NAT; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; FRANK SA, 1992, P ROY SOC B-BIOL SCI, V250, P195, DOI 10.1098/rspb.1992.0149; Hamilton W.D., 1972, Annual Rev Ecol Syst, V3, P193, DOI 10.1146/annurev.es.03.110172.001205; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; HOLLAND J J, 1991, P151; HUANG AS, 1970, NATURE, V226, P325, DOI 10.1038/226325a0; KNOLLE H, 1989, J THEOR BIOL, V136, P199, DOI 10.1016/S0022-5193(89)80226-7; Lewontin R. C., 1970, ANNU REV ECOL SYST, V1, P1, DOI [DOI 10.1146/ANNUREV.ES.01.110170.000245, 10.1146/annurev.es.01.110170.000245]; Maynard Smith J., 1982, pi; MINDICH L, 1976, J BACTERIOL, V126, P177, DOI 10.1128/JB.126.1.177-182.1976; NOWAK MA, 1994, P ROY SOC B-BIOL SCI, V255, P81, DOI 10.1098/rspb.1994.0012; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; SINCLAIR JF, 1976, VIROLOGY, V75, P198, DOI 10.1016/0042-6822(76)90018-0; Stent G., 1963, MOL BIOL BACTERIAL V; Turner PE, 1998, GENETICS, V150, P523; VIDAVER AK, 1973, J VIROL, V11, P799, DOI 10.1128/JVI.11.5.799-805.1973; VONMAGNUS P, 1954, ADV VIRUS RES, V2, P59, DOI 10.1016/S0065-3527(08)60529-1	27	430	433	1	60	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 1	1999	398	6726					441	443		10.1038/18913	http://dx.doi.org/10.1038/18913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201376				2022-12-28	WOS:000079508200056
J	Klomp, HM; Spincemaille, GHJJ; Steyerberg, EW; Habbema, JDF; van Urk, H				Klomp, HM; Spincemaille, GHJJ; Steyerberg, EW; Habbema, JDF; van Urk, H		ESES study grp	Spinal-cord stimulation in critical limb ischaemia: a randomised trial	LANCET			English	Article							PERIPHERAL VASCULAR-DISEASE; ELECTRICAL-STIMULATION; BLOOD-FLOW; LEG ISCHEMIA; PAIN; SCS; IMPROVEMENT; THERAPY	Background For patients with critical limb ischaemia, spinal-cord stimulation has been advocated for the treatment of ischaemic pain and the prevention of amputation. We compared the efficacy of the addition of spinal-cord stimulation to best medical treatment in a randomised controlled trial. Methods 120 patients with critical limb ischaemia not suitable for vascular reconstruction were randomly assigned either spinal-cord stimulation in addition to best medical treatment or best medical treatment alone. Primary outcomes were mortality and amputation. The primary endpoint was limb survival at 2 years. Findings The mean (SD) age of the patients was 72.6 years (10.3). Median (IQR) follow-up was 605 days (244-1171). 40 (67%) of 60 patients in the spinal-cord-stimulator group and 41 (68%) of 60 patients in the standard group were alive at the end of the study, (p=0.96). There were 25 major amputations in the spinal-cord-stimulator group and 29 in the standard group, (p=0.47). The hazard ratio for survival at 2 years without major amputation in the spinal-cord stimulation group compared with the standard group was 0.96 (95% CI 0.61-1.51). Interpretation Spinal-cord-stimulation in addition to best medical care does not prevent amputation in patients with critical limb ischaemia.	De Wever Hosp, Atruim Med Centrum, Dept Neurosurg, Heerlen, Netherlands; Univ Hosp Rotterdam Dijkzigt, Dept Surg, NL-3015 GD Rotterdam, Netherlands; Erasmus Univ, Ctr Clin Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	Klomp, HM (corresponding author), Univ Hosp Rotterdam Dijkzigt, Dept Gen Surg H926, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		; Steyerberg, Ewout/C-1509-2018	Klomp, Houke/0000-0003-4999-8783; Steyerberg, Ewout/0000-0002-7787-0122				AUGUSTINSSON LE, 1985, ANN SURG, V202, P104, DOI 10.1097/00000658-198507000-00017; BELCH JF, 1994, PHARMACOTHERAPY CRIT; BRACALE GC, 1989, PACE, V12, P695, DOI 10.1111/j.1540-8159.1989.tb02717.x; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; BROSETA J, 1986, J NEUROSURG, V64, P71, DOI 10.3171/jns.1986.64.1.0071; BUNT TJ, 1991, SEMIN VASC SURG, V4, P216; COOK AW, 1976, NEW YORK STATE J MED, V76, P366; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; DORMANDY JA, 1986, VASCULAR SURG ISSUES; Drummond MF, 1992, METHODS EC EVALUATIO; EssinkBot ML, 1996, QUAL LIFE RES, V5, P91, DOI 10.1007/BF00435973; FIUME D, 1989, PACE, V12, P698, DOI 10.1111/j.1540-8159.1989.tb02718.x; JACOBS MJH, 1990, VASC MED REV, V1, P215; JACOBS MJHM, 1990, J VASC SURG, V12, P354, DOI 10.1067/mva.1990.22787; Jivegard L, 1987, Eur J Vasc Surg, V1, P345, DOI 10.1016/S0950-821X(87)80062-2; JIVEGARD LEH, 1995, EUR J VASC ENDOVASC, V9, P421, DOI 10.1016/S1078-5884(05)80010-3; KEMPCZINSKI RF, 1995, VASCULAR SURG; KLOMP HM, 1995, EUR J VASC ENDOVASC, V10, P478, DOI 10.1016/S1078-5884(05)80172-8; LOGERFO FW, 1991, J VASC SURG, V13, P518, DOI 10.1016/0741-5214(91)90310-Q; MEGLIO M, 1981, J NEUROSURG, V54, P821, DOI 10.3171/jns.1981.54.6.0821; NACHBUR B, 1994, EUR J VASCULAR SURG, V8, P383, DOI 10.1016/S0950-821X(05)80954-5; Norgren L, 1990, Eur J Vasc Surg, V4, P463, DOI 10.1016/S0950-821X(05)80784-4; Norgren L, 1990, Eur J Vasc Surg, V4, P449, DOI 10.1016/S0950-821X(05)80781-9; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; RIVERS SP, 1986, SURGERY, V99, P759; RUTHERFORD RB, 1991, CIRCULATION, V83, P6; SAMPERE CT, 1989, PACE, V12, P273, DOI 10.1111/j.1540-8159.1989.tb02659.x; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004; STEUDE U, 1991, VASCULAR SURG, V25, P569; TALLIS RC, 1983, J NEUROL NEUROSUR PS, V46, P478, DOI 10.1136/jnnp.46.6.478; TROENG T, 1993, THEOR SURG, V8, P115; VANDERKLOOT WA, 1989, MPQ DLV CEN STANDARD; ZUCCO F, 1994, SPINAL CORD STIMULAT, P183	34	120	126	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1040	1044		10.1016/S0140-6736(98)05069-7	http://dx.doi.org/10.1016/S0140-6736(98)05069-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199350				2022-12-28	WOS:000079614000009
J	Deeks, JJ				Deeks, JJ			Commentary: "Switchback" allocation - dangerous bends ahead!	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIALS		Inst Hlth Sci, NHS ICRF Ctr Stat Med, Oxford OX3 7LF, England	University of Oxford	Deeks, JJ (corresponding author), Inst Hlth Sci, NHS ICRF Ctr Stat Med, Oxford OX3 7LF, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; COCHRAN WG, 1957, EXPT DESIGNS, P141; Jones BD, 1989, DEPRESSION SCHIZOPHR, P203; Meng QH, 1997, J INTERN MED, V241, P373, DOI 10.1046/j.1365-2796.1997.122139000.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9	6	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					631	632						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10215359				2022-12-28	WOS:000079089200023
J	Lehr, L; Zanni, MT; Frischkorn, C; Weinkauf, R; Neumark, DM				Lehr, L; Zanni, MT; Frischkorn, C; Weinkauf, R; Neumark, DM			Electron solvation in finite systems: Femtosecond dynamics of iodide center dot(water)(n) anion clusters	SCIENCE			English	Article							PHOTOELECTRON-SPECTROSCOPY; WATER CLUSTERS; MOLECULAR-DYNAMICS; HYDRATED ELECTRON; AQUEOUS CHLORIDE; PHOTODETACHMENT; PHOTODISSOCIATION; STATES; IONS	Electron solvation dynamics in photoexcited anion clusters of l(-)(D2O)(n=4-6) and I-(H2O)(4-6) were probed by using femtosecond photoelectron spectroscopy (FPES). An ultrafast pump pulse excited the anion to the cluster analog of the charge-transfer-to-solvent state seen for I- in aqueous solution. Evolution of this state was monitored by time-resolved photoelectron spectroscopy using an ultrafast probe pulse. The excited n = 4 clusters showed simple population decay, but in the n = 5 and 6 clusters the solvent molecules rearranged to stabilize and localize the excess electron, showing characteristics associated with electron solvation dynamics in bulk water. Comparison of the FPES of I-(D2O)(n) with I-(H2O)(n) indicates more rapid solvation in the H2O clusters.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Neumark, DM (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Zanni, Martin/K-2707-2013; Neumark, Daniel M/B-9551-2009	Neumark, Daniel M/0000-0002-3762-9473				Ayotte P, 1999, J CHEM PHYS, V110, P6268, DOI 10.1063/1.478531; Ayotte P, 1998, CHEM PHYS, V239, P485, DOI 10.1016/S0301-0104(98)00287-0; Bailey CG, 1997, CHEM PHYS LETT, V265, P185, DOI 10.1016/S0009-2614(96)01413-3; COE JV, 1990, J CHEM PHYS, V92, P3980, DOI 10.1063/1.457805; COMBARIZA JE, 1994, CHEM PHYS LETT, V221, P156, DOI 10.1016/0009-2614(94)87032-2; CRAWFORD OH, 1971, MOL PHYS, V20, P585, DOI 10.1080/00268977100100561; Franck J, 1928, Z PHYS CHEM-STOCH VE, V139, P22; GAUDUEL Y, 1995, CHEM PHYS, V197, P167, DOI 10.1016/0301-0104(95)00143-C; Greenblatt BJ, 1996, CHEM PHYS LETT, V258, P523, DOI 10.1016/0009-2614(96)00766-X; Greenblatt BJ, 1997, SCIENCE, V276, P1675, DOI 10.1126/science.276.5319.1675; GREENBLATT BJ, 1997, DISCUSS FARADAY SOC, V108, P101; HART EJ, 1962, J AM CHEM SOC, V84, P4090, DOI 10.1021/ja00880a025; JORTNER J, 1964, J PHYS CHEM-US, V68, P247, DOI 10.1021/j100784a005; Kloepfer JA, 1998, CHEM PHYS LETT, V298, P120, DOI 10.1016/S0009-2614(98)01210-X; Lee S, 1997, PHYS REV LETT, V79, P2038, DOI 10.1103/PhysRevLett.79.2038; LONG FH, 1994, J PHYS CHEM-US, V98, P7252, DOI 10.1021/j100081a003; MARKOVICH G, 1994, J CHEM PHYS, V101, P9344, DOI 10.1063/1.467965; PERERA L, 1994, J CHEM PHYS, V100, P3085, DOI 10.1063/1.466450; Serxner D, 1996, J CHEM PHYS, V105, P7231, DOI 10.1063/1.472529; SHEU WS, 1993, CHEM PHYS LETT, V213, P233, DOI 10.1016/0009-2614(93)85125-8; Silva C, 1998, PHYS REV LETT, V80, P1086, DOI 10.1103/PhysRevLett.80.1086; Staib A, 1996, J CHEM PHYS, V104, P9027, DOI 10.1063/1.471635; TAYLOR TR, UNPUB; WEYL W, 1864, POGG ANN, V123, P350; WIESENFELD JM, 1980, CHEM PHYS LETT, V73, P47, DOI 10.1016/0009-2614(80)85199-2; Xantheas SS, 1996, J PHYS CHEM-US, V100, P9703, DOI 10.1021/jp960779s	26	223	225	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					635	638		10.1126/science.284.5414.635	http://dx.doi.org/10.1126/science.284.5414.635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213684				2022-12-28	WOS:000079951100042
J	Evans, EGV; Sigurgeirsson, B				Evans, EGV; Sigurgeirsson, B		LION Study Grp	Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DERMATOPHYTE ONYCHOMYCOSIS; ANTIFUNGAL AGENTS; PREVALENCE; THERAPY	Objective To compare the efficacy and safety of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis. Design Prospective, randomised, double blind, double dummy multicentre, parallel group study lasting 72 weeks. Setting 35 centres in sis European countries. Subjects 496 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte onychomycosis of the toenail. Interventions Study patients were randomly divided into four parallel groups to receive either terbinafine 250 mg a day for 12 or 16 weeks (groups T-12 and T-16) or itraconazole 400 mg a day for 1 week in every 4 weeks for 12 or 16 weeks (groups I-3 and I-4). Main outcome measures Assessment of primary efficacy at week 72 was mycological cure, defined as negative results on microscopy and culture Of samples from the target toenail. Results At week 72 the mycological cure rates were 75.7% (81/107) in the T-12 group and 80.8% (80/99) in the T-16 group compared with 38.3% (41/107) in the I-3 group and 49.1% (53/105) in the I-3 group. All comparisons (T-12 vI(3), T-12 vI(4), T-10 vI(3), T-16 vI(4)) showed significantly higher cure rates in the terbinafine groups (all P < 0.0001). Also, all secondary clinical outcome measures were significantly in favour of terbinafine at week 72. There were no differences in the number or type of adverse events recorded in the terbinafine or itraconazole groups. Conclusion Continuous terbinafine is significantly more effective than intermittent itraconazole in the treatment of patients with toenail onychomycosis.	Univ Leeds, Publ Hlth Lab Serv, Mycol Reference Lab, Leeds LS2 9JT, W Yorkshire, England; Gen Infirm, Leeds LS2 9JT, W Yorkshire, England; Univ Iceland, Reykjavik, Iceland; Reykjavik City Hosp, Reykjavik, Iceland	University of Leeds; Leeds General Infirmary; University of Iceland; Landspitali National University Hospital	Evans, EGV (corresponding author), Univ Leeds, Publ Hlth Lab Serv, Mycol Reference Lab, Leeds LS2 9JT, W Yorkshire, England.	E.G.V.Evans@leeds.ac.uk	Sigurgeirsson, Bardur/AAP-7755-2020; Sigurgeirsson, Bárður/B-6130-2011	Sigurgeirsson, Bardur/0000-0002-9733-9742				ANDRE J, 1996, 54 ANN M AM AC DERM; BRAUTIGAM M, 1995, BRIT MED J, V311, P919, DOI 10.1136/bmj.311.7010.919; CLAYTON YM, 1994, BRIT J DERMATOL, V130, P7, DOI 10.1111/j.1365-2133.1994.tb06084.x; DeBacker M, 1996, BRIT J DERMATOL, V134, P16, DOI 10.1111/j.1365-2133.1996.tb15653.x; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; Elewski BE, 1997, ARCH DERMATOL, V133, P1317, DOI 10.1001/archderm.133.10.1317; Ellis DH, 1997, DERMATOLOGY, V194, P40, DOI 10.1159/000246184; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P911, DOI 10.1016/S0190-9622(94)70112-1; Gupta AK, 1998, LANCET, V351, P541, DOI 10.1016/S0140-6736(05)78552-4; HEIKKILA H, 1995, BRIT J DERMATOL, V133, P699; KRANING KK, 1979, J INVEST DERMATOL, V73, P395; ROBERTS DT, 1992, BRIT J DERMATOL, V126, P23, DOI 10.1111/j.1365-2133.1992.tb00005.x; SAIS G, 1995, BRIT J DERMATOL, V132, P758, DOI 10.1111/j.1365-2133.1995.tb00722.x; Schatz F, 1995, CLIN EXP DERMATOL, V20, P377, DOI 10.1111/j.1365-2230.1995.tb01353.x; Tosti A, 1996, J AM ACAD DERMATOL, V34, P595, DOI 10.1016/S0190-9622(96)80057-0	15	167	184	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1031	1035		10.1136/bmj.318.7190.1031	http://dx.doi.org/10.1136/bmj.318.7190.1031			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205099	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080140000021
J	Monaghan, J				Monaghan, J			Time to add chemotherapy to radiotherapy for cervical cancer	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England		Monaghan, J (corresponding author), Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England.							GROGAN M, 1999, 30 ANN M SOC GYN ONC; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502	4	11	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1288	1289		10.1016/S0140-6736(99)00073-2	http://dx.doi.org/10.1016/S0140-6736(99)00073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218522				2022-12-28	WOS:000080278100004
J	Vause, S; Macintosh, M				Vause, S; Macintosh, M			Evidence based case report - Use of prostaglandins to induce labour in women with a caesarean section scar	BRITISH MEDICAL JOURNAL			English	Review							PREVIOUS CESAREAN-SECTION; VAGINAL BIRTH; E(2) GEL; DELIVERY; UPDATE		Leeds Gen Infirm, Dept Obstet & Gynaecol, Leeds LS1 3EK, W Yorkshire, England	Leeds General Infirmary	Vause, S (corresponding author), St Marys Hosp, Manchester M13 0JH, Lancs, England.							ALSULEIMAN SA, 1989, J OBSTET GYNAECOL, V9, P199, DOI 10.3109/01443618909151035; ATAD J, 1986, INT J GYNECOL OBSTET, V24, P315, DOI 10.1016/0020-7292(86)90090-1; ATIENZA MF, 1980, AM J OBSTET GYNECOL, V138, P55, DOI 10.1016/0002-9378(80)90010-1; BENNET MJ, 1981, J OBSTET GYNAECOL, V2, P71; BLANCO JD, 1992, AM J PERINAT, V9, P80, DOI 10.1055/s-2007-994676; CHATTOPADHYAY K, 1988, INT J GYNECOL OBSTET, V26, P189, DOI 10.1016/0020-7292(88)90261-5; CHATTOPADHYAY SK, 1994, BRIT J OBSTET GYNAEC, V101, P498, DOI 10.1111/j.1471-0528.1994.tb13149.x; DELVALLE GO, 1994, INT J GYNECOL OBSTET, V47, P17, DOI 10.1016/0020-7292(94)90455-3; Fay R.A., 1983, J OBSTET GYNAECOL, V4, P139; FRAMM BL, 1997, AM J PERINAT, V14, P157; GARBACIAK JA, 1983, OBSTET GYNECOL, V61, P37; GOLDBERGER SB, 1989, ACTA OBSTET GYN SCAN, V68, P523; HAQ CL, 1988, AM FAM PHYSICIAN, V37, P167; JOSEPH GF, 1991, AM J OBSTET GYNECOL, V164, P1441, DOI 10.1016/0002-9378(91)91422-S; KAPLAN B, 1994, ACTA OBSTET GYN SCAN, V73, P473, DOI 10.3109/00016349409013434; Keirse MJNC, 1989, EFFECTIVE CARE PREGN, P1080; KIRK EP, 1990, AM J OBSTET GYNECOL, V162, P1398, DOI 10.1016/0002-9378(90)90898-H; LAO TT, 1987, ACTA OBSTET GYN SCAN, V66, P413, DOI 10.3109/00016348709022044; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; LELAIDIER C, 1994, BRIT J OBSTET GYNAEC, V101, P501, DOI 10.1111/j.1471-0528.1994.tb13150.x; MACKENZIE IZ, 1984, BRIT J OBSTET GYNAEC, V91, P7, DOI 10.1111/j.1471-0528.1984.tb05271.x; MACKENZIE IZ, 1990, PROGR OBSTET GYNAECO, V8, P157; MACKENZIE IZ, 1988, PROSTAGLANDINS CERVI, P53; MEEHAN FP, 1989, INT J GYNECOL OBSTET, V30, P205, DOI 10.1016/0020-7292(89)90403-7; MULROW CD, 1997, COCHRANE COLLABORATI; NORMAN M, 1992, ACTA OBSTET GYN SCAN, V71, P351, DOI 10.3109/00016349209021072; OCONNOR KM, 1983, J OBSTET GYNAECOL, V4, P86, DOI 10.3109/01443618309071249; PENSO C, 1994, CURR OPIN OBSTET GYN, V6, P417; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; SELLERS SM, 1988, 1 EUR C PROST REPR V; SHEPHERD J, 1979, BRIT MED J, V2, P108, DOI 10.1136/bmj.2.6182.108; SHEPHERD JH, 1981, OBSTET GYNECOL, V58, P596; STONE JL, 1994, AM J PERINAT, V11, P309, DOI 10.1055/s-2007-994600; TAYLOR AVG, 1993, J OBSTET GYNAECOL, V12, P333; Thomas M., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, P416, DOI 10.3109/01443619409027624; TURNER JE, 1987, J REPROD MED, V32, P815; WILLIAMS MA, 1995, GYNECOL OBSTET INVES, V40, P89, DOI 10.1159/000292312	37	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1056	1058		10.1136/bmj.318.7190.1056	http://dx.doi.org/10.1136/bmj.318.7190.1056			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205107	Green Published			2022-12-28	WOS:000080140000034
J	Schulz, HN; Brinkhoff, T; Ferdelman, TG; Marine, MH; Teske, A; Jorgensen, BB				Schulz, HN; Brinkhoff, T; Ferdelman, TG; Marine, MH; Teske, A; Jorgensen, BB			Dense populations of a giant sulfur bacterium in Namibian shelf sediments	SCIENCE			English	Article							THIOPLOCA-ARAUCAE; BEGGIATOA; NITRATE; CHILEAE; MARINE; COAST	A previously unknown giant sulfur bacterium is abundant in sediments underlying the oxygen minimum zone of the Benguela Current upwelling system. The bacterium has a spherical cell that exceeds by up to 100-fold the biovolume of the largest known prokaryotes. On the basis of 16S ribosomal DNA sequence data, these bacteria are closely related to the marine filamentous sulfur bacteria Thioploca, abundant in the upwelling area off Chile and Peru. Similar to Thioploca, the giant bacteria oxidize sulfide with nitrate that is accumulated to less than or equal to 800 millimolar in a central vacuole.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Univ Oldenburg, Inst Chem & Biol Marine Environm, D-26111 Oldenburg, Germany; Univ Barcelona, Fac Farm, E-08028 Barcelona, Spain; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Max Planck Society; Carl von Ossietzky Universitat Oldenburg; University of Barcelona; Woods Hole Oceanographic Institution	Schulz, HN (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr, D-28359 Bremen, Germany.		Jorgensen, Bo B/C-2214-2013; Schulz-Vogt, Heide/I-1397-2012; Teske, Andreas/AAQ-9577-2021; Ferdelman, Timothy G/A-3758-2013	Jorgensen, Bo B/0000-0001-9398-8027; Schulz-Vogt, Heide/0000-0003-1445-0291; Ferdelman, Timothy G/0000-0002-9701-3793				ANGERT ER, 1993, NATURE, V362, P239, DOI 10.1038/362239a0; Bremner J.M., 1983, COASTAL UPWELLING IT, P73; BRONGERSMASANDE.M, 1983, COASTAL UPWELLING IT, P421; Ferdelman TG, 1997, GEOCHIM COSMOCHIM AC, V61, P3065, DOI 10.1016/S0016-7037(97)00158-0; FOSSING H, 1995, NATURE, V374, P713, DOI 10.1038/374713a0; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; Hart T. J., 1960, Discovery Reports, V31, P123; Huettel M, 1996, APPL ENVIRON MICROB, V62, P1863, DOI 10.1128/AEM.62.6.1863-1872.1996; LARKIN J, 1989, Microbios Letters, V42, P69; MAIER S, 1984, INT J SYST BACTERIOL, V34, P414, DOI 10.1099/00207713-34-4-414; MAIER S, 1990, CAN J MICROBIOL, V36, P438, DOI 10.1139/m90-077; MAIER S, 1965, CAN J MICROBIOL, V11, P635; MANZ W, 1992, SYST APPL MICROBIOL, V15, P593, DOI 10.1016/S0723-2020(11)80121-9; McHatton SC, 1996, APPL ENVIRON MICROB, V62, P954, DOI 10.1128/AEM.62.3.954-958.1996; MOLLER MM, 1985, APPL ENVIRON MICROB, V50, P373; NELSON DC, 1989, APPL ENVIRON MICROB, V55, P2909, DOI 10.1128/AEM.55.11.2909-2917.1989; NELSON DC, 1986, APPL ENVIRON MICROB, V52, P161, DOI 10.1128/AEM.52.1.161-168.1986; OTTE S, UNPUB; SCHUETTE G, 1981, COASTAL UPWELLING, P373; Schulz HN, 1996, APPL ENVIRON MICROB, V62, P1855, DOI 10.1128/AEM.62.6.1855-1862.1996; STROTMANN B, UNPUB; Teske Andreas, 1995, Systematic and Applied Microbiology, V18, P517	22	322	338	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					493	495		10.1126/science.284.5413.493	http://dx.doi.org/10.1126/science.284.5413.493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205058				2022-12-28	WOS:000079792200049
J	Abbasi, K				Abbasi, K			The World Bank and world health - Under fire	BMJ-BRITISH MEDICAL JOURNAL			English	Article												kabbasi@bmj.com						Anand S, 1998, WORLD DEV, V26, P307, DOI 10.1016/S0305-750X(97)10019-5; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; CAULFIELD C, 1997, MASTERS ILLUSION WOR, P149; Creese A, 1997, BRIT MED J, V315, P202, DOI 10.1136/bmj.315.7102.202; KILLICK T, 1994, IMPROVING EFFECTIVEN; MCPAKE B, 1994, SOC SCI MED, V39, P1189; Murray C. J. L., 1996, GLOBAL BURDEN DIS; *PUBL INT RES GROU, 1994, WORLD BANK IND, P60; *UN, 1989, STAT WORLDS CHILDR, P16; *WORLD BANK, 1999, WORLD BANKS ROL ANN; *WORLD BANK, 1992, COUNTR EC DEP POL RE, V22, P14; *WORLD BANK, 1993, WORLD DEV REP 1993 I; *WORLD BANK, 1993, WORLD DEBT TABL 1992; *WORLD BANK, 1990, COUNTR EC DEP POL RE, V14, P11; 1998, ECONOMIST       1017	15	22	23	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	1999	318	7189					1003	1006		10.1136/bmj.318.7189.1003	http://dx.doi.org/10.1136/bmj.318.7189.1003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186VU	10195978	Green Published			2022-12-28	WOS:000079751500029
J	Smith, SA				Smith, SA			Personal view - A step towards effective self regulation	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					1017	1017		10.1136/bmj.318.7189.1017	http://dx.doi.org/10.1136/bmj.318.7189.1017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195994	Green Published			2022-12-28	WOS:000079751500052
J	Delhase, M; Hayakawa, M; Chen, Y; Karin, M				Delhase, M; Hayakawa, M; Chen, Y; Karin, M			Positive and negative regulation of I kappa B kinase activity through IKK beta subunit phosphorylation	SCIENCE			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; COMPLEX; ALPHA; IDENTIFICATION; CLONING; FAMILY; SITES; MEKK1	I kappa B [inhibitor of nuclear factor kappa B (NF-kappa B)] kinase (IKK) phosphorylates I kappa B inhibitory proteins, causing their degradation and activation of transcription factor NF-KB, a master activator of inflammatory responses. IKK is composed of three subunits-IKK alpha and IKK beta, which are highly similar protein kinases, and IKK gamma, a regulatory subunit. In mammalian cells, phosphorylation of two sites at the activation Loop of IKK beta was essential for activation of IKK by tumor necrosis factor and interleukin-1. Elimination of equivalent sites in IKK alpha, however, did not interfere with IKK activation. Thus, IKK beta, not IKK alpha, is the target for proinflammatory stimuli. Once activated, IKK beta autophosphorylated at a carboxyl-terminal serine cluster. Such phosphorylation decreased IKK activity and may prevent prolonged activation of the inflammatory response.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43477] Funding Source: Medline; NIEHS NIH HHS [R37 ES04151] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DELHASE M, UNPUB; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOEDDEL D, COMMUNICATION; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; KARIN M, P NATL ACAD SCI US, P9067; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li Z.B., UNPUB; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANO H, P NATL ACAD SCI US, P3537; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	33	719	775	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					309	313		10.1126/science.284.5412.309	http://dx.doi.org/10.1126/science.284.5412.309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195894				2022-12-28	WOS:000079636400040
J	Switzer, JA; Shumsky, MG; Bohannan, EW				Switzer, JA; Shumsky, MG; Bohannan, EW			Electrodeposited ceramic single crystals	SCIENCE			English	Article							OXIDE LAYERED NANOSTRUCTURES; SOLID ELECTROLYTES; SUPERLATTICES; FILMS; BI2O3	Single-crystal films are essential for devices because the intrinsic properties of the material, rather than its grain boundaries, can be exploited. Cubic bismuth oxide has the highest known oxide ion mobility, which makes it useful for fuel cells and sensors, but it is normally only stable from 729 degrees to 825 degrees C. The material has not been previously observed at room temperature. Single-crystal films of the high-temperature cubic polymorph of bismuth oxide were epitaxially electrodeposited from an aqueous solution onto single-crystal gold substrates. The 35.4 percent lattice mismatch was accommodated by forming coincidence Lattices in which the bismuth oxide film was rotated in relation to the gold substrate. These results provide a method for producing other nonequilibrium phases that cannot be accessed by traditional thermal processing.	Univ Missouri, Dept Chem, Rolla, MO 65409 USA; Univ Missouri, Grad Ctr Mat Res, Rolla, MO 65409 USA	University of Missouri System; Missouri University of Science & Technology; University of Missouri System; Missouri University of Science & Technology	Switzer, JA (corresponding author), Univ Missouri, Dept Chem, Rolla, MO 65409 USA.		Way, James Douglas/A-9408-2010	Way, James Douglas/0000-0001-9612-8508				AZAD AM, 1994, J MATER SCI, V29, P4135, DOI 10.1007/BF00414192; Breyfogle BE, 1996, J ELECTROCHEM SOC, V143, P2741, DOI 10.1149/1.1837101; Budevski E., 1996, ELECTROCHEMICAL PHAS, P41; Budevski E.B., 1996, ELECTROCHEMICAL PHAS, P201, DOI [10.1002/9783527614936.ch5, DOI 10.1002/9783527614936.CH5]; Depero LE, 1996, J SOLID STATE CHEM, V122, P439, DOI 10.1006/jssc.1996.0139; Golan Y, 1996, ADV MATER, V8, P631, DOI 10.1002/adma.19960080804; Golden TD, 1996, CHEM MATER, V8, P2499, DOI 10.1021/cm9602095; HARWIG HA, 1978, Z ANORG ALLG CHEM, V444, P151, DOI 10.1002/zaac.19784440118; Hsiao GS, 1997, J AM CHEM SOC, V119, P1439, DOI 10.1021/ja9630755; KOTO K, 1994, SOLID STATE IONICS, V72, P79, DOI 10.1016/0167-2738(94)90128-7; LINCOT D, 1995, APPL PHYS LETT, V67, P2355, DOI 10.1063/1.114343; MOFFAT TP, 1995, J ELECTROCHEM SOC, V142, P3767, DOI 10.1149/1.2048411; Phillips RJ, 1997, CHEM MATER, V9, P1670, DOI 10.1021/cm970074i; Shuk P, 1996, SOLID STATE IONICS, V89, P179, DOI 10.1016/0167-2738(96)00348-7; Switzer JA, 1998, J AM CHEM SOC, V120, P3530, DOI 10.1021/ja974366w; SWITZER JA, 1994, SCIENCE, V264, P1573, DOI 10.1126/science.264.5165.1573; SWITZER JA, 1990, SCIENCE, V247, P444, DOI 10.1126/science.247.4941.444; SWITZER JA, 1992, SCIENCE, V258, P1918, DOI 10.1126/science.258.5090.1918; SWITZER JA, 1987, AM CERAM SOC BULL, V66, P1521; Switzer JA, 1998, J MATER RES, V13, P909, DOI 10.1557/JMR.1998.0124; Switzer JA, 1999, J PHYS CHEM B, V103, P395, DOI 10.1021/jp983911s; SWITZER JA, UNPUB; VANLEEUWEN RA, 1995, J PHYS CHEM-US, V99, P15247, DOI 10.1021/j100041a047	23	185	188	2	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					293	296		10.1126/science.284.5412.293	http://dx.doi.org/10.1126/science.284.5412.293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195889				2022-12-28	WOS:000079636400035
J	De Strooper, B; Annaert, W; Cupers, P; Saftig, P; Craessaerts, K; Mumm, JS; Schroeter, EH; Schrijvers, V; Wolfe, MS; Ray, WJ; Goate, A; Kopan, R				De Strooper, B; Annaert, W; Cupers, P; Saftig, P; Craessaerts, K; Mumm, JS; Schroeter, EH; Schrijvers, V; Wolfe, MS; Ray, WJ; Goate, A; Kopan, R			A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE GENE; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; BETA; CLEAVAGE; PROTEOLYSIS; INHIBITION; EXPRESSION; RECEPTOR	Signalling through the receptor protein Notch, which is involved in crucial cell-fate decisions during development, requires ligand-induced cleavage of Notch. This cleavage occurs within the predicted transmembrane domain, releasing the Notch intracellular domain (MCD), and is reminiscent of gamma-secsretase-mediated cleavage of beta-amyloid precursor protein (APP), a critical event in the pathogenesis of Alzheimer's disease. a deficiency in presenilin-1 (PS1) inhibits processing of APP by gamma-secretase in mammalian cells, and genetic interactions between Notch and PS1 homologues in Caenorhabditis elegans indicate that the presenilins may modulate the Notch signalling pathway(1-4). Here we report that, in mammalian cells, PS1 deficiency also reduces the proteolytic release of NICD from a truncated Notch construct, thus identifying the specific biochemical step of the Notch signalling pathway that is affected by PS1. Moreover, several gamma-secretase inhibitors block this same step in Notch processing indicating that related protease activities are responsible for cleavage within the predicted transmembrane domains of Notch and APP. Thus the targeting of gamma-secretase for the treatment of Alzheimer's disease may risk toxicity caused by reduced Notch signalling.	Katholieke Univ Leuven VIB, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38138 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; University of Gottingen; Washington University (WUSTL); Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center; Washington University (WUSTL); Washington University (WUSTL)	De Strooper, B (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium.	Bart.Destrooper@med.kuleuven.ac.be; Kopan@Pharmsun.Wustl.Edu	De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010; Kopan, Raphael/AFG-3275-2022; Mumm, Jeff S/F-3125-2013; Kopan, Raphael/AAF-1357-2022; Ray, William J/E-9834-2016; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Mumm, Jeff/0000-0002-2575-287X				Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Robey E, 1998, CURR OPIN IMMUNOL, V10, P181, DOI 10.1016/S0952-7915(98)80247-1; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Saftig P, 1998, MOL PSYCHIATR, V3, P287, DOI 10.1038/sj.mp.4000408; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; WOLFE MS, IN PRESS BIOCHEMISTR; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; XIA W, 1997, P NATL ACAD SCI USA, V94, P8206; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	30	1488	1553	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					518	522		10.1038/19083	http://dx.doi.org/10.1038/19083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206645				2022-12-28	WOS:000079662800049
J	Richards, MA; Westcombe, AM; Love, SB; Littlejohns, P; Ramirez, AJ				Richards, MA; Westcombe, AM; Love, SB; Littlejohns, P; Ramirez, AJ			Influence of delay on survival in patients with breast cancer: a systematic review	LANCET			English	Review							PROGNOSTIC FACTORS; CARCINOMA; DIAGNOSIS; SYMPTOMS; MORTALITY; DURATION; DISEASE; WOMEN; STAGE; AGE	Background Most patients with breast cancer are detected after symptoms occur rather than through screening. The impact on survival of delays between the onset of symptoms and the start of treatment is controversial and cannot be studied in randomised controlled trials. We did a systematic review of observational studies (worldwide) of duration of symptoms and survival. Methods We identified 87 studies (101 954 patients) with direct data linking delay (including delay by patients) and survival. We classified studies for analysis by type of data in the original reports: category I studies had actual 5-year survival data (38 studies. 53 912 patients); category II used actuarial or multivariate analyses (21 studies, 25 102 patients); and category III was all other types of data (28 studies, 22 940 patients). We tested the main hypothesis that longer delays would be associated with lower survival, and a secondary hypothesis that longer delays were associated with more advanced stage, which would account for lower survival. Findings In category I studies, patients with delays of 3 months or more bad 12% lower 5-year survival than those with shorter delays (odds ratio for death 1.47 [95% CI 1.42-1.53]) and those with delays of 3-6 months had 7% lower survival than those with shorter delays (1.24 [1.17-1.30]). In category II, 13 of 14 studies with unrestricted samples showed a significant adverse relation between longer delays and survival, whereas four of five studies of only patients with operable disease showed no significant relation. In category ill, all three studies with unrestricted samples supported the primary hypothesis. The 13 informative studies showed that longer delays were associated with more advanced stage. In studies that controlled for stage, longer delay was not associated with shorter survival when the effect of stage on survival was taken into account. Interpretation Delays of 3-6 months are associated with lower survival. These effects cannot be accounted for by lead-time bias. Efforts should be made to keep delays by patients and providers to a minimum.	St Thomas Hosp, Guys Kings & St Thomass Sch Med, Imperial Canc Res Fund, Psychosocial Oncol Grp, London, England; Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford, England; Univ London St Georges Hosp, Sch Med, Hlth Ctr Evaluat Unit, London, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford; St Georges University London	Richards, MA (corresponding author), St Thomas Hosp, Dept Palliat Med, London SE1 7EH, England.							ABE O, 1992, LANCET, V339, P71; AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; ALDERSON MR, 1971, BRIT J CANCER, V25, P646, DOI 10.1038/bjc.1971.80; ANGLEM TJ, 1961, CANCER-AM CANCER SOC, V14, P1122, DOI 10.1002/1097-0142(196109/10)14:5<1122::AID-CNCR2820140533>3.0.CO;2-6; [Anonymous], 1992, Lancet, V339, P1; ARIEL IM, 1979, J SURG ONCOL, V12, P137, DOI 10.1002/jso.2930120208; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BERKSON J, 1962, ACTA UNION INT CONTR, V18, P1003; BLACK CL, 1983, SURG GYNECOL OBSTET, V157, P497; BLOOM HJG, 1965, SURGERY, V12, P892; BRIGHTMORE TG, 1970, BRIT J CANCER, V24, P644, DOI 10.1038/bjc.1970.78; BRINKLEY D, 1968, BRIT J RADIOL, V41, P215, DOI 10.1259/0007-1285-41-483-215; BUCHANAN JJ, 1928, ATLANTIC MED J, V31, P634; Burgess CC, 1998, BRIT J CANCER, V77, P1343, DOI 10.1038/bjc.1998.224; CHARLSON ME, 1985, SURG GYNECOL OBSTET, V160, P393; CRUCITTI F, 1992, CHIRUGIA TURIN, V5, P357; CUMMINGS KM, 1983, CANCER DETECT PREV, V6, P485; Davis BB, 1920, ANN SURG, V71, P270, DOI 10.1097/00000658-192003000-00004; Davis HH, 1938, ANN SURG, V107, P207, DOI 10.1097/00000658-193802000-00003; DEEKS J, 1996, 4 CRD U YORK; DELARIO A, 1959, BREAST CANC FACTORS, P123; Delgado D J, 1995, P R Health Sci J, V14, P103; DENNIS CR, 1975, CANCER-AM CANCER SOC, V35, P714, DOI 10.1002/1097-0142(197503)35:3<714::AID-CNCR2820350326>3.0.CO;2-V; DEVITT JE, 1967, CAN MED ASSOC J, V97, P1257; DOHRMANN PJ, 1982, SURG GYNECOL OBSTET, V154, P707; DONEGAN W, 1988, DIAGNOSIS CANC BREAS; EBERBACH C W, 1949, Wis Med J, V48, P132; Eggers C, 1941, ANN SURG, V113, P321, DOI 10.1097/00000658-194103000-00001; ELMENDORFF HV, 1971, LANGENBECK ARCH CHIR, V328, P169; ELWOOD JM, 1980, BRIT MED J, V280, P1291, DOI 10.1136/bmj.280.6227.1291; FELDMAN JG, 1983, CANCER, V51, P1226, DOI 10.1002/1097-0142(19830401)51:7<1226::AID-CNCR2820510709>3.0.CO;2-K; FISHER ER, 1977, CANCER-AM CANCER SOC, V40, P3160, DOI 10.1002/1097-0142(197712)40:6<3160::AID-CNCR2820400661>3.0.CO;2-P; Geschickter C, 1945, DIS BREAST; Goodwin JS, 1996, JNCI-J NATL CANCER I, V88, P1031, DOI 10.1093/jnci/88.15.1031; Greenough RB, 1907, SURG GYNECOL OBSTET, V5, P39; GREENOUGH RB, 1925, SO M J, V18, P187; Greenough RB, 1934, NEW ENGL J MED, V210, P831; HAAGENSEN CD, 1951, ANN SURG, V134, P151, DOI 10.1097/00000658-195108000-00002; Haagensen CD, 1942, ANN SURG, V116, P801, DOI 10.1097/00000658-194212000-00002; HAINSWORTH P, 1993, BREAST, V2, P37; HANDLEY RS, 1972, P ROY SOC MED, V65, P437, DOI 10.1177/003591577206500504; HARNETT WL, 1953, BRIT J CANCER, V7, P19, DOI 10.1038/bjc.1953.3; HARTMANN H, 1941, NEW INT CLIN, V3, P78; Hawkins James W., 1944, JOUR NATION CANCER INST, V4, P445; HERMANN RE, 1985, ARCH SURG-CHICAGO, V120, P746; Hoopes BF, 1942, SURGERY, V12, P892; HUGULEY CM, 1988, CANCER, V62, P1389, DOI 10.1002/1097-0142(19881001)62:7<1389::AID-CNCR2820620725>3.0.CO;2-0; HUMPHREY LJ, 1963, AM J SURG, V106, P440, DOI 10.1016/0002-9610(63)90127-2; KREYBERG L, 1953, BRIT J CANCER, V7, P37, DOI 10.1038/bjc.1953.4; Kunath CA, 1940, ARCH SURG-CHICAGO, V41, P66, DOI 10.1001/archsurg.1940.01210010069005; LALANNE CM, 1962, ACTA UNION INT CONTR, V18, P807; LIBERATI A, 1986, CANCER-AM CANCER SOC, V58, P1756; Luff AP, 1932, BMJ-BRIT MED J, V1932, P897, DOI 10.1136/bmj.1.3723.897; MACDONALD I, 1956, CANCER-AM CANCER SOC, V9, P281, DOI 10.1002/1097-0142(195603/04)9:2<281::AID-CNCR2820090213>3.0.CO;2-3; MACDONALD I, 1942, SURG GYNECOL OBSTET, V74, P75; MACKAY EN, 1965, CAN MED ASSOC J, V92, P647; MACLEAN W, 1953, J INT COLL SURG, V20, P430; MAGUIRE A, 1994, EUR J CANCER, V30A, P785, DOI 10.1016/0959-8049(94)90293-3; MAUSNER JS, 1969, CANCER, V23, P260, DOI 10.1002/1097-0142(196902)23:2<260::AID-CNCR2820230203>3.0.CO;2-A; McWhirter R., 1957, J FAC RADIOL, V8, P220; MILLER MW, 1954, AM J ROENTGENOL, V72, P942; MOORE C, 1957, ARCH SURG-CHICAGO, V75, P598, DOI 10.1001/archsurg.1957.01280160108014; NAGADOWSKA M, 1991, EUR J SURG ONCOL, V17, P609; NATHANSON IRA T., 1936, AMER JOUR CANCER, V28, P40; National Cancer Alliance, 1996, PAT CTR CANC SERV WH; NEAVE LM, 1990, BREAST CANCER RES TR, V15, P103, DOI 10.1007/BF01810782; NICOLSON WP, 1948, ANN SURG, V127, P992, DOI 10.1097/00000658-194805000-00019; NOHRMAN BA, 1949, ACTA RADIOLOGICA   S, V77, P1; Norum J, 1996, ONCOL REP, V3, P571; *OFF POP CENS SURV, 1994, SER MB1, V21; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; PATER JL, 1979, J CHRON DIS, V32, P375, DOI 10.1016/0021-9681(79)90079-1; PELTOKALLIO P, 1969, ACTA CHIR SCAND, V135, P585; Peto R, 1998, BRIT MED J, V317, P476; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Raabe NK, 1996, ACTA ONCOL, V35, P9, DOI 10.3109/02841869609098473; RABINOVICH MG, 1993, INT J ONCOL, V2, P197; Ramirez AJ, 1999, LANCET, V353, P1127, DOI 10.1016/S0140-6736(99)02142-X; *REG GEN, 1967, REG GEN STAT REV E S; *REG GEN, 1957, STAT REV ENGL WAL S; RENNAES S, 1960, ACTA CHIR SCAND    S, V266, P7; Richards MA, 1999, BRIT J CANCER, V79, P858, DOI 10.1038/sj.bjc.6690137; RICHARDS MA, 1999, IN PRESS SYSTEMATIC; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; ROBBINS GF, 1957, CANCER, V10, P338, DOI 10.1002/1097-0142(195703/04)10:2<338::AID-CNCR2820100214>3.0.CO;2-I; RUBENS RD, 1977, EUR J CANCER, V13, P805, DOI 10.1016/0014-2964(77)90134-7; SAARIO IA, 1986, ANN CHIR GYNAECOL FE, V75, P254; *SCOTT HLTH SERV, 1996, SCOTT HLTH STAT; Secretary of State for Health, 1997, NEW NHS MOD DEP; SHERIDAN B, 1971, MED J AUSTRALIA, V1, P262, DOI 10.5694/j.1326-5377.1971.tb87551.x; SHIMKIN MB, 1952, SURG GYNECOL OBSTET, V94, P645; SHORE BR, 1940, SURG GYNECOL OBSTET, V71, P515; SIMMONS CC, 1939, SURG GYNECOL OBSTET, V69, P171; SIMMONS CC, 1934, NEW ENGL J MED, V210, P836; SMITHERS DW, 1952, BRIT J RADIOL     S4, P1; TAYLOR GW, 1947, NEW ENGL J MED, V237, P475, DOI 10.1056/NEJM194709252371304; TREVES N, 1958, SURG GYNECOL OBSTET, V107, P271; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WALLGREN A, 1976, ACTA RADIOL THER PHY, V15, P1; WAXMAN BD, 1959, AM J SURG, V97, P31, DOI 10.1016/0002-9610(59)90270-3; Wevill L B, 1932, Edinb Med J, V39, P714; WHITE T T, 1960, Northwest Med, V59, P218; WILKINSON GS, 1979, J CHRON DIS, V32, P365, DOI 10.1016/0021-9681(79)90078-X	103	795	816	1	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1999	353	9159					1119	1126		10.1016/S0140-6736(99)02143-1	http://dx.doi.org/10.1016/S0140-6736(99)02143-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209974				2022-12-28	WOS:000079858400008
J	Clark, GA				Clark, GA			Modern human origins - Highly visible, curiously intangible	SCIENCE			English	Editorial Material									Arizona State Univ, Dept Anthropol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Clark, GA (corresponding author), Arizona State Univ, Dept Anthropol, Tempe, AZ 85287 USA.							BARTON CM, 1994, WORLD ARCHAEOL, V26, P185, DOI 10.1080/00438243.1994.9980272; Barton CM, 1996, J FIELD ARCHAEOL, V23, P111, DOI 10.2307/530611; Clark G. A., 1992, MIDDLE PALEOLITHIC A, P183; Clark G.A., 1997, CONCEPTUAL ISSUES MO, P60; CLARK GA, 1988, AM ANTHROPOL, V90, P357, DOI 10.1525/aa.1988.90.2.02a00070; CLARK GA, 1994, RECHERCHE, V25, P316; Clark GA., 1997, NOR ARCHAEOL REV, V30, P25, DOI [10.1080/00293652.1997.9965608, DOI 10.1080/00293652.1997.9965608]; DIBBLE HL, 1987, AM ANTIQUITY, V52, P109, DOI 10.2307/281062; Duff A. I., 1992, CAMB ARCHAEOL J, V2, P211; FEDER K, 1993, HUMAN ANTIQUITY; FRAYER DW, 1993, AM ANTHROPOL, V95, P14, DOI 10.1525/aa.1993.95.1.02a00020; Johanson D., 1996, LUCY LANGUAGE; JOLLY CJ, 1995, PHYSICAL ANTHR ARCHA; KLEIN RG, 1989, HUMAN CAREER; Kuhn SL., 1995, MOUSTERIAN LITHIC TE, DOI [10.1515/9781400864034, DOI 10.1515/9781400864034]; LINDLY JM, 1990, CURR ANTHROPOL, V31, P233, DOI 10.1086/203836; MELLARS P, 1989, CURR ANTHROPOL, V30, P349, DOI 10.1086/203755; MELLARS P, 1989, YB PHYS ANTHR, V32, P1; NEELEY MP, 1994, ANTIQUITY, V68, P275, DOI 10.1017/S0003598X00046585; STRAUS LG, 1989, NATURE, V342, P476; Tattersall I., 1998, BECOMING HUMAN; WHITE R, 1989, HUMAN REVOLUTION, P385; WILLERMET CM, 1995, J HUM EVOL, V29, P487, DOI 10.1006/jhev.1995.1071	23	33	33	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2029	+		10.1126/science.283.5410.2029	http://dx.doi.org/10.1126/science.283.5410.2029			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	180DH	10206911				2022-12-28	WOS:000079369800032
J	Walley, T; Mantgani, A				Walley, T; Mantgani, A			The UK General Practice Research Database	LANCET			English	Editorial Material							ORAL-CONTRACEPTIVES; RISK		MIRIAM HLTH CTR,BIRKENHEAD,MERSEYSIDE,ENGLAND		Walley, T (corresponding author), UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3GF,MERSEYSIDE,ENGLAND.							ANDERSON HR, 1994, HLTH NEEDS ASSESSMEN, V1; BRADLOW J, 1992, PATTERNS REFERRAL ST; FLEMING DM, 1994, BRIT MED J, V308, P134, DOI 10.1136/bmj.308.6921.134a; *GP RES DAT CO, 1996, EPIC ENCY CLIN PRACT; HALL G C, 1988, Pharmaceutical Medicine (London), V2, P345; Hollowell J, 1997, Popul Trends, P36; HOLLOWELL J, 1996, MEASURING MORBIDITY; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Lewis MA, 1996, BRIT MED J, V312, P88; MARINKER M, 1994, CONTROVERSIES HLTH C; MCCORMACK A, 1995, MORBIDITY STAT GEN P; NAZARETH I, 1993, BRIT MED J, V307, P910, DOI 10.1136/bmj.307.6909.910; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; *OFF NAT STAT, 1996, KEY HLTH STAT GEN PR; Pearson N, 1996, BMJ-BRIT MED J, V312, P1517, DOI 10.1136/bmj.312.7045.1517; RAWLINS MD, 1991, BRIT MED J, V302, P223, DOI 10.1136/bmj.302.6770.223; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102; Spitzer WO, 1996, BRIT MED J, V312, P83; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; *WHO COLL STUD CAR, 1995, LANCET, V346, P1582; *WHO COLL STUD CAR, 1995, LANCET, V346, P1575	23	531	533	2	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1097	1099		10.1016/S0140-6736(97)04248-7	http://dx.doi.org/10.1016/S0140-6736(97)04248-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213569				2022-12-28	WOS:A1997YA73400044
J	Bergers, G; Javaherian, K; Lo, KM; Folkman, J; Hanahan, D				Bergers, G; Javaherian, K; Lo, KM; Folkman, J; Hanahan, D			Effects of angiogenesis inhibitors on multistage carcinogenesis in mice	SCIENCE			English	Article							TRANSGENIC MICE; TUMOR-GROWTH; METHIONINE AMINOPEPTIDASE; ANTIANGIOGENIC THERAPY; TUMORIGENESIS; TRANSITION; FUMAGILLIN; CARCINOMA; MODELS; CANCER	Solid tumors depend on angiogenesis for their growth. In a transgenic mouse model of pancreatic islet cell carcinogenesis (RIP1-Tag2), an angiogenic switch occurs in premalignant Lesions, and angiogenesis persists during progression to expansive solid tumors and invasive carcinomas. RIP1-Tag2 mice were treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of disease progression. ACM-1470, angiostatin, BB-94, and endostatin each produced distinct efficacy profiles in trials aimed at preventing the angiogenic switch in premalignant lesions, intervening in the rapid expansion of small tumors, or inducing the regression of Large end-stage cancers. Thus, anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Childrens Hosp, Med Ctr, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Lexigen Pharmaceut, Lexington, MA 02173 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Hanahan, D (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Bergers, Gabriele/AAJ-5535-2020					ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AUERBACH R, 1982, SCIENCE, V215, P127, DOI 10.1126/science.7053564; Bergers G, 1998, INT J DEV BIOL, V42, P995; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GRANT SGN, 1991, CANCER RES, V51, P4917; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; HAGER JH, IN PRESS MECHANISMS; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HANAHAN G, 1996, EUR J CANCER, V42, P2386; Hursting Stephen D., 1997, Current Opinion in Oncology, V9, P487, DOI 10.1097/00001622-199709050-00015; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1994, CELL, V79, P314; PARANGI S, 1995, CANCER RES, V55, P6071; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Rosenberg MP, 1997, MOL CARCINOGEN, V20, P262, DOI 10.1002/(SICI)1098-2744(199711)20:3<262::AID-MC2>3.0.CO;2-N; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; Teicher BA, 1996, EUR J CANCER, V32A, P2461, DOI 10.1016/S0959-8049(96)00380-2; Vajkoczy Peter, 1999, Neoplasia (New York), V1, P31, DOI 10.1038/sj.neo.7900006; WERB Z, IN RPESS PROTEASE PR	26	816	863	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					808	812		10.1126/science.284.5415.808	http://dx.doi.org/10.1126/science.284.5415.808			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221914				2022-12-28	WOS:000080056200048
J	Rae, TD; Schmidt, PJ; Pufahl, RA; Culotta, VC; O'Halloran, TV				Rae, TD; Schmidt, PJ; Pufahl, RA; Culotta, VC; O'Halloran, TV			Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SACCHAROMYCES-CEREVISIAE; YEAST; GENE; TRAFFICKING; ENCODES; PROTEIN; ATX1	The topper chaperone for the superoxide dismutase (CCS) gene is necessary for expression of an active, copper-bound form of superoxide dismutase (SOD1) in vivo in spite of the high affinity of SOD1 for copper (dissociation constant = 6 fM) and the high intracellular concentrations of both SOD1 (10 mu M in yeast) and copper (70 mu M in yeast), In vitro studies demonstrated that purified Cu(I)-yCCS protein is sufficient for direct copper activation of apo-ySOD1 but is necessary only when the concentration of free copper ions ([Cu](free)) is strictly limited. Moreover, the physiological requirement for yCCS in vivo was readily bypassed by elevated copper concentrations and abrogation of intracellular copper-scavenging systems such as the metallothioneins, This metallochaperone protein activates the target enzyme through direct insertion of the copper cofactor and apparently functions to protect the metal ion from binding to intracellular copper scavengers. These results indicate that intracellular [Cu](free) is Limited to less than one free copper ion per cell and suggest that a pool of free copper ions is not used in physiological activation of metalloenzymes.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Northwestern University; Northwestern University; Johns Hopkins University	Culotta, VC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	vculotta@jhsph.edu; t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021; Johnson, Michael D. L./B-4352-2012	O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019457, R01GM054111, R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054111, F32 GM19457, GM 50016, GM 54111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; GOSCIN SA, 1972, BIOCHIM BIOPHYS ACTA, V289, P276, DOI 10.1016/0005-2744(72)90078-2; HAWKINS CJ, 1963, J CHEM SOC, P2996, DOI 10.1039/jr9630002996; HIROSE J, 1982, ARCH BIOCHEM BIOPHYS, V218, P179, DOI 10.1016/0003-9861(82)90334-4; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schmidt P., UNPUB; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1978, METHODS YEAST GENETI; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VALENTINE JS, 1982, COPPER PROTEINS, P292	27	1290	1327	5	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					805	808		10.1126/science.284.5415.805	http://dx.doi.org/10.1126/science.284.5415.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221913				2022-12-28	WOS:000080056200047
J	Selby, M				Selby, M			Doctors are people too	BRITISH MEDICAL JOURNAL			English	Article									Christmas Maltings Surg, Haverhill CB9 8HF, Suffolk, England		Selby, M (corresponding author), Christmas Maltings Surg, Haverhill CB9 8HF, Suffolk, England.			lowth, mary/0000-0002-0058-8591					0	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1129	1129						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213732				2022-12-28	WOS:000080166000033
J	Daniel, R; Katz, RA; Skalka, AM				Daniel, R; Katz, RA; Skalka, AM			A role for DNA-PK in retroviral DNA integration	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; MURINE LEUKEMIA-VIRUS; HAMSTER OVARY CELL; MAMMALIAN-CELLS; V(D)J RECOMBINATION; AVIAN-SARCOMA; LIGASE-IV; IN-VIVO; MUTATION	Retroviral DNA integration is catalyzed by the viral protein integrase. Here, it is shown that DNA-dependent protein kinase (DNA-PK), a host cell protein, also participates in the reaction. DNA-PK-deficient murine scid cells infected with three different retroviruses showed a substantial reduction in retroviral DNA integration and died by apoptosis. Scid cell killing was not observed after infection with an integrase-defective virus. suggesting that abortive integration is the trigger for death in these DNA repair-deficient cells. These results suggest that the initial events in retroviral integration are detected as DNA damage by the host cell and that completion of;the integration process requires the DNA-PK-mediated repair pathway.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Skalka, AM (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Daniel, Rene/0000-0002-3876-6242	NATIONAL CANCER INSTITUTE [R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI040721] Funding Source: NIH RePORTER; NCI NIH HHS [CA71515] Funding Source: Medline; NIAID NIH HHS [AI40721, AI40835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barsov EV, 1996, J VIROL, V70, P3922, DOI 10.1128/JVI.70.6.3922-3929.1996; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BROWN PO, 1998, RETROVIRUSES, P161; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DANIEL R, UNPUB; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gaken JA, 1996, J VIROL, V70, P3992; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; STOKER AW, 1988, J VIROL, V62, P1008, DOI 10.1128/JVI.62.3.1008-1015.1988; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	35	211	233	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					644	647		10.1126/science.284.5414.644	http://dx.doi.org/10.1126/science.284.5414.644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213687				2022-12-28	WOS:000079951100045
J	Justman, J; Zabezhanskaya, M				Justman, J; Zabezhanskaya, M			Severe herpes simplex infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Bronx Lebanon Hosp Ctr, Bronx, NY 10457 USA	BronxCare Health System	Justman, J (corresponding author), Bronx Lebanon Hosp Ctr, 1650 Grand Concourse,8th Floor, Bronx, NY 10457 USA.		Justman, Jessica/AAA-3572-2020						0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1253	1253		10.1056/NEJM199904223401606	http://dx.doi.org/10.1056/NEJM199904223401606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210709				2022-12-28	WOS:000079833800006
J	Beecham, L				Beecham, L			NHSE will issue circular on working time directive	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205127				2022-12-28	WOS:000080140000080
J	Frankel, S; Eachus, J; Pearson, N; Greenwood, R; Chan, P; Peters, TJ; Donovan, J; Smith, GD; Dieppe, P				Frankel, S; Eachus, J; Pearson, N; Greenwood, R; Chan, P; Peters, TJ; Donovan, J; Smith, GD; Dieppe, P			Population requirement for primary hip-replacement surgery: a cross-sectional study	LANCET			English	Article							OSTEO-ARTHRITIS; WAITING LISTS; ARTHROPLASTY; PREVALENCE; HEALTH; EPIDEMIOLOGY; DEMAND; NEEDS; KNEE; CARE	Background There has been a long-standing failure in many countries to satisfy the demand for several elective surgical treatments, including total hip replacement. We set out to estimate the population requirement for primary total hip replacement in England. Methods We undertook a cross-sectional study of a stratified random sample of 28 080 individuals aged 35 and over from 40 general practices in inner-city, urban, and rural areas of Avon and Somerset, UK. Prevalent disease was identified through a two-stage process: a self-report screening questionnaire (22 978 of 26 046 responded) and subsequent clinical examination. Incident disease was estimated from the point prevalence by statistical modelling. The requirement for total hip replacement surgery was estimated on the basis of pain and loss of functional ability, with adjustment for evidence of comorbidity and patients' treatment preferences. Findings 3169 people reported hip pain on the screening questionnaire. 2018 were invited for clinical examination, and 1405 attended. The prevalence of self-reported hip pain was 107 per 1000 (95% CI 101-113) for men and 173 per 1000 (166-180) for women, the prevalence of hip disease severe enough to require surgery was 15 . 2 (12 . 7-17 . 8) per 1000 aged 35-85 years. The corresponding annual incidence of hip disease requiring surgery was estimated as 2 . 23 (1 . 56-2 . 90),which suggests an overall requirement in England of 46 600 operations per year for patients who expressed a preference for, and were suitable for, surgery; the recent actual provision in England was about 43 500. Interpretation This research suggests that the satisfaction of demand for total hip replacement, given agreed criteria for surgery, is a realistic objective.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	stephen.frankel@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Peters, Tim/0000-0003-2881-4180				ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; *DEP HLTH, HOSP EP STAT ENGL FI; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; Fear J, 1997, BRIT J RHEUMATOL, V36, P74; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1993, RHEUM DIS CLIN N AM, V19, P607; Frankel, 1996, PRIORITY SETTING HLT; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; FRANKEL S, 1993, RATIONING RATIONALIT; Hadorn DC, 1997, BRIT MED J, V314, P131, DOI 10.1136/bmj.314.7074.131; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; LESKE MC, 1981, AM J EPIDEMIOL, V113, P606, DOI 10.1093/oxfordjournals.aje.a113138; LOWRY RJ, 1991, PUBLIC HEALTH, V105, P351, DOI 10.1016/S0033-3506(05)80594-3; MADHOK R, 1993, MAYO CLIN PROC, V68, P11, DOI 10.1016/S0025-6196(12)60013-5; MELTON LJ, 1982, NEW ENGL J MED, V307, P1242, DOI 10.1056/NEJM198211113072004; MURRAY DG, 1995, JAMA-J AM MED ASSOC, V273, P1950, DOI 10.1001/jama.1995.03520480070043; Neumann D A, 1990, Arthritis Care Res, V3, P116; NILSSON BE, 1982, SCAND J RHEUMATOL, P13; *OFF POP CENS SURV, 1991, MORT STAT; OVERGAARD S, 1992, ACTA ORTHOP SCAND, V63, P536, DOI 10.3109/17453679209154731; PERRY GH, 1972, ANN RHEUM DIS, V31, P440, DOI 10.1136/ard.31.6.440; PETERS TJ, 1995, PAEDIATR PERINAT EP, V9, P219, DOI 10.1111/j.1365-3016.1995.tb00135.x; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; Sanderson CFB, 1997, MED CARE, V35, P669, DOI 10.1097/00005650-199707000-00002; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SHELBOURNE KD, 1996, SPORTS EXERC INJURY, V2, P1; SMITH R, 1995, BRIT MED J, V310, P686, DOI 10.1136/bmj.310.6981.686; Stevens A, 1991, Health Trends, V23, P20; Warden J, 1997, BRIT MED J, V315, P1332; WILCOCK GK, 1979, INT J EPIDEMIOL, V8, P247, DOI 10.1093/ije/8.3.247	31	112	112	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	1999	353	9161					1304	1309		10.1016/S0140-6736(98)06451-4	http://dx.doi.org/10.1016/S0140-6736(98)06451-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218528				2022-12-28	WOS:000080278100010
J	Bodenheimer, T				Bodenheimer, T			Disease management - Promises and pitfalls	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHRONIC ILLNESS; DIABETES MANAGEMENT; CARE; POPULATION		Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA.							ANDERSON D, 1996, BUSINESS HLTH SA, V14, P19; Burns H, 1996, LANCET, V347, P1021, DOI 10.1016/S0140-6736(96)90151-8; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Gerson V, 1996, Bus Health, V14, P29; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Homer CJ, 1997, NEW ENGL J MED, V337, P1461, DOI 10.1056/NEJM199711133372010; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; Lucas J, 1995, Manag Care Q, V3, P14; McCulloch D K, 1998, Eff Clin Pract, V1, P12; MCCULLOCH DK, 1994, DIABETES CARE, V17, P765, DOI 10.2337/diacare.17.7.765; NICHOLS NA, 1994, MED MANAGEMENT MERGE, P105; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rubin RJ, 1998, J CLIN ENDOCR METAB, V83, P2635, DOI 10.1210/jc.83.8.2635; SADUR C, 1997, DIABETES S1, V46, pA61; SPALDING J, 1996, FAMILY PRACTICE MAR, P71; STOCKWELL DH, 1994, AM J PUBLIC HEALTH, V84, P1768, DOI 10.2105/AJPH.84.11.1768; The Boston Consulting Group, 1995, PROM DIS MAN; TODD W, 1997, DIS MANAGEMENT SYSTE; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 1997, HEALTH SERV RES, V32, P702; WAGNER EH, 1995, PATIENT EDUC COUNS, V26, P225, DOI 10.1016/0738-3991(95)00761-N; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; 1998, HEALTHCARE DEMAND DI, V4, P120; 1997, MED HLTH PERSPE 0707, P1	28	132	132	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1202	1205		10.1056/NEJM199904153401511	http://dx.doi.org/10.1056/NEJM199904153401511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202174				2022-12-28	WOS:000079687700011
J	Strawford, A; Barbieri, T; Van Loan, M; Parks, E; Catlin, D; Barton, N; Neese, R; Christiansen, M; King, J; Hellerstein, MK				Strawford, A; Barbieri, T; Van Loan, M; Parks, E; Catlin, D; Barton, N; Neese, R; Christiansen, M; King, J; Hellerstein, MK			Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DENOVO HEPATIC LIPOGENESIS; PLACEBO-CONTROLLED TRIAL; HUMAN GROWTH-HORMONE; DE-NOVO LIPOGENESIS; ALCOHOLIC HEPATITIS; MEGESTROL-ACETATE; BODY-COMPOSITION; SHORT-TERM; AIDS	Context Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. in healthy, HIV-seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength. Objective To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism. Design Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997. Setting Referral center in San Francisco, Calif. Patients Volunteer sample of 24 eugonadal men with HIV-associated weightless (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement. Intervention For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo. Main Outcome Measures Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status. Results Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8] g of nitrogen per day [P = .05]; 6.9[1.7] vs 3.8 [2.9] kg of LBM [P = .005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted CP = .02-.05] and dynamometry [P = .01 -.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results. Conclusions A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA; USDA, Western Human Nutr Res Ctr, San Francisco, CA USA; London Sch Hyg & Trop Med, Human Nutr Unit, London WC1, England; Biotechnol Gen Corp, Iselin, NJ USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley; United States Department of Agriculture (USDA); University of London; London School of Hygiene & Tropical Medicine; University of California System; University of California Los Angeles	Hellerstein, MK (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA.	march@nature.berkeley.edu		Parks, Elizabeth/0000-0001-5681-1097	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELBAUM DM, 1987, METABOLISM, V36, P945; BERNER DL, 1994, J AM OIL CHEM SOC, V71, P1291, DOI 10.1007/BF02540554; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; CANNON JG, 1989, AM J PHYSIOL, V257, pR451, DOI 10.1152/ajpregu.1989.257.2.R451; CARR A, 1998, 5 C RETR OPP INF CHI, P156; CATLIN DH, 1987, CLIN CHEM, V33, P319; Catlin DH, 1997, CLIN CHEM, V43, P1280; CATLIN DH, 1995, ENDOCRINOLOGY, P2362; COOK J G H, 1975, Annals of Clinical Biochemistry, V12, P219; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; Evans W J, 1991, Exerc Sport Sci Rev, V19, P99; FORBES GB, 1987, HUMAN BODY COMPOSITI, P64; FRUTH SI, 1995, J ORTHOP SPORT PHYS, V22, P26, DOI 10.2519/jospt.1995.22.1.26; FUJIOKA M, 1986, J CLIN ENDOCR METAB, V63, P1361, DOI 10.1210/jcem-63-6-1361; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; GRUNFELD C, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90225-8; Hellerstein MK, 1996, ANNU REV NUTR, V16, P523, DOI 10.1146/annurev.nu.16.070196.002515; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1996, MANAGEMENT HIV INFEC, P194; Hoh R, 1998, AM J CLIN NUTR, V68, P154, DOI 10.1093/ajcn/68.1.154; Klein S, 1997, AM J CLIN NUTR, V66, P683, DOI 10.1093/ajcn/66.3.683; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Kraemer W, 1995, PHYSL ASSESSMENT HUM, P115; MALHOTRA A, 1993, CLIN ENDOCRINOL, V38, P393, DOI 10.1111/j.1365-2265.1993.tb00520.x; MENDENHALL CL, 1984, NEW ENGL J MED, V311, P1464, DOI 10.1056/NEJM198412063112302; MENDENHALL CL, 1993, HEPATOLOGY, V17, P564, DOI 10.1002/hep.1840170407; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; NINDL BC, 1994, FASEB J, V8, pA724; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; ROTH VR, 1998, 5 C RETR OPP INF FEB, P157; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; SILVA M, IN PRESS AIDS; Strawford A, 1999, J ACQ IMMUN DEF SYND, V20, P137, DOI 10.1097/00042560-199902010-00005; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; TVEDE N, 1993, INT J SPORTS MED, V14, P275, DOI 10.1055/s-2007-1021177; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; Wheeler David A., 1996, P332; World Health Organization, 1985, Technical Report Series	41	142	144	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1282	1290		10.1001/jama.281.14.1282	http://dx.doi.org/10.1001/jama.281.14.1282			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208143				2022-12-28	WOS:000079628700032
J	Wong, ZYH; Stebbing, M; Ellis, JA; Lamantia, A; Harrap, SB				Wong, ZYH; Stebbing, M; Ellis, JA; Lamantia, A; Harrap, SB			Genetic linkage of beta and gamma subunits of epithelial sodium channel to systolic blood pressure	LANCET			English	Article							HUMAN HYPERTENSION; PSEUDOHYPOALDOSTERONISM TYPE-1; CARDIOVASCULAR-DISEASE; MUTATIONS; POPULATION; LESSONS; TRAITS	Background Mutations in the genes on chromosome 16p12 that encode the beta and gamma subunits of the epithelial sodium channel (SCNNIB and SCNNIG, respectively) have been linked with rare sodium-dependent forms of low and high blood pressure. Other DNA variants in or around these genes may contribute to variation in blood pressure and the risk of coronary heart disease and stroke. Methods We studied 286 white families from the general population in Victoria, Australia. Each family comprised both parents and two natural children. All participants were genotyped at chromosome 16p12 by use of four highly polymorphic microsatellite markers. Quantitative phonotype measurements were correlated with genotype in identity-by-descent sibling-pair linkage analyses. Findings We found significant linkage between systolic blood pressure and chromosome 16p12 after parametric analyses (p=0.0003) and non-parametric analyses (p=0.001). The mean difference in systolic blood pressure between siblings identical-by-descent at these loci was half as large (7.1 mm Hg) as the difference between siblings non-identical at these loci (14.0 mm Hg, p=0.001). No linkage between chromosome 16p12 and diastolic blood pressure or body-mass index was observed. Interpretation Chromosome 16p12 and the SCNNIB and SCNNIG genes are implicated in the physiological variation of systolic blood pressure. Our findings are important in explaining individual cardiovascular risk within the general population.	Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia	University of Melbourne	Harrap, SB (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia.		Ellis, Justine A/G-5006-2011	Harrap, Stephen/0000-0003-2907-6714; Ellis, Justine/0000-0003-4103-4445				Antikainen R, 1998, J HYPERTENS, V16, P577, DOI 10.1097/00004872-199816050-00004; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Chang HG, 1996, J HYPERTENS, V14, P1417, DOI 10.1097/00004872-199612000-00005; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Fuller PJ, 1996, J HYPERTENS, V14, P1383, DOI 10.1097/00004872-199612000-00001; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRAP SB, 1994, LANCET, V344, P169, DOI 10.1016/S0140-6736(94)92762-6; KANNEL WB, 1976, AM J CARDIOL, V37, P269, DOI 10.1016/0002-9149(76)90323-4; Kreutz R, 1997, HYPERTENSION, V29, P131, DOI 10.1161/01.HYP.29.1.131; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Luft Friedrich C., 1997, American Journal of Clinical Nutrition, V65, p612S, DOI 10.1093/ajcn/65.2.612S; MESSERLI FH, 1997, ARCH INTERN MED, V157, P2407; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; Persu A, 1998, HYPERTENSION, V32, P129, DOI 10.1161/01.HYP.32.1.129; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SAFAR ME, 1994, AM J MED SCI, V307, pS3; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; WATT GCM, 1988, J CARDIOVASC PHARM, V12, pS21; White PC, 1996, HYPERTENSION, V28, P927, DOI 10.1161/01.HYP.28.6.927	26	51	52	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1222	1225		10.1016/S0140-6736(98)10118-6	http://dx.doi.org/10.1016/S0140-6736(98)10118-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217082				2022-12-28	WOS:000079744100010
J	Veigel, C; Coluccio, LM; Jontes, JD; Sparrow, JC; Milligan, RA; Molloy, JE				Veigel, C; Coluccio, LM; Jontes, JD; Sparrow, JC; Milligan, RA; Molloy, JE			The motor protein myosin-I produces its working stroke in two steps	NATURE			English	Article							ACTIN-FILAMENTS; FORCE GENERATION; LIVER; SUBFRAGMENT-1; MECHANISM; INVITRO; RELEASE; MUSCLE; MOVE	Many types of cellular motility including muscle contraction, are driven by the cyclical interaction of the motor protein myosin with actin filaments, coupled to the breakdown of ATP. It is thought that myosin binds to actin and then produces force and movement as it 'tilts' or 'rocks' into one or more subsequent, stable conformations(1,2). Here we use an optical-tweezers transducer to measure the mechanical transitions made by a single myosin head while it is attached to actin We find that two members of the myosin-I family, rat liver myosin-I of relative molecular mass 130,000 (M-r 130K) and chick intestinal brush-border myosin-I, produce movement in two distinct steps. The initial movement (of roughly 6 nanometres) is produced within 10 milliseconds of actomyosin binding, and the second step (of roughly 5.5 nanometres) occurs after a variable time delay The duration of the period following the second step is also variable and depends on the concentration of ATP. At the highest time resolution possible (about I millisecond), we cannot detect this second step when studying the single-headed subfragment-1 of fast skeletal muscle myosin II. The slower kinetics of myosin-I have allowed us to observe the separate mechanical states that contribute to its working stroke.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Boston Biomed Res Inst, Boston, MA 02114 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of York - UK; Boston Biomedical Research Institute; Scripps Research Institute	Molloy, JE (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.	jeml@york.ac.uk		Molloy, Justin/0000-0002-8307-2450				COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; Colquhoun David, 1995, P483; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Iwane AH, 1997, BIOCHEM BIOPH RES CO, V230, P76, DOI 10.1006/bbrc.1996.5861; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Molloy J. E., 1995, Biophysical Journal, V68, P298; MOLLOY JE, 1987, NATURE, V328, P449, DOI 10.1038/328449a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105	24	244	246	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					530	533		10.1038/19104	http://dx.doi.org/10.1038/19104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206648				2022-12-28	WOS:000079662800052
J	Solter, D; Gearhart, J				Solter, D; Gearhart, J			Biomedicine - Putting stem cells to work	SCIENCE			English	Editorial Material									Max Planck Inst Immunol, Dept Dev Biol, Freiburg, Germany; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Max Planck Society; Johns Hopkins University	Solter, D (corresponding author), Max Planck Inst Immunol, Dept Dev Biol, Freiburg, Germany.	solter@immunbio.mpg.de; gearhart@jhmi.edu	Solter, Davor/Q-5476-2019					Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kolata Gina, 1999, N Y Times Web, pF2; LIPSICH LA, 1979, NATURE, V281, P74, DOI 10.1038/281074a0; Marshall E, 1998, SCIENCE, V282, P1390, DOI 10.1126/science.282.5393.1390; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Rossant J, 1999, NAT BIOTECHNOL, V17, P23, DOI 10.1038/5194; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Smith A, 1998, CURR BIOL, V8, pR802, DOI 10.1016/S0960-9822(07)00504-0; Solter D, 1998, NATURE, V394, P315, DOI 10.1038/28485; SOLTER D, 1985, COLD SPRING HARB SYM, V50, P45, DOI 10.1101/SQB.1985.050.01.008; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	12	90	106	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1468	1470		10.1126/science.283.5407.1468	http://dx.doi.org/10.1126/science.283.5407.1468			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10206877				2022-12-28	WOS:000078959200030
J	Horton, R				Horton, R			ICRF: from mayhem to meltdown	LANCET			English	Editorial Material																			0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1043	1044		10.1016/S0140-6736(05)70449-9	http://dx.doi.org/10.1016/S0140-6736(05)70449-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213542				2022-12-28	WOS:A1997YA73400003
J	Laferl, H				Laferl, H			Pleural effusion and ascites on return from Pakistan	LANCET			English	Article							FEVER				Laferl, H (corresponding author), KAISER FRANZ JOSEF HOSP,MED DEPT INFECT DIS & TROP MED 4,KUNDRATSTR 3,A-1100 VIENNA,AUSTRIA.							Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P353; Chan YC, 1995, T ROY SOC TROP MED H, V89, P619, DOI 10.1016/0035-9203(95)90412-3; NIMMANNITYA S, 1996, MANSONS TROPICAL DIS, P721; SCHWARZ TF, 1996, ARCH VIROL         S, V11, P57; WITTESJO B, 1993, SCAND J INFECT DIS, V25, P699, DOI 10.3109/00365549309008566	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1072	1072		10.1016/S0140-6736(97)08170-1	http://dx.doi.org/10.1016/S0140-6736(97)08170-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213550				2022-12-28	WOS:A1997YA73400011
J	Aronson, J				Aronson, J			When I use a word ... Hepatojugular reflux	BRITISH MEDICAL JOURNAL			English	Article																		DALTON HR, 1997, FINAL MB GUIDE SUCCE; ELLIOTT DL, 1997, HIST PHYSICAL EXAMIN; Sapira JD, 1990, ART SCI BEDSIDE DIAG; TALLEY N, 1996, CLIN EXAMINATION SYS; TIMMIS AD, 1995, PRINCIPLES CLIN MED	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1172	1172						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221938				2022-12-28	WOS:000080277900027
J	Selby, M				Selby, M			Ethical dilemma - Dealing with racist patients	BRITISH MEDICAL JOURNAL			English	Editorial Material											Selby, M (corresponding author), Christmas Maltings, Haverhill CB9 8HF, Suffolk, England.			lowth, mary/0000-0002-0058-8591					0	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1129	1129						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213732				2022-12-28	WOS:000080166000034
J	Rice, G; Anderson, C; Risch, N; Ebers, G				Rice, G; Anderson, C; Risch, N; Ebers, G			Male homosexuality: Absence of linkage to microsatellite markers at Xq28	SCIENCE			English	Article							MALE SEXUAL ORIENTATION; CHROMOSOME	Several lines of evidence have implicated genetic factors in homosexuality. The most compelling observation has been the report of genetic linkage of male homosexuality to microsatellite markers on the X chromosome. This observation warranted further study and confirmation. Sharing of alleles at position Xq28 was studied in 52 gay male sibling pairs from Canadian families. Four markers at Xq28 were analyzed (DXS1113, BGN, Factor 8, and DXS1108). Allele and haplotype sharing for these markers was not increased over expectation. These results do not support an X-linked gene underlying male homosexuality.	Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Western University (University of Western Ontario); Stanford University	Rice, G (corresponding author), Univ Western Ontario, Dept Clin Neurol Sci, 339 Windermere Rd, London, ON N6A 5A5, Canada.			Ebers, George/0000-0003-4771-4177				BAILEY JM, 1993, ARCH GEN PSYCHIAT, V50, P217; BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; BARON M, 1993, BRIT MED J, V307, P337, DOI 10.1136/bmj.307.6900.337; BARON M, 1993, BIOL PSYCHIAT, V33, P759, DOI 10.1016/0006-3223(93)90016-7; BYNE W, 1993, ARCH GEN PSYCHIAT, V50, P228; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5; HINDS D, COMMUNICATION; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; PILLARD RC, 1986, ARCH GEN PSYCHIAT, V43, P808; PILLARD RC, 1981, ARCH SEX BEHAV, V10, P465, DOI 10.1007/BF01541437; RISCH N, 1993, SCIENCE, V262, P2063, DOI 10.1126/science.8266107	13	137	144	4	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					665	667		10.1126/science.284.5414.665	http://dx.doi.org/10.1126/science.284.5414.665			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213693				2022-12-28	WOS:000079951100051
J	Mantzoros, CS				Mantzoros, CS			The role of leptin in human obesity and disease: A review of current evidence	ANNALS OF INTERNAL MEDICINE			English	Review							POLYCYSTIC-OVARY-SYNDROME; HUMAN OB GENE; BODY-MASS INDEX; CEREBROSPINAL-FLUID LEPTIN; SYMPATHETIC-NERVE ACTIVITY; EARLY-ONSET OBESITY; PLASMA LEPTIN; SERUM LEPTIN; SHORT-TERM; MESSENGER-RNA	Purpose: To review recent advances in the pathophysiology and potential clinical applications of leptin, an adipose tissue-derived hormone. Data Sources: A MEDLINE search of the literature on leptin and the bibliographies of relevant papers. Study Selection: All 1320 publications on leptin. Data Extraction: All identified articles were reviewed. Cited publications were selected on the basis of study quality and relevance to human obesity and disease. Data Synthesis: Leptin is a 16-kilodalton adipocyte-derived hormone that circulates in the serum in the free and bound form. Serum levels of leptin reflect the amount of energy stored in adipose tissue. Short-term energy imbalance as well as serum levels of several cytokines and hormones influence circulating leptin levels. Leptin acts by binding to specific receptors in the hypothalamus to alter the expression of several neuropeptides that regulate neuroendocrine function and energy intake and expenditure. Thus, leptin plays an important role in the pathogenesis of obesity and eating disorders and is thought to mediate the neuroendocrine response to food deprivation. Phase I and II trials recently showed that leptin administration to humans is safe, and ongoing phase III trials are assessing the efficacy of leptin as a treatment for obesity and related disorders. Availability of leptin or smaller and more soluble leptin analogues for clinical studies in humans is expected to significantly advance understanding of the mechanisms underlying energy homeostasis in humans. Conclusions: Leptin is significantly broadening our understanding of the mechanisms underlying neuroendocrine function, body weight, and energy homeostasis. Elucidation of these mechanisms is expected to result in the development of novel therapeutic approaches for obesity and eating disorders.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mantzoros, CS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, RN 325,330 Brookline Ave, Boston, MA 02215 USA.	cmantzor@bidmc.harvard.edu	Mantzoros, Christos/Y-2902-2019		NIDDK NIH HHS [P30 DK 46200] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Audi L, 1998, MOL PSYCHIATR, V3, P544, DOI 10.1038/sj.mp.4000418; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; BALLAUFF A, 1999, IN PRESS MOL PSYCHIA; Barinaga M, 1996, SCIENCE, V274, P1466; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bornstein SR, 1997, DIABETES, V46, P1235, DOI 10.2337/diabetes.46.7.1235; Brzechffa PR, 1996, J CLIN ENDOCR METAB, V81, P4166, DOI 10.1210/jc.81.11.4166; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Carro E, 1997, ENDOCRINOLOGY, V138, P2203, DOI 10.1210/en.138.5.2203; Casabiell X, 1997, J CLIN ENDOCR METAB, V82, P4270, DOI 10.1210/jc.82.12.4270; Chapman IM, 1997, CLIN ENDOCRINOL, V46, P175, DOI 10.1046/j.1365-2265.1997.1200936.x; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Cizza G, 1997, J CLIN ENDOCR METAB, V82, P2747, DOI 10.1210/jc.82.8.2747; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Considine RV, 1996, BIOCHEM BIOPH RES CO, V220, P735, DOI 10.1006/bbrc.1996.0473; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; Conway GS, 1997, HUM REPROD, V12, P633, DOI 10.1093/humrep/12.4.633; Costa A, 1997, NEUROREPORT, V8, P1131, DOI 10.1097/00001756-199703240-00014; Cumin F, 1996, INT J OBESITY, V20, P1120; Deuschle M, 1996, HORM METAB RES, V28, P714, DOI 10.1055/s-2007-979885; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Donahoo WT, 1997, J CLIN ENDOCR METAB, V82, P4139, DOI 10.1210/jc.82.12.4139; Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Espat NJ, 1996, AM J PHYSIOL-REG I, V271, pR185, DOI 10.1152/ajpregu.1996.271.1.R185; FAROOKI LS, 1998, 8 INT C OB, P7; Ferron F, 1997, CLIN ENDOCRINOL, V46, P289, DOI 10.1046/j.1365-2265.1997.1260938.x; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Friedman JM, 1998, NUTR REV, V56, pS38; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P2849, DOI 10.1210/jc.82.9.2849; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; Gong DW, 1996, J BIOL CHEM, V271, P3971; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3861, DOI 10.1210/jc.81.11.3861; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Grunfeld C, 1996, J CLIN ENDOCR METAB, V81, P4342, DOI 10.1210/jc.81.12.4342; Haffner SM, 1997, INT J OBESITY, V21, P393, DOI 10.1038/sj.ijo.0800419; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hassink SG, 1996, PEDIATRICS, V98, P201; Haynes WG, 1997, HYPERTENSION, V30, P619, DOI 10.1161/01.HYP.30.3.619; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Hebebrand J, 1997, MOL PSYCHIATR, V2, P330, DOI 10.1038/sj.mp.4000282; Henderson JT, 1996, CYTOKINE, V8, P784, DOI 10.1006/cyto.1996.0104; Hickey MS, 1997, AM J PHYSIOL-ENDOC M, V272, pE562, DOI 10.1152/ajpendo.1997.272.4.E562; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Jackson EK, 1997, AM J PHYSIOL-RENAL, V272, pF333, DOI 10.1152/ajprenal.1997.272.3.F333; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Jenkins AB, 1997, DIABETOLOGIA, V40, P348, DOI 10.1007/s001250050686; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Karlsson C, 1997, J CLIN ENDOCR METAB, V82, P4144, DOI 10.1210/jc.82.12.4144; Kiess W, 1996, HORM METAB RES, V28, P708, DOI 10.1055/s-2007-979883; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Kolaczynski JW, 1996, J CLIN ENDOCR METAB, V81, P4162, DOI 10.1210/jc.81.11.4162; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Larsson H, 1996, J CLIN ENDOCR METAB, V81, P4428, DOI 10.1210/jc.81.12.4428; Laughlin GA, 1997, J CLIN ENDOCR METAB, V82, P1692, DOI 10.1210/jc.82.6.1692; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Legradi G, 1997, ENDOCRINOLOGY, V138, P2569, DOI 10.1210/en.138.6.2569; Licinio J, 1998, P NATL ACAD SCI USA, V95, P2541, DOI 10.1073/pnas.95.5.2541; Licinio J, 1997, NAT MED, V3, P575, DOI 10.1038/nm0597-575; Lonnqvist F, 1997, J CLIN INVEST, V99, P2398, DOI 10.1172/JCI119422; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; Lynn RB, 1996, BIOCHEM BIOPH RES CO, V219, P884, DOI 10.1006/bbrc.1996.0328; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; Malmstrom R, 1996, DIABETOLOGIA, V39, P993; Mantzoros C, 1997, J CLIN ENDOCR METAB, V82, P1845, DOI 10.1210/jc.82.6.1845; Mantzoros C S, 1995, Adv Endocrinol Metab, V6, P193; Mantzoros CS, 1998, J AM COLL NUTR, V17, P270, DOI 10.1080/07315724.1998.10718758; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1687, DOI 10.1210/jc.82.6.1687; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P497, DOI 10.1210/jc.82.2.497; Mantzoros CS, 1998, OBES RES, V6, P179, DOI 10.1002/j.1550-8528.1998.tb00335.x; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Mantzoros CS, 1999, MOL PSYCHIATR, V4, P8, DOI 10.1038/sj.mp.4000497; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Mantzoros CS, 1998, DIABETES, V47, P230, DOI 10.2337/diabetes.47.2.230; Mantzoros CS, 1997, MOL PSYCHIATR, V2, P377, DOI 10.1038/sj.mp.4000323; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P2856, DOI 10.1210/jc.82.9.2856; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Masuzaki H, 1997, J CLIN ENDOCR METAB, V82, P2542, DOI 10.1210/jc.82.8.2542; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matsuda J, 1997, J CLIN ENDOCR METAB, V82, P1642, DOI 10.1210/jc.82.5.1642; McGregor GP, 1996, ENDOCRINOLOGY, V137, P1501, DOI 10.1210/en.137.4.1501; Merabet E, 1997, J CLIN ENDOCR METAB, V82, P847, DOI 10.1210/jc.82.3.847; Miell JP, 1996, HORM METAB RES, V28, P704, DOI 10.1055/s-2007-979882; Mikhail AA, 1997, BLOOD, V89, P1507, DOI 10.1182/blood.V89.5.1507.1507_1507_1512; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Murakami T, 1997, BIOCHEM BIOPH RES CO, V231, P26, DOI 10.1006/bbrc.1996.6030; Niki T, 1996, DIABETES, V45, P675, DOI 10.2337/diabetes.45.5.675; Nolan JJ, 1996, DIABETES, V45, P1276, DOI 10.2337/diabetes.45.9.1276; Ostlund RE, 1996, J CLIN ENDOCR METAB, V81, P3909, DOI 10.1210/jc.81.11.3909; PapaspyrouRao S, 1997, J CLIN ENDOCR METAB, V82, P1635, DOI 10.1210/jc.82.5.1635; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; Remesar X, 1997, FEBS LETT, V402, P9, DOI 10.1016/S0014-5793(96)01477-9; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; Rogol AD, 1998, J CLIN ENDOCR METAB, V83, P1089, DOI 10.1210/jc.83.4.1089; RohnerJeanrenaud F, 1996, NEW ENGL J MED, V334, P324, DOI 10.1056/NEJM199602013340511; Ronnemaa T, 1997, ANN INTERN MED, V126, P26, DOI 10.7326/0003-4819-126-1-199701010-00004; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Rouru J, 1997, J CLIN ENDOCR METAB, V82, P1697, DOI 10.1210/jc.82.6.1697; Ryan AS, 1996, J CLIN ENDOCR METAB, V81, P4433, DOI 10.1210/jc.81.12.4433; Saad MF, 1997, J CLIN ENDOCR METAB, V82, P579, DOI 10.1210/jc.82.2.579; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Scholz GH, 1996, HORM METAB RES, V28, P718, DOI 10.1055/s-2007-979886; Schrauwen P, 1997, METABOLISM, V46, P420, DOI 10.1016/S0026-0495(97)90059-7; Schubring C, 1996, EUR J PEDIATR, V155, P830, DOI 10.1007/BF02002918; Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1997, NEW ENGL J MED, V336, P1802, DOI 10.1056/NEJM199706193362507; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; Shek EW, 1998, HYPERTENSION, V31, P409, DOI 10.1161/01.HYP.31.1.409; Shimizu H, 1997, J ENDOCRINOL, V154, P285, DOI 10.1677/joe.0.1540285; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Sinha MK, 1996, BIOCHEM BIOPH RES CO, V228, P733, DOI 10.1006/bbrc.1996.1724; Sivan E, 1997, DIABETES, V46, P917, DOI 10.2337/diabetes.46.5.917; Sivitz WI, 1997, ENDOCRINOLOGY, V138, P3395, DOI 10.1210/en.138.8.3395; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; Snitker S, 1997, OBES RES, V5, P338, DOI 10.1002/j.1550-8528.1997.tb00561.x; Spicer LJ, 1997, ENDOCRINOLOGY, V138, P3374, DOI 10.1210/en.138.8.3374; Steiner RA, 1996, ENDOCRINOLOGY, V137, P4533, DOI 10.1210/en.137.11.4533; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tritos NA, 1997, DIABETOLOGIA, V40, P1371, DOI 10.1007/s001250050838; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Ur E, 1996, HORM METAB RES, V28, P744, DOI 10.1055/s-2007-979891; Utriainen T, 1996, DIABETES, V45, P1364, DOI 10.2337/diabetes.45.10.1364; Valcavi R, 1997, J CLIN ENDOCR METAB, V82, P1632, DOI 10.1210/jc.82.5.1632; Wabitsch M, 1996, DIABETES, V45, P1435, DOI 10.2337/diabetes.45.10.1435; Wolf G, 1997, NUTR REV, V55, P85, DOI 10.1111/j.1753-4887.1997.tb01602.x; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yarasheski KE, 1997, METABOLISM, V46, P303, DOI 10.1016/S0026-0495(97)90258-4; Yoshida T, 1997, BIOCHEM BIOPH RES CO, V232, P822, DOI 10.1006/bbrc.1997.6378; Yu WH, 1997, P NATL ACAD SCI USA, V94, P1023, DOI 10.1073/pnas.94.3.1023; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; Zakrzewska KE, 1997, DIABETES, V46, P717, DOI 10.2337/diabetes.46.4.717; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zumbach MS, 1997, J CLIN ENDOCR METAB, V82, P4080, DOI 10.1210/jc.82.12.4080	160	450	484	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					671	680		10.7326/0003-4819-130-8-199904200-00014	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215564				2022-12-28	WOS:000079786600007
J	Wessels, T; Baerlocher, C; McCusker, LB				Wessels, T; Baerlocher, C; McCusker, LB			Single-crystal-like diffraction data from polycrystalline materials	SCIENCE			English	Article							RAY-POWDER DIFFRACTION; INITIO STRUCTURE DETERMINATION; OVERLAPPING REFLECTIONS; GENETIC ALGORITHM; ZEOLITE; INTENSITIES	A method for solving structures from powder diffraction data was developed, and its validity was demonstrated on three complex structures. The method uses a textured sample and exploits the high intensity and parallel nature of synchrotron radiation. In principle, crystal structures as complex as those routinely solved by single-crystal methods can be determined with this approach. For example, the as-synthesized form of the zeolite UTD-1, with 69 nonhydrogen atoms in the asymmetric unit, could be solved directly. With this method, a larger range of structural complexity becomes accessible to scientists interested in the structures of polycrystalline materials that cannot be grown as single crystals.	ETH Zurich, Lab Kristallog, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	McCusker, LB (corresponding author), ETH Zurich, Lab Kristallog, CH-8092 Zurich, Switzerland.			McCusker, Lynne/0000-0003-0074-1733				ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P1045, DOI 10.1107/S002188989400422X; Andreev YG, 1998, MATER SCI FORUM, V278-2, P14, DOI 10.4028/www.scientific.net/MSF.278-281.14; Andreev YG, 1997, J APPL CRYSTALLOGR, V30, P294, DOI 10.1107/S0021889896013556; Bunge H, 1993, TEXTURE ANAL MAT SCI; DAVID WIF, 1987, J APPL CRYSTALLOGR, V20, P316, DOI 10.1107/S0021889887086618; DEEM MW, 1992, J AM CHEM SOC, V114, P7189, DOI 10.1021/ja00044a035; Freyhardt CC, 1996, NATURE, V381, P295, DOI 10.1038/381295a0; Giacovazzo C, 1996, ACTA CRYSTALLOGR A, V52, P331, DOI 10.1107/S0108767395013651; GIES H, 1995, Z KRISTALLOGR, V210, P475, DOI 10.1524/zkri.1995.210.7.475; GILMORE CJ, 1991, ACTA CRYSTALLOGR A, V47, P830, DOI 10.1107/S0108767391005421; Grosse-Kunstleve RW, 1997, J APPL CRYSTALLOGR, V30, P985, DOI 10.1107/S0021889897005013; Harris KDM, 1998, ACTA CRYSTALLOGR A, V54, P632, DOI 10.1107/S0108767398003389; HASTINGS JB, 1984, J APPL CRYSTALLOGR, V17, P85, DOI 10.1107/S0021889884011043; JANSEN J, 1993, Z KRISTALLOGR, V206, P33, DOI 10.1524/zkri.1993.206.Part-1.33; Lasocha W, 1997, J APPL CRYSTALLOGR, V30, P561, DOI 10.1107/S0021889897011023; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; Lobo RF, 1997, J AM CHEM SOC, V119, P8474, DOI 10.1021/ja9708528; Reck G., 1997, TEXTURE MICROSTRUCT, V29, P103; Shankland K, 1997, Z KRISTALLOGR, V212, P550, DOI 10.1524/zkri.1997.212.8.550; Shankland K, 1997, J MATER CHEM, V7, P569, DOI 10.1039/a606998c; WESSELS T, UNPUB	21	56	57	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					477	479		10.1126/science.284.5413.477	http://dx.doi.org/10.1126/science.284.5413.477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205053				2022-12-28	WOS:000079792200044
J	Colhoun, H				Colhoun, H			Confirmation needed for genes for hypertension	LANCET			English	Editorial Material							BLOOD-PRESSURE; ANGIOTENSINOGEN GENE; ASSOCIATION; LINKAGE; POLYMORPHISM; CHINESE; SUBUNIT; REGION; LOCUS; RENIN		UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Colhoun, H (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.			Colhoun, Helen/0000-0002-8345-3288				CAULFIELD M, 1995, J CLIN INVEST, V96, P687, DOI 10.1172/JCI118111; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; Chiang FT, 1997, CLIN GENET, V51, P370; Cusi D, 1997, LANCET, V349, P1353, DOI 10.1016/S0140-6736(97)01029-5; CUSI D, 1998, LANCET, V53, P1471; Gu C, 1998, HUM BIOL, V70, P77; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Julier C, 1997, HUM MOL GENET, V6, P2077, DOI 10.1093/hmg/6.12.2077; Kotanko P, 1997, HYPERTENSION, V30, P773, DOI 10.1161/01.HYP.30.4.773; Krushkal J, 1998, HUM MOL GENET, V7, P1379, DOI 10.1093/hmg/7.9.1379; Kunz R, 1997, HYPERTENSION, V30, P1331, DOI 10.1161/01.HYP.30.6.1331; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Niu TH, 1998, J CLIN INVEST, V101, P188, DOI 10.1172/JCI119876; RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857; Schunkert H, 1998, HYPERTENSION, V32, P510, DOI 10.1161/01.HYP.32.3.510; Sharma P, 1998, HYPERTENSION, V32, P676, DOI 10.1161/01.HYP.32.4.676; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Svetkey LP, 1996, HYPERTENSION, V27, P1210, DOI 10.1161/01.HYP.27.6.1210; Watson B, 1996, HYPERTENSION, V28, P478, DOI 10.1161/01.HYP.28.3.478; Wu DA, 1996, J CLIN INVEST, V97, P2111, DOI 10.1172/JCI118648; 1998, NAT GENET, V20, P217	21	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1200	1201		10.1016/S0140-6736(99)00001-X	http://dx.doi.org/10.1016/S0140-6736(99)00001-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217074				2022-12-28	WOS:000079744100002
J	McGrath, JA				McGrath, JA			Dyskeratosis congenita: new clinical and molecular insights into ribosome function	LANCET			English	Editorial Material							INACTIVATION; CARRIERS		Guys Hosp, St Johns Inst Dermatol, Dept Cell & Mol Pathol, London SE1 7EH, England; Univ London Kings Coll Hosp, London SE1 7EH, England; St Thomas Hosp, Sch Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	McGrath, JA (corresponding author), Guys Hosp, St Johns Inst Dermatol, Dept Cell & Mol Pathol, London SE1 7EH, England.		McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964				Devriendt K, 1997, AM J HUM GENET, V60, P581; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Knight S, 1998, BRIT J HAEMATOL, V103, P990, DOI 10.1046/j.1365-2141.1998.01103.x; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; Vulliamy TJ, 1997, BLOOD, V90, P2213; Zinsser F, 1906, IKONOGR DERMATOL HYO, V5, P219	6	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1204	1205		10.1016/S0140-6736(99)00011-2	http://dx.doi.org/10.1016/S0140-6736(99)00011-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217077				2022-12-28	WOS:000079744100005
J	Cordes, MHJ; Walsh, NP; McKnight, CJ; Sauer, RT				Cordes, MHJ; Walsh, NP; McKnight, CJ; Sauer, RT			Evolution of a protein fold in vitro	SCIENCE			English	Article							ARC REPRESSOR; STAPHYLOCOCCAL NUCLEASE; T4 LYSOZYME; CRYSTAL-STRUCTURE; HYDROPHOBIC CORE; SIDE-CHAIN; INSERTION; MUTANT; ACCOMMODATION; CONSEQUENCES	A "switch" mutant of the Arc repressor homodimer was constructed by interchanging the sequence positions of a hydrophobic core residue, Leucine 12, and an adjacent surface polar residue, asparagine 11, in each strand of an intersubunit beta sheet. The mutant protein adopts a fold in which each beta strand is replaced by a right-handed helix and side chains in this region undergo significant repacking, The observed structural changes allow the protein to maintain solvent exposure of polar side chains and optimal burial of hydrophobic side chains. These results suggest that new protein folds can evolve from existing folds without drastic or large-scale mutagenesis.	MIT, Dept Biol, Cambridge, MA 02139 USA; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA	Massachusetts Institute of Technology (MIT); Boston University	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399; McKnight, Christopher/0000-0002-3237-0896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BONVIN AMJJ, 1994, J MOL BIOL, V236, P328, DOI 10.1006/jmbi.1994.1138; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BREG JN, 1989, BIOCHEMISTRY-US, V28, P9826, DOI 10.1021/bi00451a042; BRUNGER AT, 1987, X PLOR V3 1 MANUAL; BURGERING MJM, 1995, BIOPOLYMERS, V35, P217, DOI 10.1002/bip.360350210; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; HEINZ DW, 1994, J MOL BIOL, V236, P869, DOI 10.1006/jmbi.1994.1195; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KEEFE LJ, 1994, PROTEIN SCI, V3, P391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P3344, DOI 10.1021/bi00010a025; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; OHLENDORF DH, 1983, J MOL BIOL, V169, P757, DOI 10.1016/S0022-2836(83)80169-7; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; PRUSINER SB, 1994, PHILOS T ROY SOC B, V343, P447, DOI 10.1098/rstb.1994.0043; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SCHILDBACH JF, 1995, BIOCHEMISTRY-US, V34, P1405, DOI 10.1021/bi00004a035; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; Vetter IR, 1996, PROTEIN SCI, V5, P2399, DOI 10.1002/pro.5560051203; WEST MW, 1995, PROTEIN SCI, V4, P2032, DOI 10.1002/pro.5560041008	26	95	95	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					325	327		10.1126/science.284.5412.325	http://dx.doi.org/10.1126/science.284.5412.325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195898				2022-12-28	WOS:000079636400044
J	Golombek, MP				Golombek, MP			Martian climate - A message from warmer times	SCIENCE			English	Editorial Material							IMPACT CRATERS; LANDING SITE; MARS; DEGRADATION; MORPHOLOGY; RATES		CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Golombek, MP (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	mgolombek@jpl.nasa.gov						[Anonymous], 1992, LUNAR PLANETARY SCI; ARVIDSON R, 1979, NATURE, V278, P533, DOI 10.1038/278533a0; BAKER VR, 1986, J GEOPHYS RES-SOLID, V91, P3561, DOI 10.1029/JB091iB03p03561; BARLOW NG, 1995, J GEOPHYS RES-PLANET, V100, P23307, DOI 10.1029/95JE02492; BREED CS, 1979, J GEOPHYS RES, V84, P8183, DOI 10.1029/JB084iB14p08183; BRIDGES NT, IN PRESS J GEOPHYS R; Carr M.H, 1996, WATER MARS; Christensen, 1992, MARS, P686; Craddock RA, 1997, J GEOPHYS RES-PLANET, V102, P13321, DOI 10.1029/97JE01084; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; GOLOMBEK MP, IN PRESS J GEOPHYS R; GRANT JA, 1993, J GEOPHYS RES-PLANET, V98, P11025, DOI 10.1029/93JE00121; GREELEY R, IN PRESS J GEOPHYS R; Greeley R., 1992, MARS, P730; Hartmann W.K., 1981, BASALTIC VOLCANISM T, P1049; HVILD SF, 1997, SCIENCE, V278, P1768; JUDSON S, 1964, J GEOPHYS RES, V69, P3395, DOI 10.1029/JZ069i016p03395; KRINSLEY DH, 1972, AM SCI, V60, P286; KUENEN PH, 1960, SCI AM, V202, P94; LANDIS GA, 1998, EOS, V79, pF549; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Matijevic JR, 1997, SCIENCE, V278, P1765, DOI 10.1126/science.278.5344.1765; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; Pettijohn F.J., 1987, SAND SANDSTONE; PIKE RJ, 1984, LUNAR PLANET SCI, V15, P645; SAUNDERS I, 1983, EARTH SURF PROC LAND, V8, P473, DOI 10.1002/esp.3290080508; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139	30	14	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1470	1471		10.1126/science.283.5407.1470	http://dx.doi.org/10.1126/science.283.5407.1470			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10206878				2022-12-28	WOS:000078959200031
J	Miller, TE; Sage, WM				Miller, TE; Sage, WM			Disclosing physician financial incentives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; HEALTH-CARE; CONSUMERS WANT; QUALITY; INFORMATION; PAYMENT; TRUST; SERVICES; IMPACT; PLANS	Federal and state regulatory initiatives as well as court decisions increasingly require managed care organizations to disclose physician financial incentives and have raised the issue of disclosure by physicians themselves. These mandates are based on ethical and legal principles arising from the patient-physician relationship and the relationship between health plan sponsors and enrollees. Disclosing incentives also serves important policy objectives: it can inform enrollees' choice of plan, reinforce enrollees' capacity to understand and exercise other rights under managed care, and discourage use of compensation methods that might compromise patients' access to treatment. However, significant conceptual and practical questions remain about implementing a disclosure mandate, Unresolved issues include the timing, content, and scope of disclosure, the relationship of disclosure to patients' substantive rights, and the impact of disclosure on trust between patients and physicians. These uncertainties exemplify the challenges facing policymakers, plans, and physicians as they determine how best to inform patients about managed care.	CUNY Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA; Columbia Univ, Columbia Law Sch, New York, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Miller, TE (corresponding author), CUNY Mt Sinai Sch Med, Dept Hlth Policy, 1425 Madison Ave,Box 1077, New York, NY 10029 USA.	Tracy_Miller@smptlink.mssm.edu						*ADV COMM CONS PRO, 1997, CONS BILL RIGHTS RES; *AM MED ASS COUNC, 1990, COD MED ETH REP COUN, P130; Baker LC, 1999, JAMA-J AM MED ASSOC, V281, P432, DOI 10.1001/jama.281.5.432; BEAUCHAMP TL, 1992, PRINCIPLES BIOMEDICA; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; Blumenthal D, 1996, HEALTH AFFAIR, V15, P170, DOI 10.1377/hlthaff.15.2.170; Breyer Stephen, 1982, REGULATION ITS REFOR; Cangialose CB, 1997, AM J MANAG C, V3, P1153; Christensen KT, 1997, J LAW MED ETHICS, V25, P199, DOI 10.1111/j.1748-720X.1997.tb01894.x; *COMM SERV SOC, 1996, WHAT MED BEN UND WHA; Conrad DA, 1998, JAMA-J AM MED ASSOC, V279, P853, DOI 10.1001/jama.279.11.853; DAVIS K, 1997, MANAGED CARE CHOICE; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; FURROW BR, 1996, WIDENER L S J, V1, P1; GLASSON J, 1995, JAMA-J AM MED ASSOC, V273, P330, DOI 10.1001/jama.1995.03520280076044; GLIED S, 1997, CHRONIC CONDITION WH; GOLDSCHMID HJ, 1979, BUSINESS DISCLOSURE; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; HALL MA, 1997, MAKING MED SPENDING; *HARV U KAIS FAM F, 1997, IS THER MAN CAR BACK; HAVIGHURST CC, 1995, HLTH CARE CHOICES PR; Hellinger FJ, 1998, AM J MANAG CARE, V4, P663; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Hibbard JH, 1996, MED CARE RES REV, V53, P28, DOI 10.1177/107755879605300102; HIRSH D, 1990, MOL BIOL REP, V14, P115, DOI 10.1007/BF00360438; *HLTH CAR BUR OFF, 1998, PUBL MIS SOM HMOS FA; *HLTH POL TRACK SE, 1998, NAT C STAT LEG SEPT; Isaacs SL, 1996, HEALTH AFFAIR, V15, P31, DOI 10.1377/hlthaff.15.4.31; Jackall R, 1988, MORAL MAZES WORLD CO; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KRASNER WL, 1995, 1995 HLTH LAW HDB; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; McCormack LA, 1996, HEALTH CARE FINANC R, V18, P15; MCGRAW DC, 1995, GEORGETOWN LAW J, V83, P1821; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MEHLMAN MJ, 1990, U PITT LAW REV, V51, P365; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Miller TE, 1998, J LAW MED ETHICS, V26, P89, DOI 10.1111/j.1748-720X.1998.tb01665.x; Miller TE, 1997, JAMA-J AM MED ASSOC, V278, P1102, DOI 10.1001/jama.278.13.1102; *NY STAT TASK FORC, 1992, OTH MUST CHOOS; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; RODWIN MA, 1996, SETON HALL L REV, V26, P1007; SAGE WM, 1997, 1997 HLTH LAW HDB; SAGE WM, 1997, ACHIEVING QUALITY MA; Schlackman N, 1989, QRB Qual Rev Bull, V15, P234; SOFAER S, 1993, HEALTH AFFAIR, V12, P76, DOI 10.1377/hlthaff.12.suppl_1.76; *US GEN ACC OFF, 1998, CONS HLTH CAR INF MA; WOLF SM, 1996, J LAND USE ENV LAW, V11, P217; 1998, FED REG         0626, V63, P34989; 1996, FED REG         0327, V61, P13430; 1998, FED REG         0626, V63, P34968; 1997, 1997 COMP PERFORMANC	53	40	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1424	1430		10.1001/jama.281.15.1424	http://dx.doi.org/10.1001/jama.281.15.1424			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185ZF	10217059				2022-12-28	WOS:000079701000033
J	Denoyelle, F; Marlin, S; Weil, D; Moatti, L; Chauvin, P; Garabedian, EN; Petit, C				Denoyelle, F; Marlin, S; Weil, D; Moatti, L; Chauvin, P; Garabedian, EN; Petit, C			Clinical features of the prevalent form of childhood deafness, DFNB1, due to a connexin-26 gene defect: implications for genetic counselling	LANCET			English	Article							SYNDROMIC RECESSIVE DEAFNESS; NONSYNDROMIC HEARING-LOSS; MYOSIN-VIIA GENE; SENSORINEURAL DEAFNESS; MUTATIONS; IDENTIFICATION	Background DFNB1, the locus of an autosomal recessive form of deafness due to mutations in the connexin-26 gene (CX26 or GJB2) is one of the most frequent hereditary defects in human beings. To date, no clinical characterisation of the DFNB1 inner-ear defects has been reported, which precludes the provision of prognostic information and genetic counselling. Methods We enrolled, in a prospective study, 140 children from 104 families affected by sensorineural deafness with various degrees of hearing loss. The children either belonged to a family affected by autosomal recessive deafness (DFNB family) or represented sporadic cases. We searched for mutations in the 5' non-coding exon and in the coding region of CX26. Audiometric and radiological features were investigated and compared in deaf children with and without CX26 mutations. Findings CX26 mutations were present in 43 (49%) of the 88 families with cases of prelingual deafness versus none of;the 16 families with postlingual forms of deafness (p < 0 . 01). The inner-ear defects of 54 prelingually deaf children with biallelic CX26 mutations were compared with the defects in 57 prelingually deaf children without CX26 mutations. DFNB1 deafness varied from mild to profound, associated with sloping or flat audiometric curves and a radiologically normal inner ear. Hearing loss was not progressive in 11 of 16 cases tested, and variations in the severity of deafness between siblings were common. Interpretation The characteristic audiometric and radiological features of DFNB1 should be the reference used to guide the investigation,by CX26 molecular diagnostic tests,of deaf children with a compatible phenotype. Prognostic information can now be given to families: the hearing loss in DFNB1 deafness is non-progressive in most cases, at least up to young adulthood. An important element for genetic counselling is that the severity of hearing loss due to DFNB1 is extremely variable and cannot be predicted, even within families.	Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France; Hop Enfants Armand Trousseau, Serv ORL, Paris, France; Univ Paris 06, Fac Med St Antoine, INSERM,U444, Unite Rech Epidemiol & Sci Informat, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Petit, C (corresponding author), Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France.		Chauvin, Pierre/S-2981-2019; Chauvin, Pierre/G-1095-2015	Chauvin, Pierre/0000-0002-9183-6406; Chauvin, Pierre/0000-0002-9183-6406; Petit, Christine/0000-0002-9069-002X; marlin, sandrine/0000-0002-4115-9806; Denoyelle, Francoise/0000-0003-4338-9258				BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; FISHER NA, 1994, OTOLARYNG CLIN N AM, V27, P511; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; GORLIN RJ, 1995, HEREDITARY HEARING L, V28, P43; HUYGEN PLM, 1993, INT J PEDIATR OTORHI, V25, P39, DOI 10.1016/0165-5876(93)90008-Q; Jackler RK, 1987, LARYNGOSCOPE 2 S40, V3, P2; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Lench N, 1998, LANCET, V351, P415, DOI 10.1016/S0140-6736(98)24006-2; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LIU XZ, 1994, ANN OTO RHINOL LARYN, V103, P428, DOI 10.1177/000348949410300602; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; PABLA HS, 1991, INT J PEDIATR OTORHI, V22, P161, DOI 10.1016/0165-5876(91)90035-A; PARVING A, 1985, INT J PEDIATR OTORHI, V9, P31, DOI 10.1016/S0165-5876(85)80003-3; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Ressot C, 1998, J NEUROSCI, V18, P4063; Scott DA, 1998, HUM MUTAT, V11, P387, DOI 10.1002/(SICI)1098-1004(1998)11:5<387::AID-HUMU6>3.3.CO;2-#; Vartiainen E, 1997, INT J PEDIATR OTORHI, V41, P175, DOI 10.1016/S0165-5876(97)00080-3; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	27	331	358	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1298	1303		10.1016/S0140-6736(98)11071-1	http://dx.doi.org/10.1016/S0140-6736(98)11071-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218527				2022-12-28	WOS:000080278100009
J	Lucas, RJ; Freedman, MS; Munoz, M; Garcia-Fernandez, JM; Foster, RG				Lucas, RJ; Freedman, MS; Munoz, M; Garcia-Fernandez, JM; Foster, RG			Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors	SCIENCE			English	Article							SEROTONIN N-ACETYLTRANSFERASE; BLUE-LIGHT PHOTORECEPTORS; RETINOHYPOTHALAMIC TRACT; CGMP-PHOSPHODIESTERASE; RETINAL DEGENERATION; BETA-SUBUNIT; RD MOUSE; PHOTOENTRAINMENT; MUTATION; PIGMENT	In mammals, ocular photoreceptors mediate an acute inhibition of pineal melatonin by light. The effect of rod and cone loss on this response was assessed by combining the rd mutation with a transgenic ablation of cones (cl) to produce mice lacking both photoreceptor classes. Despite the loss of all known retinal photoreceptors, rd/rd cl mice showed normal suppression of pineal melatonin in response to monochromatic light of wavelength 509 nanometers. These data indicate that mammals have additional ocular photoreceptors that they use in the regulation of temporal physiology.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Oviedo, Dept Morfol & Biol Celular, Oviedo 33072, Spain	Imperial College London; University of Oviedo	Lucas, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.		Llamosas, Marta Muñoz/A-7667-2008	Llamosas, Marta Muñoz/0000-0002-9832-3523; Lucas, Robert/0000-0002-1088-8029; Garcia-Fernandez, Jose M./0000-0003-1347-8305				Arendt J., 1995, MELATONIN MAMMALIAN; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2547, DOI 10.1073/pnas.69.9.2547; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; EBIHARA S, 1986, SCIENCE, V231, P491, DOI 10.1126/science.3941912; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; LUCAS RJ, IN PRESS ENDOCRINOLO; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Provencio I, 1998, J COMP NEUROL, V395, P417, DOI 10.1002/(SICI)1096-9861(19980615)395:4<417::AID-CNE1>3.0.CO;2-4; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Rodieck R.W., 1998, 1 STEPS SEEING; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; vonSchantz M, 1997, BRAIN RES, V770, P131, DOI 10.1016/S0006-8993(97)00791-9; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WETTERBERG L, 1993, LIGHT BIOL RHYTHMS M, V62	27	392	400	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					505	507		10.1126/science.284.5413.505	http://dx.doi.org/10.1126/science.284.5413.505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205062				2022-12-28	WOS:000079792200053
J	Goldberg, RJ; Samad, NA; Yarzebski, J; Gurwitz, J; Bigelow, C; Gore, JM				Goldberg, RJ; Samad, NA; Yarzebski, J; Gurwitz, J; Bigelow, C; Gore, JM			Temporal trends in cardiogenic shock complicating acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY-WIDE PERSPECTIVE; WORCESTER-HEART-ATTACK; AORTIC BALLOON COUNTERPULSATION; TISSUE-PLASMINOGEN-ACTIVATOR; CORONARY-CARE UNIT; GUSTO-I TRIAL; ANGIOPLASTY THERAPY; GENDER DIFFERENCES; SURVIVAL RATES; MORTALITY	Background Limited information is available on trends in the incidence of and mortality due to cardiogenic shock complicating acute myocardial infarction. We studied the incidence of cardiogenic shock complicating acute myocardial infarction and in-hospital death rates among patients with this condition in a single community from 1975 through 1997. Methods We conducted an observational study of 9076 residents of metropolitan Worcester, Massachusetts, who were hospitalized with confirmed acute myocardial infarction in all local hospitals during 11 one-year periods between 1975 and 1997. Our study included periods before and after the advent of reperfusion therapy. Results The incidence of cardiogenic shock remained relatively stable over time, averaging 7.1 percent among patients with acute myocardial infarction. The results of a multivariable regression analysis indicated that the patients hospitalized during recent study years were not at a substantially lower risk for shock than patients hospitalized in the mid-to-late 1970s. Patients in whom cardiogenic shock developed had a significantly greater risk of dying during hospitalization (71.7 percent) than those who did not have cardiogenic shock (12.0 percent, P<0.001). A significant trend toward an increase in in-hospital survival among patients with cardiogenic shock in the mid-to-late 1990s was found in crude and adjusted analyses. Conclusions Our findings indicate no significant change in the incidence of cardiogenic shock complicating acute myocardial infarction over a 23-year period. However, the short-term survival rate has increased in recent years at the same time as the use of coronary reperfusion strategies has increased. (N Engl J Med 1999;340:1162-8.) (C)1999, Massachusetts Medical Society.	Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA; Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Amherst	Goldberg, RJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, 55 Lake Ave N, Worcester, MA 01655 USA.	roberr.goldberg@ummc.ummed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1986, LANCET, V1, P397; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; Berger PB, 1997, CIRCULATION, V96, P122; BOLOOKI H, 1989, CIRCULATION, V79, P137; CALIFF RM, 1994, NEW ENGL J MED, V330, P1724, DOI 10.1056/NEJM199406163302406; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; COL NF, 1994, AM J CARDIOL, V73, P149, DOI 10.1016/0002-9149(94)90206-2; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; DOMANSKI MJ, 1994, AM J CARDIOL, V74, P724, DOI 10.1016/0002-9149(94)90318-2; GACIOCH GM, 1992, J AM COLL CARDIOL, V19, P647, DOI 10.1016/S0735-1097(10)80286-4; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDBERG R, 1979, JOHNS HOPKINS MED J, V144, P73; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOLDBERG RJ, 1989, CIRCULATION, V79, P1369, DOI 10.1161/01.CIR.79.6.1369; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; HANDS ME, 1989, J AM COLL CARDIOL, V14, P40, DOI 10.1016/0735-1097(89)90051-X; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; Holmes DR, 1997, LANCET, V349, P75, DOI 10.1016/S0140-6736(96)03031-0; KILLIP T, 1989, J AM COLL CARDIOL, V14, P47, DOI 10.1016/0735-1097(89)90052-1; KOBAYASHI M, 1984, JPN CIRC J, V48, P650, DOI 10.1253/jcj.48.650; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LEE L, 1991, J AM COLL CARDIOL, V17, P599, DOI 10.1016/S0735-1097(10)80171-8; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEOR J, 1993, AM J MED, V94, P265, DOI 10.1016/0002-9343(93)90058-W; Moscucci Mauro, 1995, Cardiology Clinics, V13, P391; ONEILL WW, 1992, J AM COLL CARDIOL, V19, P915, DOI 10.1016/0735-1097(92)90270-W; PAGLEY PR, 1993, ARCH INTERN MED, V153, P625, DOI 10.1001/archinte.153.5.625; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; SCHEIDT S, 1973, NEW ENGL J MED, V288, P979, DOI 10.1056/NEJM197305102881901; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	37	404	424	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1162	1168		10.1056/NEJM199904153401504	http://dx.doi.org/10.1056/NEJM199904153401504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202167	Green Published			2022-12-28	WOS:000079687700004
J	Tabbal, SD; Harik, SI				Tabbal, SD; Harik, SI			Cerebral histoplasmosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Columbia University; University of Arkansas System; University of Arkansas Medical Sciences	Tabbal, SD (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1176	1176		10.1056/NEJM199904153401506	http://dx.doi.org/10.1056/NEJM199904153401506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202169				2022-12-28	WOS:000079687700006
J	Wang, HG; Pathan, N; Ethell, IM; Krajewski, S; Yamaguchi, Y; Shibasaki, F; McKeon, F; Bobo, T; Franke, TF; Reed, JC				Wang, HG; Pathan, N; Ethell, IM; Krajewski, S; Yamaguchi, Y; Shibasaki, F; McKeon, F; Bobo, T; Franke, TF; Reed, JC			Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD	SCIENCE			English	Article							CELL-DEATH; BCL-2 FAMILY; PERMEABILITY TRANSITION; NEURON SURVIVAL; CYCLOSPORINE-A; PHOSPHORYLATION; PROTEIN; AKT; ACTIVATION; MITOCHONDRIA	The Ca2+-activated protein phosphatase calcineurin induces apoptosis, but the mechanism is unknown. Calcineurin was found to dephosphorylate BAD, a pro-apoptotic member of the Bcl-2 family, thus enhancing BAD heterodimerization with Bcl-x(L) and promoting apoptosis. The Ca2+-induced dephosphorylation of BAD correlated with its dissociation from 14-3-3 in the cytosol and translocation to mitochondria where Bcl-x(L) resides. In hippocampal neurons, L-glutamate, an inducer of Ca2+ influx and calcineurin activation, triggered mitochondrial targeting of BAD and apoptosis, which were both suppressible by coexpression of a dominant-inhibitory mutant of calcineurin or pharmacological inhibitors of this phosphatase. Thus, a Ca2+-inducible mechanism for apoptosis induction operates by regulating BAD phosphorylation and Localization in cells.	Burnham Inst, La Jolla, CA 92037 USA; Univ S Florida, Dept Pharmacol & Therapeut, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Sanford Burnham Prebys Medical Discovery Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Harvard Medical School; Columbia University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-institute.org	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Ethell, Iryna/0000-0002-1324-6611	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69381] Funding Source: Medline; NIA NIH HHS [AG-1593] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Bao J, UNPUB; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; FURUYA Y, 1994, CANCER RES, V54, P6167; HARADA H, IN PRESS MOL CELL; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kitada S, 1998, AM J PATHOL, V152, P51; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; PATHAN N, UNPUB; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wood AM, 1998, J NEUROCHEM, V70, P677; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	37	978	1023	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					339	343		10.1126/science.284.5412.339	http://dx.doi.org/10.1126/science.284.5412.339			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195903				2022-12-28	WOS:000079636400049
J	Beral, V; Bull, D; Doll, R; Key, T; Peto, R; Reeves, G; Calle, EE; Heath, CW; Coates, RJ; Liff, JM; Franceschi, S; Talamini, R; Chantarakul, N; Koetsawang, S; Rachawat, D; Morabia, A; Schuman, L; Stewart, W; Szklo, M; Bain, C; Schofield, F; Siskind, V; Band, P; Coldman, AJ; Gallagher, RP; Hislop, TG; Yang, P; Duffy, SW; Kolonel, LM; Nomura, AMY; Oberle, MW; Ory, HW; Peterson, HB; Wilson, HG; Wingo, PA; Ebeling, K; Kunde, D; Nishan, P; Colditz, G; Martin, N; Pardthaisong, T; Silpisornkosol, S; Theetranont, C; Boosiri, B; Chutivongse, S; Jimakorn, P; Virutamasen, P; Wongsrichanalai, C; McMichael, AJ; Rohan, T; Ewertz, M; Adami, HO; Bergkvist, R; Persson, I; Paul, C; Skegg, DCG; Spears, GFS; Boyle, P; Evstifeeva, T; Daling, JR; Hutchinson, WB; Malone, K; Noonan, EA; Stanford, JL; Thomas, DB; Weiss, NS; White, E; Andrieu, N; Bramond, A; Clavel, F; Gairard, B; Lansac, J; Piana, L; Renaud, R; Fine, SRP; Cuevas, HR; Ontiveros, P; Palet, A; Salazar, SB; Aristizabal, N; Cuadros, A; Bachelor, A; Le, MG; Deacon, J; Peto, J; Taylor, CN; Modan, B; Ron, E; Friedman, GD; Hiatt, RA; Levi, F; Bishop, T; Kosmelj, K; PrimicZakelj, M; Ravnihar, B; Stare, J; Beeson, WL; Fraser, G; Bulbrook, RD; Cuzick, J; Fentiman, IS; Hayward, JL; Wang, DY; McPherson, K; Hanson, RL; Leske, MC; Mahoney, MC; Nasca, PC; Varma, AO; Weinstein, AL; Moller, TR; Olsson, H; Ranstam, J; Goldbohm, RA; vandenBrandt, PA; Apelo, RA; Baens, J; delaCruz, JR; Javier, B; Lacaya, LB; Ngelangel, CA; LaVecchia, C; Negri, E; Marubini, E; Ferraroni, M; Gerber, M; RIchardson, S; Segala, C; Gatei, D; Kenya, P; Kungu, A; Mati, JG; Brinton, LA; Hoover, R; Schairer, C; Spirtas, R; Lee, HP; Rookus, MA; vanLeeuwen, FE; Schoenberg, JA; Gammon, MD; Clarke, EA; Jones, L; Neil, A; Vessey, M; Yeates, D; Crossley, B; Hermon, C; Jones, S; Lewis, C; Collins, R; Mabuchi, K; Preston, D; Hannaford, P; Kay, C; RoseroBixby, L; Yuan, JM; Wei, HY; Yun, T; Zhiheng, C; Berry, G; Booth, JC; Jelihovsky, T; MacLennan, R; Shearman, R; Wang, QS; Baines, CJ; Miller, AB; Wall, C; Lund, E; Stalsberg, H; Katsouyanni, K; Trichopoulos, D; Dabancens, A; Martinez, L; Molina, R; Salas, O; Alexander, FE; Folsom, AR; Chilvers, CED; Bernstein, L; Haile, RW; PaganiniHill, A; Pike, MC; Ross, RK; Ursin, G; Yu, MC; Longnecker, MP; Newcomb, P; Bergkvist, L; Farley, TMN; Holck, S; Meirik, O				Beral, V; Bull, D; Doll, R; Key, T; Peto, R; Reeves, G; Calle, EE; Heath, CW; Coates, RJ; Liff, JM; Franceschi, S; Talamini, R; Chantarakul, N; Koetsawang, S; Rachawat, D; Morabia, A; Schuman, L; Stewart, W; Szklo, M; Bain, C; Schofield, F; Siskind, V; Band, P; Coldman, AJ; Gallagher, RP; Hislop, TG; Yang, P; Duffy, SW; Kolonel, LM; Nomura, AMY; Oberle, MW; Ory, HW; Peterson, HB; Wilson, HG; Wingo, PA; Ebeling, K; Kunde, D; Nishan, P; Colditz, G; Martin, N; Pardthaisong, T; Silpisornkosol, S; Theetranont, C; Boosiri, B; Chutivongse, S; Jimakorn, P; Virutamasen, P; Wongsrichanalai, C; McMichael, AJ; Rohan, T; Ewertz, M; Adami, HO; Bergkvist, R; Persson, I; Paul, C; Skegg, DCG; Spears, GFS; Boyle, P; Evstifeeva, T; Daling, JR; Hutchinson, WB; Malone, K; Noonan, EA; Stanford, JL; Thomas, DB; Weiss, NS; White, E; Andrieu, N; Bramond, A; Clavel, F; Gairard, B; Lansac, J; Piana, L; Renaud, R; Fine, SRP; Cuevas, HR; Ontiveros, P; Palet, A; Salazar, SB; Aristizabal, N; Cuadros, A; Bachelor, A; Le, MG; Deacon, J; Peto, J; Taylor, CN; Modan, B; Ron, E; Friedman, GD; Hiatt, RA; Levi, F; Bishop, T; Kosmelj, K; PrimicZakelj, M; Ravnihar, B; Stare, J; Beeson, WL; Fraser, G; Bulbrook, RD; Cuzick, J; Fentiman, IS; Hayward, JL; Wang, DY; McPherson, K; Hanson, RL; Leske, MC; Mahoney, MC; Nasca, PC; Varma, AO; Weinstein, AL; Moller, TR; Olsson, H; Ranstam, J; Goldbohm, RA; vandenBrandt, PA; Apelo, RA; Baens, J; delaCruz, JR; Javier, B; Lacaya, LB; Ngelangel, CA; LaVecchia, C; Negri, E; Marubini, E; Ferraroni, M; Gerber, M; RIchardson, S; Segala, C; Gatei, D; Kenya, P; Kungu, A; Mati, JG; Brinton, LA; Hoover, R; Schairer, C; Spirtas, R; Lee, HP; Rookus, MA; vanLeeuwen, FE; Schoenberg, JA; Gammon, MD; Clarke, EA; Jones, L; Neil, A; Vessey, M; Yeates, D; Crossley, B; Hermon, C; Jones, S; Lewis, C; Collins, R; Mabuchi, K; Preston, D; Hannaford, P; Kay, C; RoseroBixby, L; Yuan, JM; Wei, HY; Yun, T; Zhiheng, C; Berry, G; Booth, JC; Jelihovsky, T; MacLennan, R; Shearman, R; Wang, QS; Baines, CJ; Miller, AB; Wall, C; Lund, E; Stalsberg, H; Katsouyanni, K; Trichopoulos, D; Dabancens, A; Martinez, L; Molina, R; Salas, O; Alexander, FE; Folsom, AR; Chilvers, CED; Bernstein, L; Haile, RW; PaganiniHill, A; Pike, MC; Ross, RK; Ursin, G; Yu, MC; Longnecker, MP; Newcomb, P; Bergkvist, L; Farley, TMN; Holck, S; Meirik, O		Collaborative Group on Hormonal Factors in Breast Cancer	Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer	LANCET			English	Article							ORAL-CONTRACEPTIVE USE; REQUIRING PROLONGED OBSERVATION; ESTROGEN-PROGESTIN REPLACEMENT; POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; UNITED-STATES; RISK-FACTORS; EXOGENOUS ESTROGENS; BODY-MASS; ASSOCIATION	Background The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and reanalysed about 90% of the worldwide epidemiological evidence on the relation between risk of breast cancer and use of hormone replacement therapy (HRT). Methods Individual data on 52 705 women with breast cancer and 108 411 women without breast cancer from 51 studies in 21 countries were collected, checked, and analysed centrally, The main analyses are based on 53 865 postmenopausal women with a known age al menopause, of whom 17 830 (33%) had used HRT at some time, The median age at first use was 48 years, and 34% of ever-users had used HRT for 5 years or longer, Estimates of the relative risk of breast cancer associated with the use of HRT were obtained after stratification of all analyses by study, age at diagnosis, time since menopause, body-mass index, parity, and the age a woman was when her first child was born. Findings Among current users of HRT or those who ceased use 1-4 years previously, the relative risk of having breast cancer diagnosed increased by a factor of 1.023 (95% CI 1.011-1.036; 2p=0.0002) for each year of use; the relative risk was 1.35 (1.21-1.49; 2p=0.00001) for women who had used HRT for 5 years or longer(average duration of use in this group 11 years), This increase is comparable with the effect on breast cancer of delaying menopause, since among never-users of HRT the relative risk of breast cancer increases by a factor of 1.028 (95% CI 1.021-1.034) for each year older at menopause, 5 or more years after cessation of HRT use, there was no significant excess of breast cancer overall or in relation to duration of use, These main findings did not vary between individual studies, Of the many factors examined that might affect the relation between breast cancer risk and use of HRT, only a woman's weight and body-mass index had a material effect: the increase in the relative risk of breast cancer associated with long durations of use in current and recent users was greater for women of lower than of higher weight or body-mass index, There was no marked variation in the results according to hormonal type or dose but little information was available about long durations of use of any specific preparation, Cancers diagnosed in women who had ever used HRT tended to be less advanced clinically than those diagnosed in never-users, In North America and Europe the cumulative incidence of breast cancer between the ages of 50 and 70 in never-users of HRT is about 45 per 1000 women, The cumulative excess numbers of breast cancers diagnosed between these ages per 1000 women who began use of HRT at age 50 and used it for 5, 10, and 15 years, respectively, are estimated to be 2 (95% CI 1-3), 6 (3-9), and 12 (5-20), Whether HRT affects mortality from breast cancer is not known. Interpretation The risk of having breast cancer diagnosed is increased in women using HRT and increases with increasing duration of use, This effect is reduced after cessation of use of HRT and has largely, if not wholly, disappeared after about 5 years, These findings should be considered in the context of the benefits and other risks associated with the use of HRT.			Beral, V (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, GIBSON BLDG, OXFORD OX2 6HE, ENGLAND.		Fentiman, Ian/AAB-9886-2020; Richardson, Sylvia T/G-4691-2015; Negri, Eva/B-7244-2013; Hiatt, Robert/AAQ-1537-2021; franceschi, silvia/M-2452-2014; Boyle, Peter/A-4380-2014; Negri, Eva Vanna Lorenza/AAC-5698-2019; Ranstam, Jonas/A-4386-2009; Fentiman, Ian S/I-7644-2019; Clavel-Chapelon, Francoise/G-6733-2014; Brinton, Louise A/G-7486-2015; Katsouyanni, Klea/D-4856-2014; Ferraroni, Monica/D-6548-2017; Ursin, Giske/U-6637-2017; Colditz, Graham/A-3963-2009	Richardson, Sylvia T/0000-0003-1998-492X; Negri, Eva/0000-0001-9712-8526; franceschi, silvia/0000-0003-4181-8071; Boyle, Peter/0000-0001-6251-0610; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Ranstam, Jonas/0000-0002-8287-7273; Brinton, Louise A/0000-0003-3853-8562; Katsouyanni, Klea/0000-0002-0132-9575; Ferraroni, Monica/0000-0002-4542-4996; Ursin, Giske/0000-0002-0835-9507; Colditz, Graham/0000-0002-7307-0291; Bishop, Tim/0000-0002-8752-8785; Szklo, Moyses/0000-0001-9433-6266; La Vecchia, Carlo/0000-0003-1441-897X; Lund, Eiliv/0000-0002-8071-8711; Yuan, Jian-Min/0000-0002-4620-3108; Ewertz, Marianne/0000-0002-5965-969X				ALEXANDER FE, 1987, J EPIDEMIOL COMMUN H, V41, P101, DOI 10.1136/jech.41.2.101; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Calle EE, 1996, CONTRACEPTION, V54, pS1; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; Goodman MT, 1997, PREV MED, V26, P144, DOI 10.1006/pmed.1996.9979; HARRIS RE, 1992, J NATL CANCER I, V84, P1575, DOI 10.1093/jnci/84.20.1575; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAY CR, 1988, BRIT J CANCER, V58, P675, DOI 10.1038/bjc.1988.285; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LAVECCHIA C, 1992, INT J CANCER, V50, P161, DOI 10.1002/ijc.2910500131; LAVECCHIA C, 1995, BRIT J CANCER, V72, P244, DOI 10.1038/bjc.1995.310; LEE NC, 1987, J NATL CANCER I, V79, P1247; Levi F, 1996, EUR J CANCER PREV, V5, P259, DOI 10.1097/00008469-199608000-00006; LIPWORTH L, 1995, INT J CANCER, V62, P548, DOI 10.1002/ijc.2910620510; MARUBINI E, 1988, CANCER, V61, P173, DOI 10.1002/1097-0142(19880101)61:1&lt;173::AID-CNCR2820610129&gt;3.0.CO;2-P; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; MORABIA A, 1993, PREV MED, V22, P178, DOI 10.1006/pmed.1993.1015; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NGELANGEL CA, 1994, PHILIPP J INTERN MED, V32, P231; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAVNIHAR B, 1988, NEOPLASMA, V35, P109; RAVNIHAR B, 1979, EUR J CANCER, V15, P395, DOI 10.1016/0014-2964(79)90074-4; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROOKUS MA, 1994, LANCET, V344, P844, DOI 10.1016/S0140-6736(94)92826-6; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SCHUURMAN AG, 1995, CANCER CAUSE CONTROL, V6, P416, DOI 10.1007/BF00052181; SEGALA C, 1991, BRIT J CANCER, V64, P919, DOI 10.1038/bjc.1991.427; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; TALAMINI R, 1985, INT J EPIDEMIOL, V14, P70, DOI 10.1093/ije/14.1.70; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMAS DB, 1990, BRIT J CANCER, V61, P110; Thomas HV, 1997, J NATL CANCER I, V89, P396, DOI 10.1093/jnci/89.5.396; URSIN G, 1992, EPIDEMIOLOGY, V3, P414, DOI 10.1097/00001648-199209000-00006; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; WANG DY, 1987, EUR J CANCER CLIN ON, V23, P1541, DOI 10.1016/0277-5379(87)90098-8; WEINSTEIN AL, 1993, INT J EPIDEMIOL, V22, P781, DOI 10.1093/ije/22.5.781; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	66	1987	2027	4	110	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	1997	350	9084					1047	1059		10.1016/s0140-6736(97)08233-0	http://dx.doi.org/10.1016/s0140-6736(97)08233-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213546	hybrid			2022-12-28	WOS:A1997YA73400007
J	LaRusso, N				LaRusso, N			Search for medical treatment for primary biliary cirrhosis	LANCET			English	Editorial Material											LaRusso, N (corresponding author), MAYO CLIN & MAYO FDN,DIV GASTROENTEROL,ROCHESTER,MN 55905, USA.							BERK PD, 1997, SEM LIV DIS 1 FEB, V17; Kaplan MM, 1997, ANN INTERN MED, V126, P682, DOI 10.7326/0003-4819-126-9-199705010-00002; Neuberger J, 1997, LANCET, V350, P875, DOI 10.1016/S0140-6736(97)05419-6	3	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1046	1046		10.1016/S0140-6736(05)70452-9	http://dx.doi.org/10.1016/S0140-6736(05)70452-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213545				2022-12-28	WOS:A1997YA73400006
J	de Camargo, OAK; Bode, H				de Camargo, OAK; Bode, H			Agranulocytosis associated with lamotrigine	BRITISH MEDICAL JOURNAL			English	Letter									Univ Ulm, Sozialpadiat Zentrum, D-89077 Ulm, Germany	Ulm University	de Camargo, OAK (corresponding author), Univ Ulm, Sozialpadiat Zentrum, Schillerstr 15, D-89077 Ulm, Germany.		de Camargo, Olaf Kraus/G-8419-2011	de Camargo, Olaf Kraus/0000-0002-7927-7189				Mackay FJ, 1997, EPILEPSIA, V38, P881, DOI 10.1111/j.1528-1157.1997.tb01252.x; NICHOLSON RJ, 1995, BRIT MED J, V310, P504, DOI 10.1136/bmj.310.6978.504b; STEINER TJ, 1996, INT C S SERIES, V214, P31	3	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1179	1179						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221944				2022-12-28	WOS:000080277900032
J	Karsenti, D; Blanc, P; Bacq, Y; Metman, EH				Karsenti, D; Blanc, P; Bacq, Y; Metman, EH			Hepatotoxicity associated with zolpidem treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Letter							HEPATITIS; ALPIDEM		CHU Trousseau, Serv Hepatogastroenterol, F-37044 Tours, France; CHU Bretonneau, Serv Pharmacol Clin, F-37044 Tours, France	CHU Tours; CHU Tours	Karsenti, D (corresponding author), CHU Trousseau, Serv Hepatogastroenterol, F-37044 Tours, France.							AUSSET P, 1995, GASTROEN CLIN BIOL, V19, P222; BATY V, 1994, GASTROEN CLIN BIOL, V18, P1129; BENICHOU C, 1990, J HEPATOL, V11, P272; GARNIER R, 1994, J TOXICOL-CLIN TOXIC, V32, P391, DOI 10.3109/15563659409011040; QUENEAU PE, 1994, 1 INT S HEP CLIN PHA, P38	5	10	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	1999	318	7192					1179	1179						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221943				2022-12-28	WOS:000080277900031
J	Reverte-Cejudo, D; Sanchez-Bayle, M				Reverte-Cejudo, D; Sanchez-Bayle, M			Devolving health services to Spain's autonomous regions	BRITISH MEDICAL JOURNAL			English	Article									Hosp Gen Segovia, E-40002 Segovia, Spain; Hosp Nino Jesus, E-28009 Madrid, Spain		Reverte-Cejudo, D (corresponding author), Hosp Gen Segovia, E-40002 Segovia, Spain.							Benach J., 1998, INFORME SESPAS 1998, P141	1	27	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1204	1205						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221953				2022-12-28	WOS:000080277900040
J	Joynt, R				Joynt, R			Pseudogaps and extrinsic losses in photoemission experiments on poorly conducting solids	SCIENCE			English	Article							ELECTRONIC-STRUCTURE; NORMAL-STATE; SPECTRA; BI2SR2CACU2O8+DELTA; (TASE4)(2)I; GAP	A photoelectron emitted from a conducting solid may suffer a substantial energy change through ohmic Losses that can drastically alter the Line shape on the millielectron volt scale that is now observable through improved resolution. Almost all of this energy Loss occurs after the electron Leaves the solid. These Losses are expected to be important in isotropic materials with relatively Low conductivity, such as certain colossal magnetoresistance manganates, and in very electrically anisotropic materials, such as one-dimensional conductors, and may also affect interpretation of photoemission in superconductors with high transition temperatures. The electric field of the photoelectron can penetrate the solid, and extrinsic losses of this type can mimic pseudogap effects and other peculiar features of photoemission in cubic manganates, as illustrated for La0.67Ca0.33MnO3.	Univ Wisconsin, Dept Phys, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Joynt, R (corresponding author), Univ Wisconsin, Dept Phys, 1150 Univ Ave, Madison, WI 53706 USA.							COOPER JR, 1979, PHYS REV B, V19, P2404, DOI 10.1103/PhysRevB.19.2404; DARDEL B, 1991, PHYS REV LETT, V67, P3144, DOI 10.1103/PhysRevLett.67.3144; DESSAU DS, IN PRESS INT J MOD B; DESSAU DS, IN PRESS HDB MAGNETO; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; IBACH H, 1994, SURF SCI, V299, P116, DOI 10.1016/0039-6028(94)90650-5; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Okimoto Y, 1997, PHYS REV B, V55, P4206, DOI 10.1103/PhysRevB.55.4206; Park JH, 1996, PHYS REV LETT, V76, P4215, DOI 10.1103/PhysRevLett.76.4215; Pickett WE, 1996, PHYS REV B, V53, P1146, DOI 10.1103/PhysRevB.53.1146; Renner C, 1998, PHYS REV LETT, V80, P149, DOI 10.1103/PhysRevLett.80.149; Shannon N, 1996, J PHYS-CONDENS MAT, V8, P10493, DOI 10.1088/0953-8984/8/49/037; SHIRLEY DA, 1972, PHYS REV B, V5, P4709, DOI 10.1103/PhysRevB.5.4709; TERRASI A, 1995, PHYS REV B, V52, P5592, DOI 10.1103/PhysRevB.52.5592; TOUGAARD S, 1984, SURF SCI, V143, P482, DOI 10.1016/0039-6028(84)90554-5; ZWICK F, 1998, PHYS REV LETT, V81, P3144	16	60	60	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					777	779		10.1126/science.284.5415.777	http://dx.doi.org/10.1126/science.284.5415.777			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221903	Green Submitted			2022-12-28	WOS:000080056200037
J	Chamberlain, G; Steer, P				Chamberlain, G; Steer, P			ABC of labour care - Labour in special circumstances	BRITISH MEDICAL JOURNAL			English	Review									Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England	Singleton Hospital; Imperial College London	Chamberlain, G (corresponding author), Singleton Hosp, Swansea SA2 8QA, W Glam, Wales.							ERIKIM M, 1993, GUIDE EFFECTIVE CARE, P145; James DK, 1999, HIGH RISK PREGNANCY; Maternal and Child Health Research Consortium, 2000, CONF ENQ STILLB DEAT; Mercey D, 1998, BMJ-BRIT MED J, V316, P241, DOI 10.1136/bmj.316.7127.241	4	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1124	1127		10.1136/bmj.318.7191.1124	http://dx.doi.org/10.1136/bmj.318.7191.1124			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213729	Green Published			2022-12-28	WOS:000080166000031
J	Ballestas, ME; Chatis, PA; Kaye, KM				Ballestas, ME; Chatis, PA; Kaye, KM			Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; PERMITS STABLE REPLICATION; KAPOSIS-SARCOMA; CELL-LINES; INFECTED-CELLS; LYMPHOMA; IDENTIFICATION; SEQUENCES; BINDING; PROTEIN	Primary effusion Lymphoma (PEL) cells harbor Kaposi's sarcoma-associated herpesvirus (KSHV) episomes and express a KSHV-encoded Latency-associated nuclear antigen (LANA). In PEL cells, LANA and KSHV DNA colocalized in dots in interphase nuclei and along mitotic chromosomes. In the absence of KSHV DNA, LANA was diffusely distributed in the nucleus or on mitotic chromosomes. In Lymphoblasts, LANA was necessary and sufficient for the persistence of episomes containing a specific KSHV DNA fragment. Furthermore, LANA colocalized with the artificial KSHV DNA episomes in nuclei and along mitotic chromosomes. These results support a model in which LANA tethers KSHV DNA to chromosomes during mitosis to enable the efficient segregation of KSHV episomes to progeny cells.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; NEN Life Sci Prod, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaye, KM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			Ballestas, Mary/0000-0003-0660-9477	NATIONAL CANCER INSTITUTE [R01CA067380] Funding Source: NIH RePORTER; NCI NIH HHS [CA67380-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GROGAN EA, 1983, P NATL ACAD SCI-BIOL, V80, P7650, DOI 10.1073/pnas.80.24.7650; HARRIS A, 1985, J VIROL, V56, P328, DOI 10.1128/JVI.56.1.328-332.1985; Jones D, 1998, NEW ENGL J MED, V339, P444, DOI 10.1056/NEJM199808133390705; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kellam P, 1997, J Hum Virol, V1, P19; Kung SH, 1996, J VIROL, V70, P1738, DOI 10.1128/JVI.70.3.1738-1744.1996; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; Renne R, 1996, J VIROL, V70, P8151, DOI 10.1128/JVI.70.11.8151-8154.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Szekely L, 1998, J GEN VIROL, V79, P1445, DOI 10.1099/0022-1317-79-6-1445; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	34	569	589	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					641	644		10.1126/science.284.5414.641	http://dx.doi.org/10.1126/science.284.5414.641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213686				2022-12-28	WOS:000079951100044
J	Mosterd, A; D'Agostino, RB; Silbershatz, H; Sytkowski, PA; Kannel, WB; Grobbee, DE; Levy, D				Mosterd, A; D'Agostino, RB; Silbershatz, H; Sytkowski, PA; Kannel, WB; Grobbee, DE; Levy, D			Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; NATIONAL-HEALTH; ARTERY DISEASE; SECULAR TRENDS; SERIAL CHANGES; RISK-FACTORS; MORTALITY; CRITERIA; DECLINE	Background Men and women with hypertension are at increased risk for cardiovascular disease, especially when left ventricular hypertrophy is present. We examined temporal trends in the use of antihypertensive medications and studied the relation between their use, the prevalence of high blood pressure, and the presence of electrocardiographic evidence of left ventricular hypertrophy. Methods A total of 10,333 participants in the Framingham Heart Study who were 45 to 74 years of age underwent a total of 51,756 examinations from 1950 to 1989. Data were obtained on blood pressure and the use of antihypertensive medications, and electrocardiograms were assessed for left ventricular hypertrophy. The generalized-estimating-equation method was used to test for trends over time. Results From 1950 to 1989, the rate of use of antihypertensive medications increased from 2.3 percent to 24.6 percent among men and from 5.7 percent to 27.7 percent among women. The age-adjusted prevalence of systolic blood pressure of at least 160 mm Hg or diastolic blood pressure of at least 100 mm Hg declined from 18.5 percent to 9.2 percent among men and from 28.0 percent to 7.7 percent among women. This decline was accompanied by age-adjusted reductions in the prevalence of electrocardiographic evidence of left ventricular hypertrophy, from 4.5 percent to 2.5 percent among men and from 3.6 percent to 1.1 percent among women. Conclusions Our findings support the notion that the increasing use of antihypertensive medication has resulted in a reduced prevalence of high blood pressure and a concomitant decline in left ventricular hypertrophy in the general population. Our observations may in part explain the considerable decline in mortality from cardiovascular disease observed since the late 1960s. (N Engl J Med 1999;340:1221-7) (C) 1999, Massachusetts Medical Society.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Div Cardiol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands; NHLBI, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Dept Math, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Utrecht University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Boston University	Levy, D (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Grobbee, Diederick/C-7651-2014	Levy, Daniel/0000-0003-1843-8724; Grobbee, Diederick/0000-0003-4472-4468	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHIZAWA N, 1989, J AM COLL CARDIOL, V13, P165, DOI 10.1016/0735-1097(89)90566-4; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CHAMBERS J, 1995, BRIT MED J, V311, P273, DOI 10.1136/bmj.311.7000.273; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FEINLEIB M, 1992, MONOGRAPHS EPIDEMIOL, V16, P261; FROHLICH ED, 1992, NEW ENGL J MED, V327, P1768; GHALI JK, 1991, J AM COLL CARDIOL, V17, P1277, DOI 10.1016/S0735-1097(10)80135-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1992, AM J PUBLIC HEALTH, V82, P1593, DOI 10.2105/AJPH.82.12.1593; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LANTI M, 1990, AM J CARDIOL, V66, P1181, DOI 10.1016/0002-9149(90)91095-N; LEE DK, 1992, JAMA-J AM MED ASSOC, V268, P3201; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; Levy D, 1998, NEW ENGL J MED, V339, P915, DOI 10.1056/NEJM199809243391309; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACMAHON S, 1989, AM J CARDIOL, V63, P202, DOI 10.1016/0002-9149(89)90286-5; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; *NAT HEART LUNG BL, 1998, MORB MORT 1998 CHART; PRINGLE SD, 1989, J AM COLL CARDIOL, V13, P1377, DOI 10.1016/0735-1097(89)90314-8; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; Sytkowski PA, 1996, AM J EPIDEMIOL, V143, P338, DOI 10.1093/oxfordjournals.aje.a008748; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; VANHOOF R, 1991, AM J MED, V90, pS55, DOI 10.1016/0002-9343(91)90438-4; Verdecchia P, 1998, CIRCULATION, V97, P48, DOI 10.1161/01.CIR.97.1.48; 1985, HYPERTENSION, V7, P105	39	205	213	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1221	1227		10.1056/NEJM199904223401601	http://dx.doi.org/10.1056/NEJM199904223401601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210704				2022-12-28	WOS:000079833800001
J	Light, DW				Light, DW			Good managed care needs universal health insurance	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							COST	Although the increase of corporate managed care has helped to reduce excesses and costs, continued gains in cost-effectiveness depend on good clinically managed care. Benefits of clinically managed care depend on stable contracts and universal coverage. Instead, employers are decreasing coverage and creating a market of "lemons" in which low-cost plans are rewarded for cost-cutting tactics. These tactics have spawned movements that demand rights for patients and providers. Choosing to shore up those rights, however, will increase the number of uninsured persons. This tragic choice, which no other industrialized nation has permitted, will not be resolved until some form of universal health insurance is implemented.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Stratford, NJ 08084 USA	University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center	Light, DW (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.							Bodenheimer T, 1998, NEW ENGL J MED, V338, P1003, DOI 10.1056/NEJM199804023381422; Carrasquillo O, 1999, NEW ENGL J MED, V340, P109, DOI 10.1056/NEJM199901143400206; Carrasquillo O, 1999, AM J PUBLIC HEALTH, V89, P36, DOI 10.2105/AJPH.89.1.36; *CTR STUD HLTH SYS, 1998, 13 CTR STUD HLTH SYS; *CTR STUD HLTH SYS, 1998, 17 CTR STUD HLTH SYS; Daniels Norman, 1996, BENCHMARKS FAIRNESS; Enthoven AC, 1980, HLTH PLAN ONLY PRACT; Enthoven Alain C., 1988, THEORY PRACTICE MANA; GABEL J, 1998, FINANCIAL BURDEN SEL; GINSBERG P, 1998, PERSPECTIVE HLTH SYS, P1; KILBORN PT, 1999, NY TIMES        0123, pA9; Kuttner R, 1999, NEW ENGL J MED, V340, P248, DOI 10.1056/NEJM199901213400324; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; LEVAN R, 1998, NEARLY ONE 5 URBAN A; *LEW GROUP, 1997, MAN CAR SAV EMPL HOU; LIGHT DW, 1994, LANCET, V344, P1197, DOI 10.1016/S0140-6736(94)90512-6; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; LONG SH, 1998, DATA B CTR STUDYING, V15; Pear Robert, 1998, N Y Times Web, pA10; RASELL ME, 1995, NEW ENGL J MED, V332, P1164, DOI 10.1056/NEJM199504273321711; Reinhardt UE, 1997, JAMA-J AM MED ASSOC, V278, P1446, DOI 10.1001/jama.278.17.1446; Rice DP, 1998, JAMA-J AM MED ASSOC, V279, P1030, DOI 10.1001/jama.279.13.1030; SHEARER G, 1998, HIDDEN VIEW GROWING; STEINBERG J, 1999, NY TIMES        1203, pA1; STEINHAUER J, 1999, NY TIMES        0119, pB6; *US SEN, 1997, EMPL BAS HLTH INS CO; White Joseph, 1995, COMPETING SOLUTIONS; 1998, N ENGL J MED, V338, P1084	28	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					686	689		10.7326/0003-4819-130-8-199904200-00016	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215566				2022-12-28	WOS:000079786600009
J	Stewart, PM				Stewart, PM			Mineralocorticoid hypertension	LANCET			English	Article							GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; 11-BETA-HYDROXYSTEROID DEHYDROGENASE-ACTIVITY; ECTOPIC ADRENOCORTICOTROPIN SYNDROME; SUPPRESSIBLE HYPER-ALDOSTERONISM; CHIMERIC GENE DUPLICATIONS; CORTISOL CORTISONE SHUTTLE; EPITHELIAL SODIUM-CHANNEL; STEROID 11-BETA-HYDROXYLASE; LIDDLES SYNDROME; PRIMARY HYPERALDOSTERONISM	Hypertension with hypokalaemia and suppression of plasma renin activity is known as mineralocorticoid hypertension. Although mineralocorticoid hypertension accounts for a small number of patients labelled as having "essential" hypertension, it is a potentially reversible cause of high blood pressure. The most common cause of mineralocorticoid hypertension is probably primary aldosteronism; controlled posture studies to measure plasma renin activity and aldosterone concentrations, followed by adrenal imaging, will ensure the differential diagnosis between an aldosterone-producing adenoma and idiopathic adrenal hyperplasia in most case. Three monogenic forms of mineralocorticoid hypertension have been described: glucocorticoid-suppressible hyperaldosteronism, Liddle's syndrome, and apparent mineralocorticoid excess, which have provided new insights into mineralocorticoid hormone action. Many patients with mineralocorticold-based hypertension are now known to have normal serum potassium concentrations. Until the true prevalence of primary aldosteronism and monogenic forms of mineralocorticoid hypertension are defined, a high index of suspicion is needed in every hypertensive patient. Hypertensive patients with hypokalaemia, together with those with severe hypertension or a family history of hypertension or stroke, should be screened for mineralocorticoid excess.	Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Stewart, PM (corresponding author), Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.	p.m.stewart@bham.ac.uk						ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Barzon L, 1998, J CLIN ENDOCR METAB, V83, P55, DOI 10.1210/jc.83.1.55; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1994, ENDOCRIN METAB CLIN, V23, P2; Bubien JK, 1996, AM J PHYSIOL-CELL PH, V270, pC208, DOI 10.1152/ajpcell.1996.270.1.C208; Carroll J, 1996, J CLIN ENDOCR METAB, V81, P4310, DOI 10.1210/jc.81.12.4310; CONN JW, 1955, J LAB CLIN MED, V45, P3; DESIMONE G, 1985, HYPERTENSION, V7, P204, DOI 10.1161/01.HYP.7.2.204; DIMARTINONARDI J, 1987, CLIN ENDOCRINOL, V27, P49, DOI 10.1111/j.1365-2265.1987.tb00838.x; DLUHY RG, 1995, STEROIDS, V60, P48, DOI 10.1016/0039-128X(94)00010-A; DOPPMAN JL, 1992, RADIOLOGY, V184, P677, DOI 10.1148/radiology.184.3.1509049; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FALLO F, 1985, CLIN ENDOCRINOL, V22, P777, DOI 10.1111/j.1365-2265.1985.tb00168.x; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FAVIA G, 1992, WORLD J SURG, V16, P680, DOI 10.1007/BF02067355; FERRISS JB, 1978, AM HEART J, V95, P375, DOI 10.1016/0002-8703(78)90370-8; FONTES RG, 1991, AM J HYPERTENS, V4, P786, DOI 10.1093/ajh/4.9.786; FRASER R, 1989, CLIN ENDOCRINOL, V31, P701, DOI 10.1111/j.1365-2265.1989.tb01295.x; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1989, ENDOCRINOLOGY, V125, P2224, DOI 10.1210/endo-125-4-2224; FUNDER JW, 1995, STEROIDS, V60, P1, DOI 10.1016/0039-128X(95)90001-U; GADALLAH MF, 1995, AM J KID DIS, V83, P969; Gagner M, 1997, ANN SURG, V226, P238, DOI 10.1097/00000658-199709000-00003; GIANCHETTI G, 1998, P 80 ANN M END SOC, P2; GILL JR, 1981, J CLIN ENDOCR METAB, V53, P331, DOI 10.1210/jcem-53-2-331; GITTLER RD, 1995, J CLIN ENDOCR METAB, V80, P3438, DOI 10.1210/jcem.80.12.8530580; GLEASON PE, 1993, J UROLOGY, V150, P1365, DOI 10.1016/S0022-5347(17)35781-6; GOMEZSANCHEZ CE, 1984, J CLIN ENDOCR METAB, V59, P1022, DOI 10.1210/jcem-59-5-1022; GOMEZSANCHEZ EP, 1992, AM J PHYSIOL, V263, pE1125; GORDON RD, 1994, CLIN EXP PHARMACOL P, V21, P315, DOI 10.1111/j.1440-1681.1994.tb02519.x; GORDON RD, 1992, LANCET, V340, P159, DOI 10.1016/0140-6736(92)93225-C; GROSS MD, 1984, AM J MED, V77, P839, DOI 10.1016/0002-9343(84)90521-7; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; Jamieson A, 1996, J CLIN ENDOCR METAB, V81, P2298; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KORNEL L, 1994, AM J HYPERTENS, V7, P100, DOI 10.1093/ajh/7.1.100; Kupari M, 1998, CIRCULATION, V97, P569; LAMBERTS SWJ, 1992, J CLIN ENDOCR METAB, V74, P313, DOI 10.1210/jc.74.2.313; Li A, 1998, AM J HUM GENET, V63, P370, DOI 10.1086/301955; Li AR, 1997, J HYPERTENS, V15, P1397, DOI 10.1097/00004872-199715120-00005; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LIM PO, 1998, J ENDOCRINOL S, V156, P22; Litchfield WR, 1998, HYPERTENSION, V31, P445, DOI 10.1161/01.HYP.31.1.445; LUND JO, 1981, ACTA MED SCAND, P54; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; Monchik JM, 1996, SURGERY, V120, P919; MONDER C, 1986, J CLIN ENDOCR METAB, V63, P550, DOI 10.1210/jcem-63-3-550; MORNET E, 1989, J BIOL CHEM, V264, P20961; Morris DJ, 1998, HYPERTENSION, V31, P469, DOI 10.1161/01.HYP.31.1.469; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Mune T, 1996, HYPERTENSION, V27, P1193, DOI 10.1161/01.HYP.27.6.1193; ORTH DN, 1998, WILLIAMS TXB ENDOCRI, P517; PADFIELD PL, 1981, LANCET, V2, P83; PASCOE L, 1995, J CLIN INVEST, V96, P2236, DOI 10.1172/JCI118279; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P8327, DOI 10.1073/pnas.89.17.8327; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SORO A, 1995, HYPERTENSION, V25, P67, DOI 10.1161/01.HYP.25.1.67; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STEWART PM, 1990, CLIN SCI, V78, P49, DOI 10.1042/cs0780049; STEWART PM, 1987, LANCET, V2, P821; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Stewart PM, 1996, CLIN ENDOCRINOL, V44, P493, DOI 10.1046/j.1365-2265.1996.716535.x; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P3617, DOI 10.1210/jc.80.12.3617; STOWASSER M, 1995, CLIN EXP PHARMACOL P, V22, P460, DOI 10.1111/j.1440-1681.1995.tb02044.x; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; TARAZI RC, 1973, NEW ENGL J MED, V289, P1330, DOI 10.1056/NEJM197312202892502; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; ULICK S, 1992, J CLIN ENDOCR METAB, V74, P963, DOI 10.1210/jc.74.5.963; Ullian ME, 1996, HYPERTENSION, V27, P1346, DOI 10.1161/01.HYP.27.6.1346; Vallotton MB, 1996, CLIN ENDOCRINOL, V45, P47, DOI 10.1111/j.1365-2265.1996.tb02059.x; WALKER BR, 1993, CLIN ENDOCRINOL, V39, P221, DOI 10.1111/j.1365-2265.1993.tb01778.x; WALKER BR, 1992, CLIN SCI, V83, P171, DOI 10.1042/cs0830171; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P529, DOI 10.1210/jc.80.2.529; Walmsley D, 1996, CLIN ENDOCRINOL, V45, P141, DOI 10.1046/j.1365-2265.1996.d01-1557.x; WANG C, 1981, J CLIN ENDOCR METAB, V52, P1027, DOI 10.1210/jcem-52-5-1027; Watson B, 1996, HYPERTENSION, V28, P478, DOI 10.1161/01.HYP.28.3.478; WEINBERGER MH, 1993, ARCH INTERN MED, V153, P2125, DOI 10.1001/archinte.153.18.2125; WHITE EA, 1980, NEW ENGL J MED, V303, P1503, DOI 10.1056/NEJM198012253032603; WHITE PC, 1994, ENDOCR REV, V15, P421, DOI 10.1210/er.15.4.421; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; WOODLAND E, 1985, CLIN EXP PHARMACOL P, V12, P245, DOI 10.1111/j.1440-1681.1985.tb02640.x; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; Young WF, 1997, ENDOCRINOLOGIST, V7, P213, DOI 10.1097/00019616-199707040-00003	93	117	128	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	1999	353	9161					1341	1347		10.1016/S0140-6736(98)06102-9	http://dx.doi.org/10.1016/S0140-6736(98)06102-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218547				2022-12-28	WOS:000080278100042
J	Freedman, MS; Lucas, RJ; Soni, B; von Schantz, M; Munoz, M; David-Gray, Z; Foster, R				Freedman, MS; Lucas, RJ; Soni, B; von Schantz, M; Munoz, M; David-Gray, Z; Foster, R			Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors	SCIENCE			English	Article							GANGLION-CELLS; LIGHT; MICE; RHYTHMS; PIGMENT; RETINA; SYSTEM; OPSIN; RD/RD; CLOCK	Circadian rhythms of mammals are entrained by light to follow the daily solar cycle (photoentrainment). To determine whether retinal rods and cones are required for this response, the effects of light on the regulation of circadian wheel-running behavior were examined in mice lacking these photoreceptors. Mice without cones (cl) or without both rods and cones (rdta/cl) showed unattenuated phase-shifting responses to light. Removal of the eyes abolishes this behavior. Thus, neither rods nor cones are required for photoentrainment, and the murine eye contains additional photoreceptors that regulate the circadian clock.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Oviedo, Dept Morfol & Biol Celular, Oviedo 33072, Spain	Imperial College London; University of Oviedo	Foster, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Alexander Fleming Bldg, London SW7 2AZ, England.		Jansen, Heiko T./A-5770-2008; Llamosas, Marta Muñoz/A-7667-2008; von Schantz, Malcolm/C-5962-2014	Jansen, Heiko T./0000-0003-0178-396X; Llamosas, Marta Muñoz/0000-0002-9832-3523; von Schantz, Malcolm/0000-0002-9911-9436; Lucas, Robert/0000-0002-1088-8029				BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; FOSTER RG, 1993, J BIOL RHYTHM, V8, pS17; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; GARCIAFERNANDEZ JM, 1995, NEUROSCI LETT, V187, P33; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Lupi D, 1999, NEUROSCIENCE, V89, P363, DOI 10.1016/S0306-4522(98)00353-4; McCall MA, 1996, EXP EYE RES, V63, P35, DOI 10.1006/exer.1996.0089; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; Oren DA, 1998, SCIENCE, V279, P333, DOI 10.1126/science.279.5349.333; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; PROVENCIO I, 1995, BRAIN RES, V694, P183, DOI 10.1016/0006-8993(95)00694-L; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; vonSchantz M, 1997, BRAIN RES, V770, P131, DOI 10.1016/S0006-8993(97)00791-9; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C	23	576	596	3	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					502	504		10.1126/science.284.5413.502	http://dx.doi.org/10.1126/science.284.5413.502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205061				2022-12-28	WOS:000079792200052
J	Ono, T; Miyajima, H; Shigeto, K; Mibu, K; Hosoito, N; Shinjo, T				Ono, T; Miyajima, H; Shigeto, K; Mibu, K; Hosoito, N; Shinjo, T			Propagation of a magnetic domain wall in a submicrometer magnetic wire	SCIENCE			English	Article							GIANT MAGNETORESISTANCE; REVERSAL; PARTICLES; FILMS; SIZE	The motion of a magnetic domain wall in a submicrometer magnetic wire was detected by use of the giant magnetoresistance effect. Magnetization reversal in a submicrometer magnetic wire takes place by the propagation of a magnetic domain wall, which can be treated as a "particle." The propagation velocity of the magnetic domain wall was determined as a function of the applied magnetic field.	Keio Univ, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan; Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Keio University; Kyoto University	Ono, T (corresponding author), Keio Univ, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan.		Mibu, Ko/E-2277-2014; Ono, Teruo/AAR-1164-2020	Mibu, Ko/0000-0002-6416-1028; 				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Bertotti G., 1998, HYSTERESIS MAGNETISM; CHANG T, 1994, J APPL PHYS, V75, P5553, DOI 10.1063/1.355686; Chudnovsky E. M., 1998, MACROSCOPIC QUANTUM; GIORDANO N, 1994, PHYSICA B, V194, P1009, DOI 10.1016/0921-4526(94)90834-6; HIRAYAMA T, 1993, APPL PHYS LETT, V63, P418, DOI 10.1063/1.110011; Kirilyuk A, 1997, J MAGN MAGN MATER, V171, P45, DOI 10.1016/S0304-8853(96)00744-5; Malozemoff A.P., 1979, MAGNETIC DOMAIN WALL; Ono T, 1998, APPL PHYS LETT, V72, P1116, DOI 10.1063/1.120941; Otani Y, 1997, MATER RES SOC SYMP P, V475, P215, DOI 10.1557/PROC-475-215; SUGITA Y, UNPUB; TATARA G, 1994, PHYS REV LETT, V72, P772, DOI 10.1103/PhysRevLett.72.772; TELESNIN RV, 1969, IEEE T MAGN, VMAG5, P232, DOI 10.1109/TMAG.1969.1066494; Wernsdorfer W, 1996, PHYS REV LETT, V77, P1873, DOI 10.1103/PhysRevLett.77.1873	14	320	321	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					468	470		10.1126/science.284.5413.468	http://dx.doi.org/10.1126/science.284.5413.468			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205050				2022-12-28	WOS:000079792200041
J	Bleyer, AJ; Hylander, B; Sudo, H; Nomoto, Y; de la Torre, E; Chen, RA; Burkart, JM				Bleyer, AJ; Hylander, B; Sudo, H; Nomoto, Y; de la Torre, E; Chen, RA; Burkart, JM			An international study of patient compliance with hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY	Context International differences in compliance of patients undergoing hemodialysis are poorly characterized and could contribute to international survival differences. Objective To compare international differences in patient compliance with hemodialysis treatments. Design A prospective observational study of patients undergoing hemodialysis in 1995 and a cross-sectional survey of health care professionals caring for hemodialyzed patients in 1996. Setting and Patients Four dialysis centers in the southeastern United States with 415 patients undergoing hemodialysis, 1 center in Sweden with 84 patients, and 4 centers in Japan with 194 patients participated in the prospective observational study. In the cross-sectional survey, nurses and nephrologists from the United States (n = 49), Japan (n = 21), and Sweden (n = 16) responded to questions regarding the compliance of their patients undergoing hemodialysis. Main Outcome Measures Percentage of patients who miss a dialysis treatment and number of missed dialysis treatments. Results Of 415 US patients, 147 missed 699 treatments over a 6-month period (28.1 missed treatments per 100 patient-months or 2.3% of all prescribed treatments). During a 3-month period, there were 0 missed treatments per 100 patient-months for patients from Japan and 0 missed treatments per 100 patient-months for patients from Sweden (P<.001). In the cross-sectional survey, the mean (SD) estimated percentage of patients missing a treatment per month was 4% (3%) for the United States, 0% for Japan, and 0.1% (3%) for Sweden (P<.001). Conclusions Noncompliance is much more common in US patients undergoing hemodialysis than Swedish and Japanese patients. The implications of these results for international differences in survival deserve further study.	Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Winston Salem, NC 27157 USA; Karolinska Hosp, S-10401 Stockholm, Sweden; Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan	Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Karolinska University Hospital; Tokai University	Bleyer, AJ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ableyer@wfubmc.edu						Anderson GF, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.6.163; Bleyer A J, 1996, Nephrol News Issues, V10, P35; BLEYER AJ, 1995, J AM SOC NEPHROL, V6, P593; Gaylin W, 1996, HASTINGS CENT REP, V26, P43, DOI 10.2307/3528763; KIMMEL PL, 1995, J AM SOC NEPHROL, V5, P1826; KITAGAWA T, 1995, AM J EPIDEMIOL, V142, P612; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Scarr S, 1996, SCAND J PSYCHOL, V37, P93, DOI 10.1111/j.1467-9450.1996.tb00642.x; SHERMAN RA, 1994, AM J KIDNEY DIS, V24, P921, DOI 10.1016/S0272-6386(12)81061-4; Tsukamoto Y, 1996, Med Law, V15, P195; *US REN DAT SYST, 1996, AM J KIDNEY DIS S2, V28, pS146; *US REN DAT SYST, 1996, USRDS 1996 ANN DAT R, P14; 1997, DIAL TRANSPLANTATION, V26, pL6	13	68	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1211	1213		10.1001/jama.281.13.1211	http://dx.doi.org/10.1001/jama.281.13.1211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	181VW	10199431	Bronze			2022-12-28	WOS:000079464400036
J	Wei, Y; Yu, LL; Bowen, J; Gorovsky, MA; Allis, CD				Wei, Y; Yu, LL; Bowen, J; Gorovsky, MA; Allis, CD			Phosphorylation of histone H3 is required for proper chromosome condensation and segregation	CELL			English	Article							TETRAHYMENA-THERMOPHILA; LINKER HISTONES; SACCHAROMYCES-CEREVISIAE; CHROMATIN CONDENSATION; PROTEIN COMPLEXES; 13S CONDENSIN; OKADAIC ACID; BETA-TUBULIN; CELL-CYCLE; IN-VITRO	Phosphorylation of histone H3 at serine 10 occurs during mitosis in diverse eukaryotes and correlates closely with mitotic and meiotic chromosome condensation. To better understand the function of H3 phosphorylation in vivo, we created strains of Tetrahymena in which a mutant H3 gene (S10A) was the only gene encoding the major H3 protein. Although both micronuclei and macronuclei contain H3 in typical nucleosomal structures, defects in nuclear divisions were restricted to mitotically dividing micronuclei; macronuclei, which are amitotic, showed no defects. Strains lacking phosphorylated H3 showed abnormal chromosome segregation, resulting in extensive chromosome loss during mitosis. During meiosis, micronuclei underwent abnormal chromosome condensation and failed to faithfully transmit chromosomes. These results demonstrate that H3 serine 10 phosphorylation is causally linked to chromosome condensation and segregation in vivo and is required for proper chromosome dynamics.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Gorovsky, MA (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	micro@dialup.rochester.edu; allis@virginia.edu			NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM21793, GM40922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Ajiro K, 1996, EUR J BIOCHEM, V241, P923, DOI 10.1111/j.1432-1033.1996.00923.x; ALLEN SL, 1967, SCIENCE, V155, P575, DOI 10.1126/science.155.3762.575; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ALLIS CD, 1980, CELL, V20, P55; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CassidyHanley D, 1997, GENETICS, V146, P135; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; DOERDER FP, 1980, DEV GENET, V1, P205; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1977, COLD SPRING HARB SYM, V42, P493; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; MERRIAM EV, 1988, GENETICS, V120, P389; MIZZEN CM, 1999, IN RPESS COLD SPRING, V63; Murray AW, 1998, SCIENCE, V282, P425, DOI 10.1126/science.282.5388.425; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Strunnikov AV, 1998, TRENDS CELL BIOL, V8, P454, DOI 10.1016/S0962-8924(98)01370-1; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Sweet MT, 1997, J BIOL CHEM, V272, P916, DOI 10.1074/jbc.272.2.916; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; VACQUIER VD, 1989, DEV BIOL, V133, P111, DOI 10.1016/0012-1606(89)90302-3; Van Hooser A, 1998, J CELL SCI, V111, P3497; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1998, TRENDS CELL BIOL, V8, P266; WENKERT D, 1984, J CELL BIOL, V98, P2107, DOI 10.1083/jcb.98.6.2107; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yu LL, 1997, MOL CELL BIOL, V17, P6303, DOI 10.1128/MCB.17.11.6303	64	560	581	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					99	109		10.1016/S0092-8674(00)80718-7	http://dx.doi.org/10.1016/S0092-8674(00)80718-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199406	hybrid			2022-12-28	WOS:000079843900012
J	Petitou, M; Herault, LP; Bernat, A; Driguez, PA; Duchaussoy, P; Lormeau, JC; Herbert, JM				Petitou, M; Herault, LP; Bernat, A; Driguez, PA; Duchaussoy, P; Lormeau, JC; Herbert, JM			Synthesis of thrombin-inhibiting heparin mimetics without side effects	NATURE			English	Article							ANTITHROMBIN-III; FACTOR-XA; PENTASACCHARIDE; OLIGOSACCHARIDES; ANALOGS	Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of the polysaccharide heparin(1) has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass(2). Despite this improvement, heparin-induced thrombocytopaenia(3) (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages(4), remain significant side effects of heparinotherapy. Breakthroughs in oligosaccharide chemistry(5) made possible the total synthesis of the pentasaccharide antithrombin-binding site of heparin(6,7). This pentasaccharide represents a new family of potential antithrombotic drugs, devoid of thrombin inhibitory properties, and free of undesired interactions with blood and vessel components. To obtain more potent and well-tolerated antithrombotic drugs, we wished to synthesize heparin mimetics able to inhibit thrombin, that is, longer oligosaccharides. Like thrombin inhibition, undesired interactions are directly correlated to the charge and the size of the molecules(8), so we had to design structures that were able to discriminate between thrombin and other proteins, particularly PF4. Here we describe the use of multistep converging synthesis to obtain sulphated oligosaccharides that meet these requirements.	Sanofi Rech, F-31036 Toulouse, France	Sanofi-Aventis; Sanofi France	Herbert, JM (corresponding author), Sanofi Rech, 195 Route Espagne, F-31036 Toulouse, France.	jean-marc.herbert@sanofi.com						ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BASTEN J, 1992, BIOORG MED CHEM LETT, V2, P905, DOI 10.1016/S0960-894X(00)80585-5; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; GROOTENHUIS PDJ, 1995, NAT STRUCT BIOL, V2, P736, DOI 10.1038/nsb0995-736; Herbert JM, 1996, CIRC RES, V79, P590, DOI 10.1161/01.RES.79.3.590; JIN J, 1997, P NATL ACAD SCI USA, V94, P14683; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1989, HEPARIN; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PAULSEN H, 1982, ANGEW CHEM INT EDIT, V21, P155, DOI 10.1002/anie.198201553; Petitou M, 1997, J MED CHEM, V40, P1600, DOI 10.1021/jm960726z; Petitou M, 1998, ANGEW CHEM INT EDIT, V37, P3009, DOI 10.1002/(SICI)1521-3773(19981116)37:21<3009::AID-ANIE3009>3.0.CO;2-F; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; SHERIDAN D, 1986, BLOOD, V67, P27; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Thomas DP, 1997, THROMB HAEMOSTASIS, V78, P1422; UMETSU T, 1978, THROMB HAEMOSTASIS, V39, P74; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; Westerduin P, 1994, Bioorg Med Chem, V2, P1267, DOI 10.1016/S0968-0896(00)82078-7	27	279	292	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					417	422		10.1038/18877	http://dx.doi.org/10.1038/18877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201371				2022-12-28	WOS:000079508200051
J	Henderson, J; North, K; Griffiths, M; Harvey, I; Golding, J				Henderson, J; North, K; Griffiths, M; Harvey, I; Golding, J		Avon Longitudinal Study Pregnancy Childhood Tea	Pertussis vaccination and wheezing illnesses in young children: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ASTHMA; INFECTION; SYMPTOMS; ALLERGY; ADULTS; IGE	Objectives To examine the relation between pertussis vaccination and the prevalence of wheezing illnesses in young children. Design Prospective cohort study. Setting Three former health districts comprising Avon Health Authority. Subjects 9444 of 14 138 children enrolled in the Avon longitudinal study of pregnancy and childhood and for whom data on wheezing symptoms, vaccination status, and 15 environmental and biological variables were available. Main outcome measures Episodes of wheezing from birth to 6 months, 7-18 months, 19-30 months, and 31-42 months. These time periods were used to derive five categories of wheezing illness: early wheezing (not after 18 months); late onset wheezing (after 18 months); persistent wheezing (at every time period); recurrent wheezing (any combination of two or more episodes for each period); and intermittent wheezing (any combination of single episodes of reported wheezing). These categories were stratified according to parental self reported asthma or allergy. Results Unadjusted comparisons of the defined wheezing illnesses in vaccinated and non-vaccinated children showed no significant association between pertussis vaccination and any of the wheezing outcomes regardless of stratification for parental asthma or allergy. Wheeze was more common in non-vaccinated children at 18 months, and there was a tendency for late onset wheezing to be associated with non-vaccination in children whose parents did not have asthma, but this was not significant. After adjustment for environmental and biological variables, logistic regression analyses showed no significant increased relative risk for any of the wheezing outcomes in vaccinated children: early wheezing (0.99, 95% confidence interval 0.80 to 1.23), late onset wheezing (0.85, 0.69 to 1.05), persistent wheezing (0.91, 0.41 to 1.79), recurrent wheezing (0.96, 0.72 to 1.26), and intermittent wheezing (1.06, 0.81 to 1.37). Conclusions No evidence was found that pertussis vaccination increases the risk of wheezing illnesses in young children. Further follow up of this population with objective measurement of allergy and bronchial responsiveness is planned to confirm these observations.	Univ Bristol, Fdn Study Infant Death Unit, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Unit Paediat & Perinatal Epidemiol, Bristol BS2 1TQ, Avon, England; St Michaels Hosp, Dept Ear Nose & Throat, Bristol BS2 8EG, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Bristol; University of East Anglia	Henderson, J (corresponding author), Univ Bristol, Fdn Study Infant Death Unit, Inst Child Hlth, Bristol BS2 8BJ, Avon, England.		Northstone, Kate/A-8165-2011	Northstone, Kate/0000-0002-0602-1983; Golding, Jean/0000-0003-2826-3307	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramson M, 1996, J ASTHMA, V33, P189, DOI 10.3109/02770909609054551; ATMAR RL, 1990, VACCINE, V8, P217, DOI 10.1016/0264-410X(90)90049-R; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Feeney M, 1997, LANCET, V350, P764, DOI 10.1016/S0140-6736(97)03192-9; GOLDING J, 1996, CONT REV OBSTET GYNA, V8, P89; HAUS M, 1988, LANCET, V1, P711; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; SALISBURY D, 1996, IMMUNISATION INFECT; SCHUSTER A, 1993, CLIN INVESTIGATOR, V71, P208; Silverman M, 1997, THORAX, V52, P936, DOI 10.1136/thx.52.11.936; WJST M, 1994, ANN ALLERGY, V73, P450	15	73	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1173	1176						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221941	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080277900028
J	Sessions, SK; Franssen, RA; Horner, VL				Sessions, SK; Franssen, RA; Horner, VL			Morphological clues from multilegged frogs: Are retinoids to blame?	SCIENCE			English	Article							REGENERATING AXOLOTL LIMBS; VITAMIN-A; POSITIONAL MEMORY; RANA-TEMPORARIA; ACID; PATTERN; DEFORMITIES; AXIS	Morphological analysis was performed on multilegged deformed frogs representing five species from 12 different Localities in California, Oregon, Arizona, and New York. The pattern of duplicated Limbs was consistent with mechanical perturbation by trematode infestation but not with the effects of retinoids.	Hartwick Coll, Dept Biol, Oneonta, NY 13820 USA		Sessions, SK (corresponding author), Hartwick Coll, Dept Biol, Oneonta, NY 13820 USA.							Blaustein AR, 1997, P NATL ACAD SCI USA, V94, P13735, DOI 10.1073/pnas.94.25.13735; BRYANT SV, 1992, DEV BIOL, V152, P1, DOI 10.1016/0012-1606(92)90152-7; BRYANT SV, 1987, AM ZOOL, V27, P675; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARDINER DM, 1989, J EXP ZOOL, V251, P47, DOI 10.1002/jez.1402510107; Gardiner DM, 1996, INT J DEV BIOL, V40, P797; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; Harrison R, 1969, HARRISON STAGE DESCR; Helgen Judy, 1998, P288; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; JOHNSON PT, 1998, THESIS STANFORD U; Johnson PTJ, 1999, SCIENCE, V284, P802, DOI 10.1126/science.284.5415.802; KIM WS, 1986, DEV BIOL, V114, P170, DOI 10.1016/0012-1606(86)90393-3; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1993, DEV BIOL, V159, P379, DOI 10.1006/dbio.1993.1249; MADEN M, 1981, J EMBRYOL EXP MORPH, V63, P243; MADEN M, 1983, DEV BIOL, V98, P409, DOI 10.1016/0012-1606(83)90370-6; Ouellet M, 1997, J WILDLIFE DIS, V33, P95, DOI 10.7589/0090-3558-33.1.95; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P35; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; SESSIONS SK, 1990, J EXP ZOOL, V254, P38, DOI 10.1002/jez.1402540107; SESSIONS SK, 1989, AM ZOOL, V29, pA73; SESSIONS SK, UNPUB; STOCUM DL, 1991, CELL, V67, P5, DOI 10.1016/0092-8674(91)90565-G; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; Van Valen L., 1974, Journal Herpet, V8, P109; VOLPE EP, 1981, UNDERSTANDING EVOLUT	30	77	86	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					800	802		10.1126/science.284.5415.800	http://dx.doi.org/10.1126/science.284.5415.800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221911				2022-12-28	WOS:000080056200045
J	Davis, KL; Mohs, RC; Marin, D; Purohit, DP; Perl, DP; Lantz, M; Austin, G; Haroutunian, V				Davis, KL; Mohs, RC; Marin, D; Purohit, DP; Perl, DP; Lantz, M; Austin, G; Haroutunian, V			Cholinergic markers in elderly patients with early signs of Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACETYLTRANSFERASE ACTIVITY; NUCLEUS BASALIS; CORTICAL BIOPSY; SENILE DEMENTIA; DEFICITS; PHYSOSTIGMINE; RECOVERY; PLAQUES; SCALE; RISK	Context A central tenet of Alzheimer disease (AD) is the loss of cortical cholinergic function and cholinergic markers in postmortem brain specimens. Whether these profound deficits in cholinergic markers found in end-stage patients are also found in patients with much earlier disease is not known. Objective To determine whether cholinergic deficits in AD precede, follow, or occur in synchrony with the earliest signs of cognitive deterioration. Design, Setting, and Patients Postmortem study of nursing home residents with Clinical Dementia Rating (CDR) Scale scores of 0.0 to 2.0 and 4.0 to 5.0 who underwent autopsy between 1986 and 1997, comparing the activity of the cholinergic marker enzymes in the cortices of 66 elderly subjects with no (CDR score = 0.0; n = 18), questionable (CDR score = 0.5; n = 11), mild (CDR score = 1.0; n = 22), or moderate (CDR score = 2.0; n = 15) dementia vs subjects with severe dementia (CDR score = 4.0-5.0; n = 15). Main Outcome Measures Activity of the cholinergic marker enzymes choline acetyltransferase and acetylcholinesterase in 9 neocortical brain regions. Results The activity of choline acetyltransferase and acetylcholinesterase in 9 neocortical brain regions did not differ significantly in subjects with CDR scores of 0.0 to 2.0, but was significantly lower in subjects with severe dementia (CDR score = 4.0-5.0), Choline acetyltransferase levels were significantly correlated with severity of neuropathological lesions of AD, as measured by density of neuritic plaques and neurofibrillary tangles. Conclusions Although neocortical cholinergic deficits are characteristic of severely demented AD patients, in this study, cholinergic deficits were not apparent in individuals with mild AD and were not present until relatively late in the course of the disease. These results suggest that patients with more severe disease should be a target for cholinergic treatment.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; Jewish Home & Hosp, New York, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Davis, KL (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Perl, Daniel/GPS-9879-2022		NIA NIH HHS [AG02219, AG05138] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG002219] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARTUS RT, 1986, PHARMACOL BIOCHEM BE, V24, P1287, DOI 10.1016/0091-3057(86)90186-3; BIERER LM, 1995, J NEUROCHEM, V64, P749; BOWEN DM, 1982, J NEUROL SCI, V57, P191, DOI 10.1016/0022-510X(82)90026-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; DAMASIO H, 1989, LESION ANAL NEUROPSY, P184; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1978, SCIENCE, V201, P272, DOI 10.1126/science.351807; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEKOSKY ST, 1992, ANN NEUROL, V32, P625; FARLOW MR, 1995, RES ADV ALZHEIMERS D, P284; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; HAROUTUNIAN V, 1994, SCHIZOPHR RES, V12, P137, DOI 10.1016/0920-9964(94)90071-X; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; HAROUTUNIAN V, IN PRESS ARCH NEUROL; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LI G, 1995, AM J PSYCHIAT, V152, P424; MARTIN EM, 1987, NEUROLOGY, V37, P1201, DOI 10.1212/WNL.37.7.1201; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; PERRY EK, 1977, LANCET, V1, P189; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SANTUCCI AC, 1989, PROGR CLIN BIOL RES, P1111; SILVERMAN JM, 1994, ARCH GEN PSYCHIAT, V51, P577; WENK GL, 1984, BRAIN RES, V293, P184, DOI 10.1016/0006-8993(84)91468-9	30	406	422	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1401	1406		10.1001/jama.281.15.1401	http://dx.doi.org/10.1001/jama.281.15.1401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217056	Bronze			2022-12-28	WOS:000079701000030
J	Hermann, HP; Pieske, B; Schwarzmuller, E; Keul, J; Just, H; Hasenfuss, G				Hermann, HP; Pieske, B; Schwarzmuller, E; Keul, J; Just, H; Hasenfuss, G			Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; GLUCOSE-INSULIN-POTASSIUM; SARCOPLASMIC-RETICULUM; DILATED CARDIOMYOPATHY; RABBIT HEART; INOTROPISM; MODULATION; TRIAL	Background Pyruvate, as an intermediate in the Krebs cycle, is an important source of energy for myocardium and improves contractility of normal, hypoxic, and postischaemic animal myocardium. We investigated the effect of intracoronary pyruvate in patients with congestive heart failure. Methods Haemodynamic measurements were done in eight patients with dilated cardiomyopathy after two 15 min infusions of pyruvate into the left main coronary artery and after saline washout of pyruvate. Findings There were no significant differences between the two pyruvate concentrations. Application of pyruvate resulted in a 23% increase in cardiac index (p<0 . 05), a 38% increase in stroke-volume index (p<0 . 05), and a 36% decrease in pulmonary capillary wedge pressure (p<0 . 05). Heart rate decreased significantly by 11%. Mean aortic pressure and systemic vascular resistance did not change. Most of the effects of pyruvate were reversed 15 min after the infusion stopped. Interpretation Pyruvate has the profile of a favourable inotropic substance. Other modes of administration need to be studied.	Univ Gottingen, Zentrum Innere Med, Abt Kardiol & Pneumol, D-37075 Gottingen, Germany; Univ Freiburg, Med Klin 8, Abt Rehabil & Pravent Sportmed, D-7800 Freiburg, Germany; Univ Freiburg, Apotheke Klinikums, D-7800 Freiburg, Germany; Univ Freiburg, Med Klin 3, Abt Kardiol & Angiol, D-7800 Freiburg, Germany	University of Gottingen; University of Freiburg; University of Freiburg; University of Freiburg	Hasenfuss, G (corresponding author), Univ Gottingen, Zentrum Innere Med, Abt Kardiol & Pneumol, Robert Koch Str 40, D-37075 Gottingen, Germany.							Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; BUNGER R, 1989, EUR J BIOCHEM, V180, P221, DOI 10.1111/j.1432-1033.1989.tb14637.x; BUNGER R, 1975, PFLUG ARCH EUR J PHY, V353, P317, DOI 10.1007/BF00587028; Chen WN, 1998, CIRC RES, V83, P898; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; Hasenfuss G, 1996, CIRCULATION, V94, P3155, DOI 10.1161/01.CIR.94.12.3155; HASENFUSS G, 1992, CIRC RES, V70, P1225, DOI 10.1161/01.RES.70.6.1225; HASENFUSS G, 1996, CIRCULATION S, V94, P546; HASENFUSS G, 1997, CIRCULATION S1, V96, P524; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LAUGHLIN MR, 1994, J MOL CELL CARDIOL, V26, P1525, DOI 10.1006/jmcc.1994.1173; LIEDTKE AJ, 1979, CIRC RES, V43, P189; MALLET RT, 1994, BBA-MOL CELL RES, V1224, P22, DOI 10.1016/0167-4889(94)90109-0; Martin BJ, 1998, AM J PHYSIOL-HEART C, V274, pH8, DOI 10.1152/ajpheart.1998.274.1.H8; MENTZER RM, 1989, ANN SURG, V209, P629, DOI 10.1097/00000658-198905000-00016; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Pieske B, 1996, J CLIN INVEST, V98, P764, DOI 10.1172/JCI118849; SCHOLZ TD, 1995, AM J PHYSIOL-HEART C, V268, pH82, DOI 10.1152/ajpheart.1995.268.1.H82; XIANG JZ, 1995, CARDIOVASC RES, V29, P391, DOI 10.1016/0008-6363(96)88597-X	21	85	90	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1321	1323		10.1016/S0140-6736(98)06423-X	http://dx.doi.org/10.1016/S0140-6736(98)06423-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218531				2022-12-28	WOS:000080278100013
J	Selker, EU				Selker, EU			Gene silencing: Repeats that count	CELL			English	Review							DE-NOVO METHYLATION; CHALCONE SYNTHASE; TRANSGENE REPEATS; RNA DEGRADATION; PLANTS; DNA; EXPRESSION; PETUNIA; ARABIDOPSIS; MAINTENANCE		Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Selker, EU (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.							BENDER J, 1995, CELL, V83, P725, DOI 10.1016/0092-8674(95)90185-X; Dieguez MJ, 1998, MOL GEN GENET, V259, P207, DOI 10.1007/s004380050806; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; HOBBS SLA, 1993, PLANT MOL BIOL, V21, P17, DOI 10.1007/BF00039614; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Luff B, 1999, MOL CELL, V3, P505, DOI 10.1016/S1097-2765(00)80478-5; Malagnac F, 1997, CELL, V91, P281, DOI 10.1016/S0092-8674(00)80410-9; Mette MF, 1999, EMBO J, V18, P241, DOI 10.1093/emboj/18.1.241; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Stam M, 1997, PLANT J, V12, P63, DOI 10.1046/j.1365-313X.1997.12010063.x; Todd JJ, 1996, PLANT CELL, V8, P687, DOI 10.1105/tpc.8.4.687; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	20	130	140	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					157	160		10.1016/S0092-8674(00)80725-4	http://dx.doi.org/10.1016/S0092-8674(00)80725-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219236	Bronze			2022-12-28	WOS:000079779800004
J	Briscoe, J; Sussel, L; Serup, P; Hartigan-O'Connor, D; Jessell, TM; Rubenstein, JLR; Ericson, J				Briscoe, J; Sussel, L; Serup, P; Hartigan-O'Connor, D; Jessell, TM; Rubenstein, JLR; Ericson, J			Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling	NATURE			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; MOTOR-NEURONS; MICE LACKING; NERVOUS-SYSTEM; FLOOR PLATE; NEURAL-TUBE; EXPRESSION; CNS; DIFFERENTIATION; RAT	During vertebrate development, the specification of distinct cell types is thought to be controlled by inductive signals acting at different concentration thresholds(1). The degree of receptor activation in response to these signals is a known determinant of cell fate(2), but the later steps at which graded signals are converted into all-or-none distinctions in cell identity remain poorly resolved. In the ventral neural tube, motor neuron and interneuron generation depends on the graded activity of the signalling protein Sonic hedgehog (Shh)(3-5). These neuronal subtypes derive from distinct progenitor cell populations that express the homeodomain proteins Nkx2.2 or Pax6 in response to graded Shh signalling(6,7). In mice lacking Pax6, progenitor cells generate neurons characteristic of exposure to greater Shh activity(6,8). However, Nkx2.2 expression expands dosally in Pax6 mutants(6), raising the possibility that Pax6 controls neuronal pattern indirectly. Here we provide evidence that Nkx2.2 has a primary role in ventral neuronal patterning. In Nkx2.2 mutants, Pax6 expression is unchanged but cells undergo a ventral-to-dorsal transformation in fate and generate motor neurons rather than interneurons. Thus, Nkx2.2 has an essential role in interpreting graded Shh signals and selecting neuronal identity.	Univ Calif San Francisco, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of California System; University of California San Francisco; Columbia University; Howard Hughes Medical Institute	Rubenstein, JLR (corresponding author), Univ Calif San Francisco, Nina Ireland Lab Dev Neurobiol, 402 Parnassus Ave,LPP1 Box 0984, San Francisco, CA 94143 USA.		Serup, Palle/A-7407-2011	Serup, Palle/0000-0002-0858-590X; Ericson, Johan/0000-0002-8019-7127; Briscoe, James/0000-0002-1020-5240				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Fan CM, 1996, MOL CELL NEUROSCI, V7, P519, DOI 10.1006/mcne.1996.0037; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Hartigan DJ, 1996, GENE, V168, P271, DOI 10.1016/0378-1119(95)00745-8; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JIMENEZ F, 1995, EMBO J, V14, P3487, DOI 10.1002/j.1460-2075.1995.tb07355.x; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LEBER SM, 1995, J NEUROSCI, V15, P1236; MACDONALD R, 1995, DEVELOPMENT, V121, P2397; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pabst O, 1998, MECH DEVELOP, V73, P85, DOI 10.1016/S0925-4773(98)00035-5; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Qiu MS, 1998, MECH DEVELOP, V72, P77, DOI 10.1016/S0925-4773(98)00018-5; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	30	574	591	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					622	627		10.1038/19315	http://dx.doi.org/10.1038/19315			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217145				2022-12-28	WOS:000079754700058
J	de Lonlay-Debeney, P; Poggi-Travert, F; Fournet, JC; Sempoux, C; Vici, CD; Brunelle, F; Touati, G; Rahier, J; Junien, C; Nihoul-Fekete, C; Robert, JJ; Saudubray, JM				de Lonlay-Debeney, P; Poggi-Travert, F; Fournet, JC; Sempoux, C; Vici, CD; Brunelle, F; Touati, G; Rahier, J; Junien, C; Nihoul-Fekete, C; Robert, JJ; Saudubray, JM			Clinical features of 52 neonates with hyperinsulinism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOCAL ADENOMATOUS HYPERPLASIA; SULFONYLUREA RECEPTOR GENE; FAMILIAL HYPERINSULINISM; PARTIAL PANCREATECTOMY; DIABETES-MELLITUS; HYPOGLYCEMIA; INFANCY; MUTATION; TERM; DIAGNOSIS	Background Neonatal hyperinsulinemic hypoglycemia is often resistant to medical therapy and is often treated with near-total pancreatectomy. However, the pancreatic lesions may be focal and treatable by partial pancreatic resection. Methods We studied 52 neonates with hyperinsulinism who were treated surgically. The type and location of the pancreatic lesions were determined by preoperative pancreatic catheterization and intraoperative histologic studies. Partial pancreatectomy was performed in infants with focal lesions, and near-total pancreatectomy was performed in those with diffuse lesions. The postoperative outcome was determined by measurements of plasma glucose and glycosylated hemoglobin and by oral glucose-tolerance tests. Results Thirty neonates had diffuse beta-cell hyperfunction, and 22 had focal adenomatous islet-cell hyperplasia. Among the latter, the lesions were in the head of the pancreas in nine, the isthmus in three, the body in eight, and the tail in two. The clinical manifestations were similar in both groups. The infants with focal lesions had no symptoms of hypoglycemia and had normal preprandial and postprandial plasma glucose and glycosylated hemoglobin values and normal results on oral glucose-tolerance tests after partial pancreatectomy (performed in 19 of 22 neonates). By contrast, after near-total pancreatectomy, 13 of the patients with diffuse lesions had persistent hypoglycemia, type 1 diabetes mellitus developed in 8, and hyperglycemia developed in another 7; overall, only 2 patients with diffuse lesions had normal plasma glucose concentrations in the first year after surgery. Conclusions Among neonates with hyperinsulinism, about half may have focal islet-cell hyperplasia that can be treated with partial pancreatectomy. These neonates can be identified through pancreatic catheterization and intraoperative histologic studies. (N Engl J Med 1999;340:1169-75,) (C)1999, Massachusetts Medical Society.	Hop Necker Enfants Malad, Serv Metab, Federat Pediat, Dept Pediat, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Pathol, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Radiol, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Surg, F-75743 Paris 15, France; Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Clin Univ St Luc, Dept Pathol, B-1200 Brussels, Belgium; Bambino Gesu Pediat Hosp, Div Metab, Rome, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Bambino Gesu	Saudubray, JM (corresponding author), Hop Necker Enfants Malad, Serv Metab, Federat Pediat, Dept Pediat, 149 Rue Sevres, F-75743 Paris 15, France.		; Dionisi-Vici, Carlo/K-2045-2018	Sempoux, Christine/0000-0003-1375-3979; Dionisi-Vici, Carlo/0000-0002-0007-3379				BORDI C, 1982, DIABETES CARE, V5, P122, DOI 10.2337/diacare.5.2.122; BRUINING G J, 1990, Current Opinion in Pediatrics, V2, P758, DOI 10.1097/00008480-199008000-00024; BRUNELLE F, 1989, PEDIATR RADIOL, V19, P100, DOI 10.1007/BF02387895; Craver RD, 1997, J PEDIATR SURG, V32, P1526, DOI 10.1016/S0022-3468(97)90584-4; deLonlay P, 1997, J CLIN INVEST, V100, P802, DOI 10.1172/JCI119594; DUBOIS J, 1995, PEDIATR RADIOL, V25, P512, DOI 10.1007/BF02015782; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998, DIABETES CARE S1, V21, pS5; GLASER B, 1993, J PEDIATR-US, V123, P644, DOI 10.1016/S0022-3476(05)80970-9; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GOOSSENS A, 1989, AM J SURG PATHOL, V13, P766, DOI 10.1097/00000478-198909000-00006; GOUDSWAARD WB, 1986, HUM PATHOL, V17, P46, DOI 10.1016/S0046-8177(86)80154-X; HOREV Z, 1991, J PEDIATR-US, V119, P717, DOI 10.1016/S0022-3476(05)80285-9; JAFFE R, 1980, LAB INVEST, V42, P356; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LABRUNE P, 1990, J PEDIATR SURG, V25, P1246, DOI 10.1016/0022-3468(90)90519-F; LEIBOWITZ G, 1995, J CLIN ENDOCR METAB, V80, P386, DOI 10.1210/jc.80.2.386; LYONNET S, 1989, LANCET, V2, P671; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; POGGITRAVERT F, 1994, JOURN PAR PED PAR, P29; RAHIER J, 1984, DIABETOLOGIA, V26, P282; Rahier J, 1998, HISTOPATHOLOGY, V32, P15; SCARLETT JA, 1977, NEW ENGL J MED, V297, P1029, DOI 10.1056/NEJM197711102971903; Sempoux C, 1998, J CLIN ENDOCR METAB, V83, P1455, DOI 10.1210/jc.83.5.1455; Shilyansky J, 1997, J PEDIATR SURG, V32, P342, DOI 10.1016/S0022-3468(97)90207-4; SOLCIA E, 1997, TUMORS PANCREAS, P238; SPITZ L, 1992, ARCH DIS CHILD, V67, P201, DOI 10.1136/adc.67.2.201; Stanley CA, 1997, PEDIATR CLIN N AM, V44, P363, DOI 10.1016/S0031-3955(05)70481-8; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; THOMAS CG, 1977, ANN SURG, V185, P505, DOI 10.1097/00000658-197705000-00002; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1991, J PEDIATR-US, V119, P721, DOI 10.1016/S0022-3476(05)80286-0; THORNTON PS, 1993, J PEDIATR-US, V123, P637, DOI 10.1016/S0022-3476(05)80969-2; Touati G, 1998, EUR J PEDIATR, V157, P628, DOI 10.1007/s004310050900; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495	36	191	198	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1169	1175		10.1056/NEJM199904153401505	http://dx.doi.org/10.1056/NEJM199904153401505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202168	Bronze			2022-12-28	WOS:000079687700005
J	Keys, HM; Bundy, BN; Stehman, FB; Muderspach, LI; Chafe, WE; Suggs, CL; Walker, JL; Gersell, D				Keys, HM; Bundy, BN; Stehman, FB; Muderspach, LI; Chafe, WE; Suggs, CL; Walker, JL; Gersell, D			Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	29th Annual Meeting of the Society-of-Gynecologic-Oncologists	FEB 07-11, 1998	ORLANDO, FL	Soc Gynecol Oncologists			GYNECOLOGIC ONCOLOGY GROUP; SQUAMOUS-CELL CARCINOMA; UTERINE CERVIX; THERAPY; IRRADIATION; PROGNOSIS; CANCER; RADIOTHERAPY; CHEMOTHERAPY; PLATINUM	Background Bulky stage IB cervical cancers have a poorer prognosis than smaller stage I cervical cancers. For the Gynecologic Oncology Group, we conducted a trial to determine whether weekly infusions of cisplatin during radiotherapy improve progression-free and overall survival among patients with bulky stage IB cervical cancer. Methods Women with bulky stage IB cervical cancers (tumor, greater than or equal to 4 cm in diameter) were randomly assigned to receive radiotherapy alone or in combination with cisplatin (40 mg per square meter of body-surface area once a week for up to six doses; maximal weekly dose, 70 mg),followed in all patients by adjuvant hysterectomy. Women with evidence of lymphadenopathy on computed tomographic scanning or lymphangiography were ineligible unless histologic analysis showed that there was no lymph-node involvement. The cumulative dose of external pelvic and intracavitary radiation was 75 Gy to point A (cervical parametrium) and 55 Gy to point B (pelvic wall). Cisplatin was given during external radiotherapy, and adjuvant hysterectomy was performed three to six weeks later. Results The relative risks of progression of disease and death among the 183 women assigned to receive radiotherapy and chemotherapy with cisplatin, as compared with the 186 women assigned to receive radiotherapy alone, were 0.51 (95 percent confidence interval, 0.34 to 0.75) and 0.54 (95 percent confidence interval, 0.34 to 0.86), respectively. The rates of both progression-free survival (P<0.001) and overall survival (P=0.008) were significantly higher in the combined-therapy group at four years. In the combined-therapy group there were higher frequencies of transient grade 3 (moderate) and grade 4 (severe) adverse hematologic effects (21 percent, vs. 2 percent in the radiotherapy group) and adverse gastrointestinal effects (14 percent vs. 5 percent). Conclusions Adding weekly infusions of cisplatin to pelvic radiotherapy followed by hysterectomy significantly reduced the risk of disease recurrence and death in women with bulky stage IB cervical cancers. (N Engl J Med 1999;340:1154-61.) (C)1999, Massachusetts Medical Society.	Albany Med Coll, Dept Radiat Oncol, Albany, NY 12208 USA; Roswell Pk Canc Inst, Stat Off, Gynecol Oncol Grp, Buffalo, NY USA; Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Univ So Calif, Sch Med, Div Gynecol Oncol, Los Angeles, CA USA; Eastern Virginia Med Sch, Div Gynecol Oncol, Norfolk, VA 23501 USA; Univ Tennessee, Coll Med, Dept Obstet & Gynecol, Chattanooga, TN USA; Erlanger Med Ctr, Dept Gynecol Oncol, Chattanooga, TN USA; Univ Oklahoma Hlth Sci, Dept Obstet & Gynecol, Gynecol Oncol Sect, Oklahoma City, OK USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Albany Medical College; Roswell Park Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of Southern California; Eastern Virginia Medical School; University of Tennessee System; University of Tennessee Health Science Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL)	Keys, HM (corresponding author), Gynecol Oncol Grp, Adm Off, Suite 1945,1234 Market St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 27469, CA 37517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANC, P155; BLESSING JA, 1990, CHEMOTHERAPY GYNECOL, P63; BONOMI P, 1985, J CLIN ONCOL, V3, P1079, DOI 10.1200/JCO.1985.3.8.1079; CARDE P, 1981, INT J RADIAT ONCOL, V7, P929, DOI 10.1016/0360-3016(81)90011-0; CHANG HC, 1992, GYNECOL ONCOL, V44, P182, DOI 10.1016/0090-8258(92)90036-I; Cochran W.G., 1967, STAT METHODS; COX DR, 1972, J R STAT SOC B, V34, P187; DELGADO G, 1989, GYNECOL ONCOL, V35, P314, DOI 10.1016/0090-8258(89)90070-X; DELGADO G, 1990, GYNECOL ONCOL, V38, P352, DOI 10.1016/0090-8258(90)90072-S; DURRANCE FY, 1969, AMER J ROENTGENOL RA, V106, P831, DOI 10.2214/ajr.106.4.831; GALLION HH, 1985, CANCER, V56, P262, DOI 10.1002/1097-0142(19850715)56:2<262::AID-CNCR2820560210>3.0.CO;2-A; HEATON D, 1990, GYNECOL ONCOL, V38, P323, DOI 10.1016/0090-8258(90)90066-T; HOMESLEY HD, 1980, SURG GYNECOL OBSTET, V150, P529; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lin JC, 1996, GYNECOL ONCOL, V61, P101, DOI 10.1006/gyno.1996.0105; MALFETANO J, 1993, CANCER, V71, P3703, DOI 10.1002/1097-0142(19930601)71:11<3703::AID-CNCR2820711138>3.0.CO;2-8; MALFETANO JH, 1991, GYNECOL ONCOL, V42, P44, DOI 10.1016/0090-8258(91)90228-W; Malfetano JH, 1997, GYNECOL ONCOL, V67, P203, DOI 10.1006/gyno.1997.4865; MALKASIAN GD, 1977, GYNECOL ONCOL, V5, P109, DOI 10.1016/0090-8258(77)90015-4; MALVIYA VK, 1989, AM J CLIN ONCOL-CANC, V12, P434, DOI 10.1097/00000421-198910000-00015; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MONYAK DJ, 1988, NATL CANCER I MONOGR, V6, P369; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; OQUINN AG, 1980, GYNECOL ONCOL, V9, P68, DOI 10.1016/0090-8258(80)90010-4; PEREZ CA, 1979, CANCER, V43, P1062, DOI 10.1002/1097-0142(197903)43:3<1062::AID-CNCR2820430342>3.0.CO;2-F; PEREZ CA, 1992, CANCER, V69, P2796, DOI 10.1002/1097-0142(19920601)69:11<2796::AID-CNCR2820691127>3.0.CO;2-O; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; RUNOWICZ CD, 1989, GYNECOL ONCOL, V34, P395, DOI 10.1016/0090-8258(89)90180-7; RUTLEDGE FN, 1976, CANCER, V38, P596, DOI 10.1002/1097-0142(197607)38:1<596::AID-CNCR2820380184>3.0.CO;2-C; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; STEHMAN FB, 1991, CANCER, V67, P2776, DOI 10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L; THOMS WW, 1992, INT J RADIAT ONCOL, V23, P491, DOI 10.1016/0360-3016(92)90003-Z; WALLNER KE, 1987, INT J RADIAT ONCOL, V13, P587, DOI 10.1016/0360-3016(87)90076-9	33	1443	1516	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1154	1161		10.1056/NEJM199904153401503	http://dx.doi.org/10.1056/NEJM199904153401503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	185TZ	10202166	Bronze			2022-12-28	WOS:000079687700003
J	Chamberlain, G; Zander, L				Chamberlain, G; Zander, L			ABC of labour care - Induction	BRITISH MEDICAL JOURNAL			English	Review									Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Guys Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England; Kings Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England; St Thomas Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England	Singleton Hospital; Guy's & St Thomas' NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust	Chamberlain, G (corresponding author), Singleton Hosp, Swansea SA2 8QA, W Glam, Wales.							ALLOTT HA, 1993, BRIT J OBSTET GYNAEC, V100, P898, DOI 10.1111/j.1471-0528.1993.tb15103.x; BISHOP EH, 1964, OBSTET GYNECOL, V24, P267; CHAMBERLAIN G, 1997, HOMEBIRTHS, P45; CROWLEY P, 1998, CROCHRANE LIB; *DEP HLTH, 1996, REP CONF ENQ MAT DEA; OCONNOR RA, 1994, BRIT J HOSP MED, V52, P559; Reichler A, 1995, CURR OPIN OBSTET GYN, V7, P432; ROBERTS LJ, 1991, BRIT J OBSTET GYNAEC, V98, P1102, DOI 10.1111/j.1471-0528.1991.tb15361.x; 1997, DRUG THERAPEUTICS B, V35, P17	9	14	13	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					995	998		10.1136/bmj.318.7189.995	http://dx.doi.org/10.1136/bmj.318.7189.995			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195975	Green Published			2022-12-28	WOS:000079751500027
J	Teramoto, S; Matsuse, T; Fukuchi, Y; Ouchi, Y				Teramoto, S; Matsuse, T; Fukuchi, Y; Ouchi, Y			Simple two-step swallowing provocation test for elderly patients with aspiration pneumonia	LANCET			English	Article									Tokyo Univ Hosp, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Juntendo Univ, Dept Resp Med, Tokyo 1138431, Japan	University of Tokyo; Juntendo University	Teramoto, S (corresponding author), Tokyo Univ Hosp, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Daniels SK, 1998, ARCH PHYS MED REHAB, V79, P14, DOI 10.1016/S0003-9993(98)90200-3; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251, DOI 10.1164/ajrccm.150.1.8025758; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; Teramoto S, 1998, CHEST, V113, P1733, DOI 10.1378/chest.113.6.1733; TERAMOTO S, IN PRESS CHEST	5	70	72	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1243	1243		10.1016/S0140-6736(98)05844-9	http://dx.doi.org/10.1016/S0140-6736(98)05844-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217091				2022-12-28	WOS:000079744100019
J	Li, LL; Keverne, EB; Aparicio, SA; Ishino, F; Barton, SC; Surani, MA				Li, LL; Keverne, EB; Aparicio, SA; Ishino, F; Barton, SC; Surani, MA			Regulation of maternal behavior and offspring growth by paternally expressed Peg3	SCIENCE			English	Article							IMPRINTED GENE; MICE; OXYTOCIN; PROTEIN; GENOMES; BRAIN; RATS	Imprinted genes display parent-of-origin-dependent monoallelic expression that apparently regulates complex mammalian traits, including growth and behavior. The Peg3 gene is expressed in embryos and the adult brain from the paternal allele only. A mutation in the Peg3 gene resulted in growth retardation, as well as a striking impairment of maternal behavior that frequently resulted in death of the offspring. This result may be partly due to defective neuronal connectivity, as well as reduced oxytocin neurons in the hypothalamus, because mutant mothers were deficient in milk ejection. This study provides further insights on the evolution of epigenetic regulation of imprinted gene dosage in modulating mammalian growth and behavior.	Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Physiol Lab, Cambridge CB2 1QR, England; Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England; Tokyo Inst Technol, Ctr Gene Res, Midori Ku, Yokohama, Kanagawa 226, Japan	University of Cambridge; University of Cambridge; University of Cambridge; Tokyo Institute of Technology	Surani, MA (corresponding author), Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.	as10021@mole.bio.cam.ac.uk		Aparicio, Samuel/0000-0002-0487-9599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLRINGER JF, 1980, J REPROD FERTIL, V59, P223, DOI 10.1530/jrf.0.0590223; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CALDWELL JD, 1987, NEUROENDOCRINOLOGY, V46, P39, DOI 10.1159/000124794; CATTANACH BM, 1997, GENOMIC IMPRINTING, P118; FUNDELE RH, 1997, GENOMIC IMPRINTING, P98; HATTON GI, 1987, NEUROSCIENCE, V21, P923, DOI 10.1016/0306-4522(87)90047-9; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Keverne EB, 1996, DEV BRAIN RES, V92, P91, DOI 10.1016/0165-3806(95)00209-X; Kikyo N, 1997, DEV BIOL, V190, P66, DOI 10.1006/dbio.1997.8681; Kim J, 1997, GENOME RES, V7, P532, DOI 10.1101/gr.7.5.532; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; MCCARTHY MM, 1990, HORM BEHAV, V24, P365, DOI 10.1016/0018-506X(90)90015-P; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NOIROT E, 1969, ANIM BEHAV, V17, P542, DOI 10.1016/0003-3472(69)90161-4; NUMAN M, 1994, ACTA PAEDIATR, V83, P19, DOI 10.1111/j.1651-2227.1994.tb13261.x; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; SCOTT I, 1996, J NEUROENDOCRINOL, V8, P847; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275; YEO JAG, 1986, PHYSIOL BEHAV, V37, P23, DOI 10.1016/0031-9384(86)90378-1	26	409	416	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					330	333		10.1126/science.284.5412.330	http://dx.doi.org/10.1126/science.284.5412.330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195900				2022-12-28	WOS:000079636400046
J	Yu, SP; Yeh, CH; Strasser, U; Tian, M; Choi, DW				Yu, SP; Yeh, CH; Strasser, U; Tian, M; Choi, DW			NMDA receptor-mediated K+ efflux and neuronal apoptosis	SCIENCE			English	Article							METHYL-D-ASPARTATE; OUTWARD POTASSIUM CURRENT; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; SYNAPTIC PLASTICITY; DIVALENT-CATIONS; CORTICAL-NEURONS; CELL-DEATH; RAT-BRAIN; GLUTAMATE	Neuronal death induced by activating N-methyl-D-aspartate (NMDA) receptors has been linked to Ca2+ and Na+ influx through associated channels. Whole-cell recording from cultured mouse cortical neurons revealed a NMDA-evoked outward current, INMDA-K, carried by K+ efflux at membrane potentials positive to -86 millivolts, Cortical neurons exposed to NMDA in medium containing reduced Na+ and Ca2+ (as found in ischemic brain tissue) Lost substantial intracellular K+ and underwent apoptosis. Both K+ loss and apoptosis were attenuated by increasing extracellular K+, even when voltage-gated Ca2+ channels were blocked. Thus NMDA receptor-mediated K+ efflux may contribute to neuronal apoptosis after brain ischemia.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Choi, DW (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA.	choid@neuro.wustl.edu			NINDS NIH HHS [NS 32636, NS 30337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337, P01NS032636] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANWYL R, 1977, J PHYSIOL-LONDON, V273, P367, DOI 10.1113/jphysiol.1977.sp012099; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Chen J, 1997, J NEUROCHEM, V69, P232; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FINIELS F, 1995, J NEUROCHEM, V65, P1027; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; HARVEY JA, 1968, BIOCHEM J, V108, P269, DOI 10.1042/bj1080269; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Ogden F, 1998, J NEUROSCI RES, V53, P677, DOI 10.1002/(SICI)1097-4547(19980915)53:6<677::AID-JNR6>3.0.CO;2-2; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Qin ZH, 1996, BRAIN RES, V725, P166, DOI 10.1016/S0006-8993(96)00200-4; ROSE K, METHODS TOXICOLOGY I, V46, P93; Rudolph JG, 1997, NEUROSCI LETT, V221, P149, DOI 10.1016/S0304-3940(96)13313-9; SCHOUSBOE A, 1977, J NEUROCHEM, V29, P999, DOI 10.1111/j.1471-4159.1977.tb06503.x; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takahashi M, 1996, BRAIN RES, V735, P1, DOI 10.1016/S0006-8993(96)00536-7; TEICHBERG VI, 1981, MOL CELL BIOCHEM, V39, P281, DOI 10.1007/BF00232580; Tenneti L, 1998, J NEUROCHEM, V71, P946; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Yu S. P., 1996, Society for Neuroscience Abstracts, V22, P1721; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; [No title captured]	52	194	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					336	339		10.1126/science.284.5412.336	http://dx.doi.org/10.1126/science.284.5412.336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195902				2022-12-28	WOS:000079636400048
J	Davidson, MB; Schriger, DL; Peters, AL; Lorber, B				Davidson, MB; Schriger, DL; Peters, AL; Lorber, B			Relationship between fasting plasma glucose and glycosylated hemoglobin - Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-ENZYMATIC GLYCOSYLATION; GLYCATION END-PRODUCTS; COLLAGEN-LINKED FLUORESCENCE; MAILLARD REACTION-PRODUCTS; NONENZYMATIC GLYCATION; LENS CRYSTALLINS; SKIN COLLAGEN; IMMUNOCHEMICAL DETECTION; MELLITUS; COMPLICATIONS	Context New criteria for the diagnosis of type 2 diabetes mellitus have recently been introduced that lowered the diagnostic fasting plasma glucose (FPC) concentration from 7.8 to 7.0 mmol/L (140 to 126 mg/dL). Objective To determine if individuals with diabetes diagnosed by the new FPC concentration criterion would have excessive glycosylation (elevated hemoglobin [HbA(1c)] levels). Definitions We determined the distribution of HbA(1c) levels in individuals using 4 classifications: (1) normal by the new criterion (FPG concentration <6.1 mmol/L [110 mg/dL]; (2) impaired fasting glucose by the new criterion (FPG concentration of 6.1-6.9 mmol/L [110-125 mg/dL]); (3) diabetes diagnosed solely by the new FPG concentration criterion of 7.0 through 7.7 mmol/L (126-139 mg/dL); and (4) diabetes diagnosed. by the previous FPG concentration criterion of 7.8 mmol/L (140 mg/dL) or higher. Design Cross-sectional analysis of 2 large data sets (NHANES III and Meta-Analysis Research Group [MRG] on the Diagnosis of Diabetes Using Glycated Hemoglobin) that contained individuals in whom FPG concentrations, 2-hour glucose concentrations using an oral glucose tolerance test, and an HbA(1c) level were simultaneously measured. We cross-tabulated FPG concentrations (<6.1 mmol/L [110 mg/dL], 6.1-6.9 mmol/L [110-125 mg/dL],7.0-7.7 mmol/L [126-139 mg/dl],and greater than or equal to 7.8 mmol/L [140 mg/dl]) and HbA(1c) levels separated into 3 intervals: normal, less than the upper limit of normal (ULN); slightly elevated, ULN to ULN plus 1%; and high, higher than ULN plus 1%. Results Among subjects with normal FPC concentrations, HbA(1c) levels in the NHANES I II land the MRC) data sets were normal in 97.3% (96.2%), slightly elevated in 2.7% (3.6%), and high in 0.1% (0.2%). Among individuals with impaired fasting glucose, HbA(1c) concentrations were normal in 86.7% (81.4%), slightly elevated in 13.1% (16.4%), and high in 0.2% (2.2%). Among diabetic patients diagnosed by the new FPC criterion only, HbA(1c) levels were normal in 60.9% (59.6%), slightly elevated in 35.8% (32.8%), and high in 3.4% (7.6%). In diabetic patients diagnosed by the former FPG criterion, HbA(1c) levels were normal in 18.6% (16.7%), slightly elevated in 32.5% (21.0%), and high in 48.9% (62.3%). Conclusions About 60% of the new cohort of diabetic patients in both data sets have normal HbA(1c) levels. We believe that diabetes should not be diagnosed in those with FPC concentrations less than 7.8 mmol/L (140 mg/dL) unless excessive glycosylation is evident. Individuals without excessive glycosylation but with moderate elevations of FPG concentrations (6.1-7.7 mmol/L [110-139 mg/dl]) should be diagnosed as having impaired fasting glucose and treated with an appropriate diet and exercise. This diagnostic labeling achieves the goal of early intervention without subjecting these persons to the potentially negative insurance, employment, social, and psychological consequences of a diagnosis of diabetes mellitus.	Charles R Drew Univ Med & Sci, Clin Trials Unit, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA	Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Davidson, MB (corresponding author), Charles R Drew Univ Med & Sci, Clin Trials Unit, 1731 E 120th St,AFH Bldg,Mailpoint30, Los Angeles, CA 90059 USA.			Schriger, David/0000-0003-0242-1127; Peters, Anne/0000-0003-0520-0776				[Anonymous], 1995, DIABETES, V44, P968; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; Bucala R., 1995, DIABETES REV, V3, P258; *BUR CENS, 1995, CURR PO REP SER; CEFALU WT, 1991, DIABETES, V40, P902, DOI 10.2337/diabetes.40.7.902; Clements RS, 1998, J DIABETES COMPLICAT, V12, P28, DOI 10.1016/S1056-8727(97)00051-2; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; DAVIDSON MB, 1995, DIABETES CARE, V18, P1065, DOI 10.2337/diacare.18.7.1065; DOMINICZAK MH, 1990, DIABETES CARE, V13, P468, DOI 10.2337/diacare.13.5.468; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592; GARLICK RL, 1988, DIABETES, V37, P1144, DOI 10.2337/diabetes.37.8.1144; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HARRIS MI, 1995, DIABETES AM, P591; JARRETT RJ, 1976, LANCET, V2, P1009; KANESHIGE H, 1987, DIABETES, V36, P822, DOI 10.2337/diabetes.36.7.822; KNOWLER WC, 1994, DIABETES CARE, V17, P445, DOI 10.2337/diacare.17.5.445; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LUTJENS A, 1985, DIABETOLOGIA, V28, P87; LYONS TJ, 1985, DIABETOLOGIA, V28, P2, DOI 10.1007/BF00276991; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLENNAN S, 1986, DIABETIC MED, V3, P141, DOI 10.1111/j.1464-5491.1986.tb00725.x; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Ono Y, 1998, DIABETES RES CLIN PR, V41, P131, DOI 10.1016/S0168-8227(98)00074-6; PAISEY RB, 1984, BRIT MED J, V288, P669, DOI 10.1136/bmj.288.6418.669; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PETTITT DJ, 1980, LANCET, V2, P1050; Rohlfing C, 1998, DIABETES, V47, pA70; SAYEGH HA, 1979, LANCET, V2, P431, DOI 10.1016/S0140-6736(79)91489-2; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SENSI M, 1995, DIABETES RES CLIN PR, V28, P9, DOI 10.1016/0168-8227(94)01061-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; Tanaka Y, 1998, DIABETES CARE, V21, P116, DOI 10.2337/diacare.21.1.116; TARSIO JF, 1985, DIABETES, V34, P477, DOI 10.2337/diabetes.34.5.477; TATTERSALL RB, 1982, COMPLICATIONS DIABET, P271; UITTO J, 1982, CONNECT TISSUE RES, V10, P287, DOI 10.3109/03008208209008054; VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916; VLASSARA H, 1983, DIABETES, V32, P670, DOI 10.2337/diabetes.32.7.670; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; Wolffenbuttel BHR, 1996, LANCET, V347, P513, DOI 10.1016/S0140-6736(96)91141-1; World Health Organization Expert Committee on Diabetes Mellitus, 1980, 646 WHO	54	139	143	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1203	1210		10.1001/jama.281.13.1203	http://dx.doi.org/10.1001/jama.281.13.1203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199430				2022-12-28	WOS:000079464400035
J	Chantler, C				Chantler, C			The role and education of doctors in the delivery of health care	LANCET			English	Article							DEATH		Univ London Kings Coll, Guys Kings & St Thomas Med & Dent Sch, London SE1 8WA, England	University of London; King's College London	Chantler, C (corresponding author), Univ London Kings Coll, Guys Kings & St Thomas Med & Dent Sch, Waterloo Bridge House, London SE1 8WA, England.							BROMMELS M, 1998, FOSTERING LEARNING M, P5; Chantler C., 1993, ROLE HOSP CONSULTANT; CHANTLER C, 1990, MANAGING HLTH RESULT, P74; Chantler C., 1994, TREAT DOCTORS ROLE C; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; DOMENIGHETTI G, 1995, LANCET, V346, P1376, DOI 10.1016/S0140-6736(95)92395-0; *GEN MED CONC, 1999, SEEK PAT CONS; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; Illich I, 1995, BRIT MED J, V311, P1652, DOI 10.1136/bmj.311.7021.1652; LIGHT D, 1998, IMPROVED NHS BETTER; McCormick J, 1996, LANCET, V348, P667, DOI 10.1016/S0140-6736(96)03512-X; Mintzberg H., 1983, STRUCTURE 5 DESIGNIN; Porter R., 1997, GREATEST BENEFIT MAN; Portillo M, 1998, BRIT MED J, V317, P37, DOI 10.1136/bmj.317.7150.37; Schon D.A, 2017, REFLECTIVE PRACTITIO; SKRABANEK P, 1989, FOLLIES FALLACIES ME; Tin W, 1997, BMJ-BRIT MED J, V314, P107, DOI 10.1136/bmj.314.7074.107	17	88	91	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1178	1181		10.1016/S0140-6736(99)01075-2	http://dx.doi.org/10.1016/S0140-6736(99)01075-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209997				2022-12-28	WOS:000079858400048
J	Tasche, MJA; vanderWouden, JC; Uijen, JHJM; Ponsioen, BP; Bernsen, RMD; vanSuijlekomSmit, LWA; deJongste, JC				Tasche, MJA; vanderWouden, JC; Uijen, JHJM; Ponsioen, BP; Bernsen, RMD; vanSuijlekomSmit, LWA; deJongste, JC			Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma	LANCET			English	Article							PRESCHOOL-CHILDREN; YOUNG-CHILDREN; DELIVERY; AEROSOL; AEROCHAMBER; MEDICATION; INFANTS; SPACER	Background Inhalation therapy with sodium cromoglycate is recommended as the first-line prophylactic treatment for moderate asthma in children. The availability of spacer devices with face-masks has extended the applicability of metered-dose inhalers to younger children. We studied the feasibility and effects of this therapy compared with placebo in children aged 1-4 years. Methods 218 children aged 1-4 years with moderate asthma were recruited through 151 general practitioners between March, 1995, and March, 1996. They were randomly assigned sodium cromoglycate (10 mg three times daily) or placebo, given by inhaler with spacer device and face-mask for 5 months. Rescue medication (ipratropium plus fenoterol aerosol) was available during the baseline period of 1 month and the intervention period. Parents completed a daily symptom-score list. The primary outcome measure was the proportion of symptom-free days in months 2 to 5. Analysis was by both intention to treat and on treatment. Findings 167 (77%) children completed the trial. 131 (78%) of these children used at least 80% of the recommended dose. Of the 51 children who stopped prematurely, 23 had difficulties with inhaled treatment. The mean proportion of symptom-free days for both groups was greater for the treatment period than for the baseline period (95% CI for mean difference 5.1 to 17.5 cromoglycate, 11.9 to 23.3 placebo). However there were no differences between the sodium cromoglycate and placebo groups in the proportion of symptom-free days (mean 65.7 [SD 25.3] vs 64.3 [24.5]%; 95% CI for difference -8.46 to 5.70) or in any other outcome measure. Interpretation Our study in a general practice setting shows that inhalation therapy with a spacer device and face-mask is feasible in a majority of children below the age of 4 years. However, long-term prophylactic therapy with inhaled sodium cromoglycate is not more effective than placebo in this age-group.	ERASMUS UNIV ROTTERDAM, DEPT PEDIAT, NL-3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DIV PEDIAT RESP MED, NL-3000 DR ROTTERDAM, NETHERLANDS; SOPHIA CHILDRENS UNIV HOSP, ACAD HOSP ROTTERDAM, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	Tasche, MJA (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT GEN PRACTICE, ROOM FF321, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		van der Wouden, Johannes C/C-2597-2009; van der Wouden, Johannes C/O-5109-2019	van der Wouden, Johannes C/0000-0001-6639-6050				AGERTOFT L, 1994, ARCH DIS CHILD, V71, P217, DOI 10.1136/adc.71.3.217; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; [Anonymous], 1993, BRIT MED J, V306, P776; BERTELSEN A, 1986, ALLERGY, V41, P266, DOI 10.1111/j.1398-9995.1986.tb02027.x; BISGAARD H, 1995, ARCH DIS CHILD, V73, P226, DOI 10.1136/adc.73.3.226; BISGAARD H, 1996, EUR RESPIR J, V8, P28; COGSWELL JJ, 1985, ARCH DIS CHILD, V60, P736, DOI 10.1136/adc.60.8.736; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DELGIUDICE MM, 1982, MOD PROBL PAEDIATR, V21, P122; DIRKSEN WJ, 1992, HUISARTS WETENSCHAP, V35, P355; DOULL IJM, 1995, ARCH DIS CHILD, V72, P321, DOI 10.1136/adc.72.4.321; FURFARO S, 1994, ARCH DIS CHILD, V71, P331, DOI 10.1136/adc.71.4.331; GELLERBERNSTEIN C, 1982, RESPIRATION, V43, P294, DOI 10.1159/000194497; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; GLASS J, 1981, ARCH DIS CHILD, V56, P648, DOI 10.1136/adc.56.8.648; HENRY RL, 1984, ARCH DIS CHILD, V59, P54, DOI 10.1136/adc.59.1.54; HILLER EJ, 1977, ARCH DIS CHILD, V52, P875, DOI 10.1136/adc.52.11.875; HOAG JE, 1991, ANN ALLERGY, V66, P53; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Konig P, 1996, J ALLERGY CLIN IMMUN, V98, P1103, DOI 10.1016/S0091-6749(96)80198-9; LENNEY W, 1978, ARCH DIS CHILD, V53, P474, DOI 10.1136/adc.53.6.474; LUYT DK, 1993, BMJ-BRIT MED J, V306, P1386, DOI 10.1136/bmj.306.6889.1386; MCCORMICK A, 1995, MORBIDITY STAT GEN P; RAO CR, 1972, LINEAR STAT INFERENC, P427; SALMON B, 1990, ARCH DIS CHILD, V65, P401, DOI 10.1136/adc.65.4.401; SILVERMAN M, 1996, EUR RESPIR J, V9, P1; SLY RM, 1988, ANN ALLERGY, V60, P403; VARSANO I, 1983, HELV PAEDIATR ACTA, V38, P335; WARNER JO, 1995, BRIT MED J, V311, P663, DOI 10.1136/bmj.311.7006.663; WILSON N, 1996, EUR RESPIR J, V21, P8; YUKSEL B, 1992, RESP MED, V86, P131, DOI 10.1016/S0954-6111(06)80229-5; Zeffren B S, 1996, Adv Pediatr, V43, P423	33	49	52	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	1997	350	9084					1060	1064		10.1016/S0140-6736(97)05333-6	http://dx.doi.org/10.1016/S0140-6736(97)05333-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213547	Green Submitted			2022-12-28	WOS:A1997YA73400008
J	Beecham, L				Beecham, L			Suspension of doctors should be as short as possible	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1218	1218						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221968				2022-12-28	WOS:000080277900073
J	Skowyra, D; Koepp, DM; Kamura, T; Conrad, MN; Conaway, RC; Conaway, JW; Elledge, SJ; Harper, JW				Skowyra, D; Koepp, DM; Kamura, T; Conrad, MN; Conaway, RC; Conaway, JW; Elledge, SJ; Harper, JW			Reconstitution of G(1) cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1	SCIENCE			English	Article							N-END RULE; CONJUGATING ENZYME; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; RAPID DEGRADATION; DNA-BINDING; G1 CYCLINS; YEAST; PROTEIN; PHOSPHORYLATION	Control of cyclin Levels is critical for proper cell cycle regulation. In yeast, the stability of the Ci,,cyclin Cln1 is controlled by phosphorylation-dependent ubiquitination. Here it is shown that this reaction can be reconstituted in vitro with an SCF E3 ubiquitin ligase complex. Phosphorylated Cln1 was ubiquitinated by SCF (Skp1Cdc53-F-box protein) complexes containing the F-box protein Grr1, Rbx1, and the E2 Cdc34. Rbx1 promotes association of Cdc34 with Cdc53 and stimulates Cdc34 auto-ubiquitination in the context of Cdc53 or SCF complexes. Rbx1, which is also a component of the von Hippe-Lindau tumor suppressor complex, may define a previously unrecognized class of E3-associated proteins.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Harper, JW (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA.			Harper, Jeffrey/0000-0002-6944-7236; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137, R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM41628, GM54137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Potuschak T, 1998, P NATL ACAD SCI USA, V95, P7904, DOI 10.1073/pnas.95.14.7904; Schneider BL, 1998, NATURE, V395, P86, DOI 10.1038/25774; SKOWYRA DK, UNPUB; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	28	355	367	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					662	665		10.1126/science.284.5414.662	http://dx.doi.org/10.1126/science.284.5414.662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213692				2022-12-28	WOS:000079951100050
J	Vorchheimer, DA; Badimon, JJ; Fuster, V				Vorchheimer, DA; Badimon, JJ; Fuster, V			Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; CHIMERIC 7E3 ANTIBODY; C7E3 FAB; UNSTABLE ANGINA; RANDOMIZED TRIAL; PLAQUE RUPTURE; THROMBOSIS; BLOCKADE; INHIBITION	Context Thrombus formation on disrupted atherosclerotic plaque is the major cause of acute coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac events in patients with acute coronary syndromes. The platelet glycoprotein (GP) IIb/IIIa receptor is the final common pathway of platelet aggregation. Objectives To review mechanisms of platelet activation and aggregation and the role of the GP IIb/IIIa receptor in the acute coronary syndromes and to summarize completed clinical trials of GP IIb/IIIa receptor antagonists. Data Sources English-language journal articles, reviews from a MEDLINE search from 1993 through 1998, as well as abstracts and presentations from major national or international cardiology meetings through November 1998. Study Selection/Data Extraction Randomized, placebo-controlled clinical trials testing intravenous GP IIb/IIIa receptor antagonists and having more than 500 subjects were included. Data quality and validity included publication or presentation venue. Data Synthesis/Conclusions The GP IIb/IIIa receptor is the final common pathway of platelet aggregation. Intravenous monoclonal antibody and peptide and nonpeptide antagonists of the GP IIb/IIIa receptor have been tested in randomized, placebo-controlled trials of the acute coronary syndromes and percutaneous coronary interventions, For patients undergoing percutaneous revascularization, these agents have demonstrated efficacy in reducing death, myocardial infarction, or urgent reintervention. Odds ratios of death or myocardial infarction at 30 days range from 0.42 to 0.84 for the drugs in these studies. More modest benefits have been seen in trials of IIb/IIIa receptor antagonists for patients with the acute coronary syndromes, with odds ratios for death or myocardial infarction at 30 days ranging from 0.70 to 0.89, The efficacy of oral agents for chronic GP IIb/IIIa receptor antagonism has not been sufficiently studied.	CUNY, Mt Sinai Med Ctr, Zena & Michael A Weiner Cardiovasc Inst, Coronary Care Unit, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Clin Trials Unit, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Cardiovasc Biol Res Labs, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Fuster, V (corresponding author), CUNY, Mt Sinai Med Ctr, Zena & Michael A Weiner Cardiovasc Inst, Coronary Care Unit, 1 Gustave L Levy,Box 1030, New York, NY 10029 USA.	valentin_fuster@smtplink.mssm.edu	Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				AGUIRRE FV, 1995, CIRCULATION, V91, P2882, DOI 10.1161/01.CIR.91.12.2882; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Antman EM, 1998, J AM COLL CARDIOL, V31, p191A, DOI 10.1016/S0735-1097(97)84535-4; Badimon JJ, 1997, EUR J CLIN INVEST, V27, P568, DOI 10.1046/j.1365-2362.1997.1480697.x; BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Berkowitz SD, 1997, CIRCULATION, V95, P809; Berkowitz SD, 1997, CIRCULATION, V96, P3810; BOEHRER JD, 1994, AM J CARDIOL, V74, P1166, DOI 10.1016/0002-9149(94)90474-X; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; BRESNAHAN DR, 1985, J AM COLL CARDIOL, V6, P285, DOI 10.1016/S0735-1097(85)80161-3; Cairns JA, 1998, CHEST, V114, p611S, DOI 10.1378/chest.114.5_Supplement.611S; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CANNON C, 1999, 48 ANN SCI SESS AM C; Cannon CP, 1998, CIRCULATION, V97, P340; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; Coller BS, 1995, EUR HEART J, V16, P11, DOI 10.1093/eurheartj/16.suppl_L.11; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; Coller BS, 1997, CIRCULATION, V96, P3828; COLLER BS, 1994, SEMIN HEMATOL, V31, P301; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; ELLIS SG, 1997, CIRCULATION, V96, P87; FALK E, 1991, AM J CARDIOL, V68, pB28, DOI 10.1016/0002-9149(91)90382-U; FALK E, 1983, BRIT HEART J, V50, P127; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FITZGERALD GA, 1998, CARDIOVASCULAR THROM, P121; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GEORGE JN, 1990, BLOOD, V75, P1383; Gold HK, 1997, CIRCULATION, V95, P1755; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hamm C. W., 1998, European Heart Journal, V19, P117; Hanrath P, 1997, CIRCULATION, V96, P1445; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; Harrington RA, 1998, CIRCULATION, V98, P359; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kereiakes DJ, 1997, CIRCULATION, V96, P1117, DOI 10.1161/01.CIR.96.4.1117; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lincoff AM, 1997, J AM COLL CARDIOL, V30, P149, DOI 10.1016/S0735-1097(97)00110-1; Madan M, 1997, CIRCULATION, V96, P901; MARCUS AJ, 1996, ATHEROSCLEROSIS CORO, P607; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; Muller TH, 1997, CIRCULATION, V96, P1130, DOI 10.1161/01.CIR.96.4.1130; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1998, 20 C EUR SOC CARD AU; Peterson JG, 1998, CIRCULATION, V98, P360; Phillips DR, 1997, CIRCULATION, V96, P1488, DOI 10.1161/01.CIR.96.5.1488; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; PLOW EF, 1985, BLOOD, V66, P724; *PRISM STUD INV, 1998, CIRCULATION, V338, P1498; Reverter JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859; Simoons ML, 1997, LANCET, V349, P1429; Tcheng JE, 1997, LANCET, V349, P1422; Tcheng JE, 1998, J AM COLL CARDIOL, V31, p55A, DOI 10.1016/S0735-1097(97)83944-7; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VAUGHAN DE, 1991, CIRCULATION, V84, P84, DOI 10.1161/01.CIR.84.1.84; Vorchheimer DA, 1998, CIRCULATION, V97, P312	65	90	99	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1407	1414		10.1001/jama.281.15.1407	http://dx.doi.org/10.1001/jama.281.15.1407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217057	Bronze			2022-12-28	WOS:000079701000031
J	Beecham, L				Beecham, L			The young should be protected from alcohol dangers	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205127				2022-12-28	WOS:000080140000078
J	Nolan, PC				Nolan, PC			You can but try	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1050	1050		10.1136/bmj.318.7190.1050	http://dx.doi.org/10.1136/bmj.318.7190.1050			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205104	Green Published			2022-12-28	WOS:000080140000031
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	10	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1370	1370		10.1016/S0140-6736(05)74374-9	http://dx.doi.org/10.1016/S0140-6736(05)74374-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218568				2022-12-28	WOS:000080278100067
J	Hage, T; Sebald, W; Reinemer, P				Hage, T; Sebald, W; Reinemer, P			Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface	CELL			English	Article							RECEPTOR-GAMMA-CHAIN; HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; T-CELLS; PROTEIN; IL-4; ASTHMA; IDENTIFICATION; EFFICIENCY; CYTOKINES	Interleukin-4 (IL-4) is a principal regulatory cytokine during an immune response and a crucial determinant for allergy and asthma. IL-4 binds with high affinity and specificity to the ectodomain of the IL-4 receptor cu chain (IL4-BP). Subsequently, this intermediate complex recruits the common gamma chain (gamma c), thereby initiating transmembrane signaling. The crystal structure of the intermediate complex between human IL-4 and IL4-BP was determined at 2.3 Angstrom resolution. It reveals a novel spatial orientation of the two proteins, a small but unexpected conformational change in the receptor-bound IL-4, and an interface with three separate clusters of trans-interacting residues. Novel insights on ligand binding in the cytokine receptor family and a paradigm for receptors of IL-2, IL-7, IL-9, and IL-15, which all utilize gamma c, are provided.	Univ Wurzburg, Theodor Boveri Inst Biowissen Schaften, Biozentrum, Inst Physiol Chem 2, D-97074 Wurzburg, Germany; Bayer AG, Pharmaforsch PH R LSC NP, D-42096 Wuppertal, Germany	University of Wurzburg; Bayer AG	Sebald, W (corresponding author), Univ Wurzburg, Theodor Boveri Inst Biowissen Schaften, Biozentrum, Inst Physiol Chem 2, D-97074 Wurzburg, Germany.	sebald@biozentrum.uni-wuerzburg.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Grunewald SM, 1997, J BIOL CHEM, V272, P1480, DOI 10.1074/jbc.272.3.1480; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GUSTCHINA A, 1995, PROTEINS, V21, P140, DOI 10.1002/prot.340210208; Hage T, 1998, EUR J BIOCHEM, V258, P831, DOI 10.1046/j.1432-1327.1998.2580831.x; HOFFMAN RC, 1995, PROTEIN SCI, V4, P382; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V53, P240; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Obiri NI, 1997, J IMMUNOL, V158, P756; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shanafelt AB, 1998, P NATL ACAD SCI USA, V95, P9454, DOI 10.1073/pnas.95.16.9454; Shen BJ, 1996, EUR J BIOCHEM, V240, P252, DOI 10.1111/j.1432-1033.1996.0252h.x; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEIGEMANN W, 1991, CRYSTALLOGRAPHIC COM, V5, P115; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; WALTER MR, 1992, J BIOL CHEM, V267, P20371; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	54	173	191	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					271	281		10.1016/S0092-8674(00)80736-9	http://dx.doi.org/10.1016/S0092-8674(00)80736-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219247	Bronze			2022-12-28	WOS:000079779800015
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Editorial Material									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1281	1281		10.1016/S0140-6736(05)75208-9	http://dx.doi.org/10.1016/S0140-6736(05)75208-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217124				2022-12-28	WOS:000079744100070
J	Jacobs, C; Domian, IJ; Maddock, JR; Shapiro, L				Jacobs, C; Domian, IJ; Maddock, JR; Shapiro, L			Cell cycle-dependent polar localization of an essential bacterial histidine kinase that controls DNA replication and cell division	CELL			English	Article							SIGNAL-TRANSDUCTION; CAULOBACTER-CRESCENTUS; 2-COMPONENT REGULATORS; ESCHERICHIA-COLI; PROTEIN-KINASES; IDENTIFICATION; TRANSLOCATION; CHEMOTAXIS; CHROMOSOME; ORIGIN	The master CtrA response regulator functions in Caulobacter to repress replication initiation in different phases of the cell cycle. Here, we identify an essential histidine kinase, CckA, that is responsible for CtrA activation by phosphorylation. Although CckA is present throughout the cell cycle, it moves to a cell pole in S phase, and upon cell division it disperses. Removal of the membrane-spanning region of CckA results in loss of polar localization and cell death. We propose that polar CckA functions to activate CtrA just after the initiation of DNA replication, thereby preventing premature reinitiations of chromosome replication. Thus, dynamic changes in cellular location of critical signal proteins provide a novel mechanism for the control of the prokaryote cell cycle.	Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	Stanford University; University of Michigan System; University of Michigan	Shapiro, L (corresponding author), Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA.	shapiro@cmgm.stanford.edu			NIGMS NIH HHS [GM3250615120MZ, GM51426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALLEY MRK, 1991, GENETICS, V129, P333; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; DOMIAN IJ, 1998, THESIS STANFORD U SC; ELY B, 1991, METHOD ENZYMOL, V204, P372; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Jenal U, 1998, EMBO J, V17, P5658, DOI 10.1093/emboj/17.19.5658; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAZOUR GJ, 1991, P NATL ACAD SCI USA, V88, P6941, DOI 10.1073/pnas.88.16.6941; Quon KC, 1998, P NATL ACAD SCI USA, V95, P120, DOI 10.1073/pnas.95.1.120; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Roberts RC, 1996, J BACTERIOL, V178, P1829, DOI 10.1128/jb.178.7.1829-1841.1996; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Stephens C, 1997, J BACTERIOL, V179, P5355, DOI 10.1128/jb.179.17.5355-5365.1997; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439	28	204	206	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					111	120		10.1016/S0092-8674(00)80719-9	http://dx.doi.org/10.1016/S0092-8674(00)80719-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199407	Bronze			2022-12-28	WOS:000079843900013
J	Lanz, RB; McKenna, NJ; Onate, SA; Albrecht, U; Wong, JM; Tsai, SY; Tsai, MJ; O'Malley, BW				Lanz, RB; McKenna, NJ; Onate, SA; Albrecht, U; Wong, JM; Tsai, SY; Tsai, MJ; O'Malley, BW			A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex	CELL			English	Article							TRANSCRIPTION FACTOR COUP; THYROID-HORMONE RECEPTOR; PROGESTERONE-RECEPTOR; RESPONSE ELEMENTS; ANDROGEN RECEPTOR; NUCLEAR RECEPTORS; ACTIVATION; GENE; PROTEIN; TRANSACTIVATION	Nuclear receptors play critical roles in the regulation of eukaryotic gene expression. We report the isolation and functional characterization of a novel transcriptional coactivator, termed steroid receptor RNA activator (SRA). SRA is selective for steroid hormone receptors and mediates transactivation via their aminoterminal activation function. We provide functional and mechanistic evidence that SRA acts as an RNA transcript; transfected SRA, unlike other steroid receptor coregulators, functions in the presence of cycloheximide, and SRA mutants containing multiple translational stop signals retain their ability to activate steroid receptor-dependent gene expression. Biochemical fractionation shows that SRA exists in distinct ribonucleoprotein complexes, one of which contains the nuclear receptor coactivator steroid receptor coactivator 1. We suggest that SRA may act to confer functional specificity upon multiprotein complexes recruited by liganded receptors during transcriptional activation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Albrecht, Urs/A-9831-2011	Albrecht, Urs/0000-0002-0663-8676; Wong, Jiemin/0000-0002-5311-842X; McKenna, Neil/0000-0001-6689-0104				Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUIPER GGJM, 1993, BIOCHEM J, V296, P161, DOI 10.1042/bj2960161; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LENG XH, 1994, J BIOL CHEM, V269, P31436; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; MCKENNA NJ, 1999, IN PRESS ENDOCRINE R; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	41	629	667	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					17	27		10.1016/S0092-8674(00)80711-4	http://dx.doi.org/10.1016/S0092-8674(00)80711-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199399	Bronze			2022-12-28	WOS:000079843900005
J	Kandela, P				Kandela, P			Doctors' handwriting	LANCET			English	Editorial Material																		1915, LANCET          0102, P56; 1953, LANCET          0704, P44; 1953, LANCET          0613, P1201; 1953, LANCET          0516, P1001; 1953, LANCET          0704, P43; 1953, LANCET          0627, P1314; 1953, LANCET          0606, P1157	7	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1109	1109		10.1016/S0140-6736(05)76477-1	http://dx.doi.org/10.1016/S0140-6736(05)76477-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199388				2022-12-28	WOS:000079614000071
J	Shaw, J; Creed, F; Price, J; Huxley, P; Tomenson, B				Shaw, J; Creed, F; Price, J; Huxley, P; Tomenson, B			Prevalence and detection of serious psychiatric disorder in defendants attending court	LANCET			English	Article							MENTAL DISORDER; PRISONERS; DIVERSION; CUSTODY	Background Diversion programmes in magistrates' courts are designed to provide immediate advice or access to mental-health treatment facilities for defendants when appropriate. The prevalence of serious psychiatric disorder and the proportion of defendants who might require transfer are unknown. We undertook a study to address these issues and to find out whether defendants with such disorders are reliably detected by court personnel and referred to psychiatric staff in court diversion programmes. Methods A two-phase screening method used questionnaires for psychiatric disorder (the general health questionnaire and psychotic screening questionnaire) and screening instruments for alcohol and substance misuse followed by standard psychiatric interview (schedules for clinical assessment in neuropsychiatry). The detection rate of defendants with serious psychiatric disorder by court staff was observed. Findings The frequency of serious psychiatric disorder was 1.31% (three of 229) among defendants appearing in court direct from the community and 6.57% (96 of 1460) among those held in custody overnight. Of the 99 defendants with serious psychiatric disorder, 34 had schizophrenia and other psychoses and 55 had depressive disorders. 42 (76%) of the 55 individuals with depressive disorders had suicidal ideas, which were recorded on the first-phase screening questionnaire in many cases. Only 14 of 96 defendants from overnight custody with serious psychiatric disorder were detected by court staff and referred to the court diversion programme. Interpretation There is a substantial rate of psychiatric disorder in the court population, which is not satisfactorily detected with the current system. Brief screening questionnaires and training of court staff are probably necessary for detection of people with serious psychiatric disorder passing through the courts.	Whittingham Hosp, Gulid Community Healthcare NHS Trust, Langdale Unit, Whittingham PR3 2JH, England; Manchester Royal Infirm, Sch Psychiat & Behav Sci, Manchester, Lancs, England; Univ Manchester, Dept Psychiat Social Work, Manchester, Lancs, England	University of Manchester; University of Manchester	Shaw, J (corresponding author), Whittingham Hosp, Gulid Community Healthcare NHS Trust, Langdale Unit, Whittingham PR3 2JH, England.		Huxley, Peter/AAE-7007-2019					BEBBINGTON P, 1995, INT J METHOD PSYCH, V5, P11; Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; BLUMENTHAL S, 1992, BRIT MED J, V305, P1322, DOI 10.1136/bmj.305.6865.1322; COOKE DJ, 1991, BRIT J PSYCHIAT, V158, P785, DOI 10.1192/bjp.158.6.785; Deasy, 1998, SURVEY PSYCHIAT MORB; *DEP HLTH HOM OFF, 1992, REV HLTH SOC SERV ME; FOSTER K, 1996, 8 OPCS; Goldberg D., 1988, USERS GUIDE GEN HEAL; JOSEPH PLA, 1993, BRIT J PSYCHIAT, V162, P325, DOI 10.1192/bjp.162.3.325; LAMB HR, 1982, ARCH GEN PSYCHIAT, V39, P17; MITCHISON S, 1994, MED SCI LAW, V34, P324, DOI 10.1177/002580249403400410; Pickles A, 1995, Stat Methods Med Res, V4, P73, DOI 10.1177/096228029500400106; Purchase ND, 1996, BRIT MED J, V313, P531; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; TEPLIN LA, 1990, AM J PUBLIC HEALTH, V80, P663, DOI 10.2105/AJPH.80.6.663; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	17	44	46	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1053	1056		10.1016/S0140-6736(98)08094-5	http://dx.doi.org/10.1016/S0140-6736(98)08094-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184LQ	10199353				2022-12-28	WOS:000079614000012
J	LaCroix, AZ; Burke, W				LaCroix, AZ; Burke, W			Breast cancer and hormone replacement therapy	LANCET			English	Editorial Material							ESTROGEN		UNIV WASHINGTON,WOMENS HLTH CARE CTR,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	LaCroix, AZ (corresponding author), UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,GRP HLTH COOPERAT PUGET SOUND,DEPT EPIDEMIOL,SEATTLE,WA 98109, USA.							Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; CAULEY JA, 1996, JAMA-J AM MED ASSOC, V276, P611; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CUMMINGS SR, J BONE MINERAL RES S, pS139; KING RJB, 1991, J STEROID BIOCHEM, V39, P811, DOI 10.1016/0960-0760(91)90030-9; Kuller LH, 1997, ENVIRON HEALTH PERSP, V105, P593, DOI 10.2307/3433376; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; *WOM HLTH IN STUD, IN PRESS CONTROLLED; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903	11	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1042	1043		10.1016/S0140-6736(97)22041-6	http://dx.doi.org/10.1016/S0140-6736(97)22041-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213541				2022-12-28	WOS:A1997YA73400002
J	Littlewood, R; Douyon, C				Littlewood, R; Douyon, C			Clinical findings in three cases of zombification	LANCET			English	Article									UCL, DEPT PSYCHIAT, LONDON WC1E 6BT, ENGLAND; POLYCLIN MED, PORT AU PRINCE, HAITI	University of London; University College London	Littlewood, R (corresponding author), UCL, DEPT ANTHROPOL, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.							ARISTIDE JB, 1993, TOUT HOMME EST UN HO; Brodwin P, 1996, MED MORALITY HAITI C; Davis Wade, 1988, PASSAGE DARKNESS ETH; Decosse Sarah., 1996, THIRST JUSTICE DECAD; DIEDERICH B, 1972, PAPA DOC HAITI ITS D; DOUYON L, 1972, B CTR PSYCHIAT NEURO, V11, P5; DOUYON L, 1980, HAITI SANTE, V2, P19; FARMER Paul, 1992, AIDS ACCUSATION HAIT; HURSTON ZN, 1938, VODOO GODS; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; LAROSE S, 1977, SYMBOLS SENTIMENTS; LITTLEWOOD R, 1993, PATHOLOGY IDENTITY W; Mars LP, 1945, MAN, V45, P38, DOI 10.2307/2792947; METRAUX A, 1958, VAUDON HAITIEN; Nicholls David, 1979, DESSALINES DUVALIER; STJOHN S, 1884, HAYRI BLACK REPUBLIC; THOMSON I, 1992, BONJOUR BLANC; TORDA TA, 1973, MED J AUSTRALIA, V1, P599, DOI 10.5694/j.1326-5377.1973.tb110574.x; 1984, LANCET, V2, P1220	19	17	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1094	1096		10.1016/S0140-6736(97)04449-8	http://dx.doi.org/10.1016/S0140-6736(97)04449-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213568				2022-12-28	WOS:A1997YA73400043
J	Spigset, O; Martensson, B				Spigset, O; Martensson, B			Fortnightly review - Drug treatment of depression	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTIDEPRESSANT DRUGS; MAJOR DEPRESSION; FLUOXETINE; AUGMENTATION; FLUVOXAMINE; RECURRENCE; EFFICACY		Trondheim Reg & Univ Hosp, Dept Clin Pharmacol, N-7006 Trondheim, Norway; Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden	Norwegian University of Science & Technology (NTNU); Karolinska Institutet; Karolinska University Hospital	Spigset, O (corresponding author), Trondheim Reg & Univ Hosp, Dept Clin Pharmacol, N-7006 Trondheim, Norway.	olav.spigset@relis.rit.no						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andersen B, 1990, J AFFECT DISORDERS, V18, P289; Anderson I M, 1998, Depress Anxiety, V7 Suppl 1, P11, DOI 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.3.CO;2-O; Aronson R, 1996, ARCH GEN PSYCHIAT, V53, P842, DOI 10.1001/archpsyc.1996.01830090090013; Bertilsson L, 1996, CNS DRUGS, V5, P200, DOI 10.2165/00023210-199605030-00006; Burnett FE, 1998, REV CONTEMP PHARMACO, V9, P303; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Crott R, 1998, ACTA PSYCHIAT SCAND, V97, P241, DOI 10.1111/j.1600-0447.1998.tb09995.x; Danish University Antidepressant Group, 1993, J AFFECT DISORDERS, V28, P105; DILSAVER SC, 1994, DRUG SAFETY, V10, P103, DOI 10.2165/00002018-199410020-00002; DONOGHUE JM, 1996, BRIT J PSYCHIAT, V168, P164; DUNLOP SR, 1990, PSYCHOPHARMACOL BULL, V26, P173; FRANK E, 1993, PSYCHOPHARMACOL BULL, V29, P457; Goldstein DJ, 1997, OBSTET GYNECOL, V89, P713, DOI 10.1016/S0029-7844(97)00070-7; GRAM LF, 1986, PSYCHOPHARMACOLOGY, V90, P131; Haddad P, 1998, BMJ-BRIT MED J, V316, P1105, DOI 10.1136/bmj.316.7138.1105; KASPER S, 1997, INT J PSYCHIAT CLIN, V1, P55; Lane R, 1997, J CLIN PSYCHOPHARM, V17, P208, DOI 10.1097/00004714-199706000-00012; LIMA MS, 1998, COCHRANE LIB; Martensson B, 1996, INT J TECHNOL ASSESS, V12, P554, DOI 10.1017/S0266462300010886; Martin RM, 1997, BRIT MED J, V314, P646, DOI 10.1136/bmj.314.7081.646; McAskill R, 1998, BRIT J PSYCHIAT, V173, P203, DOI 10.1192/bjp.173.3.203; MontejoGonzalez AL, 1997, J SEX MARITAL THER, V23, P176; Nelson JC, 1998, J CLIN PSYCHIAT, V59, P35; Nemeroff CB, 1996, AM J PSYCHIAT, V153, P311; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; Paykel ES, 1998, PSYCHOPATHOLOGY, V31, P5, DOI 10.1159/000029018; PRESKORN SH, 1995, J CLIN PSYCHIAT, V56, P12; Rouillon F, 1998, J CLIN PSYCHIAT, V59, P32; Spigset O, 1998, CNS DRUGS, V9, P111, DOI 10.2165/00023210-199809020-00004; Terra JL, 1998, INT CLIN PSYCHOPHARM, V13, P55, DOI 10.1097/00004850-199803000-00001; THASE ME, 1995, CNS DRUGS, V4, P261, DOI 10.2165/00023210-199504040-00004; TRINDADE E, 1997, 3E CAN COORD OFF HLT; Weiss M, 1997, J CLIN PSYCHIAT, V58, P196, DOI 10.4088/JCP.v58n0504	34	38	41	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	1999	318	7192					1188	1191						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195XR	10221948				2022-12-28	WOS:000080277900035
J	Samanta, A; Beardsley, J				Samanta, A; Beardsley, J			Evidence based case report - Low back pain: which is the best way forward?	BRITISH MEDICAL JOURNAL			English	Review							CONTROLLED TRIAL		Leicester Royal Infirm NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England		Samanta, A (corresponding author), Leicester Royal Infirm NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England.							CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; CAREY T, 1995, ACP J CLUB, V123, P7; Clinical Standards Advisory Group for Back Pain, 1994, BACK PAIN REP CSAG C; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; ERNST E, 1997, COCHRANE COLLABORATI; Evans G., 1996, LOW BACK PAIN EVALUA; Frazier LM, 1992, ACP J CLUB, V114, P6; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GADSBY JG, 1997, COCHRANE COLLABORATI; HAYNES B, 1998, BEST EVIDENCE; LAWRENCE V, 1993, ACP J CLUB, V118, P9; Sackett D. L., 1997, EVIDENCE BASED MED P; Shekelle P., 1995, ACP J CLUB, V123, P33; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; STANKOVIC R, 1995, SPINE, V20, P469, DOI 10.1097/00007632-199502001-00010	15	14	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1122	1123		10.1136/bmj.318.7191.1122	http://dx.doi.org/10.1136/bmj.318.7191.1122			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213728	Green Published			2022-12-28	WOS:000080166000030
J	Yarnell, WS; Roberts, JW				Yarnell, WS; Roberts, JW			Mechanism of intrinsic transcription termination and antitermination	SCIENCE			English	Article							ESCHERICHIA-COLI RNA; PHAGE-LAMBDA; NASCENT RNA; ELONGATION COMPLEX; CHAIN ELONGATION; POLYMERASE ALTER; BETA-SUBUNIT; DNA HYBRID; SEQUENCES; PROMOTER	Gene expression is modulated by regulatory elements that influence transcription elongation by RNA polymerase: terminators that disrupt the elongation complex and release RNA, and regulators that overcome termination signals. RNA release from Escherichia coli RNA polymerase can be induced by a complementary oligonucleotide that replaces the upstream half of the RNA hairpin stem of intrinsic terminator transcripts, implying that RNA hairpins act by extracting RNA from the transcription complex. A transcription antiterminator inhibits this activity of oligonucleotides and therefore protects the elongation complex from destabilizing attacks on the emerging transcript. These effects illuminate the structure of the complex and the mechanism of transcription termination.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Roberts, JW (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; Roberts Jeffrey W., 1996, P27; RYDER A, UNPUB; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL W, UNPUB; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T	43	259	271	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					611	615		10.1126/science.284.5414.611	http://dx.doi.org/10.1126/science.284.5414.611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213678				2022-12-28	WOS:000079951100036
J	Catherwood, E; Fitzpatrick, WD; Greenberg, ML; Holzberger, PT; Malenka, DJ; Gerling, BR; Birkmeyer, JD				Catherwood, E; Fitzpatrick, WD; Greenberg, ML; Holzberger, PT; Malenka, DJ; Gerling, BR; Birkmeyer, JD			Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Review						cost-benefit analysis; atrial fibrillation; electric countershock; amiodarone; aspirin	LOW-DOSE AMIODARONE; COMMUNITY STROKE PROJECT; CONGESTIVE-HEART-FAILURE; SINUS RHYTHM; RANDOMIZED TRIAL; DRUG-THERAPY; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; QUINIDINE THERAPY; ADVERSE REACTIONS	Background: Physicians managing patients with nonvalvular atrial fibrillation must consider the risks, benefits, and costs of treatments designed to restore and maintain sinus rhythm compared with those of rate control with antithrombotic prophylaxis. Objective: To compare the cost-effectiveness of cardioversion, with or without antiarrhythmic agents, with that of rate control plus warfarin or aspirin. Design: A Markov decision-analytic model was designed to simulate long-term health and economic outcomes. Data Sources: Published literature and hospital accounting information. Target Population: Hypothetical cohort of 70-year-old patients with different baseline risks for stroke. Time Horizon: 3 months. Perspective: Societal. Intervention: Therapeutic strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and rate control with antithrombotic treatment. Outcome Measures: Expected costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness. Results of Base-Case Analysis: Strategies involving cardioversion alone were more effective and less costly than those not involving this option. For patients at high risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was most cost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on relapse. This strategy was also preferred for the moderate-risk cohort (3.6% per year), but the benefit was more expensive ($18 900 per QALY). In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relapse was optimal. Results of Sensitivity Analysis: The choice of optimal strategy and incremental cost-effectiveness was substantially influenced by the baseline risk for stroke, rate of stroke in sinus rhythm, efficacy of warfarin, and costs and utilities for long-term warfarin and amiodarone therapy. Conclusions: Cardioversion alone should be the initial management strategy for persistent nonvalvular atrial fibrillation. On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective for patients at moderate to high risk for ischemic stroke.	Dartmouth Coll, Hitchcock Med Ctr, Div Cardiol, Lebanon, NH 03756 USA; Dartmouth Coll, Dartmouth Med Sch, Hanover, NH 03756 USA; Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, Dept Surg, White River Jct, VT USA	Dartmouth College; Dartmouth College	Catherwood, E (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Div Cardiol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Blackshear JL, 1996, MAYO CLIN PROC, V71, P150, DOI 10.4065/71.2.150; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Chan Kwan-Leung, 1998, Annals of Internal Medicine, V128, P639; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; COHEN IS, 1977, PROG CARDIOVASC DIS, V20, P151, DOI 10.1016/0033-0620(77)90004-4; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Cronenwett JL, 1997, J VASC SURG, V25, P298, DOI 10.1016/S0741-5214(97)70351-3; DEBELL LS, 1997, MOSBYS COMPLETE DRUG; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DISCH DL, 1994, ANN INTERN MED, V120, P449, DOI 10.7326/0003-4819-120-6-199403150-00001; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECKMAN MH, 1995, CHEST, V108, pS457, DOI 10.1378/chest.108.4_Supplement.457S; Eckman MH, 1998, ARCH INTERN MED, V158, P1669, DOI 10.1001/archinte.158.15.1669; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESTES NAM, 1992, JAMA-J AM MED ASSOC, V267, P3332, DOI 10.1001/jama.267.24.3332; EWY GA, 1994, CLIN CARDIOL, V17, P79, DOI 10.1002/clc.4960170207; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FRAIRE AE, 1993, SOUTHERN MED J, V86, P67, DOI 10.1097/00007611-199301000-00014; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gentile F, 1998, J AM COLL CARDIOL, V31, p195A, DOI 10.1016/S0735-1097(97)84553-6; Gilligan DM, 1996, AM J MED, V101, P413, DOI 10.1016/S0002-9343(96)00194-5; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; Grace AA, 1998, NEW ENGL J MED, V338, P35, DOI 10.1056/NEJM199801013380107; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HIRSH J, 1995, CHEST S, V108, pS2315; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Hohnloser SH, 1997, PACE, V20, P1989, DOI 10.1111/j.1540-8159.1997.tb03606.x; Holloway RG, 1996, NEUROLOGY, V46, P854; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANDEFELD CS, 1989, AM J MED, V87, P144; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lee KL, 1997, CLIN CARDIOL, V20, P372, DOI 10.1002/clc.4960200414; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LEVY S, 1994, CARDIOVASC DRUG THER, V8, P769, DOI 10.1007/BF00877125; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; Mackstaller LL, 1997, CLIN CARDIOL, V20, P640, DOI 10.1002/clc.4960200711; Maisel WH, 1997, ANN INTERN MED, V127, P281, DOI 10.7326/0003-4819-127-4-199708150-00004; Marrin CAS, 1997, ANN THORAC SURG, V64, P690, DOI 10.1016/S0003-4975(97)00526-2; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; McNamara RL, 1997, ANN INTERN MED, V127, P775, DOI 10.7326/0003-4819-127-9-199711010-00001; MIDDLEKAUFF HR, 1992, ANN INTERN MED, V116, P1017, DOI 10.7326/0003-4819-116-12-1017; MIDDLEKAUFF HR, 1993, AM J CARDIOL, V72, pF75, DOI 10.1016/0002-9149(93)90967-H; MORGANROTH J, 1985, AM HEART J, V110, P1176, DOI 10.1016/0002-8703(85)90008-0; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NATTEL S, 1995, AM HEART J, V130, P1094, DOI 10.1016/0002-8703(95)90214-7; NYGAARD TW, 1986, JAMA-J AM MED ASSOC, V256, P55, DOI 10.1001/jama.256.1.55; Olsson SB, 1996, J INTERN MED, V239, P3; Opolski G, 1997, CLIN CARDIOL, V20, P337, DOI 10.1002/clc.4960200407; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; PETERSEN P, 1989, LANCET, V1, P175; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; Prystowsky E N, 1996, Am J Cardiol, V78, P35, DOI 10.1016/S0002-9149(96)00564-4; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Prystowsky EN, 1997, ANN INTERN MED, V126, P244, DOI 10.7326/0003-4819-126-3-199702010-00012; REIMOLD SC, 1992, AM HEART J, V124, P924, DOI 10.1016/0002-8703(92)90974-Z; Roy D, 1997, AM J CARDIOL, V80, P464, DOI 10.1016/S0002-9149(97)00396-2; Seto TB, 1997, J AM COLL CARDIOL, V29, P122, DOI 10.1016/S0735-1097(96)00448-2; Simons GR, 1997, AM J CARDIOL, V80, P1551, DOI 10.1016/S0002-9149(97)00773-X; Singh BN, 1997, CLIN CARDIOL, V20, P608, DOI 10.1002/clc.4960200706; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Sopher SM, 1997, J AM COLL CARDIOL, V30, P799; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; Stollberger C, 1998, ANN INTERN MED, V128, P630, DOI 10.7326/0003-4819-128-8-199804150-00004; SUNG RJ, 1994, CARDIOVASC DRUG THER, V8, P773, DOI 10.1007/BF00877126; Tieleman RG, 1997, AM J CARDIOL, V79, P53, DOI 10.1016/S0002-9149(96)00675-3; *US NAT CTR HLTH S, 1991, VIT STAT US A, V2; VANGELDER I, 1995, PACE, V18, P797; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 1997, AM J CARDIOL, V79, P1198; Yuan Z, 1998, AM J PUBLIC HEALTH, V88, P395, DOI 10.2105/AJPH.88.3.395; ZAREMBSKI DG, 1995, ARCH INTERN MED, V155, P1885, DOI 10.1001/archinte.155.17.1885	106	49	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					625	+		10.7326/0003-4819-130-8-199904200-00002	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00002			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215558				2022-12-28	WOS:000079786600001
J	Mortimer, PP				Mortimer, PP			Mr N the milker, and Dr Koch's concept of the healthy carrier	LANCET			English	Article									Cent Publ Hlth Lab, Div Virus Reference, Hepatitis & Retrovirus Lab, London NW9 5HT, England	Public Health England	Mortimer, PP (corresponding author), Cent Publ Hlth Lab, Div Virus Reference, Hepatitis & Retrovirus Lab, London NW9 5HT, England.							BROCK TD, 1988, R KOCH LIFE MED BACT, P255; BURROWS W, 1954, TXB MICROBIOLOGY, P404; BUTTON JTH, 1994, COMMUNICABLE DIS CON; Houston ACL, 1910, BMJ-BRIT MED J, V2, P1499; JOHNSTONE RW, 1910, REPORT LOCAL GOVT BO; LEDINGHAM JCG, 1912, CARRIER PROBLEM INFE, P44; Ledingham JCG., 1910, REPORT LOCAL GOVT BO; LENTZ O, 1910, BRIT MED J, V2, P1501; MACCONKEY AT, 1908, J HYG, P322; Sack RB, 1998, LANCET, V352, P1570, DOI 10.1016/S0140-6736(05)61040-9; 1998, CDR WEEKLY, V8, P337	11	25	25	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1354	1356		10.1016/S0140-6736(98)11315-6	http://dx.doi.org/10.1016/S0140-6736(98)11315-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218549				2022-12-28	WOS:000080278100044
J	Passalacqua, R; Campione, F; Caminiti, C; Salvagni, S; Barilli, A; Bella, M; Barni, S; Barsanti, G; Caffo, O; Carlini, P; Cinquemani, G; Di Costanzo, F; Giustini, L; Labianca, R; Mazzei, A; Olmeo, N; Paccagnella, A; Toscano, L; Cocconi, G				Passalacqua, R; Campione, F; Caminiti, C; Salvagni, S; Barilli, A; Bella, M; Barni, S; Barsanti, G; Caffo, O; Carlini, P; Cinquemani, G; Di Costanzo, F; Giustini, L; Labianca, R; Mazzei, A; Olmeo, N; Paccagnella, A; Toscano, L; Cocconi, G			Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy	LANCET			English	Article							COMPLEMENTARY; PREVALENCE; MEDICINE	Background An emotional campaign promoting the Di Bella cancer therapy was launched by the Italian media in 1997. Its effects on patients' hopes, feelings, and decisionmaking processes were largely unknown. We undertook an investigation of this issue. Methods Between Feb 25 and March 31, 1998,a ten-item. questionnaire was distributed to 1300 unselected adult patients attending 13 cancer-centres throughout Italy. Four expert psycho-oncologists reviewed the design and validity of the contents of the:questionnaire. Sociodemographic information was also collected. Findings 1120 (86%) questionnaires were-returned and analysed. The main sources of information were television/radio (62%) and newspapers (26%); only 5% cited doctors;,The campaign induced optimism in the patients about the efficacy of the method (ineffective 1%, effective 42%, uncertain 57%), and 53% said their hope of cure was increased. However, 48% felt more confused. 24% do not discuss new treatments with their oncologists, and 20% would like to but cannot. When choosing a treatment, the advice of a trusted doctor was judged more important than scientific progress (53% vs 32%) and 63% would try even unproven treatments in the hope of a cure. Replies to, many of the questions were influenced by patients' educational attainment and by the degree of communication with their oncologists. Interpretation Science cannot prevent the harm caused by such campaigns and their psychological consequences, particularly for less educated patients. When making decisions, patients are looking for hope from the treatment trust in their doctor, both of which depend on effective doctor-patient communications that therefore need to be improved.	Univ Hosp, Div Med Oncol, Parma, Italy; Univ Hosp, Epidemiol Unit, Parma, Italy; Univ Bologna, Dept Psychol, I-40126 Bologna, Italy; San Gerardo Hosp, Div Med Oncol, Monza, Italy; Campo Marte Hosp, Oncol Serv, Lucca, Italy; S Chiara Hosp, Div Med Oncol, Trent, Italy; Ist Regina Elena, Div Med Oncol 1, I-00161 Rome, Italy; NCI, Psychol Serv, Naples, Italy; S Maria Hosp, Div Med Oncol, Terni, Italy; Murri Hosp, Oncol Serv, Fermo, Italy; Osped Riuniti Bergamo, Med Oncol Unit, I-24100 Bergamo, Italy; NCI, Div Med Oncol, Bari, Italy; USL 1, Div Med Oncol, Sassari, Italy; USL 12, Div Med Oncol, Venice, Italy; S Luigi Hosp, Div Med Oncol, Catania, Italy	University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Bologna; San Gerardo Hospital; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Fondazione Pascale; Ospedali Riuniti di Bergamo	Passalacqua, R (corresponding author), Azienda Osped, Div Oncol, Via Gramsci 14, I-43100 Parma, Italy.		Salvagni, Stefania/AAC-5798-2021; Labianca, Roberto/N-1847-2016; Caffo, Orazio/AAE-5485-2020; Caminiti, Caterina/K-4532-2016; Caminiti, Caterina/AAE-3130-2022	Labianca, Roberto/0000-0001-7149-822X; Caffo, Orazio/0000-0001-7968-2531; Caminiti, Caterina/0000-0002-3196-2435; Caminiti, Caterina/0000-0002-3196-2435				Abbott A, 1998, NATURE, V391, P217, DOI 10.1038/34503; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1026, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1026::AID-CNCR4>3.3.CO;2-#; Crocetti E, 1996, TUMORI, V82, P539, DOI 10.1177/030089169608200605; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fernandez CV, 1998, J CLIN ONCOL, V16, P1279, DOI 10.1200/JCO.1998.16.4.1279; Fleiss J. L., 1981, STAT METHODS RATES P, V2; *ISTAT NAT I STAT, 1996, INTR IT; Jacobs Joseph J., 1997, P2993; LEVY MHJ, 1988, AM SOC CLIN ONCOLOGY, P195; LOJACONO G, 1998, EPIDEMIOL PREVENT, V22, P3; Milano G, 1998, Epidemiol Prev, V22, P82; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; SIMINI B, 1998, LANCET, V351, P8941; Turone F, 1998, BRIT MED J, V316, P327, DOI 10.1136/bmj.316.7128.327a	15	23	23	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1310	1314		10.1016/S0140-6736(98)10253-2	http://dx.doi.org/10.1016/S0140-6736(98)10253-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218529				2022-12-28	WOS:000080278100011
J	Premawardhena, AP; de Silva, CE; Fonseka, MMD; Gunatilake, SB; de Silva, HJ				Premawardhena, AP; de Silva, CE; Fonseka, MMD; Gunatilake, SB; de Silva, HJ			Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PREMEDICATION	Objective To assess the efficacy and safety of low dose adrenaline injected subcutaneously to prevent acute adverse reactions to pol)specific antivenom serum in patients admitted to hospital after snake bite. Design Prospective, double blind, randomised, placebo controlled trial. Setting District general hospital in Sri Lanka. Subjects 105 patients with signs of envenomation after snake bite, randomised to receive either adrenaline (cases) or placebo (controls) immediately before infusion of antivenom serum. Interventions Adrenaline 0.25 ml (1:1000). Main outcome measures Development of acute adverse reactions to serum and side effects attributable to adrenaline. Results 56 patients (cases received adrenaline and 49 (controls) received placebo as pretreatment Six (11%) adrenaline patients and 21 (43%) control patients developed acute adverse reactions to antivenom serum (P = 0.0002), Significant reductions in acute adverse reactions to serum were also seen in the adrenaline patients for each category of mild, moderate, and severe reactions. There were no significant adverse effects attributable to adrenaline. Conclusions Use of 0.25 mi of 1:1000 adrenaline given subcutaneously immediately before administration of antivenom serum to patients with envenomation after snake bite reduces the incidence of acute adverse reactions to serum.	Base Hosp, Polonnaruwa, Sri Lanka; Univ Kelaniya, Fac Med, Dept Med, Ragama, Sri Lanka	University Kelaniya	de Silva, HJ (corresponding author), Base Hosp, Polonnaruwa, Sri Lanka.		Premawardhena, Anuja/GLN-5388-2022	Premawardhena, Anuja/0000-0003-0605-9081				HEILBORN H, 1986, J ALLERGY CLIN IMMUN, V78, P1174, DOI 10.1016/0091-6749(86)90268-X; KARUNARATHNE KED, 1973, CEYLON MED J, V1, P37; Sutherland S K, 1976, Aust Fam Physician, V5, P272; SUTHERLAND SK, 1992, MED J AUSTRALIA, V157, P734; TIBBALLS J, 1994, MED J AUSTRALIA, V160, P4, DOI 10.5694/j.1326-5377.1994.tb138191.x; WEERASINGHE W M T, 1983, Ceylon Medical Journal, V28, P182	6	88	93	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1041	1043		10.1136/bmj.318.7190.1041	http://dx.doi.org/10.1136/bmj.318.7190.1041			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205101	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080140000027
J	Zakrzewska, JM				Zakrzewska, JM			Fortnightly review - Oral cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NECK-CANCER; HEAD; EPIDEMIOLOGY; PREVALENCE; MANAGEMENT; PREVENTION		St Bartholomews & Royal London Sch Med & Dent, Dept Oral Med, London E1 2AD, England	University of London; Queen Mary University London	Zakrzewska, JM (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Oral Med, London E1 2AD, England.	j.m.zak@mds.qmw.ac.uk	Zakrzewska, Joanna M./AAC-7378-2020	Zakrzewska, Joanna M./0000-0001-7805-5851				Ahmed S, 1997, BRIT J GEN PRACT, V47, P431; *AM COLL PHYS, 1998, BEST EV 2 LINK MED R; BHATTI N, 1995, J I HLTH ED, V32, P112; BOYLE P, 1992, Current Opinion in Oncology, V4, P471; Chaturvedi SK, 1996, SUPPORT CARE CANCER, V4, P186, DOI 10.1007/BF01682338; *COCHR COLL, 1998, BEST EV 2 LINK MED R; DIMITROULIS G, 1992, ORAL ONCOL, V28B, P23, DOI 10.1016/0964-1955(92)90007-N; DIMITROULIS G, 1998, ORAL CANC SYNOPSIS P; Edwards D, 1997, BRIT MED J, V315, P1589, DOI 10.1136/bmj.315.7122.1589; ElSayed S, 1996, J CLIN ONCOL, V14, P838, DOI 10.1200/JCO.1996.14.3.838; GOLDSTEIN AM, 1994, ORAL ONCOL, V30B, P319, DOI 10.1016/0964-1955(94)90032-9; GUPTA P C, 1986, Indian Journal of Cancer, V23, P206; Gupta P C, 1995, Oral Dis, V1, P54; GUPTA PC, 1992, J ORAL PATHOL MED, V21, P433, DOI 10.1111/j.1600-0714.1992.tb00970.x; HARRISON LB, 1997, HEAD NECK-J SCI SPEC, V19, P160; Hindle I, 1996, BRIT J ORAL MAX SURG, V34, P471, DOI 10.1016/S0266-4356(96)90111-4; Horowitz AM, 1996, J PUBLIC HEALTH DENT, V56, P319, DOI 10.1111/j.1752-7325.1996.tb02459.x; *INT AG RES CANC, 1986, IARC MONOGR, V38; *INT AG RES CANC, 1989, IARC MON, V42; JOHNSON W, 1991, ORAL CANC DETECTION; JOVANOVIC A, 1992, ORAL ONCOL, V28B, P37; Jungner Gunnar, 1968, PRINCIPLES PRACTICE, P34; KING GN, 1995, NEW ENGL J MED, V332, P1052, DOI 10.1056/NEJM199504203321602; MACFARLANE GJ, 1994, CANCER CAUSE CONTROL, V5, P259, DOI 10.1007/BF01830246; McKaig RG, 1998, HEAD NECK-J SCI SPEC, V20, P250, DOI 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.0.CO;2-O; *NAT SCREEN COMM, 1988, 1 NCS DEP HLTH; Swango PA, 1996, J PUBLIC HEALTH DENT, V56, P309, DOI 10.1111/j.1752-7325.1996.tb02458.x; VELANOVICH V, 1990, ARCH OTOLARYNGOL, V116, P951	28	31	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1051	1054		10.1136/bmj.318.7190.1051	http://dx.doi.org/10.1136/bmj.318.7190.1051			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205105	Green Published			2022-12-28	WOS:000080140000032
J	Joos, F; Plattner, GK; Stocker, TF; Marchal, O; Schmittner, A				Joos, F; Plattner, GK; Stocker, TF; Marchal, O; Schmittner, A			Global warming and marine carbon cycle feedbacks an future atmospheric CO2	SCIENCE			English	Article							OCEAN CIRCULATION; MODEL; DIOXIDE; SENSITIVITIES; PALEOCLIMATE	A low-order physical-biogeochemical climate model was used to project atmospheric carbon dioxide and global warming for scenarios developed by the Intergovernmental Panel on Climate Change. The North Atlantic thermohaline circulation weakens in all global warming simulations and collapses at high levels of carbon dioxide. Projected changes in the marine carbon cycle have a modest impact on atmospheric carbon dioxide. Compared with the control, atmospheric carbon dioxide increased by 4 percent at year 2100 and 20 percent at year 2500. The reduction in ocean carbon uptake can be mainly explained by sea surface warming. The projected changes of the marine biological cycle compensate the reduction in downward mixing of anthropogenic carbon, except when the North Atlantic thermohaline circulation collapses.	Univ Bern, Inst Phys, Bern, Switzerland	University of Bern	Joos, F (corresponding author), Univ Bern, Inst Phys, Bern, Switzerland.		Joos, Fortunat/B-4118-2018; Schmittner, Andreas/O-9647-2015; Plattner, Gian-Kasper/A-5245-2016; Schmittner, Andreas/A-3101-2008; Stocker, Thomas/B-1273-2013	Joos, Fortunat/0000-0002-9483-6030; Schmittner, Andreas/0000-0002-8376-0843; Plattner, Gian-Kasper/0000-0002-3765-0045; 				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; JOOS F, 1991, NATURE, V349, P772, DOI 10.1038/349772a0; Joos F, 1996, TELLUS B, V48, P397, DOI 10.1034/j.1600-0889.1996.t01-2-00006.x; Joos F., 1996, PHYS CHEM EARTH, V21, P471, DOI [DOI 10.1016/S0079-1946(97)81144-5, 10.1016/S0079-1946(97)81144-5]; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Leggett J., 1992, CLIMATE CHANGE 1992, P69; MaierReimer E, 1996, CLIM DYNAM, V12, P711, DOI 10.1007/s003820050138; MANABE S, 1994, J CLIMATE, V7, P5, DOI 10.1175/1520-0442(1994)007<0005:MCROAC>2.0.CO;2; Marchal O, 1998, TELLUS B, V50, P290, DOI 10.1034/j.1600-0889.1998.t01-2-00006.x; MARCHAL O, IN PRESS CLIM DYN; MATEAR RJ, IN PRESS TELLUS B; MIKOLAJEWICZ U, 1998, 263 M PLANCK I MET, P1; Sarmiento JL, 1996, SCIENCE, V274, P1346, DOI 10.1126/science.274.5291.1346; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; SCHIMEL D, 1997, IPCC TECHN PAP 3 STA, P1; Shine KP, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P41; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; SIEGENTHALER U, 1992, TELLUS B, V44, P186, DOI 10.1034/j.1600-0889.1992.t01-2-00003.x; SIEGENTHALER U, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P140; Stauffer B, 1998, NATURE, V392, P59, DOI 10.1038/32133; STOCKER TF, 1992, J CLIMATE, V5, P773, DOI 10.1175/1520-0442(1992)005<0773:AZACOA>2.0.CO;2; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; Wigley TML, 1996, NATURE, V379, P240, DOI 10.1038/379240a0; WRIGHT DG, 1992, J GEOPHYS RES-OCEANS, V97, P12707, DOI 10.1029/92JC01168	24	222	231	17	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					464	467		10.1126/science.284.5413.464	http://dx.doi.org/10.1126/science.284.5413.464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205049				2022-12-28	WOS:000079792200040
J	Kops, GJPL; de Ruiter, ND; De Vries-Smits, AMM; Powell, DR; Bos, JL; Burgering, BMT				Kops, GJPL; de Ruiter, ND; De Vries-Smits, AMM; Powell, DR; Bos, JL; Burgering, BMT			Direct control of the Forkhead transcription factor AFX by protein kinase B	NATURE			English	Article							INSULIN-RESPONSE SEQUENCE; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; FAMILY MEMBER; S6 KINASE; ACTIVATION; RAS; STIMULATION; LONGEVITY	The phosphatidylinositol-3-OH-kinase (PI(3)K) effector protein kinase B (refs 1, 2) regulates certain insulin-responsive genes(3,4) but the transcription factors regulated by protein kinase B have yet to be identified. Genetic analysis in Caenorhabditis elegans has shown that the Forkhead transcription factor daf-16 is regulated by a pathway consisting of insulin-receptor-like daf-2 and PI(3)K-like age-1 (refs 5-8). Here we show that protein kinase B phosphorylates AFX, a human orthologue of daf-16 (refs 5, 6, 9), both in vitro and in vivo. Inhibition of endogenous PI(3)K and protein kinase B activity prevents protein kinase B-dependent phosphorylation of AFX and reveals residual protein kinase B-independent phosphorylation that requires Ras signalling towards the Ra1 GTPase. In addition, phosphorylation of AFX by protein kinase B inhibits its transcriptional activity. Together, these results delineate a pathway for PT(3)K-dependent signalling to the nucleus.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Utrecht University; Utrecht University; Baylor College of Medicine	Burgering, BMT (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	b.m.t.burgering@med.uu.nl		Kops, Geert/0000-0003-3555-5295				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peters U, 1997, HUM GENET, V100, P569, DOI 10.1007/s004390050553; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	30	933	963	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					630	634		10.1038/19328	http://dx.doi.org/10.1038/19328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217147				2022-12-28	WOS:000079754700060
J	Besterman, EMM				Besterman, EMM			A memorable patient - All in the family	BRITISH MEDICAL JOURNAL			English	Article																		TEARE D, 1958, BRIT HEART J, V20, P1	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					977	977		10.1136/bmj.318.7189.977	http://dx.doi.org/10.1136/bmj.318.7189.977			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195967	Green Published			2022-12-28	WOS:000079751500019
J	Essex, C				Essex, C			A mistake that changed my practice - The wrong notes	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					990	990		10.1136/bmj.318.7189.990	http://dx.doi.org/10.1136/bmj.318.7189.990			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195973	Green Published			2022-12-28	WOS:000079751500025
J	Reagan, P				Reagan, P			Helen	LANCET			English	Article											Reagan, P (corresponding author), 2406 NE 19th Ave, Portland, OR 97212 USA.								0	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1265	1267		10.1016/S0140-6736(98)12219-5	http://dx.doi.org/10.1016/S0140-6736(98)12219-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217100				2022-12-28	WOS:000079744100042
J	Cobb, LA; Fahrenbruch, CE; Walsh, TR; Copass, MK; Olsufka, M; Breskin, M; Hallstrom, AP				Cobb, LA; Fahrenbruch, CE; Walsh, TR; Copass, MK; Olsufka, M; Breskin, M; Hallstrom, AP			Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-ARREST; COUNTERSHOCK; MANAGEMENT; SURVIVAL; IMPACT; DEATH	Context Use of automated external defibrillators (AEDs) by first arriving emergency medical technicians (EMTs) is advocated to improve the outcome for out-of-hospital ventricular fibrillation (VF). However, adding AEDs to the emergency medical system in Seattle, Wash, did not improve survival. Studies in animals have shown improved outcomes when cardiopulmonary resuscitation (CPR) was administered prior to an initial shock for VF of several minutes' duration. Objective To evaluate the effects of providing 90 seconds of CPR to persons with out-of-hospital VF prior to delivery of a shock by first-arriving EMTs. Design Observational, prospectively defined, population-based study with 42 months of preintervention analysis (July 1, 1990-December 31, 1993) and 36 months of postintervention analysis (January 1, 1994-December 31, 1996). Setting Seattle fire department-based, 2-tiered emergency medical system. Participants A total of 639 patients treated for out-of-hospital VF before the intervention and 478 after the intervention. Intervention Modification of the protocol for use of AEDs, emphasizing approximately 90 seconds of CPR prior to delivery of a shock. Main Outcome Measures Survival and neurologic status at hospital discharge determined by retrospective chart review as a function of early (<4 minutes) and later (greater than or equal to 4 minutes) response intervals. Results Survival improved from 24% (155/639) to 30% (142/478) (P = .04). That benefit was predominantly in patients for whom the initial response interval was 4 minutes or longer (survival, 17% [56/321] before vs 27% [60/220] after; P = .01). In a multivariate logistic model, adjusting for differences in patient and resuscitation factors between the periods, the protocol intervention was estimated to improve survival significantly (adds ratio, 1.42; 95% confidence interval, 1.07-1.90; P = .02). Overall, the proportion of victims who survived with favorable neurologic recovery increased from 17% (106/634) to 23% (109/474) (P = .01). Among survivors, the proportion having favorable neurologic function at hospital discharge increased from 71% (106/150) to 79% (109/138) (P<.11). Conclusion The routine provision of approximately 90 seconds of CPR prior to use of AED was associated with increased survival when response intervals were 4 minutes or longer.	Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Biostat, Seattle, WA 98104 USA; Seattle Fire Dept, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Cobb, LA (corresponding author), Univ Washington, Harborview Med Ctr, Dept Med, Box 359748, Seattle, WA 98104 USA.							Brown CG, 1996, ANN EMERG MED, V27, P184, DOI 10.1016/S0196-0644(96)70346-3; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; COBB LA, 1992, CIRCULATION, V85, P98; COBB LA, 1975, CIRCULATION, V52, P223; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; DITCHEY RV, 1992, CARDIOVASC RES, V26, P791, DOI 10.1093/cvr/26.8.791; DIXON WJ, 1990, BMDP STAT SOFTWARE M, P9; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; *EM CARD CAR COMM, 1991, AM J EMERG MED, V9, P91; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; Ferguson JJ, 1998, CIRCULATION, V97, P1217; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; Joyce S M, 1998, Prehosp Emerg Care, V2, P13, DOI 10.1080/10903129808958833; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; Martens P, 1993, Eur J Med, V2, P430; NIEMANN JT, 1992, CIRCULATION, V85, P281, DOI 10.1161/01.CIR.85.1.281; NOC M, 1994, J LAB CLIN MED, V124, P421; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; SCHNEIDER T, 1994, RESUSCITATION, V27, P197, DOI 10.1016/0300-9572(94)90033-7; Sweeney TA, 1998, ANN EMERG MED, V31, P234, DOI 10.1016/S0196-0644(98)70313-0; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEAVER WD, 1987, J AM COLL CARDIOL, V10, P1259, DOI 10.1016/S0735-1097(87)80128-6	27	519	546	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1182	1188		10.1001/jama.281.13.1182	http://dx.doi.org/10.1001/jama.281.13.1182			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199427	Bronze			2022-12-28	WOS:000079464400032
J	Fink, HW; Schonenberger, C				Fink, HW; Schonenberger, C			Electrical conduction through DNA molecules	NATURE			English	Article							HOLOGRAPHY	The question of whether DNA is able to transport electrons has attracted much interest, particularly as this ability may play a role as a repair mechanism after radiation damage to the DNA helix(1). Experiments addressing DNA conductivity have involved a large number of DNA strands doped with intercalated donor and acceptor molecules, and the conductivity has been assessed from electron transfer rates as a function of the distance between the donor and acceptor sites(2,3). But the experimental results remain contradictory, as do theoretical predictions(4). Here we report direct measurements of electrical current as a function of the potential applied across a few DNA molecules associated into single ropes at least 600 nm long, which indicate efficient conduction through the ropes. We find that the resistivity values derived fi om these measurements are comparable to those of conducting polymers, and indicate that DNA transports electrical current as efficiently as a good semiconductor. This property, and the fact that DNA molecules of specific composition ranging in length from just a few nucleotides to chains several tens of micrometres long can be routinely prepared, makes DNA ideally suited for the construction of mesoscopic electronic devices.	Univ Basel, Inst Phys, CH-4056 Basel, Switzerland	University of Basel	Fink, HW (corresponding author), Univ Basel, Inst Phys, Klingelbergstr 82, CH-4056 Basel, Switzerland.	finkhw@ubaclu.unibas.ch	Schönenberger, Christian/N-3187-2017	Schönenberger, Christian/0000-0002-5652-460X				Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; FINK HW, 1990, PHYS REV LETT, V65, P1204, DOI 10.1103/PhysRevLett.65.1204; Fink HW, 1997, J OPT SOC AM A, V14, P2168, DOI 10.1364/JOSAA.14.002168; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; Schmid H, 1997, APPL PHYS LETT, V70, P2679, DOI 10.1063/1.118978	8	1043	1098	6	221	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					407	410		10.1038/18855	http://dx.doi.org/10.1038/18855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201370				2022-12-28	WOS:000079508200047
J	Tetsu, O; McCormick, F				Tetsu, O; McCormick, F			beta-catenin regulates expression of cyclin D1 in colon carcinoma cells	NATURE			English	Article							CANCER; OVEREXPRESSION; GENE; ACTIVATION; PROMOTER; COMPLEX; XENOPUS; LESSONS; LEF-1; APC	Mutations in the adenomatous polyposis coli (APC) tumour-suppressor gene occur in most human colon cancers(1) Loss of functional APC protein results in the accumulation of beta-catenin(2). Mutant forms of beta-catenin have been discovered in colon cancers that retain wild-type APC genes(3,4), and also in melanomas(5), medulloblastomas(6), prostate cancer(7) and gastric(8) and hepatocellular(9,10) carcinomas. The accumulation of beta-catenin activates genes that are responsive to transcription factors of the TCF/LEF family, with which beta-catenin interacts(11-15). Here we show that beta-catenin activates transcription from the cyclin D1 promoter, and that sequences within the promoter that are related to consensus TCF/LEF-binding sites are necessary for activation. The oncoprotein p21(ras) further activates transcription of the cyclin D1 gene, through sites within the promoter that bind the transcriptional regulators Ets or CREB. Cells expressing mutant beta-catenin produce high levels of cyclin D1 messenger RNA and protein constitutively. Furthermore, expression of a dominant-negative form of TCF in colon-cancer cells strongly inhibits expression of cyclin DI without affecting expression of cyclin D2, cyclinE, or cyclin-dependent kinases 2, 4 or 6. This dominant-negative TCF causes cells to arrest in the G1 phase of the cell cycle; this phenotype can be rescued by expression of cyclin D1 under the cytomegalovirus promoter. Abnormal levels of beta-catenin may therefore contribute to neoplastic transformation by causing accumulation of cyclin D1.	Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA.	mccormick@cc.ucsf.edu		Tetsu, Osamu/0000-0003-1820-7539				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; GEISE K, 1995, GENE DEV, V9, P995; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUBER O, 1996, MECH DEVELOP, V59, P310; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lahti JM, 1997, J BIOL CHEM, V272, P10859; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Zhang T, 1997, CANCER RES, V57, P169; Zurawel RH, 1998, CANCER RES, V58, P896	28	3148	3256	2	196	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					422	426		10.1038/18884	http://dx.doi.org/10.1038/18884			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201372				2022-12-28	WOS:000079508200052
J	Donnan, GA; Carey, LM; Saling, MM				Donnan, GA; Carey, LM; Saling, MM			More (or less) on Broca	LANCET			English	Editorial Material							COORDINATING SPEECH ARTICULATION; BRAIN REGION		Austin & Repatriat Med Ctr, Dept Neurol, Heidelberg, Vic 3084, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Donnan, GA (corresponding author), Austin & Repatriat Med Ctr, Dept Neurol, Heidelberg, Vic 3084, Australia.		Carey, Leeanne/AAZ-9844-2021; DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403; Carey, Leeanne/0000-0001-6376-8613				Broca P. A., 1865, B SOC ANTHROPOL PAR, V6, P493; Donnan GA, 1997, LANCET, V349, P221, DOI 10.1016/S0140-6736(05)64855-6; Dronkers NF, 1996, NATURE, V384, P159, DOI 10.1038/384159a0; Head H., 1926, APHASIA KINDRED DISO; MOHR JP, 1976, STUDIES NEUROLINGUIS, V1, P201; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Price CJ, 1996, BRAIN, V119, P919, DOI 10.1093/brain/119.3.919	7	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1031	1032		10.1016/S0140-6736(99)90052-1	http://dx.doi.org/10.1016/S0140-6736(99)90052-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199346				2022-12-28	WOS:000079614000005
J	Frost, G; Leeds, AA; Dore, CJ; Madeiros, S; Brading, S; Dornhorst, A				Frost, G; Leeds, AA; Dore, CJ; Madeiros, S; Brading, S; Dornhorst, A			Glycaemic index as a determinant of serum HDL-cholesterol concentration	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; METABOLIC CONTROL; DIETARY FIBER; GLYCEMIC LOAD; INSULIN; RISK; CARBOHYDRATE; FAT; FOODS	Background Diet influences the prevalence of coronary heart disease (CHD). Insulin sensitivity and concentrations of HDL cholesterol, two metabolic predictors of CHD, are also influenced by diet. Dietary carbohydrates with a high glycaemic index cause a high postprandial glucose and insulin response, and are associated with decreased insulin sensitivity and an increased risk of CHD. This study examined whether the glycaemic index or dietary carbohydrates is a determinant of serum HDL-cholesterol concentrations. Method Dietary, anthropometric, and biochemical data from the 1986-87 Survey of British Adults (n=2200) were reanalysed by a multiple regression model, which examined the relation between serum total cholesterol, HDL-cholesterol, and calculated LDL-cholesterol concentrations and various dietary characteristics, including the type of carbohydrate, the glycaemic index, and fat intake. Findings Among the 1420 participants with complete data, there was a significant negative relation between serum HDL-cholesterol concentration and the glycaemic index of the diet for both men (regression coefficient -0.00724 [95% CI -0.0101 to -0.00434], p=0.02) and women (-0.01326 [-0.0162 to -0.0102], p<0.0001). No other significant relation was found with total cholesterol or LDL-cholesterol concentration or with any other dietary carbohydrate or fat constituent. Interpretation In a cross-sectional study of middle-aged adults, the glycaemic index of the diet was the only dietary variable significantly related to serum HDL-cholesterol concentration. Thus, the glycaemic index of the diet is a stronger predictor than dietary fat intake of serum HDL-cholesterol concentration.	Hammersmith Hosp NHS Trust, Dept Nutr & Dietet, London W12 0HS, England; Univ London Kings Coll, Dept Nutr, London WC2R 2LS, England; Univ London Imperial Coll Sci Technol & Med, Dept Metab Stat & Evaluat, London, England; Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Invest Sci, London, England	Imperial College London; University of London; King's College London; Imperial College London; Imperial College London	Frost, G (corresponding author), Hammersmith Hosp NHS Trust, Dept Nutr & Dietet, London W12 0HS, England.	gfrost@rpms.ac.uk	Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970				BORNET FRJ, 1987, AM J CLIN NUTR, V45, P588, DOI 10.1093/ajcn/45.3.588; CHEN YDI, 1993, J CLIN ENDOCR METAB, V76, P347, DOI 10.1210/jc.76.2.347; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; FAO/WHO, 1998, CARB HUM NUTR REP JO; FONTVIEILLE AM, 1992, DIABETIC MED, V9, P444, DOI 10.1111/j.1464-5491.1992.tb01815.x; FOSTERPOWELL K, 1995, AM J CLIN NUTR, V62, P871; Frost G, 1996, METABOLISM, V45, P669, DOI 10.1016/S0026-0495(96)90129-8; Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GREGORY J, 1998, DIETARY NUTR SURVEY; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; JENKINS DJA, 1982, AM J CLIN NUTR, V35, P1339, DOI 10.1093/ajcn/35.6.1339; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P66, DOI 10.1093/ajcn/46.1.66; Jeppesen J, 1998, J INTERN MED, V243, P293; Liu S, 1998, FASEB J, V12, pA260; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; Marshall JA, 1997, DIABETOLOGIA, V40, P430, DOI 10.1007/s001250050697; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; SLABBER M, 1994, AM J CLIN NUTR, V60, P48, DOI 10.1093/ajcn/60.1.48; TENKANEN L, 1994, ARCH INTERN MED, V154, P2714, DOI 10.1001/archinte.1994.00420230107012; VANDOKKUM W, 1990, EUR J CLIN NUTR, V44, P665; Wolever T M, 1990, World Rev Nutr Diet, V62, P120; WOLEVER TMS, 1995, DIABETES CARE, V18, P962, DOI 10.2337/diacare.18.7.962; WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x	28	289	303	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1045	1048		10.1016/S0140-6736(98)07164-5	http://dx.doi.org/10.1016/S0140-6736(98)07164-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199351				2022-12-28	WOS:000079614000010
J	Beecham, L				Beecham, L			BMA chairman questions comprehensiveness of NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1218	1218						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221968				2022-12-28	WOS:000080277900072
J	Merke, DP; Tajima, T; Baron, J; Cutler, GB				Merke, DP; Tajima, T; Baron, J; Cutler, GB			Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX1 gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADRENAL HYPOPLASIA CONGENITA; KALLMANN SYNDROME; JAPANESE PATIENTS; HETEROGENEITY; CONVERSION; DIAGNOSIS; DNA		NICHD, DEB, NIH, Bethesda, MD 20892 USA; US PHS, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); United States Public Health Service	Merke, DP (corresponding author), NICHD, DEB, NIH, Bldg 10,Rm 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.		Toshihiro, Tajima/A-5720-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000640] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000640] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Georgopoulos NA, 1997, J CLIN ENDOCR METAB, V82, P213, DOI 10.1210/jc.82.1.213; GUO WW, 1995, JAMA-J AM MED ASSOC, V274, P324, DOI 10.1001/jama.274.4.324; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; HARDELIN JP, 1993, HUM MOL GENET, V2, P373, DOI 10.1093/hmg/2.4.373; HARTSHORNE GM, 1996, REPROD ENDOCRINOLOGY, P436; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; Kinoshita E, 1997, HORM RES, V48, P29, DOI 10.1159/000185364; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; Lo Ten Foe J R, 1997, EUR J HUM GENET, V5, P137; Meloni A, 1996, HUM MUTAT, V8, P183, DOI 10.1002/(SICI)1098-1004(1996)8:2<183::AID-HUMU12>3.3.CO;2-C; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nakae J, 1996, J CLIN ENDOCR METAB, V81, P3680, DOI 10.1210/jc.81.10.3680; Nakae J, 1997, J CLIN ENDOCR METAB, V82, P3835, DOI 10.1210/jc.82.11.3835; Schwartz M, 1997, HUM GENET, V99, P83; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Takahashi T, 1997, J PEDIATR-US, V130, P485, DOI 10.1016/S0022-3476(97)70217-8; Yanase T, 1996, J CLIN ENDOCR METAB, V81, P530, DOI 10.1210/jc.81.2.530; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZANGENBERG G, 1995, NAT GENET, V10, P407, DOI 10.1038/ng0895-407	23	78	83	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1248	1252		10.1056/NEJM199904223401605	http://dx.doi.org/10.1056/NEJM199904223401605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210708				2022-12-28	WOS:000079833800005
J	Preiser, PR; Jarra, W; Capiod, T; Snounou, G				Preiser, PR; Jarra, W; Capiod, T; Snounou, G			A rhoptry-protein-associated mechanism of clonal phenotypic variation in rodent malaria	NATURE			English	Article							PLASMODIUM-YOELII; MULTIGENE FAMILY; GENE; ERYTHROCYTES; FALCIPARUM; EXPRESSION; MEROZOITES; PARASITE; INVASION; VIVAX	The recognition and invasion of host cells are mediated by components of the apical complex of the ookinete, sporozoite and merozoite stages of Plasmodium parasites'. The paired rhoptries (organelles involved in host-cell recognition) in the epical complex contain many proteins of as-yet unknown function. In the rodent malaria agent P, yoelii yoelii, a multigene family codes for merozoite rhoptry proteins of relative molecular mass 235,000 (p235 proteins)(2,3); these proteins are thought to determine the subset of erythrocytes that the parasites invade(4,5). Further support for this idea came from the identification of a region in p235 with weak but significant homology to reticulocyte-binding protein-2 of P. vivax(6-8) and the demonstration that at least one p235 member binds to the erythrocyte surface membrane(9). Here, using single, micromanipulated P.y.yoelii parasites, we describe a new mechanism of gene expression by which the merozoites originating from a single schizont each express a distinct member of this multigene family. We propose that this nerv type of clonal phenotypic variation provides the parasite with a survival strategy in the mammalian host; this strategy contributes to the observed chronicity of malarial infections. This phenomenon is genetically and functionally distinct from classical antigenic variation, which is mediated by the var multigene family of P. falciparum(10-13).	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Natl Inst Med Res, Dept Neurophysiol & Neuropharmacol, London NW7 1AA, England; Northwick Pk Hosp, Imperial Coll Sch Med, Dept Infect & Trop Med, Lister Unit, Harrow HA1 3UJ, Middx, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Imperial College London	Preiser, PR (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.		Preiser, Peter R/A-2201-2011; Snounou, Georges/F-3352-2011; CAPIOD, Thierry/K-4234-2017	Snounou, Georges/0000-0002-6133-6398; CAPIOD, Thierry/0000-0002-8448-7041; , Peter/0000-0003-4331-7000				BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BORRE MB, 1995, MOL BIOCHEM PARASIT, V70, P149, DOI 10.1016/0166-6851(95)00025-V; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; FREEMAN RR, 1980, NATURE, V284, P366, DOI 10.1038/284366a0; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Galinski MR, 1996, PARASITOL TODAY, V12, P20, DOI 10.1016/0169-4758(96)80641-7; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; JARRA W, 1989, PARASITE IMMUNOL, V11, P1, DOI 10.1111/j.1365-3024.1989.tb00644.x; KEEN J, 1990, MOL BIOCHEM PARASIT, V42, P241, DOI 10.1016/0166-6851(90)90167-K; KEEN JK, 1994, MOL BIOCHEM PARASIT, V65, P171, DOI 10.1016/0166-6851(94)90125-2; Ogun SA, 1996, MOL BIOCHEM PARASIT, V76, P321, DOI 10.1016/0166-6851(95)02540-5; Preiser PR, 1998, EXP PARASITOL, V89, P50, DOI 10.1006/expr.1998.4259; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Sinha KA, 1996, MOL BIOCHEM PARASIT, V76, P329, DOI 10.1016/0166-6851(95)02546-4; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1	17	111	112	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					618	622		10.1038/19309	http://dx.doi.org/10.1038/19309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217144				2022-12-28	WOS:000079754700057
J	Gu, K; Cowie, CC; Harris, MI				Gu, K; Cowie, CC; Harris, MI			Diabetes and decline in heart disease mortality in US adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; CARDIOVASCULAR-DISEASE; UNITED-STATES; POPULATION; PREVALENCE; TRENDS; MELLITUS; AGREEMENT; GLUCOSE	Context Mortality from coronary heart disease has declined substantially in the United States during the past 30 years. However, it is unknown whether patients with diabetes have also experienced a decline in heart disease mortality. Objective To compare adults with diabetes with those without diabetes for time trends in mortality from all causes, heart disease, and ischemic heart disease. Design, Setting, and Participants Representative cohorts of subjects with and without diabetes were derived from the First National Health and Nutrition Examination Survey (NHANES I) conducted between 1971 and 1975 (n = 9639) and the NHANES I Epidemiologic Follow-Lap Survey conducted between 1982 and 1984 (n = 8463), The cohorts were followed up prospectively for mortality for an average of 8 to 9 years. Main Outcome Measure Changes in mortality rates per 1000 person-years for all causes, heart disease, and ischemic heart disease for the 1982-1984 cohort compared with the 1971-1975 cohort. Results For the 2 periods, nondiabetic men experienced a 36.4% decline in age-adjusted heart disease mortality compared with a 13.1 % decline far diabetic men, Age-adjusted heart disease mortality declined 27% in nondiabetic women but increased 23% in diabetic women. These patterns were also found for all-cause mortality and ischemic heart disease mortality. Conclusions The decline in heart disease mortality in the general US population has been attributed to reduction in cardiovascular risk factors and improvement in treatment of heart disease, The smaller declines in mortality for diabetic subjects in the present study indicate that these changes may have been less effective for people with diabetes, particularly women.	NIDDKD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Harris, MI (corresponding author), NIDDKD, NIH, Natcher Bldg,Room 5AN24,45 Ctr Dr,MSC 6600, Bethesda, MD 20892 USA.	harrism@ep.niddk.nih.gov						BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; CHIANG CL, 1961, VITAL STAT; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P155; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; HARRIS MI, 1994, DIABETES CARE, V17, P1337, DOI 10.2337/diacare.17.11.1337; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HAVLIK RJ, 1978, DHEW PUBLICATION; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; KAHN HA, 1989, STATISTICAL METHODS, P217; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; Leibson CL, 1997, AM J EPIDEMIOL, V146, P12, DOI 10.1093/oxfordjournals.aje.a009187; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MELTON LJ, 1983, DIABETES CARE, V6, P427, DOI 10.2337/diacare.6.5.427; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Sievers ML, 1996, DIABETES CARE, V19, P107, DOI 10.2337/diacare.19.2.107; STAMLER J, 1985, CARDIOLOGY, V72, P11, DOI 10.1159/000173836; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304	22	595	618	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1291	1297		10.1001/jama.281.14.1291	http://dx.doi.org/10.1001/jama.281.14.1291			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208144	Bronze			2022-12-28	WOS:000079628700033
J	Schatz, M				Schatz, M			Asthma and pregnancy	LANCET			English	Editorial Material							PERINATAL OUTCOMES; WOMEN; GROWTH		Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA	Kaiser Permanente	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA.							Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; *NAT ASTHM ED PROG, 1993, NIH PUBL; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M., 1998, CAN J ALLERGY CLIN I, V3, P242; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X	17	27	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1999	353	9160					1202	1204		10.1016/S0140-6736(99)00111-7	http://dx.doi.org/10.1016/S0140-6736(99)00111-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217076				2022-12-28	WOS:000079744100004
J	McDermott, MF; Aksentijevich, I; Galon, J; McDermott, EM; Ogunkolade, BW; Centola, M; Mansfield, E; Gadina, M; Karenko, L; Pettersson, T; McCarthy, J; Frucht, DM; Aringer, M; Torosyan, Y; Teppo, AM; Wilson, M; Karaarslan, HM; Wan, Y; Todd, I; Wood, G; Schlimgen, R; Kumarajeewa, TR; Cooper, SM; Vella, JP; Amos, CI; Mulley, J; Quane, KA; Molloy, MG; Ranki, A; Powell, RJ; Hitman, GA; O'Shea, JJ; Kastner, DL				McDermott, MF; Aksentijevich, I; Galon, J; McDermott, EM; Ogunkolade, BW; Centola, M; Mansfield, E; Gadina, M; Karenko, L; Pettersson, T; McCarthy, J; Frucht, DM; Aringer, M; Torosyan, Y; Teppo, AM; Wilson, M; Karaarslan, HM; Wan, Y; Todd, I; Wood, G; Schlimgen, R; Kumarajeewa, TR; Cooper, SM; Vella, JP; Amos, CI; Mulley, J; Quane, KA; Molloy, MG; Ranki, A; Powell, RJ; Hitman, GA; O'Shea, JJ; Kastner, DL			Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes	CELL			English	Article							TUMOR-NECROSIS-FACTOR; PERIODIC-FEVER; LYMPHOPROLIFERATIVE SYNDROME; ERYTHROPOIETIN RECEPTOR; RHEUMATOID-ARTHRITIS; MEDITERRANEAN FEVER; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; HUMAN NEUTROPHILS; CHROMOSOME 12P13	Autosomal dominant periodic fever syndromes are characterized by unexplained episodes of fever and severe localized inflammation. In seven affected families, we found six different missense mutations of the 55 kDa tumor necrosis factor receptor (TNFR1), five of which disrupt conserved extracellular disulfide bonds. Soluble plasma TNFR1 levels in patients were approximately half normal. Leukocytes bearing a C52F mutation showed increased membrane TNFR1 and reduced receptor cleavage following stimulation. We propose that the autoinflammatory phenotype results from impaired downregulation of membrane TNFR1 and diminished shedding of potentially antagonistic soluble receptor. TNFR1-associated periodic syndromes (TRAPS) establish an important class of mutations in TNF receptors. Detailed analysis of one such mutation suggests impaired cytokine receptor clearance as a novel mechanism of disease.	St Bartholomews & Royal London Hosp Sch Med & Den, Med Unit, London E1 1BB, England; NIAMSD, Genet Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; NIAMSD, Lymphocyte Cell Biol Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; NIAMSD, Clin Invest Sect, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; Univ Nottingham, Queens Med Ctr, Sch Clin Lab Sci, Div Mol & Clin Immunol, Nottingham NG7 2UH, England; Univ Helsinki, Cent Hosp, Dept Dermatol, Helsinki 00029, Finland; Univ Helsinki, Cent Hosp, Dept Med, Div Internal Med, Helsinki 00029, Finland; Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki 00029, Finland; Natl Univ Ireland Univ Coll Cork, Dept Med, Cork, Ireland; Natl Univ Ireland Univ Coll Cork, Dept Rheumatol, Cork, Ireland; New Childrens Hosp, Dept Clin Genet, Westmead, NSW, Australia; Univ Vermont, Coll Med, Rheumatol & Clin Immunol Unit, Burlington, VT 05405 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Nottingham; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University College Cork; University College Cork; University of Sydney; University of Vermont; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Womens & Childrens Hospital Australia	Kastner, DL (corresponding author), St Bartholomews & Royal London Hosp Sch Med & Den, Med Unit, London E1 1BB, England.	m.f.mcdermott@mds.qmw.ac.uk; kastnerd@arb.niams.nih.gov	McDermott, Michael Francis/GZM-5330-2022; McDermott, Michael/S-8490-2019; Gadina, Massimo/R-4195-2019; Galon, Jerome/G-9838-2019; Aksentijevich, Ivona/AAF-1335-2019	McDermott, Michael/0000-0002-1015-0745; Galon, Jerome/0000-0001-9635-1339; 	NIAMS NIH HHS [AR44422] Funding Source: Medline; NIGMS NIH HHS [GM52607] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044422, ZIAAR041123, Z01AR041123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052607] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADERKA D, 1996, CYTOKINE GROWTH F R, V7, P2331; Aksentijevich I, 1997, CELL, V90, P797; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Bernot A, 1997, NAT GENET, V17, P25; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Centola M, 1998, HUM MOL GENET, V7, P1581, DOI 10.1093/hmg/7.10.1581; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Douni E, 1998, J EXP MED, V188, P1343, DOI 10.1084/jem.188.7.1343; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; DRENTH JPH, 1994, HUM GENET, V94, P616, DOI 10.1007/BF00206953; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GARCIA I, 1995, EUR J IMMUNOL, V25, P2401, DOI 10.1002/eji.1830250841; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; MCDERMOTT EM, 1997, FAMILIAL MEDITERRANE, P24; McDermott MF, 1998, AM J HUM GENET, V62, P1446, DOI 10.1086/301886; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Mulley J, 1998, AM J HUM GENET, V62, P884, DOI 10.1086/301793; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Peschon JJ, 1998, J IMMUNOL, V160, P943; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Valimaki M, 1985, Duodecim, V101, P2428; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILLIAMSON LM, 1982, Q J MED, V51, P469; ZAKS N, 1997, FAMILIAL MEDITERRANE, P211	51	957	998	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					133	144		10.1016/S0092-8674(00)80721-7	http://dx.doi.org/10.1016/S0092-8674(00)80721-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199409	Bronze			2022-12-28	WOS:000079843900015
J	Smith, O				Smith, O			Medicine - Fear of flying	SCIENCE			English	Editorial Material																		Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					61	61		10.1126/science.284.5411.61	http://dx.doi.org/10.1126/science.284.5411.61			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10215531				2022-12-28	WOS:000079509000027
J	Yamaguchi, Y; Takagi, T; Wada, T; Yano, K; Furuya, A; Sugimoto, S; Hasegawa, J; Handa, H				Yamaguchi, Y; Takagi, T; Wada, T; Yano, K; Furuya, A; Sugimoto, S; Hasegawa, J; Handa, H			NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation	CELL			English	Article							C-TERMINAL DOMAIN; ACCURATE TRANSCRIPTION INITIATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ACTIVATED TRANSCRIPTION; LARGEST SUBUNIT; P-TEFB; PHOSPHORYLATION; PURIFICATION; PROTEIN	DRB is a classic inhibitor of transcription elongation by RNA polymerase II (pol II). Since DRB generally affects class II genes, factors involved in this process must play fundamental roles in pol II elongation. Recently, two elongation factors essential for DRB action were identified, namely DSIF and P-TEFb. Here we describe the identification and purification from HeLa nuclear extract of a third protein factor required for DRB-sensitive transcription. This factor, termed negative elongation factor (NELF), cooperates with DSIF and strongly represses pol II elongation. This repression is reversed by P-TEFb-dependent phosphorylation of the pol II C-terminal domain. NELF is composed of five polypeptides, the smallest of which is identical to RD, a putative RNA-binding protein of unknown function. This study reveals a molecular mechanism for DRB action and a regulatory network of positive and negative elongation factors.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan	Tokyo Institute of Technology; Kyowa Kirin Ltd	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X				Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Chadwick GA., 1989, MET MATER, V5, P6; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHENG JH, 1993, BIOCHEM J, V294, P589, DOI 10.1042/bj2940589; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 1996, MOL CELL BIOL, V16, P2848; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KIM WY, 1988, J BIOL CHEM, V263, P18880; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moore DD, 1995, GLOB MOB SURV; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Thompson NE, 1996, METHOD ENZYMOL, V274, P513; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WADA T, 1991, J VIROL, V65, P557, DOI 10.1128/JVI.65.2.557-564.1991; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WATAMORI TS, 1990, APHASIOLOGY, V4, P9, DOI 10.1080/02687039008249051; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; YAMAGUCHI Y, 1999, IN PRESS J BIOL CHEM; YUE Z, 1997, P NATL ACAD SCI USA, V94, P12989; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	55	548	568	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					41	51		10.1016/S0092-8674(00)80713-8	http://dx.doi.org/10.1016/S0092-8674(00)80713-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199401	Bronze			2022-12-28	WOS:000079843900007
J	Rudge, P				Rudge, P			Are clinical trials of therapeutic agents for MS long enough?	LANCET			English	Editorial Material							REMITTING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; RELAPSE RATE; DOUBLE-BLIND; DISABILITY		UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Rudge, P (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.							DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; JACOBS LD, 1996, ANN NEUROL, V39, P254; Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; NOTEWORTHY JH, 1998, NEUROLOGY, V52, P1342; RUDGE P, 1989, J NEUROL NEUROSUR PS, V52, P559, DOI 10.1136/jnnp.52.5.559; SIPE JC, 1994, LANCET, V344, P9, DOI 10.1016/S0140-6736(94)91046-4; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1033	1034		10.1016/S0140-6736(98)00407-3	http://dx.doi.org/10.1016/S0140-6736(98)00407-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199348				2022-12-28	WOS:000079614000007
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Treatment allocation in controlled trials: why randomise?	BRITISH MEDICAL JOURNAL			English	Article									Imperial Canc Res Fund, Med Stat Grp, Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England; St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of Oxford; St Georges University London	Altman, DG (corresponding author), Imperial Canc Res Fund, Med Stat Grp, Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England.							ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BLACK N, 1996, BRIT MED J, V312, P115; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SMITHELLS RW, 1980, LANCET, V1, P339; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; WALD N, 1991, LANCET, V338, P131	7	206	217	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1209	1209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221955				2022-12-28	WOS:000080277900042
J	Kliewer, SA; Lehmann, JM; Willson, TM				Kliewer, SA; Lehmann, JM; Willson, TM			Orphan nuclear receptors: Shifting endocrinology into reverse	SCIENCE			English	Review							RETINOID-X RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTORS; HIGH-AFFINITY LIGAND; PPAR-GAMMA; FATTY-ACIDS; SIGNALING PATHWAY; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; PEROXISOME PROLIFERATORS; TERMINAL DIFFERENTIATION	Steroid and thyroid hormones and vitamin A metabolites (retinoids) regulate the expression of complex gene programs by binding to members of the nuclear receptor family of Ligand-activated transcription factors. The nuclear receptor family also includes many "orphan" members that currently lack known Ligands but that represent candidate receptors for new hormones. Recently, natural and synthetic Ligands have been identified for several orphan receptors and used to dissect their biological roles. This "reverse endocrinology" strategy has resulted in the discovery of unanticipated nuclear signaling pathways for retinoids, fatty acids, eicosanoids, and steroids with important physiological and pharmacological ramifications.	Glaxo Wellcome Res & Dev, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline	Kliewer, SA (corresponding author), Glaxo Wellcome Res & Dev, Dept Mol Endocrinol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	sak15922@glaxowellcome.com	feinstein, doug/M-9414-2019					Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, COMMUNICATION; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARKS D, COMMUNICATION; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1997, CURR PHARM DESIGN, V3, P1; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; XU E, IN PRESS MOL CELL; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	55	395	407	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					757	760		10.1126/science.284.5415.757	http://dx.doi.org/10.1126/science.284.5415.757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221899				2022-12-28	WOS:000080056200033
J	Serra, S; Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E				Serra, S; Cavazzoni, C; Chiarotti, GL; Scandolo, S; Tosatti, E			Pressure-induced solid carbonates from molecular CO2 by computer simulation	SCIENCE			English	Article							PHASE; PSEUDOPOTENTIALS; TEMPERATURE; BEHAVIOR; SPECTRA; GPA	A combination of ab initio molecular dynamic simulations and fully relaxed total energy calculations is used to predict that molecular CO2 should transform to nonmolecular carbonate phases based on CO4 tetrahedra at pressures in the range of 35 to 60 gigapascals. The simulation suggests a variety of competing phases, with a more facile transformation of the molecular phase at high temperatures. Thermodynamically, the most stable carbonate phase at high pressure is predicted to be isostructural to SiO2 alpha-quartz (low quartz). A class of carbonates, involving special arrangements of CO4 tetrahedra, is found to be more stable than all the other silica-like polymorphs.	Int Sch Adv Studies, I-34014 Trieste, Italy; Ist Nazl Fis Mat, I-34014 Trieste, Italy; Int Ctr Theoret Phys, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; Abdus Salam International Centre for Theoretical Physics (ICTP)	Chiarotti, GL (corresponding author), Int Sch Adv Studies, Via Beirut 4, I-34014 Trieste, Italy.		Chiarotti, Guido/A-9909-2012; Scandolo, Sandro/AAC-9081-2019	Scandolo, Sandro/0000-0003-3826-4813				AOKI K, 1994, SCIENCE, V263, P356, DOI 10.1126/science.263.5145.356; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Bernard S, 1998, PHYS REV LETT, V81, P2092, DOI 10.1103/PhysRevLett.81.2092; DOWS DA, 1973, J CHEM PHYS, V58, P5009, DOI 10.1063/1.1679088; ENGLISH CA, 1974, P ROY SOC LOND A MAT, V340, P57, DOI 10.1098/rspa.1974.0140; FOCHER P, 1994, EUROPHYS LETT, V26, P345, DOI 10.1209/0295-5075/26/5/005; Gygi F, 1998, COMP MATER SCI, V10, P63, DOI 10.1016/S0927-0256(97)00086-4; Iota V, 1999, SCIENCE, V283, P1510, DOI 10.1126/science.283.5407.1510; KLEINMAN L, 1982, PHYS REV LETT, V48, P1425, DOI 10.1103/PhysRevLett.48.1425; KUCHTA B, 1988, PHYS REV B, V38, P6265, DOI 10.1103/PhysRevB.38.6265; LIU LG, 1984, EARTH PLANET SC LETT, V71, P104, DOI 10.1016/0012-821X(84)90056-6; LU R, 1995, PHYS REV B, V52, P3985, DOI 10.1103/PhysRevB.52.3985; MILLER RC, 1964, APPL PHYS LETT, V5, P17, DOI 10.1063/1.1754022; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; OLIJNYK H, 1988, J CHEM PHYS, V88, P4204, DOI 10.1063/1.453828; Olijnyk H, 1998, PHYS REV B, V57, P879, DOI 10.1103/PhysRevB.57.879; SCANDOLO S, 1995, PHYS REV LETT, V74, P4015, DOI 10.1103/PhysRevLett.74.4015; Shen Y. R., 1984, PRINCIPLES NONLINEAR; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993	19	111	114	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					788	790		10.1126/science.284.5415.788	http://dx.doi.org/10.1126/science.284.5415.788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221907				2022-12-28	WOS:000080056200041
J	Kamura, T; Koepp, DM; Conrad, MN; Skowyra, D; Moreland, RJ; Iliopoulos, O; Lane, WS; Kaelin, WG; Elledge, SJ; Conaway, RC; Harper, JW; Conway, JW				Kamura, T; Koepp, DM; Conrad, MN; Skowyra, D; Moreland, RJ; Iliopoulos, O; Lane, WS; Kaelin, WG; Elledge, SJ; Conaway, RC; Harper, JW; Conway, JW			Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE EXIT; F-BOX; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENE; IDENTIFICATION; PATHWAY; CDC53; PROTEOLYSIS	The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in most human kidney cancers. The VHL protein is part of a complex that includes Elongin B, Elongin C, and Cullin-2, proteins associated with transcriptional elongation and ubiquitination. Here it is shown that the endogenous VHL complex in rat liver also includes Rbx1, an evolutionarily conserved protein that contains a RING-H2 fingerlike motif and that interacts with Cullins. The yeast homolog of Rbx1 is a subunit and potent activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cyclin-dependent kinase inhibitor Sic1 and for the G(1) to S cell cycle transition. These findings provide a further Link between VHL and the cellular ubiquitination machinery.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conway, JW (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.		高, 雨莉/HGU-8187-2022	Conaway, Joan/0000-0002-2786-0663; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11085] Funding Source: Medline; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	31	636	662	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					657	661		10.1126/science.284.5414.657	http://dx.doi.org/10.1126/science.284.5414.657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213691				2022-12-28	WOS:000079951100049
J	Yank, V; Rennie, D				Yank, V; Rennie, D			Disclosure of researcher contributions: A study of original research articles in The Lancet	ANNALS OF INTERNAL MEDICINE			English	Article							AUTHORSHIP; COIN	Background: Authorship disputes and abuses have increased in recent years. In response to a proposal that researcher contributions be specified for readers, The Lancet began disclosing such contributions at the end of original articles. Objective: To analyze the descriptions researchers use for their contributions and to determine how the order of names on the byline corresponds to these contributions, whether persons listed on the byline fulfill a lenient version of the criteria for authorship specified by the International Committee of Medical Journal Editors (the Vancouver Group), and whether the contributions of persons listed as contributors overlap with the contributions of those who are acknowledged. Design: Descriptive study. Measurements: A taxonomy of researchers' contributions was developed and applied to researchers' self-reported contributions to original research articles published in The Lancet from July to December 1997. Results: Contributors lists occupied little page space (mean, 2.5 cm of column length). Placement on the byline did not indicate the specific category of task performed, although the first contributor position corresponded to a significantly greater number of contributions (mean numbers of contributions: first-contributor position, 3.23; second-contributor position, 2.51; third-contributor position, 2.20; and fourth-contributor position, 2.51) (P < 0.01). Forty-four percent of contributors on the byline did not fulfill a lenient version of the Vancouver Group's criteria for authorship. Sixty percent of the most common categories of activities described on contributors lists overlapped with those on acknowledgments lists. Conclusions: Publication of lists that specify contributions to research articles is feasible and seems to impart important information. The criteria for authorship outlined by the Vancouver Group do not seem to be congruent with the self-identified contributions of researchers.	Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rennie, D (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Box 0936, San Francisco, CA 94143 USA.							Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; Davies D, 1996, CAN MED ASSOC J, V155, P877; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P300; Godlee F, 1996, BRIT MED J, V312, P1501, DOI 10.1136/bmj.312.7045.1501a; Hoen WP, 1998, JAMA-J AM MED ASSOC, V280, P217, DOI 10.1001/jama.280.3.217; Horton R, 1998, LANCET, V351, P688, DOI 10.1016/S0140-6736(98)22010-1; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEDERBERG J, 1993, SCIENTIST       0208, P10; Lundberg GD, 1996, JAMA-J AM MED ASSOC, V276, P75, DOI 10.1001/jama.276.1.75; MOULOPOULOS SD, 1983, BRIT MED J, V287, P1608, DOI 10.1136/bmj.287.6405.1608; Northridge M, 1998, AM J PUBLIC HEALTH, V88, P733, DOI 10.2105/AJPH.88.5.733; Proto AV, 1998, RADIOLOGY, V206, P1; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Rennie D, 1998, AM J PUBLIC HEALTH, V88, P828, DOI 10.2105/AJPH.88.5.828; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; TACKER M, 1998, CBE VIEWS, V21, P131; Wilcox LJ, 1998, JAMA-J AM MED ASSOC, V280, P216, DOI 10.1001/jama.280.3.216; Willner IR, 1998, ANN INTERN MED, V128, P111, DOI 10.7326/0003-4819-128-2-199801150-00006; 1998, AM J PUBLIC HLTH, V88, P721; 1985, BR MED J CLIN RES ED, V291, P722; 1993, JAMA, V269, P2282	23	120	130	1	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					661	670		10.7326/0003-4819-130-8-199904200-00013	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215563				2022-12-28	WOS:000079786600006
J	Sandeman, DR				Sandeman, DR			Will clinical governance make a difference?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1085	1085		10.1136/bmj.318.7190.1085	http://dx.doi.org/10.1136/bmj.318.7190.1085			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205134	Green Published			2022-12-28	WOS:000080140000082
J	Rohatgi, R; Ma, L; Miki, H; Lopez, M; Kirchhausen, T; Takenawa, T; Kirschner, MW				Rohatgi, R; Ma, L; Miki, H; Lopez, M; Kirchhausen, T; Takenawa, T; Kirschner, MW			The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly	CELL			English	Article							ALDRICH-SYNDROME PROTEIN; DEPOLYMERIZING PROTEIN; LISTERIA-MONOCYTOGENES; BINDING; RAC; CYTOSKELETON; MOTILITY; RHO; PHOSPHORYLATION; REORGANIZATION	Although small GTP-binding proteins of the Rho family have been implicated in signaling to the actin cytoskeleton, the exact nature of the linkage has remained obscure. We describe a novel mechanism that links one Rho family member, Cdc42, to actin polymerization. N-WASP, a ubiquitously expressed Cdc42-interacting protein, is required for Cdc42-stimulated actin polymerization in Xenopus egg extracts. The C terminus of N-WASP binds to the Arp2/3 complex and dramatically stimulates its ability to nucleate actin polymerization. Although full-length N-WASP is less effective, its activity can be greatly enhanced by Cdc42 and phosphatidylinositol (4,5) bisphosphate. Therefore, N-WASP and the Arp2/3 complex comprise a core mechanism that directly connects signal transduction pathways to the stimulation of actin polymerization.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 108, Japan	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Tokyo	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Ma, Le/A-3733-2013	Ma, Le/0000-0003-2769-9416	NHLBI NIH HHS [5PO1 HL 59561-02] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026875, R37GM026875] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALROW E, 1988, ANTIBODIES LAB MANUA, P283; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NOBES CD, 1995, J CELL SCI, V108, P225; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAN AL, 1997, GENE DEV, V11, P2295; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zigmond SH, 1998, CURR BIOL, V8, pR654, DOI 10.1016/S0960-9822(07)00415-0	37	1045	1057	0	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					221	231		10.1016/S0092-8674(00)80732-1	http://dx.doi.org/10.1016/S0092-8674(00)80732-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219243	Bronze			2022-12-28	WOS:000079779800011
J	Shou, WY; Seol, JH; Shevchenko, A; Baskerville, C; Moazed, D; Chen, ZWS; Jang, J; Shevchenko, A; Charbonneau, H; Deshaies, RJ				Shou, WY; Seol, JH; Shevchenko, A; Baskerville, C; Moazed, D; Chen, ZWS; Jang, J; Shevchenko, A; Charbonneau, H; Deshaies, RJ			Exit from mitosis is triggered by Tem1-dependent release of the protein phosphatase Cdc14 from nucleolar RENT complex	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MULTICOPY SUPPRESSOR; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; CDK-INHIBITOR; BUDDING YEAST; M-PHASE; KINASE; GENE	Exit from mitosis in budding yeast requires a group of essential proteins-including the GTPase Tem1 and the protein phosphatase Cdc14-that downregulate cyclin-dependent kinase activity. We identified a mutation, net1-1, that bypasses the lethality of tem 1 Delta. NEM encodes a novel protein, and mass spectrometric analysis reveals that it is a key component of a multifunctional complex, denoted RENT (for regulator of nucleolar silencing and telophase), that also contains Cdc14 and the silencing regulator Sir2. From G1 through anaphase, RENT localizes to the nucleolus, and Cdc14 activity is inhibited by Net1. In late anaphase, Cdc14 dissociates from RENT, disperses throughout the cell in a Tem1-dependent manner, and ultimately triggers mitotic exit. Nucleolar sequestration may be a general mechanism for the regulation of diverse biological processes.	CALTECH, Div Biol, Pasadena, CA 91125 USA; European Mol Biol Lab, Peptide & Prot Grp, D-69012 Heidelberg, Germany; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	California Institute of Technology; European Molecular Biology Laboratory (EMBL); Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Deshaies, RJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	deshaies@cco.caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354; Shou, Wenying/0000-0001-5693-381X	NATIONAL CANCER INSTITUTE [R29CA059935, R01CA059935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Harlow E., 1988, ANTIBODIES LAB MANUA; IMIGER S, 1995, CELL, V81, P269; INO H, 1993, BRAIN RES, V614, P131, DOI 10.1016/0006-8993(93)91026-O; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; PARKES V, 1992, NUCLEIC ACIDS RES, V20, P5617, DOI 10.1093/nar/20.21.5617; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; Shirayama M, 1996, MOL GEN GENET, V251, P176; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Toyn JH, 1997, GENETICS, V145, P85; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	54	595	606	1	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					233	244		10.1016/S0092-8674(00)80733-3	http://dx.doi.org/10.1016/S0092-8674(00)80733-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219244	Bronze			2022-12-28	WOS:000079779800012
J	Thorogood, M				Thorogood, M			Risk of stroke in users of oral contraceptives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Thorogood, M (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	m.thorogood@lshtm.ac.uk						Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1996, LANCET, V348, P498; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1255	1256		10.1001/jama.281.14.1255	http://dx.doi.org/10.1001/jama.281.14.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208126				2022-12-28	WOS:000079628700002
J	Andersson, R; Lambe, M; Bergstrom, R				Andersson, R; Lambe, M; Bergstrom, R			Fertility patterns after appendicectomy: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							SUSPECTED APPENDICITIS; TUBAL INFERTILITY; APPENDECTOMY; WOMEN; PERFORATION; LAPAROSCOPY; RISK; AGE	Objective To examine fertility patterns in women who had their appendix removed in childhood. Design Historical cohort study with computerised data and fertility data for this cohort and for an age matched cohort of women from the Swedish general population. The cohorts were followed to 1994, Setting General population. Participants 9840 women who were under 15 years when they underwent appendicectomy between 1964 and 1983; 47 590 control women, Main outcome measures Diagnoses at discharge. Distributions of age at birth of first child among women with perforated and non-perforated appendix and women who underwent appendicectomy but were found Co have a normal appendix compared with control women by using survival analysis methods. Parity distributions at the latest update of the registry were also examined, Results Women with a history of perforated appendix had a similar rate of first birth as the control women (adjusted hazard ratio 0.95; 95% confidence interval 0.88 to 1.04) and had a similar distribution of parity at the end of follow up. Women who had had a normal appendix removed had an increased rate of first births (1.48; 1.42 to 1.54) and on average had their first child at an earlier age and reached a higher parity than control women. Conclusion A history of perforated appendix in childhood does not seem to have long term negative consequences on female fertility. This may have important implications for the management of young women with suspected appendicitis as the liberal attitude to surgical explorations with a subsequently high rate of removal of a normal appendix is often justified by a perceived increased risk of infertility after perforation. Women whose appendix was found to be normal at appendicectomy in childhood seem to belong to a subgroup with a higher fertility than the general population.	Univ Hosp, Div Surg, Linkoping, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Uppsala Univ, Dept Stat, Uppsala, Sweden	Karolinska Institutet; Uppsala University	Andersson, R (corresponding author), Ryhov Hosp, Dept Surg, S-55185 Jonkoping, Sweden.			Lambe, Mats/0000-0002-4624-3767				ANDERSSON R, 1994, BRIT MED J, V308, P107, DOI 10.1136/bmj.308.6921.107; ANDERSSON RE, 1992, EUR J SURG, V158, P37; BULL P, 1932, ACTA CHIR SCAND, V71, P155; CANTON G, 1984, GEN HOSP PSYCHIAT, V6, P191, DOI 10.1016/0163-8343(84)90039-2; Geerdsen J P, 1988, Nord Med, V103, P62; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; JADALLAH FA, 1994, EUR J SURG, V160, P41; JOYCE PR, 1981, AUST NZ J SURG, V51, P465, DOI 10.1111/j.1445-2197.1981.tb05987.x; KALLEN B, 1988, EPIDEMIOLOGY HUMAN R, P107; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; LALOS O, 1988, EUR J OBSTET GYN R B, V29, P129, DOI 10.1016/0028-2243(88)90139-6; MALT RA, 1986, NEW ENGL J MED, V315, P1546, DOI 10.1056/NEJM198612113152409; MUELLER BA, 1986, NEW ENGL J MED, V315, P1506, DOI 10.1056/NEJM198612113152402; PURI P, 1989, J PEDIATR SURG, V24, P547, DOI 10.1016/S0022-3468(89)80503-2; RAAF LE, 1969, ACTA CHIR SCAND, V135, P67; SPIRTOS NM, 1987, AM J OBSTET GYNECOL, V156, P90, DOI 10.1016/0002-9378(87)90212-2; THOMPSON WM, 1971, J PEDIATR SURG, V6, P458, DOI 10.1016/S0022-3468(71)80008-8; TRIMBOSKEMPER T, 1982, FERTIL STERIL, V37, P384; VASSILAS CA, 1988, BRIT J PSYCHIAT, V152, P706, DOI 10.1192/bjp.152.5.706; WIIG JN, 1979, ACTA CHIR SCAND, V145, P409	20	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					963	967		10.1136/bmj.318.7189.963	http://dx.doi.org/10.1136/bmj.318.7189.963			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195964	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000079751500016
J	Harte, J; Kinzig, A; Green, J				Harte, J; Kinzig, A; Green, J			Self-similarity in the distribution and abundance of species	SCIENCE			English	Article							PATTERNS; AREA	If the fraction of species in area A that are also found in one-half of that area is independent of A, the distribution of species is self-similar and a number of observed patterns in ecology, including the widely cited species-area relationship connecting species richness to censused area, follow. Self-similarity also leads to a species-abundance distribution, which deviates considerably from the commonly assumed Lognormal distribution and predicts considerably more rare species than the latter. Because the abundance distribution is derived under the condition of self-similarity, it:may be widely applicable beyond ecology.	Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Nucl Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Harte, J (corresponding author), Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA.	jharte@socrates.berkeley.edu	Green, Jessica/C-4828-2009					Arrhenius O, 1921, J ECOL, V9, P95, DOI 10.2307/2255763; Blackburn TM, 1998, AM NAT, V151, P68, DOI 10.1086/286103; Bramwell ST, 1998, NATURE, V396, P552, DOI 10.1038/25083; Cody Martin L., 1993, P147; Condit R, 1996, J ECOL, V84, P549, DOI 10.2307/2261477; Gaston K.J., 1994, RARITY, P1; HANSKI I, 1982, OIKOS, V38, P210, DOI 10.2307/3544021; HANSKI I, 1993, HIST GEOGRPAHICAL DE; Harte J, 1997, OIKOS, V80, P417, DOI 10.2307/3546614; HARTE J, IN PRESS OIKOS; Hubbell SP, 1986, CONSERVATION BIOL SC, P205; KEMPTON RA, 1974, J ANIM ECOL, V43, P381, DOI 10.2307/3371; Kunin WE, 1998, SCIENCE, V281, P1513, DOI 10.1126/science.281.5382.1513; Kunin WE, 1997, BIOL CONSERV, V82, P369, DOI 10.1016/S0006-3207(97)00042-6; Leitner WA, 1997, OIKOS, V79, P503, DOI 10.2307/3546894; MANDELBROT B, 1971, LECT NOTE PHYS, V12, P333; Mandlebrot B., 1983, FRACTAL GEOMETRY NAT; May R.M., 1975, P81; NEE S, 1991, P ROY SOC B-BIOL SCI, V243, P161, DOI 10.1098/rspb.1991.0026; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; STINE B, 1997, BRIT BIRDS, V90, P1; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669	24	267	295	3	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					334	336		10.1126/science.284.5412.334	http://dx.doi.org/10.1126/science.284.5412.334			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195901				2022-12-28	WOS:000079636400047
J	Lin, Y; Sun, L; Nguyen, LV; Rachubinski, RA; Goodman, HM				Lin, Y; Sun, L; Nguyen, LV; Rachubinski, RA; Goodman, HM			The pex16p homolog SSE1 and storage organelle formation in Arabidopsis seeds	SCIENCE			English	Article							YEAST YARROWIA-LIPOLYTICA; PEROXISOME BIOGENESIS; THALIANA; PROTEIN; MUTANTS; PLANTS; BODIES	Mature Arabidopsis seeds are enriched in storage proteins and lipids, but lack starch. In the shrunken seed 1 (sse1) mutant, however, starch is favored over proteins and lipids as the major storage compound. SSE1 has 26 percent identity with Pex16p in Yarrowia lipolytica and complements pex16 mutants defective in the formation of peroxisomes and the transportation of plasma membrane- and cell wall-associated proteins, In Arabidopsis maturing seeds, SSE1 is required for protein and oil body biogenesis, both of which are endoplasmic reticulum-dependent. Starch accumulation in sse1 suggests that starch formation is a default storage deposition pathway.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Univ Alberta, Dept Anat & Cell Biol, Edmonton, AB T6G 2H7, Canada	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Alberta	Lin, Y (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEWLEY DJ, 1994, SEEDS PHYSL DEV GERM, pCH1; Chen ZJ, 1998, AM J BOT, V85, P492, DOI 10.2307/2446432; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MANSFIELD SG, 1992, CAN J BOT, V70, P151, DOI 10.1139/b92-021; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; MINET M, 1992, PLANT J, V2, P417; Miquel M., 1995, SEED DEV GERMINATION, P169; OLSEN LJ, 1995, ANNU REV PLANT PHYS, V46, P123, DOI 10.1146/annurev.pp.46.060195.001011; Sarmiento C, 1997, PLANT J, V11, P783, DOI 10.1046/j.1365-313X.1997.11040783.x; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Vitale A., 1995, SEED DEV GERMINATION, P73	17	86	108	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					328	330		10.1126/science.284.5412.328	http://dx.doi.org/10.1126/science.284.5412.328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195899				2022-12-28	WOS:000079636400045
J	Struhl, G; Greenwald, I				Struhl, G; Greenwald, I			Presenilin is required for activity and nuclear access of Notch in Drosophila	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; IN-VIVO; RECEPTOR; LIN-12; GENE; EXPRESSION; CLEAVAGE; HOMOLOG	Presenilins are membrane proteins with multiple transmembrane domains that are thought to contribute to the development of Alzheimer's disease by affecting the processing of P-amyloid precursor protein(1). Presenilins also facilitate the activity of transmembrane receptors of the LIN-12/Notch family(2-5). After ligand-induced processing, the intracellular domain of LIN-12/Notch can enter the nucleus and participate in the transcriptional control of downstream target genes(6-9). Here we show that null mutations in the Drosophila Presenilin gene abolish Notch signal transduction and prevent its intracellular domain from entering the nucleus. Furthermore, we provide evidence that presenilin is required for the proteolytic release of the intracellular domain from the membrane following activation of Notch by ligand.	Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.	struhl@cuccfa.ccc.columbia; greenwald@cuccfa.ccc.columbia.edu						BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; CHOU TB, 1992, GENETICS, V131, P643; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Hong CS, 1997, NEUROREPORT, V8, P665, DOI 10.1097/00001756-199702100-00017; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; LI XQ, 1994, PHYS PLASMAS, V1, P3008, DOI 10.1063/1.870541; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marfany G, 1998, J NEUROGENET, V12, P41, DOI 10.3109/01677069809108554; MENNE TV, 1994, DEVELOPMENT, V120, P123; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5	28	690	723	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					522	525		10.1038/19091	http://dx.doi.org/10.1038/19091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206646				2022-12-28	WOS:000079662800050
J	Ye, YH; Lukinova, N; Fortini, ME				Ye, YH; Lukinova, N; Fortini, ME			Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants	NATURE			English	Article							CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; VESTIGIAL GENE; WING FORMATION; IN-VIVO; EXPRESSION; RECEPTOR; PROTEIN; SIGNAL; DELTA	Presenilin proteins have been implicated both in developmental signalling by the cell-surface protein Notch and in the pathogenesis of Alzheimer's disease. Loss of presenilin function leads to Notch/lin-12-like mutant phenotypes in Caenorhabditis elegans(1,2) and to reduced Notch1 expression in the mouse paraxial mesoderm(3). In humans, presenilins that are associated with Alzheimer's disease stimulate overproduction of the neurotoxic 42-amino-acid beta-amyloid derivative (A beta 42) of the amyloid-precursor protein APP(4). Here we describe loss-of-function mutations in the Drosophila Presenilin gene that cause lethal Notch-like phenotypes such as maternal neurogenic effects during embryogenesis, loss of lateral inhibition within proneural cell dusters, and absence of wing margin formation. We show that presenilin is required for the normal proteolytic production of carboxy-terminal Notch fragments that are needed for receptor maturation and signalling, and that genetically it acts upstream of both the membrane-bound form and the activated nuclear form of Notch. Our findings provide evidence for the existence of distinct processing sites or modifications in the extracellular domain of Notch. They also link the role of presenilin in Notch signalling to its effect on amyloid production in Alzheimer's disease.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Fortini, ME (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	fortini@mail.med.upenn.edu						Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOOH PJ, 1993, DEVELOPMENT, V117, P493; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1994, DEVELOPMENT, V120, P1433; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	30	444	469	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					525	529		10.1038/19096	http://dx.doi.org/10.1038/19096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206647				2022-12-28	WOS:000079662800051
J	Nightingale, SL				Nightingale, SL			New information for physicians regarding mammography results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-28	WOS:000079464400008
J	Katan, MB				Katan, MB			Are there good and bad carbohydrates for HDL cholesterol?	LANCET			English	Editorial Material							GLYCEMIC INDEX		Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands; Agr Univ Wageningen, Div Human Nutr & Epidemiol, NL-6703 HD Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Katan, MB (corresponding author), Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands.							FOSTERPOWELL K, 1995, AM J CLIN NUTR, V62, p871S, DOI 10.1093/ajcn/62.4.871S; Katan MB, 1997, NEW ENGL J MED, V337, P563; LEWIS B, 1981, LANCET, V2, P1310; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; Wolever TMS, 1997, DIABETES CARE, V20, P452, DOI 10.2337/diacare.20.3.452	5	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1029	1030		10.1016/S0140-6736(98)00405-X	http://dx.doi.org/10.1016/S0140-6736(98)00405-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199344				2022-12-28	WOS:000079614000003
J	Sanchez, LM; Chirino, AJ; Bjorkman, PJ				Sanchez, LM; Chirino, AJ; Bjorkman, PJ			Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules	SCIENCE			English	Article							T-CELL RECEPTOR; 3-DIMENSIONAL STRUCTURE; EXPRESSION ANALYSIS; FC RECEPTOR; MOUSE CD1; COMPLEX; PEPTIDE; ZN-ALPHA(2)-GLYCOPROTEIN; ANTIGENS; PROTEIN	Zn-alpha(2)-glycoprotein (ZAC) is a soluble protein that is present in serum and other body fluids. ZAG stimulates lipid degradation in adipocytes and causes the extensive fat tosses associated with some advanced cancers. The 2.8 angstrom crystal structure of ZAC resembles a class I major histocompatibility complex (MHC) heavy chain, but ZAG does not bind the class I light chain beta(2)-microglobutin. The ZAG structure includes a large groove analogous to class I MHC peptide binding grooves. Instead of a peptide, the ZAG groove contains a nonpeptidic compound that may be implicated in lipid catabolism under normal or pathological conditions.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Bjorkman, PJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUERGI W, 1961, J BIOL CHEM, V236, P1066; BUNDRED NJ, 1987, HISTOPATHOLOGY, V11, P603, DOI 10.1111/j.1365-2559.1987.tb02670.x; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FREIJE JP, 1991, FEBS LETT, V290, P247, DOI 10.1016/0014-5793(91)81271-9; FUEYO A, 1994, GENE, V145, P245, DOI 10.1016/0378-1119(94)90014-0; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Hirai K, 1998, CANCER RES, V58, P2359; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Li P, COMMUNICATION; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Ogikubo O, 1998, BIOCHEM BIOPH RES CO, V252, P257, DOI 10.1006/bbrc.1998.9614; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfaff M., 1997, INTEGRIN LIGAND INTE, P101, DOI [10.1007/978-1-4757-4064-6_4, DOI 10.1007/978-1-4757-4064-6_4]; Plaksin D, 1997, J IMMUNOL, V159, P4408; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANCHEZ LM, 1992, CANCER RES, V52, P95; Sanchez LM, 1997, P NATL ACAD SCI USA, V94, P4626, DOI 10.1073/pnas.94.9.4626; SANCHEZ LM, UNPUB; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHIBATA S, 1982, NEPHRON, V31, P170, DOI 10.1159/000182638; Simister NE, 1997, BIOCHEM SOC T, V25, P481, DOI 10.1042/bst0250481; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; TAKAGAKI M, 1994, BIOCHEM BIOPH RES CO, V201, P1339, DOI 10.1006/bbrc.1994.1851; Todorov PT, 1998, CANCER RES, V58, P2353; TYSOECALNON VA, 1991, BIOCHEM J, V277, P359, DOI 10.1042/bj2770359; UEYAMA H, 1994, J BIOCHEM, V116, P677, DOI 10.1093/oxfordjournals.jbchem.a124579; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	60	109	114	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1999	283	5409					1914	1919		10.1126/science.283.5409.1914	http://dx.doi.org/10.1126/science.283.5409.1914			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206894				2022-12-28	WOS:000079228600048
J	Dobson, R				Dobson, R			Welsh Assembly candidates target inequalities in health	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1167	1167						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221936				2022-12-28	WOS:000080277900019
J	Connerney, JEP; Acuna, MH; Wasilewski, PJ; Ness, NF; Reme, H; Mazelle, C; Vignes, D; Lin, RP; Mitchell, DL; Cloutier, PA				Connerney, JEP; Acuna, MH; Wasilewski, PJ; Ness, NF; Reme, H; Mazelle, C; Vignes, D; Lin, RP; Mitchell, DL; Cloutier, PA			Magnetic lineations in the ancient crust of Mars	SCIENCE			English	Article							GLOBAL SURVEYOR MISSION; ANOMALY MAP; MAGSAT; FIELD	The Mars Global Surveyor spacecraft, in a highly elliptical polar orbit, obtained vector magnetic field measurements above the surface of Mars (altitudes >100 kilometers). Crustal magnetization, mainly confined to the most ancient, heavily cratered martian highlands, is frequently organized in east-west-trending linear features, the Longest extending over 2000 kilometers. Crustal remanent magnetization exceeds that of terrestrial crust by more than an order of magnitude. Groups of quasi-parallel linear features of alternating magnetic polarity were found. They are reminiscent of similar magnetic features associated with sea floor spreading and crustal genesis on Earth but with a much Larger spatial scale. They may be a relic of an era of plate tectonics on Mars.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Delaware, Bartol Res Inst, Newark, DE 19716 USA; Ctr Etud Spatiale Rayonnements, F-31028 Toulouse, France; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Rice Univ, Dept Space Phys & Astron, Houston, TX 77005 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Delaware; University of California System; University of California Berkeley; Rice University	Connerney, JEP (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		connerney, john/I-5127-2013	connerney, jack/0000-0001-7478-6462				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; ACUNA MH, 1992, J GEOPHYS RES-PLANET, V97, P7799, DOI 10.1029/92JE00344; Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BANERDT WB, 1992, MARS, P249; Blakely R. J., 1995, POTENTIAL THEORY GRA; CLARK DA, 1983, B AUST SOC EXPLOR GE, V14, P49, DOI DOI 10.1071/EG983049; CONNERNEY JEP, 1981, J GEOPHYS RES-SPACE, V86, P7679, DOI 10.1029/JA086iA09p07679; LANE MD, 1999, LUNAR PLANET SCI C, V30; LANGEL RA, 1982, GEOPHYS RES LETT, V9, P273, DOI 10.1029/GL009i004p00273; LANGEL RA, 1982, GEOPHYS RES LETT, V9, P269, DOI 10.1029/GL009i004p00269; MAYHEW MA, 1982, GEOPHYS RES LETT, V9, P311, DOI 10.1029/GL009i004p00311; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MERRILL RT, 1983, EARTHS MAGNETIC FIEL, P140; PEPIN RO, 1992, MARS, P120; PITMAN WC, 1966, SCIENCE, V154, P1164, DOI 10.1126/science.154.3753.1164; RAVAT DN, 1993, TECTONOPHYSICS, V220, P157, DOI 10.1016/0040-1951(93)90229-D; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; SCHUBERT G, 1997, ENCY PLANETARY SCI, P416; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; TALWANI M, 1965, GEOPHYSICS, V30, P797, DOI 10.1190/1.1439654; Tsvetkov YP, 1997, J GEOMAGN GEOELECTR, V49, P689, DOI 10.5636/jgg.49.689; VINE FJ, 1965, SCIENCE, V150, P485, DOI 10.1126/science.150.3695.485; VINE FJ, 1963, NATURE, V199, P4897; WILSON JT, 1965, NATURE, V207, P343, DOI 10.1038/207343a0	26	358	365	3	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					794	798		10.1126/science.284.5415.794	http://dx.doi.org/10.1126/science.284.5415.794			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221909	Green Submitted			2022-12-28	WOS:000080056200043
J	Johnson, PTJ; Lunde, KB; Ritchie, EG; Launer, AE				Johnson, PTJ; Lunde, KB; Ritchie, EG; Launer, AE			The effect of trematode infection on amphibian limb development and survivorship	SCIENCE			English	Article							DEFORMITIES; BEHAVIOR	The causes of amphibian deformities and their role in widespread amphibian declines remain conjectural. Severe Limb abnormalities were induced at high frequencies in Pacific treefrogs (Hyla regilla) exposed to cercariae of a trematode parasite (Ribeiroia sp.). The abnormalities closely matched those observed at field sites, and an increase in parasite density caused an increase in abnormality frequency and a decline in tadpole survivorship. These findings call for further investigation of parasite infection as a cause of amphibian deformities in other sites and species.	Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA; James Cook Univ N Queensland, Dept Zool & Trop Ecol, Townsville, Qld 4811, Australia	Stanford University; James Cook University	Johnson, PTJ (corresponding author), Claremont McKenna Coll, WM Keck Sci Ctr, Roberts Environm Ctr, 925 N Mills Rd, Claremont, CA 91711 USA.		Ritchie, Euan/N-1088-2014; Lunde, Kevin/D-4202-2009	Ritchie, Euan/0000-0003-4410-8868; JOHNSON, PIETER/0000-0002-7997-5390				Bakker TCM, 1997, ECOLOGY, V78, P1098, DOI 10.1890/0012-9658(1997)078[1098:PICIBA]2.0.CO;2; Blaustein AR, 1997, P NATL ACAD SCI USA, V94, P13735, DOI 10.1073/pnas.94.25.13735; Gosner K. L., 1960, Herpetologica, V16, P183; HELGEN JC, 1998, STATUS CONSERVATION, pCH29; HELLUY S, 1990, CAN J ZOOL, V68, P1214, DOI 10.1139/z90-181; Kaiser J, 1997, SCIENCE, V278, P2051, DOI 10.1126/science.278.5346.2051; KUPFERBERG SJ, COMMUNICATION; La Clair JJ, 1998, ENVIRON SCI TECHNOL, V32, P1453, DOI 10.1021/es971024h; MUELLER JF, 1970, J PARASITOL, V56, P840, DOI 10.2307/3277738; Northcote Thomas G., 1992, Monographiae Biologicae, V68, P551; Ouellet M, 1997, J WILDLIFE DIS, V33, P95, DOI 10.7589/0090-3558-33.1.95; Schmidt CW, 1997, ENVIRON SCI TECHNOL, V31, pA324, DOI 10.1021/es9723693; SESSIONS SK, 1990, J EXP ZOOL, V254, P38, DOI 10.1002/jez.1402540107; Sessions SK, 1999, SCIENCE, V284, P800, DOI 10.1126/science.284.5415.800; Stauffer JR, 1997, BIOSCIENCE, V47, P41, DOI 10.2307/1313005; TIETGE JE, 1997, DISCUSSION FINDINGS; TYLER MJ, 1998, AUSTR FROGS NATURAL, P141; Wake DB, 1998, TRENDS ECOL EVOL, V13, P379, DOI 10.1016/S0169-5347(98)01428-1	18	271	291	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					802	804		10.1126/science.284.5415.802	http://dx.doi.org/10.1126/science.284.5415.802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221912				2022-12-28	WOS:000080056200046
J	Gott, VL; Greene, PS; Alejo, DE; Cameron, DE; Naftel, DC; Miller, DC; Gillinov, AM; Laschinger, JC; Pyeritz, RE				Gott, VL; Greene, PS; Alejo, DE; Cameron, DE; Naftel, DC; Miller, DC; Gillinov, AM; Laschinger, JC; Pyeritz, RE			Replacement of the aortic root in patients with Marfan's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASCENDING AORTA; ANEURYSMS; OPERATION; GENE	Background Replacement of the aortic root with a prosthetic graft and valve in patients with Marfan's syndrome may prevent premature death from rupture of an aneurysm or aortic dissection. We reviewed the results of this surgical procedure at 10 experienced surgical centers. Methods A total of 675 patients with Marfan's syndrome underwent replacement of the aortic root. Survival and morbidity-free survival curves were calculated, and risk factors were determined from a multivariable regression analysis. Results The 30-day mortality rate was 1.5 percent among the 455 patients who underwent elective repair, 2.6 percent among the 117 patients who underwent urgent repair (within 7 days after a surgical consultation), and 11.7 percent among the 103 patients who underwent emergency repair (within 24 hours after a surgical consultation). Of the 675 patients, 202 (30 percent) had aortic dissection involving the ascending aorta. Forty-six percent of the 158 adult patients with aortic dissection and a documented aortic diameter had an aneurysm with a diameter of 6.5 cm or less. There were 114 late deaths (more than 30 days after surgery); dissection or rupture of the residual aorta (22 patients) and arrhythmia (21 patients) were the principal causes of late death. The risk of death was greatest within the first 60 days after surgery, then rapidly decreased to a constant level by the end of the first year. Conclusions Elective aortic-root replacement has a low operative mortality. In contrast, emergency repair, usually for acute aortic dissection, is associated with a much higher early mortality. Because nearly half the adult patients with aortic dissection had an aortic-root diameter of 6.5 cm or less at the time of operation, it may be prudent to undertake prophylactic repair of aortic aneurysms in patients with Marfan's syndrome when the diameter of the aorta is well below that size. (N Engl J Med 1999;340:1307-13.) (C)1999, Massachusetts Medical Society.	Johns Hopkins Hosp, Div Cardiac Surg, Baltimore, MD 21287 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Stanford Univ, Med Ctr, Dept Cardiothorac Surg, Stanford, CA 94305 USA; St Joseph Hosp, Div Cardiac Surg, Baltimore, MD USA; Allegheny Univ Hlth Sci, Dept Human Genet, Pittsburgh, PA USA	Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham; Stanford University	Gott, VL (corresponding author), Johns Hopkins Hosp, Div Cardiac Surg, 618 Blalock Bldg, Baltimore, MD 21287 USA.		Pyeritz, Reed/A-1364-2010; Alejo, Diane/GPX-8603-2022	Alejo, Diane/0000-0003-2751-9577; Greene, Peter/0000-0002-2524-0217; Miller, D. Craig/0000-0001-7619-0080	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baer RW, 1943, B JOHNS HOPKINS HOSP, V72, P309; BENTALL H, 1968, THORAX, V23, P338, DOI 10.1136/thx.23.4.338; BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989; Coady MA, 1997, J THORAC CARDIOV SUR, V113, P476, DOI 10.1016/S0022-5223(97)70360-X; DAVID TE, 1995, EUR J CARDIO-THORAC, V9, P175, DOI 10.1016/S1010-7940(05)80141-1; DAVID TE, 1992, J THORAC CARDIOV SUR, V103, P617; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Fleischer KJ, 1997, ANN THORAC SURG, V63, P1012, DOI 10.1016/S0003-4975(97)00061-1; GOTT VL, 1992, CHEST SURG CLIN N AM, V2, P425; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; Marfan AB, 1896, B MEM SOC MED HOP P, V13, P220; MCKUSICK VA, 1955, CIRCULATION, V11, P321, DOI 10.1161/01.CIR.11.3.321; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; PEREIRA L, 1994, NEW ENGL J MED, V331, P148, DOI 10.1056/NEJM199407213310302; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; PYERITZ RE, 1997, EMERY RIMOINS PRINCI, V1, P1027; SARSAM MAI, 1993, J THORAC CARDIOV SUR, V105, P435; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; Yacoub MH, 1998, J THORAC CARDIOV SUR, V115, P1080, DOI 10.1016/S0022-5223(98)70408-8	21	411	435	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1307	1313		10.1056/NEJM199904293401702	http://dx.doi.org/10.1056/NEJM199904293401702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219065				2022-12-28	WOS:000080001700002
J	Manian, FA				Manian, FA			Whither continuity of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	29	29	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1362	1363		10.1056/NEJM199904293401712	http://dx.doi.org/10.1056/NEJM199904293401712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219075				2022-12-28	WOS:000080001700012
J	Beecham, L				Beecham, L			BMA receives assurances on Health Bill	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1149	1149						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213758				2022-12-28	WOS:000080166000089
J	Marzoli, A; Renne, PR; Piccirillo, EM; Ernesto, M; Bellieni, G; De Min, A				Marzoli, A; Renne, PR; Piccirillo, EM; Ernesto, M; Bellieni, G; De Min, A			Extensive 200-million-year-old continental flood basalts of the Central Atlantic Magmatic Province	SCIENCE			English	Article							PASSIVE MARGINS; UNITED-STATES; NORTH-AMERICA; AGE; BASIN; PLUME; THOLEIITES; EXTINCTION; EVOLUTION; BRAZIL	The Central Atlantic Magmatic Province (CAMP) is defined by tholeiitic basalts that crop out in once-contiguous parts of North America, Europe, Africa, and South America and is associated with the breakup of Pangea. 40Ar/39Ar and paleomagnetic data indicate that CAMP magmatism extended over an area of 2.5 million square kilometers in north and central Brazil, and the total aerial extent of the magmatism exceeded 7 million square kilometers in a few million years, with peak activity at 200 million years ago. The magmatism coincided closely in time with a major mass extinction at the Triassic-Jurassic boundary.	Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Trieste, Dipartimento Sci Terra, I-34127 Trieste, Italy; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Sao Paulo, Inst Astron & Geofis, BR-01550890 Sao Paulo, Brazil; Univ Padua, Dipartimento Mineral & Petrol, I-35100 Padua, Italy	Berkeley Geochronolgy Center; University of Trieste; University of California System; University of California Berkeley; Universidade de Sao Paulo; University of Padua	Renne, PR (corresponding author), Berkeley Geochronol Ctr, 2455 Ridge Rd, Berkeley, CA 94709 USA.	prenne@bgc.org	Marzoli, Andrea/W-9406-2019; Ernesto, Marcia/C-4330-2012	Marzoli, Andrea/0000-0003-0093-2759; Ernesto, Marcia/0000-0002-7778-9551; Renne, Paul/0000-0003-1769-5235; De Min, Angelo/0000-0002-2820-3497				*3M CO, 1979, J CHEM SOC; ALIBERT C, 1985, EARTH PLANET SC LETT, V73, P81, DOI 10.1016/0012-821X(85)90036-6; Almeida F.F.M., 1986, REV BRAS GEOCIENCIAS, V16, P325; Baksi AK, 1997, EARTH PLANET SC LETT, V151, P139, DOI 10.1016/S0012-821X(97)81844-4; BELLIENI G, 1990, NEUES JB MINER ABH, V162, P1; CAMPBELL IH, 1990, EARTH PLANET SC LETT, V99, P79, DOI 10.1016/0012-821X(90)90072-6; Courtillot V., 1996, Geological Society of America Special Paper, V307, P513; Cox K. G., 1988, CONTINENTAL FLOOD BA, P239, DOI DOI 10.1007/978-94-015-7805-9_7; Deckart K, 1997, EARTH PLANET SC LETT, V150, P205, DOI 10.1016/S0012-821X(97)00102-7; Duncan RA, 1997, J GEOPHYS RES-SOL EA, V102, P18127, DOI 10.1029/97JB00972; DUNNING GR, 1990, GEOLOGY, V18, P795, DOI 10.1130/0091-7613(1990)018<0795:UPZABA>2.3.CO;2; DUPUY C, 1988, EARTH PLANET SC LETT, V87, P100, DOI 10.1016/0012-821X(88)90067-2; ERNESTO M, 1995, INT UN GEOD GEOPH M; FIECHTNER L, 1992, GEOL RUNDSCH, V81, P45, DOI 10.1007/BF01764538; FOWELL SJ, 1995, REV PALAEOBOT PALYNO, V86, P211, DOI 10.1016/0034-6667(94)00147-C; GUERREIRO SDC, 1986, MUNCHNER GEOPHYS MIT, V1, P37; HART S, 1989, MANTLE CONVECTION, P261; HEIMANN A, 1994, EARTH PLANET SC LETT, V121, P19, DOI 10.1016/0012-821X(94)90029-9; HODYCH JP, 1992, GEOLOGY, V20, P51, DOI 10.1130/0091-7613(1992)020<0051:DTMITE>2.3.CO;2; HOLBROOK WS, 1993, NATURE, V364, P433, DOI 10.1038/364433a0; IRVING E, 1982, GEOPHYS SURV, V5, P141, DOI 10.1007/BF01453983; KENT DV, 1995, J GEOPHYS RES-SOL EA, V100, P14965, DOI 10.1029/95JB01054; Leitch AM, 1998, EARTH PLANET SC LETT, V161, P161, DOI 10.1016/S0012-821X(98)00147-2; MAY PR, 1971, GEOL SOC AM BULL, V82, P1285, DOI 10.1130/0016-7606(1971)82[1285:POTDDA]2.0.CO;2; McHone JG, 1996, GEOLOGY, V24, P319; MONTESLAUAR CR, 1994, EARTH PLANET SC LETT, V128, P357, DOI 10.1016/0012-821X(94)90156-2; OLSEN PE, 1987, SCIENCE, V237, P1025, DOI 10.1126/science.3616622; PEGRAM WJ, 1990, EARTH PLANET SC LETT, V97, P316, DOI 10.1016/0012-821X(90)90049-4; Piccirillo E.M., 1988, MESOZOIC FLOOD VOLCA; RABINOWITZ PD, 1979, J GEOPHYS RES, V84, P5973, DOI 10.1029/JB084iB11p05973; RAPALINI AE, 1993, TECTONOPHYSICS, V220, P127, DOI 10.1016/0040-1951(93)90227-B; RAUP DM, 1986, SCIENCE, V231, P833, DOI 10.1126/science.11542060; REIM J, 1979, Patent No. 4224516; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; Renne PR, 1996, EARTH PLANET SC LETT, V144, P199, DOI 10.1016/0012-821X(96)00155-0; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103; SCHOTT JJ, 1981, EARTH PLANET SC LETT, V53, P457, DOI 10.1016/0012-821X(81)90050-9; SUTTER JF, 1988, US GEOLOGICAL SURVEY, V1776, P194; Wilson M, 1997, J GEOL SOC LONDON, V154, P491, DOI 10.1144/gsjgs.154.3.0491; Withjack MO, 1998, AAPG BULL, V82, P817; WITTE WK, 1991, GEOL SOC AM BULL, V103, P1648, DOI 10.1130/0016-7606(1991)103<1648:MAPPFL>2.3.CO;2; Yang ZY, 1996, J GEOPHYS RES-SOL EA, V101, P8025, DOI 10.1029/95JB03717	43	601	608	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	1999	284	5414					616	618		10.1126/science.284.5414.616	http://dx.doi.org/10.1126/science.284.5414.616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213679				2022-12-28	WOS:000079951100037
J	Aylin, P; Bunting, J; De Stavola, B; Coleman, MP				Aylin, P; Bunting, J; De Stavola, B; Coleman, MP			Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Imperial Coll Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Off Natl Stat, Hlth & Demog, London SW1V 2QQ, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Aylin, P (corresponding author), St Marys Hosp, Imperial Coll Med, Dept Epidemiol & Publ Hlth, Praed St, London W2 1PG, England.		Aylin, Paul/A-1073-2014; Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807; De Stavola, Bianca Lucia/0000-0001-7853-0528; Aylin, Paul/0000-0003-4589-1743				BRESLOW NE, 1987, IARC SCI PUBL, V82, P168; *NAT CJD SURV UN, 1997, 6 NCJDSU; ROBERTS GW, 1995, BRIT MED J, V311, P1419, DOI 10.1136/bmj.311.7017.1419a; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134	4	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1044	1045		10.1136/bmj.318.7190.1044	http://dx.doi.org/10.1136/bmj.318.7190.1044			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205102	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080140000028
J	Laroia, G; Cuesta, R; Brewer, G; Schneider, RJ				Laroia, G; Cuesta, R; Brewer, G; Schneider, RJ			Control of mRNA decay by heat shock ubiquitin proteasome pathway	SCIENCE			English	Article							MESSENGER-RNA DEGRADATION; CYCLE MUTANT TS85; PROTEIN-DEGRADATION; BINDING PROTEIN; RICH ELEMENT; C-FOS; TRANSLATION; STABILITY; REGION	Cytokine and proto-oncogene messenger RNAs (mRNAs) are rapidly degraded through AU-rich elements in the 3' untranslated region. Rapid decay involves AU-rich binding protein AUF1, which complexes with heat shock proteins hsc70-hsp70, translation initiation factor elF4G, and poly(A) binding protein. AU-rich mRNA decay is associated with displacement of elF4G from AUF1, ubiquitination of AUF1, and 'degradation of AUF1 by proteasomes. Induction of hsp70 by heat shock, down-regulation of the ubiquitin-proteasome network, or inactivation of ubiquitinating enzyme E1 all result in hsp70 sequestration of AUF1 in the perinucleus-nucleus, and all three processes block decay of AU-rich mRNAs and AUF1 protein. These results link the rapid degradation of cytokine mRNAs to the ubiquitin-proteasome pathway.	NYU, Sch Med, Dept Microbiol & Biochem, New York, NY 10016 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	New York University; Wake Forest University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol & Biochem, New York, NY 10016 USA.	schner01@mcrcr6.med.nyu.edu			NCI NIH HHS [CA52443, CA42357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042357, R01CA052443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Bush KT, 1997, J BIOL CHEM, V272, P9086; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAROIA G, UNPUB; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	26	343	349	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					499	502		10.1126/science.284.5413.499	http://dx.doi.org/10.1126/science.284.5413.499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205060				2022-12-28	WOS:000079792200051
J	Smylie, DE				Smylie, DE			Viscosity near Earth's solid inner core	SCIENCE			English	Article							TRANSLATIONAL OSCILLATIONS; DYNAMICS	Anomalous splitting of the two equatorial translational modes of oscillation of Earth's solid inner core is used to estimate the effective viscosity just outside its boundary. Superconducting gravimeter observations give periods of 3.5822 +/- 0.0012 (retrograde) and 4.0150 +/- 0.0010 (prograde) hours. With the use of Ekman layer theory to estimate viscous drag forces, an inferred single viscosity of 1.22 x 10(11) Pascal seconds gives calculated periods of 3.5839 and 4.0167 hours for the two modes, close to the observed values. The large effective viscosity is consistent with a fluid, solid-liquid mixture surrounding the inner core associated with the "compositional convection" that drives Earth's geodynamo.	York Univ, Dept Earth & Atmospher Sci, N York, ON M3J 1P3, Canada	York University - Canada	Smylie, DE (corresponding author), York Univ, Dept Earth & Atmospher Sci, N York, ON M3J 1P3, Canada.							Braginsky SI, 1963, DOKL AKAD NAUK SSSR, V149, P8; BUFFETT BA, 1995, GEOPHYS J INT, V120, P103, DOI 10.1111/j.1365-246X.1995.tb05914.x; Buffett BA, 1997, NATURE, V388, P571, DOI 10.1038/41534; BULLEN KE, 1985, INTRO THEORY SEISMOL, P321; BULLEN KE, 1965, INTRO THEORY SEISMOL, P220; COURTIER N, 1998, 6 S STUD EARTHS DEEP, V80, P135; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; Glatzmaier GA, 1996, PHYSICA D, V97, P81, DOI 10.1016/0167-2789(96)00100-5; JACOBS JA, 1953, NATURE, V172, P297, DOI 10.1038/172297a0; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; LAMB H, 1932, HYDRODYNAMICS, P644; LOPER DE, 1981, PHYS EARTH PLANET IN, V24, P302, DOI 10.1016/0031-9201(81)90117-5; SLICHTER L, 1961, P NATL ACAD SCI USA, V47, P186, DOI 10.1073/pnas.47.2.186; SMYLIE DE, 1981, PHYS EARTH PLANET IN, V24, P308, DOI 10.1016/0031-9201(81)90118-7; SMYLIE DE, 1984, REP PROG PHYS, V47, P855, DOI 10.1088/0034-4885/47/7/002; SMYLIE DE, 1992, GEOPHYS J INT, V108, P465, DOI 10.1111/j.1365-246X.1992.tb04629.x; SMYLIE DE, 1993, J GEOMAGN GEOELECTR, V45, P1347, DOI 10.5636/jgg.45.1347; SMYLIE DE, 1992, SCIENCE, V255, P1678, DOI 10.1126/science.255.5052.1678; Smylie DE, 1998, PHYS EARTH PLANET IN, V106, P1, DOI 10.1016/S0031-9201(97)00114-3; SMYLIE DE, 1998, 6 S STUD EARTHS DEEP; STACEY FD, 1992, PHYSICS EARTH, P283; STEVENSON DJ, 1983, J GEOPHYS RES, V88, P2445, DOI 10.1029/JB088iB03p02445; STEVENSON DJ, 1980, PHYS EARTH PLANET IN, V22, P42, DOI 10.1016/0031-9201(80)90099-0; Widmer R, 1988, 17 INT C MATH GEOPH	25	34	40	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					461	463		10.1126/science.284.5413.461	http://dx.doi.org/10.1126/science.284.5413.461			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205048				2022-12-28	WOS:000079792200039
J	Sheikh, A				Sheikh, A			An important lesson - TB or not TB	BRITISH MEDICAL JOURNAL			English	Article													Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056					0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					979	979		10.1136/bmj.318.7189.979	http://dx.doi.org/10.1136/bmj.318.7189.979			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195969	Green Published, Green Submitted			2022-12-28	WOS:000079751500021
J	Morris, A				Morris, A			BMJ should stop confusing its readers over national differences	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1221	1221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221973	Green Published			2022-12-28	WOS:000080277900075
J	Beecham, L				Beecham, L			GPs want walk in centres piloted properly	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1149	1149						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213758				2022-12-28	WOS:000080166000090
J	Kim, YH; Park, JH; Hong, SH; Koh, JY				Kim, YH; Park, JH; Hong, SH; Koh, JY			Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator	SCIENCE			English	Article							CORTICAL NEURONAL INJURY; ZINC NEUROTOXICITY; MOUSE HIPPOCAMPUS; CELL-CULTURE; DEATH; INHIBITOR-1; APOPTOSIS; SEIZURE; STROKE; BRAIN	Human recombinant tissue plasminogen activator (tPA) may benefit ischemic stroke patients by dissolving clots. However, independent of thrombolysis, tPA may also have deleterious effects on neurons by promoting excitotoxicity. Zinc neurotoxicity has been shown to be an additional key mechanism in brain injuries. Hence, if tPA affects zinc neurotoxicity, this may provide additional insights into its effect on neuronal death. independent of its proteolytic action. tPA markedly attenuated zinc-induced cell death in cortical culture, and, when injected into cerebrospinal fluid, also reduced kainate seizure-induced hippocampal neuronal death in adult rats.	Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, Seoul 138736, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea	University of Ulsan; Seoul National University (SNU)	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, 388-1 Poongnap Dong Songpa Gu, Seoul 138736, South Korea.	jkko@www.amc.seoul.kr	Koh, Jae-Young/C-9014-2011; Kim, Yang-Hee/N-7614-2013	Koh, Jae-Young/0000-0002-4318-495X; Kim, Yang-Hee/0000-0002-0595-8547				Alberts MJ, 1997, AM J CARDIOL, V80, pD29, DOI 10.1016/S0002-9149(97)00582-1; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOW HS, 1994, BRAIN RES, V639, P102, DOI 10.1016/0006-8993(94)91769-8; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; KOH YH, 1984, NEUROSCIENCE, V60, P1049; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lekieffre D, 1997, BRAIN RES, V776, P88, DOI 10.1016/S0006-8993(97)00992-X; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Sensi SL, 1997, J NEUROSCI, V17, P9554; Suh S. W., 1996, Society for Neuroscience Abstracts, V22, P2101; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Welling TH, 1996, J SURG RES, V66, P36, DOI 10.1006/jsre.1996.0369; WHITELAW A, 1995, ACTA PAEDIATR, V84, P933, DOI 10.1111/j.1651-2227.1995.tb13795.x; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x; Zivin JA, 1997, DRUGS, V54, P83, DOI 10.2165/00003495-199700543-00012	34	130	137	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	1999	284	5414					647	650		10.1126/science.284.5414.647	http://dx.doi.org/10.1126/science.284.5414.647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213688				2022-12-28	WOS:000079951100046
J	Salo, JA; Soisalon-Soininen, S; Bondestam, S; Mattila, PS				Salo, JA; Soisalon-Soininen, S; Bondestam, S; Mattila, PS			Familial occurrence of abdominal aortic aneurysm	ANNALS OF INTERNAL MEDICINE			English	Article						aortic aneurysm, abdominal; genetic predisposition to disease; age factors; sex factors; ultrasonography	PERIPHERAL VASCULAR-DISEASE; HIGH PREVALENCE; POPULATION; VARIABILITY; ULTRASOUND; RELATIVES; DIAMETER; AGE	Background: A family history of abdominal aortic aneurysm has been reported to increase the risk for developing the disease. Objective: To determine the risk for abdominal aortic aneurysm in first-degree relatives of patients with the disease. Design: Cross-sectional ultrasonographic screening study. Setting: University Central Hospital, Helsinki, Finland. Patients: 238 of 325 living first-degree relatives of patients having surgery for abdominal aortic aneurysm (age > 50 years; 98 men and 110 women) and 281 controls (135 men and 149 women) without a family history of abdominal aortic aneurysm. Measurements: Ultrasonography was used to measure aortic diameter in 101 male relatives and 140 female relatives (241 of the 325 persons at risk [74%]) and in 281 controls. Results: Three siblings had already undergone surgery for abdominal aortic aneurysm. Eleven siblings (all brothers) (11 of 101 [10.9%]) had ultrasonographic evidence of abdominal aortic aneurysm (aortic diameter > 30 mm). In the control group, 2 men (1.5%) and 2 women (1.3%) had an aneurysm. Thirty siblings and no controls had dilatation of the abdominal aorta (aortic diameter, 20 to 29 mm). Neither the age nor the sex of the proband affected risk for developing abdominal aortic aneurysm among first-degree relatives. Family history increased the risk for an aneurysm by 4.33-fold (95% CI, 1.32-fold to 14.23-fold), male sex increased the risk by 12.21-fold (CI, 2.63-fold to 56.64-fold), and age (by decade) increased the risk by 1.93-fold (CI, 1.15-fold to 3.25-fold). Conclusion: Aging brothers of patients with known abdominal aortic aneurysm have the highest risk for developing the disease; the prevalence of the disease in siblings older than 60 years of age is 18%.	Univ Helsinki, Cent Hosp, Dept Thorac & Cardiovasc Surg, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Diagnost Radiol, FIN-00290 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Salo, JA (corresponding author), Univ Helsinki, Cent Hosp, Dept Thorac & Cardiovasc Surg, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.			Mattila, Petri/0000-0003-1911-1811				ADAMS DCR, 1993, EUR J VASCULAR SURG, V7, P709, DOI 10.1016/S0950-821X(05)80721-2; ADAMSON J, 1992, BRIT J SURG, V79, P897, DOI 10.1002/bjs.1800790914; ALLARDICE JT, 1988, BRIT J SURG, V75, P240, DOI 10.1002/bjs.1800750318; BAIRD PA, 1995, LANCET, V346, P601, DOI 10.1016/S0140-6736(95)91436-6; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; BENGTSSON H, 1993, J VASC SURG, V18, P74, DOI 10.1067/mva.1993.42107; CLIFTON MA, 1977, BRIT J SURG, V64, P765, DOI 10.1002/bjs.1800641102; COLE CW, 1989, CAN J SURG, V32, P117; COLE CW, 1989, CAN J SURG, V32, P65; COLE J, 1989, BMJ-BRIT MED J, V299, P493; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1985, BRIT J SURG, V72, P851, DOI 10.1002/bjs.1800721102; Cronenwett J L, 1995, Semin Vasc Surg, V8, P124; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; FITZGERALD P, 1995, BRIT J SURG, V82, P483, DOI 10.1002/bjs.1800820418; GALLAND RB, 1991, BRIT J SURG, V78, P1259, DOI 10.1002/bjs.1800781036; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; Jaakkola P, 1996, EUR J SURG, V162, P611; Jaakkola P, 1996, EUR J VASC ENDOVASC, V12, P230, DOI 10.1016/S1078-5884(96)80112-2; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; KARANJIA PN, 1994, STROKE, V25, P627, DOI 10.1161/01.STR.25.3.627; KATZ DA, 1994, J VASC SURG, V19, P980, DOI 10.1016/S0741-5214(94)70209-8; Law M R, 1994, J Med Screen, V1, P110; LEDERLE FA, 1995, J VASC SURG, V21, P945, DOI 10.1016/S0741-5214(95)70222-9; LUCAROTTI ME, 1992, BRIT J SURG, V79, P641, DOI 10.1002/bjs.1800790714; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; MAJUMDER PP, 1991, AM J HUM GENET, V48, P164; NORRGARD O, 1984, SURGERY, V95, P650; PEARCE WH, 1993, SURGERY, V114, P691; SALO JA, 1989, WORLD J SURG, V13, P484, DOI 10.1007/BF01660764; TILSON MD, 1984, AM J SURG, V147, P551, DOI 10.1016/0002-9610(84)90020-5; TWOMEY A, 1984, BRIT J SURG, V71, P307; WEBSTER MW, 1991, J VASC SURG, V13, P9; WOLF YG, 1995, J VASC SURG, V22, P417, DOI 10.1016/S0741-5214(95)70009-9	36	68	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					637	+		10.7326/0003-4819-130-8-199904200-00003	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215559				2022-12-28	WOS:000079786600002
J	Tolle, SW; Rosenfeld, AG; Tilden, VP; Park, Y				Tolle, SW; Rosenfeld, AG; Tilden, VP; Park, Y			Oregon's low in-hospital death rates: What determines where people die and satisfaction with decisions on place of death?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE; PREFERENCES; EXPERIENCE; SYSTEM; HOME; LIFE	Where Americans die is much more influenced by what part of the country they live in than by what their preferences are for location of death. Although most Americans report a preference for death at home, a majority still die in acute care hospitals. We describe the experiences of patients who died in Oregon (the state that currently has the lowest in-hospital death rate in the United States-31%) and the views of their families. We examine the factors influencing respect for dying patients' preferred location of death. Data from Oregon studies confirm that decisions to avoid hospital admission are far more common than discharge of the actively dying. Do-not-resuscitate orders were reported for 91% of nursing home residents in one study and living wills were reported for 67% of a random sample of adult Oregon decedents in a second study. In the second study, decisions not to start treatment were far more common than decisions to stop treatment (79% compared with 21%). Only 2.4% of families reported that "too little" treatment was given. Throughout the United States, use and availability of beds in acute care hospitals have been confirmed to be the principal determining factors in location of death. Within that constraint, however, the availability of other resources and services both facilitates the process of arranging for patients to die outside the hospital and improves satisfaction with the quality of terminal care.	Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Div Gen Internal Med, Sch Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Sch Nursing, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Tolle, SW (corresponding author), Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Div Gen Internal Med, Sch Med, UHN-86,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Berwick DM, 1996, ANN INTERN MED, V125, P839, DOI 10.7326/0003-4819-125-10-199611150-00009; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; *CTR HLTH STAT, 1998, OR OCC DEATHS; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; *GALL ORG, 1996, KNOWL ATT REL HOSP C; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; *HMO, 1997, 72 HMO; Holtzman J, 1996, J AM GERIATR SOC, V44, P258, DOI 10.1111/j.1532-5415.1996.tb00911.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633; MCCORMICK WC, 1991, J GEN INTERN MED, V6, P524, DOI 10.1007/BF02598221; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MURPHY P, 1998, DYING INNER CITY HOS, P12; *NAT CTR HLTH STAT, 1993, NAT MORT FOLL SURV; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; Teno JM, 1997, J AM GERIATR SOC, V45, P939, DOI 10.1111/j.1532-5415.1997.tb02963.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1998, DARTMOUTH ATLAS HLTH, P94	23	61	62	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					681	685		10.7326/0003-4819-130-8-199904200-00015	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215565				2022-12-28	WOS:000079786600008
J	Dubernard, JM; Owen, E; Herzberg, G; Lanzetta, M; Martin, X; Kapila, H; Dawahra, M; Hakim, NS				Dubernard, JM; Owen, E; Herzberg, G; Lanzetta, M; Martin, X; Kapila, H; Dawahra, M; Hakim, NS			Human hand allograft: report on first 6 months	LANCET			English	Article							COMPOSITE TISSUE ALLOTRANSPLANTATION; RAT LIMB ALLOGRAFT; LONG-TERM; CLINICAL-APPLICATION; NERVE REGENERATION; TRANSPLANTATION; FK-506; IMMUNOSUPPRESSION; CYCLOSPORINE; FK506	Background Long-term survival of animal limb allografts with new immunosuppressant combinations and encouraging results of autologous limb replantations led us to believe that clinical application of hand transplantation in human beings was viable. Methods On Sept 23, 1998, we transplanted the right distal forearm and hand of a brain-dead man aged 41 years on to a man aged 48 years who had had traumatic amputation of the distal third of his right forearm. The donor's arm was irrigated with UW organ preservation solution at 4 degrees C, amputated 5 cm above the elbow, and transported in a cool container. We dissected the donor limb and the recipient's arm simultaneously to identify anatomical structures. Appropriate lengths of viable structures were matched. Transplantation involved bone fixation, arterial and venous anastomoses (ischaemic time 12 . 5 h), nerve sutures, joining of muscles and-tendons, and skin closure. Immunosuppression included antithymocyte globulins, tacrolimus, mycophenolic acid, and prednisone. Maintenance therapy included tacrolimus, mycophenolic acid, and prednisone. Follow-up included routine post-transplant laboratory tests, skin biopsies, intensive physiotherapy, and psychological support. Findings The initial postoperative course was uneventful. No surgical complications were seen. Immunosuppression was well tolerated. Mild clinical and histological signs of cutaneous rejection were seen at weeks 8-9 after surgery. These signs disappeared after prednisone dose was increased (from 20 mg/day to 40 mg/day) and topical application of immunosuppressive creams (tacrolimus, clobetasol). Intensive physiotherapy led to satisfactory progress of motor function. Sensory progress (Tinel's sign) was excellent and reached the wrist crease (20 cm) on day 100 for the median and ulnar nerves, and at least 24 cm to the palm by 6 months when deep pressure, but not light touch sensation, could be felt at the mid palm. Interpretation Hand allotransplantation is technically feasible. Currently available immunosuppression seems to prevent acute rejection. If no further episode of rejection occurs, the functional prognosis of this graft should be similar to if not better than that reported in large series of autoreconstruction.	Hop Edouard Herriot, Serv Chirurg Transplantat & Urol, F-69437 Lyon 03, France; Hop Edouard Herriot, Serv Orthoped & Chirurg Membre Super, F-69437 Lyon, France; Australia & Outer Sydney Hand & Microsurg Unit, Microsearch Fdn, Sydney, NSW, Australia; St Marys Hosp, Transplantat Unit, London, England; Univ Milan, San Gerardo Hosp, Hand Surg & Reconstruct Microsurg Unit, Monza, Italy	CHU Lyon; CHU Lyon; Imperial College London; San Gerardo Hospital; University of Milan	Dubernard, JM (corresponding author), Hop Edouard Herriot, Serv Chirurg Transplantat & Urol, F-69437 Lyon 03, France.							Barker JH, 1998, TRANSPLANT P, V30, P2787; BENHAIM P, 1993, TRANSPLANTATION, V56, P911, DOI 10.1097/00007890-199310000-00026; BLACK KS, 1991, S COMP TISS TRANSP R; Buttemeyer R, 1996, PLAST RECONSTR SURG, V97, P139; Carpenter JP, 1997, J VASC SURG, V26, P32, DOI 10.1016/S0741-5214(97)70144-7; CHEN ZW, 1981, ORTHOP CLIN N AM, V12, P849; DiGiovanna JJ, 1998, TRANSPL P, V30, P2771, DOI 10.1016/S0041-1345(98)00806-9; FEALY MJ, 1994, ANN SURG, V219, P88, DOI 10.1097/00000658-199401000-00014; First MR, 1998, TRANSPLANT P, V30, P2768, DOI 10.1016/S0041-1345(98)00805-7; Gold BG, 1998, NEUROSCI LETT, V241, P25, DOI 10.1016/S0304-3940(97)00960-9; Gold BG, 1997, MOL NEUROBIOL, V15, P285, DOI 10.1007/BF02740664; Graham B, 1998, J HAND SURG-AM, V23A, P783, DOI 10.1016/S0363-5023(98)80151-2; GUIMBERTEAU JC, 1992, PLAST RECONSTR SURG, V89, P1137; Hewitt CW, 1998, TRANSPLANT P, V30, P2704, DOI 10.1016/S0041-1345(98)00792-1; HEWITT CW, 1995, TRANSPLANT P, V27, P1414; Hofmann GO, 1998, TRANSPLANT P, V30, P2754, DOI 10.1016/S0041-1345(98)00803-3; Jones TR, 1998, TRANSPLANT P, V30, P2746, DOI 10.1016/S0041-1345(98)00802-1; KUROKI H, 1995, TRANSPLANT P, V27, P348; Llull R, 1998, TRANSPLANT P, V30, P2692, DOI 10.1016/S0041-1345(98)00791-X; MACKINNON SE, 1992, PLAST RECONSTR SURG, V90, P695, DOI 10.1097/00006534-199210000-00024; MARSHALL V, 1997, PROCUREMENT PRESERVA, P115; Meuli-Simmen C, 1998, J RECONSTR MICROSURG, V14, P131, DOI 10.1055/s-2007-1000156; MEYER VE, 1985, J HAND SURG-AM, V10A, P989, DOI 10.1016/S0363-5023(85)80020-4; MORALES RG, 1998, TRANSPLANTATION, V65, P956; Muramatsu K, 1997, ACTA ORTHOP SCAND, V68, P581, DOI 10.3109/17453679708999031; NOLAN LM, 1993, J HAND SURG-AM, V18A, P153, DOI 10.1016/0363-5023(93)90264-4; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; Shirbacheh MV, 1998, TRANSPLANT P, V30, P2739, DOI 10.1016/S0041-1345(98)00800-8; STARK GB, 1987, TRANSPLANT P, V19, P3968; VANDENHELDER TBM, 1994, TRANSPLANTATION, V57, P427, DOI 10.1097/00007890-199402150-00020; Wang MS, 1997, J PHARMACOL EXP THER, V282, P1084; WERKELE T, 1998, TRANSPL P, V30, P2708	32	521	561	1	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1315	1320		10.1016/S0140-6736(99)02062-0	http://dx.doi.org/10.1016/S0140-6736(99)02062-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218530				2022-12-28	WOS:000080278100012
J	Strachan, DP; Carrington, D; Mendall, MA; Ballam, L; Morris, J; Butland, BK; Sweetnam, PM; Elwood, PC				Strachan, DP; Carrington, D; Mendall, MA; Ballam, L; Morris, J; Butland, BK; Sweetnam, PM; Elwood, PC			Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over years in the Caerphilly prospective heart disease study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; CARDIOVASCULAR RISK-FACTORS; HELICOBACTER-PYLORI; MYOCARDIAL-INFARCTION; ASSOCIATION; INFECTION; ATHEROSCLEROSIS; ANTIBODIES; MEN; SEROPOSITIVITY	Objectives To investigate the effect of Chlamydia pneumoniae infection on future development of ischaemic heart disease and mortality Design Prospective longitudinal study. Setting Caerphilly South Wales. Subjects Plasma specimens were collected during 1979-83 from 1773 men aged 45-59 years. These were tested for IgG and IgA antibodies to C pneumoniae (TW183) by microimmunonfluorescence. Outcome measures 13 year mortality and incident ischaemic heart disease events were ascertained from death certificates, hospital records, and electrocardiographic changes at follow up every 4 to 5 years. Results 642 men (36.2%) had Ige antibodies at a titre of greater than or equal to 1 in 16, of whom 362 (20.4% of all men) also had detectable IgA antibodies. The prevalence of ischaemic heart disease (a history of past or current disease) at entry was similar at all IgG antibody titres but was positively related to IgA antibody titre. IgA antibody titre was positively correlated with plasma viscosity but not with other cardiovascular risk factors. Incidence of ischaemic heart disease was not associated with either IgG antibody titre or IgA antibody titre, but there were stronger and significant relations of IgA antibodies with all cause mortality and fatal ischaemic heart disease, which persisted after adjustment for conventional cardiovascular risk factors. The odds ratios associated with detectable IgA antibodies were 1.07 (95% confidence interval 0.75 to 1.53) for all incident ischaemic heart disease, 1.83 (1.17 to 2.85) for fatal ischaemic heart disease, and 1.50 (1.10 to 2.04) for all cause mortality Conclusion This is the first prospective demonstration of an association between IgA antibodies to C pneumoniae, a putative marker of chronic infection, and subsequent risk of death from ischaemic heart disease. In contrast to earlier case-control studies, Ige antibodies were not associated with either prevalent or incident ischaemic heart disease.	St Georges Hosp Med Sch, Dept Publ Hlth Sci, London SW17 0RE, England; St Georges Hosp Med Sch, Dept Med Microbiol, London SW17 0RE, England; St Georges Hosp Med Sch, Div Gastroenterol Endocrinol & Metab, London SW17 0RE, England; Llandough Hosp, Epidemiol Unit S Wales, MRC, Penarth CF64 2XW, S Glam, Wales	St Georges University London; St Georges University London; St Georges University London	Strachan, DP (corresponding author), St Georges Hosp Med Sch, Dept Publ Hlth Sci, London SW17 0RE, England.	d.strachan@sghms.ac.uk		Butland, Barbara/0000-0001-9952-3108				BAINTON D, 1992, BRIT HEART J, V68, P60; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HAHN DL, 1992, ARTERIOSCLER THROMB, V12, P945, DOI 10.1161/01.ATV.12.8.945; Jackson LA, 1997, AM J PATHOL, V150, P1785; KARVONEN M, 1994, INT J EPIDEMIOL, V23, P1315, DOI 10.1093/ije/23.6.1315; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; Laurila A, 1997, BRIT MED J, V314, P1456, DOI 10.1136/bmj.314.7092.1456; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Mendall MA, 1996, BRIT MED J, V312, P1061; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; Miettinen H, 1996, EUR HEART J, V17, P682; MORRISON RP, 1989, J EXP MED, V170, P1271, DOI 10.1084/jem.170.4.1271; Office of Population Censuses and Surveys, 1980, CLASS OCC; Ossewaarde JM, 1998, EPIDEMIOL INFECT, V120, P93, DOI 10.1017/S0950268897008303; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Saikku P, 1997, SCAND J INFECT DIS, P53; *STAT CORP, 1999, STAT REF MAN REL 3 1, V81, P248; Strachan DP, 1998, CIRCULATION, V98, P1286, DOI 10.1161/01.CIR.98.13.1286; Strachan DP, 1999, HEART, V81, P248, DOI 10.1136/hrt.81.3.248; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; WAGELS G, 1994, J CLIN MICROBIOL, V32, P2820, DOI 10.1128/JCM.32.11.2820-2823.1994; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	30	104	108	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1035	1039		10.1136/bmj.318.7190.1035	http://dx.doi.org/10.1136/bmj.318.7190.1035			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205100	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080140000022
J	Henny, M; Oberholzer, S; Strunk, C; Heinzel, T; Ensslin, K; Holland, M; Schonenberger, C				Henny, M; Oberholzer, S; Strunk, C; Heinzel, T; Ensslin, K; Holland, M; Schonenberger, C			The fermionic Hanbury Brown and Twiss experiment	SCIENCE			English	Article							QUANTUM SHOT-NOISE; MULTITERMINAL DIFFUSIVE CONDUCTORS; SCATTERING-THEORY	A Hanbury Brown and Twiss experiment for a beam of electrons has been realized in a two-dimensional electron gas in the quantum Hall regime. A metallic split gate serves as a tunable beam splitter to partition the incident beam into transmitted and reflected partial beams. In the nonequilibrium case the fluctuations in the partial beams are shown to be fully anticorrelated. demonstrating that fermions exclude each other. In equilibrium, the cross-correlation of current fluctuations at two different contacts is also found to be negative and nonzero, provided that a direct transmission exists between the contacts.	Univ Basel, Inst Phys, CH-4056 Basel, Switzerland; Swiss Fed Inst Technol, Solid State Phys Lab, CH-8093 Zurich, Switzerland; Univ Glasgow, Dept Elect, Glasgow G12 8QQ, Lanark, Scotland	University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Glasgow	Schonenberger, C (corresponding author), Univ Basel, Inst Phys, Klingelbergstr 82, CH-4056 Basel, Switzerland.	schonenberg@ubaclu.unibas.ch	Schönenberger, Christian/N-3187-2017	Schönenberger, Christian/0000-0002-5652-460X; Heinzel, Thomas/0000-0001-5149-4379				BAYM G, NUCLTH9804026; Blanter YM, 1997, PHYS REV B, V56, P2127, DOI 10.1103/PhysRevB.56.2127; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; BUTTIKER M, 1990, PHYS REV LETT, V65, P2901, DOI 10.1103/PhysRevLett.65.2901; BUTTIKER M, 1992, PHYS REV B, V46, P12485, DOI 10.1103/PhysRevB.46.12485; BUTTIKER M, 1992, SEMICONDUCT SEMIMET, V35, P191, DOI 10.1016/S0080-8784(08)62394-7; BUTTIKER M, 1998, PHYSICS WORLD    MAR, P30; DEJONG MJM, 1996, NATO ASI SERIES E, V345, P225; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; Dieleman P, 1997, PHYS REV LETT, V79, P3486, DOI 10.1103/PhysRevLett.79.3486; Gramespacher T, 1998, PHYS REV LETT, V81, P2763, DOI 10.1103/PhysRevLett.81.2763; HANBURYBROWN R, 1954, PHILOS MAG, V45, P663; HANBURYBROWN R, 1956, NATURE, V178, P1046, DOI DOI 10.1038/1781046A0; Henny M, 1999, PHYS REV B, V59, P2871, DOI 10.1103/PhysRevB.59.2871; HOSS T, CONDMAT9901129; Iannaccone G, 1998, PHYS REV LETT, V80, P1054, DOI 10.1103/PhysRevLett.80.1054; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Kumar A, 1996, PHYS REV LETT, V76, P2778, DOI 10.1103/PhysRevLett.76.2778; Landauer R, 1998, NATURE, V392, P658, DOI 10.1038/33551; LANDAUER R, 1988, IBM J RES DEV, V32, P306, DOI 10.1147/rd.323.0306; LIU RC, 1994, PHYS REV B, V49, P10520, DOI 10.1103/PhysRevB.49.10520; Liu RC, 1998, NATURE, V391, P263, DOI 10.1038/34611; LOUDON R, 1980, REP PROG PHYS, V43, P913, DOI 10.1088/0034-4885/43/7/002; MARTIN T, 1992, PHYS REV B, V45, P1742, DOI 10.1103/PhysRevB.45.1742; MORGAN BL, 1966, PHYS REV LETT, V16, P1012, DOI 10.1103/PhysRevLett.16.1012; Oliver WD, 1999, SCIENCE, V284, P299, DOI 10.1126/science.284.5412.299; PURCELL EM, 1956, NATURE, V178, P1448; Reznikov M, 1998, SUPERLATTICE MICROST, V23, P901, DOI 10.1006/spmi.1997.0559; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; SILVERMAN MP, 1987, PHYS LETT A, V120, P442, DOI 10.1016/0375-9601(87)90106-X; Steinbach AH, 1996, PHYS REV LETT, V76, P3806, DOI 10.1103/PhysRevLett.76.3806; Sukhorukov EV, 1998, PHYS REV LETT, V80, P4959, DOI 10.1103/PhysRevLett.80.4959	32	347	348	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					296	298		10.1126/science.284.5412.296	http://dx.doi.org/10.1126/science.284.5412.296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195890	Green Submitted			2022-12-28	WOS:000079636400036
J	Krieger, LM				Krieger, LM			Medicare antifraud initiatives: Effects on resident education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Krieger, LM (corresponding author), Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.							Cameron JL, 1997, ANN SURG, V225, P445, DOI 10.1097/00000658-199705000-00002; HALLAM K, 1998, MODERN HEALTHCA 0528, P14; SMITH M, 1998, FORBES          0518, P43; *T JEFF U T, 1996, HEALTHC FINANC MANAG, V50, P10; 1997, FED REG, V62, P7350	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1227	1227		10.1001/jama.281.13.1227	http://dx.doi.org/10.1001/jama.281.13.1227			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199436	hybrid			2022-12-28	WOS:000079464400041
J	Quintner, JL; Cohen, ML				Quintner, JL; Cohen, ML			Fibromyalgia falls foul of a fallacy	LANCET			English	Editorial Material							PAIN; DISABILITY; FIBROSITIS; DISORDER		Wyllie Arthrit Ctr, Shenton Pk, WA 6008, Australia; St Vincent Med Ctr, Darlinghurst Arthrit Ctr, Darlinghurst, NSW, Australia; St Vincent Med Ctr, Pain Res Clin, Darlinghurst, NSW, Australia		Quintner, JL (corresponding author), Wyllie Arthrit Ctr, 17 Lemnos St, Shenton Pk, WA 6008, Australia.							ARMSTRONG J, 1825, LANCET, V7, P65; Beard GM., 1869, BOSTON MED SURG J, V3, P217, DOI [10.1056/nejm186904290801301, 10.1056/NEJM186904290801301, DOI 10.1056/NEJM186904290801301]; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cohen M. L., 1996, RAIN REV, V3, P181; COHEN ML, 1993, LANCET, V342, P906, DOI 10.1016/0140-6736(93)91950-Q; Cohen ML, 1998, MED J AUSTRALIA, V168, P402, DOI 10.5694/j.1326-5377.1998.tb138995.x; COHEN ML, 1995, J MUSCULOSKELET PAIN, V3, P49; CROFT P, 1994, BRIT MED J, V309, P696, DOI 10.1136/bmj.309.6956.696; GOLDENBERG DL, 1995, ANN RHEUM DIS, V54, P3, DOI 10.1136/ard.54.1.3; Gowers W R, 1904, Br Med J, V1, P117; Habershon S O, 1868, Br Med J, V1, P603; Hadler NM, 1997, POSTGRAD MED, V102, P161, DOI 10.3810/pgm.1997.08.284; Head H, 1922, Br Med J, V1, P1; HORMELL RS, 1940, JAMA-J AM MED ASSOC, V223, P754; International Association for the Study of Pain, 1986, PAIN, V3, pS216; Kosek E, 1995, PAIN, V63, P335, DOI 10.1016/0304-3959(95)00061-5; LAUTENBACHER S, 1994, PAIN, V59, P45, DOI 10.1016/0304-3959(94)90046-9; Lewis T, 1944, LANCET, V1, P619; Littlejohn GO, 1998, MED J AUSTRALIA, V168, P398; McDermid AJ, 1996, PAIN, V66, P133, DOI 10.1016/0304-3959(96)03059-X; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; Rockwell A. D., 1971, PRACTICAL TREATISE N; Scadding JG, 1996, LANCET, V348, P594, DOI 10.1016/S0140-6736(96)02049-1; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; SMYTHE HA, 1979, CLIN RHEUM DIS, V5, P823; Wolfe F, 1996, J RHEUMATOL, V23, P534; Wolfe F, 1997, J RHEUMATOL, V24, P1247; Wolfe F, 1997, ANN RHEUM DIS, V56, P268, DOI 10.1136/ard.56.4.268; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2	30	40	40	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1092	1094		10.1016/S0140-6736(98)06468-X	http://dx.doi.org/10.1016/S0140-6736(98)06468-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199368				2022-12-28	WOS:000079614000044
J	Karvonen, M; Cepaitis, Z; Tuomilehto, J				Karvonen, M; Cepaitis, Z; Tuomilehto, J			Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							CUMULATIVE INCIDENCE; BCG-VACCINATION; MELLITUS; CHILDHOOD; CHILDREN; FINLAND; IDDM; IMMUNIZATION; RISK	Objectives To determine the effect of Haemophilus influenzae type b vaccination and its timing on the risk of type 1 diabetes in Finnish children. Design Cumulative incidence and relative risk of type 1 diabetes was compared among three birth cohorts of Finnish children: those born during the 24 months before the H influenzae type b vaccination trial, those in the trial cohort who were vaccinated at 3 months of age and later with a booster vaccine, and those in the trial cohort who were vaccinated at 24 months of age only. The probability of type 1 diabetes was estimated using regression analysis assuming that there were no losses to 10 year follow up and no competing risks. Setting Finland (total population 5 million and annual birth rate 1.3%). Subjects 128 936 children born from 1 October 1983 to 1 September 1985, and 116 352 children born from 1 October 1985 to 31 August 1987. Main outcome measures Probability of type 1 diabetes among children vaccinated with H influenzae type b and non-vaccinated children. Results No statistically significant difference was found at any time during the 10 year follow up in the risk of type 1 diabetes between the children born before the vaccination period and those vaccinated at the age of 24 months only (relative risk 1.01). The difference in the risk between the cohort vaccinated first at the age of 3 months and the cohort vaccinated at the age of 24 months only was not statistically significant either (1.06). Conclusion It is unlikely that H influenzae type b vaccination or its timing cause type 1 diabetes in children.	Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Karvonen, M (corresponding author), Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Mannerheimintie 166, FIN-00300 Helsinki, Finland.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; Classen DC, 1997, INFECT DIS CLIN PRAC, V6, P449, DOI 10.1097/00019048-199706070-00007; Classen JB, 1996, DIABETOLOGIA, V39, P500, DOI 10.1007/BF00400684; Classen JB, 1999, BRIT MED J, V318, P193, DOI 10.1136/bmj.318.7177.193; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P873, DOI 10.1007/BF03035306; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FURMAN BL, 1981, BRIT J EXP PATHOL, V62, P504; HARADA M, 1990, DIABETES RES CLIN PR, V8, P85, DOI 10.1016/0168-8227(90)90017-N; Heijbel H, 1997, DIABETES CARE, V20, P173, DOI 10.2337/diacare.20.2.173; HUIYU Q, 1993, J IMMUNOL, V150, P2072; HYOTY H, 1993, DIABETOLOGIA, V36, P1303, DOI 10.1007/BF00400810; Jefferson T, 1998, BRIT MED J, V317, P159, DOI 10.1136/bmj.317.7152.159; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Parent ME, 1997, DIABETES CARE, V20, P767, DOI 10.2337/diacare.20.5.767; REWERS M, 1988, DIABETES, V37, P1113; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; SOMERSALO O., 1960, Ann. Paediat. Fenn., V6, P253; Takala A K, 1994, Duodecim, V110, P1783; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; TUOMILEHTO J, 1999, IN PRESS DIABETOLOGI, V42	22	69	69	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1169	1172						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221937	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080277900026
J	Brooke, J; Bitko, D; Rosenbaum, TF; Aeppli, G				Brooke, J; Bitko, D; Rosenbaum, TF; Aeppli, G			Quantum annealing of a disordered magnet	SCIENCE			English	Article							FERROMAGNETISM; GLASS	Traditional simulated annealing uses thermal fluctuations for convergence in optimization problems. Quantum tunneling provides a different mechanism for moving between states, with the potential for reduced time scales. Thermal and quantum annealing are compared in a model disordered magnet, where the effects of quantum mechanics can be tuned by varying an applied magnetic field. The results indicate that quantum annealing hastens convergence to the optimum state.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; NEC Res Inst, Princeton, NJ 08540 USA	University of Chicago; NEC Corporation	Rosenbaum, TF (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.							BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; BITKO D, 1997, THESIS U CHICAGO; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; HANSEN PE, 1975, PHYS REV B, V12, P5315, DOI 10.1103/PhysRevB.12.5315; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; MYDOSH JA, 1993, SPIN GLASSES EXPT IN; REICH DH, 1986, PHYS REV B, V34, P4956, DOI 10.1103/PhysRevB.34.4956; REICH DH, 1990, PHYS REV B, V42, P4631, DOI 10.1103/PhysRevB.42.4631; STEPHEN MJ, 1981, J PHYS C SOLID STATE, V14, P1665, DOI 10.1088/0022-3719/14/11/026; WU WH, 1991, PHYS REV LETT, V67, P2076, DOI 10.1103/PhysRevLett.67.2076; WU WH, 1993, PHYS REV LETT, V71, P1919, DOI 10.1103/PhysRevLett.71.1919	15	355	362	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					779	781		10.1126/science.284.5415.779	http://dx.doi.org/10.1126/science.284.5415.779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221904	Green Submitted, Green Accepted			2022-12-28	WOS:000080056200038
J	Urbano, FL; Nguyen, MT				Urbano, FL; Nguyen, MT			Herpes simplex esophagitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Partners Primary Care, Medford, NJ 08055 USA; Grad Hosp Philadelphia, Philadelphia, PA 19146 USA	University of Pennsylvania	Urbano, FL (corresponding author), Partners Primary Care, Medford, NJ 08055 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1254	1254		10.1056/NEJM199904223401607	http://dx.doi.org/10.1056/NEJM199904223401607			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210710				2022-12-28	WOS:000079833800007
J	Feinberg, J				Feinberg, J			Withdrawal of prophylaxis against Pneumocystis carinii pneumonia	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; THERAPY		Univ Cincinnati, Med Ctr, Ctr Infect Dis, Cincinnati, OH 45267 USA	University of Cincinnati	Feinberg, J (corresponding author), Univ Cincinnati, Med Ctr, Ctr Infect Dis, Cincinnati, OH 45267 USA.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Rodriguez-Guardado A, 1998, AIDS, V12, P2355; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118	8	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1287	1287		10.1016/S0140-6736(99)00123-3	http://dx.doi.org/10.1016/S0140-6736(99)00123-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218521				2022-12-28	WOS:000080278100003
J	Davies, T				Davies, T			Emyr Wyn Jones - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					1014	1014		10.1136/bmj.318.7189.1014	http://dx.doi.org/10.1136/bmj.318.7189.1014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195989	Green Published			2022-12-28	WOS:000079751500048
J	Osganian, SK; Stampfer, MJ; Spiegelman, D; Rimm, E; Cutler, JA; Feldman, HA; Montgomery, DH; Webber, LS; Lytle, LA; Bausserman, L; Nader, PR				Osganian, SK; Stampfer, MJ; Spiegelman, D; Rimm, E; Cutler, JA; Feldman, HA; Montgomery, DH; Webber, LS; Lytle, LA; Bausserman, L; Nader, PR			Distribution of and factors associated with serum homocysteine levels in children - Child and Adolescent Trial for Cardiovascular Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA HOMOCYST(E)INE; RISK FACTOR; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; DIETARY PATTERNS; BLOOD-PRESSURE; UNITED-STATES; FOLIC-ACID; FOLATE	Context Although evidence suggests that homocysteine is a risk factor for cardiovascular disease in adults, little information exists on homocysteine levels in children. Objectives To describe the distribution of serum homocysteine concentrations among children and to examine the association between homocysteine levels and several characteristics, including serum levels of folic acid and vitamins B-12 and B-6. Design Cross-sectional analysis. Setting School-based cohort from California, Louisiana, Minnesota, and Texas. Participants A total of 3524 US schoolchildren, aged 13 and 14 years, from the Child and Adolescent Trial for Cardiovascular Health (completed in 1994). Measurement conducted in 1997. Main Outcome Measure Nonfasting serum total homocysteine concentration. Results The distribution of homocysteine values ranged from 0.1 to 25.7 mu mol/L (median, 4.9 mu mol/L). Geometric mean homocysteine concentration was significantly higher in boys (5.22 mu mol/L) than girls (4.84 mu mol/L); blacks (5.51 mu mol/L) than whites (4.96 mu mol/L) or Hispanics (4.93 mu mol/L); nonusers of multivitamins (5.09 mu mol/L) than users (4.82 mu mol/L); and smokers (5.19 mu mol/L) than nonsmokers (5.00 mu mol/ L). Serum homocysteine was significantly inversely correlated with serum levels of folic acid (r = -0.36; P = .001), vitamin B-12 (r = -0.21; P = .001), and vitamin B, (r = -0.18; P = .001). Serum homocysteine was not significantly associated with serum lipid levels or family history of cardiovascular disease and was only weakly related to body mass index and systolic blood pressure. After multivariate adjustment, homocysteine remained independently associated with sex, race, serum folic acid and vitamin B-12 levels, and systolic blood pressure. Conclusions The distribution of homocysteine levels in children is substantially lower than that observed for adults; however, a small percentage of children are still potentially at elevated risk for future cardiovascular disease. Serum folic acid may be an important determinant of homocysteine levels in children.	New England Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; Univ Texas, Hlth Sci Ctr, Ctr Hlth Promot Res & Dev, Houston, TX USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN USA; Univ Calif San Diego, Div Community Pediat, San Diego, CA USA; Miriam Hosp, Lipoprot Anal Lab, Providence, RI USA; Brown Univ, Sch Med, Providence, RI 02912 USA	HealthCore, Inc; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University; Tulane University; University of Texas System; University of Texas Health Science Center Houston; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; Lifespan Health Rhode Island; Miriam Hospital; Brown University	Osganian, SK (corresponding author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA.	voulao@neri.org	Feldman, Henry/M-2302-2013; Lytle, Leslie/AAA-8226-2020	Hoelscher, Deanna/0000-0002-0910-5031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL039880, U01HL039906, U01HL039852] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL-39880, U01-HL-39852, U01-HL-39906] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfthan G, 1997, LANCET, V349, P397, DOI 10.1016/S0140-6736(97)80014-1; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ARMITAGE P, 1971, STATISTICAL METHODS, P271; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BERG K, 1992, CLIN GENET, V41, P315; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; COOPER BA, 1984, CLIN BIOCHEM, V17, P95, DOI 10.1016/S0009-9120(84)90266-2; CRANE NT, 1995, AM J PUBLIC HEALTH, V85, P660, DOI 10.2105/AJPH.85.5.660; ELSHAMI AS, 1983, CLIN CHEM, V29, P2115; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; KANNEL WB, 1972, J PEDIATR-US, V80, P544, DOI 10.1016/S0022-3476(72)80049-0; LAUER RM, 1988, PEDIATRICS, V82, P309; LINDENBAUM J, 1983, BLOOD, V61, P624; Littel RC, 1996, SAS SYSTEM MIXED MOD; Luepker RV, 1996, JAMA-J AM MED ASSOC, V275, P768, DOI 10.1001/jama.275.10.768; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MCGILL HC, 1980, CHILDHOOD PREVENTION, P41; McNeely MDD, 1984, CLIN CHEM, P1402; MORRISON JA, 1981, CARDIOVASC REV REP, V2, P1269; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; REED T, 1991, CLIN GENET, V39, P425; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; Shimakawa T, 1997, ANN EPIDEMIOL, V7, P285, DOI 10.1016/S1047-2797(97)00004-5; SHIN YS, 1983, CLIN CHIM ACTA, V127, P77, DOI 10.1016/0009-8981(83)90077-3; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stone EJ, 1996, PREV MED, V25, P384, DOI 10.1006/pmed.1996.0071; SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323; Tamura T, 1997, AM J CLIN NUTR, V66, P1299, DOI 10.1093/ajcn/66.6.1299; Tonstad S, 1996, PEDIATR RES, V40, P47, DOI 10.1203/00006450-199607000-00009; Tucker KL, 1996, J NUTR, V126, P3025, DOI 10.1093/jn/126.12.3025; Ubbink JB, 1996, J NUTR, V126, pS1254, DOI 10.1093/jn/126.suppl_4.1254S; UBBINK JB, 1994, NUTR REV, V52, P383, DOI 10.1111/j.1753-4887.1994.tb01369.x; UELAND PM, 1989, J LAB CLIN MED, V114, P473; *US DEP HHS, 1996, NATL CTR HLTH STAT 3; *US FDA, 1996, FED REGISTER, V61, P8781; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; Vilaseca MA, 1997, CLIN CHEM, V43, P690; VONECKARDSTEIN A, 1994, ARTERIOSCLER THROMB, V14, P460, DOI 10.1161/01.ATV.14.3.460; VOORS AW, 1979, AM J EPIDEMIOL, V109, P320, DOI 10.1093/oxfordjournals.aje.a112685; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; WEBBER LS, 1995, AM J EPIDEMIOL, V141, P428, DOI 10.1093/oxfordjournals.aje.a117445; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; Zondervan KT, 1996, INT J EPIDEMIOL, V25, P70, DOI 10.1093/ije/25.1.70	58	117	123	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1189	1196		10.1001/jama.281.13.1189	http://dx.doi.org/10.1001/jama.281.13.1189			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199428	Bronze			2022-12-28	WOS:000079464400033
J	Irvine, D				Irvine, D			The performance of doctors: the new professionalism	LANCET			English	Article							MEDICINE; BRISTOL; GMC		Gen Med Council, London W1N 6JE, England		Irvine, D (corresponding author), Gen Med Council, 178 Great Portland St, London W1N 6JE, England.							*BMA, 1999, MOR POLL; CALMAN K, 1994, BRIT MED J, V309, P1140, DOI 10.1136/bmj.309.6962.1140; CHANTLER C, 1999, LANCET, V353; *GEN MED COUNC, 1999, REV REP STEER GROUP; *GEN MED COUNC, 1998, GOOD MED PRACT; *GEN MED COUNC, 1998, MAINT GOOD MED PRACT; *GEN MED COUNC, 1995, GOOD MED PRACT; Horton R, 1998, LANCET, V351, P1900; Horton R, 1998, LANCET, V352, P1166, DOI 10.1016/S0140-6736(05)60528-4; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; IRVINE D, 1996, PRACTICE QUALITY; IRVINE D, 1999, MED MISHAPS PIECES P, P185; Kennedy I, 1983, UNMASKING MED; Klein R., 1998, REGULATING MED PROFE; ROBINSON J, 1999, MED MISHAPS PIECES P, P246; ROSENTHAL MM, 1999, MED MISHAPS PIECES P; ROSENTHAL MM, 1995, INCOMPETENT DOCTOR C; *SECR STAT HLTH, 1997, CMND3807; Secretary of State for Health, 1998, 1 CLASS SERV QUAL NE; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917; SMITH R, 1989, BRIT MED J, V298, P1241, DOI 10.1136/bmj.298.6682.1241; SMITH R, 1995, BRIT MED J, V310, P1515, DOI 10.1136/bmj.310.6993.1515; STACEY M, 1992, REGULATING BRIT MED; Treasure T, 1998, BMJ-BRIT MED J, V316, P1685, DOI 10.1136/bmj.316.7146.1685; 1992, TIMES           0302; 1998, DAILY TELEGRAPH 1121; 1998, GUARDIAN        1123; 1999, GUARDIAN        0202	29	99	103	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1174	1177		10.1016/S0140-6736(99)91160-1	http://dx.doi.org/10.1016/S0140-6736(99)91160-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209996				2022-12-28	WOS:000079858400047
J	Dusheiko, G				Dusheiko, G			A pill a day, or two, for hepatitis B?	LANCET			English	Editorial Material							LIVER-TRANSPLANTATION; LAMIVUDINE; VIRUS; PROPHYLAXIS; REPLICATION; RECIPIENTS; RECURRENCE; SELECTION; TRIAL		UCL Royal Free & Univ Coll Sch Med, Dept Med, London NW3 2QG, England	University of London; University College London	Dusheiko, G (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Med, London NW3 2QG, England.		Dusheiko, Geoffrey M/C-7677-2010					Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; Chan TM, 1998, GASTROENTEROLOGY, V115, P177, DOI 10.1016/S0016-5085(98)70380-4; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Foli A, 1996, ANTIVIR RES, V32, P91, DOI 10.1016/0166-3542(95)00985-X; Gilson R. J. C., 1996, Hepatology, V24, p281A; Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; Heald AE, 1996, ANTIMICROB AGENTS CH, V40, P1514, DOI 10.1128/AAC.40.6.1514; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444; Jung YO, 1998, TRANSPLANTATION, V66, P733, DOI 10.1097/00007890-199809270-00007; Korba BE, 1996, ANTIVIR RES, V29, P49, DOI 10.1016/0166-3542(95)00915-9; Kruger M, 1996, Liver Transpl Surg, V2, P253, DOI 10.1002/lt.500020402; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; Markowitz JS, 1998, HEPATOLOGY, V28, P585, DOI 10.1002/hep.510280241; Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243; Nery JR, 1998, TRANSPLANTATION, V65, P1615, DOI 10.1097/00007890-199806270-00013; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321	17	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1032	1033		10.1016/S0140-6736(98)00294-3	http://dx.doi.org/10.1016/S0140-6736(98)00294-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199347				2022-12-28	WOS:000079614000006
J	Hibberd, ML; Sumiya, M; Summerfield, JA; Booy, R; Levin, M				Hibberd, ML; Sumiya, M; Summerfield, JA; Booy, R; Levin, M		Meningococcal Res Grp	Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease	LANCET			English	Article							NEISSERIA-MENINGITIDIS; PROTEIN GENE; COMPLEMENT DEFICIENCIES; INNATE IMMUNITY; SERINE-PROTEASE; MUTATIONS; DEFECT; POLYMORPHISM; POPULATION; ACTIVATION	Background The reasons why meningococcal disease develops in only a small proportion of individuals carrying the causative bacteria are unknown. Differences in host responses to bacterial colonisation are thought to be involved, since people with deficiencies in the terminal components of the complement pathway, or of properdin, are susceptible to meningococcal disease. We postulate that genetic variants of mannose-binding lectin (MBL), a plasma opsonin that initiates another pathway of complement activation, might similarly cause susceptibility to meningococcal disease. Methods The frequency of variants of the MBL gene was ascertained in children with meningococcal disease and controls from two independent studies; one hospital-based (194 patients and 272 controls [patients with noninfectious disorders]), and one community-based (72 patients and 110 controls [healthy individuals]), by means of PCR and restriction-enzyme digestion, with confirmation by DNA sequencing. Findings The proportion of people homozygous for MBL-variant alleles was higher in patients with meningococcal disease than in controls in the hospital study (15 [7.7%] vs four [1.5%]; odds ratio 6.5 [95% CI 2.0-27.2]) and in the community study (six [8.3%] vs three [2.7%]; 4.5 [0.9-29.1]). The population attributable fraction of cases attributable to MBL variants (homozygous and heterozygous) was 32%, Interpretation The MBL pathway is a critical determinant of meningococcal-disease susceptibility, and genetic variants of MBL might account for a third of all disease cases.	St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England; St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med, London W2 1PG, England; Inst Child Hlth, London, England	Imperial College London; Imperial College London; University of London; University College London	Levin, M (corresponding author), St Marys, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England.	m.levin@ic.ac.uk	Hibberd, Martin L/D-5050-2009	Levin, Michael/0000-0003-2767-6919; Hibberd, Martin/0000-0001-8587-1849				CARTWRIGHT K, 1995, MENINGOCOCCAL DIS, P159; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; DENSEN P, 1987, NEW ENGL J MED, V316, P922, DOI 10.1056/NEJM198704093161506; deVries FP, 1996, INFECT IMMUN, V64, P2998, DOI 10.1128/IAI.64.8.2998-3006.1996; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fearon DT, 1977, NATURE, V388, P323, DOI DOI 10.1038/40967; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FIJEN CAP, 1989, LANCET, V2, P585; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; Hammerschmidt S, 1996, EMBO J, V15, P192, DOI 10.1002/j.1460-2075.1996.tb00347.x; Jack DL, 1998, J IMMUNOL, V160, P1346; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MARSDEN HO, 1995, J IMMUNOL, V155, P3013; Mead R, 1997, LANCET, V349, P1669, DOI 10.1016/S0140-6736(05)62635-9; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; NADEL S, 1995, MENINGOCOCCAL DIS, P207; OHTA M, 1990, J BIOL CHEM, V265, P1980; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; SUPER M, 1989, LANCET, V2, P1236; TABONA P, 1995, IMMUNOLOGY, V85, P153; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1	33	289	295	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1049	1053		10.1016/S0140-6736(98)08350-0	http://dx.doi.org/10.1016/S0140-6736(98)08350-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199352				2022-12-28	WOS:000079614000011
J	Mullikin, JC; McMurray, AA				Mullikin, JC; McMurray, AA			DNA sequencing - Sequencing the genome, fast	SCIENCE			English	Editorial Material									Wellcome Trust, Sanger Ctr, Hinxton CB10 1SA, Cambs, England	Wellcome Trust Sanger Institute	Mullikin, JC (corresponding author), Wellcome Trust, Sanger Ctr, Genome Campus, Hinxton CB10 1SA, Cambs, England.							Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; KAMBARA H, 1993, NATURE, V361, P565, DOI 10.1038/361565a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	4	27	29	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1867	1868		10.1126/science.283.5409.1867	http://dx.doi.org/10.1126/science.283.5409.1867			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206892				2022-12-28	WOS:000079228600030
J	Armstrong, P; Armstrong, H				Armstrong, P; Armstrong, H			Decentralised health care in Canada	BRITISH MEDICAL JOURNAL			English	Article									Carleton Univ, Sch Social Work, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Sch Canadian Studies, Ottawa, ON K1S 5B6, Canada	Carleton University; Carleton University	Armstrong, H (corresponding author), Carleton Univ, Sch Social Work, Ottawa, ON K1S 5B6, Canada.							ARMSTRONG P, 1998, UNIVERSAL HLTH CARE; *CAN I HLTH INF, 1998, NAT HLTH EXP TRENDS; *CAN ROYAL COMM HL, 1964, FIN REP; EVANS R, 1993, POLICY OPTIONS   JUL, P37; *NAT FOR HLTH STRI, 1997, CAN HLTH ACT BUILD L, V2; NELSON J, 1995, CANADIAN FORUM   JAN, P7; *STA CAN, 1998, CAN YB 1997; TAYLOR M, 1978, HLTH INSURANCE CANAD, P7; WICKENS B, 1998, MACLEANS        0615, P21	9	12	12	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1201	1204						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221952				2022-12-28	WOS:000080277900039
J	Furrer, H; Egger, M; Opravil, M; Bernasconi, E; Hirschel, B; Battegay, M; Telenti, A; Vernazza, PL; Rickenbach, M; Flepp, M; Malinverni, R				Furrer, H; Egger, M; Opravil, M; Bernasconi, E; Hirschel, B; Battegay, M; Telenti, A; Vernazza, PL; Rickenbach, M; Flepp, M; Malinverni, R		Swiss HIV Cohort Study	Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; AEROSOLIZED PENTAMIDINE; HIV-INFECTION; TOXOPLASMIC ENCEPHALITIS; MAINTENANCE THERAPY; RANDOMIZED TRIAL; CD4 PERCENTAGE; AIDS PATIENTS; IMPACT; SWITZERLAND	Background It is unclear whether primary prophylaxis against Pneumocystis carinii pneumonia can be discontinued in patients infected with the human immunodeficiency virus (HIV) who are successfully treated with combination antiretroviral therapy. We prospectively studied the safety of stopping prophylaxis among patients in the Swiss HIV Cohort Study. Methods Patients were eligible for our study if their CD4 counts had increased to at least 200 cells per cubic millimeter and 14 percent of total lymphocytes while they were receiving combination antiretroviral therapy, with these levels sustained for at least 12 weeks. Prophylaxis was stopped at study entry, and patients were examined every three months thereafter. The development of P. carinii pneumonia was the primary end point, and the development of toxoplasmic encephalitis the secondary end point. Results Of the 262 patients included in our analysis, 121 (46.2 percent) were positive for IgG antibodies to Toxoplasma gondii at base line. The median CD4 count at study entry was 325 per cubic millimeter (range, 210 to 806); the median nadir CD4 count was 110 per cubic millimeter (range, 0 to 240). During a median follow-up of 11.3 months (range, 3.0 to 18.8), prophylaxis was resumed in nine patients, and two patients died. There were no cases of P. carinii pneumonia or toxoplasmic encephalitis. The one-sided upper 99 percent confidence limit for the incidence of P. carinii pneumonia was 1.9 cases per 100 patient-years (based on 238 patient-years of followup). The corresponding figure for toxoplasmic encephalitis was 4.2 per 100 patient-years (based on 110 patient-years of follow-up). Conclusions Stopping primary prophylaxis against Fl carinii pneumonia appears to be safe in HIV-infected patients who are receiving combination antiretroviral treatment and who have had a sustained increase in their CD4 counts to at least 200 cells per cubic millimeter and to at least 14 percent of total lymphocytes. (N Engl J Med 1999;340:1301-6.) (C)1999, Massachusetts Medical Society.	Inselspital, HIV Sprechstunde, CH-3010 Bern, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Spital Zurich, Abt Infektionskrankheiten & Spitalhyg, Zurich, Switzerland; Osped Reg Lugano, Lugano, Switzerland; Univ Geneva, Hop Cantonal, Div Malad Infect, CH-1211 Geneva, Switzerland; Univ Basel, Kantonsspital, Med Poliklin, CH-4031 Basel, Switzerland; CHU Vaudois, Div Malad Infect, CH-1011 Lausanne, Switzerland; Kantonsspital, Klin Innere Med A, St Gallen, Switzerland; Swiss HIV Cohort Study, Coordinat & Data Ctr, Lausanne, Switzerland	University of Bern; University Hospital of Bern; University of Bristol; University of Zurich; University Zurich Hospital; University of Geneva; Kantonsspital Aarau AG (KSA); University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Furrer, H (corresponding author), Inselspital, HIV Sprechstunde, CH-3010 Bern, Switzerland.		Furrer, Hansjakob/G-6768-2013; Telenti, Amalio/AAY-1674-2021	Furrer, Hansjakob/0000-0002-1375-3146; Egger, Matthias/0000-0001-7462-5132				[Anonymous], 1986, MMWR-MORBID MORTAL W, V35, P757; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Bucher HC, 1997, J ACQ IMMUN DEF SYND, V15, P104, DOI 10.1097/00042560-199706010-00002; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Chaisson RE, 1998, AIDS, V12, P29, DOI 10.1097/00002030-199801000-00004; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Currier J S, 1998, AIDS Clin Care, V10, P73; CURRIER JS, 1998, AIDS CLIN CARE, V10, P79; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KIDD PG, 1993, AIDS, V7, P933, DOI 10.1097/00002030-199307000-00005; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MASUR H, 1993, NEW ENGL J MED, V328, P1136; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; OPRAVIL M, 1995, CLIN INFECT DIS, V20, P531, DOI 10.1093/clinids/20.3.531; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; TORRES RA, 1993, AM J MED, V95, P573, DOI 10.1016/0002-9343(93)90352-P; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; *USPHS IDSA PREV O, 1997, CLIN INFECT DIS S3, V25, pS299	33	201	209	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1301	1306		10.1056/NEJM199904293401701	http://dx.doi.org/10.1056/NEJM199904293401701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219064	Green Published			2022-12-28	WOS:000080001700001
J	Welton, AJ; Vickers, MR; Cooper, JA; Meade, TW; Marteau, TM				Welton, AJ; Vickers, MR; Cooper, JA; Meade, TW; Marteau, TM			Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study	BRITISH MEDICAL JOURNAL			English	Article							THERAPY	Objective to investigate whether including a placebo arm in a clinical trial of hormone replacement therapy influenced women's stated willingness to participate. Design quasirandomised, interview based study: Setting 10 group practices in the Medical Research Council's General Practice Research Framework. Participants 436 postmenopausal women aged 45-64 who had not had a hysterectomy. Main outcome measures Stated willingness to enter a placebo arm, 85 (39%) indicated their willingness to enter compared with 65 (30%) of the 218 women told about the trial with the placebo arm (P = 0.06). Part of this difference was due to explicit reluctance to take a placebo. Altruism and personal benefit were the reasons most frequently given for wanting to take part in a trial. The reasons most frequently cited for not wanting to take part were reluctance to restart periods, not wanting to take unknown or unnecessary tablets, or not wanting to interfere with present good health. Conclusion for preventive trials the inclusion of a placebo arm may reduce patients' willingness to participate.	St Bartholomews & Royal London Hosp, Sch Med & Dent, Wolfson Inst Prevent Med, MRC,Epidemiol & Med Care Unit, London EC1M 6BQ, England; Univ London Kings Coll, Psychol & Genet Res Grp, London SE1 9RT, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; University of London; King's College London	Welton, AJ (corresponding author), St Bartholomews & Royal London Hosp, Sch Med & Dent, Wolfson Inst Prevent Med, MRC,Epidemiol & Med Care Unit, London EC1M 6BQ, England.			Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; Fisher LD., 1997, BIOMETRICS, V53, P1182; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HUNTER MS, 1994, MATURITAS, V20, P13, DOI 10.1016/0378-5122(94)90096-5; MATTSON ME, 1985, CONTROL CLIN TRIALS, V6, P156, DOI 10.1016/0197-2456(85)90121-7; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *OFF POP CENS SURV, 1993, STAND OCC CLASS; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Wilkes HC, 1996, BRIT MED J, V312, P473	10	87	86	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1114	1117		10.1136/bmj.318.7191.1114	http://dx.doi.org/10.1136/bmj.318.7191.1114			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213724	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080166000026
J	Jones, J				Jones, J			Breast cancer treatment delays affect survival	BRITISH MEDICAL JOURNAL			English	News Item																		Ramirez AJ, 1999, LANCET, V353, P1127, DOI 10.1016/S0140-6736(99)02142-X; Sainsbury R, 1999, LANCET, V353, P1132	2	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					959	959		10.1136/bmj.318.7189.959	http://dx.doi.org/10.1136/bmj.318.7189.959			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195954	Green Published			2022-12-28	WOS:000079751500007
J	Coates, AS				Coates, AS			Breast cancer: delays, dilemmas, and delusions	LANCET			English	Editorial Material							SURVIVAL		Australian Canc Soc, Sydney, NSW 2006, Australia; Univ Sydney, Australian New Zealand Breast Canc Trials Grp, Sydney, NSW 2006, Australia	University of Sydney	Coates, AS (corresponding author), Australian Canc Soc, Sydney, NSW 2006, Australia.							AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; ELWOOD JM, 1980, BRIT MED J, V280, P1291, DOI 10.1136/bmj.280.6227.1291; National Research Council [NRC]. (US), 1995, COLL AGR LAND GRANT, P1; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9	5	54	56	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1112	1113		10.1016/S0140-6736(99)00082-3	http://dx.doi.org/10.1016/S0140-6736(99)00082-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209969				2022-12-28	WOS:000079858400002
J	Caterina, MJ; Rosen, TA; Tominaga, M; Brake, AJ; Julius, D				Caterina, MJ; Rosen, TA; Tominaga, M; Brake, AJ; Julius, D			A capsaicin-receptor homologue with a high threshold for noxious heat	NATURE			English	Article							SENSORY NEURONS; CHANNELS; TRANSDUCTION; ACTIVATION; PROTEIN; CALCIUM; INVITRO; TRP	Pain-producing heat is detected by several classes of nociceptive sensory neuron that differ in their thermal response thresholds(1-3). The cloned capsaicin receptor, also known as the vanilloid receptor subtype 1 (VR1), is a heat-gated ion channel that has been proposed to mediate responses of small-diameter sensory neurons to moderate (43 degrees C) thermal stimuli(4,5). VR1 is also activated by protons, indicating that it may participate in the detection of noxious thermal and chemical stimuli in vivo. Here we identify a structurally related receptor, VRL-1, that does not respond to capsaicin, acid or moderate heat. Instead, VRL-1 is activated by high temperatures, with a threshold of similar to 52 degrees C. Within sensory ganglia, VRL-1 is most prominently expressed by a subset of medium- to large-diameter neurons, making it a candidate receptor for transducing high-threshold heat responses in this dass of cells. VRL-1 transcripts are not restricted to the sensory nervous system, indicating that this channel may be activated by stimuli other than heat. We propose that responses to noxious heat involve these related, but distinct, ion-channel subtypes that together detect a range of stimulus intensities.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CMAPBELL JN, 1986, SPINAL AFFERENT PROC, P59; Colbert HA, 1997, J NEUROSCI, V17, P8259; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; DUBNER R, 1977, PAIN TRIGEMINAL REGI, P57; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Helliwell RJA, 1998, NEUROSCI LETT, V250, P177, DOI 10.1016/S0304-3940(98)00475-3; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; LAWSON SN, 1985, J PHYSL, V371, pP59; LEEM JW, 1993, J NEUROPHYSIOL, V69, P1684, DOI 10.1152/jn.1993.69.5.1684; LIGHT AR, 1979, J COMP NEUROL, V186, P117, DOI 10.1002/cne.901860202; MARSH SJ, 1987, NEUROSCIENCE, V23, P275, DOI 10.1016/0306-4522(87)90289-2; McCarthy PW, 1997, J COMP NEUROL, V388, P541; MEYER RA, 1994, TXB PAIN, P13; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nagy I, 1999, NEUROSCIENCE, V88, P995, DOI 10.1016/S0306-4522(98)00535-1; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Todd AJ, 1998, NEUROSCIENCE, V85, P459, DOI 10.1016/S0306-4522(97)00669-6; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WINTER J, 1993, NEUROSCIENCE, V57, P747, DOI 10.1016/0306-4522(93)90021-7; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	30	1133	1199	8	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					436	441		10.1038/18906	http://dx.doi.org/10.1038/18906			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201375				2022-12-28	WOS:000079508200055
J	Hsieh, JC; Kodjabachian, L; Rebbert, ML; Rattner, A; Smallwood, PM; Samos, CH; Nusse, R; Dawid, IB; Nathans, J				Hsieh, JC; Kodjabachian, L; Rebbert, ML; Rattner, A; Smallwood, PM; Samos, CH; Nusse, R; Dawid, IB; Nathans, J			A new secreted protein that binds to Wnt proteins and inhibits their activities	NATURE			English	Article							XENOPUS EMBRYOS	The Wnt proteins constitute a large family of extracellular signalling molecules that are found throughout the animal kingdom and are important for a wide variety of normal and pathological developmental processes(1,2). Here we describe Wnt-inhibitory factor-1 (WIF-1), a secreted protein that binds to Wnt proteins and inhibits their activities. WIF-1 is present in fish, amphibia and mammals, and is expressed during Xenopus and zebrafish development in a Complex pattern that includes paraxial presomitic mesoderm, notochord, branchial arches and neural crest derivatives. We use Xenopus embryos to show that WIF-1 overexpression affects somitogenesis (the generation of trunk mesoderm segments), in agreement with its normal expression in paraxial mesoderm. In vitro, WIF-1 binds to Drosophila Wingless and Xenopus Wnt8 produced by Drosophila S2 cells. Together with earlier results obtained with the secreted Frizzled-related proteins(1.2), our results indicate that Wnt proteins interact with structurally diverse extracellular inhibitors, presumably to fine-tune the spatial and temporal patterns of Wnt activity.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; Stanford Univ, Med Ctr, Sch Med, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Stanford University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.		Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Nathans, Jeremy/0000-0001-8106-5460; Kodjabachian, Laurent/0000-0002-4000-612X; Rattner, Amir/0000-0001-9542-6212				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; MOON RT, 1993, DEVELOPMENT, P85; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; PEIFER M, 1993, DEVELOPMENT, V118, P1191; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	17	559	608	2	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					431	436		10.1038/18899	http://dx.doi.org/10.1038/18899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201374				2022-12-28	WOS:000079508200054
J	Denton, MD; Magee, CC; Sayegh, MH				Denton, MD; Magee, CC; Sayegh, MH			Immunosuppressive strategies in transplantation	LANCET			English	Review							RENAL-ALLOGRAFT REJECTION; RABBIT ANTITHYMOCYTE GLOBULIN; RANDOMIZED CONTROLLED TRIAL; T-CELL; LONG-TERM; MYCOPHENOLATE-MOFETIL; MONOCLONAL-ANTIBODY; TACROLIMUS FK506; CYCLOSPORINE MICROEMULSION; KIDNEY-TRANSPLANTATION		Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Renal Div,Lab Immunogenet & Transplantat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sayegh, MH (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Renal Div,Lab Immunogenet & Transplantat, Boston, MA 02115 USA.	msayegh@rics.bwh.harvard.edu						[Anonymous], 1998, Transplantation, V65, P235; AZUMA H, 1995, TRANSPLANTATION, V59, P460; BACKMAN L, 1998, TRANSPL SOC 17 WORLD, P116; Bennett WM, 1996, KIDNEY INT, V50, P1089, DOI 10.1038/ki.1996.415; Burk ML, 1997, ANN PHARMACOTHER, V31, P1370, DOI 10.1177/106002809703101115; BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; Chandraker A, 1997, TRANSPLANTATION, V63, P1053, DOI 10.1097/00007890-199704270-00002; Chandraker A, 1998, J CLIN INVEST, V101, P2309, DOI 10.1172/JCI2299; Cole E, 1998, TRANSPLANTATION, V65, P505, DOI 10.1097/00007890-199802270-00009; Dantal J, 1996, TRANSPLANTATION, V62, P1502, DOI 10.1097/00007890-199611270-00020; Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1; Delmonico FL, 1997, TRANSPLANTATION, V63, P1243; Denton M D, 1998, Pediatr Transplant, V2, P6; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GASTON RS, 1995, NEW ENGL J MED, V332, P752; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Giral M, 1997, TRANSPLANTATION, V63, P1004, DOI 10.1097/00007890-199704150-00017; GOLDBERG LC, 1995, TRANSPLANTATION, V59, P1285, DOI 10.1097/00007890-199505000-00011; GREWAL H, 1998, TRANSPLANTATION, V65, pS167; Halloran P, 1997, TRANSPLANTATION, V63, P39, DOI 10.1097/00007890-199701150-00008; Hata Y, 1996, Clin Transpl, P381; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; HUTCHINSON IV, 1998, GRAFT, V1, P186; Jensik SC, 1998, TRANSPLANT P, V30, P1216, DOI 10.1016/S0041-1345(98)00216-4; Jordan ML, 1997, TRANSPLANTATION, V63, P223, DOI 10.1097/00007890-199701270-00008; KAHAN B, 1998, TRANSPLANTATION, V65, pS167; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kahan BD, 1996, TRANSPLANTATION, V62, P599, DOI 10.1097/00007890-199609150-00010; Kaplon RJ, 1996, TRANSPLANTATION, V61, P356, DOI 10.1097/00007890-199602150-00004; Kelly PA, 1997, PHARMACOTHERAPY, V17, P1148; Keown P, 1998, KIDNEY INT, V54, P938, DOI 10.1046/j.1523-1755.1998.00042.x; Keown P, 1996, TRANSPLANTATION, V61, P1029; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KIRKMAN RL, 1991, TRANSPLANTATION, V51, P107, DOI 10.1097/00007890-199101000-00016; Kobashigawa J, 1998, TRANSPLANTATION, V66, P507, DOI 10.1097/00007890-199808270-00016; KRENSKY AM, 1990, NEW ENGL J MED, V322, P510, DOI 10.1056/NEJM199002223220805; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lazarovits AI, 1996, NATURE, V380, P717, DOI 10.1038/380717a0; Levisetti MG, 1997, J IMMUNOL, V159, P5187; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LIU Z, 1993, J EXP MED, V177, P1643, DOI 10.1084/jem.177.6.1643; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; Massy ZA, 1996, J AM SOC NEPHROL, V7, pA3063; Mathew TH, 1998, TRANSPLANTATION, V65, P1450, DOI 10.1097/00007890-199806150-00007; Mayer AD, 1997, TRANSPLANTATION, V64, P436, DOI 10.1097/00007890-199708150-00012; Murgia MG, 1996, KIDNEY INT, V49, P209, DOI 10.1038/ki.1996.28; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; NEUHAUS P, 1994, LANCET, V344, P423; Noel PJ, 1996, J IMMUNOL, V157, P636; Opelz G, 1998, TRANSPLANT P, V30, P1716, DOI 10.1016/S0041-1345(98)00402-3; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; PERICO N, 1995, J AM SOC NEPHROL, V5, P1618; Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013; Platt JL, 1997, CURR OPIN NEPHROL HY, V6, P284, DOI 10.1097/00041552-199705000-00014; Ratcliffe PJ, 1996, LANCET, V348, P643, DOI 10.1016/S0140-6736(96)02510-X; Russell ME, 1996, J CLIN INVEST, V97, P833, DOI 10.1172/JCI118483; Sayegh MH, 1996, KIDNEY INT, V49, pS13; SAYEGH MH, 1994, TRANSPLANTATION, V57, P1295, DOI 10.1097/00007890-199405150-00001; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMID C, 1995, TRANSPLANTATION, V60, P729, DOI 10.1097/00007890-199510150-00020; Sheil AGR, 1997, TRANSPL P, V29, P825, DOI 10.1016/S0041-1345(96)00151-0; Shin GT, 1998, TRANSPLANTATION, V65, P313, DOI 10.1097/00007890-199802150-00003; Sievers TM, 1997, PHARMACOTHERAPY, V17, P1178; SOLLINGER HW, 1992, ANN SURG, V216, P513, DOI 10.1097/00000658-199210000-00014; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; Spencer CM, 1997, DRUGS, V54, P925, DOI 10.2165/00003495-199754060-00009; SQUIFFLET J, 1997, RANDOMIZED STUDY BTI, P693; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; Suthanthiran M, 1998, NEPHROL DIAL TRANSPL, V13, P21, DOI 10.1093/ndt/13.suppl_1.21; SUTHANTHIRAN M, 1989, TRANSPLANTATION, V47, P348, DOI 10.1097/00007890-198902000-00033; SUTHANTHIRAN M, 1998, GRAFT, V1, P173; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; Van Parijs L, 1998, SCIENCE, V280, P243; Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; VINCENTI F, 1998, TRANSPLANTATION, V65, pS190; Vu MD, 1997, TRANSPLANTATION, V64, P1853, DOI 10.1097/00007890-199712270-00039; Weir MR, 1997, TRANSPLANTATION, V64, P1706, DOI 10.1097/00007890-199712270-00013; Wood KJ, 1997, CURR OPIN IMMUNOL, V9, P662, DOI 10.1016/S0952-7915(97)80046-5; WOOD KJ, 1991, CURR OPIN IMMUNOL, V3, P710, DOI 10.1016/0952-7915(91)90101-6	87	323	337	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1083	1091		10.1016/S0140-6736(98)07493-5	http://dx.doi.org/10.1016/S0140-6736(98)07493-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199367				2022-12-28	WOS:000079614000043
J	Gordon, JW				Gordon, JW			Genetic enhancement in humans	SCIENCE			English	Editorial Material							GERM LINE TRANSMISSION; MOUSE EMBRYOS; STEM-CELLS; EXPRESSION; MICE; TRANSFORMATION; INJECTION; SKI		CUNY Mt Sinai Sch Med, Ctr Lab Anim Sci, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gordon, JW (corresponding author), CUNY Mt Sinai Sch Med, Ctr Lab Anim Sci, New York, NY 10029 USA.	jgordon@smtplink.mssm.edu						BOWEN RA, 1994, BIOL REPROD, V50, P664, DOI 10.1095/biolreprod50.3.664; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; COSTANTINI F, 1981, NATURE, V294, P92, DOI 10.1038/294092a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; Kramer KJ, 1997, INSECT BIOCHEM MOLEC, V27, P887, DOI 10.1016/S0965-1748(97)00078-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1994, TRANSGENIC RES, V3, P401, DOI 10.1007/BF01976771; PURSEL VG, 1987, VET IMMUNOL IMMUNOP, V17, P303, DOI 10.1016/0165-2427(87)90149-8; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; STOCK G, 1998, SUMMARY REPORT ENG H; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	20	29	33	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2023	2024		10.1126/science.283.5410.2023	http://dx.doi.org/10.1126/science.283.5410.2023			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10206908				2022-12-28	WOS:000079369800027
J	Beecham, L				Beecham, L			Juniors predict chaos at the millennium	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1218	1218						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221968				2022-12-28	WOS:000080277900071
J	Malt, UF; Robak, OH; Madsbu, HP; Bakke, O; Loeb, M				Malt, UF; Robak, OH; Madsbu, HP; Bakke, O; Loeb, M			The Norwegian naturalistic treatment study of depression in general practice (NORDEP) - I: randomised double blind study	BRITISH MEDICAL JOURNAL			English	Article							MAJOR DEPRESSION; PRIMARY-CARE; MANAGEMENT; PLACEBO	Objective To evaluate the efficacy of emotional support and counselling combined with placebo or antidepressants with single or dual mechanism of action in the treatment of depression in primary care. Design Randomised double blind study. Setting Several locations in Norway. Subjects 372 patients with depression. Main outcome measures Improvement (clinical remission) reported both by the patient (Montgomery Asberg depression rating scale) and the physician (clinical global improvement and impression scales). Results Intention to treat analyses showed 47% remission in patients randomised to placebo compared with 61% remission in patients randomised to sertraline (odds ratio 0.56, 95% confidence interval 0.33 to 0.96) and 54% in patients randomised to mianserin (0.75, 0.44 to 1.27). Women responded better than men (1.86, 1.17 to 2.96). Subgroup analyses showed that subjects with recurrent depression (n = 273) responded more frequently to sertraline than to placebo (0.43, 0.23 to 0.82) than those having their first episode of depression (1.18,. 0.39 to 3.61). Statistically significant interactions between type of drug treatment and history of depression were not shown by logistic regression. Conclusion The combination of active drug and simple psychological treatment (counselling, emotional support, and close follow up over a 24 week period) was more effective than simple psychological treatment alone, in particular for those with recurrent depression. Overall, women may benefit more than men. If confirmed in future;studies, the findings should lead to more differentiated treatment guidelines for depression in primary care.	Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, N-0027 Oslo, Norway; Psychiat Ctr No Vestfold, N-3080 Holmestrand, Norway; Elverum Legesenter, N-2401 Elverum, Norway; Aust Agder Cent Hosp, Dept Psychiat, N-4800 Arendal, Norway; Ulleval Hosp, Norwegian Insurance Agencies, N-0407 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo	Malt, UF (corresponding author), Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, N-0027 Oslo, Norway.			Malt, Ulrik/0000-0002-9881-2511				ALLTMAN DG, 1991, PRACTICAL STAT MED R; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bech P, 1993, ACTA PSYCHIAT S S372, V87; Coyne JC, 1997, GEN HOSP PSYCHIAT, V19, P333, DOI 10.1016/S0163-8343(97)00055-8; Depression Guideline Panel, 1993, DEPR PRIM CAR, DOI [10.1002/depr.3050020202, DOI 10.1002/DEPR.3050020202]; Ekselius L, 1997, INT CLIN PSYCHOPHARM, V12, P323, DOI 10.1097/00004850-199711000-00005; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; LANE R, 1995, J PSYCHOPHARMACOL, V9, P163, DOI 10.1177/0269881195009002011; LINGJAERDE O, 1987, ACTA PSYCHIAT S S334, V76; Montgomery S. A., 1979, BRIT J PSYCHIAT, V134, P322; MONTGOMERY SA, 1997, INT CLIN PSYCHOPH S3, V12, pS1; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Nordic Council on Medicine, 1989, NLN PUBL; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; Salokangas RKR, 1996, ACTA PSYCHIAT SCAND, V93, P427, DOI 10.1111/j.1600-0447.1996.tb10673.x; SOLOMAN DA, 1997, ARCH GEN PSYCHIAT, V54, P10001; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	18	73	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1180	1184						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221945				2022-12-28	WOS:000080277900033
J	Artavanis-Tsakonas, S; Rand, MD; Lake, RJ				Artavanis-Tsakonas, S; Rand, MD; Lake, RJ			Notch signaling: Cell fate control and signal integration in development	SCIENCE			English	Review							DORSAL/VENTRAL COMPARTMENT BOUNDARY; SENSORY ORGAN LINEAGE; SPLIT COMPLEX GENES; DOMAINS IN-VIVO; ACTIVATED NOTCH; NEUROBLAST SEGREGATION; CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL ACTIVATION; DROSOPHILA-NEUROGENESIS; INTRACELLULAR DOMAIN	Notch signaling defines an evolutionarily ancient cell interaction mechanism, which plays a fundamental role in metazoan development. Signals exchanged between neighboring cells through the Notch receptor can amplify and consolidate molecular differences, which eventually dictate cell fates. Thus, Notch signals control how cells respond to intrinsic or extrinsic developmental cues that are necessary to unfold specific developmental programs. Notch activity affects the implementation of differentiation, proliferation, and apoptotic programs, providing a general developmental tool to influence organ formation and morphogenesis.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cell Biol,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Artavanis-Tsakonas, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Cell Biol,Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.				NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Batterham P, 1996, BIOESSAYS, V18, P841, DOI 10.1002/bies.950181011; BATTERHAM P, COMMUNICATION; Berry LW, 1997, DEVELOPMENT, V124, P925; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bray S, 1998, SEMIN CELL DEV BIOL, V9, P591, DOI 10.1006/scdb.1998.0262; BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; de Celis JF, 1998, DEVELOPMENT, V125, P4617; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gho M, 1996, DEVELOPMENT, V122, P1673; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Go MJ, 1998, DEVELOPMENT, V125, P2031; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; GU Y, 1995, DEVELOPMENT, V121, P855; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jehn BM, 1999, J IMMUNOL, V162, P635; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Klueg KM, 1998, MOL BIOL CELL, V9, P1709, DOI 10.1091/mbc.9.7.1709; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; KURATA S, UNPUB; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Moohr OL, 1919, GENETICS, V4, P252; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; NYE JS, 1994, DEVELOPMENT, V120, P2421; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; REBAY I, 1993, THESIS YALE U; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seugnet L, 1997, DEVELOPMENT, V124, P2015; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Sherwood DR, 1997, DEVELOPMENT, V124, P3363; Sotillos S, 1997, DEVELOPMENT, V124, P4769; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Sun X, 1997, DEVELOPMENT, V124, P3439; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verheyen EM, 1996, GENETICS, V144, P1127; Weinmaster G, 1998, CURR OPIN GENET DEV, V8, P436, DOI 10.1016/S0959-437X(98)80115-9; Wen CH, 1997, DEVELOPMENT, V124, P4759; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WRIGHT TRF, 1970, ADV GENET, V15, P261, DOI 10.1016/S0065-2660(08)60075-9; XU T, 1990, THESIS YALE U; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zeng CY, 1998, GENE DEV, V12, P1086, DOI 10.1101/gad.12.8.1086	108	4654	4961	17	498	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					770	776		10.1126/science.284.5415.770	http://dx.doi.org/10.1126/science.284.5415.770			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221902				2022-12-28	WOS:000080056200036
J	Guidotti, LG; Rochford, R; Chung, J; Shapiro, M; Purcell, R; Chisari, FV				Guidotti, LG; Rochford, R; Chung, J; Shapiro, M; Purcell, R; Chisari, FV			Viral clearance without destruction of infected cells during acute HBV infection	SCIENCE			English	Article							HEPATITIS-B VIRUS; TRANSGENIC MICE; INTRACELLULAR INACTIVATION; T-CELLS; HEPATOCYTE; RECOVERY; CHIMPANZEES; REPLICATION; EXPRESSION; THERAPY	Viral clearance during hepatitis B virus (HBV) infection has been thought to reflect the destruction of infected hepatocytes by CD8(+) T lymphocytes. However, in this study, HBV DNA was shown to Largely disappear from the Liver and the blood of acutely infected chimpanzees Long before the peak of T cell infiltration and most of the Liver disease. These results demonstrate that noncytopathic antiviral mechanisms contribute to viral clearance during acute viral hepatitis by purging HBV replicative intermediates from the cytoplasm and covalently closed circular viral DNA from the nucleus of infected cells.	Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Bioqual Inc, Rockville, MD 20850 USA; NIH, Bethesda, MD 20892 USA	Scripps Research Institute; University of Michigan System; University of Michigan; BIOQUAL Inc.; National Institutes of Health (NIH) - USA	Chisari, FV (corresponding author), Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.		Guidotti, Luca G. G/I-8542-2018; Chisari, Francis V/A-3086-2008	Guidotti, Luca G. G/0000-0002-0205-2678; Chisari, Francis/0000-0002-4832-1044	NCI NIH HHS [R37 CA40489] Funding Source: Medline; NIAID NIH HHS [R01 AI40696, R01 AI20001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020001, R01AI040696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER LF, 1975, J INFECT DIS, V132, P451, DOI 10.1093/infdis/132.4.451; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bertoni R, 1998, J IMMUNOL, V161, P4447; BOCK CT, 1994, VIRUS GENES, V8, P215, DOI 10.1007/BF01703079; Cavanaugh VJ, 1998, J VIROL, V72, P2630, DOI 10.1128/JVI.72.4.2630-2637.1998; FEUTREN G, 1984, J IMMUNOL METHODS, V75, P85, DOI 10.1016/0022-1759(84)90227-8; FOUREL I, 1994, J VIROL, V68, P8321, DOI 10.1128/JVI.68.12.8321-8330.1994; Franco A, 1997, J IMMUNOL, V159, P2001; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Guidotti LG, 1996, P NATL ACAD SCI USA, V93, P4589, DOI 10.1073/pnas.93.10.4589; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; GUIDOTTI LG, UNPUB; HUME DA, 1987, J LEUKOCYTE BIOL, V42, P474, DOI 10.1002/jlb.42.5.474; JILBERT AR, 1992, J VIROL, V66, P1377, DOI 10.1128/JVI.66.3.1377-1388.1992; KAJINO K, 1994, J VIROL, V68, P5792, DOI 10.1128/JVI.68.9.5792-5803.1994; MORALEDA G, 1997, J VIROL, V71, P9292; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NEWBOLD JE, 1995, J VIROL, V69, P3350, DOI 10.1128/JVI.69.6.3350-3357.1995; PIGNATELLI M, 1986, HEPATOLOGY, V6, P349, DOI 10.1002/hep.1840060303; Rehermann B, 1996, NAT MED, V2, P1104, DOI 10.1038/nm1096-1104; Rochford R, 1997, VIRAL IMMUNOL, V10, P183, DOI 10.1089/vim.1997.10.183; Tay CH, 1998, CURR TOP MICROBIOL, V230, P193; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1	25	960	1051	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					825	829		10.1126/science.284.5415.825	http://dx.doi.org/10.1126/science.284.5415.825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221919				2022-12-28	WOS:000080056200053
J	Shamsian, N				Shamsian, N			Call for international community to protect children in Kosovo	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1097	1097		10.1136/bmj.318.7191.1097	http://dx.doi.org/10.1136/bmj.318.7191.1097			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213710	Green Published			2022-12-28	WOS:000080166000015
J	Mannick, JB; Hausladen, A; Liu, LM; Hess, DT; Zeng, M; Miao, QX; Kane, LS; Gow, AJ; Stamler, JS				Mannick, JB; Hausladen, A; Liu, LM; Hess, DT; Zeng, M; Miao, QX; Kane, LS; Gow, AJ; Stamler, JS			Fas-induced caspase denitrosylation	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; NITRIC-OXIDE; S-NITROSYLATION; INHIBITS APOPTOSIS; ACTIVATION; SUPPRESSION; MECHANISMS; P21(RAS); RECEPTOR; NEURONS	Only a few intracellular S-nitrosylated proteins have been identified, and it is unknown if protein S-nitrosylation/denitrosylation is a component of signal transduction cascades. Caspase-3 zymogens were found to be S-nitrosylated on their catalytic-site cysteine in unstimulated human cell Lines and denitrosylated upon activation of the Fas apoptotic pathway. Decreased caspase-3 S-nitrosylation was associated with an increase in intracellular caspase activity. Fas therefore activates caspase-3 not only by inducing the cleavage of the caspase zymogen to its active subunits, but also by stimulating the denitrosylation of its active-site thiol. Protein S-nitrosylation/denitrosylation can thus serve as a regulatory process in signal transduction pathways.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Resp Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Mannick, JB (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Gow, Andrew/AAR-2309-2020; Gow, Andrew/N-8566-2013	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, R01HL059130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057601] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59130, HL52529] Funding Source: Medline; NIGMS NIH HHS [GM57601-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; Boulakia CA, 1996, ONCOGENE, V12, P529; Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Estevez AG, 1998, J NEUROSCI, V18, P3708; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GENEVIVA GD, 1998, AM J PHYSIOL, V275, pL717; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Z, 1998, NEURON, V20, P1039, DOI 10.1016/S0896-6273(00)80484-5; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANNICK JA, UNPUB; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MANNICK JB, 1997, J BIOL CHEM, V272, P24124; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	35	643	675	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					651	654		10.1126/science.284.5414.651	http://dx.doi.org/10.1126/science.284.5414.651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213689				2022-12-28	WOS:000079951100047
J	McIntire, DD; Bloom, SL; Casey, BM; Leveno, KJ				McIntire, DD; Bloom, SL; Casey, BM; Leveno, KJ			Birth weight in relation to morbidity and mortality among newborn infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAUTERINE GROWTH-RETARDATION; FETAL; PREGNANCIES; RISK	Background At any given gestational age, infants with low birth weight have relatively high morbidity and mortality. It is not known, however, whether there is a threshold weight below which morbidity and mortality are significantly greater, or whether that threshold varies with gestational age. Methods We analyzed the neonatal outcomes of death, five-minute Apgar score, umbilical-artery blood pH, and morbidity due to prematurity for all singleton infants delivered at Parkland Hospital, Dallas, between January 11 1988, and August 31, 1996. A distribution of birth weights according to week of gestation at birth was created. Infants in the 26th through 75th percentiles for weight served as the reference group. Data on preterm infants (those born at 24 to 36 weeks of gestation) were analyzed separately from data on infants delivered at term (37 or more weeks of gestation). Results A total of 122,754 women and adolescents delivered singleton live infants without malformations between 24 and 43 weeks of gestation. Among the 12,317 preterm infants who were analyzed, there was no specific birth-weight percentile at which morbidity and mortality increased. Among 82,361 infants who were born at term and whose birth weights were at or below the 75th percentile, however, the rate of neonatal death increased from 0.03 percent in the reference group (26th through 75th percentile for weight) to 0.3 percent for those with birth weights at or below the 3rd percentile (P<0.001). The incidence of five-minute Apgar scores of 3 or less and umbilical-artery blood pH values of 7.0 or less was approximately doubled for infants at or below the 3rd birth-weight percentile (P=0.003 and P<0.001, respectively). The incidence of intubation at birth, seizures during the first day of life, and sepsis was also significantly increased among term infants with birth weights at or below the 3rd percentile. These differences persisted after adjustment for the mother's race and parity and the infant's sex. Conclusions Mortality and morbidity are increased among infants born at term whose birth weights are at or below the 3rd percentile for their gestational age. (N Engl J Med 1999;340:1234-8.) (C) 1999, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McIntire, DD (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BATTAGLI.FC, 1967, J PEDIATR-US, V71, P159, DOI 10.1016/S0022-3476(67)80066-0; BREART G, 1982, DEV PHARMACOL THERAP, V4, P116, DOI 10.1159/000457366; CUNNINGHAM FG, 1997, WILLIAMS OBSTET, P839; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; JIMENEZ JM, 1983, OBSTET GYNECOL, V61, P438; KRAMER MS, 1990, PEDIATRICS, V86, P707; LAATIKAINEN TJ, 1988, AM J OBSTET GYNECOL, V159, P891, DOI 10.1016/S0002-9378(88)80163-7; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; Manning F. A., 1995, FETAL MED PRINCIPLES, P317; *NIH, 1984, NIH PUBL; Piper JM, 1996, OBSTET GYNECOL, V87, P169, DOI 10.1016/0029-7844(95)00400-9; Seeds JW, 1998, AM J OBSTET GYNECOL, V178, P658, DOI 10.1016/S0002-9378(98)70475-2; SPINILLO A, 1995, J REPROD MED, V40, P209; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657	15	876	900	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1234	1238		10.1056/NEJM199904223401603	http://dx.doi.org/10.1056/NEJM199904223401603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210706				2022-12-28	WOS:000079833800003
J	Foucher, G				Foucher, G			Prospects for hand transplantation	LANCET			English	Editorial Material									SOS Main Emergency Hand Unit Strasbourg, F-67000 Strasbourg, France		Foucher, G (corresponding author), SOS Main Emergency Hand Unit Strasbourg, F-67000 Strasbourg, France.							DELLON AL, 1981, EVALUATION SENSIBILI, P193; DIDIERJEAN A, 1997, RECONSTRUCTIVE SURG, P151; Fansa H, 1999, J HAND SURG-BRIT EUR, V24B, P38, DOI 10.1016/S0266-7681(99)90021-9; LUNDBORG G, 1988, NERVE INJURY REPAIR, P196; ONNE L, 1962, Acta Chir Scand Suppl, VSuppl 300, P1; PILLET J, 1997, RECONSTRUCTIVE SURG, P169; Sims A C, 1985, J Hand Surg Br, V10, P281, DOI 10.1016/S0266-7681(85)80043-7; WILGIS EFS, 1982, OPERATIVE HAND SURGE, P915	8	34	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	1999	353	9161					1286	1287		10.1016/S0140-6736(99)00112-9	http://dx.doi.org/10.1016/S0140-6736(99)00112-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218520				2022-12-28	WOS:000080278100002
J	Wheeler, JG; Sethi, D; Cowden, JM; Wall, PG; Rodrigues, LC; Tompkins, DS; Hudson, MJ; Roderick, PJ				Wheeler, JG; Sethi, D; Cowden, JM; Wall, PG; Rodrigues, LC; Tompkins, DS; Hudson, MJ; Roderick, PJ		Infect Intestinal Dis Study Executive	Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To establish the incidence and aetiology of infectious intestinal disease in the community and presenting to general practitioners. Comparison with incidence and aetiology of cases reaching national laboratory based surveillance. Design Population based community cohort incidence study; general practice based incidence studies, and case linkage to national laboratory surveillance. Setting 70 general practices throughout England. Participants 459975 patients served by the practices. Community surveillance of 9776 randomly selected patients. Main outcome measures Incidence of infectious intestinal disease in community and reported to general practice. Results 781 cases were identified in the community cohort, giving an incidence of 19.4/100 person years (95% confidence interval 18.1 to 20.8). 8770 cases presented to general practice (3/3/100 person years (2.94 to 3.75)). One case was reported to national surveillance for every 1.4 laboratory identifications, 6.2 stools sent for laboratory investigation, 23 cases presenting to general practice, and 136 community cases. The ratio of cases in the community to cases reaching national surveillance was lower for bacterial pathogens (salmonella 3.2:1, campylobacter 7.6:1) than for viruses (rotavirus 35:1, small round structured viruses 1562:1). There were many cases for which no organism was identified. Conclusions Infectious intestinal disease occurs in 1 in 5 people each year, of whom 1 in 6 presents to a general practitioner. The proportion of cases not recorded by national laboratory surveillance is large and varies widely by microorganism. Ways of supplementing die national laboratory surveillance system for infectious intestinal diseases should be considered.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; Food Safety Author Ireland, Dublin 1, Ireland; Leeds Publ Hlth Lab, Leeds LS15 7TR, W Yorkshire, England; Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England; Univ Southampton, Southampton SO6 6YD, Hants, England	University of London; London School of Hygiene & Tropical Medicine; University of Southampton	Wheeler, JG (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	j.wheeler@lshtm.ac.uk	RODRIGUES, LAURA CUNHA/AAO-4130-2021	Rodrigues, Laura Cunha/0000-0001-9008-660X				*COMM MICR SAF FOO, 1990, MICR SAF FOOD 1; Cowden J M, 1995, Commun Dis Rep CDR Rev, V5, pR109; Cowden J.M., 1997, Euro Surveill, V2, P1; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Djuretic T, 1996, Commun Dis Rep CDR Rev, V6, pR78; Evans H S, 1998, Commun Dis Public Health, V1, P165; FELDMAN RA, 1994, EPIDEMIOL INFECT, V113, P41, DOI 10.1017/S095026880005144X; FLEMING DM, 1994, WEEKLY RETURNS SERVI; FRASER RC, 1981, J ROY COLL GEN PRACT, V31, P416; HODGES RG, 1956, AM J HYG, V64, P349, DOI 10.1093/oxfordjournals.aje.a119847; HOOGENBOOMVERDEGAAL AMM, 1994, EPIDEMIOL INFECT, V112, P481, DOI 10.1017/S0950268800051189; KENDALL EJC, 1982, J HYG-CAMBRIDGE, V88, P155, DOI 10.1017/S0022172400070030; MONTO AS, 1980, AM J EPIDEMIOL, V112, P323, DOI 10.1093/oxfordjournals.aje.a112998; Palmer S, 1996, EPIDEMIOL INFECT, V117, P479, DOI 10.1017/S0950268800059148; PAYMENT P, 1991, AM J PUBLIC HEALTH, V81, P703, DOI 10.2105/AJPH.81.6.703; SETHI D, 1998, INT J EPIDEMIOLOGY, V0028; SETHI D, IN PRESS COMM DIS PU; *STAT CORP, 1997, STAT STAT SOFTW REL; TOMPKINS DS, IN PRESS COMM DIS PU; TUCKMAN E, 1962, BRIT MED J, P135, DOI 10.1136/bmj.1.5272.135; Wall P G, 1996, Commun Dis Rep CDR Rev, V6, pR93	21	613	627	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1046	1050		10.1136/bmj.318.7190.1046	http://dx.doi.org/10.1136/bmj.318.7190.1046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205103	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080140000030
J	Sever, S; Muhlberg, AB; Schmid, SL				Sever, S; Muhlberg, AB; Schmid, SL			Impairment of dynamin's GAP domain stimulates receptor-mediated endocytosis	NATURE			English	Article							COATED VESICLE FORMATION; GTPASE-ACTIVATING PROTEINS; MX PROTEINS; GENE; DROSOPHILA; YEAST; MICROTUBULES; ASSEMBLES; SHIBIRE; FORMS	Dynamin is a GTP-hydrolysing protein that is an essential participant in clathrin-mediated endocytosis by cells. It self-assembles into 'collars' in vitro which also form in vivo at the necks of invaginated coated pits. This self-assembly stimulates dynamin's GTPase activity and it has been proposed that dynamin hydrolyses GTP in order to generate the force needed to sever vesicles from the plasma membrane. A mechanism is now described in which self-assembly of dynamin is coordinated by a domain of dynamin with a GTPase-activating function. Unexpectedly, when dynamin mutants defective in self-assembly-stimulated GTPase activity are overexpressed, receptor-mediated endocytosis is accelerated. The results indicate that dynamin, like other members of the GTPase superfamily, functions as a molecular regulator in receptor-mediated endocytosis, rather than as a force-generating GTPase.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schmid, SL (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Schmid, Sandra/0000-0002-1690-7024				AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERSHT A, 1995, ENZYME STRUCTURE MEC; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; Gilbert A, 1997, J CELL SCI, V110, P3105; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MELEN K, 1992, J BIOL CHEM, V267, P25898; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310	41	308	318	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					481	486		10.1038/19024	http://dx.doi.org/10.1038/19024			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206643				2022-12-28	WOS:000079662800039
J	Nightingale, SL				Nightingale, SL			Workshop on Medical Device Clinical Trial Development and Design	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1164	1164		10.1001/jama.281.13.1164	http://dx.doi.org/10.1001/jama.281.13.1164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199413				2022-12-28	WOS:000079464400009
J	Nakagawa, T; Wada, H; Sekizawa, K; Arai, H; Sasaki, H				Nakagawa, T; Wada, H; Sekizawa, K; Arai, H; Sasaki, H			Amantadine and pneumonia	LANCET			English	Article									Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Sendai, Miyagi, Japan	Tohoku University	Sasaki, H (corresponding author), Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Seiryo Machi 1-1, Sendai, Miyagi, Japan.							HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; Itoh M, 1994, Ann Nucl Med, V8, P245; Kobayashi H, 1996, LANCET, V348, P1320, DOI 10.1016/S0140-6736(05)65809-6; Nakagawa T, 1997, ARCH INTERN MED, V157, P321, DOI 10.1001/archinte.157.3.321; YAHR MD, 1989, MERRITTS TXB NEUROLO, P658	5	59	60	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1157	1157		10.1016/S0140-6736(98)05805-X	http://dx.doi.org/10.1016/S0140-6736(98)05805-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209989				2022-12-28	WOS:000079858400023
J	Weiner, AM; Maizels, N				Weiner, AM; Maizels, N			Evolution - A deadly double life	SCIENCE			English	Editorial Material							ACTIVATING POLYPEPTIDE-II; TRANSFER-RNA		Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Weiner, AM (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.							Caprara MG, 1996, CELL, V87, P1135, DOI 10.1016/S0092-8674(00)81807-3; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P9774; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; QUEVILLON S, AF021800 GENB; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147	15	15	15	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					63	64		10.1126/science.284.5411.63	http://dx.doi.org/10.1126/science.284.5411.63			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10215533				2022-12-28	WOS:000079509000029
J	Bullough, R				Bullough, R			John Bullough - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1147	1147		10.1136/bmj.318.7191.1147	http://dx.doi.org/10.1136/bmj.318.7191.1147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213757	Green Published			2022-12-28	WOS:000080166000079
J	Shaw, PJ				Shaw, PJ			Science, medicine, and the future - Motor neurone disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD; GLUTAMATE TRANSPORTER; OXIDATIVE DAMAGE; RILUZOLE; LINKAGE; SUBUNIT; MODEL; GLT-1; GENE		Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Shaw, PJ (corresponding author), Royal Victoria Infirm, Dept Neurol, Ward 11, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	Pamela.Shaw@ncl.ac.uk	Shaw, Pamela J/A-7620-2010; Shaw, Pamela J/A-5215-2009	Shaw, Pamela/0000-0002-8925-2567	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguirre T, 1998, ANN NEUROL, V43, P452, DOI 10.1002/ana.410430407; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; Chance PF, 1998, AM J HUM GENET, V62, P633, DOI 10.1086/301769; Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119; COOKSON MR, IN PRESS BRAIN PATHO; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; INCE P, 1993, NEUROPATH APPL NEURO, V19, P291, DOI 10.1111/j.1365-2990.1993.tb00443.x; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Lai EC, 1997, NEUROLOGY, V49, P1621, DOI 10.1212/WNL.49.6.1621; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; LOUWERSE ES, 1995, ARCH NEUROL-CHICAGO, V52, P559, DOI 10.1001/archneur.1995.00540300031009; Nagai M, 1998, NEUROSCI LETT, V244, P165, DOI 10.1016/S0304-3940(98)00158-X; Olkowski ZL, 1998, NEUROREPORT, V9, P239, DOI 10.1097/00001756-199801260-00012; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; Shaw PJ, 1997, J NEUROL, V244, pS3, DOI 10.1007/BF03160574; Shaw PJ, 1997, J NEUROL SCI, V147, P115, DOI 10.1016/S0022-510X(96)05316-6; SHAW PJ, IN PRESS J NEUROL; TOMKINS J, IN PRESS NEUROREPORT; Williams TL, 1997, ANN NEUROL, V42, P200, DOI 10.1002/ana.410420211	28	42	44	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	1999	318	7191					1118	1121		10.1136/bmj.318.7191.1118	http://dx.doi.org/10.1136/bmj.318.7191.1118			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213726	Green Published			2022-12-28	WOS:000080166000028
J	Adams, JS; Song, CF; Kantorovich, V				Adams, JS; Song, CF; Kantorovich, V			Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPERCALCIURIA; MINERAL DENSITY; THIAZIDE; FRACTURES; HYPERPARATHYROIDISM; ETIOLOGY; THERAPY	Background: Chronic hypercalciuria can contribute to osteoporosis, particularly in men. Objective: To ascertain the effects of resolution of hypercalciuria on bone mineral density. Design: Case series. Setting: Referral service for metabolic bone disease in a tertiary-care teaching hospital. Patients: Five male patients (42 to 66 years of age) with hypercalciuria and osteoporosis. Intervention: Hydrochlorothiazide, 25 mg twice daily, for a mean (+/- SD) of 7.8 +/- 3.6 months. Measurements: Fasting urinary calcium:creatinine ratio, serum calciotropic hormone levels, and bone mineral density before and after hydrochlorothiazide administration. Results: Hydrochlorothiazide resolved hypercalciuria and increased bone mineral density at a rate of 8% and 3% per year at the spine and hip, respectively. Conclusions: Hydrochlorothiazide treatment in hypercalciuric and osteoporotic men was associated with a rapid rebound increase in bone mineral density.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Burns & Allen Res Inst, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	adamsj@cshs.org	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00425] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams JS, 1997, ANN INTERN MED, V127, P203, DOI 10.7326/0003-4819-127-3-199708010-00004; Anderson FH, 1998, INT J CLIN PRACT, V52, P176; BURCKHARDT P, 1981, J CLIN ENDOCR METAB, V53, P550, DOI 10.1210/jcem-53-3-550; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CUMMINGS SR, 1995, AM J MED, V98, pS24, DOI 10.1016/S0002-9343(05)80041-5; Feskanich D, 1997, OSTEOPOROSIS INT, V7, P79, DOI 10.1007/BF01623465; Ghazali A, 1997, J CLIN ENDOCR METAB, V82, P32, DOI 10.1210/jc.82.1.32; Jodar E, 1997, CLIN ENDOCRINOL, V47, P279, DOI 10.1046/j.1365-2265.1997.2261041.x; JONES G, 1995, J BONE MINER RES, V10, P106; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; Pacifici R, 1997, J CLIN ENDOCR METAB, V82, P29, DOI 10.1210/jc.82.1.29; PACIFICI R, 1990, J CLIN ENDOCR METAB, V71, P138, DOI 10.1210/jcem-71-1-138; PERIS P, 1995, BRIT J RHEUMATOL, V34, P936; PERRY HM, 1982, ARCH INTERN MED, V142, P1295, DOI 10.1001/archinte.142.7.1295; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605	19	70	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					658	660		10.7326/0003-4819-130-8-199904200-00012	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215562				2022-12-28	WOS:000079786600005
J	Greaves, M				Greaves, M			Antiphospholipid antibodies and thrombosis	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIENDOTHELIAL CELL ANTIBODIES; ACTIVATED PROTEIN-C; ANTICARDIOLIPIN ANTIBODIES; VENOUS THROMBOEMBOLISM; ANTICOAGULANT-THERAPY; PRONE PATIENTS; FETAL LOSS; BETA-2-GLYCOPROTEIN-I; AUTOANTIBODIES	Antiphospholipid antibodies are associated with arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. Although the antibodies have not been conclusively shown to be causal in thrombosis and miscarriage, they are useful laboratory markers for the antiphospholipid syndrome. The identification of the syndrome is clinically important because of the risk of recurrent thrombosis and the need for antithrombotic therapy in many cases. Diagnosis and treatment of antiphospholipid syndrome is difficult, however, because of the protean clinical manifestations and associations, limitations of existing laboratory tests for antiphospholipid antibodies, and the absence of evidence-based guidance on best management.	Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Greaves, M (corresponding author), Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland.							ABUAF N, 1994, ANN BIOL CLIN-PARIS, V52, P365; ALSAEED A, 1994, BRIT J HAEMATOL, V58, P18; Amengual O, 1998, THROMB HAEMOSTASIS, V79, P276, DOI 10.1055/s-0037-1614977; ARNOUT J, 1996, THROMB HAEMOSTASIS, V75, P36; ARVIEUX J, 1993, THROMB HAEMOSTASIS, V70, P336; ARVIEUX J, 1991, J IMMUNOL METHODS, V143, P223, DOI 10.1016/0022-1759(91)90047-J; BANSCI LFJ, 1992, THROMB HAEMOSTASIS, V67, P649; BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629; Bordron A, 1998, J CLIN INVEST, V101, P2029, DOI 10.1172/JCI2261; BOWIE EJW, 1963, J LAB CLIN MED, V62, P416; BRANCH DW, 1993, AM J OBSTET GYNECOL, V168, P206, DOI 10.1016/S0002-9378(12)90915-1; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; Chamley LW, 1998, LANCET, V352, P1037, DOI 10.1016/S0140-6736(05)60080-3; CREAGH MD, 1991, J CLIN PATHOL, V44, P45, DOI 10.1136/jcp.44.1.45; CREAGH MD, 1991, BRIT J HAEMATOL, V77, P4; DAngelo A, 1997, THROMB HAEMOSTASIS, V78, P967; DellaValle P, 1996, ANN MED INTERNE, V147, P10; Feinstein D I, 1972, Prog Hemost Thromb, V1, P75; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; Ford I, 1998, BRIT J HAEMATOL, V102, P841; Galli M, 1997, THROMB HAEMOSTASIS, V78, P75; Galli M, 1998, BLOOD, V91, P1999, DOI 10.1182/blood.V91.6.1999.1999_1999_2004; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; Godeau B, 1997, BRIT J HAEMATOL, V98, P873, DOI 10.1046/j.1365-2141.1997.3063123.x; GUZMAN J, 1994, AUTOIMMUNITY, V18, P51, DOI 10.3109/08916939409014679; HAMPTON KK, 1994, NEW ENGL J MED, V331, P130; HILL MB, 1995, CLIN EXP IMMUNOL, V102, P368; JENNINGS I, 1997, THROMB HAEMOSTASIS, V77, P810; Kandiah DA, 1998, THROMB HAEMOSTASIS, V80, P250, DOI 10.1055/s-0037-1615183; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; KEELING DM, 1992, BRIT J HAEMATOL, V82, P571, DOI 10.1111/j.1365-2141.1992.tb06469.x; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; Lawrie AS, 1997, BRIT J HAEMATOL, V98, P887, DOI 10.1046/j.1365-2141.1997.3283145.x; LINDSEY NJ, 1994, BRIT J RHEUMATOL, V33, P20; LINDSEY NJ, 1993, BRIT J RHEUMATOL, V32, P123; MACHIN SJ, 1991, J CLIN PATHOL, V44, P885; MALIA RG, 1990, BRIT J HAEMATOL, V76, P101, DOI 10.1111/j.1365-2141.1990.tb07843.x; MancoJohnson MJ, 1996, J PEDIATR-US, V128, P319, DOI 10.1016/S0022-3476(96)70274-3; MARTINUZZO ME, 1995, BRIT J HAEMATOL, V89, P397, DOI 10.1111/j.1365-2141.1995.tb03317.x; Matsuda J, 1997, BRIT J HAEMATOL, V97, P227, DOI 10.1046/j.1365-2141.1997.d01-2147.x; MATSUDA J, 1994, AM J HEMATOL, V47, P56, DOI 10.1002/ajh.2830470112; MATSUURA E, 1992, J IMMUNOL, V148, P3885; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MEADE TW, 1995, AM J CARDIOL, V75, pB23, DOI 10.1016/0002-9149(95)80006-E; Moll S, 1997, ANN INTERN MED, V127, P177, DOI 10.7326/0003-4819-127-3-199708010-00001; OOSTING JD, 1993, BLOOD, V81, P2618; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PIERANGELI SS, 1995, THROMB HAEMOSTASIS, V74, P1361; PIERANGELI SS, 1992, BRIT J HAEMATOL, V82, P565, DOI 10.1111/j.1365-2141.1992.tb06468.x; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; REBER G, 1995, THROMB HAEMOSTASIS, V73, P444; ROUBEY RAS, 1995, J IMMUNOL, V154, P954; Schulman S, 1998, AM J MED, V104, P332, DOI 10.1016/S0002-9343(98)00060-6; Selva-O'Callaghan A, 1998, THROMB HAEMOSTASIS, V79, P282; SHIBATA S, 1994, BLOOD, V83, P2532; Silver RM, 1996, OBSTET GYNECOL, V87, P494, DOI 10.1016/0029-7844(95)00497-1; STHOEGER ZM, 1993, P NATL ACAD SCI USA, V90, P6464, DOI 10.1073/pnas.90.14.6464; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; Tsutsumi A, 1996, ARTHRITIS RHEUM-US, V39, P1466, DOI 10.1002/art.1780390905; Vaarala O, 1996, THROMB HAEMOSTASIS, V75, P456; Vargas-Alarcon G, 1997, J AUTOIMMUN, V10, P579, DOI 10.1006/jaut.1997.0165	65	217	238	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1348	1353		10.1016/S0140-6736(98)10362-8	http://dx.doi.org/10.1016/S0140-6736(98)10362-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218548				2022-12-28	WOS:000080278100043
J	Weverling, GJ; Mocroft, A; Ledergerber, B; Kirk, O; Gonzalez-Lahoz, J; Monforte, AD; Proenca, R; Phillips, AN; Lundgren, JD; Reiss, P				Weverling, GJ; Mocroft, A; Ledergerber, B; Kirk, O; Gonzalez-Lahoz, J; Monforte, AD; Proenca, R; Phillips, AN; Lundgren, JD; Reiss, P		EuroSIDA Study Gr	Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection	LANCET			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE; SECONDARY PROPHYLAXIS; AIDS; IMPACT; PENTAMIDINE; RESPONSES; MORTALITY; RECOVERY; DISEASE; EUROPE	Background Highly active antiretroviral therapy (HAART) has improved rates of CD4-lymphocyte recovery and decreased the incidence of HIV-1-related morbidity and mortality. We assessed whether prophylaxis against Pneumocystis carinii pneumonia (PCP) can be safely discontinued after HAART is started. Methods We investigated 7333 HIV-1-infected patients already enrolled in EuroSIDA, a continuing prospective observational cohort study in 52 centres across Europe and Israel. We did a person-years analysis of the rate of discontinuation of PCP prophylaxis and of the incidence of PCP after the introduction of HAART into clinical practice from July, 1996. Findings The rate of discontinuation of primary and secondary PCP prophylaxis increased up ro 21 . 9 discontinuations per 100 person-years of follow-up after March, 1998. 378 patients discontinued primary (319) or secondary (59) prophylaxis a median of 10 months after starting HAART. At discontinuation for primary and secondary prophylaxis, respectively, the median CD4-lymphocyte counts were 274 cells/mu L and 270 cells/mu L, the median plasma HIV-1 RNA load 500 copies/mL, and the median lowest recorded CD4-lymphocyte counts 123 cells/mu L and 60 cells/mu L. During 247 person-years of follow-up, no patient developed PCP (incidence density 0 [95% CI 0-1 . 5]). Interpretation The risk of PCP after stopping primary prophylaxis, especially in patients on HAART with a rise in CD4-lymphocyte count to more than 200 cells/mu L, is sufficiently low to warrant discontinuation of primary PCP prophylaxis. Longer follow-up is needed to confirm a similarly low risk for stopping secondary PCP prophylaxis.	Univ Amsterdam, Dept Infect Dis Trop Med & AIDS, Amsterdam, Netherlands; Univ Amsterdam, Natl AIDS Therapy Evaluat Ctr, Amsterdam, Netherlands; Univ Amsterdam, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England; UCL, Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London, England; Univ Zurich, Dept Med, Div Infect Dis, Zurich, Switzerland; Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark; Hvidovre Univ Hosp, EuroSIDA Coordinating Ctr, Copenhagen, Denmark; Hosp Carlos III, Ctr Nacl Invest Clin & Med Prevent, Serv Enfermedades Infecciosas, Madrid, Spain; Osped L Sacco, Clin Malattie Infett, Milan, Italy; Hosp Curry Cabral, Serv Med & Doencas Infecciosas, Lisbon, Portugal	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of London; University College London; University of London; University College London; University of Zurich; University of Copenhagen; University of Copenhagen; Hospital Carlos III; University of Milan; Luigi Sacco Hospital	Reiss, P (corresponding author), Univ Amsterdam, Dept Infect Dis Trop Med & AIDS, Amsterdam, Netherlands.	p.reiss@amc.uva.nl	Ledergerber, Bruno/B-5656-2009; Lundgren, Jens/AAE-6876-2019; Mocroft, Amanda/C-1527-2008; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/G-8748-2011; kirk, ole/ABB-4746-2021	Ledergerber, Bruno/0000-0002-6881-4401; Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850				Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Elliot B, 1997, LANCET, V349, P850, DOI 10.1016/S0140-6736(05)61753-9; Foudraine NA, 1998, AIDS, V12, P35, DOI 10.1097/00002030-199801000-00005; FURRER H, 1998, 12 WORLD AIDS C GEN; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Hicks CB, 1997, CLIN INFECT DIS, V24, P1023, DOI 10.1093/clinids/24.5.1023; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Kaplan JE, 1998, J INFECT DIS, V178, P1126, DOI 10.1086/515658; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; LOPEZ JC, 1999, 6 C RETR OPP INF CHI, P206; LUNDGREN B, 1993, EUR J CLIN MICROBIOL, V12, P105, DOI 10.1007/BF01967583; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MOCROFT A, 1995, STUDIES PROGNOSIS PA; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PEGLOW SL, 1990, J INFECT DIS, V161, P296, DOI 10.1093/infdis/161.2.296; Rodriguez-Guardado A, 1998, AIDS, V12, P2355; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; *USPHS IDSA PREV O, 1997, MMWR-MORBID MORTAL W, V46, P1	28	170	175	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1293	1298		10.1016/S0140-6736(99)03287-0	http://dx.doi.org/10.1016/S0140-6736(99)03287-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218526				2022-12-28	WOS:000080278100008
J	Belshaw, PJ; Walsh, CT; Stachelhaus, T				Belshaw, PJ; Walsh, CT; Stachelhaus, T			Aminoacyl-CoAs as probes of condensation domain selectivity in nonribosomal peptide synthesis	SCIENCE			English	Article							SYNTHETASE GENES; GRAMICIDIN-S; BIOSYNTHESIS; IDENTIFICATION	In nonribosomal biosynthesis of peptide antibiotics by multimodular synthetases, amino acid monomers are activated by the adenylation domains of the synthetase and loaded onto the adjacent carrier protein domains as thioesters, then the formation of peptide bonds and translocation of the growing chain are effected by the synthetase's condensation domains. Whether the condensation domains have any editing function has been unknown. Synthesis of aminoacyl-coenzyme A (CoA) molecules and direct enzymatic transfer of aminoacyl-phosphopantetheine to the carrier domains allow the adenylation domain editing function to be bypassed. This method was used to demonstrate that the first condensation domain of tyrocidine synthetase shows low selectivity at the donor residue (D-phenylalanine) and higher selectivity at the acceptor residue (L-proline) in the formation of the chain-initiating D-Phe-L-Pro dipeptidyl-enzyme intermediate.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; deCrecyLagard V, 1997, J BACTERIOL, V179, P705, DOI 10.1128/jb.179.3.705-713.1997; Dittmann E, 1997, MOL MICROBIOL, V26, P779, DOI 10.1046/j.1365-2958.1997.6131982.x; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; Jakubowski H, 1998, BIOCHEMISTRY-US, V37, P5147, DOI 10.1021/bi972528v; KELLER U, 1987, J BIOL CHEM, V262, P5852; KLEINKAUF H, 1981, ADV BIOTECHNOL, V3, P83; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Zhu WM, 1998, MOL MICROBIOL, V29, P629, DOI 10.1046/j.1365-2958.1998.00961.x	19	254	271	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					486	489		10.1126/science.284.5413.486	http://dx.doi.org/10.1126/science.284.5413.486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205056				2022-12-28	WOS:000079792200047
J	Ge, M; Chen, Z; Onishi, HR; Kohler, J; Silver, LL; Kerns, R; Fukuzawa, S; Thompson, C; Kahne, D				Ge, M; Chen, Z; Onishi, HR; Kohler, J; Silver, LL; Kerns, R; Fukuzawa, S; Thompson, C; Kahne, D			Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala	SCIENCE			English	Article							GLYCOPEPTIDE ANTIBIOTICS; ESCHERICHIA-COLI; D-ALANINE; DIMERIZATION	Vancomycin is an important drug for the treatment of Cram-positive bacterial infections. Resistance to vancomycin has begun to appear, posing a serious public health threat. Vancomycin analogs containing modified carbohydrates are very active against resistant microorganisms. Results presented here show that these carbohydrate derivatives operate by a different mechanism than vancomycin; moreover, peptide binding is not required for activity. It is proposed that carbohydrate-modified vancomycin compounds are effective against resistant bacteria because they interact directly with bacterial proteins involved in the transglycosylation step of cell wall biosynthesis. These results suggest new strategies for designing glycopeptide antibiotics that overcome bacterial resistance.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Merck Res Labs, Infect Dis, Rahway, NJ 07065 USA	Princeton University; Merck & Company	Kahne, D (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	dkahne@princeton.edu	Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				Allen NE, 1997, ANTIMICROB AGENTS CH, V41, P66, DOI 10.1128/AAC.41.1.66; Allen NE, 1997, J ANTIBIOT, V50, P677, DOI 10.7164/antibiotics.50.677; ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; BOOTH PM, 1987, J CHEM SOC CHEM COMM, P1694, DOI 10.1039/c39870001694; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; CRISTOFARO MF, 1995, J ANTIBIOT, V48, P805, DOI 10.7164/antibiotics.48.805; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; Evans DA, 1998, ANGEW CHEM INT EDIT, V37, P2700, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2700::AID-ANIE2700>3.0.CO;2-P; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; Ge M, 1998, J AM CHEM SOC, V120, P11014, DOI 10.1021/ja982414m; GE M, UNPUB; Malabarba A, 1997, MED RES REV, V17, P69, DOI 10.1002/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R; MIRELMAN D, 1976, BIOCHEMISTRY-US, V15, P1781, DOI 10.1021/bi00654a001; NAGARAJAN R, 1988, J CHEM SOC CHEM COMM, P1306, DOI 10.1039/c39880001306; NAGARAJAN R, 1989, J ANTIBIOT, V42, P63, DOI 10.7164/antibiotics.42.63; NAGARJAN R, 1993, J ANTIBIOT, V46, P1181, DOI 10.7164/antibiotics.46.1181; Nicolaou K. C., 1999, ANGEW CHEM, V111, P253; Nicolaou KC, 1998, ANGEW CHEM INT EDIT, V37, P2708, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2708::AID-ANIE2708>3.0.CO;2-E; ONISHI HR, 1974, ANN NY ACAD SCI, V235, P406, DOI 10.1111/j.1749-6632.1974.tb43280.x; PERKINS HR, 1969, BIOCHEM J, V111, P195, DOI 10.1042/bj1110195; Rao JH, 1998, SCIENCE, V280, P708, DOI 10.1126/science.280.5364.708; Rao JH, 1997, J AM CHEM SOC, V119, P10286, DOI 10.1021/ja971225l; Sharman GJ, 1997, J AM CHEM SOC, V119, P12041, DOI 10.1021/ja964477f; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; SOMNER EA, 1990, ANTIMICROB AGENTS CH, V34, P413, DOI 10.1128/AAC.34.3.413; Sundram UN, 1996, J AM CHEM SOC, V118, P13107, DOI 10.1021/ja9621298; Thompson C, 1999, J AM CHEM SOC, V121, P1237, DOI 10.1021/ja983504u; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; VANHEIJENOORT Y, 1978, FEBS LETT, V89, P141, DOI 10.1016/0014-5793(78)80540-7; VANHEIJENOORT Y, 1980, FEBS LETT, V110, P241, DOI 10.1016/0014-5793(80)80082-2; Williams DH, 1998, SCIENCE, V280, P711, DOI 10.1126/science.280.5364.711	32	312	336	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					507	511		10.1126/science.284.5413.507	http://dx.doi.org/10.1126/science.284.5413.507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205063				2022-12-28	WOS:000079792200054
J	Smyth, JM; Stone, AA; Hurewitz, A; Kaell, A				Smyth, JM; Stone, AA; Hurewitz, A; Kaell, A			Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Psychosomatic-Society	MAR 17-20, 1999	VANCOUVER, CANADA	Amer Psychosomat Soc			EMOTIONAL DISCLOSURE; HEALTH; EXPRESSION; DISEASE; QUESTIONNAIRE; VALIDATION; SURVIVAL; TRAUMAS; IMPACT; SCALE	Context Nonpharmacological treatments with little patient cost or risk are useful supplements to pharmacotherapy in the treatment of patients with chronic illness. Research has demonstrated that writing about emotionally traumatic experiences has a surprisingly beneficial effect on symptom reports, well-being, and health care use in healthy individuals. Objective To determine if writing about stressful life experiences affects disease status in patients with asthma or rheumatoid arthritis using standardized quantitative outcome measures. Design Randomized controlled trial conducted between October 1996 and December 1997. Setting Outpatient community residents drawn from private and institutional practice. Patients Volunteer sample of 112 patients with asthma (n = 61) or rheumatoid arthritis (n = 51) received the intervention; 107 completed the study, 58 in the asthma group and 49 in the rheumatoid arthritis group. Intervention Patients were assigned to write either about the most stressful event of their lives (n = 71; 39 asthma, 32 rheumatoid arthritis) or about emotionally neutral topics (n = 41; 22 asthma, 19 rheumatoid arthritis) (the control intervention); Main Outcome Measures Asthma patients were evaluated with spirometry and rheumatoid arthritis patients were clinically examined by a rheumatologist. Assessments were conducted at baseline and at 2 weeks and 2 months and 4 months after writing and were done blind to experimental condition. Results Of evaluable patients 4 months after treatment, asthma patients in the experimental group showed improvements in lung function (the mean percentage of predicted forced expiratory volume in 1 second [FEV1] improved from 63.9% at baseline to 76.3% at the 4-month follow-up; P<.001), whereas control group patients showed no change. Rheumatoid arthritis patients in the experimental group showed improvements in overall disease activity (a mean reduction in disease severity from 1.65 to 1,19 [28%] on a scale of 0 [asymptomatic] to 4 [very severe]at the 4-month follow-up; P = .001), whereas control group patients did not change. Combining all completing patients, 33 (47.1%) of 70 experimental patients had clinically relevant improvement, whereas 9 (24.3 %) of 37 control patients had improvement (P =,001). Conclusion Patients with mild to moderately severe asthma or rheumatoid arthritis who wrote about stressful life experiences had clinically relevant changes in health status at 4 months compared with those in the control group. These gains were beyond those attributable to the standard medical care that all participants were receiving. It remains unknown whether these health improvements will persist beyond 4 months or whether this exercise will prove effective with other diseases.	SUNY Stony Brook, Sch Med, Dept Psychiat, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Div Pulm Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Div Rheumatol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Smyth, JM (corresponding author), N Dakota State Univ, Dept Psychol, Minard Hall, Fargo, ND 58105 USA.		Kaell, Alan T/AAI-2462-2019; Stone, Arthur A./AAC-3610-2019	Kaell, Alan/0000-0001-8473-4551; Smyth, Joshua/0000-0002-0904-5390				AFFLECK G, 1992, J CONSULT CLIN PSYCH, V60, P119, DOI 10.1037/0022-006X.60.1.119; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Beck AT, 1967, DEPRESSION CAUSES TR; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; DONNELLY DA, 1991, J SOC CLIN PSYCHOL, V10, P334, DOI 10.1521/jscp.1991.10.3.334; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ESTERLING BA, 1994, J CONSULT CLIN PSYCH, V62, P130, DOI 10.1037/0022-006X.62.1.130; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; Greenberg MA, 1996, J PERS SOC PSYCHOL, V71, P588, DOI 10.1037/0022-3514.71.3.588; GREENBERG MA, 1992, J PERS SOC PSYCHOL, V63, P75, DOI 10.1037/0022-3514.63.1.75; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; LABATE L, IN PRESS CONT PSYCHO; MARLOWE D, 1961, J CONSULT PSYCHOL, V25, P109, DOI 10.1037/h0041627; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; MUMFORD E, 1983, LINKING HLTH MENTAL, P257; MURRAY EJ, 1994, J TRAUMA STRESS, V7, P391, DOI 10.1007/BF02102784; PAULUS HE, 1995, RHEUM DIS CLIN N AM, V21, P605; PENNEBAKER JW, 1987, J PERS SOC PSYCHOL, V52, P781, DOI 10.1037/0022-3514.52.4.781; PENNEBAKER JW, 1990, J PERS SOC PSYCHOL, V58, P528, DOI 10.1037/0022-3514.58.3.528; PENNEBAKER JW, 1986, J ABNORM PSYCHOL, V95, P274, DOI 10.1037/0021-843X.95.3.274; PENNEBAKER JW, 1988, J CONSULT CLIN PSYCH, V56, P239, DOI 10.1037/0022-006X.56.2.239; PETRIE KJ, 1995, J CONSULT CLIN PSYCH, V63, P787, DOI 10.1037/0022-006X.63.5.787; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; PROCIDANO ME, 1983, AM J COMMUN PSYCHOL, V11, P1, DOI 10.1007/BF00898416; Smyth JM, 1998, J CONSULT CLIN PSYCH, V66, P174, DOI 10.1037/0022-006X.66.1.174; SMYTH JM, IN PRESS COPING PSYC; SPIEGEL D, 1989, LANCET, V2, P888; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; TUGWELL P, 1993, J RHEUMATOL, V20, P527	33	474	482	1	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1304	1309		10.1001/jama.281.14.1304	http://dx.doi.org/10.1001/jama.281.14.1304			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184TC	10208146	Bronze			2022-12-28	WOS:000079628700035
J	Provan, D; O'Shaughnessy, DF				Provan, D; O'Shaughnessy, DF			Recent advances in haematology	BRITISH MEDICAL JOURNAL			English	Review							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; FACTOR-V LEIDEN; MYELOGENOUS LEUKEMIA; TRANSFERRIN RECEPTOR; VENOUS THROMBOSIS; MULTIPLE-MYELOMA; PROTHROMBIN GENE; KAPOSIS-SARCOMA; RESISTANCE		Southampton Gen Hosp, Dept Haematol, Southampton SO16 6UY, Hants, England	University of Southampton	Provan, D (corresponding author), Southampton Gen Hosp, Dept Haematol, Southampton SO16 6UY, Hants, England.		Provan, Drew/AAF-2766-2021	Provan, Drew/0000-0002-5110-8455				BAER AN, 1990, SEMIN ARTHRITIS RHEU, V19, P209, DOI 10.1016/0049-0172(90)90001-V; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Bayever E, 1993, Antisense Res Dev, V3, P383; Berntorp E, 1997, THROMB HAEMOSTASIS, V78, P256; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAngelo A, 1997, BLOOD, V90, P1; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; Irie A, 1997, Adv Pharmacol, V40, P207, DOI 10.1016/S1054-3589(08)60141-6; KOHGO Y, 1988, JPN J MED, V27, P64, DOI 10.2169/internalmedicine1962.27.64; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEANS RT, 1992, BLOOD, V80, P1639; POORT SR, 1994, THROMB HAEMOSTASIS, V72, P819; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; ROBERTS HR, 1993, HEMATOL ONCOL CLIN N, V7, P1269, DOI 10.1016/S0889-8588(18)30207-7; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Schrump DS, 1996, CANCER GENE THER, V3, P131; SELIGMAN PA, 1979, J BIOL CHEM, V254, P9943; TAKIYAMA O, 1995, THROMB HAEMOSTASIS, V74, P996; UCHIYAMA H, 1993, BLOOD, V82, P3712; White GC, 1997, THROMB HAEMOSTASIS, V78, P261; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140	29	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					991	994		10.1136/bmj.318.7189.991	http://dx.doi.org/10.1136/bmj.318.7189.991			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195974	Green Published			2022-12-28	WOS:000079751500026
J	Walton, R; Dovey, S; Harvey, E; Freemantle, N				Walton, R; Dovey, S; Harvey, E; Freemantle, N			Computer support for determining drug dose: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; WARFARIN THERAPY; COST-BENEFIT; CARE; MANAGEMENT; INFUSION; DOCTORS	Objective To review the effectiveness of computer support for determining optimum drug dose. Design Systematic review of comparative studies where computers gave advice to clinicians on the most appropriate drug dose. Search methods used were standard for the Cochrane Collaboration on Effective Professional Practice. Subjects Comparative studies conducted worldwide and published between 1966 and 1996. Main outcome measures For qualitative review, relative percentage differences were calculated to compare effects of computer support in different settings. For quantitative data, effect sizes were calculated and combined in mete-analyses. Results Eighteen studies met the inclusion criteria The drugs studied were theophylline, warfarin, heparin, aminoglycosides, nitroprusside, lignocaine, oxytocin, fentanyl, and midazolam. The computer programs used individualised pharmacokinetic models to calculate the most appropriate dose. Meta-analysis of data from 671 patients showed higher blood concentrations of drug with computer support (effect size 0.69, 95% confidence interval 0.36 to 1.02) and reduced time to achieve therapeutic control (0.44, 0.17 to 0.71). The total dose of drug used was unchanged, and there were fewer unwanted effects of treatment Five of six studies measuring outcomes of care showed benefit from computer assistance. Conclusions This review suggests that using computers to determine the correct dose of certain drugs in acute hospital settings is beneficial. Computers may give doctors the confidence to use higher doses when necessary, adjusting the drug dose more accurately to individual patients. Further research is necessary to evaluate the benefits in general use.	Univ Oxford, Dept Publ Hlth & Primary Care, Imperial Canc Res Fund, Gen Practice Res Grp,Inst Hlth Sci, Oxford OX3 7LF, England; Alcuin Coll, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Oxford; University of York - UK; University of York - UK	Walton, R (corresponding author), Univ Oxford, Dept Publ Hlth & Primary Care, Imperial Canc Res Fund, Gen Practice Res Grp,Inst Hlth Sci, Oxford OX3 7LF, England.			Freemantle, Nick/0000-0001-5807-5740				ALVIS JM, 1985, ANESTHESIOLOGY, V63, P41, DOI 10.1097/00000542-198507000-00006; BALDWIN L, 1995, BRIT MED J, V310, P1154, DOI 10.1136/bmj.310.6988.1154; BERO LA, 1997, COCHRANE LIB; BURTON ME, 1991, CLIN PHARMACOL THER, V49, P685, DOI 10.1038/clpt.1991.86; CASNER PR, 1993, CLIN PHARMACOL THER, V53, P684, DOI 10.1038/clpt.1993.90; *COCHR COLL EFF PR, 1996, COCHR COLL EFF PROF; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESTACHE CJ, 1990, THER DRUG MONIT, V12, P427, DOI 10.1097/00007691-199009000-00004; Dickersin K, 1995, SYSTEMATIC REV, P17; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6; Hedges LV, 2014, STAT METHODS META AN; HURLEY SF, 1986, AM REV RESPIR DIS, V134, P1219; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MUNGALL DR, 1994, CLIN PHARMACOL THER, V55, P591, DOI 10.1038/clpt.1994.73; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; RODMAN JH, 1984, ARCH INTERN MED, V144, P703, DOI 10.1001/archinte.144.4.703; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; ROSENTHAL R, 1986, PSYCHOL BULL, V99, P400, DOI 10.1037/0033-2909.99.3.400; Ruiz Ricardo, 1993, Biomedical Instrumentation and Technology, V27, P244; *SOC SURV GALL POL, 1993, COMP GP PRACT 199O S; Theil D R, 1993, J Cardiothorac Vasc Anesth, V7, P300, DOI 10.1016/1053-0770(93)90009-A; VANDENNIEUWENHUYZEN MCO, 1995, ANESTH ANALG, V81, P671, DOI 10.1097/00000539-199510000-00003; VERNER D, 1992, EUR J CLIN PHARMACOL, V43, P29, DOI 10.1007/BF02280750; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006; WILLCOURT RJ, 1994, AM J OBSTET GYNECOL, V170, P603, DOI 10.1016/S0002-9378(94)70236-5; Wolf F.M., 1986, METAANALYSIS QUANTIT	31	77	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					984	990		10.1136/bmj.318.7189.984	http://dx.doi.org/10.1136/bmj.318.7189.984			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195972	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000079751500023
J	Hu, YL; Baud, V; Delhase, M; Zhang, PL; Deerinck, T; Ellisman, M; Johnson, R; Karin, M				Hu, YL; Baud, V; Delhase, M; Zhang, PL; Deerinck, T; Ellisman, M; Johnson, R; Karin, M			Abnormal morphogenesis but intact IKK activation in mice lacking the IKK alpha subunit of I kappa B kinase	SCIENCE			English	Article							MULTIFUNCTIONAL REGULATORS; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; DROSOPHILA EMBRYO; INDUCED APOPTOSIS; CELL-DEATH; COMPLEX; BETA; DEFECTS; PHOSPHORYLATION	The oligomeric I kappa B kinase (IKK) is composed of three polypeptides: IKK alpha and IKK beta, the catalytic subunits, and IKK gamma, a regulatory subunit. IKK alpha and IKK beta are similar in structure and thought to have similar function-phosphorylation of the I kappa B inhibitors in response to proinflammatory stimuli. Such phosphorylation Leads to degradation of I kappa B and activation of nuclear factor kappa B transcription factors. The physiological function of these protein kinases was explored by analysis of IKK alpha-deficient mice. IKK alpha was not required for activation of IKK and degradation of I kappa B by proinflammatory stimuli. Instead, loss of IKK alpha interfered with multiple morphogenetic events, including Limb and skeletal patterning and proliferation and differentiation of epidermal keratinocytes.	Univ Calif San Diego, Ctr Canc, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Ctr Canc, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Delhase, Mireille/ABE-5256-2021; Hu, Yinling/G-5682-2015; Baud, Veronique/F-7699-2013; Baud, Veronique/AAL-3950-2020; Johnson, Randall/AAM-1189-2021	Delhase, Mireille/0000-0003-2312-1051; Hu, Yinling/0000-0002-4795-8537; Baud, Veronique/0000-0002-4090-718X; Baud, Veronique/0000-0002-4090-718X; Johnson, Randall/0000-0002-4084-6639	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [R01 AI43477] Funding Source: Medline; NIEHS NIH HHS [R37 ES04151] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAUD V, UNPUB; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENIRSCHKE K., 1995, PATHOLOGY HUMAN PLAC; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Joyner AL, 1993, GENE TARGETING PRACT; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520-6408(1998)22:4&lt;301::AID-DVG1&gt;3.0.CO;2-A; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOCHHAR DM, 1977, HDB TERATOLOGY, V2, P453; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	696	739	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					316	320		10.1126/science.284.5412.316	http://dx.doi.org/10.1126/science.284.5412.316			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195896				2022-12-28	WOS:000079636400042
J	Sagliocca, L; Amoroso, P; Stroffolini, T; Adamo, B; Tosti, ME; Lettieri, G; Esposito, C; Buonocore, S; Pierri, P; Mele, A				Sagliocca, L; Amoroso, P; Stroffolini, T; Adamo, B; Tosti, ME; Lettieri, G; Esposito, C; Buonocore, S; Pierri, P; Mele, A			Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial	LANCET			English	Article							A VIRUS-INFECTION; IMMUNOGLOBULIN; OUTBREAK; EPIDEMIOLOGY; ADULTS	Background Hepatitis A vaccination stops outbreaks of hepatitis A infection, but its efficacy against infection after exposure has not been proven. We investigated the use of hepatitis A vaccine to prevent secondary infections with hepatitis A virus (HAV). Methods We did a randomised controlled trial of hepatitis A vaccine in household contacts of people with sporadic HAV infection (index cases). Households (index cases and contacts) were randomly assigned to the vaccine group or unvaccinated group, according to the study week in which they were enrolled. All household contacts in the vaccine group received vaccination at the time of entry to the study. Findings During 45 days of follow-up, secondary infection had occurred in ten (13.3%) of 75 households (two families had two cases each) in the untreated group and in two (2.8%) of 71 households in the vaccine group. The protective efficacy of the vaccine was 79% (95% CI 7-95). The number of secondary infections among household contacts was 12 (5.8%) of 207 in the unvaccinated group and two (1.0%) of 197 in the vaccinated group. Therefore, 18 individuals needed to be vaccinated to prevent one secondary infection. Interpretation Hepatitis A vaccine is effective in the prevention of secondary infection of HAV and should be recommended for household contacts of primary cases of HAV infection.	Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Azienda Ospedaliera Santobono Pausilipon, Naples, Italy; Azienda Ospedaliera Cotugno, Naples, Italy; Azienda Sanit Napoli 1, Naples, Italy	Istituto Superiore di Sanita (ISS)	Mele, A (corresponding author), Ist Super Sanita, Lab Epidemiol, Viale Regina Elena 299, I-00161 Rome, Italy.		Tosti, Maria Elena/K-1424-2018	Tosti, Maria Elena/0000-0003-1392-9874				[Anonymous], [No title captured]; GOUDEMAND M, 1993, LANCET, V342, P239, DOI 10.1016/0140-6736(93)92328-Q; HADLER SC, 1983, JAMA-J AM MED ASSOC, V249, P48; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; LEDNAR WM, 1985, AM J EPIDEMIOL, V122, P226, DOI 10.1093/oxfordjournals.aje.a114093; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; MELE A, 1991, ITAL J GASTROENTEROL, V23, P341; MELE A, 1989, AM J EPIDEMIOL, V130, P540, DOI 10.1093/oxfordjournals.aje.a115368; Mele A, 1997, J HEPATOL, V26, P743, DOI 10.1016/S0168-8278(97)80237-1; MELE A, 1997, 9736 SEIEVA; PRIKAZSKY V, 1994, J MED VIROL, V44, P457, DOI 10.1002/jmv.1890440427; ROBERTSON BH, 1994, J MED VIROL, V43, P249, DOI 10.1002/jmv.1890430310; ROUMELIOTOU A, 1994, INFECTION, V22, P96, DOI 10.1007/BF01739013; SACKETT DL, 1994, BMJ-BRIT MED J, V309, P755, DOI 10.1136/bmj.309.6957.755; SHAPIRO CN, 1993, J HEPATOL, V18, pS11, DOI 10.1016/S0168-8278(05)80371-X; STROFFOLINI T, 1990, EUR J EPIDEMIOL, V6, P156, DOI 10.1007/BF00145788; VICTOR J, 1994, VACCINE, V12, P1327, DOI 10.1016/S0264-410X(94)80028-X; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WINOKUR PL, 1992, CLIN INFECT DIS, V14, P580, DOI 10.1093/clinids/14.2.580	19	104	113	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1136	1139		10.1016/S0140-6736(98)08139-2	http://dx.doi.org/10.1016/S0140-6736(98)08139-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209977				2022-12-28	WOS:000079858400011
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60607 USA.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1108	1108		10.1016/S0140-6736(05)76476-X	http://dx.doi.org/10.1016/S0140-6736(05)76476-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199387				2022-12-28	WOS:000079614000070
J	Byington, RP; Craven, TE; Furberg, CD; Pahor, M				Byington, RP; Craven, TE; Furberg, CD; Pahor, M			Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events	LANCET			English	Article							CA-2+		WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27157; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	Wake Forest University; Wake Forest Baptist Medical Center; University of Tennessee System; University of Tennessee Health Science Center								Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; MASON RP, 1992, MOL PHARMACOL, V41, P315; MAZZANTI L, 1990, DIABETES, V39, P850, DOI 10.2337/diabetes.39.7.850	3	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1075	1076		10.1016/S0140-6736(05)70455-4	http://dx.doi.org/10.1016/S0140-6736(05)70455-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213554				2022-12-28	WOS:A1997YA73400015
J	Gilchrest, BA; Eller, MS; Geller, AC; Yaar, M				Gilchrest, BA; Eller, MS; Geller, AC; Yaar, M			The pathogenesis of melanoma induced by ultraviolet radiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CUTANEOUS MALIGNANT-MELANOMA; DNA-REPAIR CAPACITY; HUMAN SKIN CELLS; MELANOCYTIC NEVI; XERODERMA-PIGMENTOSUM; SUN EXPOSURE; MONODELPHIS-DOMESTICA; ESCHERICHIA-COLI; BCL-2 PROTEIN; SUNBURN CELL		Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu			NCI NIH HHS [R01 CA 76333-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBLARD P, 1982, ARCH DERMATOL RES, V274, P195, DOI 10.1007/BF00403722; ARMSTRONG BK, 1993, MELANOMA RES, V3, P395, DOI 10.1097/00008390-199311000-00002; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; BATTISTUTTA D, 1994, LANCET, V344, P1607, DOI 10.1016/S0140-6736(94)90408-1; Bayerl C, 1995, PHOTODERMATOL PHOTO, V11, P149, DOI 10.1111/j.1600-0781.1995.tb00157.x; Bentham G, 1996, INT J EPIDEMIOL, V25, P1132, DOI 10.1093/ije/25.6.1132; BERWICK M, 1998, CUTANEOUS MELANOMA, P551; Bestak R, 1996, PHOTOCHEM PHOTOBIOL, V64, P969, DOI 10.1111/j.1751-1097.1996.tb01863.x; Brash DE, 1998, CANCER SURV, V32, P69; Breitbart M, 1997, ACTA DERM-VENEREOL, V77, P374; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DOOLEY TP, 1993, CANCER GENET CYTOGEN, V71, P55, DOI 10.1016/0165-4608(93)90202-W; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FREEMAN SE, 1989, P NATL ACAD SCI USA, V86, P5605, DOI 10.1073/pnas.86.14.5605; Gad F, 1998, J INVEST DERMATOL, V110, P690; GALLAGHER RP, 1990, J AM ACAD DERMATOL, V23, P413, DOI 10.1016/0190-9622(90)70234-9; GILCHREST BA, 1984, SKIN AGING PROCESSES, P67; GILCHREST BA, 1984, SKIN AGING PROCESSES, P17; GILCHREST BA, 1998, PIGMENTARY SYSTEM PH, P359; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; Gniadecka M, 1996, ACTA DERM-VENEREOL, V76, P429; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLMAN CDJ, 1986, J NATL CANCER I, V76, P403; *INT AG RES CANC, 1992, IARC MON EV CARC RIS, V55; JIMBOW K, 1993, DERMATOLOGY GEN MED, V1, P261; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; KELLY JW, 1986, J AM ACAD DERMATOL, V14, P1044, DOI 10.1016/S0190-9622(86)70131-X; KLEINPARKER HA, 1994, J CUTAN PATHOL, V21, P297, DOI 10.1111/j.1600-0560.1994.tb00703.x; KLIGMAN LH, 1981, JNCI-J NATL CANCER I, V67, P1289; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; KOCHEVAR IE, 1993, DERMATOLOGY GEN MED, V1, P1627; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KOH HK, 1995, CANC PREVENTION CONT, P611; Kollias N, 1996, PHOTODERMATOL PHOTO, V12, P183, DOI 10.1111/j.1600-0781.1996.tb00197.x; KOSARY CL, 1996, NIH PUBL; KRAEMER KH, 1994, J INVEST DERMATOL, V103, pS96, DOI 10.1111/1523-1747.ep12399329; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; KRAEMER KH, 1993, DERMATOLOGY GEN MED, V2, P1974; KRICKER A, 1995, INT J CANCER, V60, P489, DOI 10.1002/ijc.2910600411; KUSEWITT DF, 1991, VET PATHOL, V28, P55, DOI 10.1177/030098589102800108; LAMBERT WC, 1995, DERMATOL CLIN, V13, P169, DOI 10.1016/S0733-8635(18)30120-7; Langford IH, 1998, STAT MED, V17, P41, DOI 10.1002/(SICI)1097-0258(19980115)17:1<41::AID-SIM712>3.0.CO;2-0; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; Luther H, 1996, ARCH DERMATOL, V132, P1473, DOI 10.1001/archderm.132.12.1473; MACK TM, 1991, CANCER CAUSE CONTROL, V2, P401, DOI 10.1007/BF00054301; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; Maeda T, 1998, J INVEST DERMATOL, V110, P489; MARRETT LD, 1992, CAN MED ASSOC J, V147, P445; MARRETT LD, 1992, CAN MED ASSOC J, V147, P1764; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MIHM MC, 1973, NEW ENGL J MED, V289, P989, DOI 10.1056/NEJM197311082891901; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MITCHELL DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P741, DOI 10.1111/j.1751-1097.1991.tb02084.x; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P915, DOI 10.1001/archderm.131.8.915; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Mukhtar H., 1995, SKIN CANC MECH HUMAN, P3; *NAT CANC I, 1996, NAT CANC I MON, V70; NELEMANS PJ, 1993, ENVIRON HEALTH PERSP, V101, P252, DOI 10.2307/3431552; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; NORRIS DA, 1998, PIGMENTARY SYSTEM PH, P123; OSTERLIND A, 1988, BRIT J CANCER, V58, P385, DOI 10.1038/bjc.1988.225; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; PATHAK MA, 1991, SKIN PHARMACOL, V4, P85; PATHAK MA, 1995, MELANIN ITS ROLE HUM, V125, P34; Pavlotsky F, 1997, AM J EPIDEMIOL, V146, P78, DOI 10.1093/oxfordjournals.aje.a009193; PETERSON KR, 1988, J BACTERIOL, V170, P1; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REEDY MV, 1998, PIGMENTARY SYSTEM PH, P75; RHODES AR, 1987, JAMA-J AM MED ASSOC, V258, P3146, DOI 10.1001/jama.258.21.3146; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; Rodenas JM, 1996, CANCER CAUSE CONTROL, V7, P275, DOI 10.1007/BF00051303; RODRIGUEZVILLANUEVA J, 1995, PATHOL RES PRACT, V191, P391, DOI 10.1016/S0344-0338(11)80724-7; SCHMITZ S, 1994, HAUTARZT, V45, P517, DOI 10.1007/s001050050118; Scotto J., 1983, NIH PUBLICATION, V83-2433; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; Seykora J, 1996, SEMIN ONCOL, V23, P682; STENBACK F, 1975, EUR J CANCER, V11, P241, DOI 10.1016/0014-2964(75)90004-3; Stierner U, 1991, Acta Derm Venereol Suppl (Stockh), V168, P1; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEI QY, 1993, P NATL ACAD SCI USA, V90, P5378; Weinstock MA, 1996, PHOTOCHEM PHOTOBIOL, V63, P406, DOI 10.1111/j.1751-1097.1996.tb03056.x; WESTERDAHL J, 1992, ANTICANCER RES, V12, P1539; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2; YAAR M, 1991, J INVEST DERMATOL, V97, P611, DOI 10.1111/1523-1747.ep12482985; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; YOUNG AR, 1991, J INVEST DERMATOL, V97, P942, DOI 10.1111/1523-1747.ep12491807	95	583	593	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1341	1348		10.1056/NEJM199904293401707	http://dx.doi.org/10.1056/NEJM199904293401707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219070				2022-12-28	WOS:000080001700007
J	Tsao, JW; Kogan, SC				Tsao, JW; Kogan, SC			Indinavir crystalluria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Tsao, JW (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.			Kogan, Scott/0000-0002-2395-8479					0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1329	1329		10.1056/NEJM199904293401705	http://dx.doi.org/10.1056/NEJM199904293401705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219068				2022-12-28	WOS:000080001700005
J	Clarke, MP				Clarke, MP			There are ethical issues in ophthalmology	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1153	1153		10.1136/bmj.318.7191.1153	http://dx.doi.org/10.1136/bmj.318.7191.1153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213764	Green Published			2022-12-28	WOS:000080166000092
J	Asfaw, B; White, T; Lovejoy, O; Latimer, B; Simpson, S; Suwa, G				Asfaw, B; White, T; Lovejoy, O; Latimer, B; Simpson, S; Suwa, G			Australopithecus garhi: A new species of early hominid from Ethiopia	SCIENCE			English	Article							GENUS HOMO; MORPHOLOGY; AFARENSIS; HADAR; EVOLUTION; ORIGIN; SKULL; KENYA	The lack of an adequate hominid fossil record in eastern Africa between 2 and 3 million years ago (Ma) has hampered investigations of early hominid phylogeny. Discovery of 2.5 Ma hominid cranial and dental remains from the Hata beds of Ethiopia's Middle Awash allows recognition of a new species of Australopithecus. This species is descended from Australopithecus afarensis and is a candidate ancestor for early Homo. Contemporary postcranial remains feature a derived humanlike humeral/femoral ratio and an apelike upper arm-to-lower arm ratio.	Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Rift Valley Res Serv, Addis Ababa, Ethiopia; Kent State Univ, Div Biomed Sci, Kent, OH 44242 USA; Kent State Univ, Dept Anthropol, Kent, OH 44242 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland Museum Nat Hist, Cleveland, OH 44106 USA; Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo 1130033, Japan	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; Case Western Reserve University; Case Western Reserve University; Cleveland Museum of Natural History; University of Tokyo	White, T (corresponding author), Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA.							CHAMBERLAIN AT, 1987, J HUM EVOL, V16, P119, DOI 10.1016/0047-2484(87)90063-7; de Heinzelin J, 1999, SCIENCE, V284, P625; Grine F, 1988, EVOLUTIONARY HIST RO; HARTWIGSCHERER S, 1991, J HUM EVOL, V21, P439, DOI 10.1016/0047-2484(91)90094-C; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KIMBEL WH, 1984, AM J PHYS ANTHROPOL, V64, P337, DOI 10.1002/ajpa.1330640403; Kimbel WH, 1997, AM J PHYS ANTHROPOL, V103, P235, DOI 10.1002/(SICI)1096-8644(199706)103:2<235::AID-AJPA8>3.3.CO;2-V; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; McHenry HM, 1998, J HUM EVOL, V35, P1, DOI 10.1006/jhev.1997.0197; MCHENRY HM, 1996, CONT ISSUES HUMAN EV, P77; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; Walker A., 1993, NARIOKOTOME HOMO ERE; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0	17	300	315	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					629	635		10.1126/science.284.5414.629	http://dx.doi.org/10.1126/science.284.5414.629			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	190FH	10213683				2022-12-28	WOS:000079951100041
J	Hirota, H; Chen, J; Betz, UAK; Rajewsky, K; Gu, Y; Ross, J; Muller, W; Chien, KR				Hirota, H; Chen, J; Betz, UAK; Rajewsky, K; Gu, Y; Ross, J; Muller, W; Chien, KR			Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; INTERLEUKIN-6 DEFICIENT MICE; RXR-ALPHA; DEPENDENT PATHWAYS; VENTRICULAR MYOCYTES; TARGETED DISRUPTION; SIGNALING PATHWAYS; GENE-EXPRESSION; STEM-CELLS; IN-VITRO	Biomechanical stress is a major stimulus for cardiac hypertrophy and the transition to heart failure. By generating mice that harbor a ventricular restricted knockout of the gp130 cytokine receptor via Cre-loxP-mediated recombination, we demonstrate a critical role for a gp130-dependent myocyte survival pathway in the transition to heart failure. Such conditional mutant mice have normal cardiac structure and function, but during aortic pressure overload, these mice display rapid onset of dilated cardiomyopathy and massive induction of myocyte apoptosis versus the control mice that exhibit compensatory hypertrophy. Thus, cardiac myocyte apoptosis is a critical point in the transition between compensatory cardiac hypertrophy and heart failure. gp130-dependent cytokines may represent a novel therapeutic strategy for preventing in vivo heart failure.	Univ Calif San Diego, Sch Med, Salk NHLBI Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Cologne, Genet Inst, D-50931 Cologne, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Cologne	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, Salk NHLBI Program Mol Med, La Jolla, CA 92093 USA.	kchien@ucsd.edu	Muller, Werner/B-9044-2008; Chen, Ju/E-5579-2011	Muller, Werner/0000-0002-1297-9725; Rajewsky, Klaus/0000-0002-6633-6370				Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1998, DEVELOPMENT, V125, P1943; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Gruber PJ, 1998, DEVELOPMENT, V125, P4427; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUBALAK SW, 1996, METH MOL G, V8, P470; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Nandurkar HH, 1997, BLOOD, V90, P2148; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Romani L, 1996, J EXP MED, V183, P1345, DOI 10.1084/jem.183.4.1345; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Ross RS, 1996, DEVELOPMENT, V122, P1799; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WARE CB, 1995, DEVELOPMENT, V121, P1283; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	57	524	583	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					189	198		10.1016/S0092-8674(00)80729-1	http://dx.doi.org/10.1016/S0092-8674(00)80729-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219240	Bronze			2022-12-28	WOS:000079779800008
J	Hirsch, JA; Schubert, C; Gurevich, VV; Sigler, PB				Hirsch, JA; Schubert, C; Gurevich, VV; Sigler, PB			The 2.8 angstrom crystal structure of visual arrestin: A model for arrestin's regulation	CELL			English	Article							ROD OUTER SEGMENTS; PROTEIN-COUPLED RECEPTORS; PHOSPHORYLATED RHODOPSIN; SALT BRIDGES; ANOMALOUS DIFFRACTION; SECONDARY STRUCTURE; IN-VIVO; BINDING; SELECTIVITY; STABILITY	G protein-coupled signaling is utilized by a wide variety of eukaryotes for communicating information from the extracellular environment. Signal termination is achieved by the action of the arrestins, which bind to activated, phosphorylated G protein-coupled receptors. We describe here crystallographic studies of visual arrestin in its basal conformation. The salient features of the structure are a bipartite molecule with an unusual polar core. This core is stabilized in part by an extended carboxy-terminal tail that locks the molecule into an inactive state. In addition, arrestin is found to be a dimer of two asymmetric molecules, suggesting an intrinsic conformational plasticity. In conjunction with biochemical and mutagenesis data, we propose a molecular mechanism by which arrestin is activated for receptor binding.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06511 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA	Howard Hughes Medical Institute; Yale University; Yale University; Banner Research; Banner Health; Banner Sun Health Research Institute	Sigler, PB (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA.	sigler@csb.yale.edu	Hirsch, Joel/AAC-8000-2021; Gurevich, Vsevolod/A-3236-2008	Hirsch, Joel/0000-0001-7544-8668; Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM22324] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gerstein M, 1998, PROTEIN SCI, V7, P445; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawamura Satoru, 1995, P105; KLEYWEGT GJ, 1994, U MAP FINAL MODEL, P59; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sindelar CV, 1998, PROTEIN SCI, V7, P1898, DOI 10.1002/pro.5560070906; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; Wimley WC, 1996, P NATL ACAD SCI USA, V93, P2985, DOI 10.1073/pnas.93.7.2985; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	61	335	344	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					257	269		10.1016/S0092-8674(00)80735-7	http://dx.doi.org/10.1016/S0092-8674(00)80735-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219246	hybrid			2022-12-28	WOS:000079779800014
J	Springer, S; Spang, A; Schekman, R				Springer, S; Spang, A; Schekman, R			A primer on vesicle budding	CELL			English	Review							ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; COAT PROTEINS; COPII; LIPOSOMES; COMPLEX; SNARES		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Spang, Anne/M-7223-2019; Spang, Anne/A-7029-2008; Springer, Sebastian/AAJ-7036-2021	Spang, Anne/0000-0002-2387-6203; Spang, Anne/0000-0002-2387-6203; Springer, Sebastian/0000-0002-5527-6149				Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Gaynor EC, 1998, BBA-MOL CELL RES, V1404, P33, DOI 10.1016/S0167-4889(98)00045-7; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Reinhard C, 1999, P NATL ACAD SCI USA, V96, P1224, DOI 10.1073/pnas.96.4.1224; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698	18	228	231	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					145	148		10.1016/S0092-8674(00)80722-9	http://dx.doi.org/10.1016/S0092-8674(00)80722-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219233	Bronze			2022-12-28	WOS:000079779800001
J	Jacobs, IJ; Skates, SJ; MacDonald, N; Menon, U; Rosenthal, AN; Davies, AP; Woolas, R; Jeyarajah, AR; Sibley, K; Lowe, DG; Oram, DH				Jacobs, IJ; Skates, SJ; MacDonald, N; Menon, U; Rosenthal, AN; Davies, AP; Woolas, R; Jeyarajah, AR; Sibley, K; Lowe, DG; Oram, DH			Screening for ovarian cancer: a pilot randomised controlled trial	LANCET			English	Article							SERUM CA-125 LEVELS; CA 125; ULTRASONOGRAPHY; SONOGRAPHY; COLOR; STRATEGIES; CARCINOMA; DIAGNOSIS; PROTOCOL; MARKERS	Background The value of screening for ovarian cancer is uncertain. We did a pilot randomised trial to assess multimodal screening with sequential CA 125 antigen and ultrasonography. Methods Postmenopausal women aged 45 years or older were randomised to a control group (n=10 977) or screened group (n=10 958). Women randomised to screening were offered three annual screens that involved measurement of serum CA 125, pelvic ultrasonography if CA 125 was 30 U/mL or more, and referral for gynaecological opinion if ovarian volume was 8.8 mt or more on ultrasonography. All women were followed up to see whether they developed invasive epithelial cancers of the ovary or fallopian tube tinder cancers). Findings Of 468 women in the screened group with a raised CA 125, 29 were referred for a gynaecological opinion; screening detected an index cancer in six and 23 had false positive screening results. The positive predictive value was 20.7%. During 7-year follow-up, ten further women with index cancers were identified in the screened group and 20 in the control group. Median survival of women with index cancers in the screened group was 72.9 months and in the control group was 41.8 months (p=0.0112), The number of death's from an index cancer did not differ significantly between the control and screened groups (18 of 10 977 vs nine of 10 958, relative risk 2.0 [95% CI 0.78-5.13]). Interpretation These results show that a multimodal approach to ovarian cancer screening in a randomised trial is feasible acid justify a larger randomised trial to see whether screening affects mortality,	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, Dept Gynaecol Oncol, Gynaecol Canc Res Unit, London EC1A 7BE, England; Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, Dept Pathol, London EC1A 7BE, England; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA USA	University of London; Queen Mary University London; University of London; Queen Mary University London; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Jacobs, IJ (corresponding author), St Bartholomews Hosp, London EC1A 7BE, England.		Menon, Usha/C-4716-2008; Jacobs, Ian J/F-1743-2013	Menon, Usha/0000-0003-3708-1732; Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672; Rosenthal, Adam/0000-0001-6924-0721				BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BAST RC, 1983, NEW ENGL J MED, V309, P169; Bell R, 1998, BRIT J OBSTET GYNAEC, V105, P1136, DOI 10.1111/j.1471-0528.1998.tb09966.x; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1993, BRIT MED J, V306, P1025, DOI 10.1136/bmj.306.6884.1025; CAMPBELL S, 1982, LANCET, V1, P425; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CAMPBELL S, 1990, BRIT J OBSTET GYNAEC, V97, P304, DOI 10.1111/j.1471-0528.1990.tb01806.x; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; HELZLSOUER KJ, 1993, JAMA-J AM MED ASSOC, V269, P1123, DOI 10.1001/jama.269.9.1123; HIGGINS RV, 1989, GYNECOL ONCOL, V34, P402, DOI 10.1016/0090-8258(89)90181-9; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; Jacobs IJ, 1996, BMJ-BRIT MED J, V313, P1355, DOI 10.1136/bmj.313.7069.1355; JACOBS IJ, 1992, OBSTET GYNECOL, V80, P396; Kahn HA, 1989, STAT METHODS EPIDEMI, P119; KARLAN BY, 1993, AM J OBSTET GYNECOL, V169, P494, DOI 10.1016/0002-9378(93)90607-K; KURJAK A, 1994, J ULTRAS MED, V13, P295; SKATES SJ, 1995, CANCER, V76, P2004, DOI 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G; Tabar L, 1996, INT J CANCER, V66, P413, DOI 10.1002/(SICI)1097-0215(19960516)66:4<413::AID-IJC1>3.0.CO;2-Z; Urban N, 1997, CONTROL CLIN TRIALS, V18, P251, DOI 10.1016/S0197-2456(96)00233-4; VANNAGELL JR, 1995, CANCER, V76, P2086, DOI 10.1002/1097-0142(19951115)76:10+<2086::AID-CNCR2820761330>3.0.CO;2-L; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507	25	390	404	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1207	1210		10.1016/S0140-6736(98)10261-1	http://dx.doi.org/10.1016/S0140-6736(98)10261-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217079				2022-12-28	WOS:000079744100007
J	Shindell, D; Rind, D; Balachandran, N; Lean, J; Lonergan, P				Shindell, D; Rind, D; Balachandran, N; Lean, J; Lonergan, P			Solar cycle variability, ozone, and climate	SCIENCE			English	Article							WINTER STRATOSPHERIC CIRCULATION; MIDDLE ATMOSPHERE; INTERANNUAL VARIABILITY; NORTHERN-HEMISPHERE; UV VARIABILITY; TROPOSPHERE; MODEL; TEMPERATURE; IMPACT; QBO	Results from a global climate model including an interactive parameterization of stratospheric chemistry show how upper stratospheric ozone changes may amplify observed, 11-year solar cycle irradiance changes to affect climate. In the model, circulation changes initially induced in the stratosphere subsequently penetrate into the troposphere, demonstrating the importance of the dynamical coupling between the stratosphere and troposphere. The model reproduces many observed 11-year oscillations, including the relatively Long record of geopotential height variations; hence, it implies that these oscillations are likely driven, at Least in part, by solar variability.	NASA, Goddard Inst Space Studies, New York, NY 10025 USA; Columbia Univ, Ctr Climate Syst Res, New York, NY 10025 USA; Space Sci & Applicat Inc, New York, NY 10025 USA; USN, Res Lab, EO Hulburt Ctr Space Res, Washington, DC 20375 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; United States Department of Defense; United States Navy; Naval Research Laboratory	Shindell, D (corresponding author), NASA, Goddard Inst Space Studies, 2880 Broadway, New York, NY 10025 USA.	dshindell@giss.nasa.gov	Shindell, Drew/D-4636-2012; lionel, Scotto/K-8141-2012	Shindell, Drew/0000-0003-1552-4715; 				Arnold NF, 1998, ANN GEOPHYS-ATM HYDR, V16, P69, DOI 10.1007/s00585-997-0069-3; Austin J, 1997, Q J ROY METEOR SOC, V123, P1405, DOI 10.1002/qj.49712354113; BALACHANDRAN NK, 1995, J CLIMATE, V8, P2058, DOI 10.1175/1520-0442(1995)008<2058:MTEOUV>2.0.CO;2; BRASSEUR G, 1993, J GEOPHYS RES-ATMOS, V98, P23079, DOI 10.1029/93JD02406; Chandra S, 1996, GEOPHYS RES LETT, V23, P2935, DOI 10.1029/96GL02760; Cubasch U, 1997, CLIM DYNAM, V13, P757, DOI 10.1007/s003820050196; FriisChristensen E, 1997, ADV SPACE RES-SERIES, V20, P913, DOI 10.1016/S0273-1177(97)00499-7; GELLER MA, 1980, J ATMOS SCI, V37, P1197, DOI 10.1175/1520-0469(1980)037<1197:PWCBTT>2.0.CO;2; Haigh JD, 1999, J ATMOS SOL-TERR PHY, V61, P63, DOI 10.1016/S1364-6826(98)00117-5; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; Halliwell GR, 1997, J CLIMATE, V10, P2405, DOI 10.1175/1520-0442(1997)010<2405:DAMNAS>2.0.CO;2; Hood LL, 1997, J GEOPHYS RES-ATMOS, V102, P1355, DOI 10.1029/96JD00210; KODERA K, 1995, J GEOPHYS RES-ATMOS, V100, P14077, DOI 10.1029/95JD01172; KODERA K, 1990, GEOPHYS RES LETT, V17, P1263, DOI 10.1029/GL017i009p01263; KODERA K, 1997, NATO ASI SERIES I, V54, P83; Labitzke K, 1997, SPACE SCI REV, V80, P393, DOI 10.1023/A:1004907126955; LABITZKE K, 1977, MON WEATHER REV, V105, P762, DOI 10.1175/1520-0493(1977)105<0762:IVOTWS>2.0.CO;2; Lean JL, 1997, J GEOPHYS RES-ATMOS, V102, P29939, DOI 10.1029/97JD02092; McCormack JP, 1996, J GEOPHYS RES-ATMOS, V101, P20933, DOI 10.1029/96JD01817; McCormack JP, 1997, GEOPHYS RES LETT, V24, P2729, DOI 10.1029/97GL02900; MEHTA VM, 1995, J CLIMATE, V8, P172, DOI 10.1175/1520-0442(1995)008<0172:DVOTTA>2.0.CO;2; Naito Y, 1997, J METEOROL SOC JPN, V75, P925, DOI 10.2151/jmsj1965.75.4_925; NESMERIBES E, 1993, J GEOPHYS RES-SPACE, V98, P18923, DOI 10.1029/93JA00305; RIND D, 1995, J CLIMATE, V8, P2080, DOI 10.1175/1520-0442(1995)008<2080:MTEOUV>2.0.CO;2; RIND D, 1992, J CLIMATE, V5, P189, DOI 10.1175/1520-0442(1992)005<0189:CCATMA>2.0.CO;2; SALBY ML, 1991, J GEOPHYS RES-ATMOS, V96, P22579, DOI 10.1029/91JD02530; Shindell DT, 1998, J CLIMATE, V11, P895, DOI 10.1175/1520-0442(1998)011<0895:CCATMA>2.0.CO;2; WETHERALD RT, 1975, J ATMOS SCI, V32, P2044, DOI 10.1175/1520-0469(1975)032<2044:TEOCTS>2.0.CO;2; *WMO, 1994, 37 WORLD MET ORG GLO	29	439	457	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					305	308		10.1126/science.284.5412.305	http://dx.doi.org/10.1126/science.284.5412.305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195893				2022-12-28	WOS:000079636400039
J	Kishnani, PS; Sullivan, JA; Walter, BK; Spiridigliozzi, GA; Doraiswamy, PM; Krishnan, KRR				Kishnani, PS; Sullivan, JA; Walter, BK; Spiridigliozzi, GA; Doraiswamy, PM; Krishnan, KRR			Cholinergic therapy for Down's syndrome	LANCET			English	Article							ALZHEIMERS-DISEASE		Duke Univ, Med Ctr, Dept Pediat, Down Syndrome Clin, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA	Duke University; Duke University	Kishnani, PS (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Down Syndrome Clin, Box 3528, Durham, NC 27710 USA.							Bishop J, 1997, AM J EPIDEMIOL, V145, P134; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310	5	67	70	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1064	1065		10.1016/S0140-6736(98)05285-4	http://dx.doi.org/10.1016/S0140-6736(98)05285-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199357				2022-12-28	WOS:000079614000016
J	Logan, S				Logan, S			Iron deficiency and developmental deficit - the jury is still out - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							WEIGHT-GAIN		UCL, Sch Med, Inst Child Hlth, Systemat Reviews Training Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	Logan, S (corresponding author), UCL, Sch Med, Inst Child Hlth, Systemat Reviews Training Unit, London WC1N 1EH, England.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; Childs F, 1997, ARCH DIS CHILD, V76, P144, DOI 10.1136/adc.76.2.144; DeMaeyer E, 1985, World Health Stat Q, V38, P302; IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2; IDJRADINATA P, 1993, LANCET, V311, P14; Lozoff B., 1996, Pediatric Research, V39, p136A; MOFFATT MEK, 1994, J PEDIATR-US, V125, P527, DOI 10.1016/S0022-3476(94)70003-6	7	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 13	1999	318	7185					697	698						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182JK	10215375				2022-12-28	WOS:000079495700021
J	Eickbush, T				Eickbush, T			Transcription: Exon shuffling in retrospect	SCIENCE			English	Editorial Material							RETROTRANSPOSITION		Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Eickbush, T (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.							HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; McNaughton JC, 1997, GENOMICS, V40, P294, DOI 10.1006/geno.1996.4543; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X	9	23	24	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1465	+		10.1126/science.283.5407.1465	http://dx.doi.org/10.1126/science.283.5407.1465			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10206876				2022-12-28	WOS:000078959200028
J	Chamberlain, G; Steer, P				Chamberlain, G; Steer, P			ABC of labour care - Unusual presentations and positions and multiple pregnancy	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England	Imperial College London	Chamberlain, G (corresponding author), Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England.							HOFMEYR J, 1997, COCHRANE LIB; Johnstone FD, 1998, BRIT J OBSTET GYNAEC, V105, P811, DOI 10.1111/j.1471-0528.1998.tb10223.x	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1192	1194						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221949				2022-12-28	WOS:000080277900036
J	Beecham, L				Beecham, L			Junior doctors call for health tax	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1149	1149						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213758				2022-12-28	WOS:000080166000088
J	Wallis, DE; Boxall, EH				Wallis, DE; Boxall, EH			Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake	BRITISH MEDICAL JOURNAL			English	Article									Birmingham Heartlands Hosp, Publ Hlth Lab, Birmingham B9 5SS, W Midlands, England; Walsall Hlth Author, Walsall WS1 1TE, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham	Boxall, EH (corresponding author), Birmingham Heartlands Hosp, Publ Hlth Lab, Birmingham B9 5SS, W Midlands, England.							BOXALL EH, 1996, PREVENTION HEPATITIS; *DEP HLTH, 1998, HSC1998127; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503	3	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1112	1113		10.1136/bmj.318.7191.1112	http://dx.doi.org/10.1136/bmj.318.7191.1112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213719	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080166000024
J	Karpinski, S; Reynolds, H; Karpinska, B; Wingsle, G; Creissen, G; Mullineaux, P				Karpinski, S; Reynolds, H; Karpinska, B; Wingsle, G; Creissen, G; Mullineaux, P			Systemic signaling and acclimation in response to excess excitation energy in Arabidopsis	SCIENCE			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE; LIGHT; PHOTOINHIBITION; PROTEIN; STRESS; TRANSFORMATION; PHOTOSYNTHESIS; EXPRESSION	Land plants are sessile and have developed sophisticated mechanisms that allow for both immediate and-acclimatory responses to changing environments. Partial exposure of Low light-adapted Arabidopsis plants to excess light results in a systemic acclimation to excess excitation energy and consequent photooxidative stress in unexposed leaves. Thus, plants possess a mechanism to communicate excess excitation energy systemically, allowing them to mount a defense against further episodes of such stress. Systemic redox changes in the proximity of photosystem II, hydrogen peroxide, and the induction of antioxidant defenses are key determinants of this mechanism of systemic acquired acclimation.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Genet & Plant Physiol, SE-90183 Umea, Sweden; John Innes Ctr Plant Sci Res, Dept Appl Genet, Norwich NR4 7UH, Norfolk, England	Swedish University of Agricultural Sciences; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Karpinski, S (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Genet & Plant Physiol, SE-90183 Umea, Sweden.		Karpinski, Stanislaw/ABD-9543-2021; Creissen, Gary P/C-7481-2009; Mullineaux, Philip M/F-7723-2012	Karpinski, Stanislaw/0000-0002-4328-1207; Creissen, Gary P/0000-0003-4992-8056; Mullineaux, Philip M/0000-0002-1998-3540				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baker N. R., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P127; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Edwards A, 1996, PLANT PHYSIOL, V112, P89, DOI 10.1104/pp.112.1.89; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Foyer CH., 1997, OXIDATIVE STRESS MOL, P587; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; KARPINSKI S, 1993, PLANT PHYSIOL, V103, P1385, DOI 10.1104/pp.103.4.1385; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Krause G. H., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P43; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P691; KUBO GH, 1992, FEBS LETT, V315, P313; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Lopez-Delgado H, 1998, J EXP BOT, V49, P713, DOI 10.1093/jexbot/49.321.713; MAXWELL DP, 1995, PLANT PHYSIOL, V109, P787, DOI 10.1104/pp.109.3.787; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; RUSSELL AW, 1995, PLANT PHYSIOL, V107, P943, DOI 10.1104/pp.107.3.943; Santos M, 1996, PLANTA, V198, P64, DOI 10.1007/BF00197587; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	21	698	751	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					654	657		10.1126/science.284.5414.654	http://dx.doi.org/10.1126/science.284.5414.654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213690				2022-12-28	WOS:000079951100048
J	Drachman, DA; Newell, KL; Scully, RE; Mark, EJ; McNeely, WF; Ebeling, SH; Lev, MH; Price, BH				Drachman, DA; Newell, KL; Scully, RE; Mark, EJ; McNeely, WF; Ebeling, SH; Lev, MH; Price, BH			A 67-year-old man with three years of dementia - Multisystem neurodegenerative disease (characterized by neurofibrillary changes and few plaques), findings consistent with dementia pugilistica.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; APOLIPOPROTEIN-E EPSILON-4; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; CORTICOBASAL DEGENERATION; PICK-DISEASE; LEWY BODIES; ONE ENTITY; DIAGNOSIS		Univ Massachusetts Mem Hlth Care, Dept Neurol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University Massachusetts Worcester Hospital; University of Massachusetts System; University of Massachusetts Worcester	Drachman, DA (corresponding author), Univ Massachusetts Mem Hlth Care, Dept Neurol, Worcester, MA 01605 USA.							Ala TA, 1997, J NEUROL NEUROSUR PS, V62, P16, DOI 10.1136/jnnp.62.1.16; Brun A, 1996, ACTA NEUROL SCAND, V94, P28, DOI 10.1111/j.1600-0404.1996.tb00369.x; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chen K M, 1995, Rinsho Shinkeigaku, V35, P1549; COREYBLOOM J, 1995, NEUROLOGY, V45, P211, DOI 10.1212/WNL.45.2.211; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; DRACHMAN DA, 1992, J AM GERIATR SOC, V40, P463, DOI 10.1111/j.1532-5415.1992.tb02012.x; DRACHMAN DA, 1991, NEUROLOGY, V41, P1828; DRACHMAN DA, 1991, NEUROLOGY, V41, P1333, DOI 10.1212/WNL.41.9.1333; GEDDES JF, 1993, BRAIN, V116, P281, DOI 10.1093/brain/116.1.281; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Heutink P, 1997, ANN NEUROL, V41, P150, DOI 10.1002/ana.410410205; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; Hooten WM, 1996, J NEUROPSYCH CLIN N, V8, P10; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Jackson M, 1996, NEURODEGENERATION, V5, P339, DOI 10.1006/neur.1996.0046; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Kertesz A, 1997, ARCH NEUROL-CHICAGO, V54, P1427, DOI 10.1001/archneur.1997.00550230090024; KIERNAN JA, 1994, BRAIN, V117, P747, DOI 10.1093/brain/117.4.747; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LOPEZ OL, 1994, DEMENTIA, V5, P42, DOI 10.1159/000106693; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; MAJOORKRAKAUER D, 1994, NEUROLOGY, V44, P1872, DOI 10.1212/WNL.44.10.1872; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; Mayeux R, 1998, NEW ENGL J MED, V338, P1325; MAYEUX R, 1993, CONT NEUROLOGY SERIE, V40, P92; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mendez MF, 1996, NEUROLOGY, V47, P1189, DOI 10.1212/WNL.47.5.1189; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Miller BL, 1997, NEUROLOGY, V48, P937, DOI 10.1212/WNL.48.4.937; MITSUYAMA Y, 1993, DEMENTIA, V4, P137, DOI 10.1159/000107312; Neary D, 1997, ARCH NEUROL-CHICAGO, V54, P1425, DOI 10.1001/archneur.1997.00550230088023; Neary D, 1996, BRAIN COGNITION, V31, P176, DOI 10.1006/brcg.1996.0041; Neary D, 1995, ANN NY ACAD SCI, V769, P15, DOI 10.1111/j.1749-6632.1995.tb38128.x; Nelson LM, 1996, CLIN NEUROSCI, V3, P327; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SALAZAR AM, 1983, ANN NEUROL, V14, P17, DOI 10.1002/ana.410140104; SCHMITT HP, 1995, EUR ARCH PSY CLIN N, V245, P299, DOI 10.1007/BF02191871; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SWEARER JM, 1988, J AM GERIATR SOC, V36, P784, DOI 10.1111/j.1532-5415.1988.tb04260.x; Talbot PR, 1996, J NEURAL TRANSM-SUPP, P125; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Wilhelmsen KC, 1997, J NEURAL TRANSM-SUPP, P269	51	30	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1269	1277		10.1056/NEJM199904223401609	http://dx.doi.org/10.1056/NEJM199904223401609			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210712				2022-12-28	WOS:000079833800009
J	Stamey, TA; McNeal, JE; Yemoto, CM; Sigal, BM; Johnstone, IM				Stamey, TA; McNeal, JE; Yemoto, CM; Sigal, BM; Johnstone, IM			Biological determinants of cancer progression in men with prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDUAL CANCER; ANTIGEN ASSAYS; ADENOCARCINOMA; METASTASIS; VOLUME	Context The recent increase in ability to diagnose prostatic adenocarcinoma has created a dilemma for treatment decisions, Objective To determine whether prostate cancer progression is associated with a modified version of the Gleason grading system together with selected morphologic and clinical variables. Design Retrospective analysis of a cohort of patients with peripheral zone prostate cancers who underwent surgery between August 1983 and July 1992. Setting University hospital. Patients Radical prostatectomy specimens from 379 men treated only by surgical excision were prospectively studied for 8 morphologic variables using previously standardized techniques. Variables were percentage of each cancer occupied by Gleason grade 4/5 (% Gleason grade 4/5, the Stanford modified Gleason scale), cancer volume, vascular invasion, lymph node involvement, seminal vesicle invasion, capsular penetration, positive surgical margin, prostate weight, and preoperative prostate-specific antigen (PSA) level, Main Outcome Measure Biochemical progression of prostate cancer as indicated by serum PSA level of 0.07 ng/mL and increasing. Results Cancer grade expressed as % Gleason grade 4/5 and cancer volume were highly predictive of disease progression, In a Cox proportional hazards model that included % Gleason grade 4/5, the traditional Gleason score was not an independent predictor of treatment failure. Positive lymph node findings and intraprostatic vascular invasion were the only other variables that remained significant at the .01 level. Conclusion The % Gleason grade 4/5, cancer volume, positive lymph node findings, and intraprostatic vascular invasion were independently associated with prostate cancer progression, defined by an increasing PSA level. Techniques to accurately measure cancer volume and % Gleason grade 4/5 are needed to better predict which patient will experience cancer progression. The commonly accepted predictors of progression-capsular penetration and positive surgical margins-were not independently predictive of failure after radical prostatectomy.	Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University	Stamey, TA (corresponding author), Stanford Univ, Med Ctr, Dept Urol, 300 Pasteur Dr, Stanford, CA 94305 USA.							BABAIAN RJ, 1995, J UROLOGY, V154, P1808, DOI 10.1016/S0022-5347(01)66790-9; Cox D. R., 1984, ANAL SURVIVAL DATA; Cox DR., 1989, ANAL BINARY DATA; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Isaacs JT, 1997, AM J PATHOL, V150, P1511; MCNEAL JE, 1990, AM J SURG PATHOL, V14, P240, DOI 10.1097/00000478-199003000-00005; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; McNeal JE, 1996, AM J SURG PATHOL, V20, P1351, DOI 10.1097/00000478-199611000-00006; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1991, ANN PATHOL, V11, P263; PRESTIGIACOMO AF, 1994, J UROLOGY, V152, P1515, DOI 10.1016/S0022-5347(17)32459-X; STAMEY TA, 1995, UROLOGY, V45, P2, DOI 10.1016/S0090-4295(95)96168-2; Stamey TA, 1996, CLIN CHEM, V42, P849; VENABLES WN, 1997, MODERN APPL STAT S P, P357; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T	15	512	533	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1395	1400		10.1001/jama.281.15.1395	http://dx.doi.org/10.1001/jama.281.15.1395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217055	Bronze			2022-12-28	WOS:000079701000029
J	Majetich, SA; Jin, Y				Majetich, SA; Jin, Y			Magnetization directions of individual nanoparticles	SCIENCE			English	Article							LORENTZ MICROSCOPY; PARTICLES; REVERSAL; ALLOYS; GROWTH	The magnetization directions of individual monodomain nanoparticles as small as 5 nanometers in diameter are determined using the Foucault method of Lorentz microscopy. A model is developed to explain the images and diffraction patterns of samarium cobalt nanoparticles as a function of the aperture shift direction. Thermally induced changes in the magnetization direction of superparamagnetic magnetite nanoparticles were observed but with a much stower rate than expected, due to surface anisotropy. When the time scale for magnetization reversal is much shorter than the data acquisition time, as in carbon-coated iron cobalt alloy nanoparticles, the images show an average of such thermally induced changes.	Carnegie Mellon Univ, Dept Phys, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Majetich, SA (corresponding author), Carnegie Mellon Univ, Dept Phys, Pittsburgh, PA 15213 USA.		Majetich, Sara/B-1022-2015	Majetich, Sara/0000-0003-0848-9317				AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; BORN M, 1970, PRINCIPLES OPTICS, P420; BROWN WF, 1958, J APPL PHYS, V29, P470, DOI 10.1063/1.1723183; Charap SH, 1997, IEEE T MAGN, V33, P978, DOI 10.1109/20.560142; CHEN CW, 1986, MAGNETISM METALLURGY, P211; Chou SY, 1996, J APPL PHYS, V79, P6101, DOI 10.1063/1.362440; CULLITY BD, 1972, INTRO MAGNETIC MAT, P301; CULLITY BD, 1972, INTRO MAGNETIC MAT, P413; Dooley J, 1997, ULTRAMICROSCOPY, V67, P113, DOI 10.1016/S0304-3991(96)00098-8; FULLER HW, 1960, J APPL PHYS, V31, P238, DOI 10.1063/1.1735552; FULLER HW, 1960, J APPL PHYS, V31, P1699, DOI 10.1063/1.1735428; GIBSON GA, 1991, IEEE T MAGN, V27, P5187, DOI 10.1109/20.278782; HUTTEN A, 1995, PHYS STATUS SOLIDI A, V150, P171, DOI 10.1002/pssa.2211500115; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P178; KENT AD, 1993, SCIENCE, V262, P1249, DOI 10.1126/science.262.5137.1249; KNELLER E, 1969, MAGNETISM METALLURGY, P385; KNELLER EF, 1963, J APPL PHYS, V34, P656, DOI 10.1063/1.1729324; Kodama RH, 1996, PHYS REV LETT, V77, P394, DOI 10.1103/PhysRevLett.77.394; LEDERMAN M, 1993, J APPL PHYS, V73, P6951; Majetich SA, 1997, IEEE T MAGN, V33, P3721, DOI 10.1109/20.619550; MCCURRIE RA, 1970, J MATER SCI, V5, P825, DOI 10.1007/BF00562172; MCCURRIE RA, 1994, FERROMAGNETIC MAT ST, P142; PFEIFER F, 1980, J MAGN MAGN MATER, V19, P190, DOI 10.1016/0304-8853(80)90592-2; SALLING C, 1991, IEEE T MAGN, V27, P5184, DOI 10.1109/20.278781; SCOTT JHJ, 1995, PHYS REV B, V52, P12564, DOI 10.1103/PhysRevB.52.12564; STONER EC, 1948, PHILOS TR R SOC S-A, V240, P599, DOI 10.1098/rsta.1948.0007; Wang ZL, 1998, ADV MATER, V10, P13, DOI 10.1002/(SICI)1521-4095(199801)10:1<13::AID-ADMA13>3.0.CO;2-W; Wernsdorfer W, 1997, PHYS REV LETT, V78, P1791, DOI 10.1103/PhysRevLett.78.1791; WOHLLEBE.D, 1967, J APPL PHYS, V38, P3341, DOI 10.1063/1.1710111; Zhang JL, 1996, PHYS REV LETT, V77, P390, DOI 10.1103/PhysRevLett.77.390	30	212	215	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					470	473		10.1126/science.284.5413.470	http://dx.doi.org/10.1126/science.284.5413.470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205051				2022-12-28	WOS:000079792200042
J	Roth, MG				Roth, MG			Snapshots of ARF1: Implications for mechanisms of activation and inactivation	CELL			English	Review							ADP-RIBOSYLATION-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; COATED VESICLES; GOLGI MEMBRANES; TRANSPORT VESICLES; GDP; PHOSPHOLIPIDS; COATOMER		Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roth, MG (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA.	michael.roth@email.swmed.edu		Roth, Michael/0000-0002-9056-332X				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	24	70	73	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					149	152		10.1016/S0092-8674(00)80723-0	http://dx.doi.org/10.1016/S0092-8674(00)80723-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219234	Bronze			2022-12-28	WOS:000079779800002
J	Black, N				Black, N			High-quality clinical databases: breaking down barriers	LANCET			English	Editorial Material							SURGERY		Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.							BLACK N, 1989, BRIT MED J, V298, P586, DOI 10.1136/bmj.298.6673.586; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; BURNS F, 1998, INFORMATION HLTH; Charlton BG, 1997, QJM-MON J ASSOC PHYS, V90, P147, DOI 10.1093/qjmed/90.2.147; Coulter A, 1997, J Health Serv Res Policy, V2, P112; GRUER R, 1986, LANCET, V1, P23; Hannan E L, 1998, J Health Serv Res Policy, V3, P67; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; MCGLYNN EA, 1998, HLTH INFORMATION SYS; NUTTLEY S, 1998, J HLTH SERV RES POLI, V3, P50; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; ROWAN KM, 1994, CARE CRTICALLY ILL, V10, P148	15	87	91	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1205	1206		10.1016/S0140-6736(99)00108-7	http://dx.doi.org/10.1016/S0140-6736(99)00108-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217078				2022-12-28	WOS:000079744100006
J	Hawton, K; Simkin, S; Deeks, J; O'Connor, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C				Hawton, K; Simkin, S; Deeks, J; O'Connor, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C			Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							NEWS STORIES; SUICIDE; IMITATION; PARACETAMOL; FILMS	Objectives To determine whether a serious paracetamol overdose in the medical television drama Casualty altered the incidence and nature of general hospital presentations for deliberate self poisoning. Design Interrupted time series analysis of presentations for self poisoning at accident and emergency departments during three week periods before and after the broadcast. Questionnaire responses collected from self poisoning patients during the same periods. Setting 49 accident and emergency departments and psychiatric services in United Kingdom collected incidence data; 25 services collected questionnaire data Subjects 4403 self poisoning patients; questionnaires completed for 1047. Main outcome measures Change in presentation rates for self poisoning in the three weeks after the broadcast compared with the three weeks before, use of paracetamol and other drugs for self poisoning, and the nature of overdoses in viewers of the broadcast compared with non-viewers. Results Presentations for self poisoning increased by 17% (95% confidence interval 7% to 28%) in the week after the broadcast and by 9% (0 to 19%) in the second week. Increases in paracetamol overdoses were more marked than increases in non-paracetamol overdoses. Thirty two patients who presented in the week after the broadcast and were interviewed had seen the episode-20% said that it had influenced their decision to take an overdose, and 17% said it had influenced their choice of drug. The use of paracetamol for overdose doubled among viewers of Casualty after the episode (rise of 106%; 28% to 232%). Conclusions Broadcast of popular television dramas depicting self poisoning may have a short term influence in terms of increases in hospital presentation for overdose and changes in the choice Of drug taken. This raises serious questions about the advisability of the media portraying suicidal behaviour.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England; Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Orthopaed Surg, Oxford OX3 9DU, England; Univ Glasgow, Media Unit, Glasgow G12 8LF, Lanark, Scotland	University of Oxford; University of Oxford; University of Oxford; University of Glasgow	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				BERMAN AL, 1988, AM J PSYCHIAT, V145, P982; BERO L, 1998, COCHRANE LIB; BOLLEN KA, 1982, AM SOCIOL REV, V47, P802, DOI 10.2307/2095217; *CMA MED DAT, 1996, DIR EM SPEC CAR UN 1; Dean AG, 1994, EPIINFO VERSION 6 WO; DIGGLE RJ, 1994, ANAL LOGITUDINAL DAT; GOULD MS, 1986, NEW ENGL J MED, V315, P690, DOI 10.1056/NEJM198609113151107; *GOV STAT SERV, 1998, REG TRENDS 33 1998 E; Gunnell D, 1997, J EPIDEMIOL COMMUN H, V51, P175, DOI 10.1136/jech.51.2.175; Gunnell D., 1994, BMJ-BRIT MED J, V308, P1446, DOI DOI 10.1136/BMJ.308.6941.1446; HAFNER H, 1989, SUICIDE YOUTH PERSPE, P117; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hughes T., 1998, PSYCHIAT B, V22, P88; Kapur N, 1998, BRIT MED J, V316, P831, DOI 10.1136/bmj.316.7134.831; KESSLER RC, 1989, J NERV MENT DIS, V177, P551, DOI 10.1097/00005053-198909000-00006; O'Connor S, 1999, BRIT MED J, V318, P978, DOI 10.1136/bmj.318.7189.978; OSTROFF RB, 1985, AM J PSYCHIAT, V142, P989; PHILLIPS DP, 1974, AM SOCIOL REV, V39, P340, DOI 10.2307/2094294; PHILLIPS DP, 1986, NEW ENGL J MED, V315, P685, DOI 10.1056/NEJM198609113151106; PLATT S, 1987, BRIT MED J, V294, P954, DOI 10.1136/bmj.294.6577.954; PLATT S, 1994, PREVENTION SUICIDE, P125; SCHMIDTKE A, 1988, PSYCHOL MED, V18, P665, DOI 10.1017/S0033291700008345; Simkin S, 1995, BRIT J PSYCHIAT, V167, P754, DOI 10.1192/bjp.167.6.754; *STAT, 1997, STAT STAT SOFTW REL; WASSERMAN IM, 1984, AM SOCIOL REV, V49, P427, DOI 10.2307/2095285	25	111	114	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					972	977		10.1136/bmj.318.7189.972	http://dx.doi.org/10.1136/bmj.318.7189.972			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186VU	10195966	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000079751500018
J	Cassell, EJ				Cassell, EJ			Historical perspective of medical residency training: 50 years of changes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Cornell Univ, Weil Med Coll, Ithaca, NY 14853 USA	Cornell University	Cassell, EJ (corresponding author), Cornell Univ, Weil Med Coll, Ithaca, NY 14853 USA.							CASSELL EJ, 1995, MILBANK Q, V73, P373, DOI 10.2307/3350372	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1231	1231		10.1001/jama.281.13.1231	http://dx.doi.org/10.1001/jama.281.13.1231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	181VW	10199439				2022-12-28	WOS:000079464400044
J	Stiell, IG; Wells, GA; Field, BJ; Spaite, DW; De Maio, VJ; Ward, R; Munkley, DP; Lyver, MB; Luinstra, LG; Campeau, T; Maloney, J; Dagnone, E				Stiell, IG; Wells, GA; Field, BJ; Spaite, DW; De Maio, VJ; Ward, R; Munkley, DP; Lyver, MB; Luinstra, LG; Campeau, T; Maloney, J; Dagnone, E		OPALS Study Grp	Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program - OPALS study phase II	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 17-19, 1998	CHICAGO, IL	Soc Acad Emergency Med			EMERGENCY MEDICAL-SERVICES; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; PREHOSPITAL DEFIBRILLATION; HEALTH-PROFESSIONALS; RESUSCITATION; METAANALYSIS; TECHNICIANS; MANAGEMENT; EXPERIENCE	Context Survival rates for out-of-hospital cardiac arrest are low; published survival rates in Ontario are only 2.5%. This study represents phase II of the Ontario Prehospital Advanced Life Support (OPALS) study, which is designed to systematically evaluate the effectiveness and efficiency of various prehospital interventions for patients with cardiac arrest, trauma, and critical illnesses. Objective To assess the impact on out-of-hospital cardiac arrest survival of the implementation of a rapid defibrillation program in a large multicenter emergency medical services (EMS) system with existing basic life support and defibrillation (BLS-D) level of care. Design Controlled clinical trial comparing survival for 36 months before (phase I) and 12 months after (phase II) system optimization. Setting Nineteen urban and suburban Ontario communities (populations ranging from 16 000 to 750 000 [total, 2.7 million]). Patients All patients who had out-of-hospital cardiac arrest in the study communities for whom resuscitation was attempted by emergency responders. Interventions Study communities optimized their EMS systems to achieve the target response interval from when a call was received until a vehicle stopped with a defibrillator of 8 minutes or less for 90% of cardiac arrest cases. Working both locally and provincially, communities implemented multiple measures, including defibrillation by firefighters, base paging, tiered response agreements with fire departments, continuous quality improvement for response intervals, and province-wide revision and implementation of standard dispatch policies. All response times were obtained from a central dispatch system. Main Outcome Measure Survival to hospital discharge. Results The 4690 cardiac arrest patients studied in phase I and the 1641 in phase II were similar for all clinical and demographic characteristics, including age, sex, witnessed status, rhythm, and receipt of bystander cardiopulmonary resuscitation. The proportion of cases meeting the 8-minute response criterion improved (76.7 % vs 92.5 %; P<.001) as did most median response intervals. Overall survival to hospital discharge for all rhythm groups combined improved from 3.9% to 5.2% (P = .03). The 33% relative increase in survival represents an additional 21 lives saved each year in the study communities (approximately 1 life per 120 000 residents). The charges were estimated to be US $46 900 per life saved for establishing the rapid defibrillation program and US $2400 per life saved annually for maintaining the program. Conclusion An inexpensive, multifaceted system optimization approach to rapid defibrillation can lead to significant improvements in survival after cardiac arrest in a large BLS-D EMS system.	Univ Ottawa, Div Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Civic Hosp, Leob Hlth Res Inst, Ottawa, ON, Canada; Sunnybrook Base Hosp Program, Toronto, ON, Canada; Univ Arizona, Arizona Emergency Med Res Ctr, Tucson, AZ USA; Niagara Reg Base Hosp Program, Niagara Falls, ON, Canada; Joseph Brant Mem Hosp, Dept Emergency Med, Burlington, ON, Canada; Ontario Minist Hlth, Toronto, ON M5W 1R5, Canada; Queens Univ, Div Emergency Med, Kingston, ON, Canada; Med Res Council Canada, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Arizona; Queens University - Canada	Stiell, IG (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Clin Epidemiol Unit, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.			Spaite, Daniel/0000-0003-2601-6476; Stiell, Ian/0000-0002-2583-6408				*AM HEART ASS, 1990, TXB ADV CARD LIF SUP; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BRISON RJ, 1992, CAN MED ASSOC J, V147, P191; CARVETH SW, 1974, ARCH SURG-CHICAGO, V108, P528; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2171; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Nichol G, 1996, ANN EMERG MED, V27, P700, DOI 10.1016/S0196-0644(96)70187-7; NICHOL G, 1994, JAMA-J AM MED ASSOC, V271, P504; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PANTRIDG.JF, 1967, LANCET, V2, P271; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SHUSTER M, 1993, ANN EMERG MED, V22, P721, DOI 10.1016/S0196-0644(05)81856-6; SPAITE DW, 1995, ANN EMERG MED, V25, P697; Stapczynski JS, 1997, ACAD EMERG MED, V4, P552, DOI 10.1111/j.1553-2712.1997.tb03577.x; Stiell IG, 1998, ANN EMERG MED, V32, P180, DOI 10.1016/S0196-0644(98)70135-0; Stiell IG, 1999, ANN EMERG MED, V33, P44, DOI 10.1016/S0196-0644(99)70415-4; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TORRANCE GW, 1993, HLTH STAT HLTH POLIC; VALENZUELA TD, 1990, ANN EMERG MED, V19, P1407, DOI 10.1016/S0196-0644(05)82609-5; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003	33	264	271	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1175	1181		10.1001/jama.281.13.1175	http://dx.doi.org/10.1001/jama.281.13.1175			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	181VW	10199426	Bronze			2022-12-28	WOS:000079464400031
J	Staessen, JA; Roels, HA; Emelianov, D; Kuznetsova, T; Thijs, L; Vangronsveld, J; Fagard, R				Staessen, JA; Roels, HA; Emelianov, D; Kuznetsova, T; Thijs, L; Vangronsveld, J; Fagard, R		PheeCad Study Grp	Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study	LANCET			English	Article							DUAL-PHOTON ABSORPTIOMETRY; AMBULATORY BLOOD-PRESSURE; TOTAL-BODY CALCIUM; OSTEOPOROSIS; LEAD; RAT	Background Chronic low-level exposure to cadmium may promote calcium loss via urinary excretion. We undertook a prospective population study to investigate whether environmental exposure to cadmium lowers bone density and increases risk of fractures. Methods We measured urinary cadmium excretion, a biomarker of lifetime exposure, in people from ten districts of Belgium, of which six districts bordered on three zinc smelters. We also measured cadmium in soil and in vegetables from the districts, and collected data on incidence of fractures and height loss. Bone density was measured at the forearm just above the wrist by single photon absorptiometry, and calculated as the mean of six proximal and four distal scans. Findings Mean cadmium excretion at baseline was 8.7 nmol dairy. Across the ten districts, mean cadmium concentration in soil ranged from 0.8 to 14.7 mg/kg, and from 0.1 to 4.0 mg/kg dry weight in vegetables. Median follow-up was 6.6 years. Mean forearm bane density in proximal and distal scans was 0.54 g/cm(2) and 0.43 g/cm(2) in men, and 0.44 g/cm(2) and 0.34 g/cm(2) in women, in postmenopausal women, a twofold increase in urinary cadmium correlated with 0.01 g/cm(2) decrease in bone density (p < 0.02). The relative risks associated with doubted urinary cadmium were 1.73 (95% CI 1.16-2.57; p = 0.007) for fractures in women and 1.60 (0.94-2.72, p = 0.08) for height toss in men. Cadmium excretion in districts near smelters was 22.8% higher (p = 0.001) than in other districts, with fracture rates of 16.0 end 10.3 cases per 1000 person-years, respectively, and a population-attributable risk of 35.0%. Interpretation Even at a low degree of environmental exposure, cadmium may promote skeletal demineralisation, which may lead to increased bone fragility and raised risk of fractures.	Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, B-3000 Leuven, Belgium; Catholic Univ Louvain, Unite Toxicol Ind & Med Travail, Brussels, Belgium; Limburgs Univ Ctr, Diepenbeek, Belgium	KU Leuven; Universite Catholique Louvain; Hasselt University	Staessen, JA (corresponding author), Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.	jan.staessen@med.kuleuven.ac.be	Vangronsveld, Jaco/ABE-5907-2020; Staessen, Jan A/A-1065-2011; Kuznetsova, Tatiana/ABI-5662-2020	Vangronsveld, Jaco/0000-0003-4423-8363; Staessen, Jan A/0000-0002-3026-1637; Kuznetsova, Tatiana/0000-0003-4293-4576; Thijs, Lutgarde/0000-0002-8108-2356				BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; BRONNER F, 1986, AM J PHYSIOL, V250, pG561, DOI 10.1152/ajpgi.1986.250.5.G561; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; Chalkley SR, 1998, OCCUP ENVIRON MED, V55, P446, DOI 10.1136/oem.55.7.446; CHRISTIANSEN C, 1975, SCAND J CLIN LAB INV, V35, P425, DOI 10.3109/00365517509095763; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; HOJIMA Y, 1994, MATRIX BIOL, V14, P113, DOI 10.1016/0945-053X(94)90001-9; Jarup L, 1998, OCCUP ENVIRON MED, V55, P435, DOI 10.1136/oem.55.7.435; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; JAWOROWSKI Z, 1985, SCI TOTAL ENVIRON, V43, P103, DOI 10.1016/0048-9697(85)90034-8; JIN T, 1987, TOXICOLOGY, V45, P307, DOI 10.1016/0300-483X(87)90020-5; Kjellstrom T., 1985, CADMIUM HLTH TOXICOL, VII, P257; Kjellstrom T., 1986, CADMIUM HLTH TOXICOL, V2, P111; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LORENTZON R, 1977, CLIN SCI MOL MED, V53, P439, DOI 10.1042/cs0530439; MAZESS RB, 1981, CALCIFIED TISSUE INT, V33, P361; MCARDLE WD, 1991, EXERCISE PHYSL ENERG, P804; MIYAHARA T, 1988, TOXICOL APPL PHARM, V96, P52, DOI 10.1016/0041-008X(88)90246-3; NILAS L, 1985, J NUCL MED, V26, P1257; Nordberg GF, 1985, CADMIUM HLTH TOXICOL, VI, P103; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; SHERLOCK JC, 1983, CADMIUM 83, P107; STAESSEN J, 1991, BRIT J IND MED, V48, P710; STAESSEN JA, 1994, LANCET, V343, P1523, DOI 10.1016/S0140-6736(94)92936-X; Staessen JA, 1997, J HUM HYPERTENS, V11, P507, DOI 10.1038/sj.jhh.1000476; Staessen JA, 1996, JAMA-J AM MED ASSOC, V275, P1563, DOI 10.1001/jama.275.20.1563; VALKEMA R, 1989, EUR J NUCL MED, V15, P269, DOI 10.1007/BF00257547	29	320	336	0	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1999	353	9159					1140	1144		10.1016/S0140-6736(98)09356-8	http://dx.doi.org/10.1016/S0140-6736(98)09356-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209978				2022-12-28	WOS:000079858400012
J	Rawlins, M				Rawlins, M			In pursuit of quality: The National Institute for Clinical Excellence	LANCET			English	Article								In the UK, as elsewhere in the world, there is abundant evidence of unacceptable inequalities and inefficiencies in health care. These failures are manifest in various ways including inappropriate variations in the uptake and use of health technologies of proven value, the too frequent failure to provide patients with optimum care for the treatment of common diseases, and the too ready adoption of health technologies with no established clinical benefits. Healthcare systems worldwide are therefore struggling to find ways to ensure that their health professionals are able to provide patients with the highest possible (and affordable) standards of clinical care. The British government has committed itself to a programme of enhancing the quality of care given to National Health Service (NHS) patients. The new National Institute for Clinical Excellence (NICE) has been charge with providing NHS staff with clear and robust advice that will help them meet their own, and their patients', aspirations. The Institute's guidance will cover individual technologies as well as the management of a wide range of conditions. NICE will also advise on appropriate methods of clinical audit in those areas where it has provided guidance.	Univ Newcastle, Clin Pharmacol Unit, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Rawlins, M (corresponding author), Univ Newcastle, Clin Pharmacol Unit, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							[Anonymous], EFF HLTH CARE B; *DEP HLTH, 1999, FAST ACC MOD TREATM; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Field MJ, 1990, CLIN PRACTICE GUIDEL; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527	6	125	126	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1079	1082		10.1016/S0140-6736(99)02381-8	http://dx.doi.org/10.1016/S0140-6736(99)02381-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199366				2022-12-28	WOS:000079614000042
J	Lagercrantz, H				Lagercrantz, H			Better born too soon than too small	LANCET			English	Editorial Material											Lagercrantz, H (corresponding author), KAROLINSKA INST, DEPT WOMAN & CHILD HLTH, S-17176 STOCKHOLM, SWEDEN.							AMIELTISON C, 1994, NEWBORN INFANT ONE B; BOURGEOIS JP, 1997, IN PRESS ACTA PAED S, V422; Evrard P, 1997, ACTA PAEDIATR, V86, P20; Hutton JL, 1997, ARCH DIS CHILD-FETAL, V76, pF75, DOI 10.1136/fn.76.2.F75; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; MARSAL K, 1992, BIOL NEONATE, V62, P258; NELIGAN GA, 1976, BORN TOO SOON BORN T	8	17	18	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	1997	350	9084					1044	1045		10.1016/S0140-6736(05)70450-5	http://dx.doi.org/10.1016/S0140-6736(05)70450-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213543				2022-12-28	WOS:A1997YA73400004
J	Vokes, EE; Liebowitz, DN; Weichselbaum, RR				Vokes, EE; Liebowitz, DN; Weichselbaum, RR			Nasopharyngeal carcinoma	LANCET			English	Article							EPSTEIN-BARR-VIRUS; RETROSPECTIVE ANALYSIS; IMMUNOGENETIC ASPECTS; CELLS; CHEMOTHERAPY; SURVIVAL; GENE; DNA; IRRADIATION; EXPRESSION		UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; UNIV CHICAGO,COMM VIROL,CHICAGO,IL 60637; UNIV CHICAGO,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; University of Chicago								ALSARRAF M, 1990, J CLIN ONCOL, V8, P1342, DOI 10.1200/JCO.1990.8.8.1342; ALSARRAF M, 1996, P AN M AM SOC CLIN, V15, P313; ALTUN M, 1995, INT J RADIAT ONCOL, V32, P859, DOI 10.1016/0360-3016(95)00516-2; BACHOUCHI M, 1990, J NATL CANCER I, V82, P616, DOI 10.1093/jnci/82.7.616; BEDWINEK JM, 1980, CANCER, V45, P2725, DOI 10.1002/1097-0142(19800601)45:11<2725::AID-CNCR2820451105>3.0.CO;2-1; Bedwinek JM, 1987, PRINCIPLES PRACTICE, P479; BEHARS OH, 1993, HDB STAGING CANC MAN; BOUSSEN H, 1991, J CLIN ONCOL, V9, P1675, DOI 10.1200/JCO.1991.9.9.1675; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHAN ATC, 1995, INT J RADIAT ONCOL, V33, P569, DOI 10.1016/0360-3016(95)00218-N; CHOO R, 1991, CANCER, V68, P2120, DOI 10.1002/1097-0142(19911115)68:10<2120::AID-CNCR2820681005>3.0.CO;2-7; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEVATHAIRE F, 1988, INT J CANCER, V42, P176, DOI 10.1002/ijc.2910420206; Devergne O, 1996, MOL CELL BIOL, V16, P7098; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FEINMESSER R, 1992, NEW ENGL J MED, V326, P17, DOI 10.1056/NEJM199201023260103; Garden AS, 1996, INT J RADIAT ONCOL, V36, P1005, DOI 10.1016/S0360-3016(96)00385-9; GEBLA V, 1996, BRIT J CANCER, V68, P191; HENDERSON BE, 1976, NEW ENGL J MED, V295, P1101, DOI 10.1056/NEJM197611112952003; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1977, INT J CANCER, V20, P663, DOI 10.1002/ijc.2910200504; HOPPE RT, 1978, INT J RADIAT ONCOL, V4, P199, DOI 10.1016/0360-3016(78)90138-4; HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535; HUANG DP, 1994, CANCER RES, V54, P4003; *INT NAS CANC STUD, 1996, INT J RADIAT ONCOL, V35, P463; KAVANAGH BD, 1992, CANCER, V69, P1315, DOI 10.1002/1097-0142(19920315)69:6<1315::AID-CNCR2820690602>3.0.CO;2-2; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; KUTCHER GJ, 1991, INT J RADIAT ONCOL, V21, P169, DOI 10.1016/0360-3016(91)90176-5; Lee AWM, 1997, INT J RADIAT ONCOL, V38, P43, DOI 10.1016/S0360-3016(97)00244-7; LEE AWM, 1993, INT J RADIAT ONCOL, V26, P773, DOI 10.1016/0360-3016(93)90491-D; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lin JC, 1996, INT J RADIAT ONCOL, V36, P1127, DOI 10.1016/S0360-3016(96)00384-7; LITTLER E, 1991, LANCET, V337, P685, DOI 10.1016/0140-6736(91)90275-T; MARKS JE, 1982, CANCER-AM CANCER SOC, V50, P1042, DOI 10.1002/1097-0142(19820915)50:6<1042::AID-CNCR2820500604>3.0.CO;2-Y; MESIC JB, 1981, INT J RADIAT ONCOL, V7, P447, DOI 10.1016/0360-3016(81)90129-2; MICHEAU C, 1987, CANCER-AM CANCER SOC, V60, P2459, DOI 10.1002/1097-0142(19871115)60:10<2459::AID-CNCR2820601019>3.0.CO;2-0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NONOYAMA M, 1973, P NATL ACAD SCI USA, V70, P3265, DOI 10.1073/pnas.70.11.3265; OLMI P, 1990, INT J RADIAT ONCOL, V19, P1171, DOI 10.1016/0360-3016(90)90224-8; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PEREZ CA, 1992, INT J RADIAT ONCOL, V23, P271, DOI 10.1016/0360-3016(92)90741-Y; QUIN D, 1988, CANCER, V61, P1117; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROUSSELET G, 1993, J CLIN ONCOL, V11, P2143, DOI 10.1200/JCO.1993.11.11.2143; Roychowdhury DF, 1996, CANCER, V77, P1419, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1419::AID-CNCR1>3.0.CO;2-7; Sanguineti G, 1997, INT J RADIAT ONCOL, V37, P985, DOI 10.1016/S0360-3016(97)00104-1; SCHABINGER PR, 1985, INT J RADIAT ONCOL, V11, P2081, DOI 10.1016/0360-3016(85)90087-2; SHAM JS, 1991, HEAD NECK-J SCI SPEC, V13, P98; SIMONS MJ, 1976, J NATL CANCER I, V57, P977, DOI 10.1093/jnci/57.5.977; SIMONS MJ, 1974, INT J CANCER, V13, P122, DOI 10.1002/ijc.2910130114; TANNOCK I, 1987, J CLIN ONCOL, V5, P629, DOI 10.1200/JCO.1987.5.4.629; TEO P, 1989, INT J RADIAT ONCOL, V16, P471, DOI 10.1016/0360-3016(89)90344-1; Teo PML, 1995, ORAL ONCOL, V31B, P373, DOI 10.1016/0964-1955(95)00026-7; TRAUB NR, 1986, CELL, V47, P883; VIKRAM B, 1984, HEAD NECK SURG, V7, P123, DOI 10.1002/hed.2890070206; VIKRAM B, 1985, INT J RADIAT ONCOL, V11, P1455, DOI 10.1016/0360-3016(85)90332-3; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WANG CC, 1991, AM J CLIN ONCOL-CANC, V14, P5, DOI 10.1097/00000421-199102000-00002; WANG CC, 1987, INT J RADIAT ONCOL, V13, P953, DOI 10.1016/0360-3016(87)90030-7; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YU MC, 1988, CANCER RES, V48, P1954; YU Z, 1985, INT J RADIAT ONCOL, V11, P21; ZENG Y, 1985, INT J CANCER, V36, P545, DOI 10.1002/ijc.2910360505; ZU Z, 1985, INT J RADIAT ONCOL, V11, P2143; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	70	208	237	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1087	1091		10.1016/S0140-6736(97)07269-3	http://dx.doi.org/10.1016/S0140-6736(97)07269-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213566				2022-12-28	WOS:A1997YA73400041
J	Hopton, J; Heaney, D				Hopton, J; Heaney, D			Towards primary care groups - The development of local healthcare cooperatives in Scotland	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Dept Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Hopton, J (corresponding author), Univ Edinburgh, Dept Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland.							*SECR STAT SCOTL, 1997, DES CAR REN NAT HLTH	1	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1185	1187						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221946				2022-12-28	WOS:000080277900034
J	Grogono, GRS; Steele, BJ				Grogono, GRS; Steele, BJ			Our grandfather's patient	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1117	1117		10.1136/bmj.318.7191.1117	http://dx.doi.org/10.1136/bmj.318.7191.1117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213725	Green Published			2022-12-28	WOS:000080166000027
J	Mayes, C; Macleod, C				Mayes, C; Macleod, C			Lesson of the week - When "NAI" means not actually injured	BRITISH MEDICAL JOURNAL			English	Article							CHILD-ABUSE		Antrim Hosp, Dept Paediat, Belfast BT41 2RL, Antrim, North Ireland		Macleod, C (corresponding author), Antrim Hosp, Dept Paediat, 45 Bush Rd, Belfast BT41 2RL, Antrim, North Ireland.							ALDER R, 1983, PEDIATRICS, V72, P718; BROWN J, 1986, JAMA-J AM MED ASSOC, V256, P617, DOI 10.1001/jama.256.5.617; ELLERSTEIN NS, 1979, AM J DIS CHILD, V133, P906, DOI 10.1001/archpedi.1979.02130090034005; GELLIS S, 1979, AM J DIS CHILD, V130, P856; Hobbs C.J., 1993, CHILD ABUSE NEGLECT; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; MEADOW R, 1983, ABC CHILD ABUSE; Shira JE, 1998, PEDIATRICS, V101, P715	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1127	1128		10.1136/bmj.318.7191.1127	http://dx.doi.org/10.1136/bmj.318.7191.1127			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213731	Green Published			2022-12-28	WOS:000080166000032
J	Mannervik, M; Nibu, Y; Zhang, HL; Levine, M				Mannervik, M; Nibu, Y; Zhang, HL; Levine, M			Transcription - Transcriptional coregulators in development	SCIENCE			English	Review							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; KRUPPEL-LIKE FACTOR; HISTONE DEACETYLASE; DROSOPHILA EMBRYO; REPRESSES TRANSCRIPTION; ACTIVATED TRANSCRIPTION; RETINOBLASTOMA PROTEIN; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION	Small differences in the levels of an extracellular signaling molecule can specify cell fate during development. Threshold responses are often determined at the level of transcription. Cell-specific and spatially localized patterns of gene expression depend on combinations of sequence-specific activators and repressors that bind to extensive cis-regulatory regions. Different mechanisms for integrating this complex regulatory information are discussed, particularly the role of coregulatory proteins, which are recruited to the DNA template by sequence-specific transcription factors. Recent studies suggest that a growing set of coactivators and corepressors mediate communication between diverse upstream regulatory proteins and the core RNA polymerase II transcription complex.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Nibu, Yutaka/J-4136-2019	Nibu, Yutaka/0000-0002-4696-7503; Mannervik, Mattias/0000-0003-4999-9655; Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R01GM034431, R37GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34431, GM46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURLEY SK, 1996, NAN REV BIOCH, V65, P769; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; GRAY S, 1995, PHILOS T ROY SOC B, V349, P257, DOI 10.1098/rstb.1995.0111; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANNERVIK M, UNPUB; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAAR AM, IN PRESS NATURE; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; RACHEZ C, IN PRESS NATURE; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUNDQVIST, 1998, FEBS LETT, V429, P183; TON JK, 1998, NATURE, V395, P917; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	84	188	195	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					606	609		10.1126/science.284.5414.606	http://dx.doi.org/10.1126/science.284.5414.606			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213677				2022-12-28	WOS:000079951100035
J	Stebbins, CE; Kaelin, WG; Pavletich, NP				Stebbins, CE; Kaelin, WG; Pavletich, NP			Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function	SCIENCE			English	Article							HIPPEL-LINDAU GENE; ENDOTHELIAL GROWTH-FACTOR; RENAL-CARCINOMA; SOMATIC MUTATIONS; F-BOX; PROTEIN; PRODUCT; UBIQUITIN; BINDING; FAMILY	Mutation of the VHL tumor suppressor is associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and the majority of kidney cancers. VHL binds the ELonginC-ELonginB complex and regulates Levels of hypoxia-inducible protei ns. The structure of the ternary complex at 2.7 angstrom resolution shows two interfaces, one between VHL and ELonginC and another between ELonginC and ELonginB. Tumorigenic mutations frequently occur in a 35-residue domain of VHL responsible for ELonginC binding. A mutational patch on a separate domain of VHL indicates a second macromolecular binding site. The structure extends the similarities to the SCF (Skp1-Cul1-F-box protein) complex that targets proteins for degradation, supporting the hypothesis that VHL may function in an analogous pathway.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Biochem & Struct Biol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Stebbins, Erec/N-2565-2018	Stebbins, Erec/0000-0001-6229-5308				ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KISHIDA T, 1995, CANCER RES, V55, P4544; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takagi Y, 1997, J BIOL CHEM, V272, P27444, DOI 10.1074/jbc.272.43.27444; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	41	656	675	5	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					455	461		10.1126/science.284.5413.455	http://dx.doi.org/10.1126/science.284.5413.455			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205047				2022-12-28	WOS:000079792200038
J	Straight, AF; Shou, WY; Dowd, GJ; Turck, CW; Deshaies, RJ; Johnson, AD; Moazed, D				Straight, AF; Shou, WY; Dowd, GJ; Turck, CW; Deshaies, RJ; Johnson, AD; Moazed, D			Net1, a Sir2-associated nucleolar protein required for rDNA silencing and nucleolar integrity	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; TRANSCRIPTIONAL STATES; BINDING-PROTEIN; RIBOSOMAL DNA; BUDDING YEAST; COMPLEX; SIR2; EXPRESSION; LOCI	The Sir2 protein mediates gene silencing and repression of recombination at the rDNA repeats in budding yeast. Here we show that Sir2 executes these functions as a component of a nucleolar complex designated RENT (regulator of nucleolar silencing and telophase exit). Net1, a core subunit of this complex, preferentially cross-links to the rDNA repeats, but not to silent DNA regions near telomeres or to active genes, and tethers the RENT complex to rDNA. Net1 is furthermore required for rDNA silencing and nucleolar integrity. During interphase, Net1 and Sir2 colocalize to a subdomain within the nucleolus, but at the end of mitosis a fraction of Sir2 leaves the nucleolus and disperses as fool throughout the nucleus, suggesting that the structure of rDNA silent chromatin changes during the cell cycle. Our findings suggest that a protein complex shown to regulate exit from mitosis is also involved in gene silencing.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Calif San Francisco, Dept Microbiol, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Harvard University; Harvard Medical School; California Institute of Technology; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	danesh@hms.harvard.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354; Straight, Aaron/0000-0001-5885-7881; Shou, Wenying/0000-0001-5693-381X				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; DeRubertis F, 1996, NATURE, V384, P589; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KLAR AJS, 1979, GENETICS, V93, P37; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PRINGLE J R, 1991, P565; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RHODE PR, 1999, GENE DEV, V3, P1926; RINE J, 1987, GENETICS, V116, P9; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	49	323	327	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					245	256		10.1016/S0092-8674(00)80734-5	http://dx.doi.org/10.1016/S0092-8674(00)80734-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219245	Bronze			2022-12-28	WOS:000079779800013
J	Westerman, AM; Entius, MM; de Baar, E; Boor, PPC; Koole, R; van Velthuysen, MLF; Offerhaus, GJA; Lindhout, D; de Rooij, FWM; Wilson, JHP				Westerman, AM; Entius, MM; de Baar, E; Boor, PPC; Koole, R; van Velthuysen, MLF; Offerhaus, GJA; Lindhout, D; de Rooij, FWM; Wilson, JHP			Peutz-Jeghers syndrome: 78-year follow-up of the original family	LANCET			English	Article							LOCALIZATION; KINASE	Background The association between heredity, gastrointestinal polyposis, and mucocutaneous pigmentation in Peutz-Jeghers syndrome (PJS) was first recognised in 1921 by Peutz in a Dutch family. This original family has now been followed-up for more than 78 years. We did mutation analysis in this family to test whether the recently identified LKB1 gene is indeed the PJS gene in this family. Methods The original family was retraced and the natural history of PJS was studied in six generations of this kindred by interview, physical examination, chart view, and histological review of tissue specimens. DNA-mutation analysis was done in all available descendants. Findings Clinical features in this family included gastrointestinal polyposis, mucocutaneous pigmentation, nasal polyposis, and rectal extrusion of polyps. Survival of affected family members was reduced by intestinal obstruction and by the development of malignant disease. A novel germline mutation in the LKB1 gene was found to cosegregate with the disease phenotype in the original family. The mutant LKB1 allele carried a T insertion at codon 66 in exon 1 resulting in frameshift and stop at codon 162 in exon 4. Interpretation The morbidity and mortality in this family suggest that PJS is not a benign disease. An inactivating germline mutation in the LKB1 gene is involved in the PJS phenotype in the original and oldest kindred known to be affected by PJS.	Univ Hosp Dijkzigt, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands; Erasmus Univ, MGC Dept Clin Genet, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Erasmus University Rotterdam	Wilson, JHP (corresponding author), Univ Hosp Dijkzigt, Dept Internal Med 2, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		Lindhout, Dick/AAH-5765-2019; van Velthuysen, Marie-Louise/AAG-4895-2019	van Velthuysen, Marie-Louise/0000-0003-0435-9494; Lindhout, Dick/0000-0001-9580-624X				BARTHOLOMEW LG, 1957, GASTROENTEROLOGY, V32, P434; BARTHOLOMEW LG, 1962, SURG GYNECOL OBSTET, V115, P1; Cerqua N, 1993, Acta Otorhinolaryngol Ital, V13, P333; DEFACQ L, 1995, AM J GASTROENTEROL, V90, P1330; FARMER RG, 1963, AM J DIG DIS, V8, P953, DOI 10.1007/BF02232093; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JANCU J, 1971, AM J GASTROENTEROL, V56, P545; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LAMESCH AJ, 1983, DIS COLON RECTUM, V26, P452, DOI 10.1007/BF02556525; MANDEGOLD BC, 1969, MED WELT, V25, P1435; MORENS DM, 1975, AM J DIS CHILD, V129, P973, DOI 10.1001/archpedi.1975.02120450077019; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARA MJF, 1995, J PEDIATR-US, V126, P965; TOVAR JA, 1983, J PEDIATR SURG, V18, P1, DOI 10.1016/S0022-3468(83)80262-0; van Wijk Th W, 1950, THESIS LEIDEN NETHER; Westerman AM, 1997, J CLIN GASTROENTEROL, V25, P387, DOI 10.1097/00004836-199707000-00023; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	24	93	104	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1211	1215		10.1016/S0140-6736(98)08018-0	http://dx.doi.org/10.1016/S0140-6736(98)08018-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217080				2022-12-28	WOS:000079744100008
J	Takeda, K; Takeuchi, O; Tsujimura, T; Itami, S; Adachi, O; Kawai, T; Sanjo, H; Yoshikawa, K; Terada, N; Akira, S				Takeda, K; Takeuchi, O; Tsujimura, T; Itami, S; Adachi, O; Kawai, T; Sanjo, H; Yoshikawa, K; Terada, N; Akira, S			Limb and skin abnormalities in mice lacking IKK alpha	SCIENCE			English	Article							NF-KAPPA-B; TRANSCRIPTION; ACTIVATION; KINASE; DISRUPTION; INHIBITION; TWIST; GENE; BETA	The gene encoding inhibitor of kappa B (I kappa B) kinase alpha (IKK alpha; also called IKK1) was disrupted by gene targeting. IKK alpha-deficient mice died perinatally. In IKK alpha-deficient fetuses, Limb outgrowth was severely impaired despite unaffected skeletal development. The epidermal cells in IKK alpha-deficient fetuses were highly proliferative with dysregulated epidermal differentiation. In the basal layer, degradation of I kappa B and nuclear localization of nuclear factor kappa B (NF-kappa B) were not observed. Thus, IKK alpha is essential for NF-kappa B activation in the limb and skin during embryogenesis. In contrast, there was no impairment of NF-kappa B activation induced by either interleukin-1 or tumor necrosis factor-alpha in IKK alpha-deficient embryonic fibroblasts and thymocytes, indicating that IKK alpha is not essential for cytokine-induced activation of NF-kappa B.	Japan Sci & Technol Corp, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; Japan Sci & Technol Corp, CREST, Nishinomiya, Hyogo 6638501, Japan; Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Sch Med, Dept Dermatol, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Hyogo College of Medicine; Osaka University	Akira, S (corresponding author), Japan Sci & Technol Corp, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Takeuchi, Osamu/AAG-9359-2019; Takeuchi, Osamu/D-6007-2011; Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009	Takeuchi, Osamu/0000-0002-1260-6232; Kawai, Taro/0000-0001-7510-4662				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOUZZI VE, 1997, NAT GENET, V15, P42; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; HOWARD TD, 1997, NAT GENET, V15, P41; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Ma SH, 1997, GENE EXPRESSION, V6, P361; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; PAN D, 1993, GENE DEV, V7, P694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKEDA K, UNPUB; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	23	521	546	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					313	316		10.1126/science.284.5412.313	http://dx.doi.org/10.1126/science.284.5412.313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195895				2022-12-28	WOS:000079636400041
J	Jindal, B; Dowdal, T				Jindal, B; Dowdal, T			Medicare's role in financing graduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Bipartisan Commiss Future Medicare, Washington, DC 20002 USA		Jindal, B (corresponding author), Natl Bipartisan Commiss Future Medicare, Washington, DC 20002 USA.							ALTMAN SH, 1997, POLICY OPTIONS REFOR, P35; *C BUDG OFF, 1995, MED GRAD MED ED; *COMM FUND TASK FO, 1997, LEV PLAYING FIELD FI; *COMM IMPL NAT GRA, 1997, IMPL NAT MED ED TEST; Desmarais HR, 1997, HEALTH AFFAIR, V16, P48, DOI 10.1377/hlthaff.16.4.48; *I MED, 1996, NAT PHYS WORKF OPT B; *MED PAYM ADV COMM, 1998, HEALTHC SPEND MED PR; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; *PROSP PAYM ASS CO, 1997, REP REC C; *US GEN ACC OFF, 1989, PUBL HRD, V8933	10	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1228	1229		10.1001/jama.281.13.1228	http://dx.doi.org/10.1001/jama.281.13.1228			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199437	hybrid			2022-12-28	WOS:000079464400042
J	Burridge, K				Burridge, K			Signal transduction - Crosstalk between Rac and Rho	SCIENCE			English	Editorial Material							KINASE; MYOSIN		Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Burridge, K (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA.							Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	8	50	50	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2028	2029		10.1126/science.283.5410.2028	http://dx.doi.org/10.1126/science.283.5410.2028			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10206910				2022-12-28	WOS:000079369800031
J	Berger, A				Berger, A			Rational drug design for Alzheimer's disease - Science commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Farlow MR, 1998, NEUROLOGY, V51, pS36, DOI 10.1212/WNL.51.1_Suppl_1.S36	1	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					639	640						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10215361				2022-12-28	WOS:000079089200027
J	Acuna, MH; Connerney, JEP; Ness, NF; Lin, RP; Mitchell, D; Carlson, CW; McFadden, J; Anderson, KA; Reme, H; Mazelle, C; Vignes, D; Wasilewski, P; Cloutier, P				Acuna, MH; Connerney, JEP; Ness, NF; Lin, RP; Mitchell, D; Carlson, CW; McFadden, J; Anderson, KA; Reme, H; Mazelle, C; Vignes, D; Wasilewski, P; Cloutier, P			Global distribution of crustal magnetization discovered by the Mars Global Surveyor MAG/ER experiment	SCIENCE			English	Article							FIELD	Vector magnetic field observations of the martian crust were acquired by the Mars Global Surveyor (MCS) magnetic field experiment/electron reflectometer (MAG/ER) during the aerobraking and science phasing orbits, at altitudes between similar to 100 and 200 kilometers. Magnetic field sources of multiple scales, strength, and geometry were observed. There is a correlation between the location of the sources and the ancient cratered terrain of the martian highlands. The absence of crustal magnetism near large impact basins such as Hellas and Argyre implies cessation of internal dynamo action during the early Naochian epoch (similar to 4 billion years ago). Sources with equivalent magnetic moments as Large as 1.3 x 10(17) ampere-meter(2) in the Terra Sirenum region contribute to the development of an asymmetrical, time-variable obstacle to solar wind flow around Mars.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Delaware, Bartol Res Inst, Newark, DE 19716 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Ctr Etud Spatiale Rayonnements, F-31028 Toulouse 4, France; Rice Univ, Dept Space Phys & Astron, Houston, TX 77005 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Delaware; University of California System; University of California Berkeley; Rice University	Acuna, MH (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		connerney, john/I-5127-2013					ACHACHE J, 1987, J GEOPHYS RES-SOLID, V92, P11584, DOI 10.1029/JB092iB11p11584; ACUNA MH, 1992, J GEOPHYS RES-PLANET, V97, P7799, DOI 10.1029/92JE00344; Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; BARLOW N, 1997, ENCY PLANETARY SCI, P454; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; INGE JL, 1982, 1322 US GEOL SURV; LEMOUEL JL, 1975, GEOPHYS J ROY ASTR S, V42, P251, DOI 10.1111/j.1365-246X.1975.tb05859.x; Leweling M, 1997, PLANET SPACE SCI, V45, P1389, DOI 10.1016/S0032-0633(97)00186-4; Luhmann J.G., 1992, MARS, V1, P1090, DOI [10.2307/j.ctt207g59v.35, DOI 10.2307/J.CTT207G59V.35]; LUHMANN JG, 1991, REV GEOPHYS, V29, P121, DOI 10.1029/91RG00066; MAYHEW MA, 1979, J GEOPHYS-Z GEOPHYS, V45, P119; MOHLMANN D, 1991, PLANET SPACE SCI, V39, P83, DOI 10.1016/0032-0633(91)90130-3; PEPIN RO, 1992, MARS, P120; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Smith D., 1999, COMMUNICATION; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0	16	750	761	6	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					790	793		10.1126/science.284.5415.790	http://dx.doi.org/10.1126/science.284.5415.790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221908	Green Submitted			2022-12-28	WOS:000080056200042
J	Parent, CA; Devreotes, PN				Parent, CA; Devreotes, PN			A cell's sense of direction	SCIENCE			English	Review							DICTYOSTELIUM MYOSIN-II; PROTEIN-KINASE-C; CHEMOATTRACTANT RECEPTORS; LEADING-EDGE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; FUSION PROTEIN; RHO-GTPASES; HEAVY-CHAIN; P115 RHOGEF	In eukaryotic cells directional sensing is mediated by heterotrimeric guanine nucleotide-binding protein (G protein)-linked signaling pathways. In Dictyostelium discoideum amoebae and mammalian Leukocytes, the receptors and G-protein subunits are uniformly distributed around the cell perimeter. Chemoattractants induce the transient appearance of binding sites for several pleckstrin homology domain-containing proteins on the inner face of the membrane. In gradients of attractant these sites are persistently present on the side of the cell facing the higher concentration, even in the absence of a functional actin cytoskeleton or cell movement. Thus, the cell senses direction by spatially regulating the activity of the signal transduction pathway.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28007, GM47874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; Aizawa H, 1997, J CELL SCI, V110, P2333; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cassimeris L, 1990, Semin Cell Biol, V1, P125; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; Chung C.-A., UNPUB; CONDEELIS J, 1988, CELL MOTIL CYTOSKEL, V10, P77, DOI 10.1002/cm.970100113; Dembinsky A, 1996, J CELL BIOL, V134, P911, DOI 10.1083/jcb.134.4.911; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Fisher P R, 1990, Semin Cell Biol, V1, P87; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; JIN TX, UNPUB; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MATO JM, 1975, P NATL ACAD SCI USA, V72, P4991, DOI 10.1073/pnas.72.12.4991; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; NEWELL PC, 1992, BIOESSAYS, V14, P473, DOI 10.1002/bies.950140708; PARENT C, UNPUB; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TIAN J, 1998, MOL BIOL CELL, V9, P2949; TRANQUILLO RT, 1988, J CELL BIOL, V106, P303, DOI 10.1083/jcb.106.2.303; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANES S, UNPUB; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1974, NATURE, V249, P450, DOI 10.1038/249450a0; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585	54	704	717	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					765	770		10.1126/science.284.5415.765	http://dx.doi.org/10.1126/science.284.5415.765			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221901				2022-12-28	WOS:000080056200035
J	Wilson, J; Woods, I; Fawcett, J; Whall, R; Dibb, W; Morris, C; McManus, E				Wilson, J; Woods, I; Fawcett, J; Whall, R; Dibb, W; Morris, C; McManus, E			Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery	BRITISH MEDICAL JOURNAL			English	Article							GUT MUCOSAL HYPOPERFUSION; POSSUM SCORING SYSTEM; SURGICAL PATIENTS; CLINICAL-TRIAL; OPTIMIZATION; DOPEXAMINE; AUDIT	Objectives To determine whether preoperative optimisation of oxygen delivery improves outcome after major elective surgery, and to determine whether the inotropes, adrenaline and dopexamine, used to enhance oxygen delivery influence outcome. Design Randomised controlled trial with double blinding between inotrope groups. Setting York District Hospital, England. Subjects 138 patients undergoing major elective surgery who were at risk of developing postoperative complications either because of the surgery or the presence of coexistent medical conditions. Interventions Patients were randomised into three groups. Two groups received invasive haemodynamic monitoring, fluid, and either adrenaline or dopexamine to increase oxygen delivery Inotropic support was continued during surgery and for at least 12 hours afterwards. The third group (control) received routine perioperative care. Main outcome measures Hospital mortality and morbidity. Results Overall, 3/92 (3%) preoptimised patients died compared with 8/46 controls (17%) (P = 0.007). There were no differences in mortality between the treatment groups, but 14/46 (30%) patients in the dopexamine group developed complications compared with 24/46 (52%) patients in the adrenaline group (difference 22%, 95% confidence interval 2% to 41%) and 28 patients (61%) in the control group (31%, 11% to 50%). The use of dopexamine was associated with a decreased length of stay in hospital. Conclusion Routine preoperative optimisation of patients undergoing major elective surgery would be a significant and cost effective improvement in perioperative care.	York Dist Hosp, Dept Anaesthet, York YO31 8HE, N Yorkshire, England; York Dist Hosp, Intens Care Unit, York YO31 8HE, N Yorkshire, England		Wilson, J (corresponding author), York Dist Hosp, Dept Anaesthet, York YO31 8HE, N Yorkshire, England.							BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; BROWN RA, 1985, BRIT J PHARMACOL, V85, P599, DOI 10.1111/j.1476-5381.1985.tb10554.x; Campling EA, 1992, NATL CONFIDENTIAL EN; Copeland G P, 1991, Br J Surg, V78, P355, DOI 10.1002/bjs.1800780327; COPELAND GP, 1993, ANN ROY COLL SURG, V75, P175; ERKENS U, 1998, INTENS CARE MED, V24, pS428; Gardner M. J., 1989, STAT CONFIDENCE; *INT CAR NAT AUD R, 1998, ANN REP NAT CAS MIX; LUGO G, 1993, CRIT CARE MED, V21, P64, DOI 10.1097/00003246-199301000-00014; MeierHellmann A, 1997, CRIT CARE MED, V25, P399, DOI 10.1097/00003246-199703000-00005; MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423; MYTHEN MG, 1994, INTENS CARE MED, V20, P203, DOI 10.1007/BF01704701; SAGAR PM, 1994, BRIT J SURG, V81, P1492, DOI 10.1002/bjs.1800811031; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; SMITHIES M, 1994, CRIT CARE MED, V22, P789, DOI 10.1097/00003246-199405000-00013; TIGHE D, 1998, INTENS CARE MED, V24, pS397	18	361	377	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1099	1103		10.1136/bmj.318.7191.1099	http://dx.doi.org/10.1136/bmj.318.7191.1099			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213716	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080166000021
J	Remuzzi, G; Schieppati, A				Remuzzi, G; Schieppati, A			Lessons from the Di Bella affair	LANCET			English	Editorial Material									Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Ballmaier M, 1998, NAT MED, V4, P258, DOI 10.1038/nm0398-258b; Raschetti R, 1999, BRIT MED J, V318, P224; Simini B, 1998, LANCET, V351, P428, DOI 10.1016/S0140-6736(05)78379-3; 1998, SCRIP, V2329, P6; 1998, NATURE, V392, P421	5	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1289	1290		10.1016/S0140-6736(99)90044-2	http://dx.doi.org/10.1016/S0140-6736(99)90044-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218523				2022-12-28	WOS:000080278100005
J	Chardin, P; McCormick, F				Chardin, P; McCormick, F			Brefeldin A: The advantage of being uncompetitive	CELL			English	Review							GUANINE-NUCLEOTIDE-EXCHANGE; PLECKSTRIN-HOMOLOGY DOMAINS; SEC7 DOMAIN; FACTOR ARNO; ARF GTPASE; MEMBRANE; PROTEIN; RAS		Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Chardin, P (corresponding author), Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94115 USA.							Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BORLACKSJODIN PA, 1998, NATURE, V394, P337; BORNANCIN F, 1991, FEBS LETT, V291, P273, DOI 10.1016/0014-5793(91)81300-W; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Mansour SJ, 1998, GENOMICS, V54, P323, DOI 10.1006/geno.1998.5563; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; YAN JP, 1994, J CELL BIOL, V126, P65, DOI 10.1083/jcb.126.1.65	25	311	318	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					153	155		10.1016/S0092-8674(00)80724-2	http://dx.doi.org/10.1016/S0092-8674(00)80724-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219235	Bronze			2022-12-28	WOS:000079779800003
J	Gokhale, RS; Tsuji, SY; Cane, DE; Khosla, C				Gokhale, RS; Tsuji, SY; Cane, DE; Khosla, C			Dissecting and exploiting intermodular communication in polyketide synthases	SCIENCE			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; ORGANIZATION; BIOSYNTHESIS; DOMAIN; GENE	Modular polyketide synthases catalyze the biosynthesis of medicinally important natural products through an assembly-line mechanism. Although these megasynthases display very precise overall selectivity, we show that their constituent modules are remarkably tolerant toward diverse incoming acyl chains. By appropriate engineering of linkers, which exist within and between polypeptides, it is possible to exploit this tolerance to facilitate the transfer of biosynthetic intermediates between unnaturally linked modules. This protein engineering strategy also provides insights into the evolution of modular polyketide synthases.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	Stanford University; Stanford University; Stanford University; Brown University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.			Khosla, Chaitan/0000-0001-6529-495X	NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM22172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, CHEM BIOL, V6, P117, DOI 10.1016/S1074-5521(99)80008-8; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; McDaniel R, 1997, CHEM BIOL, V4, P667, DOI 10.1016/S1074-5521(97)90222-2; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Schupp T, 1998, FEMS MICROBIOL LETT, V159, P201, DOI 10.1111/j.1574-6968.1998.tb12861.x; Tsukamoto N, 1996, BIOCHEMISTRY-US, V35, P15244, DOI 10.1021/bi961972f	18	273	294	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					482	485		10.1126/science.284.5413.482	http://dx.doi.org/10.1126/science.284.5413.482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205055				2022-12-28	WOS:000079792200046
J	van der Horst, GTJ; Muijtjens, M; Kobayashi, K; Takano, R; Kanno, S; Takao, M; de Wit, J; Verkerk, A; Eker, APM; van Leenen, D; Buijs, R; Bootsma, D; Hoeijmakers, JHJ; Yasui, A				van der Horst, GTJ; Muijtjens, M; Kobayashi, K; Takano, R; Kanno, S; Takao, M; de Wit, J; Verkerk, A; Eker, APM; van Leenen, D; Buijs, R; Bootsma, D; Hoeijmakers, JHJ; Yasui, A			Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms	NATURE			English	Article							BLUE-LIGHT PHOTORECEPTORS; HUMAN PHOTOLYASE HOMOLOG; DNA PHOTOLYASE; CLOCK GENE; DROSOPHILA; MOUSE; CRYPTOCHROME; SIMILARITY; TIMELESS; CLONING	Many biochemical, physiological and behavioural processes show circadian rhythms which are generated by an internal timekeeping mechanism referred to as the biological clock. According to rapidly developing. models, the core oscillator driving this clock is composed of an autoregulatory transcription-(post) translation-based feedback loop involving a set of 'clock' genes(1-6). Molecular docks do not oscillate with an exact 24-hour rhythmicity but are entrained to solar day/night rhythms by light. The mammalian proteins Cry1 and Cry2, which are members of the family of plant blue-light receptors (cryptochromes) and photolyases, have been proposed as candidate light receptors for photoentrainment of the biological clock(7-10). Here we show that mice lacking the Cry1 or Cry2 protein display accelerated and delayed free-running periodicity of locomotor activity, respectively. Strikingly, in the absence of both proteins, an instantaneous and complete loss of free-running rhythmicity is observed. This suggests that, in addition to a possible photoreceptor and antagonistic clock-adjusting function, both proteins are essential for the maintenance of circadian rhythmicity.	Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Tohoku Univ, Inst Dev Aging & Canc, Inst Dev, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Erasmus Univ, Dept Clin Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands	Erasmus University Rotterdam; Tohoku University; Erasmus University Rotterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, MGC, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hoeijmakers, Jan/AAX-6972-2021; Buijs, Rudolf/AAD-5707-2020; Kanno, Shin-ichiro/AAE-4549-2019; van der Horst, Gijsbertus TJ/E-3661-2015; Weydahl, Andi/C-6391-2008	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Kobayashi-Nakamura, Kumiko/0000-0001-5579-3464				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRODY S, 1992, CHRONOBIOL INT, V9, P222, DOI 10.3109/07420529209064531; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HORTON RM, 1995, BIOTECHNIQUES, V19, P594; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Millar AJ, 1997, CURR BIOL, V7, pR474, DOI 10.1016/S0960-9822(06)00240-5; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schibler U, 1998, NATURE, V393, P620, DOI 10.1038/31337; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suarez-Lopez P, 1998, SCIENCE, V279, P1323, DOI 10.1126/science.279.5355.1323; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Yasui A, 1998, CONT CANC RES, P9; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	30	1042	1066	3	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					627	630		10.1038/19323	http://dx.doi.org/10.1038/19323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217146				2022-12-28	WOS:000079754700059
J	Rumsfeld, JS; MaWhinney, S; McCarthy, M; Shroyer, ALW; VillaNueva, CB; O'Brien, M; Moritz, TE; Henderson, WG; Grover, FL; Sethi, GK; Hammermeister, KE				Rumsfeld, JS; MaWhinney, S; McCarthy, M; Shroyer, ALW; VillaNueva, CB; O'Brien, M; Moritz, TE; Henderson, WG; Grover, FL; Sethi, GK; Hammermeister, KE			Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM MORTALITY; DISEASE; DEPRESSION; RISK	Context Health-related quality of life has not been evaluated as a predictor of mortality following coronary artery bypass graft (CABG) surgery. Evaluation of health status as a mortality predictor may be useful for preoperative risk stratification. Objective To determine whether the Physical and Mental Component Summary scores from the preoperative Short-Form 36 (SF-36) health status survey predict mortality following CABG surgery after adjustment for known clinical risk variables. Design Prospective cohort study conducted between September 1992 and December. 1996. Setting Fourteen Veterans Affairs hospitals. Patients Of the 3956 patients undergoing CABG surgery only and who were enrolled in the Processes, Structures, and Outcomes of Care in Cardiac Surgery study, the 2480 who completed a preoperative SF-36. Main Outcome Measure All-cause mortality within 180 days after surgery. Results A total of 117 deaths (4.7%) occurred within 180 days of CABG surgery. The Physical Component Summary of the preoperative SF-36 was a statistically significant risk factor for 6-month mortality after adjustment for known clinical risk factors for mortality following CABG surgery. In multivariate analysis, a 10-point lower SF-36 Physical Component Summary score had an odds ratio (OR) of 1.39 (95% confidence interval [CI], 1.11-1.77; P = .006) for predicting mortality. The SF-36 Mental Component Summary score was not associated with 6-month mortality in multivariate analyses (OR, 1.09; 95% CI, 0.92-1.29; P = .31). Conclusions The Physical Component Summary score from the preoperative SF-36 is an independent risk factor for mortality following CABG surgery. The baseline Mental Component Summary score does not appear to be predictive of mortality. Preoperative patient: self-report of the physical component of health status may be helpful for risk stratification and clinical decision making for patients undergoing CABG surgery.	Denver Vet Affairs Med Ctr, Cardiol Sect, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiothorac Surg, Denver, CO USA; Denver Vet Affairs Med Ctr, Surg Serv, Denver, CO 80220 USA; Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; Hines Vet Affairs Med Ctr, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Hines, IL USA; Tucson Vet Affairs Med CTr, Cardiothorac Surg Sect, Tucson, AZ USA; Univ Arizona, Hlth Sci Ctr, Dept Surg, Tucson, AZ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Arizona; University of Arizona Health Sciences	Rumsfeld, JS (corresponding author), Denver Vet Affairs Med Ctr, Cardiol Sect, 1055 Clermont St, Denver, CO 80220 USA.		Shroyer, Annie Laurie/B-8836-2016	Shroyer, Annie Laurie/0000-0001-6461-0623				*AM HEART ASS, 1999, 1998 HEART STROK STA; Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3; Barr J T, 1995, J Allied Health, V24, P13; Chen AY, 1996, MED DECIS MAKING, V16, P169, DOI 10.1177/0272989X9601600209; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; Ford DE, 1998, ARCH INTERN MED, V158, P1422, DOI 10.1001/archinte.158.13.1422; Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4; GROVER FL, 1994, ANN THORAC SURG, V58, P1845, DOI 10.1016/0003-4975(94)91725-6; GROVER FL, 1993, ANN THORAC SURG, V56, P1296, DOI 10.1016/0003-4975(93)90670-D; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HOSMER DW, 1989, APPL LOGISTIC REGRES; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Jones RH, 1996, J AM COLL CARDIOL, V28, P1478, DOI 10.1016/S0735-1097(96)00359-2; Kazis L, 1997, HLTH STATUS VETERANS; KAZIS LE, 1996, HLTH STATUS VETERANS; Konstam V, 1996, AM J CARDIOL, V78, P890, DOI 10.1016/S0002-9149(96)00463-8; Krumholz HM, 1996, MED CARE, V34, P754, DOI 10.1097/00005650-199608000-00003; MCCARTHY MJ, 1995, MED CARE, V33, pOS76, DOI 10.1097/00005650-199510001-00009; McHorney CA, 1997, ANN INTERN MED, V127, P743, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00061; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PERMANYERMIRALDA G, 1991, J CLIN EPIDEMIOL, V44, P779, DOI 10.1016/0895-4356(91)90130-2; *SAS I INC, 1995, LOG REGR EX US SAS S; *SAS I INC, 1992, SAS STAT SOFTW REL 6; SHROYER AL, 1995, MED CARE, V33, pOS17, DOI 10.1097/00005650-199510001-00003; SHROYER AL, 1995, MED CARE, V33, pOS26, DOI 10.1097/00005650-199510001-00004; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1994, ANNU REV PUBL HEALTH, V16, P327; Ware JE, 1993, SF36 HLTH SURVEY MAN	30	347	364	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1298	1303		10.1001/jama.281.14.1298	http://dx.doi.org/10.1001/jama.281.14.1298			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208145	Bronze			2022-12-28	WOS:000079628700034
J	Klugman, A; Hardy, S; Baldeweg, T; Gruzelier, J				Klugman, A; Hardy, S; Baldeweg, T; Gruzelier, J			Toxic effect of MDMA on brain serotonin neurons	LANCET			English	Letter							ECSTASY		Imperial Coll Sch Med, Dept Behav & Cognit Sci, London W6 8RP, England	Imperial College London	Gruzelier, J (corresponding author), Imperial Coll Sch Med, Dept Behav & Cognit Sci, London W6 8RP, England.							KRYSTAL JH, 1992, AM J DRUG ALCOHOL AB, V18, P331, DOI 10.3109/00952999209026070; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; Parrott AC, 1998, J PSYCHOPHARMACOL, V12, P79, DOI 10.1177/026988119801200110; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51	4	26	26	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1269	1270		10.1016/S0140-6736(05)66942-5	http://dx.doi.org/10.1016/S0140-6736(05)66942-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217104				2022-12-28	WOS:000079744100046
J	Huson, SM				Huson, SM			What level of care for the neurofibromatoses?	LANCET			English	Editorial Material							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CONSENSUS STATEMENT; TASK-FORCE; TYPE-1; NF1		Churchill Hosp, Oxford Radcliffe NHS Trust, Dept Clin Genet, Oxford OX3 7LJ, England	University of Oxford	Huson, SM (corresponding author), Churchill Hosp, Oxford Radcliffe NHS Trust, Dept Clin Genet, Oxford OX3 7LJ, England.							BENJAMIN CM, 1993, J MED GENET, V30, P567, DOI 10.1136/jmg.30.7.567; Cnossen MH, 1998, ARCH DIS CHILD, V78, P408, DOI 10.1136/adc.78.5.408; EVANS DGR, 1993, J LARYNGOL OTOL, V107, P401, DOI 10.1017/S002221510012328X; EVANS DGR, 1992, Q J MED, V84, P603; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Huson S. M., 1994, P1; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; HUSON SM, 1997, NEUROFIBROMATOSIS DO; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; Lutchman M, 1996, TRENDS NEUROSCI, V19, P373, DOI 10.1016/S0166-2236(96)10044-8; MOSS C, 1994, BRIT J DERMATOL, V130, P106, DOI 10.1111/j.1365-2133.1994.tb06893.x; North KN, 1997, NEUROLOGY, V48, P1121, DOI 10.1212/WNL.48.4.1121; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; Upadhyaya MCDN, 1998, NEUROFIBROMATOSIS TY; Wolkenstein P, 1996, ARCH DERMATOL, V132, P1333, DOI 10.1001/archderm.132.11.1333	15	23	24	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1114	1116		10.1016/S0140-6736(98)00155-X	http://dx.doi.org/10.1016/S0140-6736(98)00155-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209971				2022-12-28	WOS:000079858400004
J	Perrimon, N; McMahon, AP				Perrimon, N; McMahon, AP			Negative feedback mechanisms and their roles during pattern formation	CELL			English	Review							DROSOPHILA; DIFFERENTIATION; PHOSPHATASE; EXPRESSION; ANTAGONIST; ENCODES; LOOP		Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.		McMahon, Andrew P/ABE-7520-2020	Perrimon, Norbert/0000-0001-7542-472X				Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Golembo M, 1996, DEVELOPMENT, V122, P223; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; STURTEVANT MA, 1994, DEVELOPMENT, V120, P2593; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5	20	109	113	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					13	16		10.1016/S0092-8674(00)80710-2	http://dx.doi.org/10.1016/S0092-8674(00)80710-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199398	Bronze			2022-12-28	WOS:000079843900004
J	Piguet, V; Gu, F; Foti, M; Demaurex, N; Gruenberg, J; Carpentier, JL; Trono, D				Piguet, V; Gu, F; Foti, M; Demaurex, N; Gruenberg, J; Carpentier, JL; Trono, D			Nef-induced CD4 degradation: A diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GOLGI NETWORK LOCALIZATION; DI-LEUCINE MOTIF; HIV-1 NEF; DOWN-REGULATION; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; DILEUCINE MOTIF; PLASMA-MEMBRANE; COAT PROTEINS	The Nef protein of primate lentiviruses downregulates the cell surface expression of CD4 through a two-step process. First, Nef connects the cytoplasmic tail of CD4 with adaptor protein complexes (AP), thereby inducing the formation of CD4-specific clathrin-coated pits that rapidly endocytose the viral receptor. Second; Nef targets internalized CD4 molecules for degradation. Here we show that Nef accomplishes this second task by acting as a connector between CD4 and the beta subunit of COPI coatomers in endosomes. A sequence encompassing a critical acidic dipeptide, located nearby but distinct from the AP-binding determinant of HIV-1 Nef, is responsible for beta-COP recruitment and for routing to lysosomes. A novel class of endosomal sorting motif, based on acidic residues, is thus revealed, and beta-COP is identified as its downstream partner.	Univ Geneva, Fac Med, Dept Genet, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Microbiol, CH-1211 Geneva, Switzerland; Univ Geneva, Fac Med, Dept Morphol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Sci, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Trono, D (corresponding author), Univ Geneva, Fac Med, Dept Genet, CH-1211 Geneva 4, Switzerland.			Foti, Michelangelo/0000-0001-7199-4135; Piguet, Vincent/0000-0001-6079-4517; Demaurex, Nicolas/0000-0002-9933-6772	NIAID NIH HHS [R37 AI 34306-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hansen K, 1997, BIOCHEM BIOPH RES CO, V235, P455, DOI 10.1006/bbrc.1997.6821; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITNEY JA, 1995, CELL, V83, P703	69	246	250	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					63	73		10.1016/S0092-8674(00)80715-1	http://dx.doi.org/10.1016/S0092-8674(00)80715-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199403	Bronze			2022-12-28	WOS:000079843900009
J	Taylor, SI				Taylor, SI			Deconstructing type 2 diabetes	CELL			English	Review							INSULIN-RECEPTOR GENE; IMPAIRED GLUCOSE-TOLERANCE; TARGETED DISRUPTION; MUTATIONS; MICE; MELLITUS; MUSCLE; RESISTANCE; SECRETION; LESSONS		NIDDKD, Diabet Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Taylor, SI (corresponding author), NIDDKD, Diabet Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA.							Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Bell GI, 1996, ANNU REV PHYSIOL, V58, P171, DOI 10.1146/annurev.physiol.58.1.171; Bergami G, 1997, BELFAGOR, V52, P359; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; DeFronzo RA, 1997, DIABETES REV, V5, P177; ELDERS MJ, 1982, J NATL MED ASSOC, V74, P1195; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Imai Y, 1997, J CLIN ENDOCR METAB, V82, P4201, DOI 10.1210/jc.82.12.4201; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Moller DE, 1996, ENDOCRINOLOGY, V137, P2397, DOI 10.1210/en.137.6.2397; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	26	236	247	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					9	12		10.1016/S0092-8674(00)80709-6	http://dx.doi.org/10.1016/S0092-8674(00)80709-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199397	Bronze			2022-12-28	WOS:000079843900003
J	Smith, SJ				Smith, SJ			Neurobiology - Dissecting dendrite dynamics	SCIENCE			English	Editorial Material							HIPPOCAMPAL SLICES; GROWTH; SPINES; SYNAPTOGENESIS; FILOPODIA; NEURONS		Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Smith, SJ (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	sjsmith@leland.stanford.edu						BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; COOPER MW, 1992, J NEUROBIOL, V23, P814, DOI 10.1002/neu.480230704; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; Dailey ME, 1996, J NEUROSCI, V16, P2983; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; HOSOKAWA T, 1995, J NEUROSCI, V15, P5560; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; SMITH SJ, 1991, NERVE GROWTH CONE, P19; Vallano ML, 1998, CRIT REV NEUROBIOL, V12, P177, DOI 10.1615/CritRevNeurobiol.v12.i3.20; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	18	21	23	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1860	1861		10.1126/science.283.5409.1860	http://dx.doi.org/10.1126/science.283.5409.1860			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206891				2022-12-28	WOS:000079228600026
J	Carter, D				Carter, D			Sir Ian William James McAdam - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1216	1216						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221967				2022-12-28	WOS:000080277900060
J	Koivusalo, M				Koivusalo, M			Decentralisation and equity of healthcare provision in Finland	BRITISH MEDICAL JOURNAL			English	Article									Natl Res & Dev Ctr Welf & Hlth, STAKES, Globalism & Social Policy Programme, Helsinki 00531, Finland	Finland National Institute for Health & Welfare	Koivusalo, M (corresponding author), Natl Res & Dev Ctr Welf & Hlth, STAKES, Globalism & Social Policy Programme, POB 220, Helsinki 00531, Finland.							AIRINEN S, 1998, HLTH USE HLTH SERVIC, P5; ERONEN A, 1999, SOSIAALIBAROMETRI 19; FORMA P, 1999, YHTEISKUNTAPOLITIIKK, V1, P3; KALLAND M, 1996, HYOIN LEIKATTU HUONO; KAUKONEN O, 1997, SOSIAALI JA TERVEYDE, P140; KLAVUS J, 1997, COST CUTS STUDIES CU, P119; LEHTO J, 1995, HALL MUUT SOS JA TER, P182; MARTIKAINEN T, 1997, REFORMING HLTH POLIC; Mossialos E, 1997, HEALTH ECON, V6, P109, DOI 10.1002/(SICI)1099-1050(199703)6:2<109::AID-HEC251>3.0.CO;2-L; *ORG EC COOP DEV, 1998, FINL SPEC FEAT STRUC; SIHVO T, 1997, DIALOGI, V2, P18; *SOUM KUNT, 1998, KUNT JA KUNT RAH 199; *STAKES NAT RES DE, 1999, FACTS FINN SOC WELF; TAIPALE V, 1996, MIELEKAS ELAMA TYORY	14	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1198	1200						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221951				2022-12-28	WOS:000080277900038
J	Harouse, JM; Gettie, A; Tan, RCH; Blanchard, J; Cheng-Mayer, C				Harouse, JM; Gettie, A; Tan, RCH; Blanchard, J; Cheng-Mayer, C			Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL DEPLETION; HIV-1 INFECTION; PERSISTENT INFECTION; CYNOMOLGUS MONKEYS; TYPE-1; LYMPHOCYTES; AIDS; TRANSMISSION; CORECEPTOR	Infection of macaques with chimeric simian-human immunodeficiency virus (SHIV) provides an excellent in vivo model for examining the influence of envelope on HIV-1 pathogenesis. Infection with a pathogenic CCR5 (R5)-specific enveloped virus, SHIVSF162P, was compared with infection with the CXCR4 (X4)-specific SHIVSF33A.2. Despite comparable levels of viral replication, animals infected with the R5 and X4 SHIV had distinct pathogenic outcomes, SHIVSF162P caused a dramatic loss of CD4(+) intestinal T cells followed by a gradual depletion in peripheral CD4(+) T cells, whereas infection with SHIVSF33A.2 caused a profound Loss in peripheral T cells that was not paralleled in the intestine. These results suggest a critical role of co-receptor utilization in viral pathogenesis and provide a reliable in vivo model for preclinical examination of HIV-1 vaccines and therapeutic agents in the context of the HIV-1 envelope protein.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Tulane Univ, Tulane Reg Primate Res Ctr, Med Ctr, Covington, LA 70433 USA	Rockefeller University; Tulane University	Cheng-Mayer, C (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.				NCI NIH HHS [CA72822, R01 CA072822] Funding Source: Medline; NIAID NIH HHS [AI41945, R01 AI041945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI041945, R01AI041945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; Berkowitz RD, 1998, J IMMUNOL, V161, P3702; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DESROSIERS RC, 1988, ANNU REV MICROBIOL, V42, P607, DOI 10.1146/annurev.mi.42.100188.003135; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; Harouse JM, 1998, VIROLOGY, V248, P95, DOI 10.1006/viro.1998.9236; HAROUSE JM, UNPUB; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; JOAG SV, 1998, VIROLOGY, V248, P95; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUCIW PA, 1995, P NATL ACAD SCI USA, V92, P7490, DOI 10.1073/pnas.92.16.7490; Mattapallil JJ, 1998, J VIROL, V72, P6421, DOI 10.1128/JVI.72.8.6421-6429.1998; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; Nowak MA, 1997, J VIROL, V71, P7518, DOI 10.1128/JVI.71.10.7518-7525.1997; Overbaugh J, 1997, AIDS, V11, pS47; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; SAKURAGI S, 1992, J GEN VIROL, V73, P2983, DOI 10.1099/0022-1317-73-11-2983; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Slatter D., 1993, TXB SMALL ANIMAL SUR, V1; Smit-McBride Z, 1998, J VIROL, V72, P6646, DOI 10.1128/JVI.72.8.6646-6656.1998; Theodorou I, 1997, LANCET, V349, P1219; Trivedi P, 1996, J VIROL, V70, P6876, DOI 10.1128/JVI.70.10.6876-6883.1996; Veazey RS, 1997, CLIN IMMUNOL IMMUNOP, V82, P230, DOI 10.1006/clin.1996.4318; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	39	284	293	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					816	819		10.1126/science.284.5415.816	http://dx.doi.org/10.1126/science.284.5415.816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221916				2022-12-28	WOS:000080056200050
J	Tweddle, DA; Windebank, KP; Hewson, QC; Yule, SM				Tweddle, DA; Windebank, KP; Hewson, QC; Yule, SM			Drug points - Cyclosporin neurotoxicity after chemotherapy	BRITISH MEDICAL JOURNAL			English	Letter									Royal Victoria Infirm NHS Trust, Inst Child Hlth, Dept Paediat Oncol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Tweddle, DA (corresponding author), Royal Victoria Infirm NHS Trust, Inst Child Hlth, Dept Paediat Oncol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							BERTRAND Y, 1992, AM J HEMATOL, V40, P158, DOI 10.1002/ajh.2830400222; GHANY AM, 1991, TRANSPLANTATION, V52, P310, DOI 10.1097/00007890-199108000-00024; LEBLANC GA, 1990, CANCER RES, V50, P5720; OSULLIVAN DP, 1985, BRIT MED J, V290, P858, DOI 10.1136/bmj.290.6471.858-a; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1113	1113		10.1136/bmj.318.7191.1113	http://dx.doi.org/10.1136/bmj.318.7191.1113			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213720	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080166000025
J	Goodwin, JS				Goodwin, JS			Geriatrics and the limits of modern medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROSTATE-CANCER; SURVIVAL		Univ Texas, Med Branch, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Goodwin, JS (corresponding author), Univ Texas, Med Branch, Galveston, TX 77555 USA.							ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Cassell EJ, 1991, NATURE SUFFERING GOA; GOODWIN JS, 1991, J AM GERIATR SOC, V39, P627, DOI 10.1111/j.1532-5415.1991.tb03607.x; GOODWIN JS, 1995, PERSPECT BIOL MED, V38, P567; Goodwin JS, 1997, JAMA-J AM MED ASSOC, V278, P1399, DOI 10.1001/jama.278.17.1399; Illich Ivan., 1975, MED NEMESIS EXPROPRI; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Johansson JE, 1997, JAMA-J AM MED ASSOC, V278, P206; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; POSTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548; Skrabanek P., 1994, DEATH HUMANE MED RIS; SMITH TJ, 1997, J CLIN ONCOL, V5, P870	12	44	45	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1283	1285		10.1056/NEJM199904223401612	http://dx.doi.org/10.1056/NEJM199904223401612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210715				2022-12-28	WOS:000079833800012
J	Hoecker, U; Tepperman, JM; Quail, PH				Hoecker, U; Tepperman, JM; Quail, PH			SPA1, a WD-repeat protein specific to phytochrome A signal transduction	SCIENCE			English	Article							LIGHT CONTROL; BAC LIBRARY; ARABIDOPSIS; KINASE; COP1; ENCODES; PHOSPHORYLATES; MUTANTS; PATHWAY; CLONING	The five members of the phytochrome photoreceptor family of Arabidopsis thaliana control morphogenesis differentially in response to light. Genetic analysis has identified a signaling pathway that is specifically activated by phytochrome A. A component in this pathway, SPA1 (for "suppressor of phyA-105"), functions in repression of photomorphogenesis and is required for normal photosensory specificity of phytochrome A. Molecular cloning of the SPA 7 gene indicates that SPA1 is a WD (tryptophan-aspartic acid)-repeat protein that also shares sequence similarity with protein kinases. SPA1 can localize to the nucleus, suggesting a possible function in phytochrome A-specific regulation of gene expression.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	quail@nature.berkeley.edu	Rosa, Bruce/F-6393-2010	Hoecker, Ute/0000-0002-5636-9777	NIGMS NIH HHS [GM-47475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; HOECKER U, UNPUB; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Reed Jason W., 1994, Seminars in Cell Biology, V5, P327, DOI 10.1006/scel.1994.1039; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	31	218	230	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					496	499		10.1126/science.284.5413.496	http://dx.doi.org/10.1126/science.284.5413.496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205059				2022-12-28	WOS:000079792200050
J	Scheinman, SJ; Guay-Woodford, LM; Thakker, RV; Warnock, DG				Scheinman, SJ; Guay-Woodford, LM; Thakker, RV; Warnock, DG			Mechanisms of disease - Genetic disorders of renal electrolyte transport	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EPITHELIAL SODIUM-CHANNEL; LINKED RECESSIVE NEPHROLITHIASIS; CALCIUM-SENSING RECEPTOR; FAMILIAL BENIGN HYPERCALCEMIA; MOLECULAR-WEIGHT PROTEINURIA; BARTTERS-SYNDROME; CHLORIDE-CHANNEL; LIDDLES SYNDROME; CA2+-SENSING RECEPTOR; COTRANSPORTER GENE		SUNY Hlth Sci Ctr, Dept Med, Syracuse, NY 13210 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Physiol, Birmingham, AL 35294 USA; Hammersmith Hosp, MRC, Mol Endocrinol Grp, London, England	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Imperial College London	Scheinman, SJ (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.	scheinms@vax.cs.hscsyr.edu		Thakker, Rajesh/0000-0002-1438-3220	NIDDK NIH HHS [DK53161, DK46838] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053161, R01DK046838] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright F, 1937, AM J DIS CHILD, V54, P529; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCKALEW VM, 1974, MEDICINE, V53, P229, DOI 10.1097/00005792-197407000-00001; CAI Q, 1994, NEW ENGL J MED, V330, P1645, DOI 10.1056/NEJM199406093302304; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Dai LJ, 1997, KIDNEY INT, V51, P1008, DOI 10.1038/ki.1997.141; Dai LJ, 1998, AM J PHYSIOL-RENAL, V274, pF336, DOI 10.1152/ajprenal.1998.274.2.F336; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Dixon PH, 1998, J CLIN ENDOCR METAB, V83, P3615, DOI 10.1210/jc.83.10.3615; ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FOLEY TP, 1972, J PEDIATR-US, V81, P1060, DOI 10.1016/S0022-3476(72)80232-4; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; Gitelman H J, 1966, Trans Assoc Am Physicians, V79, P221; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; Guay-Woodford LM, 1998, AM J MED, V105, P151, DOI 10.1016/S0002-9343(98)00196-X; HANUKOGLU A, 1994, J PEDIATR-US, V125, P752, DOI 10.1016/S0022-3476(94)70071-0; Hebert SC, 1997, J EXP BIOL, V200, P295; Hoopes RR, 1998, KIDNEY INT, V54, P698, DOI 10.1046/j.1523-1755.1998.00061.x; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hummler E, 1997, P NATL ACAD SCI USA, V94, P11710, DOI 10.1073/pnas.94.21.11710; IGARASHI T, 1995, NEPHRON, V69, P242, DOI 10.1159/000188464; Igarashi T, 1998, KIDNEY INT, V54, P1850, DOI 10.1046/j.1523-1755.1998.00203.x; JAMISON RL, 1982, AM J MED, V73, P142, DOI 10.1016/0002-9343(82)90941-X; Karolyi L, 1997, HUM MOL GENET, V6, P17; Karolyi L, 1997, HUM MOL GENET, V6, P650; Lemmink HH, 1998, KIDNEY INT, V54, P720, DOI 10.1046/j.1523-1755.1998.00070.x; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; McKusick V.A., 1992, MENDELIAN INHERITANC; OBERFIELD SE, 1979, J CLIN ENDOCR METAB, V48, P228, DOI 10.1210/jcem-48-2-228; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Pollak MR, 1996, J AM SOC NEPHROL, V7, P2244; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; REINHART SC, 1995, J AM SOC NEPHROL, V5, P1451; Rossier BC, 1997, J AM SOC NEPHROL, V8, P980; SCHEINMAN SJ, 1993, J CLIN INVEST, V91, P2351, DOI 10.1172/JCI116467; Scheinman SJ, 1998, KIDNEY INT, V53, P3, DOI 10.1046/j.1523-1755.1998.00718.x; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schwartz ID, 1996, J NEPHROL, V9, P81; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Simon David B., 1998, Journal of the American Society of Nephrology, V9, p559A; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; Su YR, 1996, J AM SOC NEPHROL, V7, P2543; SUTTON RAL, 1992, MINER ELECTROL METAB, V18, P43; TIEDER M, 1987, NEW ENGL J MED, V316, P25; Vargas-Poussou R, 1998, AM J HUM GENET, V62, P1332, DOI 10.1086/301872; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x; Winters R W, 1991, Medicine (Baltimore), V70, P215; WRONG OM, 1994, Q J MED, V87, P473	67	137	142	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1177	1187		10.1056/NEJM199904153401507	http://dx.doi.org/10.1056/NEJM199904153401507			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202170				2022-12-28	WOS:000079687700007
J	Kandela, P				Kandela, P			Sketches from The Lancet - Railways and health	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1283	1283		10.1016/S0140-6736(05)75210-7	http://dx.doi.org/10.1016/S0140-6736(05)75210-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217125				2022-12-28	WOS:000079744100071
J	Stewart, JA; Dundas, R; Howard, RS; Rudd, AG; Wolfe, CDA				Stewart, JA; Dundas, R; Howard, RS; Rudd, AG; Wolfe, CDA			Ethnic differences in incidence of stroke: prospective study with stroke register	BRITISH MEDICAL JOURNAL			English	Article							BLACK-WHITE DIFFERENCES; CEREBROVASCULAR-DISEASE; CASE-FATALITY; NORTHERN MANHATTAN; INCIDENCE RATES; RISK-FACTORS; MORTALITY; COMMUNITY; HYPERTENSION; ENGLAND	Objective To identify ethnic differences in the. incidence of first ever stroke. Design A prospective community stroke register (1995-6) with multiple notification sources. Pathological classification of stroke in all cases was based on brain imaging or necropsy data. Rates were standardised to European and world populations and adjusted for age, sex, and social class in multivariate analysis. Setting A multi-ethnic population of 234 533 in south London, of whom 21% are black. Results 612 strokes were registered. The crude annual incidence rate tvas 1.3 strokes per 1000 population per year (95% confidence interval 1.20 to 1.41) and 1.25 per 1000 population per year (1.15 to 1.35) age adjusted to the standard European population. Incidence rates adjusted for age and sex were significantly higher in black compared with white people (P < 0.0001), with an incidence rate ratio of 2.21 (1.77 to 2.76), In multivariable analysis increasing age (P< 0.0001), male sex (P < 0.003), black ethnic group (P < 0.0001), and lower social class CP < 0.0001) in people aged 35-64 were independently associated with an increased incidence of stroke, Conclusions Incidence rates of stroke are higher in the black population; this is not explained by confounders such as social class, age, and sex. Ethnic differences in genetic, physiological, and behavioural risk factors for stroke require further elucidation to aid development of effective strategies for stroke prevention in multi-ethnic communities.	Guys Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England; St Thomass Sch Med, London SE1 3QD, England; St Thomas Hosp, Dept Neurol, London SE1 5EH, England; St Thomas Hosp, Stroke Unit, London SE1 5EH, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Wolfe, CDA (corresponding author), Guys Kings Coll, Dept Publ Hlth Sci, 5th Floor,Capital House, London SE1 3QD, England.			Dundas, Ruth/0000-0002-3836-4286; Wolfe, Charles/0000-0001-8264-0981	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CASPER M, 1991, J EPIDEMIOL COMMUN H, V45, P302, DOI 10.1136/jech.45.4.302; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; *DIR PUBL HLTH, 1996, ANN REP 1995 1996; EISENBLATTER D, 1995, STROKE, V26, P919, DOI 10.1161/01.STR.26.6.919; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HOWARD G, 1995, STROKE, V26, P1759, DOI 10.1161/01.STR.26.10.1759; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; Korv J, 1997, CEREBROVASC DIS, V7, P154, DOI 10.1159/000108182; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MALMGREN R, 1987, LANCET, V2, P1196; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; Parrish H M, 1966, Mo Med, V63, P816; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P139, DOI 10.1136/jech.47.2.139	24	231	231	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					967	971		10.1136/bmj.318.7189.967	http://dx.doi.org/10.1136/bmj.318.7189.967			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195965	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000079751500017
J	Park, YC; Burkitt, V; Villa, AR; Tong, L; Wu, H				Park, YC; Burkitt, V; Villa, AR; Tong, L; Wu, H			Structural basis for self-association and receptor recognition of human TRAF2	NATURE			English	Article							NECROSIS-FACTOR RECEPTOR; FACTOR-KAPPA-B; CRYSTAL-STRUCTURE; BINDING-SITES; PROTEIN; DOMAIN; FAMILY; ACTIVATION; MEMBERS; COMPLEX	Tumour necrosis factor (TNF)-receptor-associated factors (TRAFs) form a family of cytoplasmic adapter proteins that mediate signal transduction from many members of the TNF-receptor superfamily and the interleukin-1 receptor(1). They are important in the regulation of cell survival and cell death. The carboxy-terminal region of TRAFs (the TRAF domain) is required for self-association and interaction with receptors. The domain contains a predicted coiled-coil region that is followed by a highly conserved TRAF-C domain(2). Here we report the crystal structure of the TRAF domain of human TRAF2, both alone and in complex with a peptide from TNF receptor-2 (TNF-R2). The structures reveal a trimeric self-association of the TRAF domain, which we confirm by studies in solution. The TRAF-C domain forms a new, eight-stranded antiparallel beta-sandwich structure. The TNF-R2 peptide binds to a conserved shallow surface depression on one TRAF-C domain and does not contact the other protomers of the trimer. The nature of the interaction indicates that an SXXE motif may be a TRAF2-binding consensus sequence. The trimeric structure of the TRAF domain provides an avidity-based explanation for the dependence of TRAF recruitment on the oligomerization of the receptors by their trimeric extracellular ligands.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Cornell University; Cornell University; Columbia University	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.			Tong, Liang/0000-0002-0563-6468				Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1993, PHASES PROGRAM PACKA; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tong L, 1998, NAT STRUCT BIOL, V5, P819, DOI 10.1038/1860; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631	30	284	296	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					533	538		10.1038/19110	http://dx.doi.org/10.1038/19110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206649				2022-12-28	WOS:000079662800053
J	Oransky, I				Oransky, I			An apology for those who leave medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Oransky, I (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.		Oransky, Ivan/J-9412-2019	Oransky, Ivan/0000-0002-0746-9288				Beran RL, 1998, JAMA-J AM MED ASSOC, V280, P819, DOI 10.1001/jama.280.9.819; Galasko CSB, 1999, BRIT MED J, V318, P534, DOI 10.1136/bmj.318.7182.534a; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109	3	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1230	1230		10.1001/jama.281.13.1230	http://dx.doi.org/10.1001/jama.281.13.1230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199438	hybrid			2022-12-28	WOS:000079464400043
J	Hatch, DJ				Hatch, DJ			Propofol-infusion syndrome in children	LANCET			English	Editorial Material							INTENSIVE-CARE; SEDATION; FAILURE		Univ London, Inst Child Hlth, Portex Dept Paediat Anaesthesia & Intens Therapy, London WC1N 1EH, England	University of London; University College London	Hatch, DJ (corresponding author), Univ London, Inst Child Hlth, Portex Dept Paediat Anaesthesia & Intens Therapy, London WC1N 1EH, England.							Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; LEDINGHAM IM, 1983, LANCET, V1, P1270; MACRAE D, 1992, ANAESTHESIA, V47, P811, DOI 10.1111/j.1365-2044.1992.tb03268.x; Martin PH, 1997, BRIT J ANAESTH, V79, P276, DOI 10.1093/bja/79.3.276; NIMMO GR, 1994, ANAESTHESIA, V49, P485, DOI 10.1111/j.1365-2044.1994.tb03517.x; Notisfra Bivirkningsnaenet, 1990, UGESKRIFT LAEGER, V152, P1176; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Reed MD, 1996, CRIT CARE MED, V24, P175, DOI 10.1097/00003246-199601000-00030; SHELLY MP, 1987, ANAESTHESIA, V42, P619, DOI 10.1111/j.1365-2044.1987.tb03086.x; *US FDA, 1992, FDC REPORTS, V54, P14; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202	12	54	55	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1117	1118		10.1016/S0140-6736(99)90018-1	http://dx.doi.org/10.1016/S0140-6736(99)90018-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209973				2022-12-28	WOS:000079858400006
J	Bridges, BA				Bridges, BA			Transcription - Dirty transcripts from clean DNA	SCIENCE			English	Editorial Material							HOMOZYGOUS BRATTLEBORO RAT; MAGNOCELLULAR NEURONS; ESCHERICHIA-COLI; MUTATION		Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England	University of Sussex	Bridges, BA (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	b.a.bridges@sussex.ac.uk						BRIDGES BA, 1994, MUTAT RES, V307, P149, DOI 10.1016/0027-5107(94)90287-9; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Evans DAP, 1996, NEUROSCIENCE, V71, P1025, DOI 10.1016/0306-4522(95)00501-3; NINIO J, 1991, GENETICS, V129, P957; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; SANNA PP, 1992, ANN NY ACAD SCI, V652, P462, DOI 10.1111/j.1749-6632.1992.tb34385.x; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FW, 1994, BRAIN RES, V635, P328, DOI 10.1016/0006-8993(94)91456-7; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159	11	13	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	1999	284	5411					62	63		10.1126/science.284.5411.62	http://dx.doi.org/10.1126/science.284.5411.62			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10215532				2022-12-28	WOS:000079509000028
J	Ashe, HL; Levine, M				Ashe, HL; Levine, M			Local inhibition and long-range enhancement of Dpp signal transduction by Sog	NATURE			English	Article							DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; MORPHOGEN GRADIENT; SHORT GASTRULATION; SPEMANN ORGANIZER; GENE; SPECIFICATION; LOCALIZATION; CHORDIN; ACTIVIN	Extracellular gradients of signalling molecules can specify different thresholds of gene activity in development. A gradient of Decapentaplegic (Dpp) activity subdivides the dorsal ectoderm of the Drosophila embryo into amnioserosa and dorsal epidennis(.1,2) The proteins Short gastrulation(3) (Sog) and Tolloid(4) (Tld) are required to shape this gradient. Sog has been proposed to form an inhibitory complex with either Dpp(5) or the related ligand Screw(6,7), and is subsequently processed by the protease Tld(5). Paradoxically, Sog appears to be required for amnioserosa formation(8), which is specified by peak Dpp signalling activity(1,2). Here we show that the misexpression of sag using the even-skipped stripe-2 enhancer(9) redistributes Dpp signalling in a mutant background in which npp is expressed throughout the embryo, Dpp activity is diminished near the Sog stripe and peak Dpp signalling is detected far from this stripe. However, a tethered form of Sog suppresses local Dpp activity without augmenting Dpp activity at a distance, indicating that diffusion of Sog may be required for enhanced Dpp activity and consequent amnioserosa formation, The long-distance stimulation of Dpp activity by Sog requires Tld, whereas Sog-mediated inhibition of Dpp does not The heterologous Dpp inhibitor Noggin(10) inhibits Dpp signalling but fails to augment Dpp activity. These results suggest an unusual strategy for generating a gradient threshold of growth-factor activity, whereby Sog and its protease specify peak Dpp signalling far from a localized source of Sog.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, 401 Barker Hall, Berkeley, CA 94720 USA.			Levine, Michael/0000-0001-7629-0081				ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Kosman D, 1997, DEVELOPMENT, V124, P1343; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neul JL, 1998, CELL, V95, P483, DOI 10.1016/S0092-8674(00)81616-5; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rusch J, 1997, DEVELOPMENT, V124, P303; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON KA, 1993, DEVELOPMENT, V117, P807; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	28	150	156	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	1999	398	6726					427	431		10.1038/18892	http://dx.doi.org/10.1038/18892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182PW	10201373				2022-12-28	WOS:000079508200053
J	Mast, H; Young, WL; Koennecke, HC; Sciacca, RR; Osipov, A; PileSpellman, J; HaceinBey, L; Duong, H; Stein, BM; Mohr, JP				Mast, H; Young, WL; Koennecke, HC; Sciacca, RR; Osipov, A; PileSpellman, J; HaceinBey, L; Duong, H; Stein, BM; Mohr, JP			Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation	LANCET			English	Article							NATURAL-HISTORY; HEMORRHAGE; BRAIN; DETERMINANTS	Background A small proportion of strokes are caused by cerebral arteriovenous malformations (AVM). Treatment to prevent intracranial haemorrhage itself carries risks, and untreated AVM may in many cases have a good prognosis. We investigated the risk of subsequent symptomatic bleeding in the clinical course of AVM in patients with and without an initial haemorrhage. Methods 281 unselected, consecutive, prospectively enrolled patients with cerebral AVM were grouped according to their initial clinical presentation-142 presented with and 139 without haemorrhage. The frequency of AVM haemorrhages during the subsequent clinical course (before the start of endovascular, surgical, or radiation treatment) in the two groups was compared by means of Kaplan-Meier life-tables, log-rank test, and multivariate proportional-hazards regression models, Haemorrhage was defined as a clinically symptomatic event with signs of acute bleeding on computed tomography or magnetic resonance brain imaging, Findings During mean follow-up of 8.5 months for the haemorrhage group and 11.9 months for the nonhaemorrhage group, haemorrhages occurred in 18 (13%) of the former patients and in three (2%) of the latter (p=0.0002). The annual risk of haemorrhage was 17.8% and 2.2%, respectively. In the multivariate regression model, the adjusted hazard ratio for haemorrhage at initial presentation was 139 (95% CI 2.6-73.8; p=0.002). Deep venous drainage (hazard ratio 4.1 [1.2-14.9], p=0.029) and male sex (9.2 [2.1-41.3], p=0.004) were also significantly associated with subsequent haemorrhage, but no significant association was found for age or AVM size. The annual rate of spontaneous haemorrhage was 32.6% for men and 10.4% for women in the haemorrhage group compared with 3.3% for men and 1.3% for women in the non-haemorrhage group. Among patients with haemorrhage at initial presentation, the risk of haemorrhage fell from 32.9% in year 1 to 11.3% in subsequent years (34.2% to 31.0% in men; 31.1% to 5.5% in women). Interpretation In AVM, patients initially presenting with haemorrhage have a higher risk of subsequent bleeding than those presenting with other symptoms. The risk is higher in men than in women.	COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANESTHESIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL SURG,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT RADIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT NEUROL,D-12200 BERLIN,GERMANY	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Mohr, J/AAO-9694-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027713, R01NS034949] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34949, NS27713] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003; ITOYAMA Y, 1989, J NEUROSURG, V71, P805, DOI 10.3171/jns.1989.71.6.0805; KADER A, 1994, NEUROSURGERY, V34, P801, DOI 10.1227/00006123-199405000-00003; MARCONI F, 1993, SURG NEUROL, V39, P385, DOI 10.1016/0090-3019(93)90206-G; MARKS MP, 1990, RADIOLOGY, V176, P807, DOI 10.1148/radiology.176.3.2389040; MARKS MP, 1993, AM SOC NEUR 31 ANN M, P75; MAST H, 1995, STROKE, V26, P1215, DOI 10.1161/01.STR.26.7.1215; McCormick W., 1984, INTRACRANIAL ARTERIO, P44, DOI 10.1016/S1042-3680(18)30174-8; MCCORMICK WF, 1973, STROKE, V4, P946, DOI 10.1161/01.STR.4.6.946; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; Pollock BE, 1996, STROKE, V27, P1, DOI 10.1161/01.STR.27.1.1; SACCO RL, 1995, STROKE, V26, P14, DOI 10.1161/01.STR.26.1.14; SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918; Stein B M, 1992, Clin Neurosurg, V39, P76	15	306	314	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1065	1068		10.1016/S0140-6736(97)05390-7	http://dx.doi.org/10.1016/S0140-6736(97)05390-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213548	hybrid			2022-12-28	WOS:A1997YA73400009
J	Shtilerman, M; Lorimer, GH; Englander, SW				Shtilerman, M; Lorimer, GH; Englander, SW			Chaperonin function: Folding by forced unfolding	SCIENCE			English	Article							HYDROGEN-EXCHANGE; CONFORMATIONAL STATES; RIBULOSEBISPHOSPHATE CARBOXYLASE; POLYPEPTIDE BINDING; CRYSTAL-STRUCTURE; CYTOCHROME-C; GROEL; PROTEIN; MECHANISM; PATHWAYS	The ability of the GroEL chaperonin to unfold a protein trapped in a misfolded condition was detected and studied by hydrogen exchange. The GroEL-induced unfolding of its substrate protein is only partial, requires the complete chaperonin system, and is accomplished within the 13 seconds required for a single system turnover. The binding of nucleoside triphosphate provides the energy for a single unfolding event; multiple turnovers require adenosine triphosphate hydrolysis. The substrate protein is released on each turnover even if it has not yet refolded to the native state. These results suggest that GroEL helps partly folded but blocked proteins to fold by causing them first to partially unfold. The structure of GroEL seems well suited to generate the nonspecific mechanical stretching force required for forceful protein unfolding.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland College Park; University of Pennsylvania	Lorimer, GH (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	GL48@umail.umd.edu			NIGMS NIH HHS [GM31847, R01 GM031847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BAL Y, 1993, PROTEIN-STRUCT FUNCT, V17, P75; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; Clark AC, 1998, METHOD ENZYMOL, V290, P100; Clark AC, 1999, J MOL BIOL, V285, P1777, DOI 10.1006/jmbi.1998.2403; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DILL KA, 1995, PROTEIN SCI, V4, P561; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; ENGTANDER SW, 1906, CURR OPIN STRUC BIOL, V6, P18; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Freund C, 1998, FOLD DES, V3, P39, DOI 10.1016/S1359-0278(98)00007-8; Fuentes EJ, 1998, BIOCHEMISTRY-US, V37, P3687, DOI 10.1021/bi972579s; Gervasoni P, 1998, J MOL BIOL, V275, P663, DOI 10.1006/jmbi.1997.1481; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; GUO ZY, 1995, BIOPOLYMERS, V36, P83, DOI 10.1002/bip.360360108; HAMMACK B, 1998, BIOCHEMISTRY-US, V275, P719; Hiller R, 1997, P NATL ACAD SCI USA, V94, P11329, DOI 10.1073/pnas.94.21.11329; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Konermann L, 1997, BIOCHEMISTRY-US, V36, P5554, DOI 10.1021/bi970046d; Llorca O, 1997, FEBS LETT, V405, P195, DOI 10.1016/S0014-5793(97)00186-5; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; ROSEN BP, 1996, BIOMEMBR, V5, P241; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHLOSS JV, 1984, METHOD ENZYMOL, V90, P522; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; THIRUMALAI D, 1994, STAT MECH, P15; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; XU Z, COMMUNICATION; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	74	252	254	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					822	825		10.1126/science.284.5415.822	http://dx.doi.org/10.1126/science.284.5415.822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221918	Green Accepted, Green Submitted			2022-12-28	WOS:000080056200052
J	Melzer, D; McWilliams, B; Brayne, C; Johnson, T; Bond, J				Melzer, D; McWilliams, B; Brayne, C; Johnson, T; Bond, J		Med Res Council Cognitive Function Ageing	Profile of disability in elderly people: estimates from a longitudinal population study	BRITISH MEDICAL JOURNAL			English	Article							ENGLAND; WALES	Objectives To provide estimates of the numbers of cognitively impaired and physically disabled elderly people in England and Wales, subdivided by a range of sociodemographic, dependency, care receipt, and survival variables, to support debates on the form and funding of health and welfare programmes. Design Interviews at baseline and 2 year follow up plus data on resource use extracted from records for those with. disability. Subjects 10 377 people aged 65 years and over in Cambridgeshire, Newcastle, Nottingham, and Oxford. AU estimates weighted to population of England and Wales in 1996. Results 11% of men and 19% of women aged 65 and over were disabled, totalling 1.3 million people; 38% of these were aged 85 or over and a similar percentage were cognitively impaired. Overall, more than 80% of elderly disabled people needed help on at least a daily basis. Over a third of people with limitations to daily activity living in private households were wholly or partly dependent on formal services for help. 63% of disabled elderly people used acute hospitals during the 2 year follow up, 43% as inpatients. 53% of those with cognitive impairment and limitations to daily activity were living in institutions. Conclusions Very elderly people and those with cognitive impairment make up a large proportion of those in need of long term care. A large proportion of even the most disabled elderly people currently live outside institutions and depend on formal services as well as informal care givers. Disabled elderly people use acute hospitals extensively, underlining the interrelations between acute and long term care.	Univ Cambridge, Inst Publ Hlth, Dept Community Med, Cambridge CB2 2SR, England; Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Newcastle University - UK	Melzer, D (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Community Med, Cambridge CB2 2SR, England.		Brayne, Carol/AAA-4285-2020; Dewey, Michael E/E-2049-2010	Brayne, Carol/0000-0001-5307-663X; Dewey, Michael E/0000-0002-7522-3677; Melzer, David/0000-0002-0170-3838				BASS S, 1996, PUBLIC POLICY OLD AG; BOND J, 1982, SCOTTISH HOME HLTH S, V42; Bone M., 1995, TRENDS DEPENDENCY OL; Brayne C, 1998, PSYCHOL MED, V28, P319; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; *DEP HLTH, 1992, HLTH ELD PEOPL EP OV, V2; FOLSTEIN M, 1975, J PSYCHIATR RES, V313, P1419; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Grundy E, 1997, J EPIDEMIOL COMMUN H, V51, P531, DOI 10.1136/jech.51.5.531; *HOUS COMM HLTH CO, 1996, LONG TERM CAR FUT PR; IMPALLOMENI M, 1995, J PUBLIC HEALTH MED, V17, P171, DOI 10.1093/oxfordjournals.pubmed.a043089; Isaacs B, 1975, MEASUREMENT NEED OLD; JARVIS C, 1996, GETTING 60 PROFILE B; Laslett P., 1996, FRESH MAP LIFE EMERG; Martin J., 1988, PREVALENCE DISABILIT; McGee MA, 1998, AGE AGEING, V27, P605, DOI 10.1093/ageing/27.5.605; Melzer D, 1997, BRIT MED J, V315, P462, DOI 10.1136/bmj.315.7106.462; *MRC COGN FUNCT AG, 1998, AGEING SOC, V18, P317; Nuttall SR, 1994, J I ACTUARIES, V121, P1, DOI DOI 10.1017/S0020268100020084; *OFF POP CENS SURV, 1996, NAT POP PROJ 1994 BA; *ROYAL COMM, 1999, CMND41921; SCHULTE B, 1996, LONG TERM CARE EC IS, P149; WIENER J, 1996, HLTH POLICY STUDIES, V8	23	83	87	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1108	1111						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193YU	10213718				2022-12-28	WOS:000080166000023
J	Showstack, J; Katz, PP; Lake, JR; Brown, RS; Dudley, RA; Belle, S; Wiesner, RH; Zetterman, RK; Everhart, J				Showstack, J; Katz, PP; Lake, JR; Brown, RS; Dudley, RA; Belle, S; Wiesner, RH; Zetterman, RK; Everhart, J		NIDDK Liver Transplantation Database Grp	Resource utilization in liver transplantation - Effects of patient characteristics and clinical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; CYCLOSPORINE; CIRRHOSIS	Context Liver transplantation is among the most costly of medical services, yet few studies have addressed the relationship between the resources utilized for this procedure and specific patient characteristics and clinical practices. Objective To assess the association of pretransplant patient characteristics and clinical practices with hospital resource utilization. Design Prospective cohort of patients who received liver transplants between January 1991 and July 1994. Setting University of California, San Francisco; Mayo Clinic, Rochester, Minn; and the University of Nebraska, Omaha, Patients Seven hundred eleven patients who received single-organ liver transplants, were at least 16 years old, and had nonfulminant liver disease. Main Outcome Measure Standardized resource utilization derived from a database created by matching all services to a single price list. Results Higher adjusted resource utilization was associated with donor age of 60 years or older (28% [$53 813] greater mean resource utilization; P=.005); recipient age of 60 years or older (17% [$32 795]; P=.01); alcoholic liver disease (26% [$49 596]; P=.002); Child-Pugh class C (41% [$67 658]; P<.001); care from the intensive care unit at time of transplant (42% [$77 833]; P<.001); death in the hospital (35% [$67 076]; P<.001); and having multiple liver transplants during the index hospitalization (154% increase [$474 740 vs $186 726 for 1 transplant]; P<.001). Adjusted length of stay and resource utilization also differed significantly among transplant centers. Conclusions Clinical, economic, and ethical dilemmas in liver transplantation are highlighted by these findings. Recipients who were older, had alcoholic liver disease, or were severely ill were the most expensive to treat; this suggests that organ allocation criteria may affect transplant costs. Clinical practices and resource utilization varied considerably among transplant centers; methods to reduce variation in practice patterns, such as clinical guidelines, might lower costs while maintaining quality of care.	Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Liver Transplant Program, San Francisco, CA 94143 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Mayo Clin, Dept Med, Rochester, MN USA; Univ Nebraska, Dept Med, Omaha, NE 68182 USA; NIDDKD, Branch Epidemiol & Clin Trials, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; University of Nebraska System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Showstack, J (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, San Francisco, CA 94143 USA.	jas1@itsa.ucsf.edu	Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X; Lake, John/0000-0002-4332-0528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK002252, N01DK002253, N01DK002251] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-0-2253, N01-DK-0-2251, N01-DK-0-2252] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benjamin M, 1997, Liver Transpl Surg, V3, P337, DOI 10.1002/lt.500030322; *BLUE CROSS BLUE S, 1983, FIN REP TASK FORC LI; Deschenes M, 1998, TRANSPLANTATION, V66, P302, DOI 10.1097/00007890-199808150-00005; Detre K M, 1986, Clin Transpl, P29; DUDLEY RA, 1993, J CLIN EPIDEMIOL, V46, P261; EVANS RW, 1993, GASTROENTEROL CLIN N, V22, P451; Everhart J E, 1997, Liver Transpl Surg, V3, P220, DOI 10.1053/jlts.1997.v3.ajlts0030220; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; Hoofnagle JH, 1996, HEPATOLOGY, V24, P89, DOI 10.1002/hep.510240116; KANKAANPAA J, 1990, PREV MED, V19, P700; KATZ PP, IN PRESS INT J TECHN; LAKE JR, 1993, GASTROENTEROL CLIN N, V22, P213; LAKE JR, 1995, TRANSPLANTATION, V60, P1089, DOI 10.1097/00007890-199511270-00005; LUEBS HW, 1985, SEMIN LIVER DIS, V5, P402, DOI 10.1055/s-2008-1040639; MOSS AH, 1991, JAMA-J AM MED ASSOC, V265, P1295, DOI 10.1001/jama.265.10.1295; PAGEAUX GP, 1993, TRANSPLANT P, V25, P1135; Shaw B W Jr, 1997, Liver Transpl Surg, V3, P680; SHOWSTACK J, 1989, NEW ENGL J MED, V321, P1086, DOI 10.1056/NEJM198910193211605; SHOWSTACK J, 1990, JAMA-J AM MED ASSOC, V264, P1818, DOI 10.1001/jama.264.14.1818; STAPLETON S, 1998, AM MED NEWS     1019, V41, P1; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; STASCHAK S, 1990, TRANSPLANT P, V22, P47; Steinbrook R, 1997, NEW ENGL J MED, V336, P436, DOI 10.1056/NEJM199702063360610; UBEL PA, 1997, LIVER TRANSPLANT SUR, V3, P337; *UN NETW ORG SHAR, 1999, AM UNOS POL 3 6 ALL; *UN NETW ORG SHAR, 1994, UNOS UPDATE, V10, P26; Wei Y L, 1997, Liver Transpl Surg, V3, P10; Wennberg J. E., 1996, DARTMOUTH ATLAS HLTH; WIESNER RH, 1992, HEPATOLOGY, V16, P1290, DOI 10.1002/hep.1840160527	30	163	165	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1381	1386		10.1001/jama.281.15.1381	http://dx.doi.org/10.1001/jama.281.15.1381			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217053				2022-12-28	WOS:000079701000027
J	Reynolds, T				Reynolds, T			Putting prevention into practice: The patient's role	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					707	708		10.7326/0003-4819-130-8-199904200-00102	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215578				2022-12-28	WOS:000079786600022
J	Steer, P; Flint, C				Steer, P; Flint, C			ABC of labour care - Preterm labour and premature rupture of membranes	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England; Thames Valley Univ, London, England	Imperial College London; University of West London	Steer, P (corresponding author), Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England.							Morrison JJ, 1997, BRIT J OBSTET GYNAEC, V104, P1341, DOI 10.1111/j.1471-0528.1997.tb11002.x; *ROYAL COLL OBST G, 1997, BET AG CAR WOM PRET; *ROYAL COLL OBSTET, 1996, ANT CORT PREV RDS	3	27	30	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1059	1062		10.1136/bmj.318.7190.1059	http://dx.doi.org/10.1136/bmj.318.7190.1059			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205109	Green Published			2022-12-28	WOS:000080140000035
J	Kendrick, D; Marsh, P; Fielding, K; Miller, P				Kendrick, D; Marsh, P; Fielding, K; Miller, P			Preventing injuries in children: cluster randomised controlled trial in primary care	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD INJURY; POPULATION	Objective To assess the effectiveness of safety advice at child health surveillance consultations, provision of low cost safety equipment to families receiving means tested state benefits, home safety checks, and first aid training on frequency and severity of unintentional injuries in children at home. Design Cluster randomised controlled trial. Setting 36 general practices in Nottingham. Subjects All children aged 3-12 months registered with participating practices. Interventions A package of safety advice at child health surveillance consultations at 6-9, 12-15, and 18-24 months; provision of low cost safety equipment to families on means tested state benefits; and home safety checks and first aid training by health visitors. Outcome measures Primary outcomes measures were frequency and severity of medically attended injuries. Secondary outcome measures were self reported safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk of injury and risk of hazards assessed by postal questionnaire at baseline and follow up at 25 months. Results At baseline, both groups had similar risk factors for injury, sociodemographic characteristics, safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk No significant difference was found in frequency of at least one medically attended injury (odds ratio 0.97, 95% confidence interval 0.72 to 1.30), at least one attendance at an accident and emergency department for injury (1.02, 0.76 to 1.37), at least one primary care attendance for injury (0.75, 0.48 to 1.17), or at least one hospital admission for injury (0.69, 0.42 to 1.12). No significant difference in the secondary outcome measures was found between the intervention and control groups. Conclusions The intervention package was not effective in reducing the frequency of minor unintentional injuries in children at home, and larger trials are required to assess the effect on more severe injuries.	Univ Nottingham, Queens Med Ctr, Div Gen Practice, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Div Publ Hlth Med & Epidemiol, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Kendrick, D (corresponding author), Univ Nottingham, Queens Med Ctr, Div Gen Practice, Nottingham NG7 2UH, England.			Kendrick, Denise/0000-0003-3603-6542				*AM AC PED, 1989, INJ PREV PROGR TIPP; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BASS JL, 1991, PUBLIC HEALTH REP, V106, P437; BASS JL, 1993, PEDIATRICS, V92, P544; BASS JL, 1985, PEDIATR CLIN N AM, V32, P233; Bland JM, 1998, BRIT MED J, V316, P129; Carter Y H, 1995, Inj Prev, V1, P164, DOI 10.1136/ip.1.3.164; *CHILD ACC PREV TR, 1991, HLTH VIS ED TRAIN RE; Clamp M, 1998, BRIT MED J, V316, P1576, DOI 10.1136/bmj.316.7144.1576; *DEP HLTH, 1993, HLTH NAT KEY HDB ACC; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; GLIK D, 1993, HEALTH VALUES, V17, P19; GUYER B, 1989, AM J PUBLIC HEALTH, V79, P1521, DOI 10.2105/AJPH.79.11.1521; KENDRICK D, 1994, BRIT J GEN PRACT, V44, P372; Kendrick D, 1995, Inj Prev, V1, P159, DOI 10.1136/ip.1.3.159; Kravitz H, 1973, IMJ Ill Med J, V144, P570; KRUG A, 1994, S AFR MED J, V84, P730; LAIDMAN P, 1987, 12 HLTH ED AUTH; MOLLER J, 1997, INJ PREV, V3, P156; Pless I B., 1993, SCI BASIS CHILDHOOD; Roberts I, 1996, BRIT MED J, V312, P29, DOI 10.1136/bmj.312.7022.29; *SAS I, 1997, ENMOD PROC SAS STAT; Speller V., 1995, PREVENTING INJURY CH; *SPSS, 1990, STAT PACK SOC SCI SP; TOWNER E, 1993, REDUCING CHILDHOOD A; TOWNER E, 1996, HLTH PROMOTION CHILD; VINEIS P, 1994, EPIDEMIOLOGY, V5, P349, DOI 10.1097/00001648-199405000-00016; YANG M, 1996, MLN MACROS ADV MULTI	28	72	73	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					980	983		10.1136/bmj.318.7189.980	http://dx.doi.org/10.1136/bmj.318.7189.980			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195971	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000079751500022
J	Li, QT; Van Antwerp, D; Mercurio, F; Lee, KF; Verma, IM				Li, QT; Van Antwerp, D; Mercurio, F; Lee, KF; Verma, IM			Severe liver degeneration in mice lacking the I kappa B kinase 2 gene	SCIENCE			English	Article							INDUCED APOPTOSIS; IKK-ALPHA; ACTIVATION; PHOSPHORYLATION; COMPLEX; DEGRADATION; BETA; DISSOCIATION; EXPRESSION; COMPONENT	Phosphorylation of inhibitor of kappa B (I kappa B) proteins is an important step in the activation of the transcription nuclear factor kappa B (NF-kappa B) and requires two I kappa B kinases, IKK1 (IKK alpha) and IKK2 (IKK beta). Mice that are devoid of the IKK2 gene had extensive Liver damage from apoptosis and died as embryos, but these mice could be rescued by the inactivation of the gene encoding tumor necrosis factor receptor 1. Mouse embryonic fibroblast cells that were isolated from IKK2(-/-) embryos showed a marked reduction in tumor necrosis factor-alpha (TNF-alpha)- and interleukin-1 alpha-induced NF-kappa B activity and an enhanced apoptosis in response to TNF-alpha. IKK1 associated with NF-kappa B essential modulator (IKK gamma/IKKAP1), another component of the IKK complex. These results show that IKK2 is essential for mouse development and cannot be substituted with IKK1.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Signal Pharmaceut, San Diego, CA 92121 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1996, CELL, V87, P565; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HUNT JS, 1992, CYTOKINE, V4, P340, DOI 10.1016/1043-4666(92)90076-4; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	24	816	860	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					321	325		10.1126/science.284.5412.321	http://dx.doi.org/10.1126/science.284.5412.321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195897				2022-12-28	WOS:000079636400043
J	Richardson, WS; Wilson, MC; Guyatt, GH; Cook, DJ; Nishikawa, J				Richardson, WS; Wilson, MC; Guyatt, GH; Cook, DJ; Nishikawa, J		Evidence-Based Med Working Grp	Users' guides to the medical literature - XV. How to use an article about disease probability for differential diagnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOTHING GOES WRONG; INFECTIVE ENDOCARDITIS; DECISION-MAKING; PRIMARY-CARE; HELP ME; PREVENTION; NUMERATORS; DIZZINESS; JUDGMENT; THERAPY		McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Dept Biostat, Hamilton, ON L8S 4L8, Canada; Audie L Murphy Mem Vet Hosp, Dept Ambulatory Care, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA; Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA	McMaster University; McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.			Wilson, Mark/0000-0003-1271-9664				ALTMAN DG, 1997, EVIDENCE BASED MED P; BARONDESS JA, 1994, DIFFERENTIAL DIAGNOS; BENBADIS SR, 1994, J GEN INTERN MED, V9, P485, DOI 10.1007/BF02599217; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; FLETCHER RH, 1996, CLIN EPIDEMIOLOGY ES, P61; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; Glass R. D., 1996, DIAGNOSIS BRIEF INTR; Glasziou P, 1998, ACP J Club, V129, pA15; GUYATT GH, 1990, AM J MED, V88, P205, DOI 10.1016/0002-9343(90)90143-2; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KATSARKAS A, 1994, OTOLARYNG HEAD NECK, V110, P296, DOI 10.1016/S0194-5998(94)70772-3; Katz DA, 1997, J GEN INTERN MED, V12, P57; KNOCKAERT DC, 1992, ARCH INTERN MED, V152, P51, DOI 10.1001/archinte.152.1.51; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; Kroenke K, 1997, J GEN INTERN MED, V12, P509, DOI 10.1046/j.1525-1497.1997.00092.x; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; NEWMAN TB, 1995, JAMA-J AM MED ASSOC, V274, P1013, DOI 10.1001/jama.1995.03530130019013; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z; Sox HC, 1988, MED DECISION MAKING; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; Weber BE, 1996, AM J MED, V100, P138, DOI 10.1016/S0002-9343(97)89451-X	35	86	89	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1214	1219		10.1001/jama.281.13.1214	http://dx.doi.org/10.1001/jama.281.13.1214			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199432				2022-12-28	WOS:000079464400037
J	Bornke, C; Heye, N; Buttner, T				Bornke, C; Heye, N; Buttner, T			Rapidly progressive dementia	LANCET			English	Article							ANGIITIS		Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany	Ruhr University Bochum	Bornke, C (corresponding author), Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany.							BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; HANKEY GJ, 1991, CEREBROVASC DIS, V1, P2, DOI 10.1159/000108809; KOLODNY EH, 1968, ARCH NEUROL-CHICAGO, V19, P510, DOI 10.1001/archneur.1968.00480050080008; Moore Patricia M., 1995, Annals of Neurology, V37, pS131; REIK L, 1983, NEUROLOGY, V33, P1609, DOI 10.1212/WNL.33.12.1609	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1150	1150		10.1016/S0140-6736(98)12091-3	http://dx.doi.org/10.1016/S0140-6736(98)12091-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209980				2022-12-28	WOS:000079858400014
J	Gritsman, K; Zhang, JJ; Cheng, S; Heckscher, E; Talbot, WS; Schier, AF				Gritsman, K; Zhang, JJ; Cheng, S; Heckscher, E; Talbot, WS; Schier, AF			The EGF-CFC protein one-eyed pinhead is essential for nodal signaling	CELL			English	Article							ZEBRAFISH ORGANIZER; MESODERM INDUCTION; DROSOPHILA EMBRYO; MOUSE EMBRYO; FLOOR PLATE; RECEPTOR; AXIS; GENE; GASTRULATION; MUTATIONS	The zebrafish EGF-CFC gene one-eyed pinhead (oep) is required zygotically for the formation of the ventral neuroectoderm, endoderm, and prechordal plate. Here we report that embryos lacking both maternal and zygotic Oep activity are defective in germ layer formation, organizer development, and the positioning of the anterior-posterior axis. An identical phenotype is displayed by double mutants for the nodal-related genes squint and cyclops. Mutations in oep eliminate the response to Squint and Cyclops overexpression but are suppressed by expression of Activin and activated forms of the type I receptor ActRIB and Smad2. Expression of the murine EGF-CFC gene cripto rescues oep mutants. These results suggest a conserved role for EGF-CFC proteins as essential extracellular cofactors for Nodal signaling during vertebrate development.	NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA	New York University	Schier, AF (corresponding author), NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA.		Gritsman, Kira/J-8644-2019	Gritsman, Kira/0000-0002-1367-1167; Schier, Alexander Franz/0000-0001-7645-5325	NIGMS NIH HHS [R01GM56211, R01GM57825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057825, R01GM056211] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Chang CB, 1997, DEVELOPMENT, V124, P827; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Dodd J, 1998, SCIENCE, V282, P1654, DOI 10.1126/science.282.5394.1654; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Erter CE, 1998, DEV BIOL, V204, P361, DOI 10.1006/dbio.1998.9097; Fekany K, 1999, DEVELOPMENT, V126, P1427; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Shen MM, 1997, DEVELOPMENT, V124, P429; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Strahle U, 1997, Genes Funct, V1, P131; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Varlet I, 1997, COLD SPRING HARB SYM, V62, P105; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Yamanaka Y, 1998, GENE DEV, V12, P2345, DOI 10.1101/gad.12.15.2345; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	47	590	599	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					121	132		10.1016/S0092-8674(00)80720-5	http://dx.doi.org/10.1016/S0092-8674(00)80720-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199408	hybrid			2022-12-28	WOS:000079843900014
J	Velankar, SS; Soultanas, P; Dillingham, MS; Subramanya, HS; Wigley, DB				Velankar, SS; Soultanas, P; Dillingham, MS; Subramanya, HS; Wigley, DB			Crystal structures of complexes of PcrA DNA helicase with a DNA substrate indicate an inchworm mechanism	CELL			English	Article							COLI REP HELICASE; HEPATITIS-C VIRUS; RNA HELICASE; INDUCED DIMERIZATION; DUPLEX DNA; DOMAIN; REPLICATION; PROTEIN	We have determined two different structures of PcrA DNA helicase complexed with the same single strand tailed DNA duplex, providing snapshots of different steps on the catalytic pathway. One of the structures is of a complex with a nonhydrolyzable analog of ATP and is thus a "substrate" complex. The other structure contains a bound sulphate ion that sits in a position equivalent to that occupied by the phosphate ion produced after ATP hydrolysis, thereby mimicking a "product" complex. In both complexes, the protein is monomeric. Large and distinct conformational changes occur on binding DNA and the nucleotide cofactor. Taken together, these structures provide evidence against an "active rolling" model for helicase action but are instead consistent with an "inchworm" mechanism.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Wigley, DB (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	wigley@eric.path.ox.ac.uk		Velankar, Sameer/0000-0002-8439-5964; Soultanas, Panos/0000-0003-3578-5699; Dillingham, Mark/0000-0002-4612-7141	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; GORBALENYA AE, 1991, FEBS LETT, V291, P277, DOI 10.1016/0014-5793(91)81301-N; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LEE MS, 1990, J BIOL CHEM, V265, P17078; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	25	656	661	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					75	84		10.1016/S0092-8674(00)80716-3	http://dx.doi.org/10.1016/S0092-8674(00)80716-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199404	Bronze			2022-12-28	WOS:000079843900010
J	Hudson, CN				Hudson, CN			Elective caesarean section for prevention of vertical transmission of HIV-1 infection	LANCET			English	Editorial Material							INFANT		St Bartholomews Hosp, Dept Gynaecol, London EC1A 7BE, England	University of London; Queen Mary University London	Hudson, CN (corresponding author), St Bartholomews Hosp, Dept Gynaecol, London EC1A 7BE, England.							CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; MINDEL A, 1999, VIRAL INFECT OBSTET, P115; NEWELL ML, 1999, VIRAL INFECT OBSTET, P135; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	9	6	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1030	1031		10.1016/S0140-6736(99)00066-5	http://dx.doi.org/10.1016/S0140-6736(99)00066-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199345				2022-12-28	WOS:000079614000004
J	Parazzini, F; Ricci, E; Di Cintio, E; Chiaffarino, F; Pardi, G; Parazzini, F; Bortolus, R; D'Oro, LC; Biraghi, P; Bucceri, A; Ravizza, M; Grossi, E; Muggiasca, ML; Tibaldi, C; Prati, A; Iasci, A; Aronica, E; Ceccarelli, E; Frigerio, L; Borlone, P; Stagnizza, M; Agnoletto, V; Tognoni, G; Lazzrin, A; Massobrio, M; Garzetti, GG; Ciavattini, A; Mosca, S; Greco, P; Vimercati, A; Guerra, B; Bianchi, S; Bovicelli, L; Prati, E; Innocenti, TA; Fiscella, A; Bucceri, A; Grossi, E; Rossi, G; Rancilio, L; Ferraris, G; Vignali, M; Muggiasca, ML; Semprini, AE; Ravizza, M; Castagna, C; Della Torre, M; Martinelli, P; Sansone, M; di Lenardo, L; Russolo, A; Rubino, E; Lo Bue, G; Maccabruni, A; Arlandi, L; Citernesi, A; Villa, P; Mancuso, S; Pachi, A; Scaravelli, G; Tibaldi, C; Benedetto, C; Ziarati, N; Gabiano, C; Alberico, S; Franchi, M; Zanconato, G; Fedele, L; Newell, ML; Bailey, A; Peckham, C; Darbyshire, J; Sanchez, E; Semprini, AE; Leyes, M; Ciria, LM; Coll, O; Fortuny, C; Bogunya, JM; Paya, A; Mur, A; Casellas, M; Lain, J; Anzen, B; Lindgren, S; Rudin, C; Irion, O; Bewley, S; Kennedy, J; Mandelbrot, L; Bazin, B; Aboulker, JP; Crenn-Hebert, C; Tudal, CF; Bech, A; Lobut, R; Chemla, JP; Milliez, J; Courpotin, C; Mandelbrot, L; Firtion, G; Benifla, JL; Ottenwalter, A; Vilmer, E; Hocke, C; Douard, D; Berrebi, A; Tricoire, J; Pauly, I; Le Lorier, B; Bongain, A; Monpoux, F; Cravello, L; Perrimond, H; Newell, ML; Darbyshire, J; Peckham, C; Coll, O; Sanchez, E; Mandelbrot, L; Aboulker, JP; Bazin, B; Blanche, S				Parazzini, F; Ricci, E; Di Cintio, E; Chiaffarino, F; Pardi, G; Parazzini, F; Bortolus, R; D'Oro, LC; Biraghi, P; Bucceri, A; Ravizza, M; Grossi, E; Muggiasca, ML; Tibaldi, C; Prati, A; Iasci, A; Aronica, E; Ceccarelli, E; Frigerio, L; Borlone, P; Stagnizza, M; Agnoletto, V; Tognoni, G; Lazzrin, A; Massobrio, M; Garzetti, GG; Ciavattini, A; Mosca, S; Greco, P; Vimercati, A; Guerra, B; Bianchi, S; Bovicelli, L; Prati, E; Innocenti, TA; Fiscella, A; Bucceri, A; Grossi, E; Rossi, G; Rancilio, L; Ferraris, G; Vignali, M; Muggiasca, ML; Semprini, AE; Ravizza, M; Castagna, C; Della Torre, M; Martinelli, P; Sansone, M; di Lenardo, L; Russolo, A; Rubino, E; Lo Bue, G; Maccabruni, A; Arlandi, L; Citernesi, A; Villa, P; Mancuso, S; Pachi, A; Scaravelli, G; Tibaldi, C; Benedetto, C; Ziarati, N; Gabiano, C; Alberico, S; Franchi, M; Zanconato, G; Fedele, L; Newell, ML; Bailey, A; Peckham, C; Darbyshire, J; Sanchez, E; Semprini, AE; Leyes, M; Ciria, LM; Coll, O; Fortuny, C; Bogunya, JM; Paya, A; Mur, A; Casellas, M; Lain, J; Anzen, B; Lindgren, S; Rudin, C; Irion, O; Bewley, S; Kennedy, J; Mandelbrot, L; Bazin, B; Aboulker, JP; Crenn-Hebert, C; Tudal, CF; Bech, A; Lobut, R; Chemla, JP; Milliez, J; Courpotin, C; Mandelbrot, L; Firtion, G; Benifla, JL; Ottenwalter, A; Vilmer, E; Hocke, C; Douard, D; Berrebi, A; Tricoire, J; Pauly, I; Le Lorier, B; Bongain, A; Monpoux, F; Cravello, L; Perrimond, H; Newell, ML; Darbyshire, J; Peckham, C; Coll, O; Sanchez, E; Mandelbrot, L; Aboulker, JP; Bazin, B; Blanche, S		European Mode Delivery Collaboration	Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; CESAREAN-SECTION; ZIDOVUDINE PROPHYLAXIS; TYPE-1; MODE; INFECTION; WOMEN; RISK	Background Results from observational studies suggest that caesarean-section delivery may reduce the risk of mother-to-child transmission of HIV-1 infection in comparison with vaginal delivery. We carried out a randomised clinical trial to address this issue and to assess the extent of postdelivery complications. Methods Eligible women were between 34 and 36 weeks of pregnancy, with a confirmed diagnosis of HIV-1 infection, and without an indication for caesarean-section delivery or a contraindication to this mode of delivery. Women were randomly assigned elective caesarean-section delivery at 38 weeks of pregnancy or vaginal delivery. An infant was classified as uninfected if he or she became negative for antibody to HIV-1 by age 18 months or was negative for virus by PCR or culture on at least two occasions, with no clinical, immunological, or viral evidence of infection. From 1993, to March, 1998, 436 women were randomised. Findings We present the results of an analysis updated to November, 1998, with data on the infection status of 370 infants. Three (1.8%) of 170 infants born to women assigned caesarean-section delivery were infected, compared with 21 (10.5%) of 200 born to women assigned vaginal delivery (p<0.001). Seven (3.4%) of 203 infants of women who actually gave birth by caesarean section were infected compared with 15 (10.2%) of 167 born vaginally (p=0.009). There were few postpartum complications and no serious adverse events in either group. Interpretation Our findings provide evidence that elective caesarean-section delivery significantly lowers the risk of mother-to-child transmission of HIV-1 infection without a significantly increased risk of complications for the mother.	Ist Mario Negri, Analyt Epidemiol Unit, I-20157 Milan, Italy; Hosp Son Dureta, Mallorca, Spain; Hosp Clin Barcelona, Barcelona, Spain; Hosp Del Mar, Barcelona, Spain; Hosp Val DHebron, Barcelona, Spain; Hop Tarrassa, Tarrasa, Spain; Danderyd Hosp, Stockholm, Sweden; Karolinska Inst, Huddinge Hosp, S-10401 Stockholm, Sweden; Univ Basel, Childrens Hosp, Basel, Switzerland; Univ Hosp, Geneva, Switzerland; St Thomas Hosp, London, England; UCL, Inst Child Hlth, London WC1E 6BT, England; UCL, MRC, HIV Trials Ctr, London WC1E 6BT, England; Catalan Baleraic Grp, Barcelona, Spain; Hosp San Paolo, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; University of Barcelona; Hospital Clinic de Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Danderyds Hospital; Karolinska Institutet; University of Basel; University of Geneva; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; University of London; University College London	Parazzini, F (corresponding author), Ist Mario Negri, Analyt Epidemiol Unit, Via Eritrea 62, I-20157 Milan, Italy.		VALLET, Yannick/F-9979-2011; Mandelbrot, Laurent/AAD-3554-2019; Newell, Marie-Louise/AAE-8222-2019; Chiaffarino, Francesca/AAD-2053-2020; Greco, Pantaleo/AAC-5173-2022; Grossi, Enzo/AAF-7765-2020; VILLA, PAOLA/J-1579-2012; Ciavattini, Andrea/AAW-6212-2020; Ruiz, Emilia Sanchez/K-3013-2013; Ciavattini, Andrea/AAC-3266-2022; peckham, catherine s/I-6300-2013; vimercati, antonella/I-8114-2012; Ciavattini, Andrea/AAC-1862-2019; SHCS, MoCHIV/G-4081-2011; Bortolus, Renata/K-6396-2016; SEMPRINI, AUGUSTO ENRICO/S-6415-2017	Mandelbrot, Laurent/0000-0002-5883-7597; Newell, Marie-Louise/0000-0002-1074-7699; Chiaffarino, Francesca/0000-0001-6009-8108; Ruiz, Emilia Sanchez/0000-0003-0522-8007; Ciavattini, Andrea/0000-0002-8037-4947; vimercati, antonella/0000-0002-9862-1619; parazzini, fabio/0000-0001-5624-4854; Rossi, Gabriele/0000-0003-4350-720X; Ricci, Elena/0000-0001-5279-0444; Cavalieri d'Oro, Luca/0000-0001-7713-1293; Paya, Antonio/0000-0002-9036-1349; Villa, Paola/0000-0002-4501-3038; Iasci, Angela/0000-0002-3733-8537; GRECO, Pantaleo/0000-0003-2461-6777; Bortolus, Renata/0000-0003-3857-4133; SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012; Chatenoud, Liliane/0000-0001-9599-8229				Breslow NE, 1980, ANAL CASE CONTROL ST; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; GABIANO C, 1992, PEDIATRICS, V90, P369; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; Maguire A, 1997, AIDS, V11, P1851, DOI 10.1097/00002030-199715000-00010; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; NATALE N, 1997, IT J GYNAECOL OBST, V3, P103; NEWELL ML, 1994, LANCET, V343, P1464; NEWELL ML, 1992, LANCET, V339, P1007; Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004; Newell ML, 1998, BRIT J OBSTET GYNAEC, V105, P281, DOI 10.1111/j.1471-0528.1998.tb10087.x; NIELSEN TF, 1983, AM J OBSTET GYNECOL, V146, P911, DOI 10.1016/0002-9378(83)90963-8; Ricci E, 1999, HUM REPROD, V14, P242; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Thorne C, 1998, BRIT J OBSTET GYNAEC, V105, P704; VILLARI P, 1993, ONLINE J CURR CLIN T	20	399	423	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1035	1039						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199349				2022-12-28	WOS:000079614000008
J	Wise, RJS; Greene, J; Buchel, C; Scott, SK				Wise, RJS; Greene, J; Buchel, C; Scott, SK			Brain regions involved in articulation	LANCET			English	Article							HUMAN AUDITORY-CORTEX; COORDINATING SPEECH ARTICULATION; ANATOMY	Background The left inferior frontal gyrus (Broca's area) is generally believed to be critical for the motor act of speech. A lesion-based analysis has, however, shown that the left anterior insula is necessary for accurate articulation. We used functional imaging in normal people to show the neural systems involved in speech during different speech tasks. Methods 12 normal people underwent positron emission tomography with oxygen-15-labelled water as tracer. We measured cerebral activity while participants performed three different tasks: repetition of heard nouns at different rates; listening to single nouns at different rates; and anticipation of listening or repetition. We analysed the data with imaging software. Findings Repetition of single words did not activate Broca's area but activity in three left-lateralised regions was seen: the anterior insula, a localised region in the lateral premotor cortex, and the posterior pallidum. The left anterior insula and lateral premotor cortex showed a conjunction of activity for hearing and articulation. In addition, articulation modulated the response to hearing words in the left dorsolateral temporal cortex, the physiological expression of the speaker's auditory attention being directed towards the stimuli and not his or her articulated responses. Interpretation The formulation of an articulatory plan is a function of the left anterior insula and lateral premotor cortex and not of Broca's area. The left basal ganglia seem to be dominant for speech, although the axial muscles involved receive their motor output from both cerebral hemispheres.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England; Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; MRC, Appl Psychol Unit, Cambridge CB2 2EF, England	Imperial College London; University of London; University College London; University of Cambridge	Wise, RJS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England.	richard@wren.rpms.ac.uk	Scott, Sophie K/A-1843-2010	Scott, Sophie K/0000-0001-7510-6297	Wellcome Trust [090961] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMANN H, 1992, J NEUROL, V239, P223, DOI 10.1007/BF00839144; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; BARTH A, 1993, ANN NEUROL, V33, P451, DOI 10.1002/ana.410330507; BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; Bregman A.S., 1990, AUDITORY SCENE ANAL; BUCHMAN AS, 1986, J NEUROL NEUROSUR PS, V49, P489, DOI 10.1136/jnnp.49.5.489; Caplan D., 1987, NEUROLINGUISTICS LIN; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P476, DOI 10.1007/BF00249601; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Dhankhar A, 1997, J NEUROPHYSIOL, V77, P476, DOI 10.1152/jn.1997.77.1.476; Donnan GA, 1997, LANCET, V349, P221, DOI 10.1016/S0140-6736(05)64855-6; Dronkers NF, 1996, NATURE, V384, P159, DOI 10.1038/384159a0; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fitch RH, 1997, ANNU REV NEUROSCI, V20, P331, DOI 10.1146/annurev.neuro.20.1.331; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; KIM JS, 1994, STROKE, V25, P1994, DOI 10.1161/01.STR.25.10.1994; LEVELT WJM, 1999, IN PRESS BEHAV BRAIN; MCFARLAND DH, 1995, NEURAL CONTROL SKILL, P61; Miller G., 1951, LANGUAGE COMMUNICATI; MOHR JP, 1978, NEUROLOGY, V28, P311, DOI 10.1212/WNL.28.4.311; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; PANTEV C, 1995, ELECTROEN CLIN NEURO, V94, P26, DOI 10.1016/0013-4694(94)00209-4; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE C, 1992, NEUROSCI LETT, V146, P179, DOI 10.1016/0304-3940(92)90072-F; Price CJ, 1996, BRAIN, V119, P919, DOI 10.1093/brain/119.3.919; Tohgi H, 1996, EUR NEUROL, V36, P338, DOI 10.1159/000117290; WOOTEN GF, 1993, NEUROLOGY, V43, P1764, DOI 10.1212/WNL.43.9.1764; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	30	404	408	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1057	1061		10.1016/S0140-6736(98)07491-1	http://dx.doi.org/10.1016/S0140-6736(98)07491-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199354				2022-12-28	WOS:000079614000013
J	Stevens, KA; Parrish, JM				Stevens, KA; Parrish, JM			Neck posture and feeding habits of two Jurassic sauropod dinosaurs	SCIENCE			English	Article								Articulated digital reconstructions of two diplodocid sauropods revealed cervical poses and feeding envelopes. The necks of Diplodocus and Apatosaurus were nearly straight but gently declined such that the heads, which were themselves angled downward relative to the neck, were close to ground level in their neutral, undeflected posture. Both necks were less flexible than conventionally depicted, and Diplodocus was less capable of lateral and dorsal curvature than Apatosaurus. The results suggest that these sauropods were adapted to ground feeding or low browsing, contrary to the view that diplodocid sauropods were high browsers.	Univ Oregon, Eugene, OR 97403 USA; No Illinois Univ, De Kalb, IL 60115 USA	University of Oregon; Northern Illinois University	Stevens, KA (corresponding author), Univ Oregon, Eugene, OR 97403 USA.							ALEXANDER RM, 1985, ZOOL J LINN SOC-LOND, V83, P1, DOI 10.1111/j.1096-3642.1985.tb00871.x; ASH SR, 1998, MOD GEOL, V22, P321; BAKKER RT, 1986, DINOSAUR HERESIES, P14; Berman D. S., 1978, B CARNEGIE MUS NAT H, V8, P1; Carpenter Kenneth, 1998, Modern Geology, V23, P69; Chin Karen, 1998, Modern Geology, V23, P249; CHOY DSJ, 1992, LANCET, V340, P534, DOI 10.1016/0140-6736(92)91722-K; Chure Daniel J., 1998, Modern Geology, V23, P507; Demko T. M., 1998, MODERN GEOLOGY, V22, P283; Fiorillo Anthony R., 1994, Contributions to Geology University of Wyoming, V30, P149; Fiorillo Anthony R., 1998, Historical Biology, V13, P1; FREY E, 1988, STUTTGARTER BEITRAGE, V426, P1; George JC, 1966, AVIAN MYOLOGY; GILMORE CW, 1936, CONTRIB GEOL U WYOMI, V11; Hatcher JB., 1901, MEM CARNEGIE MUS, V1, P1, DOI [10.5962/p.234818, DOI 10.5962/P.234818]; HOHNKE LA, 1973, NATURE, V244, P309, DOI 10.1038/244309a0; KNIGHT CR, 1906, OIL PAINTING HALL VE; Litwin RJ, 1998, MOD GEOL, V22, P297; MARTIN J, 1987, OCCASIONAL PAPERS TY, V3, P154; McIntosh J.S., 1990, P345; McIntosh J. S., 1981, BULL CARNEG MUS NAT, V18, P1; MILLER CN, 1987, ANN MO BOT GARD, V74, P692, DOI 10.2307/2399447; PARRISH JD, UNPUB; PAUL GR, 1987, DINOSAURS PAST PRESE, V2, P29; Paul Gregory S., 1998, Modern Geology, V23, P179; SEYMOUR RS, 1976, NATURE, V262, P207, DOI 10.1038/262207a0; SIBBICK J, 1985, ILLUSTRATED ENCY DIN, P80; Upchurch P, 1998, ZOOL J LINN SOC-LOND, V124, P43, DOI 10.1111/j.1096-3642.1998.tb00569.x; UPCHURCH P, 1995, PHILOS T R SOC B, V349, P365, DOI 10.1098/rstb.1995.0125; Wilson JA, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011115	30	126	129	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					798	800		10.1126/science.284.5415.798	http://dx.doi.org/10.1126/science.284.5415.798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221910				2022-12-28	WOS:000080056200044
J	Nestler, JE; Jakubowicz, DJ; Reamer, P; Gunn, RD; Allan, G				Nestler, JE; Jakubowicz, DJ; Reamer, P; Gunn, RD; Allan, G			Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN-RESISTANCE; METFORMIN THERAPY; CHIROINOSITOL DEFICIENCY; GLUCOSE-TOLERANCE; RHESUS-MONKEYS; HUMAN-DISEASE; WOMEN; HYPERINSULINEMIA; RISK	Background Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of D-chiro-inositol would replenish stores of the mediator and improve insulin sensitivity. Methods We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral administration of 1200 mg of D-chiro-inositol or placebo once daily for six to eight weeks in 44 obese women with the polycystic ovary syndrome. The serum progesterone concentration was measured weekly to monitor for ovulation. Results In the 22 women given D-chiro-inositol, the mean (+/-SD) area under the plasma insulin curve after the oral administration of glucose decreased from 13,417+/-11,572 to 5158+/-6714 mu U per milliliter per minute (81+/-69 to 31+/-40 nmol per liter per minute) (P = 0.007; P=0.07 for the comparison of this change with the change in the placebo group); glucose tolerance did not change significantly. The serum free testosterone concentration in these 22 women decreased from 1.1+/-0.8 to 0.5+/-0.5 ng per deciliter (38+/-28 to 17+/-17 pmol per liter) (P = 0.006 for the comparison with the change in the placebo group). The women's diastolic and systolic blood pressure decreased by 4 mm Hg (P < 0.001 and P = 0.05, respectively, for the comparisons with the changes in the placebo group), and their plasma triglyceride concentrations decreased from 184+/-88 to 110+/-61 mg per deciliter (2.1+/-0.2 to 1.2+/-0.1 mmol per lit er) (P = 0.002 for the comparison with the change in the placebo group). None of these variables changed appreciably in the placebo group. Nineteen of the 22 women who received D-chiro-inositol ovulated, as compared with 6 of the 22 women in the placebo group (P < 0.001). Conclusions D-Chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride concentrations, (N Engl J Med 1999;340:1314-20.) (C)1999, Massachusetts Medical Society.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Hosp Clin Caracas, Dept Med, Caracas, Venezuela; Insmed Pharmaceut, Richmond, VA USA	Virginia Commonwealth University	Nestler, JE (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, POB 980111, Richmond, VA 23298 USA.	nestler@hsc.vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD035772] Funding Source: NIH RePORTER; NICHD NIH HHS [R43HD35772] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASPLIN I, 1993, P NATL ACAD SCI USA, V90, P5924, DOI 10.1073/pnas.90.13.5924; Bjorntorp P, 1996, J INTERN MED, V239, P105, DOI 10.1046/j.1365-2796.1996.364690000.x; Craig James W., 1994, P343; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; Diamanti-Kandarakis E, 1998, EUR J ENDOCRINOL, V138, P269, DOI 10.1530/eje.0.1380269; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; DUNAIF A, 1987, J CLIN ENDOCR METAB, V65, P499, DOI 10.1210/jcem-65-3-499; Ehrmann DA, 1999, DIABETES CARE, V22, P141, DOI 10.2337/diacare.22.1.141; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FRANKS S, 1995, NEW ENGL J MED, V333, P1435; Gavin JR, 1997, DIABETES CARE, V20, P1183; HO LT, 1990, DIABETIC MED, V7, P31, DOI 10.1111/j.1464-5491.1990.tb01303.x; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; LARNER J, 1994, ENDOCRINE, V2, P167; Legro RS, 1998, J CLIN ENDOCR METAB, V83, P2694, DOI 10.1210/jc.83.8.2694; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Morin-Papunen LC, 1998, FERTIL STERIL, V69, P691, DOI 10.1016/S0015-0282(98)00011-9; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; ORTMEYER HK, 1993, ENDOCRINOLOGY, V132, P646, DOI 10.1210/en.132.2.646; ORTMEYER HK, 1993, ENDOCRINOLOGY, V132, P640, DOI 10.1210/en.132.2.640; PAK Y, 1992, J BIOL CHEM, V267, P16904; PAK Y, 1993, P NATL ACAD SCI USA, V90, P7759, DOI 10.1073/pnas.90.16.7759; RAY J, 1992, J CHEM INF COMP SCI, V32, P575, DOI 10.1021/ci00009a607; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REBUFFESCRIVE M, 1989, HORM METAB RES, V21, P391, DOI 10.1055/s-2007-1009245; SODERGARD R, 1982, J STEROID BIOCHEM, V16, P801, DOI 10.1016/0022-4731(82)90038-3; SUZUKI S, 1994, DIABETES CARE, V17, P1465, DOI 10.2337/diacare.17.12.1465; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WILD RA, 1995, AM J MED, V98, pS27, DOI 10.1016/S0002-9343(99)80056-4; WILD RA, 1992, AM J OBSTET GYNECOL, V166, P1191, DOI 10.1016/S0002-9378(11)90605-X; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	41	397	424	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1314	1320		10.1056/NEJM199904293401703	http://dx.doi.org/10.1056/NEJM199904293401703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219066	Green Published			2022-12-28	WOS:000080001700003
J	Palmer, S; Torgerson, DJ				Palmer, S; Torgerson, DJ			Economics notes - Definitions of efficiency	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of York - UK	Palmer, S (corresponding author), Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				Drummond M, 1991, PROVIDING HLTH CARE; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; MOONEY G, 1986, CHOICES HLTH CARE PR; TORGERSON DJ, 1997, SCREENING DOWN SYNDR; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WILLIAMS A, 1988, J HEALTH ECON, V7, P173, DOI 10.1016/0167-6296(88)90015-X	6	132	135	2	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1136	1136		10.1136/bmj.318.7191.1136	http://dx.doi.org/10.1136/bmj.318.7191.1136			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193YU	10213735	Green Published			2022-12-28	WOS:000080166000040
J	Abbasi, K				Abbasi, K			The World Bank and world health - Focus on South Asia - I: Bangladesh	BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Abbasi, K (corresponding author), BMJ, London WC1H 9JR, England.							Buse K, 1998, LANCET, V351, P665, DOI 10.1016/S0140-6736(97)11453-2; Government of the People's Republic of Bangladesh, 1998, HLTH POP SECT PROGR; *WORLD BANK, 1997, SECT STRAT HLTH NUTR	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1066	1069		10.1136/bmj.318.7190.1066	http://dx.doi.org/10.1136/bmj.318.7190.1066			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205111	Green Published			2022-12-28	WOS:000080140000038
J	Morris, M; Eifel, PJ; Lu, JD; Grigsby, PW; Levenback, C; Stevens, RE; Rotman, M; Gershenson, DM; Mutch, DG				Morris, M; Eifel, PJ; Lu, JD; Grigsby, PW; Levenback, C; Stevens, RE; Rotman, M; Gershenson, DM; Mutch, DG			Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; PARAAORTIC LYMPH-NODES; UTERINE CERVIX; PHASE-II; STAGE-IB; IRRADIATION; THERAPY; TRIAL; PROGNOSIS	Background and Methods We compared the effect of radiotherapy to a pelvic and para-aortic field with that of pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin in women with advanced cervical cancer. Between 1990 and 1997, 403 women with advanced cervical cancer confined to the pelvis (stages IIB through IVA or stage IB or IIA with a tumor diameter of at least 5 cm or involvement of pelvic lymph nodes) were randomly assigned to receive either 45 Gy of radiation to the pelvis and para-aortic lymph nodes or 45 Gy of radiation to the pelvis alone plus two cycles of fluorouracil and cisplatin (days 1 through 5 and days 22 through 26 of radiation). Patients were then to receive one or two applications of low-dose-rate intracavitary radiation, with a third cycle of chemotherapy planned for the second intracavitary procedure in the combined-therapy group. Results Of the 403 eligible patients, 193 in each group could be evaluated. The median duration of follow-up was 43 months. Estimated cumulative rates of survival at five years were 73 percent among patients treated with radiotherapy and chemotherapy and 58 percent among patients treated with radiotherapy alone (P=0.004). Cumulative rates of disease free survival at five years were 67 percent among patients in the combined-therapy group and 40 percent among patients in the radiotherapy group (P<0.001). The rates of both distant metastases (P<0.001) and locoregional recurrences (P<0.001) were significantly higher among patients treated with radiotherapy alone. The seriousness of side effects was similar in the two groups, with a higher rate of reversible hematologic effects in the combined-therapy group. Conclusions The addition of chemotherapy with fluorouracil and cisplatin to treatment with external-beam and intracavitary radiation significantly improved survival among women with locally advanced cervical cancer. (N Engl J Med 1999;340:1137-43.) (C)1999, Massachusetts Medical Society.	Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Radiat Therapy Oncol Grp, Stat Unit, Philadelphia, PA USA; Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA; Washington Univ, Sch Med, Div Gynecol Oncol, St Louis, MO USA; NYU, Dept Radiat Oncol, New York, NY USA; SUNY Hlth Sci Ctr, Dept Radiat Oncol, Brooklyn, NY 11203 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Radiation Therapy Oncology Group (RTOG); Washington University (WUSTL); Washington University (WUSTL); New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Morris, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, 1515 Holcombe Blvd,Box 34, Houston, TX 77030 USA.	morris@mdanderson.org			NCI NIH HHS [U10CA21661, U10CA32115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ RD, 1989, GYNECOL ONCOL, V35, P130, DOI 10.1016/0090-8258(89)90029-2; BAUER M, 1986, INT J RADIAT ONCOL, V12, P1101, DOI 10.1016/0360-3016(86)90235-X; Chen MD, 1997, GYNECOL ONCOL, V67, P131, DOI 10.1006/gyno.1997.4851; Corn BW, 1998, AM J CLIN ONCOL-CANC, V21, P31, DOI 10.1097/00000421-199802000-00007; COX DR, 1972, J R STAT SOC B, V34, P187; DELGADO G, 1989, GYNECOL ONCOL, V35, P314, DOI 10.1016/0090-8258(89)90070-X; EIFEL PJ, 1990, CANCER, V65, P2507, DOI 10.1002/1097-0142(19900601)65:11<2507::AID-CNCR2820651120>3.0.CO;2-9; EIFEL PJ, 1994, INT J RADIAT ONCOL, V29, P9, DOI 10.1016/0360-3016(94)90220-8; Fields AL, 1996, GYNECOL ONCOL, V61, P416, DOI 10.1006/gyno.1996.0166; FYLES A, 1992, RADIOTHER ONCOL, V25, P273, DOI 10.1016/0167-8140(92)90247-R; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Grigsby FW, 1996, AM J CLIN ONCOL-CANC, V19, P1; Grigsby PW, 1998, INT J RADIAT ONCOL, V41, P817, DOI 10.1016/S0360-3016(98)00132-1; HRESHCHYSHYN MM, 1979, INT J RADIAT ONCOL, V5, P317, DOI 10.1016/0360-3016(79)91209-4; John M, 1996, GYNECOL ONCOL, V61, P221, DOI 10.1006/gyno.1996.0129; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P167; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; LANCIANO RM, 1991, INT J RADIAT ONCOL, V20, P667, DOI 10.1016/0360-3016(91)90007-Q; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; MALFETANO J, 1993, CANCER, V71, P3703, DOI 10.1002/1097-0142(19930601)71:11<3703::AID-CNCR2820711138>3.0.CO;2-8; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387; SHEPHERD JH, 1995, INT J GYNECOL CANCER, V5, P319; STEHMAN FB, 1993, J CLIN ONCOL, V11, P1523, DOI 10.1200/JCO.1993.11.8.1523; STEHMAN FB, 1991, CANCER, V67, P2776, DOI 10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L; THOMAS G, 1990, GYNECOL ONCOL, V38, P446, DOI 10.1016/0090-8258(90)90089-4; THOMAS G, 1984, INT J RADIAT ONCOL, V10, P1785, DOI 10.1016/0360-3016(84)90550-9	32	1664	1759	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1137	1143		10.1056/NEJM199904153401501	http://dx.doi.org/10.1056/NEJM199904153401501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202164	Bronze			2022-12-28	WOS:000079687700001
J	Rose, PG; Bundy, BN; Watkins, EB; Thigpen, JT; Deppe, G; Maiman, MA; Clarke-Pearson, DL; Insalaco, S				Rose, PG; Bundy, BN; Watkins, EB; Thigpen, JT; Deppe, G; Maiman, MA; Clarke-Pearson, DL; Insalaco, S			Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; DOSE-RATE BRACHYTHERAPY; POOR-PROGNOSIS CANCER; TERM FOLLOW-UP; PHASE I-II; RADIATION-THERAPY; UTERINE CERVIX; TREATMENT TIME; NECK-CANCER	Background and Methods On behalf of the Gynecologic Oncology Group, we performed a randomized trial of radiotherapy in combination with three concurrent chemotherapy regimens - cisplatin alone; cisplatin, fluorouracil, and hydroxyurea; and hydroxyurea alone - in patients with locally advanced cervical cancer. Women with primary untreated invasive squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix of stage IIB, III, or IVA, without involvement of the para-aortic lymph nodes, were enrolled. The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level no higher than 2 mg per deciliter (177 mu mol per liter), and adequate hepatic function. All patients received external-beam radiotherapy according to a strict protocol. Patients were randomly assigned to receive one of three chemotherapy regimens: 40 mg of cisplatin per square meter of body-surface area per week for six weeks (group 1); 50 mg of cisplatin per square meter on days 1 and 29, followed by 4 g of fluorouracil per square meter given as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea per square meter twice weekly for six weeks (group 2); or 3 g of oral hydroxyurea per square meter twice weekly for six weeks (group 3). Results The analysis included 526 women. The median duration of follow-up was 35 months. Both groups that received cisplatin had a higher rate of progression-free survival than the group that received hydroxyurea alone (P<0.001 for both comparisons). The relative risks of progression of disease or death were 0.57 (95 percent confidence interval, 0.42 to 0.78) in group 1 and 0.55 (95 percent confidence interval, 0.40 to 0.75) in group 2, as compared with group 3. The overall survival rate was significantly higher in groups 1 and 2 than in group 3, with relative risks of death of 0.61 (95 percent confidence interval, 0.44 to 0.85) and 0.58 (95 percent confidence interval, 0.41 to 0.81), respectively. Conclusions Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer. (N Engl J Med 1999;340:1144-53.) (C)1999. Massachusetts Medical Society.	Univ Hosp Cleveland, Dept Reprod Biol, Div Gynecol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Roswell Pk Canc Inst, Gynecol Oncol Grp, Buffalo, NY USA; Walter Reed Army Med Ctr, Radiat Oncol Serv, Washington, DC 20307 USA; Univ Mississippi, Dept Med, Sch Med, Div Oncol, Jackson, MS 39216 USA; Wayne State Univ, Detroit, MI USA; Hutzel Hosp, Div Gynecol Oncol, Detroit, MI 48201 USA; SUNY Hlth Sci Ctr, Div Gynecol Oncol, Brooklyn, NY 11203 USA; Duke Univ, Sch Med, Div Gynecol Oncol, Durham, NC USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Multicare Med Ctr, Dept Pathol, Tacoma, WA USA	University Hospitals of Cleveland; Case Western Reserve University; Roswell Park Cancer Institute; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Mississippi; Wayne State University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Duke University; University of Washington; University of Washington Seattle	Rose, PG (corresponding author), Gynecol Oncol Grp, Adm Off, Suite 1945,1234 Market St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 37517, CA 27469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSARRAF M, 1987, CANCER-AM CANCER SOC, V59, P259, DOI 10.1002/1097-0142(19870115)59:2<259::AID-CNCR2820590214>3.0.CO;2-1; AUSILICEFARO G, 1995, AM J CLIN ONCOL-CANC, V18, P273, DOI 10.1097/00000421-199506000-00017; Bachaud JM, 1997, AM J CLIN ONCOL-CANC, V20, P1, DOI 10.1097/00000421-199702000-00001; BALL D, 1995, INT J RADIAT ONCOL, V31, P267, DOI 10.1016/0360-3016(94)E0021-B; BEDINI AV, 1991, CANCER, V67, P357, DOI 10.1002/1097-0142(19910115)67:2<357::AID-CNCR2820670207>3.0.CO;2-9; BRENNER DE, 1987, GYNECOL ONCOL, V26, P381, DOI 10.1016/0090-8258(87)90030-8; Britten RA, 1996, INT J RADIAT ONCOL, V34, P367, DOI 10.1016/0360-3016(95)02088-8; CHANG HC, 1992, GYNECOL ONCOL, V44, P182, DOI 10.1016/0090-8258(92)90036-I; CHOO YC, 1986, GYNECOL ONCOL, V23, P94, DOI 10.1016/0090-8258(86)90120-4; CLARK BG, 1994, INT J RADIAT ONCOL, V28, P1243, DOI 10.1016/0360-3016(94)90501-0; Cochran W.G., 1967, STAT METHODS; Coppin CML, 1996, J CLIN ONCOL, V14, P2901, DOI 10.1200/JCO.1996.14.11.2901; Corn BW, 1996, AM J CLIN ONCOL-CANC, V19, P317, DOI 10.1097/00000421-199606000-00023; COUGHLIN CT, 1988, NATL CANCER I MONOGR, V6, P365; COX DR, 1972, J R STAT SOC B, V34, P187; Douple EB, 1980, CISPLATIN CURRENT ST, P125; EAPEN L, 1989, J CLIN ONCOL, V7, P230, DOI 10.1200/JCO.1989.7.2.230; Fields AL, 1996, GYNECOL ONCOL, V61, P416, DOI 10.1006/gyno.1996.0166; FLETCHER GH, 1973, BRIT J RADIOL, V46, P1; FORASTIERE AA, 1993, INT J RADIAT ONCOL, V27, P465, DOI 10.1016/0360-3016(93)90260-3; FU KK, 1985, CANCER, V55, P2123, DOI 10.1002/1097-0142(19850501)55:9+<2123::AID-CNCR2820551415>3.0.CO;2-O; GIRINSKY T, 1993, INT J RADIAT ONCOL, V27, P1051, DOI 10.1016/0360-3016(93)90522-W; HARAF DJ, 1992, LARYNGOSCOPE, V102, P630, DOI 10.1288/00005537-199206000-00007; HEATON D, 1990, GYNECOL ONCOL, V38, P323, DOI 10.1016/0090-8258(90)90066-T; HRESHCHYSHYN MM, 1979, INT J RADIAT ONCOL, V5, P317, DOI 10.1016/0360-3016(79)91209-4; JACOBS MC, 1989, INT J RADIAT ONCOL, V17, P361, DOI 10.1016/0360-3016(89)90451-3; JAMPOLIS S, 1975, RADIOLOGY, V115, P681, DOI 10.1148/15.3.681; JANERICH DT, 1995, AM J PUBLIC HEALTH, V85, P791, DOI 10.2105/AJPH.85.6.791; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kunitoh H, 1997, INT J RADIAT ONCOL, V37, P103, DOI 10.1016/S0360-3016(96)00474-9; KUSKE RR, 1989, AM J CLIN ONCOL-CANC, V12, P467, DOI 10.1097/00000421-198912000-00002; LANCIANO RM, 1991, INT J RADIAT ONCOL, V20, P667, DOI 10.1016/0360-3016(91)90007-Q; LANCIANO RM, 1993, INT J RADIAT ONCOL, V25, P391, DOI 10.1016/0360-3016(93)90058-4; Lin JC, 1996, GYNECOL ONCOL, V61, P101, DOI 10.1006/gyno.1996.0105; LUNDBECK F, 1993, ACTA ONCOL, V32, P679, DOI 10.3109/02841869309092452; MALFETANO J, 1993, CANCER, V71, P3703, DOI 10.1002/1097-0142(19930601)71:11<3703::AID-CNCR2820711138>3.0.CO;2-8; MALVIYA VK, 1989, AM J CLIN ONCOL-CANC, V12, P434, DOI 10.1097/00000421-198910000-00015; MALVIYA VK, 1991, GYNECOL ONCOL, V42, P233, DOI 10.1016/0090-8258(91)90351-5; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MONYAK D J, 1988, NCI (National Cancer Institute) Monographs, P369; MORAN RG, 1982, BIOCHEM PHARMACOL, V31, P2929, DOI 10.1016/0006-2952(82)90265-9; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Muderspach LI, 1997, GYNECOL ONCOL, V65, P336, DOI 10.1006/gyno.1997.4647; *NATL CANC I, 1997, SEER CANC INC PUBL U; *NIH OFF MED APPL, 1996, NIH CONSENSUS STATE, V14, P15; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PEREZ CA, 1995, INT J RADIAT ONCOL, V32, P1275, DOI 10.1016/0360-3016(95)00220-S; PHILLIPS RA, 1966, RADIAT RES, V29, P413, DOI 10.2307/3572022; PIVER MS, 1987, GYNECOL ONCOL, V26, P71, DOI 10.1016/0090-8258(87)90072-2; RETTENMAIER MA, 1988, CANCER, V61, P1301, DOI 10.1002/1097-0142(19880401)61:7<1301::AID-CNCR2820610704>3.0.CO;2-U; ROBERTS WS, 1989, GYNECOL ONCOL, V34, P183, DOI 10.1016/0090-8258(89)90138-8; ROSE PG, 1994, SEMIN ONCOL, V21, P47; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; SINCLAIR WK, 1968, CANCER RES, V28, P198; SOUHAMI L, 1993, INT J RADIAT ONCOL, V27, P871, DOI 10.1016/0360-3016(93)90462-5; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; STEHMAN FB, 1988, AM J OBSTET GYNECOL, V159, P87, DOI 10.1016/0002-9378(88)90499-1; STEHMAN FB, 1993, J CLIN ONCOL, V11, P1523, DOI 10.1200/JCO.1993.11.8.1523; STEHMAN FB, 1991, CANCER, V67, P2776, DOI 10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L; Stehman FB, 1997, GYNECOL ONCOL, V66, P262, DOI 10.1006/gyno.1997.4761; WEISER EB, 1989, GYNECOL ONCOL, V33, P283, DOI 10.1016/0090-8258(89)90513-1; WONG LC, 1989, GYNECOL ONCOL, V35, P159, DOI 10.1016/0090-8258(89)90035-8; ZAMBOGLOU N, 1992, CANCER INVEST, V10, P349, DOI 10.3109/07357909209024794	64	1900	2012	3	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1144	1153		10.1056/NEJM199904153401502	http://dx.doi.org/10.1056/NEJM199904153401502			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202165				2022-12-28	WOS:000079687700002
J	Johansen, KL; Mulligan, K; Schambelan, M				Johansen, KL; Mulligan, K; Schambelan, M			Anabolic effects of nandrolone decanoate in patients receiving dialysis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN GROWTH-HORMONE; CHRONIC-RENAL-FAILURE; DEPENDENT DIABETES-MELLITUS; HEMODIALYSIS-PATIENTS; MAINTENANCE HEMODIALYSIS; CARDIOVASCULAR-DISEASE; SERUM-LIPOPROTEIN; BODY-COMPOSITION; CAPD PATIENTS; RISK FACTOR	Context Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated. Objective To assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients. Design Randomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997. Setting Hospital-based outpatient dialysis unit. Patients Twenty-nine patients undergoing dialysis for at least 3 months. Intervention Nandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months. Main Outcome Measures Weight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment. Results Lean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 {2.3} mg/dL]; P = .02) but not in the placebo group (-4.0 [177] mmol/L [0.04 {2.0} mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group. Conclusions Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Nephrol, San Francisco, CA USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Endocrinol, San Francisco, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Johansen, KL (corresponding author), San Francisco Vet Affairs Med Ctr, Nephrol Sect, Box 111J,4150 Clement St, San Francisco, CA 94121 USA.	johanse@itsa.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00083] Funding Source: Medline; NIDDK NIH HHS [DK-45833] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1971, EITS MANUAL PROFILE; [Anonymous], 1991, GUID EX TEST PRESCR; Avram MM, 1996, ADV PERIT D, V12, P266; Bartens W, 1996, PERITON DIALYSIS INT, V16, P27; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; BOTERO D, 1993, J PEDIATR-US, V123, P590, DOI 10.1016/S0022-3476(05)80959-X; BRADLEY JR, 1990, CLIN SCI, V79, P239, DOI 10.1042/cs0790239; Campbell A., 1976, QUALITY AM LIFE PERC, DOI DOI 10.7758/9781610441032; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; COLES GA, 1972, Q J MED, V41, P25; CRESSMAN MD, 1992, CIRCULATION, V86, P475, DOI 10.1161/01.CIR.86.2.475; GLAZER G, 1994, METABOLISM, V43, P204, DOI 10.1016/0026-0495(94)90246-1; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HAKIM RM, 1993, AM J KIDNEY DIS, V21, P125, DOI 10.1016/S0272-6386(12)81083-3; HENDLER ED, 1974, NEW ENGL J MED, V291, P1046, DOI 10.1056/NEJM197411142912002; HURLEY BF, 1984, JAMA-J AM MED ASSOC, V252, P507, DOI 10.1001/jama.252.4.507; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; IKIZLER TA, 1994, KIDNEY INT, V46, P1178, DOI 10.1038/ki.1994.382; KOLLIND M, 1987, HORM METAB RES, V19, P156, DOI 10.1055/s-2007-1011766; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; LAZARUS JM, 1993, AM J KIDNEY DIS, V21, P99, DOI 10.1016/S0272-6386(12)80731-1; LINDHOLM DD, 1973, T AM SOC ART INT ORG, V19, P475; Lippi G, 1997, SCAND J CLIN LAB INV, V57, P507, DOI 10.3109/00365519709084601; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MANSON JM, 1986, SURGERY, V100, P188; MOORE GE, 1993, MED SCI SPORT EXER, V25, P18, DOI 10.1249/00005768-199301000-00004; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; PAINTER P, 1986, NEPHRON, V42, P47, DOI 10.1159/000183632; PAINTER P, 1984, PERIT DIAL B S, V4, pS94; POLLOCK CA, 1990, AM J KIDNEY DIS, V16, P38, DOI 10.1016/S0272-6386(12)80783-9; SARGENT JA, 1983, KIDNEY INT S13, V23, pS19; SCHULMAN G, 1993, AM J KIDNEY DIS, V21, P527, DOI 10.1016/S0272-6386(12)80399-4; TAYEK JA, 1992, CLIN RES, V40, pA95; Teruel JL, 1997, AM J KIDNEY DIS, V29, P569, DOI 10.1016/S0272-6386(97)90340-1; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; United States Renal Data System, 1994, USRDS 1994 ANN DAT R; Woodrow G, 1996, NEPHROL DIAL TRANSPL, V11, P1613, DOI 10.1093/oxfordjournals.ndt.a027623; ZIEGLER TR, 1991, J AM SOC NEPHROL, V2, P1130	40	173	177	2	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1275	1281		10.1001/jama.281.14.1275	http://dx.doi.org/10.1001/jama.281.14.1275			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208142	Bronze			2022-12-28	WOS:000079628700031
J	O'Connor, S; Deeks, O; Hawton, K; Simkin, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C				O'Connor, S; Deeks, O; Hawton, K; Simkin, S; Keen, A; Altman, DG; Philo, G; Bulstrode, C			Effects of a drug overdose in a television drama on knowledge of specific dangers of self poisoning: population based surveys	BRITISH MEDICAL JOURNAL			English	Article									Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Orthopaed Surg, Oxford OX3 9DU, England; Univ Glasgow, Media Unit, Glasgow G12 8LF, Lanark, Scotland	University of Oxford; University of Oxford; University of Oxford; University of Glasgow	O'Connor, S (corresponding author), Barrow Hosp, Directorate Mental Hlth, United Bristol Healthcare Trust, Bristol BS19 3SG, Avon, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; Gunnell D., 1994, BMJ-BRIT MED J, V308, P1446, DOI DOI 10.1136/BMJ.308.6941.1446; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hawton K, 1999, BRIT MED J, V318, P972, DOI 10.1136/bmj.318.7189.972	4	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					978	979		10.1136/bmj.318.7189.978	http://dx.doi.org/10.1136/bmj.318.7189.978			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195968	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000079751500020
J	Oliver, WD; Kim, J; Liu, RC; Yamamoto, Y				Oliver, WD; Kim, J; Liu, RC; Yamamoto, Y			Hanbury Brown and Twiss-type experiment with electrons	SCIENCE			English	Article							QUANTUM SHOT-NOISE; CONDUCTORS; CONTACTS	Fermion anti-bunching was directly observed by measuring the cross-covariance of the current fluctuations of partitioned electrons. A quantum paint contact was used to inject single-mode electrons into a mesoscopic electron beam splitter device. The beam splitter output currents showed negative cross-covariance, indicating that the electrons arrived individually at the beam splitter and were randomly partitioned into two output channels. As the relative time delay between the outputs was changed, the observed ringing in the cross-covariance was consistent with the bandwidths used to monitor the fluctuations. The result demonstrates a fermion complement to the Hanbury Brown and Twiss experiment for photons.	Stanford Univ, ERATO, Quantum Fluctuat Project, Edward L Ginzton Lab, Stanford, CA 94305 USA; NTT Corp, Basic Res Labs, Atsugi, Kanagawa 24301, Japan	Stanford University; Nippon Telegraph & Telephone Corporation	Oliver, WD (corresponding author), Stanford Univ, ERATO, Quantum Fluctuat Project, Edward L Ginzton Lab, Stanford, CA 94305 USA.	woliver@stanford.edu	Yamamoto, Yoshihisa/A-2811-2012; Liu, Robert/B-2339-2015	Yamamoto, Yoshihisa/0000-0002-4150-6804; Liu, Robert/0000-0003-2450-8194				Blanter YM, 1997, PHYS REV B, V56, P2127, DOI 10.1103/PhysRevB.56.2127; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; BURGESS RE, 1959, DISCUSS FARADAY SOC, P151, DOI 10.1039/df9592800151; BUTTIKER M, 1990, PHYS REV LETT, V65, P2901, DOI 10.1103/PhysRevLett.65.2901; BUTTIKER M, 1991, PHYSICA B, V175, P199, DOI 10.1016/0921-4526(91)90713-O; BUTTIKER M, 1992, PHYS REV B, V46, P12458; Datta S., 1996, PHYS LOW DIM STRUCT, V96, P1; DEJONG MJM, 1994, PHYS REV B, V49, P16070, DOI 10.1103/PhysRevB.49.16070; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Gramespacher T, 1998, PHYS REV LETT, V81, P2763, DOI 10.1103/PhysRevLett.81.2763; HANBURYBROWN R, 1956, NATURE, V178, P1447; Henny M, 1999, SCIENCE, V284, P296, DOI 10.1126/science.284.5412.296; Imamoglu A, 1996, PHYS LETT A, V214, P193, DOI 10.1016/0375-9601(96)00175-2; Kim J, 1999, NATURE, V397, P500, DOI 10.1038/17295; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; KOASHI M, 1993, PHYS REV LETT, V71, P1164, DOI 10.1103/PhysRevLett.71.1164; Kumar A, 1996, PHYS REV LETT, V76, P2778, DOI 10.1103/PhysRevLett.76.2778; Liu RC, 1998, NATURE, V391, P263, DOI 10.1038/34611; MARTIN T, 1992, PHYS REV B, V45, P1742, DOI 10.1103/PhysRevB.45.1742; Purcell E. M., 1956, NATURE, V178, P1449; REBKA GA, 1957, NATURE, V180, P1035, DOI 10.1038/1801035a0; REZNIKOV M, 1995, PHYS REV LETT, V75, P3340, DOI 10.1103/PhysRevLett.75.3340; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; SILVERMAN MP, 1987, PHYS LETT A, V120, P442, DOI 10.1016/0375-9601(87)90106-X; vanLangen SA, 1997, PHYS REV B, V56, pR1680, DOI 10.1103/PhysRevB.56.R1680; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; WHARAM DA, 1988, J PHYS C SOLID STATE, V21, pL209, DOI 10.1088/0022-3719/21/8/002	28	318	319	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					299	301		10.1126/science.284.5412.299	http://dx.doi.org/10.1126/science.284.5412.299			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10195891				2022-12-28	WOS:000079636400037
J	Shaywitz, SE; Shaywitz, BA; Pugh, KR; Fulbright, RK; Skudlarski, P; Mencl, VE; Constable, RT; Naftolin, F; Palter, SF; Marchione, KE; Katz, L; Shankweiler, DP; Fletcher, JM; Lacadie, C; Keltz, M; Gore, JC				Shaywitz, SE; Shaywitz, BA; Pugh, KR; Fulbright, RK; Skudlarski, P; Mencl, VE; Constable, RT; Naftolin, F; Palter, SF; Marchione, KE; Katz, L; Shankweiler, DP; Fletcher, JM; Lacadie, C; Keltz, M; Gore, JC			Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; EPISODIC MEMORY; MENSTRUAL-CYCLE; ORGANIZATION; COMPONENT	Context Preclinical studies suggest that estrogen affects neural structure and function in mature animals; clinical studies are less conclusive with many, but not all, studies showing a positive influence of estrogen on verbal memory in postmenopausal women. Objective To investigate the effects of estrogen on brain activation patterns in postmenopausal women as they performed verbal and nonverbal working memory tasks. Design Randomized, double-blind, placebo-controlled, crossover trial from 1996 through 1998. Setting Community volunteers tested in a hospital setting. Patients Forty-six postmenopausal women aged 33 to 61 years (mean [SD] age, 50.8 [4.7] years). intervention Twenty-one-day treatment with conjugated equine estrogens, 1.25 mg/d, randomly crossed over with identical placebo and a 14-day washout between treatments. Main Outcome Measures Brain activation patterns measured using functional magnetic resonance imaging during tasks involving verbal and nonverbal working memory. Results Treatment with estrogen increased activation in the inferior parietal lobule during storage of verbal material and decreased activation in the inferior parietal lobule during storage of nonverbal material. Estrogen also increased activation in the right superior frontal gyrus during retrieval tasks, accompanied by greater left-hemisphere activation during encoding. The latter pattern represents a sharpening of the hemisphere encoding/retrieval asymmetry (HERA) effect. Estrogen did not affect actual performance of the verbal and nonverbal memory tasks. Conclusions Estrogen in a therapeutic dosage alters brain activation patterns in postmenopausal women in specific brain regions during the performance of the sorts of memory function that are called upon frequently during any given day. These results suggest that estrogen affects brain organization for memory in postmenopausal women.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Haskins Labs Inc, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06510 USA; Yale Univ, Dept Appl Phys, New Haven, CT 06510 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA	Yale University; Yale University; Yale University; Haskins Laboratories; Yale University; Yale University; Yale University; University of Texas System	Shaywitz, SE (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 3333, New Haven, CT 06510 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019; Constable, R. Todd/ABE-8038-2021	Constable, R. Todd/0000-0001-5661-9521	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD025802, P01HD021888] Funding Source: NIH RePORTER; NICHD NIH HHS [P50 HD25802, P01 HD21888] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barrett-Connor E, 1998, J AM GERIATR SOC, V46, P918, DOI 10.1111/j.1532-5415.1998.tb02732.x; Cabeza R, 1997, J NEUROSCI, V17, P391; Diano S, 1997, ENDOCRINOLOGY, V138, P778, DOI 10.1210/en.138.2.778; Fiez JA, 1996, J NEUROSCI, V16, P808; Finkelstein JS, 1998, JAMA-J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067; Fletcher PC, 1997, TRENDS NEUROSCI, V20, P213, DOI 10.1016/S0166-2236(96)01013-2; HAMPSON E, 1990, BRAIN COGNITION, V14, P26, DOI 10.1016/0278-2626(90)90058-V; Haskell SG, 1997, J CLIN EPIDEMIOL, V50, P1249, DOI 10.1016/S0895-4356(97)00169-8; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Jonides J, 1998, J NEUROSCI, V18, P5026; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; Manly BFJ, 1997, RANDOMIZATION BOOTST; McEwen BS, 1997, NEUROLOGY, V48, pS8, DOI 10.1212/WNL.48.5_Suppl_7.8S; ONeal MF, 1996, PSYCHONEUROENDOCRINO, V21, P51, DOI 10.1016/0306-4530(95)00032-1; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P497, DOI 10.1016/0306-4530(92)90008-U; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Pugh KR, 1996, BRAIN, V119, P1221, DOI 10.1093/brain/119.4.1221; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; Rice Madeline M., 1997, American Journal of Medicine, V103, p26S, DOI 10.1016/S0002-9343(97)00259-3; Schacter DL, 1996, NEUROREPORT, V7, P1165, DOI 10.1097/00001756-199604260-00014; Seifer DB, 1998, FERTIL STERIL, V69, P387; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Shaywitz SE, 1996, SCI AM, V275, P98, DOI 10.1038/scientificamerican1196-98; Sherwin BB, 1996, MENOPAUSE, V3, P97, DOI 10.1097/00042192-199603020-00007; Sherwin BB, 1997, NEUROLOGY, V48, pS21, DOI 10.1212/WNL.48.5_Suppl_7.21S; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; WAGNER RK, 1987, PSYCHOL BULL, V101, P192, DOI 10.1037/0033-2909.101.2.192; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	34	323	327	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1197	1202		10.1001/jama.281.13.1197	http://dx.doi.org/10.1001/jama.281.13.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199429				2022-12-28	WOS:000079464400034
J	Wotton, D; Lo, RS; Lee, S; Massague, J				Wotton, D; Lo, RS; Lee, S; Massague, J			A Smad transcriptional corepressor	CELL			English	Article							MAD-RELATED PROTEIN; TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR GENE; FAMILY MEDIATOR SMAD1; TATA-BINDING PROTEIN; GROWTH-FACTOR-BETA; HISTONE DEACETYLASE; SIGNALING PATHWAYS; NUCLEOSOMAL DNA; MOUSE EMBRYO	Following TGF beta receptor-mediated phosphorylation and association with Smad4, Smad2 moves into the nucleus, binds to target promoters in association with DNA-binding cofactors, and recruits coactivators such as p300/CBP to activate transcription. We identified the homeodomain protein TGIF as a Smad2-binding protein and a repressor of transcription. A TGF beta-activated Smad complex can recruit TGIF and histone deacetylases (HDACs) to a Smad target promoter, repressing transcription. Thus, upon entering the nucleus, a Smad2-Smad4 complex may interact with coactivators, forming a transcriptional activation complex, or with TGIF and HDACs, forming a transcriptional repressor complex. Formation of one of these two mutually exclusive complexes is determined by the relative levels of Smad corepressors and coactivators within the cell.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA.	j-massague@ski.mskcc.org		Wotton, David/0000-0002-4652-5350; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Whitman M, 1997, NATURE, V389, P549, DOI 10.1038/39202; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	73	466	487	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					29	39		10.1016/S0092-8674(00)80712-6	http://dx.doi.org/10.1016/S0092-8674(00)80712-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199400	Bronze			2022-12-28	WOS:000079843900006
J	Bayer, T				Bayer, T			Another piece of the Alzheimer's jigsaw - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Coll Med, Llandough Hosp, Dept Geriatr Med, Memory Team, Penarth CF6 2XX, S Glam, Wales	Cardiff University	Bayer, T (corresponding author), Univ Wales Coll Med, Llandough Hosp, Dept Geriatr Med, Memory Team, Penarth CF6 2XX, S Glam, Wales.		Bayer, Antony/H-4434-2019	Bayer, Antony/0000-0002-7514-248X					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					639	639						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10215360				2022-12-28	WOS:000079089200026
J	Teasdale, GM; Nicoll, JAR; Murray, G; Fiddes, M				Teasdale, GM; Nicoll, JAR; Murray, G; Fiddes, M			Association of apolipoprotein E polymorphism with outcome after head injury	LANCET			English	Article							AMYLOID PROTEIN DEPOSITION; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; CEREBRAL-ISCHEMIA; BETA-PROTEIN; BRAIN; SURVIVAL; NEURONS; APOE; RAT	Background Variation in outcome after head injury is not fully explained by known prognostic features. Polymorphism of the apolipoprotein E gene (APOE) influences neuropathological findings in patients who die from head injuries. More people who die from head injuries than non-head-injured controls have deposits of amyloid beta-protein in the cerebral cortex, with amyloid beta-protein deposits present predominantly in patients with the APOE epsilon 4 allele. We report a prospective clinical study to test the hypothesis that patients with APOE epsilon 4 have a worse clinical outcome 6 months after head injury than those without APOE epsilon 4. Methods We studied a prospectively recruited series of patients admitted alter a head injury to a neurosurgical unit (n=93). Assessment of severity of the initial injury was by means of the Glasgow Coma Score (GCS). Outcome 6 months after injury was assessed by means of the Glasgow Outcome Scale. APOE genotypes were determined from blood samples by standard methods. Findings Detailed information on outcome was available for 89 patients. 17 (57%) of 30 patients with APOE epsilon 4 had an unfavourable outcome (dead, vegetative state, or severe disability) compared with 16 (27%) of the 59 patients without APOE epsilon 4 (p=0.006). The association remained significant when adjustment was made to control for age, GCS, and computed tomography scan findings (p=0.024). Interpretation Our findings show a significant genetic association of APOE polymorphism with outcome after head injury supporting the hypothesis of a genetically determined influence. Patients with APOE epsilon 4 are more than twice as likely as those without APOE epsilon 4 to have an unfavourable outcome 6 months after head injury. Further studies are under way to confirm and further evaluate this association.	UNIV GLASGOW,DEPT NEUROSURG,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW,LANARK,SCOTLAND; UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Glasgow; University of Glasgow; University of Edinburgh			; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MARSHALL LF, 1991, J NEUROSURG, V75, pS59; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN MF, 1995, ANN THROAC SURG, V59, P136; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; TEASDALE G, 1979, ACTA NEUROCHIR WIE S, V38, P3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	26	534	548	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1069	1071		10.1016/S0140-6736(97)04318-3	http://dx.doi.org/10.1016/S0140-6736(97)04318-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213549				2022-12-28	WOS:A1997YA73400010
J	Zhang, JZ; Weidner, DJ				Zhang, JZ; Weidner, DJ			Thermal equation of state of aluminum-enriched silicate perovskite	SCIENCE			English	Article							EARTHS LOWER MANTLE; V-T EQUATION; MGSIO3 PEROVSKITE; CRYSTAL-CHEMISTRY; HIGH-PRESSURE; FERRIC IRON; TEMPERATURE; PHASE; STRATIFICATION; DISCONTINUITY	Inferences of the chemical homogeneity of Earth's mantle depend on comparing laboratory-derived equations of state of mantle phases with seismically determined properties of the material in situ, A uniform chemical composition of the entire mantle has been found to be consistent with measurements, to date, of these properties for the end-member MgSiO3 perovskite phase. New pressure-volume-temperature data for silicate perovskite containing 5 mole percent Al2O3 has yielded different values of the equation of state parameters, with the bulk modulus being significantly smaller at lower mantle conditions than for aluminum-free perovskite, thus requiring adjustments in other components to match seismic observations.	SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zhang, JZ (corresponding author), SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA.							Anderson DL, 1989, THEORY EARTH, P147; Andrault D, 1998, AM MINERAL, V83, P1045; FEI Y, 1996, MINERAL SPECTROSCOPY, P243; Fiquet G, 1998, PHYS EARTH PLANET IN, V105, P21, DOI 10.1016/S0031-9201(97)00077-0; Funamori N, 1996, J GEOPHYS RES-SOL EA, V101, P8257, DOI 10.1029/95JB03732; HAZEN RM, 1984, REV GEOPHYS, V22, P37, DOI 10.1029/RG022i001p00037; HAZEN RM, 1981, CARNEGIE I WASHINGTO, V80, P277; Hazen RM, 1982, COMP CRYSTAL CHEM TE, P228; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; JACKSON I, 1990, J GEOPHYS RES-SOLID, V95, P21671, DOI 10.1029/JB095iB13p21671; JEANLOZ R, 1986, J GEOPHYS RES-SOLID, V91, P4665, DOI 10.1029/JB091iB05p04665; KESSON SE, 1995, EARTH PLANET SC LETT, V134, P187, DOI 10.1016/0012-821X(95)00112-P; KNITTLE E, 1986, NATURE, V319, P214, DOI 10.1038/319214a0; Kreuer KD, 1997, SOLID STATE IONICS, V97, P1, DOI 10.1016/S0167-2738(97)00082-9; LIU L, 1975, GEOPHYS RES LETT, V2, P417, DOI 10.1029/GL002i010p00417; MAO HK, 1991, J GEOPHYS RES-SOLID, V96, P8069, DOI 10.1029/91JB00176; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; McCammon CA, 1998, PHYS CHEM MINER, V25, P292, DOI 10.1007/s002690050117; MCCAMMON CA, 1992, AM MINERAL, V77, P894; ONEILL B, 1994, J GEOPHYS RES-SOL EA, V99, P19901, DOI 10.1029/94JB01752; SAXENA SK, 1990, PHYS CHEM MINER, V17, P45, DOI 10.1007/BF00209225; STIXRUDE L, 1992, SCIENCE, V257, P1099, DOI 10.1126/science.257.5073.1099; UTSUMI W, 1995, GEOPHYS RES LETT, V22, P1005, DOI 10.1029/95GL00584; WANG YB, 1994, PHYS EARTH PLANET IN, V83, P13, DOI 10.1016/0031-9201(94)90109-0; Weidner DJ, 1998, J GEOPHYS RES-SOL EA, V103, P7431, DOI 10.1029/97JB03511; WEIDNER DJ, 1994, GEOPHYS RES LETT, V21, P753, DOI 10.1029/93GL03549; Weng K., 1981, CARNEGIE I WASHINGTO, V81, P273; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; ZHANG J, IN RPESS AM MINERAL; [No title captured]	30	113	116	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					782	784		10.1126/science.284.5415.782	http://dx.doi.org/10.1126/science.284.5415.782			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221905				2022-12-28	WOS:000080056200039
J	Brauninger, A; Hansmann, ML; Strickler, JG; Dummer, R; Burg, G; Rajewsky, K; Kuppers, R				Brauninger, A; Hansmann, ML; Strickler, JG; Dummer, R; Burg, G; Rajewsky, K; Kuppers, R			Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REED-STERNBERG CELLS; HISTOLOGICAL SECTIONS; GENE REARRANGEMENTS; CLONAL RELATIONSHIP; DERIVATION; ANTIGEN; LINEAGE; ORIGIN	Background Hodgkin's disease and non-Hodgkin's B-cell lymphoma occasionally occur in the same patient, The identification of a common precursor of the two types of lymphoma would show definitively that Reed-Sternberg cells originate from B cells. Methods We studied lymphomas from two patients, one with a composite lymphoma (classic Hodgkin's disease and a follicular lymphoma in the same lymph node) and the other with a T-cell-rich B-cell lymphoma that was followed by classic Hodgkin's disease. Single Reed-Sternberg cells and non-Hodgkin's lymphoma cells from frozen sections were micromanipulated. The rearranged immunoglobulin variable-region genes (V genes) of the heavy and light chains were amplified by the polymerase chain reaction from genomic DNA and sequenced. Results In both patients, the Reed-Sternberg cells were related clonally to the non-Hodgkin's lymphoma B cells. The V genes carried somatic mutations (a hallmark of germinal-center B cells and their descendants). In both patients, some somatic mutations were shared by the Reed-Sternberg and non-Hodgkin's lymphoma cells, whereas other somatic mutations were found exclusively in one or the other cell type. Conclusions In two patients with classic Hodgkin's disease and non-Hodgkin's B-cell lymphoma, we identified a common B-cell precursor, probably a germinal-center B cell, for both lymphomas. This finding suggests that the two types of lymphoma underwent both shared and distinct transforming events and provides proof of the B-cell derivation of Reed-Sternberg cells in classic Hodgkin's disease. (N Engl J Med 1999;340:1239-47.) (C) 1999, Massachusetts Medical Society.	Goethe Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany; Mayo Clin, Dept Pathol, Rochester, MN USA; Univ Zurich, Dept Dermatol, Zurich, Switzerland; Univ Cologne, Inst Genet, Cologne, Germany	Goethe University Frankfurt; Mayo Clinic; University of Zurich; University of Cologne	Kuppers, R (corresponding author), Univ Cologne Hosp, LFI E4 R706,Joseph Stelzmannstr 9, D-50931 Cologne, Germany.	rkuppers@mac.genetik.uni-koeln.de		Rajewsky, Klaus/0000-0002-6633-6370; Kuppers, Ralf/0000-0002-6691-7191				BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; Braeuninger A, 1997, P NATL ACAD SCI USA, V94, P14211; BRAUNINGER A, IN PRESS BLOOD; Brown RE, 1997, ANN CLIN LAB SCI, V27, P329; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; COTTER FE, 1990, BRIT J HAEMATOL, V75, P449, DOI 10.1111/j.1365-2141.1990.tb07780.x; deJong D, 1996, HISTOPATHOLOGY, V28, P15, DOI 10.1046/j.1365-2559.1996.265306.x; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HANSMANN ML, 1989, HUM PATHOL, V20, P1169, DOI 10.1016/S0046-8177(89)80007-3; HARRIS NL, 1994, BLOOD, V84, P1361; Irsch J, 1998, P NATL ACAD SCI USA, V95, P10117, DOI 10.1073/pnas.95.17.10117; JAFFE ES, 1994, ANN ONCOL, V5, pS7, DOI 10.1093/annonc/5.suppl_1.S7; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Kanzler H, 1996, BLOOD, V87, P3429, DOI 10.1182/blood.V87.8.3429.bloodjournal8783429; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; KIM H, 1993, AM J CLIN PATHOL, V99, P445, DOI 10.1093/ajcp/99.4.445; Klein U, 1998, IMMUNOL REV, V162, P261; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Kuppers R, 1997, WEIRS HDB EXPT IMMUN, P2061; Marafioti T, 1997, NEW ENGL J MED, V337, P453, DOI 10.1056/NEJM199708143370703; MASON DY, 1994, AM J SURG PATHOL, V18, P526, DOI 10.1097/00000478-199405000-00014; Ohno T, 1997, NEW ENGL J MED, V337, P459, DOI 10.1056/NEJM199708143370704; Ohno T, 1998, MODERN PATHOL, V11, P485; Oudejans JJ, 1997, J PATHOL, V181, P353, DOI 10.1002/(SICI)1096-9896(199704)181:4<353::AID-PATH782>3.0.CO;2-3; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; Pinkus GS, 1997, AM J PATHOL, V150, P543; SODERSTROM KO, 1994, LANCET, V343, P422, DOI 10.1016/S0140-6736(94)91260-2; Sorg UR, 1997, PATHOLOGY, V29, P294, DOI 10.1080/00313029700169125; Vockerodt M, 1998, BLOOD, V92, P2899, DOI 10.1182/blood.V92.8.2899.420k21_2899_2907; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312; Yoshinaga H, 1996, BRIT J HAEMATOL, V95, P380, DOI 10.1046/j.1365-2141.1996.d01-1914.x	33	204	211	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1239	1247		10.1056/NEJM199904223401604	http://dx.doi.org/10.1056/NEJM199904223401604			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210707	Bronze			2022-12-28	WOS:000079833800004
J	Hu, FB; Stampfer, MJ; Rimm, EB; Manson, JE; Ascherio, A; Colditz, GA; Rosner, BA; Spiegelman, D; Speizer, FE; Sacks, FR; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Rimm, EB; Manson, JE; Ascherio, A; Colditz, GA; Rosner, BA; Spiegelman, D; Speizer, FE; Sacks, FR; Hennekens, CH; Willett, WC			A prospective study of egg consumption and risk of cardiovascular disease in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; DIETARY-CHOLESTEROL; SERUM-CHOLESTEROL; HEALTH-PROFESSIONALS; HORMONAL RESPONSES; FATTY-ACIDS; LIPOPROTEIN; PLASMA; METAANALYSIS	Context Reduction in egg consumption has been widely recommended to lower blood cholesterol levels and prevent coronary heart disease (CHD), Epidemiologic studies on egg consumption and risk of CHD are sparse. Objective To examine the association between egg consumption and risk of CHD and stroke in men and women. Design and Setting Two prospective cohort studies, the Health Professionals Follow-up Study (1986-1994) and the Nurses' Health Study (1980-1994), Participants A total of 37 851 men aged 40 to 75 years at study outset and 80 082 women aged 34 to 59 years at study outset, free of cardiovascular disease, diabetes, hypercholesterolemia, or cancer. Main Outcome Measures Incident nonfatal myocardial infarction, fatal CHD, and stroke corresponding to daily egg consumption as determined by a food-frequency questionnaire. Results We documented 866 incident cases of CHD and 258 incident cases of stroke in men during 8 years of follow-up and 939 incident cases of CHD and 563 incident cases of stroke in women during 14 years of follow-up. After adjustment for age, smoking, and other potential CHD risk factors, we found no evidence of an overall significant association between egg consumption and risk of CHD or stroke in either men or women. The relative risks (RRs) of CHD across categories of intake were less than 1 per week (1.0), 1 per week (1.06), 2 to 4 per week (1.12), 5 to 6 per week (0.90), and greater than or equal to 1 per day (1.08) (P for trend = .75) for men; and less than 1 per week (1.0), 1 per week (0.82), 2 to 4 per week (0.99), 5 to 6 per week (0.95), and greater than or equal to 1 per day (0.82) (P for trend = .95) for women. In subgroup analyses, higher egg consumption appeared to be associated with increased risk of CHD only among diabetic subjects (RR of CHD comparing more than 1 egg per day with less than 1 egg per week among diabetic men, 2.02 [95% confidence interval, 1.05-3.87; P for trend = .04], and among diabetic women, 1.49 [0.88-2.52; P for trend = .008]). Conclusions These findings suggest that consumption of up to 1 egg per day is unlikely to have substantial overall impact on the risk of CHD or stroke among healthy men and women. The apparent increased risk of CHD associated with higher egg consumption among diabetic participants warrants further research.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA; Brigham & Womens Hosp, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Frank.hu@channing.harvard.edu	Hu, Frank/C-1919-2013; Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL034594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24074, HL35464, HL34594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, ARCH INTERN MED, V151, P1071, DOI 10.1001/archinte.151.6.1071; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAWBER TR, 1982, AM J CLIN NUTR, V36, P617, DOI 10.1093/ajcn/36.4.617; Esrey KL, 1996, J CLIN EPIDEMIOL, V49, P211, DOI 10.1016/0895-4356(95)00066-6; *FED AM SOC EXP BI, 1995, 3 FED AM SOC EXP BIO, V1; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FIELDING CJ, 1986, J LIPID RES, V27, P1052; FRASER GE, 1994, AM J CLIN NUTR, V59, p1117S, DOI 10.1093/ajcn/59.5.1117S; GABH Rose, 1982, WHO MONOGRAPH SERIES; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; GINSBERG HN, 1994, ARTERIOSCLER THROMB, V14, P576, DOI 10.1161/01.ATV.14.4.576; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; GRANFELDT Y, 1991, EUR J CLIN NUTR, V45, P489; HEGSTED DM, 1986, AM J CLIN NUTR, V44, P299, DOI 10.1093/ajcn/44.2.299; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; Holt SHA, 1997, AM J CLIN NUTR, V66, P1264, DOI 10.1093/ajcn/66.5.1264; HOPKINS PN, 1992, AM J CLIN NUTR, V55, P1060, DOI 10.1093/ajcn/55.6.1060; Howell WH, 1997, AM J CLIN NUTR, V65, P1747, DOI 10.1093/ajcn/65.6.1747; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; KEYS A, 1966, AM J CLIN NUTR, V19, P175; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; PACKARD CJ, 1983, J CLIN INVEST, V72, P45, DOI 10.1172/JCI110983; Pedersen TR, 1998, AM J CARDIOL, V81, P333, DOI 10.1016/S0002-9149(97)00904-1; Pelletier X, 1996, ANN NUTR METAB, V40, P109, DOI 10.1159/000177903; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROBERTS SL, 1981, AM J CLIN NUTR, V34, P2092, DOI 10.1093/ajcn/34.10.2092; SACKS FM, 1984, LANCET, V1, P647; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SCHNOHR P, 1994, J INTERN MED, V235, P249, DOI 10.1111/j.1365-2796.1994.tb01068.x; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; *USDA, 1989, AGR HDB USDA, V8; VENKATESAN S, 1995, BIOCHEM SOC T, V23, pS278, DOI 10.1042/bst023278s; VILLAUME C, 1986, DIABETES CARE, V9, P46, DOI 10.2337/diacare.9.1.46; VORSTER HH, 1992, AM J CLIN NUTR, V55, P400; Walker AE, 1981, STROKE S1, V12, P13; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	54	332	349	0	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1387	1394		10.1001/jama.281.15.1387	http://dx.doi.org/10.1001/jama.281.15.1387			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217054	Bronze			2022-12-28	WOS:000079701000028
J	Beecham, L				Beecham, L			Family doctors will now be in the driving seat	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205127				2022-12-28	WOS:000080140000081
J	Dobson, R				Dobson, R			First clinical performance indicators for Wales show wide variation	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1026	1026		10.1136/bmj.318.7190.1026	http://dx.doi.org/10.1136/bmj.318.7190.1026			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205087	Green Published			2022-12-28	WOS:000080140000008
J	Spitz, L				Spitz, L			Robert Bransby Zachary - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1079	1079		10.1136/bmj.318.7190.1079	http://dx.doi.org/10.1136/bmj.318.7190.1079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205126	Green Published			2022-12-28	WOS:000080140000066
J	Merfeld, DM; Zupan, L; Peterka, RJ				Merfeld, DM; Zupan, L; Peterka, RJ			Humans use internal models to estimate gravity and linear acceleration	NATURE			English	Article							SQUIRREL-MONKEY; VESTIBULOOCULAR REFLEX; SEMICIRCULAR CANALS; ECCENTRIC ROTATION; OCULAR RESPONSES; VIEWING DISTANCE; ROLL TILT; MOTION; ORIENTATION; INTEGRATION	Because sensory systems often provide ambiguous information, neural processes must exist to resolve these ambiguities. It is likely that similar neural processes are used by different sensory systems. For example, many tasks require neural processing to distinguish linear acceleration from gravity(1), but Einstein's equivalence principle states that all linear accelerometers must measure both linear acceleration and gravity. Here we investigate whether the brain uses internal models, defined as neural systems that mimic physical principles, to help estimate linear acceleration and gravity(2-4). Internal models may be used in motor control(5-7), sensorimotor integration(8-10) and sensory processing(11-14), but direct experimental evidence for such models is limited. To determine how humans process ambiguous gravity and linear acceleration cues, subjects were tilted after being rotated at a constant velocity about an Earth-vertical axis. We show that the eye movements evoked by this post-rotational tilt include a response component that compensates for the estimated Linear acceleration even when no actual linear acceleration occurs. These measured responses are consistent with our internal model predictions that the nervous system can develop a non-zero estimate of linear acceleration even when no true linear acceleration is present.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Portland, OR 97209 USA	Oregon Health & Science University	Merfeld, DM (corresponding author), Massachusetts Eye & Ear Infirm, Vestibular Physiol Lab, 243 Charles St, Boston, MA 02114 USA.	dan_merfeld@meei.harvard.edu						Angelaki DE, 1999, J NEUROSCI, V19, P316, DOI 10.1523/JNEUROSCI.19-01-00316.1999; Bell C, 1997, BRAIN BEHAV EVOLUT, V50, P17, DOI 10.1159/000113352; Benson A.J., 1974, VESTIBULAR SYSTEM 2, P281, DOI [10.1007/978-3-642-65920-1_6, DOI 10.1007/978-3-642-65920-1_6]; BENSON AJ, 1966, AEROSPACE MED, V37, P889; Darlot C, 1996, BIOL CYBERN, V75, P173, DOI 10.1007/s004220050285; DICHGANS J, 1972, SCIENCE, V178, P1217, DOI 10.1126/science.178.4066.1217; Droulez J, 1989, ATTENTION PERFORM, VXIII, P495; FETTER M, 1992, EXP BRAIN RES, V91, P121; GLASAUER S, 1992, ANN NY ACAD SCI, V656, P847, DOI 10.1111/j.1749-6632.1992.tb25272.x; GOLDBERG JM, 1971, J NEUROPHYSIOL, V34, P635, DOI 10.1152/jn.1971.34.4.635; GUEDRY E, 1974, HDB SENSORY PHYSL, P1; KUO AD, 1995, IEEE T BIO-MED ENG, V42, P87, DOI 10.1109/10.362914; Lewald J, 1998, EXP BRAIN RES, V121, P230, DOI 10.1007/s002210050456; Merfeld D M, 1993, J Vestib Res, V3, P141; MERFELD DM, 1995, EXP BRAIN RES, V106, P111; MERFELD DM, 1995, EXP BRAIN RES, V106, P123; MERFELD DM, 1995, ACTA OTO-LARYNGOL, P354; ORMSBY CC, 1977, MATH BIOSCI, V34, P1, DOI 10.1016/0025-5564(77)90032-3; PAIGE GD, 1991, J NEUROPHYSIOL, V65, P1170, DOI 10.1152/jn.1991.65.5.1170; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Rao RPN, 1997, NEURAL COMPUT, V9, P721, DOI 10.1162/neco.1997.9.4.721; SCHWARZ U, 1989, SCIENCE, V245, P1394, DOI 10.1126/science.2506641; SCHWARZ U, 1991, J NEUROPHYSIOL, V66, P851, DOI 10.1152/jn.1991.66.3.851; STOCKWELL CW, 1970, ACTA OTO-LARYNGOL, V70, P170, DOI 10.3109/00016487009181874; Wilson V.J., 1979, MAMMALIAN VESTIBULAR; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; YASUI S, 1975, SCIENCE, V190, P906, DOI 10.1126/science.1188373; Young L, 1984, HDB PHYSL NERVOUS SY, P1023	28	346	353	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					615	618		10.1038/19303	http://dx.doi.org/10.1038/19303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217143				2022-12-28	WOS:000079754700056
J	Macfarlane, GT; Cummings, JH				Macfarlane, GT; Cummings, JH			Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?	BRITISH MEDICAL JOURNAL			English	Article							LACTOBACILLUS-ACIDOPHILUS; BIFIDOBACTERIUM-LONGUM; DIARRHEA; CELLS; STRAINS; MUCOSA; GROWTH; FLORA		MRC, Dunn Clin Nutr Ctr, Cambridge CB2 2DH, England		Macfarlane, GT (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Cummings, John/AAC-2007-2019; Cummings, John H/H-3538-2011					ARONSSON B, 1987, EUR J CLIN MICROBIOL, V6, P352, DOI 10.1007/BF02017639; BERNET MF, 1994, GUT, V35, P483, DOI 10.1136/gut.35.4.483; BERNET MF, 1993, APPL ENVIRON MICROB, V59, P4121, DOI 10.1128/AEM.59.12.4121-4128.1993; BLACK FT, 1989, TRAVEL MED, V1, P333; Buddington RK, 1996, AM J CLIN NUTR, V63, P709, DOI 10.1093/ajcn/63.5.709; BULLEN CL, 1971, BRIT MED J, V3, P338, DOI 10.1136/bmj.3.5770.338; Challa A, 1997, CARCINOGENESIS, V18, P517, DOI 10.1093/carcin/18.3.517; CHRISTL SU, 1992, GUT, V33, P1234, DOI 10.1136/gut.33.9.1234; CLEMENTS ML, 1981, ANTIMICROB AGENTS CH, V20, P104, DOI 10.1128/AAC.20.1.104; DEGUCHI Y, 1985, AGR BIOL CHEM TOKYO, V49, P13, DOI 10.1080/00021369.1985.10866683; DENCAMP HJM, 1984, INFECT IMMUN, V47, P332; DESIMONE C, 1992, IMMUNOPHARM IMMUNOT, V14, P331, DOI 10.3109/08923979209009228; Famularo G, 1997, PROBIOTICS THERAPEUT, P133; FULLER R, 1989, J APPL BACTERIOL, V66, P365; GIBSON GR, 1994, J APPL BACTERIOL, V77, P412, DOI 10.1111/j.1365-2672.1994.tb03443.x; GIBSON GR, 1995, GASTROENTEROLOGY, V108, P975, DOI 10.1016/0016-5085(95)90192-2; Gibson GR, 1997, PROBIOTICS THERAPEUT, P10; GORBACH SL, 1987, LANCET, V2, P1519; GOTZ V, 1979, AM J HOSP PHARM, V36, P754, DOI 10.1093/ajhp/36.6.754; HATA D, 1988, PEDIATR INFECT DIS J, V7, P669, DOI 10.1097/00006454-198809000-00018; HAYAKAWA K, 1990, Microbial Ecology in Health and Disease, V3, P293; Hidaka H., 1986, Bifidobacteria and Microflora, V5, P37; Hopkins MJ, 1998, J APPL MICROBIOL, V85, P381; ITO M, 1990, Microbial Ecology in Health and Disease, V3, P285; JOHANSSON ML, 1993, APPL ENVIRON MICROB, V59, P15, DOI 10.1128/AEM.59.1.15-20.1993; KLEEMAN EG, 1982, J DAIRY SCI, V65, P2063, DOI 10.3168/jds.S0022-0302(82)82462-4; KOLLARITSCH H, 1990, P 2 INT C TOUR HLTH, P74; KOO M, 1991, NUTR REV, V51, P137; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matsumura Kazuki, 1992, Animal Science and Technology, V63, P1157; McBain AJ, 1997, SCAND J GASTROENTERO, V32, P32, DOI 10.1080/00365521.1997.11720715; PERDIGON G, 1986, INFECT IMMUN, V53, P404, DOI 10.1128/IAI.53.2.404-410.1986; PEREYRA BS, 1993, NUTR RES, V13, P1127, DOI 10.1016/S0271-5317(05)80737-7; REDDY BS, 1993, CANCER RES, V53, P3914; ROWLAND IR, 1975, APPL MICROBIOL, V29, P7, DOI 10.1108/09600039910253850; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; SCHIFFRIN EJ, 1997, AM J CLIN NUTR S, V66, pS15; Sekine K., 1994, Bifidobacteria and Microflora, V13, P65; SILVA M, 1987, ANTIMICROB AGENTS CH, V31, P1231, DOI 10.1128/AAC.31.8.1231; STANDIFORD TJ, 1994, INFECT IMMUN, V62, P119, DOI 10.1128/IAI.62.1.119-125.1994; STONEDORSHOW T, 1987, AM J CLIN NUTR, V46, P61, DOI 10.1093/ajcn/46.1.61; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; SUSSMAN JI, 1986, REV INFECT DIS, V8, P771; TOJO M, 1987, Acta Paediatrica Japonica, V29, P160; Yamazaki S., 1982, BIFIDOBACTERIA MICRO, V1, P55, DOI [10.12938/bifidus1982.1.1_55, DOI 10.12938/BIFIDUS1982.1.1_55]; YASUI H, 1991, J DAIRY SCI, V74, P1187, DOI 10.3168/jds.S0022-0302(91)78272-6; YASUI H, 1992, Microbial Ecology in Health and Disease, V5, P155; ZANG XB, 1990, J DAIRY SCI, V73, P2702	48	188	205	5	41	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					999	1003		10.1136/bmj.318.7189.999	http://dx.doi.org/10.1136/bmj.318.7189.999			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195977	Green Published			2022-12-28	WOS:000079751500028
J	Ostroff, SM				Ostroff, SM			Continuing challenge of pneumococcal disease	LANCET			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE		Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Ostroff, SM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.							Fenoll A, 1998, J CLIN MICROBIOL, V36, P3447, DOI 10.1128/JCM.36.12.3447-3454.1998; Huebner R E, 1998, Int J Infect Dis, V3, P18, DOI 10.1016/S1201-9712(98)90090-X; Monto AS, 1999, CLIN INFECT DIS, V28, P200, DOI 10.1086/515113; Shann F, 1999, CLIN INFECT DIS, V28, P189, DOI 10.1086/515107; SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007; Song JH, 1997, CLIN INFECT DIS, V25, P747, DOI 10.1086/516945; *WHO, 1995, WHOARIRES901	7	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1201	1202		10.1016/S0140-6736(99)90051-X	http://dx.doi.org/10.1016/S0140-6736(99)90051-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217075				2022-12-28	WOS:000079744100003
J	Ramirez, AJ; Westcombe, AM; Burgess, CC; Sutton, S; Littlejohns, P; Richards, MA				Ramirez, AJ; Westcombe, AM; Burgess, CC; Sutton, S; Littlejohns, P; Richards, MA			Factors predicting delayed presentation of symptomatic breast cancer: a systematic review	LANCET			English	Review							SEEKING TREATMENT; SURVIVAL; WOMEN; STAGE	Background Delayed presentation of symptomatic breast cancer is associated with lower survival. Understanding of the factors that influence delay is important for the development of strategies to shorten delays. We did a systematic review to assess the quality and strength of evidence on risk factors for delays by patients and providers. Methods We generated hypotheses about the relation between each putative risk factor and delay, against which we tested studies. We did searches to identify papers containing original data related to risk factors for delays by patients (n=86) and providers (n=28). We critically appraised the papers for inclusion in the review according to predefined criteria. The small number of studies of adequate quality did not allow formal meta-analysis. We therefore assigned strength of evidence according to a combination of the number and size of studies supporting, not supporting, or refuting the hypotheses. Findings Most studies were deemed to be of poor quality and were excluded. Among 23 studies of adequate quality, however, there was strong evidence for an association between older age and delay by patients, and strong evidence that marital status was unrelated to delays by patients. Younger age and presentation with a breast symptom other than a lump were strong risk factors for delays by providers. Moderate evidence was shown for several other factors. Interpretation The strength of the current evidence is inadequate to inform the development of specific strategies to shorten delays by patients or providers. Clarification of the findings of this review through a major programme of primary research is urgently required.	St Thomas Hosp, Guys Kings & St Thomass Sch Med, Imperial Canc Res Fund, Psychosocial Oncol Grp, London SE1 7EH, England; UCL, Hlth Behav Unit, London, England; Univ London St Georges Hosp, Sch Med, Hlth Care Evaluat Unit, London, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; St Georges University London	Ramirez, AJ (corresponding author), St Thomas Hosp, Guys Kings & St Thomass Sch Med, Imperial Canc Res Fund, Psychosocial Oncol Grp, Riddell House, London SE1 7EH, England.			Sutton, Stephen/0000-0003-1610-0404				Adam S A, 1980, Community Med, V2, P195, DOI 10.1007/BF02549023; AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; Burgess CC, 1998, BRIT J CANCER, V77, P1343, DOI 10.1038/bjc.1998.224; BYWATERS JL, 1976, LANCET, V1, P849; CAMERON A, 1968, CANCER, V21, P1121, DOI 10.1002/1097-0142(196806)21:6<1121::AID-CNCR2820210612>3.0.CO;2-L; Caplan Lee S., 1992, Public Health Reviews, V20, P187; CAPLAN LS, 1995, AM J EPIDEMIOL, V142, P804, DOI 10.1093/oxfordjournals.aje.a117719; COATES RJ, 1992, JNCI-J NATL CANCER I, V84, P938, DOI 10.1093/jnci/84.12.938; DEEKS J, 1996, 4 CRD U YORK; Delgado D J, 1995, P R Health Sci J, V14, P103; DIXON JM, 1995, ABC BREAST DIS, P6; ELZAWAWY A, 1991, INT ATOMIC ENERGY AU, V614, P35; FACIONE NC, 1993, SOC SCI MED, V36, P1521, DOI 10.1016/0277-9536(93)90340-A; Finley M L, 1983, Prog Clin Biol Res, V130, P351; FISHER S, 1967, ARCH GEN PSYCHIAT, V16, P676; FUNCH D, 1982, ISSUES CANC SCREENIN, P212; FUNCH DP, 1984, J PSYCHOSOC ONCOL, V2, P31; GOULDMARTIN K, 1982, PREV MED, V11, P429, DOI 10.1016/0091-7435(82)90046-9; GREER S, 1974, P ROY SOC MED, V67, P470, DOI 10.1177/00359157740676P121; HUGHES JE, 1986, BRIT J SURG, V73, P997, DOI 10.1002/bjs.1800731217; HUGULEY CM, 1988, CANCER, V62, P1389, DOI 10.1002/1097-0142(19881001)62:7<1389::AID-CNCR2820620725>3.0.CO;2-0; MACARTHUR C, 1981, LANCET, V1, P601; MENON M, 1992, AUST NZ J SURG, V62, P364, DOI 10.1111/j.1445-2197.1992.tb07204.x; Mor V, 1990, J Community Health, V15, P253, DOI 10.1007/BF01350291; NEALE AV, 1986, SOC SCI MED, V23, P305, DOI 10.1016/0277-9536(86)90352-7; Nichols S, 1981, Community Med, V3, P217, DOI 10.1007/BF02549119; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; Richards MA, 1999, LANCET, V353, P1119, DOI 10.1016/S0140-6736(99)02143-1; RICHARDS MA, 1999, IN PRESS SYSTEMATIC; ROSSI S, 1990, TUMORI, V76, P559, DOI 10.1177/030089169007600609; SAMET JM, 1988, J NATL CANCER I, V80, P432, DOI 10.1093/jnci/80.6.432; SCHOTTENFELD D, 1971, GERIATRICS, V26, P121; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WORDEN JW, 1975, J PSYCHOSOM RES, V19, P69, DOI 10.1016/0022-3999(75)90052-5	34	319	332	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1127	1131		10.1016/S0140-6736(99)02142-X	http://dx.doi.org/10.1016/S0140-6736(99)02142-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209975				2022-12-28	WOS:000079858400009
J	Rosendaal, FR				Rosendaal, FR			Venous thrombosis: a multicausal disease	LANCET			English	Article; Proceedings Paper	International Congress of Hemostasis and Thrombosis	JUN   08, 1997	FLORENCE, ITALY				PROTEIN-C-DEFICIENCY; FACTOR-V LEIDEN; DEEP-VEIN THROMBOSIS; POOR ANTICOAGULANT RESPONSE; ANTITHROMBIN-III-DEFICIENCY; VON-WILLEBRAND-FACTOR; ORAL-CONTRACEPTIVES; FACTOR-VIII; RISK-FACTORS; PROTHROMBIN-GENE	The risk factors for venous thrombosis differ from those for arterial vascular disease. During the past 5 years, knowledge about the aetiology of venous thrombosis has advanced with the discovery of several factors that contribute to the incidence of thrombosis, particularly the role of coagulation abnormalities. These abnormalities are common in the general population and therefore will be present simultaneously in some individuals. The resultant gene-gene and gene-environment interactions between risk factors are the key to the understanding of why a certain person develops thrombosis at a specific point in time.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Hemostasis & Thrombosis Res Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rosendaal, FR (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, POB 9600, NL-2300 RC Leiden, Netherlands.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; ANDREW M, 1994, BLOOD, V83, P1251, DOI 10.1182/blood.V83.5.1251.1251; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P721; BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BERTINA RM, 1995, THROMB HAEMOSTASIS, V74, P449; BIENVENU T, 1991, PRESSE MED, V20, P985; Bloemenkamp KWM, 1998, THROMB HAEMOSTASIS, V80, P382, DOI 10.1055/s-0037-1615216; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V50, P350; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P423, DOI 10.1016/S0033-0620(94)80051-0; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; de Bruijn SFTM, 1998, BRIT MED J, V316, P589, DOI 10.1136/bmj.316.7131.589; den Heijer M, 1998, THROMB HAEMOSTASIS, V80, P874; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DESTEFANO V, 1995, THROMB HAEMOSTASIS, V74, P793; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FERMO I, 1995, ANN INTERN MED, V123, P747, DOI 10.7326/0003-4819-123-10-199511150-00002; FREIDERICH PW, 1996, ANN INTERN MED, V125, P955; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HAKTEN M, 1989, THROMBOSIS HAEMORRHA, P177; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HELLGREN M, 1982, GYNECOL OBSTET INVES, V14, P127, DOI 10.1159/000299460; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; JICK H, 1969, LANCET, V1, P539; Kamphuisen PW, 1998, THROMB HAEMOSTASIS, V79, P323; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Kyrle PA, 1998, ARTERIOSCL THROM VAS, V18, P1287, DOI 10.1161/01.ATV.18.8.1287; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Lensen RPM, 1996, BLOOD, V88, P4205, DOI 10.1182/blood.V88.11.4205.bloodjournal88114205; Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; Mansvelt EPG, 1998, THROMB HAEMOSTASIS, V80, P561; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; McColl MD, 1997, THROMB HAEMOSTASIS, V78, P1183; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; NORDLING CO, 1953, BRIT J CANCER, V7, P68, DOI 10.1038/bjc.1953.8; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; NUSS R, 1995, PEDIATRICS, V96, P291; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P548; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; Rintelen C, 1996, BRIT J HAEMATOL, V93, P487, DOI 10.1046/j.1365-2141.1996.5712013.x; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; Rosendaal FR, 1997, SEMIN HEMATOL, V34, P171; Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x; SCHARRER I, 1987, THROMB HAEMOSTASIS, V58, P72; SCHWARZ HP, 1984, BLOOD, V64, P1297; SIEMIATYCKI J, 1981, INT J EPIDEMIOL, V10, P383, DOI 10.1093/ije/10.4.383; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P883; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405; TAIT RC, 1995, THROMB HAEMOSTASIS, V73, P87; TAIT RC, 1994, BRIT J HAEMATOL, V87, P106, DOI 10.1111/j.1365-2141.1994.tb04878.x; Thomas D, 1994, HAEMOSTASIS THROMBOS, P1335; TSUDA S, 1991, THROMB HAEMOSTASIS, V65, P647; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Virchow RLK., 1856, GESAMMELTE ABH; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	76	1145	1186	1	45	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1167	1173		10.1016/S0140-6736(98)10266-0	http://dx.doi.org/10.1016/S0140-6736(98)10266-0			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209995	Green Published			2022-12-28	WOS:000079858400046
J	Sainsbury, R; Johnston, C; Haward, B				Sainsbury, R; Johnston, C; Haward, B			Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis	LANCET			English	Article								Background From April 1, 1999, family physicians are required to refer all patients who have suspected breast cancer in the UK urgently to hospital, to be seen within 14 days of referral. We investigated whether delays by providers in routine practice for diagnosis influence survival. Methods We did a retrospective analysis of 36 222 patients with breast cancer listed in the Yorkshire Cancer Registry. Data on delay after family-physician referral. hospital visit, and start of treatment were available, as weil as on tumour grade and stage of presentation. Results There was no evidence that provider delays of longer than 90 days adversely influenced survival. The time from family-physician referral to first hospital visit changed little (median 10 vs 13 days) from 1976 to 1995, whereas time from first visit to first treatment doubted (7 vs 13 days). More than 8% of patients younger than 50 years delayed longer than 90 days, compared with 3% of patients older than 50 years (p<0.001). 48% of younger patients had their first treatment within 30 days compared with 64% of those older than 50 (p<0.001). The survival for 5708 patients diagnosed in 1986-90 selected for survival analysis was 63% at 5 years, and 51% at 8 years. Patients who presented early and were treated in less than 30 days had significantly worse outcomes (p<0.001). Interpretation Delays by providers in months or more do not seem to be associated with decreased survival in patients presenting with breast cancer. The drive for all women with possible breast cancer to be seen within 14 days will divert resources from other services and is not supported by this study.	Huddersfield Royal Infirm, Dept Surg, Huddersfield HD3 3EA, W Yorkshire, England; NYCRIS, Leeds, W Yorkshire, England		Sainsbury, R (corresponding author), Huddersfield Royal Infirm, Dept Surg, Huddersfield HD3 3EA, W Yorkshire, England.							*BRIT ASS SURG ONC, 1995, EUR J SURG ONCOL SA, V21, P1; *BRIT BREAST GROUP, 1994, PROV BREAST SERV UK; *CLIN OUTC GROUP C, 1996, IMPR OUTC BREAST CAN; Physician Insurers Association of America, 1995, BREAST CANC STUD; Richards MA, 1999, LANCET, V353, P1119, DOI 10.1016/S0140-6736(99)02143-1; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S	8	152	154	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1132	1135						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209976				2022-12-28	WOS:000079858400010
J	Ban, C; Junop, M; Yang, W				Ban, C; Junop, M; Yang, W			Transformation of MutL by ATP binding and hydrolysis: A switch in DNA mismatch repair	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; HSP90 MOLECULAR CHAPERONE; N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY; NUCLEOTIDE-BINDING; IN-VIVO	The MutL DNA mismatch repair protein has recently been shown to be an ATPase and to belong to an emerging ATPase superfamily that includes DNA topoisomerase II and Hsp90. We report here the crystal structures of a 40 kDa ATPase fragment of E. coli MutL (LN40) complexed with a substrate analog, ADPnP, and with product ADP. More than 60 residues that are disordered in the apoprotein structure become ordered and contribute to both ADPnP binding and dimerization of LN40. Hydrolysis of ATP, signified by subsequent release of the gamma-phosphate, releases two key loops and leads to dissociation of the LN40 dimer. Dimerization of the LN40 region is required for and is the rate-limiting step in ATP hydrolysis by Mutt. The ATPase activity of MutL is stimulated by DNA and likely acts as a switch to coordinate DNA mismatch repair.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Yang, Wei/D-4926-2011; Yang, Wei/ABB-4785-2020; Ban, Changill/F-5426-2013; Junop, Murray S/E-4160-2015	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Junop, Murray S/0000-0001-6676-5717				ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FENG G, 1995, BIOTECHNIQUES, V19, P956; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PATA JD, 1995, RNA, V1, P466; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHCHERBAKOVA P, 1999, IN PRESS MOL CELL BI; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILLIAMSON MS, 1985, GENETICS, V110, P609; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	42	329	336	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	1999	97	1					85	97		10.1016/S0092-8674(00)80717-5	http://dx.doi.org/10.1016/S0092-8674(00)80717-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199405	Bronze			2022-12-28	WOS:000079843900011
J	Horton, R				Horton, R			NICE: a step forward in the quality of NHS care	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; Ramsay S, 1999, LANCET, V353, P987, DOI 10.1016/S0140-6736(99)00049-5; Webster C., 1998, NATL HLTH SERVICE PO	4	14	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	1999	353	9158					1028	1029		10.1016/S0140-6736(99)00098-7	http://dx.doi.org/10.1016/S0140-6736(99)00098-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199343				2022-12-28	WOS:000079614000002
J	Nielsen, C; Mazzone, P				Nielsen, C; Mazzone, P			Muscle pain after exercise	LANCET			English	Article							RENAL-FAILURE; RHABDOMYOLYSIS		Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Nielsen, C (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Mazzone, Peter/AAW-5401-2021	Mazzone, Peter/0000-0003-2121-0595				Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; COPELAND PM, 1994, PSYCHOTHER PSYCHOSOM, V62, P200, DOI 10.1159/000288923; KNOCHEL JP, 1972, J CLIN INVEST, V51, P1750, DOI 10.1172/JCI106976; SINGHAL PC, 1991, MINER ELECTROL METAB, V17, P335; Zager RA, 1996, KIDNEY INT, V49, P314, DOI 10.1038/ki.1996.48	5	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1062	1062		10.1016/S0140-6736(98)11354-5	http://dx.doi.org/10.1016/S0140-6736(98)11354-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199355				2022-12-28	WOS:000079614000014
J	Engelkamp, H; Middelbeek, S; Nolte, RJM				Engelkamp, H; Middelbeek, S; Nolte, RJM			Self-assembly of disk-shaped molecules to coiled-coil aggregates with tunable helicity	SCIENCE			English	Article								A disk-shaped molecule with chiral tails is shown to form Long fibers of molecular diameter and micrometer length by self-assembly in chloroform. The molecules are derived from crown ethers and contain a phthalocyanine ring. In the fibers, they have a clockwise, staggered orientation that Leads to an overall right-handed helical structure. These structures, in turn, self-assemble to form coiled-coil aggregates with left-handed helicity. Addition of potassium ions to the fibers leaves their structure intact but blocks the transfer of the chirality from the tails to the cores, leading to loss of the helicity of the fibers. These tunable chiral materials have potential in optoelectronic applications and as components in sensor devices.	Catholic Univ Nijmegen, Dept Organ Chem, NSR Ctr, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Nolte, RJM (corresponding author), Catholic Univ Nijmegen, Dept Organ Chem, NSR Ctr, Toernooiveld, NL-6525 ED Nijmegen, Netherlands.		Nolte, Roeland/C-9930-2013; Engelkamp, Hans/A-8933-2012	Nolte, Roeland/0000-0002-5612-7815; Engelkamp, Hans/0000-0001-9920-0536				[Anonymous], 1989, PHTHALOCYANINES PROP; CASERI W, 1988, MAKROMOL CHEM-RAPID, V9, P651; Engelkamp H, 1998, CHEM COMMUN, P979, DOI 10.1039/a801246f; Engelkamp H, UNPUB; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; FRANKLIN RE, 1955, NATURE, V175, P379, DOI 10.1038/175379a0; FYLES TM, 1996, COMPREHENSIVE SUPRAM, V10, pCH3; Goldhaber-Gordon D, 1997, P IEEE, V85, P521, DOI 10.1109/5.573739; HARADA N, 1983, CIRCULAR DICHROIC SP, P6; LOKEY RS, 1995, NATURE, V375, P303; PEDERSEN CJ, 1967, J AM CHEM SOC, V89, P7017, DOI 10.1021/ja01002a035; SIELCKEN OE, 1987, J AM CHEM SOC, V109, P4261, DOI 10.1021/ja00248a021; VANDERPOL JF, 1989, LIQ CRYST, V6, P577, DOI 10.1080/02678298908034177; VANNOSTRUM CF, 1995, J AM CHEM SOC, V117, P9957, DOI 10.1021/ja00145a004	14	694	700	9	234	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					785	788		10.1126/science.284.5415.785	http://dx.doi.org/10.1126/science.284.5415.785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	192AW	10221906				2022-12-28	WOS:000080056200040
J	Fox, T				Fox, T			Patients sometimes behave like our Snoopy	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1131	1131		10.1136/bmj.318.7191.1131	http://dx.doi.org/10.1136/bmj.318.7191.1131			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213733	Green Published			2022-12-28	WOS:000080166000037
J	Ussher, BB				Ussher, BB			Give a remedy a thorough trial	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1121	1121						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213727	Green Published			2022-12-28	WOS:000080166000029
J	de Heinzelin, J; Clark, JD; White, T; Hart, W; Renne, P; WoldeGabriel, G; Beyene, Y; Vrba, E				de Heinzelin, J; Clark, JD; White, T; Hart, W; Renne, P; WoldeGabriel, G; Beyene, Y; Vrba, E			Environment and behavior of 2.5-million-year-old Bouri hominids	SCIENCE			English	Article							MIDDLE-AWASH VALLEY; OLDUVAI GORGE; LONG BONES; ETHIOPIA; PERCUSSION; TANZANIA; AGES	The Hata Member of the Bouri Formation is defined for Pliocene sedimentary outcrops in the Middle; Awash Valley, Ethiopia. The Hata Member is dated to 2.5 million years ago and has produced a new species of Australopithecus and hominid postcranial remains not currently assigned to species. Spatially associated zooarchaeological remains show that hominids acquired meat and marrow by 2.5 million years ago and that they are the near contemporary of Oldowan artifacts at nearby Cona. The combined evidence suggests that behavioral changes associated with Lithic technology and enhanced carnivory may have been coincident with the emergence of the Homo clade from Australopithecus afarensis in eastern Africa.	Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Anthropol, Berkeley, CA 94720 USA; Inst Royal Sci Nat Belgique, B-1000 Brussels, Belgium; Miami Univ, Dept Geol, Oxford, OH 45056 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Minist Informat & Culture, Dept Anthropol & Archaeol, Addis Ababa, Ethiopia; Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University System of Ohio; Miami University; Berkeley Geochronolgy Center; United States Department of Energy (DOE); Los Alamos National Laboratory; Yale University	White, T (corresponding author), Univ Calif Berkeley, Museum Vertebrate Zool, Lab Human Evolutionary Studies, Berkeley, CA 94720 USA.			Renne, Paul/0000-0003-1769-5235				ASFAW B, 1991, J HUM EVOL, V21, P137, DOI 10.1016/0047-2484(91)90004-F; ASFAW B, 1999, SCIENCE, V281, pR30; Binford L.R., 1981, BONES ANCIENT MEN MO; BLUMENSCHINE RJ, 1995, J HUM EVOL, V29, P21, DOI 10.1006/jhev.1995.1046; BLUMENSCHINE RJ, 1991, J HUM EVOL, V21, P451, DOI 10.1016/0047-2484(91)90095-D; Brain C. K, 1993, TRANSVAAL MUSEUM MON, V8; CAPALDO SD, 1994, AM ANTIQUITY, V59, P724, DOI 10.2307/282345; CLARK JD, 1994, SCIENCE, V264, P1907, DOI 10.1126/science.8009220; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; Hayward NJ, 1996, TECTONICS, V15, P244, DOI 10.1029/95TC02292; HILGEN FJ, 1991, EARTH PLANET SC LETT, V107, P249; HOWELL FC, 1987, J HUM EVOL, V16, P665; Isaac G.L., 1997, KOOBI FORA RES PROJE, V5; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; RENNE PR, IN PRESS GEOL SOC AM; Semaw S, 1997, NATURE, V385, P333, DOI 10.1038/385333a0; White T.D., 1992, PREHISTORIC CANNIBAL	18	324	330	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					625	629						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	190FH	10213682				2022-12-28	WOS:000079951100040
J	Newman, A; Stein, S; Weber, J; Engeln, J; Mao, A; Dixon, T				Newman, A; Stein, S; Weber, J; Engeln, J; Mao, A; Dixon, T			Slow deformation and lower seismic hazard at the New Madrid seismic zone	SCIENCE			English	Article							INTRAPLATE STRAIN ACCUMULATION; SPACE GEODESY; UNITED-STATES; EARTHQUAKES; STRESS; PLATE; CALIFORNIA; REGIONS; FAULT; GPS	Global Positioning System (GPS) measurements across the New Madrid seismic zone (NMSZ) in the central United States show little, if any, motion. These data are consistent with platewide continuous GPS data away from the NMSZ, which show no motion within uncertainties, Both these data and the frequency-magnitude relation for seismicity imply that had the Largest shocks in the series of earthquakes that occurred in 1811 and 1812 been magnitude 8, their recurrence interval should well exceed 2500 yea rs, Longer than has been assumed. Alternatively, the Largest 1811 and 1812 earthquakes and those in the paleoseismic record may have been much smaller than typically assumed. Hence, the hazard posed by great earthquakes in the NMSZ appears to be overestimated.	Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Grand Valley State Univ, Dept Geol, Allendale, MI 49401 USA; Univ Missouri, Dept Geol Sci, Columbia, MO 65211 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA	Northwestern University; Grand Valley State University; University of Missouri System; University of Missouri Columbia; University of Miami	Stein, S (corresponding author), Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA.		Newman, Andrew V/E-7682-2012	Newman, Andrew V/0000-0001-7414-1197				BRAILE LW, 1986, TECTONOPHYSICS, V131, P1, DOI 10.1016/0040-1951(86)90265-9; CHLU A, 1992, SEISM RES LETT, V63, P375; Dixon TH, 1996, GEOPHYS RES LETT, V23, P3035, DOI 10.1029/96GL02820; Dixon TH, 1997, J GEOPHYS RES-SOL EA, V102, P12017, DOI 10.1029/96JB03902; Frankel A.D., 1996, NATL SEISMIC HAZARD; GORDON RG, 1992, SCIENCE, V256, P333, DOI 10.1126/science.256.5055.333; Grana JP, 1996, J GEOPHYS RES-SOL EA, V101, P5445, DOI 10.1029/95JB03255; HERMANN RB, 1978, B SEISMOL SOC AM, V68, P1095; HERRMANN RB, 1979, J GEOPHYS RES, V84, P3543, DOI 10.1029/JB084iB07p03543; Himes L., 1988, Seismological Research Letters, V59, P123; Johnston AC, 1996, GEOPHYS J INT, V126, P314, DOI 10.1111/j.1365-246X.1996.tb05294.x; Johnston AC, 1996, ANNU REV EARTH PL SC, V24, P339, DOI 10.1146/annurev.earth.24.1.339; JOHNSTON AC, 1985, J GEOPHYS RES-SOLID, V90, P6737, DOI 10.1029/JB090iB08p06737; Kelson KI, 1996, J GEOPHYS RES-SOL EA, V101, P6151, DOI 10.1029/95JB01815; LIU LB, 1992, SCIENCE, V257, P1666, DOI 10.1126/science.257.5077.1666; MAO, 1998, THESIS U MIAMI; Mao AL, 1999, J GEOPHYS RES-SOL EA, V104, P2797, DOI 10.1029/1998JB900033; OKAL EA, 1994, PHYS EARTH PLANET IN, V87, P55, DOI 10.1016/0031-9201(94)90021-3; RYDELEK PA, 1994, GEOPHYS RES LETT, V21, P2303, DOI 10.1029/94GL02057; SAVAGE JC, 1973, J GEOPHYS RES, V78, P832, DOI 10.1029/JB078i005p00832; SCHWEIG ES, 1994, SCIENCE, V264, P1308, DOI 10.1126/science.264.5163.1308; SEXTON JL, 1986, GEOPHYSICS, V51, P640, DOI 10.1190/1.1442118; Snay R., 1994, 1538F US GEOL SURV, pF1; SNAY RA, 1986, J GEOPHYS RES-SOLID, V91, P2695, DOI 10.1029/JB091iB12p12695; Stein S, 1993, GEODYNAMICS, V23, P5, DOI 10.1029/GD023p0005; STIRLING M, 1996, GEOPHYS J INT, V124, P883; Triep EG, 1997, J GEOPHYS RES-SOL EA, V102, P9923, DOI 10.1029/96JB03900; TUTTLE MP, 1995, GEOLOGY, V23, P253, DOI 10.1130/0091-7613(1995)023<0253:AAPEFL>2.3.CO;2; Weber J, 1998, TECTONICS, V17, P250, DOI 10.1029/97TC03550; WESNOUSKY SG, 1992, B SEISMOL SOC AM, V82, P1756; ZOBACK MD, 1981, SCIENCE, V213, P96, DOI 10.1126/science.213.4503.96	31	116	116	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					619	621		10.1126/science.284.5414.619	http://dx.doi.org/10.1126/science.284.5414.619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213680				2022-12-28	WOS:000079951100038
J	Shuttleworth, GN; David, DB; Potts, MJ; Bell, CN; Guest, PG				Shuttleworth, GN; David, DB; Potts, MJ; Bell, CN; Guest, PG			Lesson of the week - Orbital trauma: do not blow your nose	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELLULITIS; FRACTURES; SINUSITIS		Bristol Eye Hosp, Bristol BS1 2LX, Avon, England; Bristol Dent Hosp & Sch, Dept Oral & Maxillofacial Surg, Bristol BS1 2LX, Avon, England	Bristol Eye Hospital; University of Bristol	Shuttleworth, GN (corresponding author), Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.							FLEISHMAN JA, 1984, OPHTHALMOLOGY, V91, P1389; FLOOD TP, 1982, BRIT J OPHTHALMOL, V66, P269, DOI 10.1136/bjo.66.4.269; GOLDFARB MS, 1987, ANN OPHTHALMOL, V19, P97; HOLDS JB, 1992, CURR OPIN OPHTHALMOL, V3, P657, DOI 10.1097/00055735-199210000-00014; HUGHES DS, 1992, EYE, V6, P536, DOI 10.1038/eye.1992.114; KROHEL GB, 1982, OPHTHALMOLOGY, V89, P492; MAURIELLO JA, 1988, ADV OPHTHALMIC PLAST, V7, P99; PATERSON AW, 1994, BRIT J ORAL MAX SURG, V32, P80, DOI 10.1016/0266-4356(94)90132-5; ROSE GE, 1991, EYE, V5, P13; SEVEL D, 1973, BRIT J OPHTHALMOL, V57, P133, DOI 10.1136/bjo.57.2.133; SMELT GJC, 1983, BRIT MED J, V287, P1051, DOI 10.1136/bmj.287.6398.1051; WESTFALL CT, 1991, OPHTHALMIC SURG LAS, V22, P409	12	13	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1054	1055		10.1136/bmj.318.7190.1054	http://dx.doi.org/10.1136/bmj.318.7190.1054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10205106	Green Published			2022-12-28	WOS:000080140000033
J	Nakashima, K; Yanagisawa, M; Arakawa, H; Kimura, N; Hisatsune, T; Kawabata, M; Miyazono, K; Taga, T				Nakashima, K; Yanagisawa, M; Arakawa, H; Kimura, N; Hisatsune, T; Kawabata, M; Miyazono, K; Taga, T			Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; SMAD PROTEINS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; CBP/P300	The cytokines LIF (leukemia inhibitor factor) and BMP2 (bone morphogenetic protein-2) signal through different receptors and transcription factors, namely STATs (signal transducers and activators of transcription) and Smads. LIF and BMP2 were found to act in synergy on primary fetal neural progenitor cells to induce astrocytes. The transcriptional coactivator p300 interacts physically with STAT3 at its amino terminus in a cytokine stimulation-independent manner, and with Smad1 at its carboxyl terminus in a cytokine stimulation-dependent manner. The formation of a complex between STAT3 and Smad1, bridged by p300, is involved in the cooperative signaling of LIF and BMP2 and the subsequent induction of astrocytes from neural progenitors.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cell Biol, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Med Res Inst, Cell Fate Modulat Res Unit, Tokyo 1010062, Japan; Univ Tokyo, Dept Appl Biol Chem, Tokyo 1138857, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Tokyo 1708455, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Tokyo; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science	Taga, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cell Biol, Tokyo 1010062, Japan.		Hisatsune, Tatsuhiro/Q-7583-2019					Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakashima K, 1997, FEBS LETT, V401, P49, DOI 10.1016/S0014-5793(96)01430-5; NAKASHIMA K, UNPUB; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rajan P, 1998, J NEUROSCI, V18, P3620; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	27	698	726	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					479	482		10.1126/science.284.5413.479	http://dx.doi.org/10.1126/science.284.5413.479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10205054				2022-12-28	WOS:000079792200045
J	Greer, IA				Greer, IA			Thrombosis in pregnancy: maternal and fetal issues	LANCET			English	Article							ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; THROMBOEMBOLIC DISEASE; RECURRENT MISCARRIAGE; VENOUS THROMBOSIS; ANTITHROMBIN-III; S DEFICIENCY; RESISTANCE	Pulmonary thromboembolism is the main cause of maternal death in the uh and current trends show an increase. Deep-vein thrombosis underlies this disorder. Important issues include pathophysiology, diagnosis, and management of thrombosis in pregnancy, especially the use of anticoagulants. Congenital and acquired thrombophilias contribute to the pathophysiological processes that underlie miscarriage, intrauterine growth restriction, and pre-eclampsia, and raises new possibilities for intervention. The high prevalence of thrombophilic defects in the population, the association of defects with maternal and fetal disorders, and special considerations for management make it essential for obstetricians to understand this area.	Univ Glasgow, Glasgow Royal Infirm, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow	Greer, IA (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland.							Balasch J, 1997, HUM REPROD, V12, P1094; Bates SM, 1997, BAILLIERE CLIN OB GY, V11, P479, DOI 10.1016/S0950-3552(97)80023-5; Blomback M, 1998, BLOOD COAGUL FIBRIN, V9, P343, DOI 10.1097/00001721-199806000-00006; Bokarewa MI, 1997, BLOOD COAGUL FIBRIN, V8, P239, DOI 10.1097/00001721-199706000-00005; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; Brennand JE, 1999, ACTA HAEMATOL-BASEL, V101, P53, DOI 10.1159/000040922; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Clark P, 1998, THROMB HAEMOSTASIS, V79, P1166; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; DEKKER GA, 1995, AM J OBSTET GYNECOL, V173, P1042, DOI 10.1016/0002-9378(95)91324-6; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; *DEP HLTH, 1998, CONF ENQ MAT DEATHS; DESTEFANO V, 1995, THROMB HAEMOSTASIS, V74, P793; DESTEFANO V, 1994, THROMB HAEMOSTASIS, V71, P799; deVries JIP, 1997, BRIT J OBSTET GYNAEC, V104, P1248; DizonTomson DS, 1997, AM J OBSTET GYNECOL, V177, P402, DOI 10.1016/S0002-9378(97)70205-9; DizonTownson DS, 1997, J REPROD IMMUNOL, V34, P217, DOI 10.1016/S0165-0378(97)00039-9; DizonTownson DS, 1996, AM J OBSTET GYNECOL, V175, P902, DOI 10.1016/S0002-9378(96)80022-6; Gibson JL, 1998, BRIT J OBSTET GYNAEC, V105, P795, DOI 10.1111/j.1471-0528.1998.tb10212.x; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P1052; GREAVES M, IN PRESS LANCET; Greer IA, 1997, BAILLIERE CLIN OB GY, V11, P403, DOI 10.1016/S0950-3552(97)80019-3; GREER IA, 1993, BRIT J OBSTET GYNAEC, V100, P37, DOI 10.1111/j.1471-0528.1993.tb12947.x; GREER IA, 1994, HAEMOSTASIS THROMBOS, P987; Hallak M, 1997, AM J OBSTET GYNECOL, V176, P889, DOI 10.1016/S0002-9378(97)70617-3; HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P151; Horlocker TT, 1997, ANESTH ANALG, V85, P874, DOI 10.1097/00000539-199710000-00031; Hough R. E., 1996, British Journal of Haematology, V93, P136; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Leeda M, 1998, AM J OBSTET GYNECOL, V179, P135, DOI 10.1016/S0002-9378(98)70263-7; LETSKY E, 1997, BAILLIERE CLIN OB GY, P23; LINDHAGEN A, 1986, BRIT J OBSTET GYNAEC, V93, P348; Lindoff C, 1997, AM J OBSTET GYNECOL, V176, P457, DOI 10.1016/S0002-9378(97)70515-5; Lindqvist PG, 1998, THROMB HAEMOSTASIS, V79, P69; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; Lowe GDO, 1997, BAILLIERE CLIN OB GY, V11, P511, DOI 10.1016/S0950-3552(97)80025-9; Macklon NS, 1996, SCOT MED J, V41, P83, DOI 10.1177/003693309604100305; Macklon NS, 1997, BRIT J OBSTET GYNAEC, V104, P191, DOI 10.1111/j.1471-0528.1997.tb11043.x; MACKLON NS, 1995, BRIT J RADIOL, V68, P515, DOI 10.1259/0007-1285-68-809-515; MACKLON NS, 1995, BLOOD COAGUL FIBRIN, V6, P672, DOI 10.1097/00001721-199510000-00008; MACKLON NS, 1997, BAILLIERES CLIN OBST; McColl MD, 1998, BRIT J OBSTET GYNAEC, V105, P923, DOI 10.1111/j.1471-0528.1998.tb10241.x; McColl MD, 1997, THROMB HAEMOSTASIS, V78, P1183; NelsonPiercy C, 1997, BAILLIERE CLIN OB GY, V11, P489, DOI 10.1016/S0950-3552(97)80024-7; Pabinger I, 1996, ARTERIOSCL THROM VAS, V16, P742, DOI 10.1161/01.ATV.16.6.742; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; Rai RS, 1996, BRIT J OBSTET GYNAEC, V103, P842, DOI 10.1111/j.1471-0528.1996.tb09887.x; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Rotmensch S, 1997, AM J OBSTET GYNECOL, V177, P170, DOI 10.1016/S0002-9378(97)70457-5; *ROYAL COLL OBST G, 1995, REP RCOG WORK PART P; RUTHERFORD S, 1991, American Journal of Obstetrics and Gynecology, V164, P286; Sanson BJ, 1996, THROMB HAEMOSTASIS, V75, P387; Thomson AJ, 1998, LANCET, V352, P1904, DOI 10.1016/S0140-6736(05)60394-7; Vincent T, 1998, LANCET, V352, P116, DOI 10.1016/S0140-6736(98)85022-8; Walker ID, 1997, BAILLIERE CLIN OB GY, V11, P431, DOI 10.1016/S0950-3552(97)80020-X; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Zoller B, 1996, TRENDS CARDIOVAS MED, V6, P45, DOI 10.1016/1050-1738(95)00130-1	61	414	436	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1999	353	9160					1258	1265		10.1016/S0140-6736(98)10265-9	http://dx.doi.org/10.1016/S0140-6736(98)10265-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217099				2022-12-28	WOS:000079744100041
J	Freedman, LP				Freedman, LP			Increasing the complexity of coactivation in nuclear receptor signaling	CELL			English	Review							ESTROGEN-RECEPTOR; PPAR-GAMMA; ACTIVATION; INHIBITION; CBP/P300; PCAF		Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Freedman, LP (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.							Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; GARABEDIAN MJ, 1997, MOL BIOL STEROID NUC, P237; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; HAMMER GD, 1999, IN PRESS MOL CELL; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shim WS, 1999, P NATL ACAD SCI USA, V96, P208, DOI 10.1073/pnas.96.1.208; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TREMBLAY A, 1999, IN PRESS MOL CELL; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	21	359	367	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	1999	97	1					5	8		10.1016/S0092-8674(00)80708-4	http://dx.doi.org/10.1016/S0092-8674(00)80708-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188JW	10199396	Bronze			2022-12-28	WOS:000079843900002
J	Lake, JA; Jain, R; Rivera, MC				Lake, JA; Jain, R; Rivera, MC			Genomics - Mix and match in the tree of life	SCIENCE			English	Editorial Material							CHIMERIC ORIGIN; ARCHAEA		Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Lake, JA (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.		Rivera, Maria/GYU-2150-2022					Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Day Martin, 1998, P144; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; Hall Ruth M., 1998, P53; HENSEL R, 1989, CAN J MICROBIOL, V35, P81, DOI 10.1139/m89-012; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; KUNST F, 1997, NATURE, V390, P205; LAKE JA, 1982, P NATL ACAD SCI-BIOL, V79, P5948, DOI 10.1073/pnas.79.19.5948; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Pennisi E, 1998, SCIENCE, V280, P672, DOI 10.1126/science.280.5364.672; Ribeiro S, 1998, MOL BIOL EVOL, V15, P779, DOI 10.1093/oxfordjournals.molbev.a025983; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SMITH JA, 1993, SEMIN VET MED SURG, V8, P90; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Syvanen M, 1998, HORIZONTAL GENE TRAN; ZILLIG W, 1992, ORIGIN EVOLUTION CEL, P47	18	45	47	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2027	2028		10.1126/science.283.5410.2027	http://dx.doi.org/10.1126/science.283.5410.2027			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10206909				2022-12-28	WOS:000079369800030
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Designer Jell-O	SCIENCE			English	Editorial Material																		Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1872	1872						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206893				2022-12-28	WOS:000079228600034
J	Warden, J				Warden, J			NHS "cannot cope," says Tory	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1028	1028		10.1136/bmj.318.7190.1028a	http://dx.doi.org/10.1136/bmj.318.7190.1028a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10610143				2022-12-28	WOS:000080140000015
